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Abstract 
The aims of this thesis are to identify and test alternative methods for analysing and 
predicting health care costs, to construct a framework for guiding analysts in making 
better cost predictions, and to identify future areas of research in this area. The thesis 
uses costs collected from a multi-country trial measuring the cost-effectiveness of an 
evidence-based programme of antenatal care. Detailed costing studies of maternity 
services (antenatal care, childbirth and postpartum care) were done in two trial countries 
(Cuba and Thailand), and also a nontrial country, South Africa. 
Costs are broken down and reviewed by cost components: prices, resource use, and 
health service use. The review initially considers the application of economic theory to 
public health care institutions, to identify factors likely to cause cost variation between 
setting. Then the review seeks empirical evidence proving or disproving the existence of 
these factors from the health care literature, as well as a review of the methods for 
analysing health care costs. 
The empirical analysis first compares health service use, unit costs and cost per 
pregnancy between settings (between: women with different case-mix, health facilities, 
trial arms and 'study countries) and examines the causes of variation, before testing 
alternative cost prediction methods. Variations in unit cost are found to be due to several 
factors, including different levels of resource productivity, occupancy levels, staffing 
patterns, prices and exchange rates (between country), input mix and health facility size. 
Also, uncertainty and measurement error are considered likely to cause some variation 
in unit costs. Variations in health service use are due to case-mix, clinical practice, and 
accessibility differences. Again, not all variation is explained. Finally, a range of 
different cost predictions methods are tested, and their results compared with observed 
costs in each country. The most accurate cost prediction method is to build costs based 
on expected changes in resource use, health service use and morbidity rates (called the 
incremental cost impact approach). The direct and adjusted cross-country transfer 
methods (transfering costs between countries), although accurate on occasions, are less 
reliable. Cost predictions using predictors from a regression analysis are highly 
.~ 
unreliable for cross-country predictions. 
2 
Methodological issues and policy implications in relation to cost prediction and 
generalisability are discussed, including the choice of cost-prediction approach, the 
valuation methods (opportunity cost and currency conversion methods for cross-country 
predictions), the measures used for comparing the performance of cost prediction 
methods, and the limitations· of cost analyses to understand costs. It was concluded that 
caution is needed in predicting costs both within study countries due to cost variability, 
and in lower-resourced settings where u,nit costs and health service use are lower. 
Further cost analyses and testing of cost prediction methods are needed in other areas of 
health care to compare with the results from this thesis, and build a fuller picture of cost 
behaviour as well as strengths and weaknesses of alternative cost prediction methods. 
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Glossary of terms 
Accurate 
Adjusted cost transfer 
Allocative efficiency 
A verage cost 
Cost estimation 
Cost prediction 
Direct cost transfer 
Economic significance 
Economic efficiency 
Economies of scale 






Health service use 
This term is used in the context of cost prediction, where a 
cost prediction is judged 'accurate' if the 95% confidence 
interval of a predicted cost falls within the 95% confidence 
interval of observed cost. 
A cost prediction method that involves prediction of costs 
. in one setting based on the costs in another setting, but 
where adjustments are made using local data from the 
setting where costs are being predicted (if in different 
countries, adjusted transfer is in a common currency) 
... 
. .. 
Maximisation of outcome (health) with minimum cost. 
The full cost of a single health service or unit of 
production, including fixed resources and overheads. 
Costs are calculated using primary data sets (also termed 
'observed' cost). 
Costs are calculated using secondary data sets, or a 
mixture of primary and secondary data sets. 
A cost prediction method that involves prediction of costs 
in one setting based on the costs in another setting (if in 
different countries, transfer is in a common currency) 
Economic significance in this thesis is defined to occur 
when cost differences amount to more than the cost of a 
single antenatal care visit. 
Maximisation of outputs (health services) with minimum 
cost. 
A proportionate increase in all inputs leads to more than a 
proportional increase in outputs, thus leading to lower 
average costs. 
An increase in the number of health services offered 
reduces average costs. 
See 'Technical efficiency', 'Economic efficiency' and 
'Allocative efficiency' 
The price paid by a purchaser of health care resources. 
The extent to which data can be used from one setting in 
another setting. 
A generic term used to denote any complete physical 
health care structure, such as a hospital, health centre, or 
stand-alone clinic 
The member(s) of staff directly involved in health care 
activities (e.g. nurse, general practitioner, obstetrician) 
The use of specified types of health service, such as 
.~ 
inpatient days or outpatient visits 
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Incremental cost impact A cost prediction method that identifies the cost impact of 




The additional cost of a single health service or unit of 
production (sometimes approximated by variable cost). 
The value of a resource in its' best alternative use. 
Over prediction . Predicted costs are more than observed costs 




Technical efficiency score 
Under prediction 
Unit cost 
leads to. a lower average cost, as fixed costs are spread 
over a larger number of patients. 
See 'Economic significance' and 'Statistical significance'. 
A statistically significant difference between two costs 
occurs when the 95% confidence intervals of the two costs 
being compared do not overlap. 
Maximisation of outputs (health services) with given 
inputs. 
The efficiency score obtained from data envelopment 
analysis, where providers are compared in terms of chosen 
inputs and outputs. 
Predicted costs are less than observed costs. 





The motivation for this thesis arises from a growing concern expressed in the health 
economic literature with the way in which costs are being generalised 1 between health 
care settings or estimated 011 the basis of inadequate data (Drummond et al 1992, 
Jefferson et al1996, Buxton et al1997, O'Brien 1997, Bryan and Brown 1998, Walker 
and Fox-Rushby 1998, Spath et al1999, Coast et al 20~O). The concern is that, while 
the principle of general ising cost data between settings "is not wrong per se, analysts 
trying to reflect costs in their own setting often do not pay adequate attention to cross-
setting differences that may cause costs to vary. Also, cost calculations may not be 
described or costs are not presented in disaggregated form to allow assessment of 
generalisability to other settings. 
In the last 10-15 years, significant progress has been made in the economic evaluation of 
health care programmes through the establishment of an economic evaluation 
framework (Drummond et al1987) and costing guidelines2• However, these guidelines 
focus mainly on the estimation of costs and cost-effectiveness using primary research, 
with only limited guidance on how data can be extracted from secondary sources, such 
as through meta-analyses, modelling or extrapolation. Therefore, there is a gap in these 
guidelines on how cost-effectiveness data can be predicted or generalised from 
secondary sources to the settings where cost-effectiveness is needed. While some 
studies may identify important differences between secondary and primary settings, and 
make adjustments based on those observations (e.g. Menzin et al 1996), this thesis 
argues that at present a framework has not been constructed to deal with this adequately. 
This thesis aims to contribute to filling these knowledge gaps, and it is a part of the 
growing recognition of the importance of this area. For example, a recent Health 
Technology Assessment grant in the UK was awarded to examine issues of 
1 A generalisation in this thesis means 'the application of the results of a given setting to other populations 
or subpopulations' (Willke et aI1998). 
2 For example, in developed countries several costing guidelines are widely quoted in costing studies, such 
as in Drummond et al (1997), Luce et al (1996), Baladi (1996). For developing countries specifically, 
other costing guidelines are available, such as WHO (1979) for immunisation services, Philips et al (1993) 
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generalis ability. This project aims to improve how researchers tackle issues of 
generalis ability at study design stage, as well as in reporting of results. Also, The 
Department of Evidence for Health Policy at W.H.O. is currently making global cost-
effectiveness estimates for around 100 health interventions, using a costing spreadsheet 
to estimate what inputs are required to provide these interventions. Another initiative, 
The Global Forum for Health Research (based at W.H.O.) is examining whether 
standardised costing and cost-effectiveness guidelines can be made for predicting cost-
effectiveness of a set of health interventions, using available data sources at local and 
.' . 
international level (GFHR 1999). Finally, The CHEC project (Consensus on Health 
Economics Criteria list) is an international collaborative effort, aiming to develop 
criteria to assess the quality of economic evaluations in systematic reviews, and contains 
aspects of generalis ability. Therefore the theme of this thesis is timely given these 
initiatives, and the current need for a greater understanding of what factors affect cost 
generalisability. 
The rest of this chapter justifies further the theme of this thesis. First, the importance of 
costing in planning health interventions is described, and different aspects of cost are 
defined. Second, the importance of making cost predictions in health services research is 
explained, and concerns are raised concerning some of the current approaches to cost 
prediction. Therefore, potential ways of advancing the field are outlined. Third, the 
thesis aim, objectives and structure are outlined. 
1.2 Cost information in decision making 
1.2.1 Why are costs important? 
The achievement of efficiency and equity are two fundamental goals for the allocation 
of resources within public health systems. Resources are severely limited in the health 
sector, especially in developing countries, and policy makers must make choices 
between alternative health care interventions and strategies to meet health targets. 
Therefore the search for the most efficient and equitable health interventions and 
for environmental vector control, Sawert (1996) for tuberculosis control, and Kumanayarake et al (2000) 
for HIV/AIDS prevention strategies. 
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strategies using economic evaluation techniques is essential to optimise the welfare of 
society (Sawert 1996)3. 
Cost-effectiveness analysis (CEA) is one form of economic evaluation ~hat attempts to 
rationalise the decision making process, by attaching costs and health outcomes to 
different health care processes, and comparing these processes. It has even been claimed 
. that it is unethical not to take costs into account when deciding which patients get 
treated and what treatment they receive,. due to the 'sacrifice' involved in using 
." . 
resources for these patients instead of other (potential) patients (Philips 1987, Williams 
1992). 
CEAs have stringent information requirements in order to be scientifically robust, as 
well as have relevance in other health care contexts. As the numerator in cost-
effectiveness ratios, costs are essential to the reporting of economic evaluations 
(Drummond et al 1997). A recent development is the increasing use of randomised 
controlled trials (RCT) for measuring cost-effectiveness (Adams et al 1992, Mannheim 
1998). From a scientific point of view, cost measurement alongside RCTs is preferable 
over non-experimental studies and retrospective costing because costs and benefits of 
alternative programmes are measured on the same patients and under controlled 
conditions (Drummond and Davies 1991, Drummond 1994, Drummond 1995, Pocock 
1999, Petiti 2000). Cost estimation alongside these trials therefore plays a central role in 
determining cost-effectiveness. 
1.2.2 Types of cost 
In discussing 'cost', several interpretations are possible, depending on the user of 
information and the study context. Box 1.1 presents a typology of cost terms used in this 
thesis, reflecting current concepts4 about cost in health economics (Donaldson 1990, 
Rovira 1994, Baladi 1996, Gold et a11996, Drummond et al1997). 
3 Note that a balance is often struck between efficiency and equity objectives when considering the 
optimization of societal welfare, as they sometimes cannot be achieved simultaneously. 
4 However, note that different words have been used in the literature to describe these terms in Box 1.1. 
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Box 1.1 Typology of cost terms used in the thesis. 
1. PRICE. The price of a resource. For example, the cost of a doctor hour;ihe cost of a single item of 
equipment. Two alternative prices are distinguished: 
• ECONOMIC PRICE. The opportunity lost due to the use of a resource in an activity. 
• FINANCIAL PRICE. The money paid for a resource. 
Therefore the costs in 4. to 7. below can be expressed in either economic or financial values. 
2. RESOURCE USE. Quantity of resource use, in physical units. Different types of resources in the 
health sector used in this thesis are 'staff j' 'equipment', 'materials', 'drugs', 'utilities', and 'land and 
buildings'. How these are defined in this thesis is described later: 
3. HEALTH SERVICE USE. Types of health service include outpatient visits, inpatient days or 
admissions, operations, and laboratory tests. These can be expressed as a 'throughput' for a particular 
type of patient or population, and for a specified time period. 
4. UNIT COST. The cost per health service use. This can be expressed as: 
• A VERAGE COST. This includes all resource inputs to the health are process (see 2.). 
• MARGINAL COST. This includes only resource inputs that change with one unit of production. 
5. CASE COST. The cost for a single patient for a specified illness and/or over a specified time period. 
For example, the costs of a surgical case may include all outpatient visits, inpatient days, and surgical 
procedures associated with the surgery. 
6. TOTAL COST. The cost of health services for a defined population, health programme or health 
facility, and over a given time period. 
7. INCREMENTAL COST. The difference in the total cost of two or more competing treatments. For 
example, the change in costs from implementing a new procedure, such as day versus inpatient 
surgery. 
Six types of cost are distinguished: prices, resource use, unit cost, health service use, 
case cost, total cost, and incremental cost. Two of these, resource use and health service 
use, are not in monetary form, but instead what are termed here 'natural' units. 
Summarising costs in non-monetary units has the advantage that components of cost can 
be compared across borders, without having to convert local currencies to a common 
currency, which may distort the comparison (Murray et alI994). On the other hand, the 
advantages of summarising costs in monetary units are that costs are summarised and 
can be compared in a single unit or index, and the relative weights of different resources 
in overall cost can be understood. 
Several important relationships should be noted between these costs, particularly the 
construction of total costs. Figure 1.2 shows that the prices and resource uses for a 
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single use of health service (such as an outpatient visit) are combined to calculate the 
unit costs (either average or marginal) of a service. This relationship suggests that to 
/ 
understand unit cost variation, variation in each of the resources and prices that make up 
unit cost should be understood. 
Figure 1.1: Relationship between different types of 'cost'. 
Incremental Cost 
(Programme A versus B) 
',' .t 
Total Cost of 
Programme A 
Total Cost of 
ProgrammeB 
Health service use 
for activities i...n 
for all patients 
in Programme A 
Health care marginal 
cost for activities i...n 
in Programme A 
i= 
.------~~ 
Health care average cost ~ 
for activities i...n for all 
x patients in cost centre 
in Programme A 
~ II. All resources 
= 
Variable resources 
Quantity of resource 
Resource prices 
for inputs j ... m 
X use for inputs j ... m 
used in [activities i...n 
for average patient 
in Programme A 
At the next level of aggregation, unit costs are combined with health service use to 
estimate the overall cost, either of a programme ('total cost') or of a single patient ('case 
cost'). This relationship suggests that to understand total or case cost variation, variation 
in each of the components should be understood, including all elements of health 
service use (inpatient, outpatient, etc.), and each of the resources and prices that make 
up unit cost. 
At the final level of aggregation, the total or case costs of two or more forms of 
treatment are compared to estimate the incremental cost (at either the overall level or 
~ 
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patient level). Again, to understand variation in incremental cost between setting, 
variations in each of the components of incremental cost must be understood. As will be 
discussed below, this distinction between the components of different types of cost is 
important in making cost generalisations or predictions, as differences in each 
component can be compared and analysed separately, to improve the quality of the 
generalisation. 
1.3 Cost predictions 
1.3.1 What is a cost prediction? 
In costing health services there exist a variety of data sources for the analyst to choose 
from in estimating costs (Drummond and Jefferson 1996, Nuitjen 1999). For example, 
- in building the total cost of a health care programme, the components of total cost 
(prices, resource use and health service use, as shown in Box 1.2) can be measured on 
the population in the programme or a representative sample of the population. These 
sources are termed 'primary' data sources, and include routine data systems, local price 
lists, case notes, time and motion studies, and other non-routine data collection systems 
set up for the purposes of research. 
Alternatively, data to calculate costs may originate from other settings from where the 
health care intervention is being evaluated. These sources are termed 'secondary' (or 
non-primary) data sources, and include published data from other settings such as single 
clinical trials or meta-analyses of clinical trials, insurance claims databases, fee 
schedules, clinical guidelines of best practice, and modelled data based on assumptions 
or professional opinion (e.g. delphi panel technique) (Nuijten 1999). Examples of 
secondary sources include the use of costs from one centre in a multi-centre clinical trial 
to represent costs in all centres (e.g. Menzin et al1996, Schulman et al1996) or the use 
of charge data to represent actual costs (Kinosian and Eisenberg 1988)5. Although 
judgements about accuracy cannot necessarily be made based on whether costs are 
estimated from primary or secondary sources6, the use of secondary sources does 
S Charge data or fees could be argued to be primary sources, as they are collected from actual patients, 
often in the same setting as the research study. However, because these often contain a profit element or 
cross-subsidy, they rarely reflect actual cost, even when adjusted by an average cost-to-charge ratio 
(Finkler 1982). Therefore, in this thesis, they are classified as secondary sources. 
6 For example, a good secondary source may be better than a bad primary source. 
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suggest greater uncertainty, or uncertainty is not known, about whether costs refer to the 
population for whom they are supposed to represent. 
This distinction between primary and secondary data sources allows definition of the 
terms 'estimated' cost and 'predicted' cost, for use in this thesis. Therefore, a cost that is 
'predicted' is defined as a cost that is based on some or all non-primary data sources; 
that is, data sources are from outside the setting where cost estimates are required. A 
cost that is estimated is defined as a cost .t~at is based entirely on actual health care 
processes in the primary setting; that is, data sources are from the same setting as where 
cost estimates are required. Costs are therefore 'predicted' in any case where real health 
care processes are not observed in the setting where costs are required7• 
- 1.3.2 The need for predicting cost 
Although prospective costing using primary data sources could be seen as the 'gold 
standard' in costing, there are several circumstances in which secondary data sources 
may be preferable or even necessary: 
• It is unfeasible to run a new clinical trial to estimate the cost-effectiveness of an 
intervention for every new population about which a decision must be made (Willke 
et al 1998, GFHR 1999). 
• Cost data are not always available from routine data systems, due to poor 
organisation and lack of resources devoted to hospital management and accounting 
systems (O'Brien et al1992, Murray et al2000). 
• The funding allocated to conducting clinical trials is often insufficient to conduct a 
prospective costing study using primary data. Therefore, secondary data allow quick 
and relatively cheap assessments of health technology before further investments in 
health technology assessment (Attinger and Panerai 1988). 
• Costs are difficult to estimate in the early life of a new health intervention, when 
data are unavailable or they do not reflect costs that would pertain after wider 
implementation (Schulman et alI991). A linked point is that an immediate decision 
may be needed, and collection of primary data may take too long. 
7 A possible problem with this definition is that costs estimated using aggregate data from a primary 
source, as in the top-down costing approach, are not measuring actual health care processes, but only 
approximations of it. However, in this thesis these are considered primary sourrces. 
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• The types of health care for which cost estimates are required may not be provided 
by the health system at present, and therefore costs cannot be estimated based on 
current health care processes (Jefferson et alI996). /" 
• In collecting cost data alongside clinical trials, the costing study may disrupt health 
services, and even change provider and patient behaviour (Mugford et al 1998). 
• The cost analysis is a national analysis, and the model sophistication and data do not 
exist for all costs in all settings to be estimated, and a 'representative' sample is 
chosen based on convenience such as 'Yhat data areavailable (e.g. Bobadilla et al 
1994, Jha 1998). 
These circumstances indicate that cost predictions using generalised data or assumptions 
are unavoidable in many research or decision making contexts .. However, while 
unavoidable, it does not mean that generalisations should be made without attention to 
the quality or accuracy of the generalisation, a point highlighted in the next section. 
1.3.3 Problems arising when not using primary data sources 
Despite the common use of secondary sources to collect cost data, costing guidelines say 
little about the way in which secondary data sources can be used and/or adapted to 
approximate more closely costs in the primary setting, other than by encouraging 
transparency and careful interpretation. Such discretion means that poor quality cost 
study designs may be justified on the basis that the funds and data were not available for 
good quality cost data (often despite huge resources being expended on the clinical 
component of a trial). Some authors have voiced concerns about the uses of secondary 
cost data. For example, Drummond et al made the following observation about the use 
of secondary data, in considering cross-national assessments of health technology: 
" ... however, the extrapolation of the results of economic evaluations from one setting to 
another is not a straightforward matter. A number of factors are pertinent to health 
technology that are known to vary from country to country ... for example, differences in 
demography and epidemiology, differences in general and relative price 
levels ... differences in the distribution of health care resources and their availability" 
(Drummond et a11992, page 672). 
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In support of this statement, many other commentators have voiced doubts about 
transferring cost and cost-effectiveness evidence across health care settings, both within 
and between countries8• For example, in the context of mammography screening in the 
UK Bryan and Brown (1998) warned against the "naive and unthinking use" of 
published cost-effectiveness information outside the setting in which the information 
was generated, due to differences in the design of screening programmes. Glick (1997) 
also questioned whether observations about the econorruc impact of a medical therapy in 
one setting or patient population informs. use about it's impact in other settings or 
. '. 
patient populations, and recommended the use of sub-group analysis. Finally, in their 
article on sensitivity analysis, Briggs et al (1994) recognised that cost data may not be 
generalisable and suggested altering parameter values to reflect the range of values in 
other settings to test the impact on cost or cost-effectiveness. 
Many of these studies mentioned above have described or listed a number of factors that 
were considered to be important determinants of cost, and thus likely to be responsible 
for cost variation between health care settings. For example, O'Brien (1997) listed six 
threats to validity: different demography and epidemiology of diseases, clinical practice 
and conventions, incentives and regulations for health care providers, relative price 
levels, consumer preferences, and opportunity cost of resources. These and other factors 
are summarised in Table 1.1, and are grouped according to whether they affect cost 
through the supply side (health care provider) or demand side (patient), and whether 
they affect health service use or unit costs. On the patient side, the most widely quoted 
factors causing costs to vary were case-mix, patient costs, and patient access. On the 
provider side, the most widely quoted factors causing costs to vary were resource prices, 
financial incentives, and health care content. Empirical evidence for the effect of these 
factors is discussed in more detail in Chapter 4. 
8 Commentators include Attinger and Panerai 1988, Postma et al 1993, Lee et a11993, Briggs et al 1994, 
Jefferson et al 1996, O'Brien 1996, Buxton et al 1997, Mason 1997, O'Brien 1997, Glick 1997, 
Drummond et al 1997, Phelps 1997, Bryan and Brown 1998, Grieve 1999, Spath et al 1999, Coast et al 
2000. Also of some relevance are doubts raised over the external validity of clinical (effectiveness) results 
to routine practice and for broader policy uses (Fisher and Carlaw 1983, Barnett et a11987, Bailey 1994, 
Rothwell 1995, Lengeler and Snow 1996, Marchiola 1996, Fayers and Hand 1997, Wentzer et al 1997, 
Altman and Bland 1998). 
24 
Table 1.1: Factors varying between health care settings that may influence costs. 
Health care provider ('supply') factors 
Health service use, affected by: 
• Financial incentives and regulations 
• Risk aversity of providers 
• Treatment guidelines 
• Hospital policy 
• Qualifications and experience of staff 
• Referral patterns 
• Provider habits and incentives for treatment 
• Availability of services . 
• The perceived costs of alternative types of care .... 
Unit costs, affected by: 
• Content of health care 
Patient ('demand') factors 
Health service use, affected by: 
• Natural history and epidemiology of disease 
• Demography and case-mix (risk and morbidity) 
• Patient costs 
• Geographical accessibility 
• Risk aversity of patients 
• Responsiveness to care 
• Compliance with treatment and advice 
• Expectations and consumer preferences 
Unit costs, affected by: 
• Case-mix 
• Absolute prices or opportunity coist • Expectations and consumer preferences 
Patient costs • Financial incentives • 
• Relative prices and input mix, skill mix 
• Provider productivity (e.g. patients seen per day 
per staff member) 
• Occupancy 
• Quality of care 
• Risk aversity of providers 
• Treatment guidelines 
Sources: see Footnote 8. 
Given the comments and findings of these studies, researchers and decision makers still 
face the problem that there is inadequate empirical evidence for confidently making 
adjustments to costs from other settings to reflect actual costs more closely in their own 
setting, or predicting costs using alternative techniques. This problem is compounded by 
the fact that different health care settings usually differ with respect to cost 
determinants, so guidelines can at best suggest what aspects of cost should be studied, 
and help analysts make appropriate choices. Therefore, the next section provides an 
overview of methods to improve this situation. 
1.3.4 Ways of advancing the field of cost generalisability 
Several ways of increasing generalis ability have been identified. These relate to the 
conduct and presentation of published cost studies, cost analyses to understand the 
determinants of cost, and a comprehensive evaluation and comparison of cost prediction 
techniques. Each are discussed in tum. 
Conduct of cost study and presentation of cost results 
Three aspects of cost studies are discussed here. The first aspect involves the use of a 
standard approach, such as the 'reference case' (Weinstein et al 1996) so that those 
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generalising or comparing cost data know, for example, which costs were included or 
excluded, and the measurement or valuation techniques to obtain cost figures (Janowitz 
and Bratt 1992). While costing guidelines allow some discretion to the analyst in which 
data sources to use, 'consensus' articles (e.g. Drummond and Jefferson 1996, Luce et al 
1996) have argued that several aspects of costing are universally important. Aspects 
discussed include: inclusion· of relevant and important costs, a costing approach 
appropriate for the setting, detailed measurement of ' resource use, use of opportunity 
cost to reflect the value of resources, justi~cation of models and assumptions, a good 
quality sensitivity analysis, discounting, and separate presentation of components of 
cost. Inappropriate methods or unjustified assumptions in costing can cause 
considerable uncertainty in the estimates, as well as reducing the comparability with 
other studies using the reference case recommendations. Another challenge to 
-
robustness that authors should be aware of in using secondary data is analyst bias, due to 
vested interests or prior expectations (Kassirer and Angell 1994, Evans 1995, FDA 
1995). 
Therefore, transparent methods are of critical importance so that readers of economic 
evaluations know what was done, and why. However, review studies conducted to date 
have found that results of economic evaluations are largely nongeneralisable, due to 
methods used being at variance with recommendations in economic evaluation 
guidelines, or lack of statement of methods (Udvarhelyi et al 1992, Heyland et al 1996, 
Spath et al 1999). For example, Spath et al (1999) conducted a review of economic 
evalutions of adjuvant therapy in women with breast cancer to assess their applicability 
to a decision making context in France. They first applied four initial criteria to select 
studies, including statement of viewpoint, comparison of at least two competing 
alternatives, description of therapies, and precise reporting of the effectiveness of the 
therapies. These criteria ruled out 17 of 26 studies identified as economic evaluations. 
They then applied six further 'generalisability' criteria to the remaining studies9• Of the 
nine studies evaluated, none had all the necessary characteristics to be transferred to the 
setting in France, and only one study was found to have sufficiently disaggregated data 
on costs to be considered transferable to the study setting, thus allowing adjustments to 
9 (1) Was the alternative therapies were relevant to the local setting in France? (2) Were patient 
characteristics similar? (3) Were health outcomes relevant? (4) What was the cost viewpoint? (5) Were 
resource use quantities clearly stated? (6) Were unit prices of health care resources clearly specified? 
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be made. Therefore, this study highlights the problems resulting from not using or 
reporting appropriate economic evaluation methods. 
The second aspect of cost studies involves the testing of robustness of cost estimates 
(Briggs et al 1994). The standard technique advocated by economic evaluation 
guidelines is sensitivity analysis, which shows cost results under alternative assumptions 
or conditions or, alternatively, the assumptions required for study conclusions to change 
(threshold analysis). However, the main a~plication of sensitivity analysis so far has 
been static analyses (Hutton 1993, Briggset al 1995), suggesting that the ranges 
presented may reflect uncertainty inadequately. The problem with static analysis is that 
differences between settings in production relations that determine cost are not 
accounted for. More recently there have been developments in stochastic and 
multivariate sensitivity analyses, using probabilistic, montecarlo and bootstrap methods 
(Doubilet et al 1985, O'Brien et al.1994, Manning et al 1996, Hunink et al 1998, Lord 
and Asante 1999). These approaches can, in theory, take account of interrelationships 
between variables and dynamic effects, if data on these are available. 
The third aspect of costing study to improve generalis ability is the presentation of cost 
data in dis aggregated as well as aggregated form (Drummond and Jefferson 1996), to 
allow readers to assess the relevance of the cost data to his setting, and recalculate costs. 
This may involve presentation of prices and quantities separately (or at least describe 
input mix) and health service use. 
Cost analysis to understand cost determinants 
Costs are transferred more accurately if cost behaviour is understood in both primary 
and secondary settings and appropriate adjustments made (Drummond et at 1992, 
Menzin et al 1996). Economic theory suggests that cost behaviour depends on many 
interrelated factors, which are likely to vary between setting (Heathfield and Wibe 
1981). The assessment of these factors requires a variety of techniques to be performed 
for understanding unit costs and assembling evidence of cost behaviour (Sherman 1984, 
Barnum and Kutzin 1993, Ehreth 1994). Such information on cost determinants has a 
practical use, as Jian et al (1998) points out " ... to identify the most efficient way of 
providing immunisation services ... a rough quantitative notion of the relative importance 
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of factors contributing to cost variation is useful". Therefore, this thesis argues that 
understanding costs is a critical stage before cost prediction, and therefore cost analysis 
techniques and results from the literature are reviewed in detail. 
Compare the performance of different cost prediction techniques 
In their review article on methodological issues in costing health care technologies in 
clinical trials, Johnston et al (1999) recommend further empirical study in methods to 
generalise results. None of the costing gui~elines or cost analysis articles found in the 
.. 
literature search have described and tested comprehensively a range of cost prediction 
methods, nor have described means of judging what levels of inaccuracy are 
'acceptable' for the conclusions to hold. Without development in the area of cost 
prediction techniques, many economic analysts are likely to continue to predict costs 
inappropriately, or use more time-consuming and data-intensive methods when simpler 
and cheaper ones may have sufficed. For example, a reduced-list costing method that 
identifies the main economic impacts (Knapp and Beacham 1993, Howard et al 1995, 
Whynes and Walker 1995) has been shown to approximate costs well, and is likely to 
require less research time than a prediction technique such as regression analysis. 
Therefore, cost prediction methods need to be evaluated in a variety of settings and 
compared with each other using both scientific and pragmatic criteria, so that choices 
can be about optimal cost prediction methods made in a variety of settings. These 
results, together with the results of the cost analysis review, should be used to conclude 
what the advantages and disadvantages of each cost prediction method are. Therefore 
the testing of alternative cost prediction methods and understanding their performance 
under different conditions are the primary aims of this thesis. 
1.4 Thesis aims and outline 
1.4.1 Thesis aim 
The overall thesis aim is to increase current knowledge about the strengths and 
weaknesses of alternative cost analysis and cost prediction methods, in the context of 
public health care systems, and with particular emphasis on developing countries. 
This thesis aim is an important one because at present the methods for conducting cost 
analysis to understand generalisability of costs, and methods for cost prediction, are 
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underdeveloped. Further research is urgently required that reviews current concepts and 
understanding in the literature, compares alternative cost analysis and cost prediction 
methods in a variety of settings, and draws conclusions about" the strengths and 
weaknesses of alternative cost analysis and cost prediction methods. 
The context of this thesis is a multi-country trial evaluating the cost-effectiveness of the 
W.H.O. antenatal care programme (Lumbiganon et al 1998, Villar et al 2000). 
Alongside this trial, a detailed costing stud~ \Vas conducted in Cuba and Thailand. Also, 
a study was conducted in South Africa to measure costs of maternity care, and to further 
explore issues of generalisability. Maternity care is an important health care field to 
research at present because it is a priority of many countries and international 
organisations, but there have been limited economic studies done to date to allow policy 
makers to choose the most cost-effective mix of interventions (Hutton 1996, Mumford 
et al 1998, Petrou et al 2000, Hende~son et al 2000). 
The thesis objectives are therefore to: 
1. Review the current literature on the application of economic theory to health care 
costs, cost analysis and cost prediction methods, and cost analysis results, and build 
frameworks for analysing and predicting health care costs for use in this thesis. 
2. Estimate and analyse health care costs associated with pregnancy and childbirth in 
study settings, to understand cost determinants and behaviour. 
3. Evaluate the robustness and generalis ability of these costs. 
4. Test alternative methods of predicting costs, comparing cost predictions with 
observations of cost, and where predicted and observed cost differ, to examine why. 
5. Make recommendations for researchers and policy makers concerning how to 
conduct and interpret cost predictions, and recommend areas for further research. 
1.4.2 Thesis outline 
The primary aims of the literature reviews in chapters 2 to 4 are to review current 
knowledge and thinking in cost analysis and cost prediction, to provide a basis for the 
methods in this thesis, and to compare with the empirical findings of the thesis. Chapter 
2 examines health care costs in the light of economic theory. The aim of the chapter is to 
provide theoretical foundations in designing the cost analysis, and to provide a basis for 
interpreting results. The chapter summarises the production and cost functions 
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underlying health care processes, defines efficiency and outlines the economic 
relationships driving health care production and costs. The assumptions underlying 
perfect competition are examined in relation to the public health sector, and conclusions 
are drawn whether breakdown in these assumptions affects interpretation of cost and 
cost analysis results. The final section pulls together the material presented in the 
chapter by listing likely factors that detennine unit cost behaviour and thus that drive 
cost differences between setting and over time. 
Chapter 3 presents a review of cost analysis methods from the health care literature. The 
purpose of cost analysis in this thesis consists of explaining cost behaviour, particularly 
cost differences between health providers, between patients and over time. Cost analysis 
methods are divided into accounting methods and statistical methods. The rationale and 
approach of the different methods and their application to public health care institutions 
are described briefly. The methods are compared, with the use of examples, according to 
their potential and limitations for explaining cost behaviour, as well as their data 
requirements and ease of use. 
Chapter 4 critically evaluates empirical evidence on factors hypothesised to detennine 
cost identified in Chapter 2. Health service use, unit costs, differences in costing 
methodology and uncertainty are evaluated separately. The rationale for identifying the 
main cost detenninants in advance is to provide a focus for data collection and analysis, 
and avoid collecting costly information on less important or irrelevant cost 
detenninants. Therefore the chapter identifies which factors have or are likely to have 
the biggest influence on cost, and to judge which methods are the most useful in 
identifying factors. Problems are also raised concerning measurement and analysis of 
the factors. The results of this and previous chapters are used to conclude how costs may 
be predicted, whether generalising costs or making assumptions about different 
components of cost (health service use, resource use, or prices), or using known 
relationships of cost from the cost analyses to predict costs (from regression analysis). 
Chapter 5 presents the thesis methods. Data collection and analysis is justified with 
reference to the conclusions of the literature reviews. First, the W.H.O. antenatal care 
trial is described. Second, the empirical objectives of the thesis are listed. Third, the data 
30 
collection and cost estimation methods are described. Fourth, cost analysis methods are 
described, where four levels of cost variation are distinguished: the health care provider, 
the treatment group, subgroups of women with different case-mix,and country. Fifth, 
cost prediction methods are described. 
Four analysis chapters are presented. Chapter 6 presents and analyses variation in cost 
data in 'natural' resource units (health service use and'resource use) at the four levels of 
variation. Significant differences at these le,:,els are examined in terms of what factors or 
variables are responsible for the variation. In terms of health service use, causes are split 
into patient-related and provider-related, and factors identified in the review are 
compared between settings. In terms of resource use, staff productivity is given special 
focus. Other resources are compared between settings, and conclusions made about the 
likely causes of inter-facility and inter-country variations. 
Chapter 7 presents and analyses variation in unit costs to understand variations between 
settings. At the within country level, differences in resource quantities are analysed, in 
terms of their impact on unit costs, using staffing ratios, data envelopment analysis, 
recalculating costs under different capacity use assumptions, scatter plots to examine 
whether economies of scale are present, and analysis of cost profiles (e.g. input mix). At 
the between country level, in addition to these methods, the roles of price differences 
and uncertainty in causing differences in unit costs are examined. Conclusions are made 
concerning how much the hypothesised factors have explained unit cost variations. 
Chapter 8 presents and analyses variations in cost per pregnancy to understand 
variations between settings. First, the separate impacts of health service use variations 
and unit cost variations on cost per pregnancy are examined. Second, average cost per 
pregnancy for different sub-groups of women are presented and compared, using two-
way tabulations, to make preliminary conclusions about which risk factors, events and 
health service use are the main predictors of cost. Third, multiple regression analysis is 
conducted to explain cost per pregnancy variations within country, and the 
methodological and data weaknesses and implications of the results are discussed. 
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Chapter 9 uses a variety of cost prediction methods to predict unit costs and cost per 
pregnancy between country. First, the incremental cost impact and regression methods 
are applied in all countries. Second, predicted costs are compared with observed costs 
for all cost prediction methods, and conclusions drawn about the accuracy of the 
methods and whether inaccuracies are economically significance. Third, the cost 
prediction methods are critically evaluated, and results explained. Fourth, the 
implications of the Cuban and Thai results are discussed with respect to which cost 
prediction method is most likely to be accur~te for cost prediction in South Africa. 
Chapter 10 discusses methodological issues and policy implications raised in the thesis. 
The methodological issues relate to choices that must be made in predicting costs, based 
on the type of cost being predicted, the source of data, and valuation issues. Also, the 
measures used to determine accuracy and economic significance are critically evaluated. 
The limitations of the cost analysis .methods and results are discussed with respect to 
how well they contributed to an understanding of cost behaviour and cost prediction 
results. The policy issues discussed include how policy makers should interpret the 
results of the cost prediction methods, and problems associated with cost variation and 
cost prediction in lower-resourced settings. 
Chapter 11 concludes. First, the findings of each chapter are summarised. Second, the 
overall empirical, methodological and policy conclusions of the thesis are presented. 
Third, recommendations are made for researchers and policy makers. 
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2 HEALTH CARE COSTS: FOUNDATIONS IN ECONOMIC THEORY 
2.1 Introduction 
Economic theory plays a key role in informing the producers of health services of the 
cost, output and/or profit options in production, and the relations between these. 
Economic theory is useful at different levels of decision making. For example, managers 
can use it to make decisions that maximise profits or welfare at the hospital or district 
levels, and governments or international agencies can use it to make decisions that 
maximise welfare at the national level. The attainment of economic efficiency is 
dependent on appropriate choices concerning resource use and output levels, and can be 
understood using cost definitions in this thesis (see Box 1.1). 
In considering alternative cost analysis and cost prediction techniques, it is important to 
understand the neoclassical production and cost functions underlying health services. 
The aims of this chapter, therefore, are to provide an overview and critique of the 
neoclassical theory of the firm as it applies to health care costs, and to conclude whether 
neoclassical theory can contribute to understanding cost behaviour in public health care 
institutions. To pursue these aims, both microeconomic texts and health care literature 
are referenced. The findings of this chapter are taken forward to subsequent chapters in 
the analysis of costs. 
2.2 The production of health care 
2.2.1 Choosing 'output' in health sector analysis 
To understand cost behaviour in the health sector, it is important to understand the 
processes underlying the production of health sector outputs. The production of the 
outputs 'health' and 'health care' are similar to the production of any other goods in that 
inputs are transformed into these outputs via a production process. The production of 
health not only requires appropriate types of health care as an input, but also other 
predisposing factors, such as genetic factors, life style, and environmental conditions. 
Therefore, it is necessarily complex to understand the production of health (Grosskopf 
and Valdmanis 1987). The production of health care, on the other hand, is simpler in 
that it only requires human and physical resources, and a technology (method of 
production) (Jacobs 1997). While health is the ultimate aim of the health sector, this 
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thesis is largely concerned with the production of the intennediate good, health care, 
and its' associated cost. While health care could be measured using detailed process and 
quality indicators that specify the actual contents of care, these are not easily 
quantifiable and comparable. Therefore, health care is represented by. the quantity of 
health service use. This choice of output means that this thesis is focussed on 'technical' 
and 'economic', but not 'allocative', efficiency (Hoffmeyer and McCarthy 1996)10. 
However, it is implicitly recognised that such' process measures have to be 
supplemented with assessment of health outcomes and analysis of input-output 
.' . 
. - " 
relationships to achieve allocative efficiency (Birch and Maynard 1986). This section 
reviews briefly the aims of production and the definitions of efficiency in the context of 
health care production in the public sector . 
. 2.2.2 The aim of production 
A fundamental assumption in economic theory is that efficiency is desirable, although it 
is often not the sole aim of human' activity. A special feature of most health sectors is 
that they are run (at least in part) by the government or other not-for-profit 
organisations, and therefore their objective is not necessarily to maximise profits. 
Therefore the way 'efficiency' is defined, measured and interpreted differs between 
different providers, such as between private-for-profit, private-not-for-profit and public 
health care providers .. 
The supply side in economic theory deals with the technical or engineering rules 
according to which 'producing units' convert inputs into outputs, which is summarised 
in the production function (Heathfield and Wibe 1981). In addition, the concept of cost 
is at the foundation of all supply decisions, and is vital to take account of in achieving 
economic efficiency. This is summarised in the cost function, which is the dual of the 
production function (Gravelle and Rees 1992). Pragmatic considerations may lead one 
to ask how such knowledge of these relations helps infonn the manager of a for-profit 
producing unit about the optimal output of goods and services. The solution to the 
profit-maximisation problem is reached in the following steps (Chacholiades 1986): 
1. Determination of the production function. 
2. Determination of cost relationships and cost minimisation. 
3. Optimal output to maximise profit, given market supply and demand conditions. 
10 See Glossary of Terms for definitions of efficiency. 
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4. Firm's demand for factors of production (land, capital and labourll). 
Thus, the Pareto optimal equilibrium under profit-maximising, conditions can be 
determined on the basis of these four steps, under the assumption of perfect competition. 
However, several key assumptions must hold for perfect competition to exist 
(Donaldson and Gerard 1993; Folland et al1994, Frech ill 1996): 
1. The principal aim of firms is to maximise profits. 
2. There are sufficient numbers of buyers and sellers of the final good, so that no single 
.' . 
actor has any power over the price. 
3. Prices in factor markets are determined by a sufficient number of buyers and sellers. 
4. The good is homogeneous; that is, all producers produce the exact same good so that 
the market cannot be differentiated on the basis of difference of goods. 
5. There is perfect information. Buyers and sellers have the information they need on all 
relevant variables such as prices, quantities and utility. 
6. There are no barriers to entry or exit. A producer starts producing, buying necessary 
machinery, patents, etc., on terms that are equivalent to those already in the industry. 
Also, it is costless to exit the market. 
7. The good is not a public good. This essentially means that there are no externalities 
and it is rejectable (consumers have a choice over whether they consume the good). 
'Market failure', where one or more of these assumptions do not hold, has been shown 
to exist in many markets (Brown and Jackson 1990). In a public health Syste~\. if 
any, of these assumptions are likely to hold, and therefore perfect competition is 
unlikely to exist in the health care market (Folland et alI994). The breakdown of tJese 
) 
assumptions is important to examine because costs may behave differently under market 
failure than the cost relationships predicted under perfect competition. This may lead to 
one or more of price, resource use and health service use not being at their perfectly 
competitive level. In fact, if one of these is not at the perfectly competitive level (e.g. 
price), then it will lead to others not being at their perfectly competitive level either (e.g. 
11 HeaIthfield and Wibe (1987) defined these three basic factors of production as follows: 
*Land = Inputs that exist without the intervention of man. 
*Labour = The application of human effort and intelligence to bring about different states of the world. 
*Capital = Land and labour invested in a production process to allow production and increase efficiency. 
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resource use). Therefore, the implications of market failure for the levels of price, 
resource use and health service use are important to examine later. 
2.2.3 Technical efficiency 
Technical efficiency is achieved when the maximum output is produced with a given 
mix of inputs. Any discussion of technical efficiency requires an understanding of the 
production function. Healthfield and Wibe describe the production function as "the set 
of possible efficient relations between inputs and outputs given the current state of 
technological knowledge .. .it is a technical relation that can be constructed without 
reference to market conditions or prices" (Healthfield and Wibe 1987, page 12). 
Abstract models of production give the relationship between inputs and outputs in the 
form: 
Q = f(K,L,M, Xl ••• Xn) Where Q = the output of a particular good (in a time period A) 
K = machines used in time period A 
L = hours of labour input in time period A 
M = raw materials used in time period A 
Xn = other variables affecting the production process 
Production functions may take on many different mathematical forms, and often use a 
simplifying two-input assumption: capital (K) and labour (L). One commonly applied 
functional form that fits the theoretical patterns for such functions is called the Cobb-
Douglas form, in the form: Q = AKaL~ (where A is a coefficient, and a+~ = 1)12. 
The production relationship can be represented graphically using a two-input model, by 
combining capital and labour in different quantities (input mixes) to produce the same 
output. This series of combinations, the 'production possibility frontier' (PPF) or 
'isoquant', is usually a single concave line ('homothetic') which represents the same 
output, shown below in Figure 2.1 13• 
12 One ~f the disadvantages of the Cobb-Douglas production function is that it assumes constant elasticity, 
although there are refinements such as the Taylor series expansion. 
13 The isoquants in Figure 2.1 are drawn only for values where the marginal products are greater than 
zero, as MP :s; 0 is considered 'irrational'. 
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In Figure 2.1, points A and C are equal in terms of technical efficiency, as they both 
combine capital and labour efficiently to produce Ql units of output. A change of 
production from point A to point C requires substitution of labour for capital, and the 
-marginal rate of technical substitution (MRTS) describes the slope of the line. The 
concavity assumption is borne out by experience in many areas of production, and many 
studies providing empirical work to support the law of diminishing returns14• although 
there are instances where it does not hold (e.g. constant elasticity or no substitution). 
Therefore, input substitution is the underlying assumption that drives the economic 
theory of production. Various substitution options between inputs also exist in health 
care, in both the short- and long-run. For example, nurse and doctor's hours have been 
found to substitute for one another (Reinhardt 1972, Folland et al 1994), as well as 
drugs for staff time in treating mental health patients (Jacobs 1997). However, it has 
also been argued that there are limits to substitution between inputs in the health sector 
(Barnum and Kutzin 1993, Jacobs 1997). 
There are two further problems with using the two-dimensional production possibility 
frontiers concept in the health sector. First, the health sector employs multiple inputs, 
which cannot be represented graphically in more than three dimensions. In addition, 
resources are often differentiated within input categories (e.g. between skilled and 
unskilled labour). Therefore the broad categorisations used, such as labour and non-
labour input, are inadequate for representing the production function. Second, hospitals 
14 This law states that if more and more of a variable factor is applied to a fixed quantity of other factors, 
then eventually the resulting increases in output must diminish. 
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produce multiple outputs, and therefore ways of measuring and comparing different 
types of output must be used to give meaningful results from cost analysis. 
2.2.4 Economic efficiency 
While the production function describes the relationships between inputs and outputs, 
the cost function describes the relationship between outputs and costs, and therefore 
takes into account market conditions and prices. FOJ;" economic efficiency to exist, not 
only must inputs be combined in such a way for technical efficiency to exist, but also 
the combination of inputs must be chosen.' to have the lowest cost among the range of 
alternatives. Essentially, it requires that all inputs are put to their most productive use. 
Economic efficiency in production will result if each firm buys or hires inputs in 
competitive markets and if each firm minimises production costs (Heathfield and Wibe 
)981). In order to achieve economic efficiency at the firm level, input substitution 
occurs until the incremental value of the services from another unit of expenditure is the 
same for all inputs. In Figure 2.2 this occurs when the isocost line (whose gradient 
represents the relative prices of the two inputs) touches but does not cross the PPF 
corresponding to the desired output, as shown below at point B (where the slopes of the 
isocost line and isoquant are identical). 
Figure 2.2: Isocost line and economic efficiency Figure 2.3: Change in isocost line 
Capital Capital 
Isocost line A 
Point B (efficient) 
Point A (inpffir.ipnt) 
'----"'------. Labour Labour 
The cost-minimisation condition can be shown as: MRTSLK = MPPL / MPPK = w/r, 
where MRTSLK is the marginal rate of technical substitution of labour for capital, MPP 
is the Marginal Physical Product, and ow' and Or' are the rents paid to labour and capital 
(Chacholiades 1986). This can be rewritten as: w / MPPL = r / MPPK, which means that 
the extra output gained per additional unit of money spent on labour and capital must be 
exactly the same. These efficiency conditions also apply to a multi-input production 
process, where the MPP and wand r are equated across all inputs. 
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Figure 2.3 shows the change in input mix required (from point A to point B) in order to 
maintain economic efficiency after a change in the relative prices of the two inputs 
(shown by isocost lines A and B). A way of measuring the degree of substitution 
between inputs is the elasticity of substitution (Es) (Healthfield and Wibe 1987), which 
is a measure of the responsiveness of a cost-minimising firm to changes in relative input 
prices. It is defined as the ratio of percentage change in the factor input ratio to the 
percentage change in relative factor prices: 
Es = % change in factor input ratio 
% change in factor price ratio 
Therefore if a firm is a cost minimiser, and if it is possible to substitute between inputs, 
-a change in relative prices would cause a shift away from the now costlier input to the 
now relatively cheaper input. However, there are many factors preventing the 
achievement of economic efficiency in the public health sector, including labour market 
inflexibility in the short-run, due to long training periods, staff on long-term contracts, 
and slow adjustments to increase capacity, thus causing Es to be low. 
2.2.5 Cost curves 
Chapter 1 provided a categorisation of different types of 'cost', and concluded that 
several of these meanings are useful in the context of health services. These include the 
price of an input, the cost of a service, the total cost of treating a given patient, or the 
monthly/annual expenditure in a given health facility or population. This section 
examines various aspects of cost behaviour. 
2.2.5.1 Short- and long-run 
An important distinction that is made when interpreting costs is between the short- and 
the 10ng-runIS• The distinction between time periods is necessary because 'shocks' result 
in disequilibrium in the short-run due to slow adjustment of capital inputs to their 
eqUilibrium level, thus leading to higher average costs than would occur if there were 
immediate adjustment. Also, health care providers are subject to uncertainties about 
future events (such as demand), and production levels required cannot always be 
plann~d based on certain knowledge of future demand. While demand may shift rapidly, 
15 This is a simplification used to present concepts. For example, Jacobs (1997) defines the short-run as 
less than a month, and the long-run as over a month. 
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supply cannot always, due to the commitments of employing resources, whether 
physical or human capital. For fixed inputs, the cost of capital is zero in the short-run, 
and therefore the associated isocost line is horizontal (12 in Figure 2.4). This causes the 
average total cost (ATC) and average variable cost (A VC) curves to converge at qmax, as 
shown in Figure 2.5. 
Figure 2.4: Short- and long-run isoquants Figure 2.5: Cost curves in short-run 
Labour Short-run isoquantS Cost 
I~_- Long-run 
I-----~ isoquant 
Capital q max Output 
However, the use of two time periods has its' limitations, as adjustment may occur 
along a continuum, from the very short-term, such as medication use, to the very long-
term, such as building construction. Some resources, such as staff and equipment may 
be nearer the middle of this continuum. Also, adjustment will depend on the context, 
and flexibility of local markets. For example, in the case of oversupply of human capital 
in the short-run, staff mayor may not be shifted to other clinics or wards depending on 
whether they are short-staffed. In the long-run, decisions can be made that affect the 
supply of health care staff through training programmes. 
The distinction between the short-run and long-run equilibrium points are shown 
graphically in Figure 2.6. The long-run average cost curve is the envelope of all the 
short-run curves. 
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Figure 2.6: Short- and long-run equilibrium points 
Capital 
Long-run expansion path 
.~ ...... ~I""'-______ Short-run expansion path 
Q2 
I------!..-----J....!--------. Labour 
Figure 2.6 shows that in the short-run sudden changes in demand (QI to Q2), cannot be 
-accommodated by increases in capital input from Ko to KI. Therefore the increase in 
demand must be met by increasing labour input from La to LI, instead of LI*, which 
would have been eqUilibrium point if capital had adjusted. In other words, labour input 
adjusts by more than it would if capital input had been fully adjustable in the short-run. 
This represents a movement away from long-run economic efficiency, as shown by the 
long-run expansion path in Figure 2.6. 
An important question concerns how to operationalise the distinction between time 
periods (Folland et al 1994). For example, what time periods do 'short' and 'long' refer 
to? In the health sector, there are several time periods over which resources adjust, any 
time between a day and several years, and therefore more than two discrete time periods 
are required. Also, when observing hospitals over time, are they achieving long-run 
cost-minimisation? 
2.2.5.2 'Economies' 
A second important aspect of cost behaviour is the presence or absence of 'economies': 
economies of scale and economies of scope. Consideration of these relationships is 
important because they can explain cost variation over time and between health 
facilities, and help policy makers plan hospital size and health services on offer at their 
optimal level. Economies of scale occur when a proportional increase in all inputs of 
X% increases output by >X%, thus reducing average costs with increases in output. 
Average costs reduce because resources become more productive (less input per unit of 
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output). An important distinction made by economists is between returns to scale, 
which is a long-run concept, and returns to the variable factor, which is the short-run 
equivalent (Chacholiades 1986). This distinction is made explicit in order to separate 
which factors may be causing average costs to vary with changes in output, and to 
recognise the different shapes of the short- and long-run cost curves. In the long-run, all 
inputs are variable, and are assumed to adjust to their point of maximum efficiency. 
There are many factors that may be respo~sible for economies of scale, such as more 
efficient use of indivisible inputs, division of labour, and the relation between 
management size and efficiency. In the short-run, however, fixed costs are viewed as 
sunk costs (and therefore with zero opportunity cost), and are often responsible for 
decreasing average costs with increases in output towards maximum capacity. This 
-concept, 'returns to the variable factor', was recognised by Deeble "since the costs of 
providing facilities are fixed, the lower the bed occupancy ratio, the higher the average 
cost per patient treated at constant quality" Deeble (1979, page 32). However, it should 
also be recognised in the provision of health care, as in other areas of production 
activity, that as output approaches or exceeds maximum capacity, quality may be 
compromised. Hence in the health care literature 'optimal' capacity is instead discussed, 
and is often taken as around 80% of maximum capacity (Luce et alI996)16. 
Figure 2.7: Total cost curve Cost TC 
1-----+-----. Output 
Figure 2.8: Average & marginal cost curves 
MC AC 
1-----'------.... Output 
16 However, this is not due to quality considerations alone, but may also be due to demand uncertainty. 
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Figures 2.7 and 2.8 show the shapes of the total, average and marginal cost curves, in 
relation to total output, under increasing returns to scale (the downward section of the 
average cost curve in Figure 2.8), constant returns to scale (the stationary section) and 
decreasing returns to scale (the upward section). 
These relations are also summarised using isoquants, as in Figure 2.9. Isoquant Qo 
represents the output in period 1. In period 2 there is a doubling of all inputs, and the 
output options are represented in isoqtiants, Q .. Q2, Q3. Ql represents decreasing returns 
to scale, where output increases by less then double; Q2 represents constant returns to 
scale, where output increases by double, and Q3 represents increasing returns to scale, 
where output increases by more than double. The elasticity of scale is the ratio of 
proportionate increase in output to the proportionate increase in inputs. 
Figure 2.9: Returns to scale. 
Labour 
Capital 
Another type of 'economy', economies of scope, are savings derived from producing 
different products jointly in the same production unit rather than producing them 
individually in separate production units. It is often termed 'jointness' in production. 
This can be due to shared expertise and/or overhead expenses between service 
departments, or because tasks are complementary requiring a common set of 
capabilities. 
2.2.5.3 Shifts in cost curves 
Another aspect of cost behaviour is when shifts occur in the cost curve, thus changing 
productivity and costs. The position of a cost curve is determined by the same factors 
that influence the production relation, and includes case-mix, quality of care, 
technology, proportion of fixed factors compared to variable factors, and the incentive 
system under which providers operate (Jacobs 1997). Shifts occur when there are 
changes in economic conditions, such as changes in input prices and technological 
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innovation (Russell 1975, Russell 1979, Nicholson 1994), thus affecting resource use 
and output levels. In a two input model (L and K) a rise in the relative cost of labour 
will cause the expansion path of the firm to "rotate toward the capital axis (assuming 
inputs can be substituted for one another). The extent of the shift depends critically on 
(a) the importance of the input in the production function, and (b) the extent of 
substitution possible with other inputs. New technologies also affect the expansion path 
of the firm. 
2.3 Breakdown of neoclassical assumptions 
The use of assumptions in economic theory means that when assumptions break down, 
cost behaviour is likely to change. The assumptions listed earlier for perfect competition 
to exist are examined briefly below in relation to health care provision in the public 
sector. When assumptions do not hold, the impact on the understanding of cost 
behaviour is examined. Table 2.1 summarises the findings of this section. 
2.3.1 Profit-maximising behaviour. 
Some form of maximisation condition must hold for production functions to have 
economic meaning, as the producing units must be considered 'rational' in weighing the 
costs and benefits of any decision (Healthfield and Wibe 1981). Barnum and Kutzin 
argue that "the difficulty of developing an economic view of the hospital lies in the 
inadequacy of the conventional profit-maximising model of the competitive market to 
explain the incentives, and thus the objectives and behaviour of hospital managers" 
(Barnum and Kutzin 1993, page 116). 
Although profit-maximising behaviour is usually cited as the maximisation condition 
necessary for perfect competition, a weaker version - that of cost-minimisation for a 
given output - is often accepted (Nicholson 1994). Public sector health facilities are 
clearly a departure from the assumption of profit maximisation, and the following 
alternative models have been suggested (Cowing and Holtman 1983, Newhouse 1970, 
Reder 1965): 
1. Maximisation of output and quality (with a given budget). 
2. Minimisation of costs for a given output. 
3. Maximisation of profit and output. 
4. Maximisation of institutional prestige. 
44 
5. 'Satisficing' behaviour (the objective is to satisfy expectations). 
While Pauly (1987) argued that the many models to explain incentives of managers in 
non-profit organisations have similar implications with respect to cost, others have 
argued that the 'prestige' and 'satisficing' behaviour models obscure the close empirical 
relationship between cost and output. This may be because non-profit seeking 
administrators, in the absence of other incentives to nunimise costs or maximise output, 
are sheltered from competitive market ,forces tha~ are responsible for economic 
efficiency in other types of market. Salkever (1978) introduces the 'redundant resources' 
theory, where top decision makers in non-profit making hospitals pursue nonpecuniary 
goals, such as quality or quantity of care for non-profit reasons, attracting physicians 
with high salaries and high technology equipment, charity care, research, and 
-administrative slack. Also, capacity levels may be slow to adjust to changes in demand. 
The implication of this debate is that there are several variables in the welfare function 
of 'public' institutions. For example, on the demand side policies may be made to meet 
patient needs, such as improving geographical access to improve uptake of services. On 
the supply side, providers own needs may be pursued, or their constraints taken into 
account, that may not exist in the private sector. Also, the way the hospital is governed 
has implications for the supply function. For example, autonomy over the control of 
sales revenue or excess budget may change behaviour, and alter the types of patient 
services are provided for and the quality of care. In conclusion, cost comparisons 
between hospitals must take into account the fact that hospitals may be pursuing 
different, if any, maximands, thus leading to different technologies, input mix, health 
services, and cost behaviour. 
2.3.2 Price-taking 
Buyers and sellers must be price-takers of health care services for perfect competition to 
exist. This means that there must be a sufficient number of buyers and sellers, and 
buyers must judge goods according to their prices. However, these conditions are 
generally lacking in public health systems, especially in developing countries. Not only 
are many public health services not charged for, or are provided at subsidised rates, but 
also the choices patients can make over which public health facilities they attend are 
often severely limited due to geographical and financial inaccessibility. Also, patients 
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reporting at health facilities outside their district may be turned away, thus reducing 
their ability to exercise choice in a free public health care system. Consequently, due to 
the lack of market mechanism in health care, it is unlikely that price or quality 
competition exists among public health facilities in developing countries. Therefore 
many services are consumed. that people would not be willing to pay for if charged 
(whether at the market price or at cost), and important services may not be provided due 
to lack of sensitivity to public needs. The implication is that when estimating costs, 
willingness to pay and health outcomes should also be evaluated so that appropriate 
, . . . 
levels of service are provided in future. However, this point is not relevant for technical 
or economic efficiency as it deals with the demand side (allocative efficiency); therefore 
it is not studied further in this thesis. 
2.3.3 Factor markets are competitive. 
Perhaps an even more fundamental cause of inefficient provision of public health 
services is that the markets supplying the resources to produce health services are 
themselves rarely perfectly competitive (Folland et al 1994). If input prices do not 
reflect opportunity cost, then the quantity demanded, and thus health service output, will 
not be at optimal levels from society's perspective. Prices do not reflect opportunity cost 
because many of the resources purchased for use in the health sector are supplied either 
by the government (such as health care personnel or utilities) or prices are set by 
government rather than through a competitive market. For example, whether public 
sector salaries reflect market rates depends partly on the power of trade unions or 
workers. Also, the prices of imported goods may be subsidised by government, or they 
include the profits of distributors, with the implication that the prevailing price (border 
price plus carriage, insurance and freight) does not reflect the opportunity cost (Curry 
and Weiss 1993). 
2.3.4 Homogenous output 
While it is recognised that homogeneous goods are important for perfect competition to 
exist, considerable work has been done on the multi-output nature of hospitals, due to 
the differing needs of patients and the different technologies employed by health care 
providers. According to Folland et al (1994), a central problem in hospital cost function 
studies is the measure of output. This problem has at least two aspects (Tatchell 1986). 
First, hospitals and departments within hospitals differ with respect to the types of cases 
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they care for; tis is called the case-mix problem. Health care varies according to the type 
of health service offered (e.g. inpatient care or outpatient care), or the patient (e.g. 
malaria or hypertensive). Patients differ in terms of the staff time they require, as well as 
the drugs and materials consumed. Researchers have constructed various types of 
diagnostic-related groups (DRG), according to either the type of disease or the quantity 
of resources used in treating patients. 
Second, health care providers also differ with respect to the quality or content of care. 
I • - • 
This is also difficult to measure and capture in single indices for making cross-setting 
comparisons of cost. Health gain also varies by patient, even when costs are similar. For 
example, a course of antimalarials for a patient with severe malaria may not cost more 
than a course of antibiotics for a patient with mild flu, but the long-term health gain is 
-
likely to be considerably greater for the malaria patient. Therefore, hospital managers 
must decide what their optimal mix of health services is, making a trade-off between 
outpatients, inpatients, surgery, etc. The implication is that the heterogeneity of health 
services is important to take into account when interpreting costs, or comparing costs 
across settings. 
2.3.5 Perfect information 
The requirement of perfect information for perfect competition to exist applies to both 
the consumer and provider of health care. Consumers are assumed to be fully informed 
and knowledgeable, and therefore possess the ability to seek out the producer with the 
lowest prices, as well as knowing what they want and when they want it (Donaldson and 
Gerard 1993). However, in health care systems, all actors are subject to some form of 
information shortage. Consumers rely on the 'agency relationship' with providers, who 
may face incentives not to maximise consumer welfare due to financial incentives or 
resource constraints. Also, managers do not know with certainty the demand for the 
coming period17 or the full range of suppliers who could undercut the prices of current 
suppliers, and the non-storage properties of health services results in wasting resources. 
The result of the breakdown in perfect information is that patients do not seek care at the 
right time or do not receive the optimal treatment, and often health services cost more 
due to demand uncertainty and subsequent wastage. Therefore, these issues must be 
taken into account in interpreting costs, and comparing costs between settings. 
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2.3.6 Barriers to entry and exit 
The assumption that producers can enter and leave the market costlessly is obviously 
unrealistic for most markets, where investment is required in capital items and stock, as 
well as the existence of liquidation costs. In the short-term, there are significant barriers 
to the entry and exit of public providers of health services. The problems are less related 
to barriers existing in private markets such as sunk costs, but more to the bureaucratic 
and political processes of agreeing to open or close hospitals. For example, when there 
is oversupply of hospital beds, many non-economic arguments may be put forward in 
.' , 
',' 
support of keeping hospitals open, thus leading to bed capacity levels that perhaps 
would not exist in the private sector. Also, governments are limited only by their ability 
to raise taxes or use debt to finance 'uneconomic' hospitals. This over-capacity leads to 
higher cost per service (due to low occupancy rates), which should be taken into account 
in interpreting cost data. Alternatively, if there are insufficient hospitals, bed occupancy 
may be above 100%, leading to 10'Yer unit costs, but also a decline in quality of care if 
there are insufficient staff and drugs. Whichever occurs, the slow adjustment process 
that characterises many public hospitals means that average costs vary from the rate they 
would be at if hospitals were operating at 'optimal' capacity. 
2.3.7 Public good characteristics 
Health care has been argued by many to be a public good, due to positive externalities 
(such as immunization programmes) and it's associated non-rejectable nature 
(Donaldson and Gerard 1993). These are some of the arguments used to advocate the 
public provision of health care, as it would be under-provided by a private market. 
Therefore the public good characteristics of some types of health care mean that perfect 
competition does not exist in some health care markets. The implication is that, from a 
societal perspective, externalities should be included in cost measurement (if 
quantifiable). 
2.3.8 Conclusions 
The presence of several types of market failure means that health care provision in the 
public sector is a clear departure from perfect competition. Table 2.1 summarises the 
findings above concerning the breakdown of neoclassical assumptions in the public 
health care market. The implications for cost interpretation is that there are potentially 
17 Although it can be controlled using waiting lists for some health services such as elective surgery. 
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several causes of cost difference between health facilities: inefficiency, incorrect value, 
case-mix differences, product or quality differences, (dis-)economies of scale and scope, 
and differences in capacity use. The next section formalises these causes of cost 
variation into a framework for use later in the thesis. 





2. Price taking 






6. No barriers to 
entry and exit 
7. Public good 
characteristics 
Breakdown of assumption? 
Yes. Public hospitals have 
several goals, and profit 
maximisation is rarely among 
them. 
Yes. Services in public 
hospitals may not be charged 
for (at market rate). Thus 
demand does not equal WTP. 
Yes. Salaries are lower in 
public sector, while other 
inputs are taxed or subsidised. 
Yes. Patients vary by case-mix 
and the care received. 
Yes. Agency relationship and 
clinical and demand 
uncertainty. 
Yes. Bureaucracy delays 
opening/closure; sunk costs. 
Yes. There are positive extern-
alities to some health services. 
Impact of breakdown on cost interpretation 
If an acceptable maximisation condition does 
not hold, cost comparisons between hospitals 
must take into account varying levels of 
. inefficiency. Affects price, resource use, and 
output, and thus average cost. 
Costs should be interpreted alongside data on 
willingness to pay and health outcomes. Affects 
output, and thus average cost. 
Unit cost may not reflect opportunity cost, and 
therefore adjustments should be made, or 
interpretations should take this into account. 
Affects price, and thus resource use and average 
cost. 
Cost analysis should take into account case-mix 
differences, which may affect prices and 
resource use. 
Affects price, resource use, and output, and thus 
average cost. Lack of perfect information may 
lead to technical inefficiency (wastage of 
resources) or allocative inefficiency 
(unnecessary health care). 
This leads to under- or over-capacity, with an 
impact on average cost and quality of care. 
2.4 Implications for analysing cost variation 
This chapter has briefly explored the relevance of economic theory for the supply of 
health services, and discussed determinants of cost behaviour, as suggested by economic 
theory. Using the conclusions of previous sections of this chapter a list of factors is 
constructed to explain inter-setting differences in costs, to be used in later chapters in 
reviewing the cost analysis literature. Unit cost can be disaggregated by its' two 
component parts - resource quantity and resource price. 
Unit costs may vary due to quantity differences for the following reasons: 
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1. Level of X-inefficiency, where the producer is operating off the average cost curve. 
This may be due to institutional factors (e.g. rigidity in workforce, over-specialisation 
of skills, or lack of accountability), inappropriate usage (inefficient use of labour, 
equipment, drugs) or pure wastage (loss, theft, staff absence). 
2. Returns to the variable factor, where increases in throughput result in lower average 
costs due to spare capacity~ This is because when throughput increases from one time 
period to another, fixed costs are spread over a larger patient throughput. 
3. Economies of scale, where increases in ~apacity levels results in lower average costs. 
This may be due to greater division of labour, greater productivity of capital assets, or 
other economies that result when large size can be exploited (e.g. bulk purchases). 
4. Economies of scope, where more types of health care or support service influence 
average costs. 
5. Input mix, where relative resource intensity varies due to technology, teaching status, 
'level' (e.g. primary or secondary), and ownership, thus influencing average costs. 
6. Quality of care, where different quality of care influences average costs. Ceteris 
paribus, better quality services cost more due to the extra cost of improved 
management practices, and resource intensity. 
7. Case-mix, where more severely ill patients cost more, due to the higher intensity of 
resource requirements, and longer average length of stay (ALOS). 
While economic theory provides a theoretical basis for comparing production functions 
and understanding cost differences, two qualifications are worth mentioning, to allow 
correct interpretations of differences in· input use between producing units. First, 
differences in substitution options and modes of health care delivery between countries 
means that input mixes can vary greatly, thus causing differences in costs. Therefore, 
differences in staffing ratios between countries do not necessarily indicate that some are 
inefficient, because they may all be achieving efficiency, but by different methods 
depending on local practice style. Second, health systems being observed at one moment 
in time may not be efficient, but may be moving towards efficiency. Therefore, the 
speed of adjustment is also an important issue in the health sector, and it depends on 
several factors. These include whether the resource can be stored, the quality of 
communication between decision makers and those implementing policy, and the 
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availability of resources or additional funds to make required changes (Barnum and 
Kutzin 1993). 
Prices have been found to influence average costs, in two ways: 
1. Absolute price change or difference. Input prices and costs are positively correlated, 
so that in a static analysis an x% increase in prices should lead to an x% increase in 
the costs associated with that resource. However, under a fixed budget, resource use 
will decrease. Unit costs may also' vary ~ecause in one setting financial costs are 
used, and in another opportunity costs. ' 
2. Relative price change or difference. Where input substitution exists, an increase in 
the price of one input of x % will decrease the use of that input, thus meaning costs 
will not increase as much as x%. This will depend on several factors, including the 
price elasticity of demand, the cross-price elasticity of demand, budget flexibility, the 
incentive for managers to adjust resources to new levels of supply and the speed of 
this adjustment, and the presence of government regulations and procedures. 
These hypothesised causes of cost variation are taken forward to Chapter 4, where the 
cost analysis literature is reviewed, to conclude how important these causes are, and 
what the data requirements are for cost analysis (with implications for whether they can 
be studied in data-constrained settings such as developing countries). 
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3 METHODS FOR EXPLAINING COST BEHAVIOUR 
3.1 Introduction 
Researchers working on the allocation of resources in health care have been examining 
the behaviour of costs for several decades (Lave 1966, Mann and Yett 1968, Hefty 
1969, Berki 1972, Jacobs 1974, Feldstein 1974, Cowing et al 1983, Creese et al 1988, 
Mills 1990, Newbrander et al 1992, Barnum and Kutzin 1993, Butler 1995). Two 
principle reasons can be distinguished' why understanding the behaviour of costs in the 
health sector is important. The first reason concerns what the objective, or 'maximand', 
of each individual health facility is, discussed in more detail in Chapter 2. For example, 
private health facilities will choose the types and quantity of health services to maximise 
profits. In public health facilities, the objective may be to maximise hospital output with 
a given budget. For both of these, a knowledge of cost levels and behaviour through cost 
analysis are essential inputs to achieving these objectives. The second reason, as 
described in Chapter 1, concerns the need of researchers and policy makers to predict 
costs when cost data are not available or cannot be collected in the setting(s) where 
resource allocation decisions are made. Knowledge of cost determinants aids the cost 
prediction process, making it simpler and more accurate than when cost behaviour is not 
understood. 
However, understanding cost behaviour in the health sector has proved in the past to be 
a challenge, as there are numerous factors that simultaneously determine or influence 
cost, and which act differently across health care settings (Cowing et al 1983). In 
addition, as this chapter argues, the greater the required confidence in the conclusions, 
the greater the need for good quality data sets and cost analysis methods. Thus a range 
of cost analysis methods have been developed to explain cost behaviour in diverse 
settings. These methods have been classified in the literature as two types - 'accounting' 
and 'statistical' methods (Sherman 1984, Barnum and Kutzin 1993, Ehreth 1994, 
Mahapatra and Berman 1994). Barnum and Kutzin (1993) describe these as 
" ... complementary tools to examine internal efficiency issues and to generate a cost 
basis for planning and cost-recovery policies". 
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A search was made of the theoretical and empirical cost analysis literature relating to 
health care1S• The search found several papers, books or book chapters that used or 
discussed alternative cost analysis methods, although few of these provided an overview 
of their strengths and weaknesses. This chapter, therefore, aims to evaluate alternative 
methods for cost analysis, explaining their basic methodologies and application to 
public health facilities, their strengths and weaknesses in explaining cost behaviour, and 
practical issues such as their data requirements and ease of use. In particular, how the 
methods distinguish between the different ~omponents of cost described earlier (price, 
resource use and health service use) is examined. The empirical findings of these studies 
are discussed in Chapter 4. 
3.2 Accounting methods 
3.2.1 Introduction 
The aim of this section is to review 'accounting' methods of analysis that have been 
used for identifying causes of inter-setting cost variation. These methods cover a broad 
range of indicators for evaluating the performance of health care providers. They have 
been called by different names in the literature, including 'ratios' (Sherman 1984), 
'performance indicators' (Lasso 1986, Birch and Maynard 1986) and 'performance 
assessment framework' (Leggat et al 1998). The use of accounting methods varies 
according to the purpose of the analysis. On the one hand, Sherman describes ratio 
analysis as "the use of various ratios for a group of comparable hospitals to locate 
relationships that are abnormally high or low, such as cost per patient day, cost per 
patient, and personnel full-time equivalents per patient" (Sherman 1984, page 924). On 
the other hand, the Canadian Council on Health Services Accreditation define a 
performance indicator more specifically as "a measurement tool, screen or flag that is 
used to monitor, evaluate and improve the quality of client care, clinical support 
services and organisational functions that affect client outcomes" (CCHSA 1996, page 
76). The lack of comprehensive model to date is not surprising given differences in aims 
and nature of health provider organisations and researchers (Leggat et alI998). 
18 Cost studies were searched using Medline, Popline, and Bids databases for all years available. Studies 
were retrieved that explicitly stated in their abstract that different aspects of cost profile were presented or 
some form of cost analysis was done to understand the determinants and behaviour of costs. 
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This thesis leans towards the Sherman (1984) definition, as it deals mainly with 
explaining variations in cost per service or cost per patient. Accounting methods 
reviewed below include the use of cross-setting data substitution"resource and cost 
profile analysis, efficiency analysis, scatter plots, and output profiles. The main 
characteristics are summarised in Table 3.1 in the concluding section. Financial 
indicators are not reviewed because they are of limited use in public health facilities 
(Leggat et al 199819), especially in developing countries where many resources are 
donated. 
3.2.2 Cross-setting data SUbstitution 
The rationale behind data substitution is that differences between settings can be 
examined one at a time, and impact on costs and cost differences found. It uses the 
technique of sensitivity analysis, except that the ranges tested reflect the likely values 
from other settings as opposed to the range of uncertainty in the setting of the study. 
Differences in price, resource use or"health service can be examined one at a time or in 
combination. For example, the impact of price differences between two countries on 
unit cost can be examined by substituting the prices of one country in the calculations of 
the other (Butler 1995). The same technique can be applied to other types of data, such 
as resource use per visit. For example, staffing ratios from one health facility can be 
applied in another facility to see whether average costs converge. Data substitution is a 
simple technique, and has minimal data requirements, but is a potentially powerful way 
of identifying major causes of cost differences between settings. 
While data substitution can indicate the main sources of variability, it is not entirely 
reliable in understanding causes of difference between settings. Butler (1995) points out 
that the weakness of substituting data is that it is a static framework, and "does not take 
into account dynamic interactions that may occur as a result of the given substitution. 
For example, when the relative prices of resources vary between countries, simple 
substitution does not take into account input substitution that may occur to maintain 
economic efficiency. This concern challenges the usefulness of cross-country data 
transfers, as relative prices are likely to vary between any two countries due to the 
different import prices they face (Robertson et al 1991). 
19 Such as cash flow to total debt, long term debts to fixed assets, profit margin, asset turnover, etc, 
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A second weakness concerns the fact that resources are defined differently in different 
settings or countries. The calculation of relative prices depends on which resource 
categories are chosen to represent the price level of a country, unless a weighted average 
is used. For example, for comparing the relative prices of equipment ~nd staff, which 
type of staff is chosen to reflect salary levels depends on the relative importance of 
different staff categories in health care in the country of interest. A third potential 
weakness of the data substitution approach is that it requires adequate disaggregation of 
prices, resource use and health serviceiIse quantities to make the comparisons and allow 
costs to be recalculated. 
3.2.3 Resource and cost profiles 
Profiles essentially consist of different ways of tabulating data to gain further insight 
into the composition of cost. Profiles are recognised by W.H.O. as an important means 
for programme managers "to understand where the burden of cost falls, shifts in the 
burden of cost over time, and variations in cost between settings" (W.H.O. 1979, page 
21). Profiles provide ways of presenting data that help the analyst understand cost 
composition, and thus helps to identify causes of .cost variation. They are easy to 
interpret if the data are of good quality and disaggregated. Profiles can be in both 
monetary and non-monetary forms. The former has the advantage that resource use is 
compared in identical units in both aggregated and dis aggregated forms. However, 
physical quantities also have their uses, for both planning and generalisability purposes. 
For example, managers may wish to kD.ow the requirement for certain resources or types 
of health service which are in a fixed supply in the short-run. For generalisability 
purposes, the costs of a health care intervention can be built from physical ingredients 
(resource use and health service use) and then applying local prices in the country where 
primary data are required, as opposed to transferring dollar costs across international 
boundaries. However, note that there may be qualitative as well as quantitative 
differences between resources and health services, thus reducing the generalis ability of 
physical quantities across health care settings. 
The W.H.O. guidelines for cost-effectiveness analysis of vector control (Phillips et al 
1993) recommended presenting the following cost profiles to help health service 
planning, although these are also essential for making cost predictions: 
1. Recurrent cost and capital costs, by resource type (cost 'ingredients'). 
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2. Marginal cost and non-marginal (sunk or fixed) costs. 
3. Foreign exchange cost and local currency cost. 
4. Current cost and future cost. 
5. Health care and non-health care (management and overhead, training) activities. 
In addition to these five, if a health care programme involves several types of care, the 
location (fixed clinic, mobile clinic) and type of care (inpatient, outpatient, etc) can be 
provided separately. These profiles are co~binable in different forms to provide further 
information for planning and cost prediction purposes. For example, the relationship 
between unit cost and health facility size can be suggested by looking at the proportion 
of overhead cost in unit cost: if large health facilities have lower % overhead cost, 
economies of scale may exist. 
To understand cost variation between settings or over time, a range of profiles will need 
to be presented, according to the objectives of the health planner, the nature of the 
health care intervention, and the data available. The lack of routinely available data can 
present problems. In many settings in developing countries, for example, capital cost 
data for items more than a few years old and foreign exchange cost data are not easily 
available. A weakness of 2-way tabulations in explaining costs is that other factors 
causing cost differences between setting may not be taken into account, leading to 
biased estimates of variation. A point raised in Chapter 2 was that higher unit costs may 
have been due to case-mix differences instead of efficiency differences. This could have 
been due to one or a combination of a more intensive use of staff, drugs or materials, 
and equipment. Therefore, the potential effect of these other factors must be identified 
to allow appropriate conclusions (sections 3.2.6 and 3.3.2 discuss in more detail how 
output differences can be examined). 
3.2.4 Efficiency scores 
Efficiency scores essentially compare input(s) with output(s), and thus identify whether 
slack exists, or is likely to exist. Like cost profiles, efficiency scores can also be 
measured in both monetary and non-monetary (natural) units. In monetary units, the 
waste due to inefficiency is identified in money value, and total size calculated, giving a 
measure of absolute and proportional wastage (Zuckerman et al1994). The main focus 
in the health care literature is on staff inefficiency, where unproductive staff time is 
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estimated, converted to money units using salary rates, and compared with the budget or 
operating costs of a health facility or the total wage bill. For example, Lewis et al (1996) 
found that the operating budget in one hospital in the Dominican Republic was 50% 
higher than the actual costs of service delivery due to "waste, down time or other extra-
hospital activities ... suggesting a high degree of inefficiency as well as low staff 
productivity" (Lewis et al1996, page 228). 
Zuckerman et al (1994) developed the c<:mcept of 'minimum feasible co sf (MFC), 
where input wastage or inefficiency is identified and subtracted from the total cost. 
Their measure of inefficiency (n was: I = TCMFc I TCA where a value of 1 indicates 
economic efficiency. TCA is the total cost incurred by the health facility in normal 
operations. TCMFC is the cost when the maximum productivity is obtained from all 
-
inputs, and inputs are employed in their cost-minimising combinations. They identified 
wastage of staff time by interviewing the heads of departments about the amount of 
underemployment that exist~d, and whether lower skilled staff could substitute for 
higher skilled staff. Also, materials and drugs that had gone missing were estimated by 
interviewing storeroom staff. However, to collect these data requires intensive study, 
and suffers from the drawback that the supplier of information is often the one being 
evaluated for efficiency, creating incentives to withhold information. 
Many types of inefficiency have been found and quantified in the literature, although the 
MFC has not been calculated in many studies. For example, in a study of sexually-
transmitted disease treatment in Malawi, Dalyet al (1998) estimated the cost of drugs 
used ineffectively or at the wrong dosage, and found that they accounted for over 50% 
of total drug cost. 'Time-without-specific-activiti, which suggests unproductive time, 
has been used in several studies (e.g. Lewis et al1991, Bryant and Escomba 1995, Mills 
1989). However, in none of these studies was the value loss explicitly quantified in 
money units, nor the likely impact on unit cost identified. Most studies examined one 
resource at a time, as opposed to several resources simultaneously. Also, except through 
direct observation (Bryant and Essomba 1995) there limited alternative means of 
measuring the level of wastage using retrospective recall, especially from staff who are 
partly responsible for the wastage, or when researcher observation changes the way 
providers operate (the 'hawthorne' effect). 
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There are also several types of non-monetary efficiency measure, in the form of ratios, 
which allows cross-setting comparisons. The most commonly used "are input/output 
ratios - such as staff per outpatient visits, staff per bed day, staff minlltes per patient. 
Staff time is measurable in terms of the full-time equivalent (FfE), and has the 
advantage that FIEs can be ·compared across currency boundaries without having to 
make interpretations based on the currency exchange method. However, this leads to 
problems when different types of staff are ~ombined in the FIE measure. One example 
. .. 
of staff per patient ratios was Fryatt et al (1996), who tabulated the number of staff per 
100 treated tuberculosis cases in Nepal, and also numbers of suspected tuberculosis 
cases screened per staff. Although they did not compare these ratios with unit costs, they 
did show large variation in ratios between programmes operating in different districts. 
Another non-monetary efficiency .measure is the rate of capacity use, such as 
occupanclo. If a health facility has a considerably lower occupancy than others, this is 
likely to cause unit cost differences (Berman 1994, Robertson et al1984, Robertson et al 
1992). The average length of stay (ALOS) is also an important indicator of the 
efficiency level of a health facility, although ALOS should be compared for similar 
case-mixes for the comparisons to be meaningful. The Data for Decision Making project 
(DDM 1997) used occupancy rate, average length of stall and bed turnover rate22 to 
explain differences in average costs between hospitals in Egypt. The correct 
interpretation of these measures has gained some attention in the literature. For example, 
Lasso (1986) developed an analytic method for evaluating hospital performance through 
simultaneous application of these indicators, by plotting them on a graph in order to 
make conclusions about the comparative performance of groups of hospitals. In 
isolation these measures provide useful information, but their explanatory power is 
increased when they are used togethe~3. 
20 Bed Occupancy = (Total inpatient days used) + (Total inpatient days available) 
21 Average Length of Stay = (Total inpatient days used) + (Total admissions) 
22 Bed Turnover Rate = (Number of admissions) + (Number of beds) 
23 Lasso (1986) plotted bed occupancy on the X axis and turnover rate on the Y axis; average length of 
stay can be shown by drawing a straight line out from the origin to the point plotted for bed occupancy 
against turnover rate. Each graph is the divided into four sectors, the borders of which are defined by the 
average bed occupancy and turnover rate, and the hospitals are judged according to the general features of 
each sector (see text). 
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A further method for examining the impact of differences in capacity use on unit costs is 
to recalculate unit costs based on the assumption that a provider is operating at the 
optimal bed occupancy (quoted at 80% by Luce et al 1996), and compare it with actual 
unit cost. Once this influence on average cost has been shown, the. true impact of 
remaining cost determinants such as X-inefficiency can be identified. In outpatient 
services, this method requires an estimate of the potential throughput of outpatients, as 
no traditional measure of potential output, such as bed availability, has been used. 
3.2.5 2-way relationships 
Diagrams such as scatter plots and bivariate analysis (2-way correlations) are useful for 
showing 2-way tabulations of variables that may be related to each other. A much tested 
relationship in the literature is that between average cost and health facility size, to see 
whether economies of scale exist, usually done by visual inspection but also the Pearson 
correlation coefficient can be calculated to identify whether the correlation between 
average cost and size is statistically· significant. For example, Robertson et al (1992) 
plotted average cost against vaccinations per session at 20 sample sites in The Gambia, 
and concluded that average costs is inversely related to the vaccinations per session and 
also to the vaccinations per year. Also, Jian et al (1998) found a steady fall in average 
cost with increased output, suggesting that the number of accessible children was a more 
important determinant of programme cost differences than other factors. They 
concluded that provinces with higher output had the lowest average costs per 
vaccination, due mainly to economies of scale. 
However, there are potential problems with making conclusions from these scatter plots. 
The first problem concerns the "regression fallacy" when making conclusions about 
economies of scale. This was recognised by Friedman: "insofar as size itself is measured 
by actual output, or an index related to it, a much more serious bias is introduced, 
tending toward an apparent decline in costs as size increases" (Friedman 1955, page 
236)". Therefore, if actual inpatient days are used instead of number of bed days 
available, there may be a misleading indication of the existence of economies of scale. 
However, the best means of testing for economies of scale, that of observing the impact 
of equi-proportional increase in inputs on output, can rarely be observed within a single 
health facility. The next best is to compare carrying capacity across health facilities, and 
tabulate with average cost. This raises the second concern with 2-way comparisons: that 
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they fail to account for other confounding (or multiple) factors. If the health facilities are 
not homogeneous in all other ways, then the link between average cost and size is not a 
certain one. For example, bigger hospitals tend to have more services available, or may 
be a teaching hospital, thus bringing confounding variables into the, equation. This 
requires multiple variable analysis, which is best dealt with in regression analysis. 
3.2.6 Output profiles 
It has already been suggested in Chapter 2 and in the previous sections that output 
heterogeneity may 'confound' simple cost· analyses, thus reducing the strength of 
conclusions possible from 2-way comparisons described above. Tatchell (1983) argued 
that hospital output measurement has rarely been tackled directly in explaining cost 
differences, although there have been considerable developments since the time of the 
article. 'Output' has both a demand and supply side. The demand side concerns the 
illness or severity of the patient ('case-mix), while the supply side concerns the quality 
of care or the range of services provided (often termed 'scope'). 
Differences in case-mix as a cause of cost variation have been examined in many 
studies, and are important because they can cause both unit costs and case costs to vary 
between patients or settings. The source of the variation in unit costs may be both 
resource use and prices (for example, more severe case-mixes may require more 
specialised equipment or staft), while health service use differences may also contribute 
to higher case costs in more severe cases. Considerable attention has gone into 
classifying case-mix using the International Classification of Disease (lCD), Diagnostic 
Related Groups (DRG), information theory, case severity and specialty mix measures 
(these were reviewed in Tatchell 1983). For example, Evans (1971) uses ten case-mix 
factors and six age-sex factors to compare average costs between 185 acute care 
hospitals in Ontario, and concludes that it is important to classify patients by case-mix 
to make a meaningful analysis of average costs. The ability of the measures identified by 
Tatchell to explain unit cost difference varies. Some measures classify disease by area of 
the body, and are not specifically linked to resource input requirements. On the other 
hand, the DRG classification system was developed specifically to classify patients in 
homogeneous categories of clinical management, therefore approximating resource use. 
However, because hospitals manage patients differently, and treat different case-mixes, 
DRGs may not provide a sound basis on which to represent costs. An alternative 
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approach is that unit costs can be tabulated for patien~s with different key events, such 
as an operation or a morbid event, and therefore identify the main cost determinants, as 
done by Butler et al (1995) for cancer patients. ~ 
On the supply side, methods for measuring quality of care are less well developed, 
although higher quality care also potentially affects costs through different prices, 
resource use and health service use. Methods for measuring quality of care also suffer 
from definitional problems. Quality has been defined as both a process and as an 
.. ~ . 
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outcome indicator. Process indicators can be structural, defined by what resources and 
health care are available (Gilson 1992). For example, Lewis et al (1991) and Broomberg 
(1997) both gave quality scores based on the sufficiency of time devoted to patients and 
to supervision of residents, as well as availability of capital items required for minimum 
standard health care. Robertson et al (1991) used a variety of quality indicators, 
identifying health facility structure, ~ost profiles and health care processes, and using a 
questionnaire to health care personnel to determine the existence of standards or norms 
of medical practice, knowledge of these standards, and adherence to them. Structural 
quality also measures the facility mix, which is used to identify whether or not 
economies of scope exist. Tatchell (1986) distinguished between 'facilities and services 
offered' (used in Carr and Feldstein 1967) and 'services actually performed' (used in 
Watts and Klastorin 1980). 
3.2.7 Conclusions 
The methods described above have been used to examine many aspects of cost 
behaviour, and they cover all three components of case cost, namely prices, resource use 
and health service use. However, it was rare in the studies reviewed to draw the link 
between cost determinants and actual unit costs; that is, there were no statements such 
as "the cost determinant 'X' explained Y% in cost variation". However, this is more 
likely to be due to inadequacy in the methods as opposed to inadequacy in the 
application of the methods, as Sherman points out: " ... as each ratio is by nature limited 
to one input and one output, it cannot easily accommodate situations where multiple 
outputs are produced using multiple inputs ... higher costs per patient day could be due to 
the case~mix, higher prices, or higher intensity of resource use" (Sherman 1984, page 
924). Therefore the interplay of cost determinants suggested above means that cost 
determinants can rarely be identified as having a constant percentage impact on cost. 
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Leggat et al (1998) also warned that these methods are only as strong as the data 
underlying them, and therefore results must be interpreted with this in mind. The 
methods are summarised in Table 3.1, in terms of what each method can explain, the 
data required, and the limitations of the method in explaining costs. Despite the fact that 
accounting methods of cost analysis are generally static, they do allow detailed 
examination of some cost determinants (and cost components). This allows early 
conclusions concerning which cost components are dnving the cost variations observed, 
and thus these components can be examin,ed in greater detail. The importance of this 
analysis becomes greater when statistical analyses are not performed to allow additional 
interpretations of cost differences. 
The results of this section on accounting methods suggest that, while each method can 
be informative, a fuller picture is built of cost behaviour by comparing and contrasting 
the results of more than one method simultaneously (such as the 'Lasso' method 
described above). There has been limited work in this area, especially for outpatient 
care, and further testing and refinement is needed, especially as the use of regression 
analysis cannot be relied upon given its' data requirements (see next section). As well as 
data deficiencies, methods for tabulating output measures with costs were shown to 
suffer from definitional uncertainties and stringent data requirements. Despite these 
deficiencies, ratio analysis is a commonly performed technique for analysing cost data, 
and allows preliminary conclusions about the causes of unit cost variation, before 
investing further time in statistical analyses. 
'~ 
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Table 3.1: Summary of methods, uses, data requirements and limitations of accounting methods of cost analysis 
Method (with examples of applications) What can be explained Data reauirements Limitations of methods 
Cross-setting Prices Extent to which price difference Price and resource quantity data Doesn't allow for input substitution; requires I 
data causes cost relevant difference in all settings disaggregated data; requires choice of inputs I 
substitution Staff ratios Extent to which staffing pattern Staffing ratios, 'staff costs, % Training and roles of staff may differ between 
difference causes cost difference direct costs country 
CostprorIles Cost ingredients Which resources are driving cost Data on cost of all inputs Requires detailed data often not available, 
differences method should not be used in isolation 
Recurrent/capital Budget implications of change in Separate recording of capital Requires detailed data often not available, 
health care provision costs method should not be used in isolation 
Local/ international currency Importance of imports in cost; Separate recording of imported Requires detailed data often not available, 
impact of OER fluctuations costs method should not be used in isolation 
Health care / non-health care Economies of scale Direct and 'allocated' costs Requires detailed data, method should not be 
used in isolation; not definitive proof of EOS 
Primary / secondary; inpatient Optimal budget allocation between Breakdown of cost by location Requires detailed data often not available, 
/ outpatient and within health facilities method should not be used in isolation 
Resource Minutes per patient Quality of care and staff use Contact time with patient Requires detailed data collection 
prorIles Drugs per patient Drug availability and usage Prescription patterns Requires detailed data collection i 
Efficiency Minimum feasible cost Costs that could be saved by Wasted resource quantity, prices Requires detailed data collection 
scores improving efficiency of resources 
Occupancy Impact of throughput on unit cost % ward or clinic occupancy How to define and measure 'occupancy' 
Time-without-specific activity Proportion of time unaccounted for Time diaries and resource prices Requires detailed data collection 
Staff ratios Quality of care, staff use efficiency Staff and patient numbers Does not prove (in)efficiency in isolation 
Equipment ratios Quality of care, eq. use efficiency Equipment and patient numbers Does not prove (in)efficiency in isolation 
Average length of stay Quality of care, cause of occupancy Number of days per patient Does not prove (in)efficiency in isolation 
Unit cost at 100% capacity use How much unit costs change with Marginal cost, throughput Maximum t'put levels in OPD more difficult to 
throughput levels, maximum throughput define; 100% capacity may not be optimal 
2-way Scatter plot or bar charts Economies of scale, teaching status, Unit costs and potential output, Not definitive proof of EOS . or other factors; 
relationships case-mix unit costs by case-mix requires large data sets 
Output Case-mix Causes of unit /case cost variation Diagnoses/treatment of patients Definitional and measurement problems 
prorIles Quality of care Causes of unit cost variation, health Structural/perceived quality, Definitional and measurement problems and 
outcomes, health service utilisation health care content, outcomes impact of confounding variables 
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3.3 Statistical methods 
Two principal types of technique are reviewed in this section, namely econometric 
techniques and data envelopment analysis; These represent two important statistical 
techniques used in the literature for examining hospital production and cost relations. 
3.3.1 Regression analysis 
Introduction 
Econometrics, the application of regression 'analysis to economics, has long been used to 
estimate hospital cost and production relationships (Sherman 1984). In the context of 
cost analysis, the purpose of regression analysis is two-fold 
1. To understand the causes of variation in cost by relating them explanatory variables. 
2. To use the results of 1. to make predictions of what values the variable of interest 
may take in other settings. 
Econometric models are used because they can provide a better explanation than ratio 
analysis of how average and total costs change in response to differences in service mix, 
inputs, input prices and scales of operation, among others (Barnum and Kutzin 1993). 
Only statistical techniques can separate the effects of simultaneous variations on cost, 
and interactive effects of variables, such as quality, length of stay and occupancy rates 
(Deeble, 1979). 
In conducting regression analysis, several aspects of the regression need to be decided, 
namely the variable of interest (dependent variable), the variables hypothesised to 
influence or determine the variable of interest (independent variables), the model 
relating these, and the data sources. In building and interpreting the model, several 
guiding principles recommended by econometricians should be noted (McCloskey and 
Zilliak 1996, Gujarati 1999): (1) keep the model simple (i.e. 'parsimoniom') to capture 
the most important features of reality; (2) describe and justify the range of independent 
variables and the units of measurement; (3) transform the data to meet the distributional 
assumptions of the model; (4) aim for reasonable goodness-of-fit of the model; (5) 
compare. the signs and sizes of estimated coefficients with those expected from 
economic theory; (6) meet the conditions for best-linear unbiased estimators (BLUE). 
Important aspects of model building and interpretation are covered in tum below. 
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Choice of dependent variable 
Three main types of cost have been analysed in the econometrics literature within the 
health sector (refer to Appendix 1 Tables 1.1 to 1.3). These are total co~t (usually for a 
hospital or hospital department), average cost (per visit, per day), case cost (per event, 
per admission)24. The bulk of the early literature focussed on average and total costs, 
with increasing interest recently in case cost. The dependent variable chosen depends on 
which relationships are being examined, as.~ell as the sample size. For example, if the 
hospital is the unit of analysis, and sample size is greater than about 30, average or total 
costs should be the dependent variable. If the impact of multiple patient factors is also of 
interest, then case cost can be the dependent variable instead. The advantage of having 
case costs or total costs as the dependent variable is that it incorporates all three cost 
components: prices, resource use and health service use. Average cost, on the other 
hand, does not include health service use within it. A further advantage of having case 
costs as the dependent variable is that the influence of patient characteristics on cost can 
be evaluated at the individual level as opposed to the aggregate (or average) level. 
Choice of independent variables 
The first criterion for selecting independent variables is the hypothesis that they are 
related to the dependent variable. The model specification must be consistent with 
economic theory to give meaningful results. Cowing et al (1983) argue that the lack of a 
theoretically consistent framework in earlier studies of hospital cost meant that 
erroneous interpretations were made about the existence of cost relationships. Various 
categories of independent variables have been quoted as important to include In 
regression equations to avoid mis-specification, including (Cowing et al, 1983): 
1. V ariable( s) to represent the multi pIe-output dimension of hospital care. 
2. Price variable(s) when prices vary. 
3. A variable to represent whether a physician admits patients to hospital (this reflects 
the concern of supplier-induced demand in some countries). 
4. Variable(s) to represent economies of scale and scope. 
24 In addition to monetary cost being the dependent variable, health service use has also been evaluated, 
such as the determinants of length of stay. For example, Elliot (1997) examined variation in the length of 
stay following nosocomial infection, and Khoshnood (1996) the length of stay in neonatal intensive care 
units. 
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5. Variable(s) to represent differences in incentives between the public and private 
hospitals. 
Subsequently, the regression literature has focussed on teaching status, hospital, 
ownership, case-mix, and size (see Appendix 1 Tables 1.1 to 1.3 for details). Other cost 
determinants examined have been staff mix, health care quality, inflation, and 
economies of scope. The ability to include resource use variables is limited by the 
problem of heterogeneity within resource, categories ~ for example, the number of 
equipment cannot be summarised in a single index due to the variety of items within any 
health facility. This is similar for other resources, such as drugs, staff and materials. For 
resource prices, on the other hand, an index can be put together that summarises price 
differences between health facilities (cross-section or time-series). The important 
variables to include vary according to the context of the study. 
Functional fonn 
The next important aspect of model specification is the functional form. Alternatives 
include ordinary least squares, 10gitJprobit, or a survival model such as the Cox model. 
The model chosen depends on the nature of the dependent and independent variables, 
the distributions, and expected relationships. Final models are built by retaining in the 
model the statistically significant variables, and may also include non-significant 
variables that are considered important for the appropriate specification of the model. 
Alternatively, the exclusion of variables may be controlled by the software package 
using step-wise regression, although this method gives the analyst less control over 
which variables are retained or excluded. The final model is tested for heteroskedasticity 
(unequal variance for different values of dependent variable), omitted variable bias, and 
multicollinearity (correlation between independent variables) using standard statistical 
tests such as the F test and scatter plots. Also, in cluster randomisation design, if the 
variance of the different clusters are very different, the regression model must take this 
into account, otherwise standard errors are underestimated. In some cases, a 
transformation of the data is justified. For example, skewed cost data justifies a log or 
log log transformation in order to meet the distributional assumptions of the model 
(Coyle 1999). Also, the relationship between dependent and independent variables may 
not be linear, and square, square root, inverse, cubic or log terms may be added. This 
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can be examined in advance by fitting a curve, and observing whether the terms 
significantly improve on the linear fit. 
Interpretation of results 
The parameter estimates from the regression model need careful interpretation. 
1. The intercept term. The coefficient of the intercept term gives the expected cost for 
someone who has the benchmark value ('0') for all variables. In the log cost model, 
it is also used for calculating the change in cost when one of the significant 
.' . 
parameters changes value (see below). 
2. The coefficients. These are the deterministic components of the regression equation, 
and are known as 'partial slope coefficients', as they indicate the impact on the 
dependent variable of a change in the independent variable, holding all other 
independent variables constant. They are the estimators of the "true" (population) 
coefficients. Given the assumptions of the classical multiple regression model, the 
OLS estimators are unbiased and have minimum variance (BLUE property). Their 
sign, size and precision with which they are estimated are all important for judging 
whether their covariates should remain in the equation. When costs are log 
transformed, the coefficients (B) represent percentage effects on cost, which have 
generalisable uses in predicting costs. 
3. Standard errors. These are used to establish confidence intervals for the true 
parameter values. However, care should be taken in interpreting standard errors and 
statistical tests. 
4. The error term. The error term from the equation is an estimator of the population 
error term. As the relationship in the equation is not deterministic, some variable in 
the equation must account for this. The error term captures measurement error as 
well as specification error. When the error term is not homoskedastic (equal 
variance) or not normally distributed, other functional forms, such as Maximum 
Likelihood Estimator are used. 
5. R2. This is called the 'coefficient of determination' or 'goodness of fit'. In regression 
analysis, it is called the 'coefficient of multiple correlation'. It equals the regression 
sum of squares over the total sum of squares. Therefore 1- R2 represents the 
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unexplained variation in the dependent variable. The adjusted R2 (R2'Ys should be 
used when comparing different models (with different numbers of independent 
variables). This is because R21\ removes the impact of degrees of freedom and gives a 
quantity that is more comparable than R2 over models involving di~ferent numbers 
of parameters. Unlike R2, R21\ need not always increase as variables are added to the 
model, and tends to stabilise around an upper limit as variables are added (Rawlings 
1988). However, the F test is considered to be a better test of the model's strength 
than R2, because it has a distribution, aS,opposed to R2 which is an index. 
3.3.2 Data envelopment analysis 
Introduction 
Data envelopment analysis (DEA) is a mathematical programming technique, developed 
by Charnes et al (1978), following initial development by Farrel (1957). Therefore, it is 
a more recently developed and tested concept than regression analysis. Although a 
comprehensive literature review and discussion of issues was carried out by Broomberg 
(1997), the main elements are discussed here. 
DEA combines a set of multiple input and output measurements in a non-arbitrary and 
non-subjective fashion to estimate technical efficiency. It 'envelops' the data with a 
non-parametric26 production frontier, using the Pareto Efficiency criterion. In terms of 
the input criterion, a 'production unit,27 is efficient if it is not possible to decrease any 
input without an increase in any other input and without a decrease in any output. In 
terms of the output criterion, a production unit is efficient if it is not possible to decrease 
any output without a decrease in any other output and without an increase in any input 
(Broomberg 1997). Therefore, DEA not only simultaneously accommodates multiple 
outputs and inputs, but it also identi~es actual or potential inefficiencies in a manner 
more consistent with economic theory than econometric regression techniques (Sherman 
1994). Earlier studies focussed on inputs in terms of physical quantities (and thus 
2S Adjusted R2 = 1 - (1- R2)(n-lIn-k). Adjusted R2 will increase with the addition of further variables so 
long as the t value of those variables is greater than 1. 
26 This means that it does not presuppose the functional form of the technology. 
27 The basic unit of analysis in DEA is the 'production unit' and can be an-entire hospital or health care 
agency, or sub-units ofthese, such as a ward or outpatient department. 
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technical efficiency); however, later studies have included costs as independent 
variables, thus giving a measure of economic efficiency. 
The technical efficiency score 
DEA evaluates the technical efficiency of a 'production unit' relative to other 
production units in a given sample by calculating a relative technical efficiency (TE) 
score for each production unit. The most efficient production unites) are given a TE 
score of 1.0, which corresponds to the assumed production possibility frontier (pPF). 
I • • • 
Thus the proportion of providers operatirig on the production possibility frontier can be 
estimated. The TE score is defined as the ratio of the total weighted production units' 
output to total weighted input. The computation of input weights is based on the 
maximisation of the TE for each production unit, subject to some constraints on the 
selection of weights. The technical efficiency of individual observation therefore is 
estimated to reflect the radial dist~ce from the directly estimated production frontier 
(Banker et al 1986). The data indicate the reduction in resource inputs possible for 
inefficient units (at constant output), or similarly the increase in outputs possible (at 
constant resource use), assuming the production technology can be changed (Broomberg 
1997). 
The choice of input(s) and output(s) depend on the health care setting and study 
question. For example, the importance of different resources depends on the type of 
health care being evaluated, whether it is labour- or capital-intensive. Appendix 1 Table 
1.4 shows that DEA studies use a variety of inputs and outputs. Studies have often 
concluded that the results depend on which functional form is chosen, and under what 
assumptions the model is run. For example, Broomberg (1997) tested seven output 
models and three input models to compare the efficiency of profit and non-profit 
hospitals in South Africa, and concluded that the sensitivity of the model to detect 
inefficiency was reduced when more variables were specified. Also, assuming constant 
returns to scale instead of increasing returns to scale tends to decrease the TE score of 
small producing units relative to large producing units. 
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Choice of model output(s) 
Health service use, such as outpatient visits and inpatient days, is the most commonly 
used type of output. Health status is rarely considered due to the stringent study design 
required to give robust results. Broomberg (1997) chose inpatient admissions instead of 
inpatient days as the output measure in his study, because he argued the former 
represent a true hospital output, and because production of long hospital stays should 
not, per se, be seen as a desirable result. However, DEA studies to date are not very 
advanced in measuring multiple outputs in ~omparing production units. 
The most advanced specification of hospital output found in the literature is in the study 
by Grosskopf and Valdamis (1987), who distinguished between inpatient days by type 
of treatment (acute or intensive care), surgical cases, emergency room visits and 
outpatient visits. A later study by Grosskopf and Valdamis (1993) accounted for varying 
case-mix by adjusting each hospital's outputs by the hospital's corresponding case-mix 
index, which inflated or deflated the value of the outputs produced. Other studies have 
taken a much simpler approach to the specification of output. For example, Bates et al 
(1998) compared General Practitioner practices according to the number of patients 
treated under and over 65 years old. Other authors avoided the case-mix problem by 
only including in their data sets homogeneous groups of patient (Nunamaker 1983). 
Choice of model input(s) 
Appendix 1 Table 1.4 shows that a variety of inputs have been used in published 
studies, including different types of staff full-time equivalent (FTE), capital (represented 
by building size or numbers of beds), measures of cost (supply cost, staff cost, capital 
cost). Authors rarely state why they include some inputs but exclude others. 
Model specification 
The DEA model also requires that an assumption should be made about whether 
economies of scale exist or not. Some studies compared results under the assumptions 
of both constant and variable returns to scale. For example, Kooreman (1994) found that 
when size was not included in the input measure (Le. assuming constant returns to scale) 
the proportion of efficient homes went from 20.5% to 50.0%. Broomberg (1997) also 
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found that the results were sensitive to this assumption (larger hospitals benefit when 
variable returns to scale assumed). 
Other specification problems discussed in the literature include the distinction between 
inputs and outputs. For example, should quality of care and numbers of services 
(economies of scope) be included as an input or as an output? Broomberg (1997) 
included a quality of care measure as an output, and' found that it changes the relative 
efficiency of some production units. A further criticism of DEA is that it assumes a 
." . 
causal relationship between inputs and outputs, but does not assess the extent or nature 
of that causality. For example, use of inpatient days instead of inpatient admissions 
benefits hospitals with a longer length of stay, whether it is beneficial or not. Finally, the 
production possibility frontier is defined by the most efficient provider(s) in the sample; 
however, they may themselves be technically inefficient. In conclusion, correct 
interpretation is an important element of conducting a DEA. 
3.4 Comparison of methods and conclusions 
This chapter has discussed the strengths and weaknesses of a number of different 
indicators and methods for examining the causes of cost variation. These are now 
contrasted briefly in the light of their advantages and disadvantages. 
The general features of accounting and statistical methods have already been presented. 
They have both been shown to include, or be capable of including, the three cost 
components of price, resource use and health service use. However, the way these are 
analysed varied between methods. Barnum and Kutzin (1993) made a useful distinction 
between them: accounting methods can be applied usefully to a single hospital, 
involving a labour-intensive, detailed examination of hospital accounts, staffing patterns 
and admissions, while statistical methods require observations of costs and service use 
for many hospitals. 
So what are the underlying assumptions in these 'complementary' methods? Accounting 
studies, on the one hand, have an implicit underlying cost function represented by the 
sum of the products of the quantity of each input, multiplied by the respective price. 
This makes it rigid, and does not allow management or technical responses to changes 
71 
in input prices or quantities, and is therefore linear (marginal costs constant). Figure 3.1 
illustrates that accounting studies generate a point estimate of total costs at the observed 
output (point A), but does not say much about what is likely to happen with changes in 
the price or quantity of an input. 
Figure 3.1: Comparison of accounting and statistical cost functions 
Cost 
, Accounting cost function 
~ Actual (statistical) cost function 
Output 
(source: Barnum and Kutzin 1993, page 115) 
Statistical (or econometric) models, on the other hand, provide a more realistic depiction 
of how total costs change in response to differences in service mix, inputs, input prices, 
and scale of operations. It therefore allows for substitution between inputs as their 
relative prices and marginal productivity change. Statistical techniques are more 
comprehensive than ratios because they accommodate multiple outputs and inputs, 
resulting in greater confidence in the determination of causes of unit cost variation. 
However, as already discussed, the strength of conclusions from all types of cost 
analysis depends on the quality and nature of data, and whether appropriate 
transformations and functional forms are used. In this way, statistical techniques are 
more complex to perform and therefore without great care in analysis and interpretation 
there is a high chance of making erroneous conclusions. 
A potentially important underlying weakness of regression analysis is the breakdown of 
its' implicit assumptions, such as profit-maximisation or cost-minimisation conditions, 
as described in Chapter 2. This is because the cost-output relationship is obscured, 
compared to what it would be under perfectly competitive conditions. This means that 
the source of financing of hospitals, and incentives to providers, may have important 
implications for how results can be interpreted. This has lead Lewin et al (1981) to 
conclude that insights· provided by econometric techniques to guide performance 
improvement have been much more difficult in public sector organisations. 
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Appendix 1 Table 1.5 summarises characteristics of MRA and DEA approaches. DEA 
has the advantage of having few assumptions about the shape or form of the production 
and cost frontiers, as well as the distribution of the error terms. Therefore, 
heteroscedasticity and multicollinearity do not need to be identified or corrected for in 
DEA. Also, greater care is needed in MRA concerning the specification of the model: 
which variables to include and exclude, which variables have power terms, and whether 
values should be transformed into log values. DEA is a linear programming technique, 
.' . 
and does not have these problems. Both techniques are vulnerable to small number of 
observations, although DEA can be used for fewer cases. 
An advantage of DEA and some accounting measures is that they produce a single 
measure of efficiency, and can address efficiency issues directly instead of using average 
relationships. Consequently, DEA and accounting measures can pinpoint inefficient 
health care facilities from large samples, and indicate the extent of cost savings and 
efficiency gains from a shift to efficient production. As an aid to the interpretation of 
results from accounting techniques, simple statistical tests such as the Pearson 
correlation coefficient can be used to examine whether efficiency differences are 
strongly correlated with unit cost differences, while bearing in mind other possible 
causes of variation. 
DEA also has several weaknesses. First, it is neither prescriptive in what to do about 
inefficiencies, nor does it provide absolute measures of inefficiency. This is because the 
measure of inefficiency is based on the most efficient health facility in the group, which 
may itself be inefficient. DEA does not identify the efficient production function, but it 
only suggests where costs can be saved without reducing output (Sherman 1984). The 
same criticism could also be levelled at accounting studies, such as staffing ratios, 
where a choice must be made about what ratio is desirable, or efficient (high ratios, 
though, might indicate low quality of care). Also, DEA assumes causal relationships 
between inputs and outputs, whereas the relationships may be stochastic rather than 
deterministic. 
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In analysing large data sets of unit costs, it is important to know to what extent different 
methods produce different results. If statistical cost functions do not differ significantly 
from accounting functions, then little will be gained from more complex and time-
consuming analyses. Some studies have even compared MRA and DEA results on the 
same data set. For example, Banker et al (1986) compared their DEA results with data 
from a translog function, and found that only 48% of health centres were in agreement 
using the two methods (using a ranking of high, medium and low). A further 33% were 
in reasonable agreement, and 18% were in ,strong disagreement. Despite these apparent 
differences, the chi-squared test showed that the efficiency ratings were in broad 
agreement. Also, Huang and McLaughlin (1989) compared the results of DEA with the 
results of ratio and regression analyses, and found that the rankings of PHC programmes 
generally paralleled each other in all three techniques. Therefore, it is not entirely clear 
how consistent the conclusions are given by different cost analysis methods, and if 
different, why. 
In the empirical literature searched, there were few studies comparing techniques to 
make clear conclusions concerning whether they complement each other, or whether 
they instead provide contradictory results. While such a comparison is important, this 
chapter has also focussed on the differences in aims of the alternative cost analysis 
methods. The methods in many instances provide different angles on the same data, thus 
not necessarily leading to conflicting conclusions. In conclusion, if there are sufficient 
data and research time, it is beneficial to an understanding of the data to conduct several 
of these analyses, to build the most comprehensive view of cost behaviour. 
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4 CAUSES OF COST VARIATION 
4.1 Introduction 
The previous chapter, Chapter 3, reviewed methods for analysing costs for the purpose 
of understanding cost behaviour. The conclusion was drawn that a variety of methods 
can contribute to a more complete understanding of cost behaviour than if methods are 
undertaken in isolation, as on the whole they provide complementary viewpoints. The 
aim of this chapter is to summarise the finoings of empirical studies using the methods 
. '. 
reviewed, with a focus on the causes of cost variation identified in Chapter 2. This 
chapter draws on a wide body of cost analysis studies, identified using literature search 
strategies described in Chapter 3. The empirical findings from the literature review are 
presented in terms of what could be said about cost behaviour - what factors do and do 
not explain cost - to give an indication of the weight of evidence, and therefore which 
factors are likely to require further study in this thesis. 
Two approaches to cost analysis were found. One approach analyses costs at the micro 
level, where a health facility is studied in isolation, and the causes of cost variation 
examined in terms of which factors are most likely to influence or determine costs, such 
as throughput levels or staffing ratios. This approach uses accounting methods, as 
discussed in Chapter 3, and tends to focus on unit costs. The other approach analyses 
costs at the macro level, where groups of health facilities are compared, and causes of 
cost variation examined in terms of comparable indicators that are likely to explain 
these differences, such as economies of scale, case-mix, and input prices. This approach 
evaluates costs using both accounting and statistical methods (mainly the latter as 
documented in Appendix Tables 1.1 to 1.4), and can focus on unit, case or total costs as 
the dependent variable. Therefore this chapter identifies determinants of cost 
comprehensively by adopting the framework set out in the first chapter, taking into 
account causes of variation in health service use, resource use, and resource prices. In 
addition to these sources of cost variation, differences in costing methods, and the 
impact of uncertainty and measurement error are also examined. 
4 
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4.2 Health service use 
Health service use is an important determinant of total or aggregate cost, whether at the 
clinic, the ward, the hospital or the district level. Figure 1.1 in Chapter 1 showed 
calculations for costs at the individual patient level ('case cost') and at the hospital or 
programme level ('total cost'). The numbers of uses of health services are influenced by 
factors related to two actors·: the user of the health service (the 'patient') and the 
supplier of the health service (the 'provider'). Each are reviewed in tum. 
4.2.1 Patient factors 
There is a considerable literature that has examined empirically the causes of variation 
in health service use, as determined by patient factors28• A summary of those studies 
relating to the uptake for maternity services (both antenatal care and delivery) is 
presented in Table 4.1. A few factors have received most of the attention in the 
literature. These include the geographical accessibility of health services (mode of 
transport available and distance from health facility), the money cost of attending 
maternity services (money and time costs), socio-cultural factors (such as religious 
beliefs, permission from family members), and education status or general awareness of 
modem health services. Other factors studied include: whether the woman has had 
previous contact with health services; the existence of bad weather patterns that may 
make it impossible to travel (Voorhoeve et al1984); services are viewed with suspicion 
(Bamisaiye et al 1986); services are seen as upwardly mobile (Sargent 1985, Marshall 
1985); alternative health care such as traditional medicine is available; and local beliefs 
about medical care. Roos and Roos (1982) and Wennberg (1985) also found that 
intervention rates were highly dependent on socio-economic characteristics of the 
patient. While many studies examined a variety of factors preventing uptake for 
maternity services, no comprehensive checklist of these factors was found in the 
literature. 
In addition to studies focussing on one particular country or location, there are several 
review studies focussing on specific issues. For example, Thaddeus and Maine (1994) 
developed a conceptual framework for understanding why women who need care during 
pregnancy are delayed. Their "Three stages of delay model". model consisted of: 
28 Due to the relatively rich literature in health service use determinants for maternity care, only this 
literature is reviewed in this section. 
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1. Delay in deciding to seek care on the part of the individual, family, or both. This 
occurs for many of the reasons listed in Table 4.1, such as distance, cost, perceived 
quality of care, etc. / 
2. Delay in reaching an adequate health care facility. This occurs due mainly to poor 
road conditions, transport unavailability or cost. 
3. Delay in receiving adequate care at the facility. This occurs due to poor referral 
system, and shortage of supplies, equipment and trained personnel. This has 
important feedback on the stage 1 del~y. for whether the woman is likely to seek 
treatment in the future, if she or her friends received poor quality care in the past 
(see section 4.2.2). 
This is a useful model not only in explaining why women do not attend health services, 
in order to evaluate the cost differences between pregnant women, but it also informs 
policy makers and hospital managers. about the most urgent changes required to improve 
attendance rates. A second review study examined the determinants of compliance with 
iron supplementation (Galloway et alI994). Reasons for non-compliance were divided 
into three principal causes: 
1. Patient factors. These included the patient misunderstanding instructions, adverse 
side effects, frustration about the frequency and number of pills taken, fear of having 
big babies, personal problems, nausea, and lack of attendance at health facilities to 
have anaemia diagnosed. 
2. Service delivery factors. These included poor provider-use dynamics, lack of 
supplies, access, training and motivation of health care professionals (see next 
section). 
3. Programme support factors. These included a lack of commitment and financial 
support, either from higher levels of government or international support. 
These two studies are evidence that frameworks have been developed to study health 
service use, although they refer to specific health care interventions and thus cannot be 
applied without adaptation to any form of health service. In addition to the information 
on factors presented in Table 4.1, there are other factors that have received attention in 
the literature. A determinant of uptake rarely mentioned in the literature reviewed is the 
risk status and morbidity of women or their babies. For multigravidae, adverse outcomes 
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in previous pregnancies may also lead to greater numbers of visits as well as higher 
caesarean section rates (McCaw-Bins 1995). For example, previous CS is likely to 
require another CS; and previous spontaneous abortions may alert the provider to 
potential problems, thus causing more visits or inpatient stay. Also, bab.ies with certain 
characteristics, such as low birth weight, congenital malformation, low Apgar score, etc, 
are more likely to receive special attention, if the facilities are available (Samson 1991, 
Khoshnood et al 1996). However, diagnostic-related' groups have been shown to have 
limited relationship with cost, and thus are .not deemed to be highly accurate for budget 
setting purposes (Bostrom and Mitchell 1991, Voss et al1994, Khoshnood et alI996). 
In conclusion, a wide range of patient factors potentially responsible for uptake of 
maternity services have been found in the literature, and this review provides a useful 
starting point for the analysis in this thesis. However, the relevance of each factor is 
examined later in the context of the thesis, to allow focus on the most important factors. 
4.2.2 Provider factors 
There are also several factors related to the provider that influence uptake of services, 
some of which were mentioned earlier (Thaddeus and Maine 1994, Galloway et 1994). 
Also, some provider factors overlap with patient factors, such as geographical and 
financial accessibility. Less literature was found on provider factors that influence 
uptake of maternity health services compared to patient factors, especially in developing 
countries. Other factors that may influence a provider's incentive to treat or refer 
patients, such as the impact of financial incentives on practice, have received 
considerable attention, although the evidence for supplier-induced demand is mixed29• 
Physician discretion and the presence of uncertainty in clinical decision making have 
been cited as causes of wide small area variation found (Wennberg 1984). This has been 
called 'practice style' - the concept that it is the physicians set of beliefs about the 
efficacy of particular forms of care - although there no objective means of measuring it 
was found (Folland et al 1994). Wennberg and Fowler (1977) argued that practice style 
differences can be concluded when all other possible causes of small area variation are 
ruled out30• For example, both Postma et al (1993) and Rhodes et al (1997) found 
29 However, because the use of fees is limited in the study countries for this thesis, a review is not 
Eresented here. 
o These studies do not examine maternity care specifically, but their conclusions remain valid for it. 
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variations in average length of stay when an identical treatment was implemented in 
similar populations in several countries simultaneously. 
Another provider attribute, quality of care and its' impact on health service use, appears 
to have received limited attention until recently. However, few of the studies discussed 
in Chapter 3 on how to measure or represent 'quality' went as far as drawing 
quantitative links with health service use or cost (Gilson 1992, Pepperall 1995, 
Broomberg 1997). 
The compliance of the provider with current guidelines is a potentially important 
determinant of health service use of pregnant women. However, if women do not attend 
health services when they are supposed to, the causes should be distinguished: was it 
because women were not encouraged to attend, women could not attend, or another 
cause. Provider compliance with the~e guidelines depends on several factors, including 
their own education and training, the presence of equipment, trained staff and materials 
to carry out appropriate diagnostic tests, and the presence of monitoring procedures to 
make sure providers are compliant. However, due to differing medical viewpoints, risk 
assessment is subjective, and treatment and referral depends to a large degree on the risk 
aversity of the provider. 
4.3 Resource use 
The other component of case or total cost is unit cost, one component of which -
resource use - is examined in this section. Again, as in the case of health servie use, 
rarely do studies make statements about the significance (either statistical or economic) 
of the variations identified. Therefore, it is not clear to the reader whether the 
differences being investigated are important differences3l • 
This section is divided into seven sub-sections, based on the findings in Chapter 2 on 
potential causes of resource use variation, and uses the same literature as that identified 
in Chapter 3 but with a focus on empirical findings. 
31 First, differences may not be provable in a statistical sense; second, even if a difference is proved 
statistically, the money difference may not be large enough to lead to different decisions about the way 
health care is provided. 
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4.3.1 X-efficiency 
While a number of studies identified in the literature have shown evidence of inefficient 
use of resources, very few accounting studies have tested whether there exists an 
empirical link between inefficiency and unit cost (Le. are unit costs higher because of 
inefficiency? And if so, how much higher?). One study, Robertson et al (1991), did 
consider this link, and found that differences in the number of services provided per 
hour of work partly explained differences in unit costs between Ministry of Health and 
social security primary health care services in Ecuador. However, other studies that 
.' . 
identified inefficiency did not evaluate its' i~pact on u~it cost. For example, Dalyet al 
(1998) found that wasted drugs accounted for 54% of the total drug cost for STD 
treatment in Malawi, but no calculations were presented to show what unit cost would 
be if drugs had not been wasted. Similarly, Lewis et al (1991) found that only 12% of 
contracted physician time could be accounted for by patient-care activities, but the 
impact on unit costs was not examin~d, nor were they compared with unit costs of more 
'efficient' health facilities. Bryant and Essomba (1995) found that 73% of staff time was 
unproductive, but unit costs were not measured. There are many other such examples 
where authors have not provided adequate evidence for the link between efficiency and 
cost, including Mills et al (1989) in Malawi, Banta (1985) in China, Waddington et al 
(1989) in Africa, and Lewis et al (1996) in the Dominican Republic. 
As discussed in Chapter 3, DEA does not say anything about what the unit cost could be 
under absolute efficiency, although the technical efficiency score can be compared with 
unit costs across a sample of health facilities. For example, Valdmanis (1990) correlated 
the efficiency measures with costs per adjusted patient day using the partial Pearson 
coefficient, and found that the more technically efficient hospitals were more likely to 
have lower costs, ceteris paribus. Other DEA studies drew conclusions about the 
characteristics of production units most likely to have a high TE ratio. For example, 
Ozcan and Luke (1993) concluded that the population size served by the health facility 
determined efficiency, due to differences in occupancy rates. This raises a possible 
problem in the interpretation of DEA results: that the TE score may contain types of 
inefficiency that are not defined as 'X-inefficiency', such as low occupancy rates. 
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Regression studies, on the other hand, have rarely looked at the impact of X-efficiency 
on unit costs. This is largely because regression analysis is based on the assumption that 
production units are already operating on their production possibilityfrontier. However, 
differences in productivity have been suggested by studies that examine the impact of 
ownership on unit costs. The evidence from this literature is mixed, as unit costs have 
been found to be both higher 'and lower in public health facilities when compared with 
private for-profit (PFP) or private not-for-profit (PNFP) health facilities. For example, 
Beecham et al (1993) found that PFP and PNFP mental health care providers had lower 
.' . 
average costs than public providers, and Salavitabar (1982) found PFP had higher 
average costs than PNFP hospitals, and PNFP hospitals had higher average costs than 
public hospitals. On the other hand, Bays (1980), Pauly (1978) and Cowing and 
Holtman (1983) found that PFP hospitals had lower average costs than PNFP. In none 
-
of these studies was there adequate consideration of why unit costs differed, and whether 
it was due to different levels of X-ef~ciency, or for other reasons. 
4.3.2 Returns to the variable factor 
The impact of under-utilised health services has been quoted widely in the literature as 
having a significant impact on unit costs (for example, WHO 1979). However, while 
programme managers and researchers are ready to make these conclusions, empirical 
evidence is limited from the literature reviewed. For example, Berman (1986) concluded 
that differences in utilisation rates and programme management 'probably' accounted 
for most of the variation in unit costs, although the exact proportion was not determined. 
Robertson et al (1984 and 1992) concluded that the EPI programme in The Gambia 
enjoyed lower average cost as volume rose, due to the substantial proportion of fixed 
costs. The Data for Decision Making (DDM 1997a) project in Egypt used a combination 
of ratios to judge hospital performance, and causes of unit cost variation, which ranged 
from 15 to 82 Egyptian pounds per inpatient day in the study hospital. Low occupancy 
rates and high number of medical staff per bed in high cost wards were the two main 
factors explaining cost per day differences. These conclusions were made on the basis of 
2-way tabulations of these data, thus ignoring other cost impacts associated with 
increasing hospital or ward size. Many other studies have presented minimal data sets 
on the basis of which they have drawn conclusions about the impact of utilisation levels 
on unit costs (Ugalde 1984, Berman et al1989a, Berman et al 1989b, Lewis et al 1991, 
Ehreth et al1993, Janowitz 1992, Jeffers and Siebert 1974). Also, some authors did not 
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distinguish clearly between returns to the variable factor and economies of scale (see 
Chapter 2). 
None of the econometric studies found directly addressed the impact of ~mused capacity 
on unit costs. However, the important issue of planning for demand uncertainty has 
gained some attention in the· regression literature reviewed, as demand uncertainty is 
responsible for both lower and higher occupancy rates than those planned. For example, 
Friedman and Pauly (1981) studied the· imp~ct of stochastic demand on the service level 
and average costs of hospitals, and found average costs highly sensitive to the utilisation 
rate (expected + actual output). Results from other studies indicate that demand 
uncertainty accounts for some of the observed excess capacity of hospitals, and that it 
leads to decreasing costs when hospital utilisation changes (Lave and Lave 1970, Joseph 
and Folland 1972). Gaynor and Anderson (1995) found using regression analysis that 
hospital costs would reduce 0.34% if. bed capacity was reduced by 1 % in the USA; also 
they concluded there would be savings of US$2.19 million (1992 prices) from 
increasing occupancy rates from 65% (1992) to previous rates of76% in 1980. 
Studies using DEA also did not make specific conclusions about returns to the variable 
factor, although some studies concluded that they explained why some health facilities 
were operating at below 100% efficiency. For example, Banker et al (1986) found that 
hospitals with high capacity utilisation (>82.6%) were more likely to be technically 
efficient, although hospitals with low capacity utilisation «71.3 %) could also be 
technically efficient. Also they found that no hospitals with high capacity utilisation 
were in the lowest technical efficiency range. This finding suggests that low occupancy 
is picked up in the TE ratio. 
In conclusion, the link between occupancy rate or capacity use and unit cost is 
unambiguous, and potentially an important detenninant of unit cost if the fixed cost 
element of unit cost is high. Therefore the link with health service use (section 4.2) 
should be recognised. Returns to the variable factor are relatively easy to diagnose using 
simple methods, such as recalculating average cost based on different capacity use 
assumptions. 
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4.3.3 Economies of scale 
Whether economies of scale exist, and what the optimal size of health facilities or health 
care programmes (e.g. immunisation) are, have been the subject of ~a large number of 
cost studies. However, there is considerably mixed evidence in the literature regarding 
economies of scale. A review carried out by the Nuffield Institute for Health concluded 
that economies of scale are more likely to exist in acute hospitals with 100-200 beds, 
whereas diseconomies of scale are likely to exist in hospitals with more than 300-600 
beds (Nlli 1996). This lack of definitive conclusion is supported by the studies 
.' . 
presented in Appendix 1 Tables 1 to 4. Co~ing et al (i 983) have also shown that in 
small hospitals (less than 100 beds) there is little evidence of significant economies of 
scale. 
USing accounting techniques, scatter plots have been used for assessing the general 
relationship between size and average cost, with generally positive findings of 
economies of scale (Robertson et al 1992, Brenzel and Claquin 1994, Jian et al 1998, 
I 
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Flessa 1998). Gilson (1992) concluded that economies of scale probably existed for 
immunisati~n-se;Vices, but not for curative or delivery care. However, these accounting 
studies suffer from/)the confounding effect of other variables that determine average 
costs, and that must be allowed for. Also, many of these studies had a small sample, 
which reduces the statistical power of cross-facility comparisons. 
4.3.4 Economies of scope 
The impact of the number of services available or used by patients on unit costs has 
been examined in econometric studies (see Appendix 1 Tables 1.1 to 1.3). Again, there 
is very mixed evidence of their existence. Cowling and Holtman (1983), Hornbrook and 
Monheit (1985), Custer and Willke (1991) and Bitran-Dicowsky and Dunlop (1993) all 
found significant economies of scope, while Barnum and Kutzin (1993) and Scott and 
Parkin (1995) did not find strong evidence. Therefore, the regression analysis literature 
reviewed is inconclusive about whether or not economies of scope exist at a general 
level. Again, economies of scope are context-specific. 
The only accounting study found that examined the existence of economies of scope 
was by Robertson et al (1991), which compared the unit costs of health facilities in 
Ecuador with and without dental services (as an indicator of the number of facilities 
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provided). Using visual examination, they found a negative correlation between number 
of health services and unit costs, although they admitted that this could have been 
confounded by differences in staff productivity. No studies in the review using data 
envelopment analysis have examined in detail whether economies of scope exist, except 
Valdmanis (1990) who found that overall technical efficiency is inversely related to the 
number of services available" (although this association was not strong). It should be 
noted, however, that most cost analysis studies compared homogeneous groups of health 
facilities, and therefore the question of cost variation being caused by economies of 
. . . . 
scope did not arise. This suggests it is important to compare the homogeneity of the 
health facilities with respect to service availability before including a 'scope' variable. 
4.3.5 Input mix 
The influence of input mix on unit cost has not been examined much in the reviewed 
articles, with only few examples found. Input mix can be defined either by the 
percentage contribution of different "resource ingredients to cost (in monetary units) 
which only gives a measure of relative intensity, or the observed resource use measured 
in physical quantities (which gives a truer measure of 'intensity' as compared to an 
average value defined for the purpose of measuring intensity). Note that resource use 
intensity is likely to be highly dependent on prices and the elasticity of substitution (see 
section 4.4). Using regression analysis Zuckerman et al (1994) found that the intensity 
of resource use explained some of the unit cost differences between hospitals in the 
USA, with hospital inefficiency increasing with the intensity of input use. Their 
conclusions took into account that the frontier estimates may not have incorporated 
other outputs or quality levels that increased intensity of resource use give rise to. 
Mills (1990) argued that differences in input mix should be expected where the level 
and location of hospitals differ. For example, specialised hospitals may have a lower 
share of wages due to more sophisticated buildings or due to more expenditure on 
support services and utilities. Also, the proportion of labour cost may also be low in 
developing countries due to lack of skilled manpower (leading to substitution of other 
inputs). However, a lower share of wages does not necessarily indicate lower staff 
intensity~ as other items may be relatively more expensive, such as when developing 
countries face world prices for drugs and equipment but local prices for non-traded 
goods. Prices mayor may not have a strong influence on choice of input mix, but will in 
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any case influence the relative shares of different types of input, assuming inputs can 
substitute for eachother. 
Some studies were found that used regression analysis to determine optimal levels of 
input mix. For example, Wan et al (1987) used regression analysis to determine the 
optimal staff mix (numbers of residents per dentist) to minimise unit costs. Wouters 
(1993) found that the staff mix of health centres in Nigeria critically determined unit 
costs. Finally, prescribing patterns (Creese, 1984) and vaccines use (Berman, 1991) 
.' . 
have also been found to change input mix, and thus unit cost. Teaching status has also 
been examined with respect to how it influences the quality of care and unit costs, 
although the evidence is ambiguous. Soderlund et al (1995) found that teaching status 
and higher labour input did not influence costs, whereas many regression studies have 
found higher costs in teaching hospitals (e.g. Cowper 1997). 
4.3.6 Quality of care 
Few studies found in the literature search examined the influence of quality of care on 
unit costs. Despite this, some form of quality indicator was often included. Increasing 
quality has been found in some studies to increase unit costs, although increase in 
quality may lead to efficiency gains thus having the oppose effect on unit costs (Gilson 
1992). The cause of unit cost increases can be both increases in resource use and 
resource prices (section 4.4), especially in private hospitals where better quality staff 
may be attracted with higher salaries. Berry (1973) found that quality-enhanced service 
hospitals cost 16% more per inpatient day that basic service hospitals in the USA. 
Gilson (1992) found an association between structural quality and total cost. On the 
other hand, she did not find significant associations between average cost and quality, or 
average cost and health service utilisation. 
The relationship between quality of care and other economic variables has also been 
examined. For example, Cohen (1970) found that optimal hospital size increased with 
increases in the quality of care provided, thus suggesting that it may be difficult to 
disentangle quality and scale effects when estimating hospital cost functions. Baron 
(1978) found that the quality of obstetric units increased with size. Broomberg (1997) 
and Kooreman (1994) both found that when a structural quality index was included in 
the output measure it affected the size of inefficiency observed. Most regression analysis 
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and DEA studies, however, have made the simplifying assumption that quality was 
identical between health facilities (Sherman 1984, Bannick et al 1995, Valdmanis 
1990). In conclusion, the joint problems of defining and measuring quality of care 
makes it difficult to capture quality aspects as a determinant of cost, despite its' 
potential importance as a determinant of unit cost. 
4.3.7 Case-mix 
The impact of case-mix on unit cost, re,source use and length of stay has been examined 
by numerous studies using regression analysis, which have generally found a highly 
significant impact of case-mix on cost (see Appendix 1 Tables 1 to 3). The expected 
impact is unambiguous, as more severely ill patients will stay longer (except when they 
die) as well as require more resources per day. Also, more severe cases may require 
more advanced equioment or better quality staff, with higher prices. Feldstein (1967) 
found that case-mix differences explained 27.5% of cost per case differences between a 
sample of hospitals in the USA, and Evans (1971) explained 51.4% of cost per inpatient 
day differences between hospitals using case-mix measures. Salhever (1972) found that 
changes in case-mix over time had a greater impact on hospital cost inflation than 
supply factors. Lave et al (1972) found that a high proportion of difficult cases led to 
higher than average costs. 
More recently, Soderlund et al (1995) found that case-mix differences accounted for 
approximately 77% of the differences in cost per finished consultant episode between 
providers, from nine acute-care NHS hospitals in the UK. Using 10 case-mix variables 
Watts and Klastorin (1980) found that case-mix and average cost were positively 
correlated, explaining as much as 70% of unit cost variation between hospitals. Other 
studies have compared case-mix and resource use, such as Bostrom and Mitchell (1991) 
who found that nursing input varied enormously between four levels of DRG rating. 
Also, McCrone et a1 (1998) found several patient factors (such as age, place of birth, 
suicide risk) had a significant impact on the case costs of mental health care services; 
however, only 31.5% of cost variation was explained. Many other socio-demographic 
characteristics were found not to have influence on costs. 
Non-significant results of relationships between case-mix and costs have also been 
found. For example, Butler et a1 (1995) classified patients by stage of detection of 
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cancer, and still found an enormous inter-patient cost variation within the same stage, 
although cost differences between stages also emerged. In conclusion, the link between 
case-mix and costs depends not only on whether the case-mix measure is indicative of 
cost, but also on the range of severity within. a single category. Therefore, although 
confounding effects should be sought, case-mix is a potentially important source of cost 
variation between health facilities that treat different profiles of patients. 
4.4 Resource price 
4.4.1 Absolute price 
Butler (1995) argued that when input prices are the same for all hospitals in a costing 
study, then prices cannot possibly be a source of cost variation, and so can be ignored. 
However, prices often vary within as well as between countries, and therefore prices 
cannot necessarily be assumed to be the same. For example, staff salaries may be greater 
at referral or urban health facilities than at primary care or rural ones; the price of other 
materials and equipment depends on whether bulk purchases are made. 
Despite the direct effect of price differences on unit costs, and the ease of identifying 
this effect using sensitivity analysis, surprisingly few studies were found in the review 
that evaluated the extent to which price differences cause unit cost differences. One 
study, Pauly (1978), found that differences in input prices between hospitals explained 
only 6% of cost variation. Cromwell et al (1987) found that part of the cost per 
admission differences (between 13 % and 61 %) between urban and rural hospitals was 
due to differences in wages between these locations, accounting for up to 33% of the 
variation. The impact of inflation on unit costs over time was also examined by Jeffers 
and Siebert (1974), who found that rising factor input prices accounted for 80% of the 
rise in average cost in a single hospital between 1960 and 1969. 
At the global level, Barnum and Kutzin found a positive correlation between average 
(health care) costs and GNP per capita: " ... the richer countries (Belize, St. Lucia, 
Turkey, Jamaica) have the highest unit costs, and the poorest nations (Malawi, Niger), 
have the lowest unit costs" (Barnum and Kutzin 1993, page 19). Also, in a multi-
country costing study of stroke care, Grieve (1999) found the costs per patient were 
higher in Western European countries (UK, France, Denmark) than Eastern European 
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countries (Lithuania, Poland). These findings are hardly surprising since personnel 
usually make up the largest share of cost, and wage rates are highly correlated with per 
capita income. On the other hand, countries with low prices may- also have more 
intensive use of resources, thus obscuring the relationship between the price levels and 
average costs. In conclusion, differences in price levels of health sector resources are an 
important determinant of unit cost, and are likely to explain unit cost differences, 
particularly over time and between countries with different income levels. 
4.4.2 Relative price 
Limited empirical work was found in the review on the relationship between relative 
prices and input mix in the health sector, and whether input substitution takes place. The 
impact of differences in relative prices between settings is more difficult to model, as 
input substitution must be taken into account, thus changing the input mix (discussed in 
section 4.2.5). One example, Grieve (1999), tabulated staff mix with relative prices of 
different categories of staff (nurse and doctors) in six European countries to allow 
preliminary conclusions that a low relative price of one category of staff does not 
necessarily lead to a higher input share. Four studies were found that included price 
variables as independent variables in econometric equations (Baron 1974, Baron 1978, 
Pauly 1978, Conrad and Strauss 1983, Cowing and Holtman 1983). The mechanism by 
which relative prices influenced the input mix was not entirely clear from the results of 
these studies, and therefore the substitutability of inputs was not known. However, one 
of these (Conrad and Strauss 1983) found that nursing and ancillary services were 
complementary to capital items, while general services were substitutes for capital 
items. 
4.5 Costing methods 
The impact of differences in costing methods, such as cost inclusion criteria or cost 
measurement techniques, on unit costs is potentially a highly significant cause of unit 
cost variation between settings (Janowitz 1992, Guyatt and Tanner 1996, Schulman et al 
1996). However, differences in costing methods were cited surprisingly little in the 
studies reviewed as a possible source of unit cost variation. This was partly because in 
many of these the costing methods were standardised to make estimates comparable, or 
they were assumed not to be a cause of cost variation. However, economic evaluations 
of multi-centre and multi-national trials are becoming increasingly common, where 
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different costing methods are used across centres. For example, Coast et al (2000) used 
different sources of resource use and valuation data to cost five hospital-at-home 
schemes, thus reducing comparability. Jonsson and Weinstein (l92}) described the 
differences in costing methods necessary in an economic evaluation taking place in 14 
countries: in the USA a cost-to-charge ratio was applied to hospital charges; in Canada 
unit costs were estimated using accounts and general cost allocation methods; in 
European countries, costs were assembled from a variety of sources, including published 
studies, accounts, and tariffs. 
In cost analysis studies that used secondary data sources, the potential sources of cost 
variation are greater; however, few analysts in the studies reviewed considered in detail 
the differences in costing methodologies. In their cost comparisons, Postma et al (1993) 
admitted that some unit cost estimates used bills instead of costs, and may have included 
different costs. Grosskopf and Valdamis (1987) and Rosenman et al (1997) both found 
that costing methods and accounting methods varied considerably across health 
providers, such as between private and public organisations, or between health 
maintenance organisations. These differences included the definition of items, and 
calculation of net assets. However, rarely did study authors comment on whether the 
same information was available in all participating facilities, and what was done when 
data were missing. 
Subsequently, it was mainly the review studies, such as Barnum and Kutzin (1993) and 
Janowitz and Bratt (1992) that argued that the costing methods may account for a part of 
unit cost variation. For example, Barnum and Kutzin distinguished broadly between 
step-down analyses and 'other' accounting studies in the literature. They concluded that 
the latter type contained fewer details and insights than do the former, as the step-down 
analyses enable scrutiny of the hospital production process to enable the best assignment 
of costs to the outputs to which they are related. Also, authors constructing cost-
effectiveness league tables encourage standardisation of costing methods to improve 
comparability of cost-effectiveness ratios (Gerard 1992). 
Janowitz· and Bratt (1992) suggested that one of the major obstacles to cost 
comparability in cost studies of family planning services was the lack of standard 
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approach or format for gathering cost data. They cited several types of methodological 
issues that contribute to the difficulty of comparing estimates, although they were not 
evaluated empirically in their study. ~~ 
1. Exclusion of some costs from estimates,. 
2. Varying methodologies for allocating time and overhead, 
3. Inconsistent treatment of capital costs, 
4. Classification of training as a capital or a recurrent cost, 
5. Treatment of "free" components, and 
6. Differences in exchange rates. 
The importance of point 5, the treatment of free components, was raised by the 
Partnership for Child Development project (PCD 1998), that showed that economic cost 
exceeded financial cost by 44%, after including the time cost of voluntary labour and 
money cost of donated drugs in the former. This raises the issue of 'opportunity' cost, 
where the prices paid for resources do not necessarily reflect market rates (as market 
prices are assumed to equal opportunity cost - the 'true' cost to society of using a 
resource) (Curry and Weiss 1993). While some attempts have been made to identify 
opportunity cost (the 'next best' use of the a resource - Little and Mirrlees 1982), these 
techniques may not be entirely appropriate for the health sector, whose aim is 
maximisation of health, and not maximisation of national income or foreign exchange 
earnings (which are the focus of the development project appraisal literature). Therefore, 
in conducting costing studies in the health sector the analyst is instead recommended to 
use financial price (unless opportunity cost is available), and provide some range where 
opportunity cost is likely to fall in a sensitivity analysis (Drummond et alI997). 
In conclusion, costing methods need to be scrutinised in all cost comparison studies, 
even in primary cost studies that use a standardised method in different health facilities, 
due to differences in interpretation of instructions by researchers and differences in the 
availability of data. 
4.6 Uncertainty 
Uncertainty potentially plays an important part in understanding causes of cost variation. 
Uncertainty exists in different forms, including: insufficient observations on a parameter 
or missing data, inaccuracies in recording systems or outdated price data, uncertainty in 
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cost apportionment from overhead to health care departments, valuation uncertainty, or 
uncertainty in generalising data across settings (Briggs et al 1994, Manning et al 1996). 
Uncertainty can either lead to biased estimates of cost, or wider confidence intervals in 
cost. However, for uncertainty to be a cause of cost variation, at least 0Il:e of these must 
be different between settings. In. making cross-setting comparisons of cost, differences 
in uncertainty were rarely cited as a source of cost variation. 
4.7 Implications for cost prediction methods 
The review of the cost analysis literature in this chapter found that few studies identified 
were successful in explaining cost variation comprehensively, nor in using the full range 
of cost analysis methods. Despite the general poor quality or lack of comprehensiveness 
of cost analysis studies reviewed, the literature reviews in Chapters 2-4 have been useful 
in identifying several useful frameworks. The first framework clarified the relationships 
between important components of cost, namely health service use, resource use and 
prices (see Box 1.1 and Figure 1.1). The second framework clarified the alternative cost 
analysis methods available for the analyst, and what the purpose, strengths and 
weaknesses of each were. The third framework identified and separated various factors 
that were hypothesised to cause costs to vary, using economic theory. These 
frameworks, and the literature reviews that have served to inform these frameworks, 
will be used to identify alternative approaches to cost prediction, as well as be used to 
judge or explain the successes and failures of these cost prediction approaches. 
The main implication for cost prediction methods of the cost analysis framework is that 
cost predictions are most likely to be accurate when all components of cost are taken 
into account in a cost prediction. To understand causes of variation in these cost 
components requires the application of cost analysis methods identified above. 
However, in the absence of detailed cost data to perform these analyses before a 
prediction, cost predictions are made with inadequate understanding of cost 
determinants in a setting. This no doubt would change over time, as more research is 
conducted into determinants of cost, and the performance of alternative cost prediction 
techniques is known in advance with more certainty. At this stage, therefore, alternative 
cost prediction methods should be identified and tested, to draw conclusions about their 
strengths and weaknesses. Five different cost prediction techniques, derived from the 
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cost analysis literature, are presented below, with examples from previous cost studies 
that have predicted costs. 
1. In the absence of any local data and other techniques for cost prediction, it may be 
necessary to assume that the same level of costs exist across different settings. This 
method is termed the 'direct transfer method'. All types of cost in Box 1.1 can be 
transferred in this way. If the settings are in different countries, the method for currency 
exchange must be decided between' nominal exchange rates or some measure of 
.' , 
purchasing power parity. This method does not take account of different patterns of 
baseline resource use and/or relative prices of inputs in different settings, which may be 
a disadvantage for cross-country predictions where differences are more likely to exist. 
Examples from the literature for transfer of health service use include Kinosian and 
Eisenberg (1988) and Rodby et al (1996), who both used the health service use rates 
from a single ReT to model cost-effectiveness in other settings. Examples from the 
literature for transfer of unit cost include Politi et al (1995) who assumed average costs 
per inpatient day from a published study represented costs represented costs in all public 
hospitals in The Gambia. An increasingly used form of direct transfer has been the use 
of unit costs from one centre in a multi-centre trial in the other centres. For example, 
unit costs proxied by DRG rates were transferred directly from Sweden to four other 
Scandinavian countries in the Scandinavian Simvastatin Survival Study (Jonsson et al 
1996). Also, Medicare DRG reimbursement rates in the USA were used for ten other 
countries in the GUSTO trial (Mark et al, 1995). Few examples of direct transfer of total 
costs were found in the literature. Those found include Broomberg et al (1996) who 
transferred the costs of a mass media campaign from the Dominican Republic to the rest 
of developing countries, at a cost of $440,000 for a city-wide programme with similar 
levels of output. No adjustments were made for differences in income level across 
country. Also, Maine (1986) and Tinker and Koblinsky (1992) both used total health 
care costs of investments in infrastructure and recurrent expenses to estimate the cost-
effectiveness of alternative Safe Motherhood options in developing countries 
(specifying three different levels of health system development proxied by per capita 
income). 
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2. If some local data are available on one or more of the cost components, and costs 
from the original study are disaggregated, then an adjusted transfer may be possible, 
using the technique of sensitivity analysis to substitute the local data into the cost 
calculation to produce a hybrid cost (Le. one that contains both local and generalised 
data). Therefore, if cost determinants are known to vary between settings, such as 
determinants of resource use '(case-mix, resource use intensity, returns to the variable 
factor, or staff productivity) or health service use, appropriate adjustments can be made. 
This method is termed the 'adjusted transfer method'. In theory, this method should 
. . . . 
" 
produce more accurate predictions than the direct transfer method, due to the use of 
local data in the calculation. In practice, it may involve (i) transferring health service use 
data, and applying local unit costs, (ii) using local health service use data and applying 
transferred unit costs, (iii) using key local prices or resource use in estimating unit costs. 
Examples in the literature include Edelson et al (1990) and Goldman et al (1991) who 
predicted total costs using drug prices .from a survey of local pharmacies in conjunction 
with Medicare charges for inpatient care to estimate the local specific costs. Also, 
Walker et al (1991) predicted total costs using unit costs data from a single trial, and 
adjusting these for expected differences in staff and computer usage, as well as reducing 
compliance (and therefore health service use) rates. Simon (1986) predicted the costs of 
hospitalisation, by inflating unit costs from a previous year, and adding costs that had 
been excluded to reflect the viewpoint of their study. A study by Goodman et al (1999) 
predicted costs of insecticide spraying to reduce malaria morbidity in a range of 
countries, using a number of different data sources. Data sources included a review of 
the literature, programme budgets, price catalogues for internationally traded goods, and 
consultation with field staff to collect data or ensure assumptions were realistic. 
Adjustments to transferred data were made using local data to increase the accuracy of 
the predictions. As a final example, Menzin et al (1996) used the results of a ReT in the 
USA to estimate the total costs of rhDNase in the treatment of cystic fibrosis in four 
European countries. Health service utilisation data were transferred adjusting for local 
practice patterns - likelihood of hospitalization (consultation with experts) and 
associated mean length of stay (from case notes and consultation with experts). Unit 
costs were applied from each country, which were adjusted to be comparable due to 
differing costing methodologies (some details were provided): 
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3. A third technique uses knowledge of cost relationships that are relatively stable or 
constant across health care setting. For example, some studies (e.g. Knapp and Beacham 
1993, Whynes and Walker 1995) have identified the most costly partsDf interventions 
to generate a reduced-list costing. Likewise, a costing method can be derived from the 
recognition that some resources contribute the most to cost, and thus based on 
assumptions about the proportion can be scaled up to approximate total cost. The 
'simplified staff costing method' assumes that the cost relationships between staff cost 
and total cost is relatively stable. Therefore, average costs are predicted using local 
.' . 
staffing cost data and throughput, which are 'scaled up' using data about proportion of 
staff cost to total costs in other settings. However, no studies were found in the literature 
search that predicted unit costs based on staff cost alone. 
-
4. A fourth technique predicts the expected changes in the costs of current care due to a 
change in health care appproach, using local data and assumptions about impacts. In this 
thesis, it is termed the 'incremental cost impact method'. This approach considers the 
evidence from other settings as well as expert opinion about how the ingredients of care, 
the use of services and morbidity levels are altered under a new form of care, and then 
makes estimates of the impact on costs in the local context. The incremental cost impact 
method is different from the adjusted transfer method, in that prices and resource 
quantities are not transferred from other settings. Instead they are built from 
expectations of values in the local setting, based purely on local evidence and 
assumptions. One example of the incremental cost impact method was the 
'Reproductive Health Care Costing Spreadsheet' (Weissman et al 1999) which used a 
generalised framework to estimate the cost per woman of applying the W.H.O. Mother-
Baby Package in Uganda based on local data, compared to the costs of current care, 
giving an incremental cost. Another example of the incremental cost impact method 
from the research literature is a study by Boulanger et al (1999) which compared actual 
treatment costs of childhood sicknesses with the hypothetical costs if the health provider 
had followed the Integrated Management of Childhood lllnesses (IMCI) in rural Kenya. 
Actual treatment costs were estimated by extracting treatment information from health 
cards. IMCI treatment costs were predicted by multiplying high and low dosage 
requirements by drug prices, thus giving a high and low cost estimate, and an 
incremental cost. This method requires detailed data on coverage rates, prevalence and 
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incidence of specified conditions, health sector infrastructure, referral patterns, and 
typical resource use and costs. 
5. A fifth and final technique uses a regression model to identify C?st determinants, 
which are then used to predict costs for another setting with a' different set of 
parameters. It thus assumes that cost determinants are similar in different settings. This 
technique is called the 'regression method'. In the'regression literature (such as those 
studies provided in Appendix 1 Tables 1.~ .~o 1.3) few studies were found to go beyond 
the bounds of the data set and predict' costs in different settings or populations, and 
compare predicted with observed costs. Non-monetary cost dependent variables have 
been modelled as well as monetary dependent variables. For example, Khooshnood et al 
(1996) predicted the length of stay in neonatal intensive units, and found that birth 
-
weight, survival, and total parental nutrition together explained 66% of the variability of 
length of stay between neonates. Also, Cowper et al (1997) found that clinical, 
demographic, hospital and regional characteristics only explained 16% of variation in 
length of stay between coronary artery bypass surgery patients in the USA. Of particular 
relevance for this thesis, there were a number of studies that predicted episode costs 
using regression analysis (see Appendix 1 Table 1.3). For example, Dudley et al (1993) 
compared the predictions of five statistical models with observed data, on the cost of 
coronary artery bypass graft surgery. They predicted mean cost for a hypothetical typical 
patient by inserting the median characteristics in the equation, and found that the models 
varied in terms of predictive accuracy. 
95 
5 CONTEXT AND METHODS 
This chapter describes the World Health Organization (W.H.O.) ~ antenatal care 
randomised controlled trial (which forms the context of the empirical work of this 
thesis), lists the empirical objectives, and describes methods of data collection and 
analysis. 
5.1 The W.H.O. antenatal care trial 
The W.H.O. recently evaluated the impact of an evidence-based programme of antenatal. 
care (ANC) in four countries. In this trial, economic and quality of care components 
were planned as well as the clinical and health impact. This section describes important 
aspects of the trial briefly, but the reader is referred to Appendix 2 for a summary 
-
description of clinical component information, Appendix 3 for a description of 
economic evaluation methods (Mugford, Hutton and Fox-Rushby 1998), and to 
Lumbiganon et al (1998) for a fuller description of trial context and methods. 
The hypothesis of the W.H.O. antenatal care trial was: "A new model of antenatal care 
which includes only those components shown to be effective in improving maternal, 
perinatal and neonatal outcomes, is more efficient than the traditional model with regard 
to specific maternal and perinatal endpoints, among singleton pregnancies, and is not 
more expensive" (WHO 1996, page 9) .. 
Study design and sample size. This trial was designed to be a multicentre multi-country 
randomised controlled trial. Trial centres were in Argentina, Cuba, Saudi Arabia and 
Thailand32• The sample size needed from the four study sites was 19,087 subjects 
(Donner et al 1998). The trial randomisation design was based on health facilities rather 
than patients (,cluster' design). This was necessary to reduce the risk of treatment 
contamination, to encourage the participation of the women, and to facilitate logistic and 
administrative convenience in the implementation of the intervention. 
32 These countries were chosen for two principal reasons: there was a minimum level of antenatal care 
in place to act as the comparison group; there was the basic infrastructure (research facilities and data 
systems) for high quality research. 
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The intervention: In each country at least six health facilities33 provided the new 
antenatal programme, and at least six the current model of care. The new programme 
consisted of tests, clinical procedures and follow~up actions scientifically demonstrated 
to be effective in improving maternal and newborn outcomes, avoi~ing the use of 
technology not affordable in developing country settings. These interventions were 
distributed among four visits over the entire course of a low risk pregnancy. Appendix 2 
Table 2.2 provides a summary of the contents of the new ANC programme. 
Health outcomes: The effectiveness of the programmes was compared in terms of two 
primary outcomes: low birth weight and an index of maternal morbiditJ4. In addition, 
several secondary outcomes and process outcomes (including perceived quality of care, 
satisfaction, and cost) were compared (see Appendix 2 Table 2.3). 
Study sites: A description of study, sites is provided in Appendix 2 Table 2.1. In 
Thailand, the trial took place in Khon Kaen province in north-east Thailand, where there 
are a total of 20 district hospitals (serving 193 health centres) of which 12 district 
hospitals participated in the ANC trial. There are also three central hospitals in Khon 
Kaen city itself that provide both routine and high risk care for pregnant women (a 
university hospital, a regional hospital, and a maternal and child health hospital). Nurse 
midwives are the main providers of antenatal care. Most ANC is provided in the district 
hospitals, and about 90% of women deliver their babies at the health care facility where 
they had their ANC. Caesarean section is available in most district hospitals. The ANC 
schedule follows the traditional 'Western' recommendations. 
In Cuba, the trial took place in three municipalities in the capital, Havana city. All five 
policlinics in Old and Central Havana participated, and two policlinics (out of 5) in East 
Havana. 100% of deliveries take place in maternity hospitals. ANC is provided by 
general practitioners or obstetric specialists, complemented by a comprehensive system 
of social, medical and nutritional services. The amount and content of care is almost 
equivalent to the best ANC in developed countries. 
33 In Cuba and Saudi Arabia. policlinics; in Thailand. district hospitals; in Argentina. health centres & 
hospitals. 
34 The presence of at least one of the following: (a) pre-eclampsia or eclampsia during pregnancy or 
within 24 hours of delivery; (b) postpartum anaemia (haemoglobin <90 gIL); or (c) severe urinary tract 
infection/pyelonephritis. defined as an episode requiring antibiotic treatment and/or hospitalisation. 
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In addition to Cuba and Thailand, funds were also granted to the ANC trial economic 
group to conduct a study to predict the cost-effectiveness of the W.H.O. ANC 
programme in a setting in South Africa35• The 'setting chosen wasUmlazi Township, 
located in KwaZulu Natal province, 20 km South of the City of Durban. Six health 
centres provide primary health care in this township, five of which provided antenatal 
care at the time of the study. Prince Mshiyeni Memorial hospital, located in the 
township, is a large general hospital, and is responsible for roughly 20 health centres in 
the region. The ANC schedule follows ,the traditional 'Western' recommendations, 
although a large proportion of women report late during their pregnancies. The 
institutional delivery rate is about 60%36. Prince Mshiyeni hospital is the main place 
where women from Umlazi deliver, and a small proportion deliver in the health centres. 
Economic evaluation. An economic evaluation was included in the planning phase of 
the trial, and funding was provided to estimate the unit costs of maternity care in two of 
the countries (Cuba and Thailand) and also cost-effectiveness prediction in South 
Africa. The economic studr7, as a sub-component of the antenatal care trial, based its' 
aims and scope on the primary hypothesis of the trial, which contained a clear reference 
to the economic outcome. Therefore, the overall aim of the economic study was to 
assess whether the new programme of antenatal care was more cost-effective than the 
existing level of service, including costs to both the health service and the women of 
attending ANC. 
5.2 Aim and objectives of empirical study 
As was stated in the introduction, the overall thesis aim is to increase current knowledge 
about the strengths and weaknesses of alternative cost analysis' and cost prediction 
methods, in the context of public health care systems, and with particular emphasis on 
developing countries. To fulfil this aim, costs of selected maternity services are 
estimated in the study settings; costs are compared and analysed; the generalis ability of 
costs is examined; costs are predicted using selected methods; and cost predictions are 
3S A pilot study was conducted in South Africa to decide whether it could participate in the W.H.O. ANC 
trial; however, loss-to-follow-up rates after delivery were well above the acceptable level of 5%. 
36 This rate was obtained from the pilot study for the antenatal care trial, performed by Professor Ross. Of 
the roughly 40% of women that did not have an institutional delivery, only half responded to the request 
to contact the research centre of Professor Ross following delivery. '"' 
37 See the methods paper in Appendix 3 for a fuller description of the economic component of the trial. 
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compared with estimated costs. With these in mind, specific data collection and analysis 
objectives were set, based on six research questions. 
1. What are the costs of antenatal and delivery care in study countries? 
[J Measure physical resource use, and average and marginal costs of selected 
maternity services in·a sample of health facilities in Cuba, Thailand and South 
Africa. 
[J Extract relevant health service use data from the W.H.O. data set to calculate the 
.. 
average cost per case (including care during pregnancy, delivery and the 
postpartum) for women in control and intervention arms in Cuba and Thailand. 
[J Collect relevant health service use data on a sample of women to calculate the 
average cost per case for current care in South Africa. 
[J Present US$ costs using nominal exchange rates and purchasing power parity. 
2. How robust are these costs? 
[J Evaluate critically the costing framework and economic study design, and 
identify important areas of data and model uncertainty. 
[J Conduct a sensitivity analysis and present ranges on unit and case costs to reflect 
uncertainty in cost estimates. 
3. What is the variability of these costs? 
[J Present unit cost components by health facility and month. 
[J Present distributions of health service use and cost per case in each health 
facility, arm and country. 
[J Show the profiles of unit cost and cost per pregnancy, by resource type. 
4. What factors account for cost variation? 
[J Examine causes of variation between health facility, trial arm and country, using 
those factors identified to cause cost variation in the literature review, for: 
~ Health service use. 
~ Resource use (per health service use). 
~. Unit cost (average and marginal cost). 
~ Case cost (using average and marginal cost). 
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5. How accurate are cost predictions using alternative methods? 
CJ Predict costs in Cuba and Thailand using available meth~ds, and judge the 
accuracy of these predictions. 
CJ Predict costs in South Africa, and compare results. 
CJ Discuss the strengths and weaknesses of cost prediction methods. 
6. What are the implications for those wis~ing to make cost predictions and interpret 
research? 
CJ To conclude what factors cause elements of cost to vary between setting, how 
much these relationships vary between setting, and therefore factors that affect 
the generalis ability of cost data. 
CJ To conclude which cost prediction methods are potentially best in different 
research settings. 
CJ To conclude what measures are possible to increase the generalis ability of cost 
data. 
CJ To make recommendations based on these findings for researchers and policy 
makers. 
The next three sections describe the methods of data collection and cost analysis. 
5.3 Methods of data collection and cost estimation 
5.3.1 Overview of data requirements and data sources 
Table 5.1 classifies the data according to 'types of data' and 'sources of data'. Data are 
classified by: cost, cost determinants, clinical information, patient characteristics and 
outcomes, and macroeconomic data38• The three main data sources for this thesis are 
primary sources in the economic study, secondary sources in the economic study, and 
data extracted from the trial data set (see footnote to Table 5.1). 
38 All data tabulations and analyses were done using Microsoft Excel © spreadsheets, unless otherwise stated. 
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Table 5.1: Types of data and sources of data used in the thesis. 
Tl:~e of data Cuba and Thailand (both trial arms) South Africa (current care onll:} 
1. Aspects of • Prices of resources • Prices of resources 
cost • Quantity input for each, activity • Quantity input for each activity 
• Overhead costs • Overhead costs 
• Unit costs and cost profiles • Unit costs and cost profiles 
• Health service use • Health service use 
• Total and incremental costs • Total and incremental costs 
• Cost ~er ~regnancl: • Cost ~er ~regnancl: 
2. Cost • Management practices • Management practices 
determinants • Wastage and inefficiency • Wastage and inefficiency 
• Capacity use and throughput • Capacity use and throughput 
• Input:output ratios • Input:output ratios 
• Health facility size and services • Health facility size and services 
• Average length of stay • Average length ofstay 
• Structural quality indicators • Structural quality indicators 
• Compliance with WHO protocol 
3. Health • Content of new programme of ANC • Content of current ANC 
provider • Content of current ANC (guidelines) (guidelines) 
- information Departures from clinical protocol • Departures from clinical protocol • 
• Referral patterns • Referral patterns 
• Incentives to providers • Incentives to providers 
• Staff categories (qualifications, • Staff categories (qualifications, 
roles and ~al: scales) roles and pay scales) 
4. Patient and • Numbers of health service use • Numbers of health service use 
population • Rates of risk and morbidity • Rates of risk and morbidity 
level • Socioeconomic and demographic • Socioeconomic & demographic 
information variables variables 
5. Macroecon- • Nominal exchange rates • Nominal exchange rates 
omic • Inflation rates • Inflation rates 
information • Purchasing ~ower ~aritl: • Purchasing ~ower ~aritl: 
TABLE KEY: In bold: Primary data measured by the economic study. 
In italics: Data collected from secondary data sources in economic study. 
In normal: Data collected by the antenatal care trial. 
5.3.2 Health service use data sources 
Health service use data on all trial women in Cuba and Thailand were extracted from the 
trial data set (from SPSS for Windows © files), and presented by health facility, by trial 
arm and by country. Mean and median values and distributions are provided for health 
service use in tables and histograms. Confidence intervals are estimated using +/- 1.96 
S.E .. For inpatient antenatal care, the average inpatient days per admitted case and per 
trial woman are presented. For Cuba, inpatient admissions are split by whether they 
classify as low or high risk (as there are separate wards for women of different risk). 
Similarly for neonatal care the average length of stay is presented for both admitted 
cases and for all trial babies. For postpartum stay the mean and median length of stay 
following vaginal delivery and CS and reported separately. 
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Similar data were presented for South Africa. However, because the trial was not 
conducted in South Africa, arrangements were made to conduct an additional survey. In 
this survey, data on 800 women delivering in Prince Mshiyeni Memorial hospital was 
extracted from antenatal and labour/delivery cards, and entered in the W.H.O. trial 
summary forms. However, for logistical reasons this was not a prospective survey. 
Instead, records were collected in chronological order from the record room of the 
hospital, starting in January 1998, until 800 forms were filled in. Of these 785 had 
" . 
complete data. 
5.3.3 Unit cost estimation 
Costing health services requires several decisions to be made concerning the costing 
methodology. These include deciding which cost centres to estimate unit costs for, the 
costing approach (whether top-down or bottom-up costing), the methods for physical 
resource measurement and monetary' valuation, the methods of cost allocation across 
cost centres, and the choice of sample size. These are discussed below in tum. 
Table 5.2 shows the types of health care in each health facility for which unit costs are 
estimated. In Thailand, all types of care are provided in the district hospitals located in 
Khon Kaen province, and these costs are estimated from primary sources in the costing 
study. The other three hospitals in Thailand provide all types of maternity care (mainly 
to high risk women) in Khon Kaen city. In Cuba, only outpatient care is provided to 
women in the policlinics, and therefore inpatient care costs were collected in America 
Arias hospital, over 70% of trial women received their inpatient care. In South Africa, 
five health centres in the jurisdiction of Prince Mshiyeni were chosen as the sample 
health facilities, where outpatient care and normal vaginal delivery care are provided. 
Prince Mshiyeni hospital provides inpatient care, where unit costs were collected. 
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Table 5.2: Health facilities and types of care where unit costs were estimated. 
Country and health facilities Number of Type of heaalth care' 
facilities OPV IPD VD CS PPD NND 
Thailand 
District hospitals 
Sririgarind University hospital 




America Arias hospital 















.' ~ ~ 
~ ~ ~ (~) 
~ ~ ~ ;,; 
~ ~ ~ ~ 
~ ~ ~ ~ 
x x x X 
~ ~ ~ ~ 










Health centres 5 ~ . . x ~ x x X Primary 
Prince Mshiyeni hospital 1 ~ ~ ~ ~ ~ ~ Primary 
I OPV: outpatient visit; IPD: inpatient day (during pregnancy); VD: vaginal delivery; CS: caesarean section; PPD: 
postpartum inpatient day; NND: neonatal intensive care day. 'V' and 'x' indicate that the type of care in the column 
heading is I is not (respectively) provided at the health facility (-ies) in the corresponding row. '(V)' means that 
neonatal intensive care costs were approximated by adult IPD costs, as incubators were in the same ward. 
2 Data source: a costing study conducted in 1989 (Kosuwun et alI989). Unit costs were adjusted to 1998. 
3 Data source: a costing study conducted in 1996 (WiJaiporn 1996). Unit costs were adjusted to 1998. 
4 Unit costs at the regional hospital were estimated as the average of Sririgarind and Khon Kaen hospitals 
S Unit costs of all other maternity hospitals were assumed to be the same as in America Arias hospital 
The choice of costing approach used in the ANC trial was described and justified in 
Mugford, Hutton and Fox-Rushby (1998). Unit costs were estimated using the top-down 
approach for all types of health care in all countries, except caesarean section in 
Thailand39• A step-down allocation procedure was used that best reflected the flow of 
services between departments, and that could be applied in a standardised way in all 
countries. Costs were collected to refer to the period September 1997 to April 1998 in 
Cuba (8 months of unit cost data), October 1996 to December 1997 in Thailand (15 
months of unit cost data), and January to April 1998 in South Africa (4 months of unit 
cost data)4o. The information collected for each resource ingredient is presented in Table 
5.3 below. 
39 A bottom-up costing approach was used for caesarean section in Thailand, because the operating 
theatres in the district hospitals were general in nature, and therefore the top-down costing approach 
would not have captured specifically the unit cost of a CS.. ' 
40 The original target for the number of months of unit cost data was 12 months in all countries. In Cuba. 
less were obtained as research time for data collection was underestimated; in South Africa, less were 
obtained as data on patient outcomes had to be collected within the same research budget; in Thailand, 
more were obtained. to collect unit cost information in the period after the economic crisis in late-1997. 
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Table 5.3: Types and frequency of data collected for each health care resource 
Resource Types of data collected 
ingredient Physical resource quantity Frequencyl Monetary value / Frequencyl 
Staff All staff in health facility by Monthly Monthly gross salary Monthly 
cost centre Value of accommodation 
Equipment All equipment in health facility One-off Purchase price (some) One-off 
by cost centre, purchase year, Current price (most) 
length of life 
One-off Drugs Drugs consumed by a sample of One-off Current price 
15 pregnant women per facility 
Materials All materials consumed by Monthly Current price Monthly 
relevant cost centres 
Utilities Number of utility outlets in each One-off Monthly cost for each utility Monthly 
cost centre in entire health facility 
Buildings Floor space in each cost centre, One-off Construction cost (most) One-off 
construction year, length of life Monthly rental value (some) 
1 'Monthly' means that mformatlOn was collected for each calendar month for the data collectIOn penod. 
'One-off means that data collection was needed once only to cover the whole data collection period. 
The identification of the opportunity cost of resources represented a challenge, as the 
financial cost paid for resources does not necessarily equal the opportunity cost (Garber 
et alI996). The general approach of Drummond et al (1997) was adopted in this thesis, 
where the existing market price was used unless there was some particular reason to do 
otherwise. Drummond et al (1997) argued that the main reason to 'do otherwise' was if 
the analyst is convinced that to leave prices unadjusted would introduce substantial bias 
into the study, but only if there is a clear way of making the adjustment. Therefore, the 
existence of market failure was assessed in all resource markets, as indicated by the 
existence of monopoly or monopsony power, government subsidy, or cross-subsidy. 
Also, the impact of government-imposed restrictions on trade (internal or external) such 
as taxes was examined. In order to increase the consistency in collecting information on 
opportunity cost, and give the approach some background in economic theory, a step-
by-step approach was used to identify the appropriate price of the resource to 
approximate opportunity cost, illustrated in Box 5.1. This approach is based on the 
general approach of the development project appraisal literature for identifying the 
opportunity cost, or 'shadow price' (Gittinger 1984, Curry and Weiss 1993, Layard and 
Glaister 1994, MacArthur 1997). This approach involves first identifying if the good has 
a world price (either a traded good or a potentially traded good), and if not, whether it 
has a price in the local economy that represents a competitive market rate. 
Unit costs are represented by both average and marginal costs, and are presented for all 
relevant cost centres in US$ at nominal exchange rates and at 'purchasing power parity 
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(PPP). Nominal exchange rates were collected on 8 January 1998, as this was the mid-
point of the trial, and was the point in time that was common to data collection periods 
in all countries. However, as US$ values converted using nominal exchange rates do not 
necessarily reflect the relative cost to the. countries incurring the costs (compared to 
other goods), an alternative conversion method was considered essential for making 
cross-country cost comparisons. Therefore, PPPs were also used. However, as PPP rates 
were not available for Cuba from international sources, a home-made PPP measure was 
constructed that allowed a fair and consistent comparison between countries taking into 
... 
account local purchasing power (see Appendix 4 Table 4.1 for description of method 
and results). Cost profiles are also presented, by resource, and by department (direct 
health care, technical support, laboratory, administration, general). Also, the coefficient 
of variation (standard deviation + mean) is presented to show the extent of inter-month 
variation in each cost centre. 
To allow testing of whether unit costs vary between health facilities, some measure of 
variability within each cost centre is needed to allow calculation of confidence intervals. 
Variability in unit cost can come from two sources: inter-patient variability, or 
variability over time. However, the former could not be presented, as unit costs were not 
collected on individual patients. Therefore, variability was calculated using unit costs 
from the number of months for which unit costs were estimated41 • However, in 
interpreting and using these confidence intervals, it is recognised that this measure of 
variability does not reflect variability in all the resource ingredients or by patient. 
41 Confidence intervals are based on the inter-month variability using the 't' distribution due to the small 
number of observations (months of data), using the formula [mean +/- (t' x sI...Jn)], where t' is taken from 
the t distribution using 2-tailed a. at 0.05 and degrees of freedom n-l; s is the standard deviation, and n is 
the number of months of data. These confidence intervals are based on the premise that average costs for 
each month are independent of each other (that is, there is no predictable seasonal variation), which is 
confirmed by examining the time patterns of cost and activity data. 
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Box 5.1: Step-by-step approach to identify the opportunity cost of health care resources. 
Question 1 - "Is the resource imported?" 
Answer J(a):Yes, it is imported. The good is a Traded Good (TG) and has an in~ernational price that 
should include carriage, insurance and freight (elF). To this should be added the local transport and 
distribution costs (='domestic margin') to approximate the local opportunity cost. Profit elements, 
import subsidies, and import taxes are 'transfers' and therefore subtracted from cost. FINISH. 
Answer J(b): No it is not imported, or its' origin is unknown. Go to Question 2. 
Question 2 - "Could the resource be imported?" 
Answer 2(a): Yes, it could be imported. The good is classified as a Potentially Tradeable Good 
(PTG) and also has an international price, which can be obtained on the international market if it 
were exported (giving foreign exchange). or if it were imported (giving the minimum cost of 
obtaining it). If this is available, then the domestic price (production and transport cost) should be 
ignored, as it does not reflect the opportunity cost of the good, assuming the good could be 
imported. On the other hand, if the good is restricted by government quotas, and the policy is 
unlikely to change in the near future, then it may be unrealistic to value the resource in this way, and 
the domestic price should be used. Also, if the international price is not available, or too difficult to 
find, then the domestic price should be used. The characteristics of the domestic market should be 
studied (e.g. whether it is a government or private supplier, and whether it is sold at a subsidised 
rate, at cost, or at a profit). END. 
Answer 2(b): No, it cannot be imported. The good is classified as a non-traded good (NTG), and is 
most likely to be labour, utilities and buildings. Go to Question 3. 
Question 3 - Is there a market and price for the resource? 
Answer 3( a) Yes, there is a market and price for the resource. This means that a clear and objective 
way of valuing price is needed. For example, staff salaries, telephone bills, and building rental 
indicates that some market and price system exists for the resource. Once this value has been found, 
go to Question 4. 
Answer 3(b): No, there is no market or price system for the resource. This means that another 
method is required for estimating the opportunity cost of the resource. Go to Question 5. 
Question 4 - Does the cost or price approximate the opportunity cost? 
Answer 4(a): Yes, the cost or price does approximate the opportunity cost. Then it is assumed that a 
perfect market exists, or at least there are no significant government subsidies, or monopolgy 
position. Therefore, no adjustments are necessary, and this cost or price can be used in the economic 
evaluation. END. 
Answer 4(b): No, the cost or price· does not approximate the opportunity cost. Then a clear and 
objective way of making adjustments is required. For example, are data available from elsewhere 
that better approximates the opportunity cost, such as private sector wages instead of public sector 
wages? A good knowledge of the market conditions is needed, including both supply factors (e.g. is 
the resource in fixed or variable supply?) and demand factors (e.g. what is the strength of local 
demand for the resource?). It should also be noted whether the non-traded good contains any traded 
goods, because if it does they should be valued at the shadow exchange rate. END. 
Question 5 - Can the cost or price of the non-market good be approximated from other 
sources? 
Answer 5( a): Yes, the cost can be approximated using other data sources. Then assess the relevance 
or appropriateness of the other source for valuation of the resource. For example, volunteer labour 
input can be approximated by the opportunity cost of a health worker doing the same job. END. 
Answer 5(b): No, the cost cannot be approximated using other data sources. Then it may be best to 
interview health care staff or patients about willingness to pay for certain resources, or make them 
give an estimated market value. If this is impossible, then leave the resource out altogether, and 
make a note in the tables to say why it was left out. END. 
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5.3.4 Cost per pregnancy estimation 
Cost per pregnancy is calculated for all women not excluded from the data analysis by 
the trial criteria42• Cost per pregnancy (CPP) is calculated as follows: --
n m 
CPPk = L L [HSUij X UCij] k 
i=l j=l . 
Where 
HSUij = Health Service Use of the ith type of ser~iCe in the jth facility of the kth woman 
UCij = Unit Cost of the ith type of service in the jth facility 
i : As described above, health services included in cost per pregnancy were: outpatient and inpatient 
antenatal care, delivery care, postpartum care for the woman, neonatal intensive care. 
j : As described above, there were six control and six intervention arm facilities which women were 
-randomised to in Cuba and Thailand, and five clinics in South Africa. 
k : There were a total of 5604 women in Cuba, 6369 women in Thailand and 785 women in South 
Africa included in the cost per pregnancy calculations. 
Average cost per pregnancy (ACPP) is calculated for each woman, each health facility 
(the woman 'belongs' to the health facility where she was recruited to the ANC trial), 
and both trial arms, using the average cost data. Likewise marginal cost per pregnancy 
(MCPP) is calculated using marginal costs. Comparing CPP in control and intervention 
arms gives the incremental cost (new versus current antenatal care). Mean and median 
values and distributions are provided for CPP at each level of aggregation in tables and 
histograms. Median cost per case is important to present in addition to mean cost, due to 
the skewed nature of cost data, and gives a more realistic view of central tendency. 
However, for the purposes of decision making, mean values are more appropriate, as 
they allow the analyst to calculate the total budget requirement of an intervention, and 
therefore mean values are the main focus of the cost analysis. Confidence intervals are 
approximated using +/- 1.96 standard errors of the mean value. Although cost per 
pregnancy distributions are expected to be positively skewed, standard errors were not 
estimated using the bootstrapping method for two reasons (1) distributions have to be 
very seriously non-Normal for bootstrapped estimates to be essential and (2) because 
confidence intervals are not used for testing differences between facilities. Mean values 
42 Women who had abortions, who were not pregnant and who were lost-to-follow-up are excluded. 
107 
are also compared between trial arms using log costs, to estimate mean difference taking 
accout of the skewness of the data. 
5.3.5 Health service performance and description 
Health service performance and description data were collected to explain cost size and 
variability, and provide a context for making cost generalisations. Data collected are 
listed in Table 6.1. They include qualitative information on health care structure and 
management approach, health care content and quality, and some quantitative data on 
population characteristics (such as s~cio ... demographic. variables and risk status) and 
provider performance (such as throughput and capacity use). 
5.3.6 Project management 
There were economics teams in the UK, Cuba, Thailand and South Africa (see 
Appendix 4 Table 4.3 for details). The UK team was responsible primarily for setting up 
the economics study, supervising the other teams and providing technical support, 
liaising with the antenatal care trial Steering Committee, and analysing the final data set. 
The local teams were responsible for organising the data collection in each of their 
countries, and reporting to the UK economics team. Several field visits were made by 
the UK economics team during the study. Guy Hutton (GH), and sometimes Miranda 
Mugford (MM) or Julia Fox-Rushby (JFR), made at least one trip to each country in 
each of 1996, 1997, and 1998 (see Appendix 4 Table 4.4). While the main purpose of 
these trips and the data collection was to meet the primary objective of the economic 
evaluation alongside the W.H.O. ANC trial, other information was collected during 
these trips and meetings held with key researchers and policy makers for input to the 
thesis methods and results. Also, additional cost data required for the thesis were 
collected by both the local economics teams and by GH during field visits. The project 
was managed from the UK by GH, MM and JFR, with monthly project meetings and 
regular email and fax contact with the centres, for progress monitoring and trouble 
shooting. Also, there were five steering group meetings and one principal investigator 
meeting between 1995 and 1999, all of which were attended by the UK economics team. 
5.4 Analysis of robustness of costs 
Uncertainty exists in both health service use and unit costs, which make up cost per 
pregnancy. Therefore it is important to examine separately the robustness of each of 
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these components, to assess whether data uncertainty or changes in model assumptions 
changes or influences the results and conclusi~ns of the cost study. Conclusions of 
interest to be examined are at the within and between country~levels: (1) does 
uncertainty lead to different cost per pregnancy between trial arms, and therefore a 
different incremental cost? (2) does uncertainty lead to different cost per pregnancy 
between countries, and therefore different conclusions regarding cross-country 
differences? 
5.4.1 Uncertainty in health service use 
At the within country level, it is useful to calculate what changes in health service use in 
the intervention arm would be required for a change in incremental cost to 'no 
difference' (Le. mean difference equal to zero). For this, a threshold analysis is 
conducted. For example, if in the base case the W.H.O. programme costs less than the 
current programme, what increase in caesareaan section rate or number of ANC visits is 
required for there to be no cost difference between trial arms? The threshold rates for 
each type of health service use would then be compared with the upper 95% confidence 
limit measured by the trial, to make conclusions about the likelihood of such a value 
being observed. A similar analysis is presented briefly for the between country level, 
where threshold values are obtained where no significant differences in cost per 
pregnancy exist between countries. 
5.4.2 Uncertainty in unit costs .' 
Uncertainty in unit costs in this study is represented using sensitivity analysis, where 
uncertain data inputs and costing methods are identified, and alternative methods or 
values are substituted to give a new range on unit cost (Briggs et al1994). Therefore, 
the resulting ranges represent a 'deterministic' distribution (O'Brien et al1994), as there 
are limited opportunities for attaching probabilities to alternative values. However, in 
addition to the one-way testing of alternative values or methods, several uncertain 
elements are combined in a multi-way sensitivity analysis. 
For the within country analysis, there are limited options for identifying differences in 
degrees of uncertainty between trial arm, as identical costing methods were applied to 
both intervention and control health facilities. The only type of care whose unit cost 
could possibly be influenced by the W.H.O. programme is outpatient antenatal care (as 
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the programme was unlikely to influence inpatient health service use significantly 
enough to cause changes in unit costs). Given that the top-down costing approach might 
not have picked up changes in unit costs under the new programme, a thfeshold analysis 
is performed to identify what the outpatient ANC unit cost would have to be for there to 
be a zero incremental cost per pregnancy. The threshold unit cost is compared with the 
range of unit costs observed in intervention health facilities, and conclusions made 
about the likelihood of these occurring. 
For the between country analysis, it is possible that different levels of uncertainty could 
have been partly responsible for unit cost differences, and ultimately cost per pregnancy 
differences. Therefore, aspects of the costing study design and implementation were 
evaluated, and sources of uncertainty classified under four main types (Briggs et al 
1994): (1) No or insufficient observations on a parameter. (2) Inaccuracies in recording 
systems. (3) Uncertainty over which is the best method to value a parameter. (4) 
Uncertainty over generalis ability of values across settings. Appendix 4 Tables 4.5 to 4.8 
provide details of the degree of uncertainty in each source found in the each country, 
and includes details of the base case value or costing approach, and the possible 
alternative value(s) or approach(es). 
While many sources of uncertainty were found, some were concluded to be relatively 
important (either because the uncertainty is minimal or the overall impact on costs is 
likely to be small), and therefore only a few areas of uncertainty were tested (written in 
bold in Appendix 4 Tables 4.5 to 4.8). The problem with providing alternative values or 
approaches is that they should be backed up with evidence (and probability of 
occurrence if possible) (Drummond et al 1997). However, due to the lack of such data 
for many areas of uncertainty, many of the ranges or alternatives are assumed for 
convenience. In fact, it is likely that the ranges chosen overestimated the true ranges, 
and therefore the resulting ranges on unit costs are unlikely to occur. The variables 
chosen for inclusion in the multi-way sensitivity analysis were: (1) increase cost of 
trade abies by 50% to account for possible unfavourable exchange rate variations or 
changes of world supplier. (2) Increase wages by 50% to reflect an alternative value for 
. . 
opportunity cost. (3) Halve and double the length of life of capital goods used in the 
base case, to reflect uncertainty and variation in the actual length of useful life of these 
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goods. (4) Insufficient number of months in Cuba and South Africa, where adjustments 
are made based on variability in Thailand to account for the smaller sample size in 
/ 
months of unit cost data. In addition to these sources of uncertaInty, results are 
presented at the black market exchange rate for Cuba and an alternative exchange rate 
(nominal exchange rate in May 1999) for Thailand and South Africa. 
5.5 Analysis of cost variation 
Following the distinction between costs 3?d the identification of components of total 
cost (introduced in Chapter 1 Box 1.1 and Figure 1.1, and discussed in detail in the 
literature review chapters), four types of cost were chosen for analysis of variation. 
These were health service use, resource use, unit cost, and cost per pregnancy (case 
cost). The purpose of separating cost per pregnancy into its' component parts is that it 
helps explain similarities and variations in cost per pregnancy, a process which 
contributes to understanding whether such costs can be generalised or predicted between 
settings. In addition, analysis of health service use and resource use, which are presented 
in non-monetary units, allows cross-country comparisons without the complication of 
currency conversion, and the associated burden of interpreting costs presented in a 
common currency such as US$. 
The purpose of this section is to describe how each type of cost is analysed. Before this, 
some general principals and procedures are presented. The first section distinguishes 
between different levels of cost variation, and clarifies which are of most interest to cost 
generalis ability. The second section discusses briefly the procedures for judging 
significance In cost variation, distinguishing between statistical and economic 
significance. 
5.5.1 Levels of cost variation 
This section briefly outlines which variations are studied for the four types of cost and 
why. Table 5.4 tabulates the various levels of variation for each type of cost. 
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Table 5.4: Levels of comparison for different cost components 
Cost component Between Between Between trial Between country 
women groups facility arm Intervention Control 
Health service use A C G K P 
Resource use No data D H L· Q 
Unit cost No data E I M R 
Cost per pregnancy B F J N S 
(the letters A to S are referred to in the text below) 
Comparison between groups of women: As stated, unit costs were not measured on an 
individual woman basis (due to the adoption of the top-down costing approach) whereas 
health service use was (A), allowing for calculation of cost per pregnancy (B) for all 
women. While analysing health service use (A) determinants on a patient level using 
multiple regression analysis may give interesting results, the picture would be 
incomplete as only one type of health service use can be examined as the dependent 
variable in a single regression equation, and therefore the focus of the regression 
analysis is on cost per pregnancy (B) as the dependent variable. 
Comparison between individual health facilities: Although health facilities are generally 
homogeneous within country with respect to approaches to health care (Piaggio et al 
1998), it is possible that cost components vary significantly between health facilities. 
Therefore, comparison of relevant aspects of health facilities may help towards an 
understanding of why costs vary between health facility (if they do) and has important 
implications for the generalis ability of the costs results within country. For example, if 
cost per pregnancy varies unexplainably between health facility (F), this throws doubts 
on the usefulness of the results for policy makers. However, if variations do not exist, or 
variations can be explained, such as unit cost variation being caused by different staffing 
levels (D) or health service use (C), the results have some use for policy makers. 
Therefore, variations in all types of cost are examined. 
Comparison between trial arm: The comparison between trial arms is important to 
examine in making conclusions about whether the W.H.O. programme has brought 
about changes in cost per pregnancy (J). However, note that changes in cost per 
pregnancy.can come from anyone of the three components (price, resource use, health 
service use), and that if cost per pregnancy remains unchanged between arm, it does not 
mean differences do not exist in sub-components. For example, the new programme 
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may involve less antenatal visits (G) but more resource use per visit (H), thus balancing 
each other out to have no overall impact on cost per pregnancy. Therefore, it is 
important to understand the behaviour of each cost component;/ to know their 
contribution to change in cost per pregnancy. Also, the threshold analysis (described 
earlier) provides information to allow tentative conclusions about the likelihood of a 
zero mean incremental cost occurring. 
Comparison between country: The final comparison, and one that is not undertaken 
" , 
until the results are understood completely at the countrY level, is between countries. As 
shown in the final two columns of Table 5.4, two types of comparison are possible, each 
with their uses. The first is a comparison between intervention arms between country, as 
this shows whether the new programme has been adopted in a similar way, with similar 
health service use (K), resource use (L), or even unit cost (M). The second, comparison 
between control arms, is also useful in that heterogeneity between country is understood, 
and the relative costs in the intervention arms interpreted in the light of the 'starting 
point'. The content of the control arms may help explain disparities in health service use 
in intervention arms in different countries. 
5.5.2 'Significant' variation 
For the purpose of this thesis, a distinction is made between two types of significance. 
The first, statistical significance, is useful for saying with a pre-defined level of 
confidence whether a difference could be due to chance. The second, economic 
significance, is useful for saying whether a difference is economically meaningful. 
Judgements about both types of variation are important ,at the cost analysis stage, 
because if differences are not significant, either statistically or economically, then it is 
less worthwhile to examine the causes of these differences. 
For the determination of statistical significance, there is a recognised method of judging 
significance using statistical tests based on assumptions about the sample distribution 
approximating the popUlation distribution (Gujarati 1999) (described for each type of 
cost below). However, the determination of economically meaningful differences is not 
as clear-cut. This is because economic value is a highly context-specific phenomenon, 
whether absolute or relative values are used. For this thesis, a criterion for judging 
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economic meaning must be set. However, few precedents were found in the health 
economics literature (Drummond and O'Brien 1993, Birch 1997). 
While absolute value may be preferable on pragmatic grounds (such as whether the cost 
difference is enough to change a decision), data are not available from the study settings 
on the cost differences at which decision makers would change their decision, whether 
at the unit cost or the cost per pregnancy level. Relative value, on the other hand, is 
potentially a more generalisable measure, but is also limited by the fact that the 
.' , 
economic meaning of a percentage change in cost is' highly context -specific. It also 
suffers the disadvantage that if the percentage difference is high, but it is the percentage 
of a very small amount, economic meaning is concluded when in fact it may not exist. 
However, as it is the only criterion left available to judge cost differences in this thesis, 
relative value is used. The next question concerns: relative value of what? As antenatal 
care is the focus of the current thesis, it seems appropriate to choose the cost of an 
antenatal visit as the measure of relative value. Differences in unit costs between health 
facilities are therefore judged on the basis that a difference in unit cost of at least one 
antenatal visit is interpreted as economically meaningful. Differences in cost per 
pregnancy between trial arms are judged on the basis of equivalent numbers of antenatal 
visits, and again, differences in cost per pregnancy of at least one antenatal visit is 
interpreted as economically meaningful. However, this is recognised as arbitrary, and 
the costs of different types of health service and implications for economic significance 
are discussed. 
5.5.3 Analysis of health service use variation 
The first question concerns "to what extent are differences in health service use 
significantly different?" Comparisons of health service use are made at the health 
facility level for variables with distributions using the t test43 which allows for the 
cluster effect, and at the trial arm and country levels using the F test. For dummy health 
service use parameters, where the answer is either 'yes' or 'no' (e.g. caesarean section 
rate), the chi-squared test is used. The second question concerns, if variations are 
statistically different, "what factors are causing these variations?" Appendix 4 Tables 
4.9 and 4.10 summarise those variables identified from the literature review in Chapter 
4 and examined in the thesis that potentially explain rates of health service use, using 
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patient and provider factors respectively. Most of these variables are relevant for uptake 
of outpatient ANC, but some (e.g. costs of services, risk levels, morbidity) are also 
relevant for explaining variations in inpatient ANC, delivery typ{ and neonatal 
admission. 
Data are collected and compared on factors affecting health service use, such as 
geographical access, health service costs, transport costs, familiarity with health 
services, risk levels and morbidity. For example, geographical accessibility is examined 
by comparing the average distance from' ~iinic for different populations, as well as 
average transport travel time, and transport availability and cost. The sources for these 
data are trial data, including the women's cost survey, satisfaction survey, and the main 
trial summary forms. It should be noted that for all of these sources, the studies were 
designed to make conclusions about differences between arm, and therefore differences 
between individual clinics can only be examined in an exploratory manner. 
Appendix 4 Table 4.10 lists the provider factors under study that potentially influence 
all types of health service use. These include financial incentives to providers, 
compliance with guidelines, quality of care, and attitudes to risk. For many of these 
variables there is simply a yes/no answer. Thus a picture is built of which clinics or 
countries are expected to have the higher or lower levels of health service use. 
5.5.4 Analysis of resource use variation 
In order to identify and explain unit cost differences, resource use is presented in the 
form of an input output ratio. For some resources this is more difficult to do, for two 
main reasons: (1) the top-down approach to costing was used and therefore exact uses of 
some resources for individuals was not recorded, such as materials and equipment, and 
(2) some resources cannot be measured on an individual level without extremely 
detailed data collection, such as the use of electricity or of furniture per patient. 
Therefore for some resources, ratios are not presented. The methods of analysis for each 
type of resource are shown in Table 5.5 .. 
43 The t test fails only if distributions are severely non-Normal. 
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Table 5.5: Cost analysis methods to analyse variation in physical resource units 
Resource Analysis methods 
Staff 1. Staffing structures in all participating health facilities are tabulated and 
discussed, and nurse/doctor and health care/support staff ratios are provided. 
2. Input/output ratios are tabulated and compared graphically between health 
facilities and with occupancy, and differences examined. 
3. Data envelopment analysis is used to estimate technical efficiency of outpatient 
ANC provision within each country, and inpatient care in Thailand, using 
average monthly staff numbers as the input and average monthly throughput as 
the output. The model is run under assumptions of variable and constant returns 
to scale. 
Equipment General profiles of equipment in participating health facilities are compared. 
Drugs For outpatient care, the results of a drug survey (llsing the antenatal records of a 
sample of women in each health facility) are used to tabulate types and quantity of 
drugs prescribed to women in Cuba and Thailand, and general trends discussed. 
Materials Aspects of material usage are discussed, and conclusions made about differences. 
Utilities A brief description is given of utility use. 
Buildings A brief description is given of building use, and input/output ratios are tabulated and 
compared (throughput per square metre per month). 
Other Bed occupancy rates and average length of stay are compared using the Lasso method 
(Lasso 1986). 
5.5.5 Analysis of unit cost variation 
The first stage in unit cost analysis is to tabulate and compare unit costs, identifying 
statistically significant differences. The statistical method used for comparing unit costs 
depends on the type of comparison. First, unit cost comparisons between any two cost 
centres are made using the F test, as it gives more precision than a t test. A On' by om' 
ANOVA is used, On' being the number of facilities and Om' the number of months of 
data. The interpretation of the results from these comparisons based on month-to-month 
instead of patient-by-patient variation has already been discussed. Second unit cost 
comparisons between two groups of facilities, such as trial arms, are also made using the 
F test, where a 'p' by 'q' ANOVA is used, 'p' being number of groups being compared 
and 'q' the number of health facilities in each group. This test takes into account the 
cluster design of the ANC trial. Confidence intervals are provided for the differences. 
Economically meaningful differences are judged using the criterion 'the percent cost of 
an ANC visit'. 
In the literature reVIew, a number of po~sible causes of unit cost variation were 
described and evidence for their impact on unit cost was presented. Not all the methods 
identified in the review are used in this thesis, due to data limitations to explain 
differences (case-mix and quality of care, which receive only superficial attention), and 
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to minimal expected impact in the study settings (economies of scope, as servIces 
offered did not vary between randomised health facilities within country). Table 5.6 
summarises the methods that are used to explain unit cost variations, and the 
hypothesised impact of different factors on unit cost (from Chapters 2 and 4). 
Table 5.6: Impact of hypothesised factors on unit cost and methods for assessment 
Factor Hypothesised impact on unit cost Methods for assessment 
of factor 
X-efficiency Wastage (X-inefficiency) increases 1. DEA (inputs: average monthly staff costs 
unit cost and total cost of capital stock; output: 
. . average activity data) . 
2. Tabulate staff ratios with unit cost 
3. Recalculate unit costs using staff ratio of 
mostproductive health facility 
Returns to the The presence of spare capacity 1. Tabulate monthly throughput & unit cost 
variable factor increases average cost 2. Re-estimate costs at 80% & 100% capacity 
Economies of Larger providers may use resources 1. Tabulate health provider size & unit cost 
scale more productively, thus lowers AC 2. Tabulate % overhead cost & unit cost 
Input mix Greater resource intensity increases 1. Tabulate resource intensity ratios & prices 
unit cost 
Case-mix More severely ill patients increase 1. Tabulate risk conditions & unit cost 
unit cost 2. Tabulate morbidity levels & unit cost 
Prices Higher prices increase unit cost 1. Compare unit cost ratios and price ratios 
2. Recalculate unit costs based on prices in 
other countries 
Costing Inappropriate methodology reduces 1. Critically evaluate costing methods 
methodology the accuracy of unit cost 2. Examine differences in costing methods 
Uncertainty Affects the size and confidence 1. One-way and multi-way sensitivity 
intervals of unit cost (either analysis (described earlier) 
direction) 
The main analyses expected to explain unit costs are data envelopment analysis44 (to 
. estimate a technical efficiency score for outpatient care in all countries, and inpatient 
care in Thailand), recalculation of unit costs using staff productivity of most efficient 
health facility, recalculation of unit costs under assumptions of operating at optimal 
(80%) and full (100%) capacity, examination of economies of scale using cross-
sectional data, and analysis of input mix. Case-mix differences using morbidity profiles 
are also examined. Also, for the between country unit cost comparison, the impact of 
price differences on unit costs is explored, and unit costs are compared under alternative 
costing and currency exchange methods. 
5.5.6 Analysis of cost per pregnancy variation 
There are four stages in analysis of cost per pregnancy variation. First, statistically 
significant differences are sought in average cost per pregnancy (ACPP), marginal cost 
44 Using IDEAS software 6.0.2 Standard, 1 Consulting Inc ©. 
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per pregnancy (MCPP) and median values. The threshold analysis (described earlier) is 
presented to make conclusions about the robustness of the differences identified . 
./ 
Second, cost per pregnancy at the facility, arm and country levels are tabulated 
graphically with health service use rates, as well as unit costs, to identify which are most 
responsible for cost per pregnancy variations. Third, women are grouped by case-mix 
(risk factors and events) and compared to see which ones appear to predict cost per 
pregnancy using bivariate analysis (using the Pearson'correlation coefficient). While it is 
recognised that bivariate analysis does not take into account multiple determinants of 
.' . 
cost, it is potentially useful for identifying variables to be included in multiple 
regression analysis (MRA). Fourth, multiple regression analysis is performed, the 
methods of which are described next. 
The purposes of the regression analysis are: to understand and explain the variation in 
cost per pregnancy (the dependent variable) in study countries in terms of hypothesised 
determinants of cost (independent variables); and to use these results to predict costs in 
other settings. This thesis uses several principles recommended by econometricians in 
model building and interpretation (McCloskey and Zilliak 1996, Gujarati 1999), 
described in Chapter 3. The rest of this section is outlined as follows. First, the 
dependent and independent variables are listed and justified, with recourse to economic 
theory. Second, the various approaches to running the regressions are described, and the 
approach( es) to be used chosen and justified. Third, tests done on the regression results 
are described, to check the best-linear unbiased estimator (BLUE) properties of the 
model. Fourth, the approach to interpretation of the results is described. The methods 
used for the application of the results to predict costs in the same and other settings are 
described in the next section, under 'cost prediction methods'. 
Choice of dependent variable in MRA 
Costs are combined for several types of maternity care, to capture the 'cost per 
pregnancy'. These include outpatient and inpatient antenatal care, delivery care, 
postpartum inpatient stay, and neonatal intensive care. While each of these could be 
chosen as dependent variables, the purpose of this thesis is to predict the overall costs of 
the W.H.O. antenatal care programme. Countries are analysed deparately. While all 
women from both trial arms are included in the regression, there is a dummy variable 
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for trial arm. Due to the skewed distribution of most cost data, and the distribution of 
cost per pregnancy is no exception, data are transformed to log values or log log values, 
/' 
and if the error term is still not adequately normally distributed~' the maximum 
likelihood estimator approach is used. If the log of total cost approximates a normal 
distribution, then no alternative measures such as bootstrapping are required. 
Choice of independent variables in MRA 
In specifying the regression model, the factors that are most likely to have a relationship 
. . . . 
with the dependent variables are consider~d, and the· ~xpected sign predicted, using 
economic theory as the guiding principal. Second, scatter plots are used to confirm these 
relationships. Univariate regression analysis is also used to give an indication of the 
expected regression coefficients. Consideration is given to those variables that should 
remain in the model irrespective of whether they are statistically significant. 
Following the results of previous studies reviewed in the literature (Chapter 3), 
independent variables are classified under women's risk characteristics (at the start of 
pregnancy), pregnancy and delivery 'events' (morbidity or predictors of health service 
use), provider characteristics (where women receive their care), and health service use 
by the women. Appendix 4 Tables 4.11 to 4.13 give the variables available under each 
of these four categories, with their expected relationship to cost, expected size, expected 
collinearity with other variables, and variable interpretation (dummy or continuous) 
described for each variable. 
Some variables are not included, such as tetanus immunisation and iron 
supplementation, as there is minimal variability between women. A quality of care 
variable was not estimated, therefore the results implicitly assume identical quality 
between health providers. Input prices, sector of ownership, and rural/urban location are 
not included as they do not vary within the same country. Finally, neonatal death is not 
included due to the very low occurrence «0.1 %). 
Appendix 4 Table 4.11 shows 11 a priori risk factors. For all except the age and 
previous pregnancy variables, an increase is likely to be associated with an increase in 
costs. This includes number of years at school, as education is more likely to increase 
~. 
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uptake for services than have the opposite effect. The main concern for multicollinearity 
for these risk factors is between previous abortionlstillbirthILBW baby/surgery with 
'last pregnancy adverse outcome'. Also, previous adverse outcome~~e likely to be 
associated with higher age as older women have higher parity. 
Appendix 4 Table 4.12 shows three main pregnancy events as regressors - gestational 
age at first visit (before or after 20 weeks), referral to a higher level of care during 
pregnancy, and an adverse event during pregnancy. The latter two are tested for 
. . . . . 
correlation. Several events around delivery are also tested for their influence on cost per 
pregnancy, including preterm, pOStterm, prelabour rupture of membranes, induced 
labour, breech presentation at delivery, elective CS, and adverse diagnosis at labour. 
Again, correlation is assessed between these variables. Postpartum information includes 
birth weight, apgar scores at 1 and 5 minutes, congenital malformation, and the presence 
of postpartum syphilis or anaemia. Generic measures of case-severity or diagnostic-
related groups are not used because they are poor predictors of cost, and also these data 
are not available from the antenatal care trial. 
Appendix 4 Table 4.13 also shows a selection of provider characteristics, including 
whether the new or old ANC programme is being practised, staff efficiency in out- and 
inpatient departments, occupancy rates, and health provider size (for economies of 
scale). The inclusion of such predictors of average cost means that average costs 
themselves are not included. Also, health service use variables are included for the main 
types of health care, including the number of antenatal visits, and dummy variables for 
whether a woman was admitted during pregnancy, the type of delivery, and whether her 
baby was admitted to intensive care. Dummy variables are used for inpatient admission 
instead of actual number of days admitted for, in order to enable the model to be applied 
to data where numbers of days on a patient basis may not be available. 
For all continuous variables, a curve is estimated (for log cost), to see whether a square, 
cubic or square root term is a better fit that the linear term. 
Running the regressionS"5 
45 Regressions were run using SPSS for Windows software version 9.0. 
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This section discusses the procedures for performing the regression analysis. While the 
nature of the variables being tested may suggest in advance the functional form or 
statistical tests required, some choices regarding analytic methods also have to be left 
until some preliminary regressions are run and the data examined. 
First, the functional form chosen for testing was as ordinary least squares (OLS). 
Logistic regression analysis has been excluded, because the final model should do more 
than just predict whether a woman is high or low cost (according to an arbitrary cut-off 
. point). Other models, such as Weibull or Cox, have been excluded because they are 
essentially survival models and not particularly appropriate here. Maximum likelihood 
estimator and generalised least squares models are compared to ensure the OLS is the 
best functional form for the data. 
Second, the normality of the response· variable (log cost or log log per pregnancy) is 
assessed using histograms. While it is recognised that the log transformation may reduce 
the problem of skewed data (thus ensuring the BLUE condition is met), outlying values 
are also examined in terms of their impact on the results. Dudley (1993) argued that the 
regression coefficients in OLS can be greatly affected by extreme high cost patients. 
Therefore, if log cost is still seriously positively skewed, and log log cost does not 
improve it, the bootstrap technique is applied to estimate the standard errors. While the 
bootstrap standard errors are likely to be similar to analytical ones if residual resampling 
is done, they are larger if casewise resampling is done. However, the practice of OLS 
suggests that minor deviations from normalty do not matter. Log values to the base 10 
are used in the base case analysis, and compared with log values to the base e to see if 
there is a better fit or if the distribution of the error term is better. 
Third, the likely impact of the cluster design of the W.H.O. trial is assessed by 
comparing the variances of log cost per pregnancy for all the clusters. The variability of 
costs in the clusters (variability in cluster 1 I variability in cluster 2) is compared with 
the F distribution, to see if they vary in any meaningful way (at the 5% level). If there is 
significant variation, the regression model is run to take account of the cluster design. 
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model are overstated. If important variables are omitted from the model, the F test will 
be significant. Also, there exists irrelevant variable bias, due to inclusion of irrelevant 
variables. This increases R2, despite having no real effect on Y. Finding specification 
error requires some judgement on the part of the analyst, and assessment of changes in 
results as variables are added to or removed from the regression equation. However, 
care is taken not to 'over fit' the model, which involves including variables that have 
limited relevance outside the study setting. 
5.6 Cost prediction 
Cost predictions are made in and between all countries (methods described below). Cost 
predictions are compared to cost observations and accuracy tabulated, using both 
rela_tive (%) and US$ values. Cost predictions are judged to be 'accurate' if the 
confidence intervals of predicted and observed costs overlap. Whether differences 
between predicted and observed cost are economically significant is judged based on 
whether the difference is more than the cost of one ANC visit. 
5.6.1 The incremental cost impact method 
As described in Chapter 4, the incremental cost impact method involves examining the 
required changes in current care to meet new guidelines, and identifying cost impact 
based on available local data. Where potential sizes of impact are identified, intervals 
are provided to reflect a judgement about the likely range of the impact. In applying the 
, .-
ICIM to identify the cost impact of the W.H.O. ANC programme, the following are 
examined: 
• Impact on the timing and number of antenatal visits, and location of visits, based on 
W.H.O. recommendations and expected visit rate of women with adverse events. 
• Impact on the content of visits, including risk assessment, health care provided, and 
advice and counselling. Information on the contents of the W.H.O. recommended 
programme are taken from the W.H.O. trial 'Manual of clinical activities', while 
information on the contents of current antenatal practices are taken from the clinic 
and patient baseline surveys. 
• Impact on health service use. This takes into account differences in referral policy 
and scheduling of appointments as well as differences in morbidity rates. Also, 
assume that proportions of 'no treatment' rates for adverse events are identified 
earlier and treated under the W.H.O. ANC programme. 
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• Impact on unit cost. This takes into account differences in the resources required for 
the change in intervention, as well as possible changes in throughput. 
~/ 
• Impact on cost per pregnancy. This is evaluated by combining the two components 
of cost per pregnancy - health service use and unit cost - to estimate overall cost. 
5.6.2 Regression analysis cost predictors 
The basic methods for regression analysis used in this thesis have been described 
already. While cost prediction is . done using the results of the MRA, other 
considerations must be taken into account~ . as well as further tests to see how well the 
model predicts. For example, if parameters are included that have limited relevance 
outside the data set that generated the coefficients, it may be wise to test the model with 
these omitted, or make adjustments to the model. Also, concern for a high R2 should be 
balanced against the risks of including too many independent variables that add only 
marginally to the predictive power. Also, functional forms need to be decided in 
predicting cost. For example, the logistic and Cox models are better than ordinary least 
squares (OLS) at predicting the proportion of patients with high cost (given some 
arbitrary cut-off point). However, as Dudley (1993) argues, OLS is generally an accurate 
predictor of mean cost, and therefore where the main aim of cost prediction is to predict 
mean cost, as in this study, this is an appropriate functional form to use. 
The implications of the results of the .. regression analyses for cost predictions are 
explored in detail. For example, whether the coefficients have similar signs and 
magnitude between countries is identified, and if not, reasons for differences are sought. 
Similarity between country would suggest some generalis ability of results across 
countries, and therefore predictive power. This means that coefficients from the 
regression model can be useful in predicting changes in cost per pregnancy between 
populations of women and providers with different characteristics. However, if the 
magnitude of coefficients diverge, then causes are sought: are the model or data 
inadequate? or do different cost determinants exist between country? 
5.6.3 Direct transfer method 
The direct transfer method involves substituting cost per pregnancy ~n one country into 
another country, where the mean, median and confidence intervals are transferred using 
both nominal exchange rates and PPP. 
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5.6.4 Adjusted transfer method 
Two main types of adjusted transfer of cost per pregnancy are used. These are: 
1. Transferring average costs, but using local health service use rates. This involves 
assuming identical unit costs across countries, using both nominal exchange rates 
and purchasing power parities. 
2. Transferring health service use rates, but using local unit costs. This involves 
assuming identical health service use rates across countries. 
5.6.5 Simplified staff cost method.' ',' 
The simplified staff cost method for predicting average costs was descibed briefly in 
Chapter 4, and is based on the observation that the largest proportion of average costs 
are accounted for by staff costs46,47 (Barnum and Kutzin 1993). Therefore, the average 
contribution of staff costs to total direct costs for each country (X%) is used to predict 
total direct costs, by scaling up by (11X% )/100. Then the average contribution of direct 
costs to total costs for each country (Y%) is used to predict total health care costs, by 
scaling up by (IN%)/100. This gives the equation: 
DCr= llXx IN x DCs 
Where UCT = Unit cost including costs of direct health care and overhead departments 
UCs = Unit cost including only costs of direct staff (staff cost/throughput) 
X = (approximate % of direct health care costs that are staff costs)/lOO 
Y = (approximate % of total costs that are direct health care costs)/lOO 
Therefore with DCs. X and Y, DCr can be predicted. The % values required for X and Y 
are taken as the average for each country, with upper and lower values reflecting the 
95% confidence limits for each country. DCs was estimated using data on the number of 
staff in the clinic or ward (N), average salaries for different types of staff (S), and 
monthly throughput data (T), using the following formula: 
n 
DCs = [L NiSi] / T where i = 1 ... n reflects the number of staff categories 
i=l 
46 The exceptions are when health services are particularly drug/equipment intem;ive, or when imported 
goods are very expensive compared to non-traded goods such as staff. 
47 While this method was not found in the literature, the need for a quick costing method in Argentina and 
Saudi Arabia (for the W.H.O. antenatal care trial) requiring minimum data lead to the development of this 
technique of average cost prediction. 
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6 CAUSES OF VARIATION IN 'NATURAL' RESOURCE UNITS 
/ 
The literature review concluded that to understand whether costs collected in one health 
care setting can be used to predict costs in other settings, the determinants of cost and 
the causes of cost variation should first be understood. The methods chapter argued that 
costs are more comparable between settings, particularly international settings, in their 
'natural' units48 - that is, before they are converted to'monetary values. This is because 
of the problems associated with transferring monetary cost when it is unclear whether 
'.' 
the prices used reflect opportunity cost and when there are alternative currency 
exchange methods to use, but uncertainty about which one is most appropriate for cross-
country comparisons or generalisations. Also, an understanding of variation in natural 
unit~ will contribute to the understanding of unit cost and cost per pregnancy variation 
in subsequent chapters. Therefore, this chapte~ identifies relative costs in natural units, 
tests for statistically significant differences, and examines the causes of inter-setting 
differences where they exist. Section 6.1 focuses on health service use, and Section 6.2 
on resource use. 
6.1 Causes of variation in health service use 
6.1.1 Variation between trial arms 
6.1.1.1 Size of variations 
Tables 6.1 and 6.2 below show the average rates of health service use for women 
recruited to intervention and control arms in the W.H.O. antenatal care trial in Cuba and 
Thailand. Within country variation is the focus of this section, with a view to explaining 
why rates varied between arms (the control group and the intervention group). 
Outpatient care 
Table 6.1 shows that in Cuba the mean difference in ANC visits between trial arm is 5.6 
visits, which is a statistically significantly difference (a mean of 7.5 visits per woman in 
the intervention arm and 13.1 visits in the control arm). The 95% confidence interval of 
48 'Natural' units are defined in this thesis to include both 'health service use' (numbers of visits, days or 
surgical case) and 'resource use' (amount of resource use per visit, day or surgical case). 
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difference between means is 5.47 to 5.8 visits49• In Thailand the mean difference 
between trial arms in ANC visits of 2.7 visits is also a statistically significantly 
difference (a mean of 4.4 visits per woman in the intervention arm and 7.1 visits in the 
control arm). The 95% confidence interval of difference between means is 2.58 to 2.88. 
Also, statistically significant difference in medians were found using the Wilcoxon rank 
sum test. Differences for both Cuba and Thailand are economically meaningful, in that 
the reduction in visits in the new programme is more than one in both countries. 
Table 6.1: Outpatient antenatal care visits in 'Cuba and Thailand. 
Outpatient antenatal care Country and 






































1 Statistically significant difference in medians were found using the Wilcoxon rank sum test; 
CI - confidence interval; CL - confidence limit. 
Inpatient care 
Table 6.2 shows rates of use of inpatient care in Cuba and Thailand. In general, rates of 
inpatient admission and lengths of inpatient stay in Cuba are higher in the intervention 
arm than the control arm: the average length of stay (ALOS) for high risk patients is 2.7 
days longer in the intervention group (p<0.05). Rates of caesarean section are almost 
identical between trial arms in Cuba. Finally, there are similar rates of neonatal 
admission to intensive care in both arms, but the ALOS in the intervention group is on 
average 1.3 days longer (p>0.05). 
In Thailand, there are no statistically significant differences between arm for inpatient 
ANC. For postpartum caesarean patients the ALOS is 0.73 days longer in the control 
group (p<0.05), and for vaginal delivery ALOS os 0.3 days longer in the control arm 
(p<0.05). Caesarean section rates are 1.9 percentage points higher in the intervention 
49 Although this confidence interval, using independent samples t test, does not reflect the skewed nature 
of the data (see Appendix 5 Figure 5.1), the difference is large enough to be confident that a statistically 
significant difference exists. ' 
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arm (7.3% versus 5.4%, p<O.05), and a higher proportion of babies are admitted in the 
intervention arm (4.4% versus 3.2%, p<O.05). The next section explores why these 
statistically significant differences might have occurred. 
Table 6.2: Inpatient health service use in study countries. 
Country and Inpatient ANC Deliveries Postpartum stay Neonatal ICU 
trial arm % admissions ALOS (days) % distribution ALOS (days) % ALOS 




Int. arm avo 10.6% 4.1% 13.6 11.0 77.4% 22.7% 3.22 6.03 5.38% 12.00 
Cont. arm avo 10.0% 3.2% 13.1 8.3 76.6% 23.2% 3.07 5.82 6.25% 10.68 
Difference -0.6% -0.9% -0.5 -2.7 -0.8% +0.5% -0.15 . -0.21 0.87% -1.32 
95% CI of diff. NS NS NS -5.2--0.1 NS1 -0.36-0.4 -0.6-0.2 NS2 -3.7-1.2 
THAILAND ALL 
Int. arm avo 2.8% 2.9 92.7% 7.3% 1.79 2.26 4.4% 6.66 
Cont. arm avo 2.6% 3.2 94.6% 5.4% 1.49 2.99 3.2% 7.44 
Difference 0.2% 0.3 -1.9% +1.9% -0.3 0.73 1.2% 0.78 
95% CI of diff. NS -0.5-1.2 SIG3 -0.34--0.24 0.34-1.1 SIG4 -2.8-4.3 
Table key: ALOS = Average length of stay; ICU = intensive care unit; LR = low risk; HR = high risk; VO 
= vaginal delivery; CS = caesarean section; NS = Not statistically different; SIG = Statistically different; 
ANC - antenatal care. 
1 The difference of 0.5% between the control 'and intervention arms for CS rate was not found to be 
statistically different at p=0.05, using the chi-squared test. 
2 The difference of 0.87% between the control and intervention arms for neonatal admission in Cuba was 
not found to be statistically different at p=0.05, using the chi-squared test. 
3 The difference of 1.9% between the control and intervention arms for CS rate was found to be 
statistically different at p=0.05, using the chi-squared test. 
4 The difference of 1.2% between the control and intervention arms for neonatal admission in Thailand 
was found to be statistically different at p=0.05, using the chi-squared test. 
6.1.1.2 Causes of variations 
Outpatient care 
The first and possibly most important health service use difference to explain is the 
reduction in antenatal visits due to the 'intervention' in both Cuba and Thailand. As 
described in the methods chapter, the intervention recommended a 4 visit minimum for 
low risk women, and further visits if indicated. This rate is almost reached (in terms of 
the average) in Thailand (4.4 visit average) and there is a substantial reduction in Cuba 
(to a 7.8 visit average). The trial Steering Committee is in agreement that the principal 
reason for this reduction was the successful implementation of the W.H.O. programme 
of antenatal care. The main evidence supporting this conclusion is that the reduction was 
experienced in intervention clinics but not in control clinics, supported by the baselines 
surveys that showed clinics to have similar characteristics, including average visit rates 
(Piaggio et al 1998). 
Appendix 5 Table 5.1 suggests other possible factors explaining why ANC visit rates 
varied between intervention and control arms. These factors implicitly raise questions 
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over the success of the matching of clinics in the cluster design of the trial, and whether 
minor (random) differences were in fact responsible for differences observed in trial 
/ 
outcomes. While most of these factors were found to vary insignificantly between arms, 
some factors were found to vary. In Cuba, these included: 
• The medicine cost per visit to women was higher in the control group. This would 
have a disincentive effect on attending health care in the control arm. 
• Before the trial, women were expected to be concerned about receiving less visits in 
the W.H.O. ANC programme. However, the satisfaction survey results showed that 
more women in the intervention group in Cuba said they were happy with the 
antenatal care they received than in the control group (93% versus 87%). 
• Syphilis tests were done on the spot in the intervention policlinics, meaning that 
patients did not have to come back again for the results and treatment. 
• Some risks and morbidity rates were different between arm. These are shown in 
Appendix 5 Table 5.2. Risk differerices included higher rates of hospital admission 
for hypertension in the last pregnancy (3% versus 1 %) and higher rates of previous 
reproductive tract surgery (4% versus 1 %) in the intervention group. More women 
were referred in the intervention arm (15% versus 12%). 
In Thailand, some other differences were observed between control and intervention 
arms, summarised in Appendix 5 Table 5.1: 
• The travel method differed marginally, suggesting that women in the control arm 
were slightly more mobile because a larger proportion used private motorbike to 
attend ANC - 15% more women than in the intervention arm. Despite this, mean 
travel time and travel cost were identical between arms. 
• Waiting and treatment times in control clinics were 32 minutes longer than in the 
intervention arm (98 minutes versus 66 minutes mean), thus acting as a disincentive 
for women to attend ANC in the control arm. 
• Cost per visit incurred by women for medications was on average 20 Baht higher in 
the control arm, but nutritional supplements were 16 Baht higher in the intervention 
arm, thus balancing the cost difference. 
• Lost earnings per woman were 30 Baht higher in intervention arm (for those women 
losing income). This was not because they earned more, per se, but because only 22 
women lost income in the control arm versus 37 women in the intervention arm. 
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• Satisfaction with spacing of visits in the new programme was lower (66% versus 
85%) as well as satisfaction with the number of visits (72% versus 90%). However, 
/' 
when asked about overall satisfaction with the service, the groups w~re more equal 
(95.5% versus 97.5%). 
• More women attended ANC early in the control group (32% versus 38% reported by 
12 weeks, and 53% versus 63% by 16 weeks), thus possibly leading to more visits. 
• Bleeding during pregnancy was more commonly reported in the intervention arm 
(103 versus 35 women) and more womep were treated for urinary tract infection (56 
versus 28 women). 
These results from Cuba and Thailand show mixed evidence to explain why ANC visits 
were- higher in the control arms. Several of these factors may have influenced the 
average numbers of visits in each trial arm, and but these data do not allow a 
quantitative link to be drawn between each individual factor and the number of ANC 
visits. 
Inpatient and delivery care 
Although the W.H.O. antenatal care programme did not provide guidelines for 
management of inpatients, some differences were observed. Table 6.2 showed that 
inpatient admission rates were not significantly different between arm, but that average 
length of stay did vary significantly between trial arms for high risk admissions in Cuba 
and for postpartum stay in Thailand. 
Although statistically non-significant, women in the intervention group in Cuba were 
referred for higher level care more often (14.6% versus 12.5%), leading to a higher 
admission rate (15.2% versus 12.8%). The higher admission rate was due to more cases 
of the following: 11 pre-eclampsia, 10 prelabour rupture of membranes (PROM), 12 
malpresentation, 11 multiple gestation, 5 urinary tract infection (UTI), 8 cardiac disease, 
and 8 vaginal bleeding. Most of these differences are unlikely to be caused by quality 
differences between antenatal care programmes. The higher rates of admission during 
pregnancy and neonatal admission and CS rate in the intervention arm in Thailand may 
have been the result of chance. On the other hand, they may have been caused by the 
providers practising the new programme were (a) more efficient in diagnosing 
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conditions, and/or (b) more risk averse. However, these factors were not measured to 
explain variation. 
Admission rates and length of stay were higher in the intervention arm than the control 
arm in Cuba for postpartum care and for neonatal intensive care ALOS. However, these 
differences are not explainable using data on maternal and neonatal delivery outcomes 
from the trial data set50• Finally, a higher proportion 'of neonates were admitted to the 
intensive care unit (lCU) in the interven~()n arm in Thailand (4.4% versus 3.2%, 
p<O.05), although they had a lower ALOS in the intervention arm. This may have been 
due to non-significantly higher rates of morbidity and CS in the intervention arm, thus 
affecting the neonate's condition. 
A general problem faced in this study in trying to explain different rates of admission 
and length of stay between trial arms is that there are a wide range of pregnancy events 
and outcomes, but these have not been captured on a generic case-mix scale. Therefore 
ill health, and its' link to hospital admission and length of stay, could not be compared 
more exactly between trial arms. In addition, while the randomisation of clusters should 
have provided trial arms with well matched background (a priori) characteristics, it is 
possible that there still existed some random differences between arms, thus causing 
significant differences in some outcomes that were not related to the intervention under 
study. This point can be illustrated using anecdotal evidence, such as in the case of Si 
Chompoo hospital (control arm, Thailand) which had a policy of discharging normal 
vaginal deliveries on the same day as delivery, thus helping explain the lower 
postpartum ALOS in the control arm. This example provides further rationale for 
examining health service use at the individual health facility level, discussed in the next 
section. 
6.1.2 Variation between individual health facilities 
Table 6.3 below shows health service use data at the individual health facility level, as 
well as showing aggregated rates by trial arm and by country (Appendix 5 Table 5.4 
shows a more complete version of this table, with median values and numbers of cases). 
50 Rates of low birth weight were the same across trial arms; adverse diagnosis at delivery was higher in 
the intervention arm (16% versus 13%). 
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The results show some rates to be very similar between health facilities, but show other 
rates to be disparate between health facilities, requiring further examination. 
Table 6.3: Health service use data by health facility, trial arm, and country. 
Country and Outpatient ANC Inpatient ANC Deliveries Postpartum NeonatallCU 
health care Average visits ALOS (days) Percentage ALOS (days) ALOS (days) 
provider Mean Median LR HR ALL VD CS VD CS Mean ALL 
CUBA 
13 de Marzo 7.5 6 16.3 10.5 2.22 77 23 3.0 6.8 11.5 0.61 
Albarran 7.8 6 10.6 14.0 1.81 82 18 3.3 5.5 14.4 0.69 
Galvan 7.3 5 17.3' 9.5 2.56 74 26 3.8 6.3 13.8 1.17 
Manduley 7.6 5 12.2 11.1 '1.76 75 " 25 2.9 5.7 10.4 0.49 
Romay 7.4 5 15.6 11.3 2.15 76 24 3.1 6.2 12.6 0.75 
Zuluetta 7.3 5 10.1 5.9 1.24 79 21 3.3 5.6 7.7 0.42 
A v. intervention 7.50 6 13.61 10.92 1.95 77.4 22.6 3.22 6.03 12.0 0.7 
Aballi 13.3 13 14.9 7.1 1.77 77 23 3.1 6.0 9.8 0.55 
Escalona 13.0 12 15.0 6.7 1.93 76 24 3.2 5.7 11.0 0.81 
Guiteras 12.4 12 14.1 8.7 0.94 79 21 3.3 5.2 9.6 0.65 
Reina 13.0 13 11.3 11.7 1.32 76 24 2.9 5.5 10.1 0.42 
Tamayo 13.6 13 8.5 8.4 1.06 77 23 2.9 6.0 14.1 0.76 
Vantroi 13.1 13 13.3 8.0 1.50 77 23 3.1 6.4 10.2 0.65 
Average control 13.14 13 13.07 8.25 1.53 76.6 23.4 3.04 5.82 10.68 0.6 
AVERAGE ALL 10.23 12 13.31 9.65 1.75 77.0 23.0 3.15 5.92 11.27 0.66 
THAILAND 
Chumpae 4.05 4 2.5 0.075 94 6 2.11 3.96 4.79 0.30 
Banphai 4.58 4 2.0 0.019 91 9 1.79 3.83 11.89 0.59 
Phuwiang 4.74 4 3.4 0.086 87 3 1.40 2.26 7.88 0.11 
Manjakiri 4.43 4 2.9 0.099 95 5 1.53 2.48 3.94 0.13 
Khaosuankwang 4.24 4 4.0 0.157 97 3 1.69 2.05 2.78 0.08 
Waeng Noi 4.47 4 2.3 0.087 95 5 1.95 1.53 6.17 0.18 
Av. intervention 4.38 4 2.87 .073 93.0 7.0 1.78 3.00 7.44 0.28 
Kranuan 6.56 7 3.4 0.141 93 7 1.50 4.95 5.16 0.12 
Nongsonghong 6.19 6 1.8 0.022 96 4 1.73 3.32 5.14 0.33 
Phol 8.11 8 4.2 0.106 93 7 1.92 3.70 12.68 0.50 
Nongrua 6.37 6 2.0 0.010 95 5 1.43 4.65 3.40 0.13 
Srichompoo 7.10 7 3.0 0.005 98 2 1.03 0.23 6.75 0.09 
Nampong 8.42 9 2.6 0.193 93 7 1.49 2.85 8.94 0.50 
Control average 7.11 7 3.19 0.085 95.0 5.0 1.64 2.26 6.60 0.25 
AVERAGE ALL 5.71 5 3.02 0.080 94.0 6.0 1.64 2.61 7.02 0.27 
SOUTH AFRICA 
Prince Mshiyeni 5.97 6 6.9 2.330 0.78 0.22 2.21 ,7.33 3.13 1.69 
TABLE KEY: ANC - antenatal care; LOS - length of stay; HR - high risk woman; LR -low risk woman; 




Outpatient antenatal care, in general, shows consistency between health facilities within 
the same trial arm. This can be seen in column 3 of Table 6.3, where ANC visits in the 
intervention arms varies between 7.3 (Galvan) and 7.8 (Albarran) visits per woman in 
Cuba, and between 4.05 (Chumpae) and 4.74 (Puvieng) in Thailand. ill the control arm, 
there is slightly greater variability, between 12.4 (Guiteras) and 13.6 (Tamayo) visits per 
woman in Cuba, and between 6.19 (Nongsonghong) and 8.42 (Nampong) in Thailand. 
This is likely to be because there was less st~dardisation of ANC procedures in control 
than intervention hospitals. While it is useful to be able to identify causes of variation 
between health facilities, there are limited variations in women's characteristics between 
Nongsonghong and Nampong district hospitals in Thailand (see Appendix 5 Table 5.3). 
How~ver, previous inpatient admission and previous low birth weight rates were higher 
in Nampong than the average, suggesting that case-mix may have been heavier there, 
thus leading to more visits. However, there were few other factors explaining why ANC 
visit rates varied across clinics. 
ill terms of other factors determining numbers of ANC visits, the data on factors listed 
in Appendix 5 Table 5.1 are not able to show variation between individual health 
facilities, due to small sample sizes (around 30 per facility). 
Inpatient care 
illpatient admission and length of stay during pregnancy varied between health facilities 
in both Cuba and Thailand, with rates in some health facilities several times those of 
other health facilities (see Table 6.3). ill Cuba for example, Guiteras had a third the 
number of inpatient days per trial woman compared with Galvan. Table 6.3 also shows 
that Tamayo had a low rate, and 13 de Marzo and Romay had high rates. The rate of 
referral partly explains these rates, with 7.3% of women referred in Guiteras, and around 
16% of women in Galvan and 13 de Marzo, compared with the Cuban average of 
13.6%. ill general, clinics with high inpatient days (IPD) per woman had higher risk 
status at the start of pregnancy, but there were similar rates of pregnancy events in all 
clinics. 
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In Thailand, Nongrua and Sichompoo had by far the lowest average number of inpatient 
days, well under one tenth the rates of recorded in Khaosangkuang and Nampong. High 
IPD rates can be partly explained through a high referral rate in NaniI>ong (11 % of 
women), and significantly higher sexually transmitted disease treatment rates, urinary 
tract infection cases and bleeding rates in both Khaosangkuang and Nampong. Also, 
there were no referrals in Nongrua (out of 400 women) and only 1 referral in Si 
Chompoo (out of 595 women). 
Although the CS rate in Cuba was almost 'identical between trial arm, it ranges from 
18.4% in Albarran to 25.7% in Galvan (a statistically significant difference using chi-
squared test, p<0.05). In Thailand, the CS rate ranged from 2% in Sichompoo to 12.6% 
in Puvieng (also a statistically significant difference). This large variation in Thailand is 
mainly due to differences in cephalo-pelvic disproportion, previous CS, breech position, 
failure to progress, and fetal distress. The results suggest that hospitals manage labour 
differently, although practices were not studied in detail to support such an assertion. 
The postpartum ALOS per woman were similar between policlinics in Cuba, but in 
Thailand ALOS ranged from 1.0 in Sichompoo to 2.1 in Chumpae following vaginal 
delivery, and from 0.23 in Sichompo051 to 5.0 in Kranuan following CS.· Sichompoo 
had such low rates due to a policy to discharge women as quickly as possible following 
delivery. The trial data set provided no detailed information on health states of women 
.. 
following delivery (except alive/dead), and therefore causes of variation cannot be 
examined further. 
Intensive care days per neonate ranged from 0.42 in Zuluetta to 1.17 in Galvan (p<0.05). 
The low days per neonate in Zuluetta were not due to a low admission rate, but because 
ALOS was low at 7.7 days compared to the country average of 11.3 days. Galvan, on the 
other hand, had both a high admission rate and a high ALOS (13.8 days per admission). 
The LBW rate was high in both Zuluetta and Galvan; therefore these 2-way 
comparisons do not explain why days per neonate are low in Zuluetta. In Thailand, days 
per neonate ranged from 0.08 in Khaosankuang to 0.59 in Banphai (p<0.05). The low 
days per neonate in Khaosankuang were partly due to a low admission rate compared to 
other hospitals, as well as a low ALOS per admission. Likewise, days per neonate were 
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high in Banphai, Phon and Nampong due to a higher ALaS per admission, and a high 
admission rate. The LBW rate was similar across hospitals, although it is low in 
Nongrua and high in Manjakiri and Waengnoi. In conclusion, it appears that the 
measures of case-mix do not predict ALas. On the other hand, as already mentioned, 
the availability of neonatal intensive care facilities varied between hospital. 
6.1.3 Variation between countries 
Outpatient care 
Visits per woman in the intervention arm range from 4.4 in Thailand to 7.5 in Cuba, and 
in the control arm from 5.97 in South Africa, to 7.1 in Thailand, to 13.1 in Cuba. Table 
6.4 lists the same factors as those in Appendix 5 Table 5.1, at the country level, to 
examine whether they could explain differences in numbers of antenatal visit between 
countries. Several reasons are discernible from Table 6.4 why women in Cuba may 
receive more ANC visits than other countries. These include the fact that services are 
more convenient to attend, they have shorter waiting times in the clinics and paid leave 
from employment, there are generally less cultural barriers to modem health services, 
and women have been educated for longer. Also, there are no private alternatives to the 
public health system in Cuba. Data from Appendix 5 Tables 5.2 and 5.3 show that 
women in Cuba have higher risk status, from previous pregnancies and abortions. 
Attendance rates may be below the recommended 10-12 visits during pregnancy in 
South Africa because health services are not highly accessible geographically, and 
because clinics are always very crowded and women have to wait many hours before 
and during care. Also, women in South Africa may be more constrained than the other 
countries by whether her partner, husband or their family allows her to attend ANC. 
On the other hand, rates of illness episode are lower in Cuba than Thailand and South 
Africa. Appendix 5 Tables 5.2 amd 5.3 show that case-mix variables vary significantly 
between country for both risk factors and events during pregnancy, some of which 
determine health service use (through more antenatal visits and inpatient admissions). 
For example, a higher proportion of women in Cuba have previous abortions and 
negative previous birth outcomes (partly due to higher parity), leading to higher risk 
status, and thus more antenatal visits and higher CS rate. Also, the fact that women 
51 This rate is from a very small sample size. 
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reported the earliest in pregnancy in Cuba partly explains the high average number of 
visits there. On the other hand, previous surgery on reproductive tract (15%), last baby 
low birth weight (LBW) (24.4%) and hypertensive diseases of pregnancy (11 %) are all 
high in South Africa, where women receive an average of only 6 antenatal visits. 
However, the late reporting of women in South Africa (80% not attended by the 20th 
week) is likely to account for their low rate. 
Table 6.4: Assessment of factors explaining health service use variation between country. 
Determinants of Data available on factors being . Cuba Thailand South Africa 
health service use compared 
Patient factors 
Accessibility Average distance from the clinic < 1 km 0-20 km 0-20km 
Average time from the clinic 5-10 minutes 30-35 minutes 30 minutes 
Availability or use of transport Walkable Bus& Taxi or by foot 
Average cost of transport 1.4 Peso return motorbike R3.0 return 
28 Baht return 
Cost of health Cost of consultation 0.7 Peso (gift) Zero Zero 
services Cost of medicines 3 Peso I visit 85 Baht I visit R1.41 visit 
Cost of items advised Extra food 60 Baht I visit R2.91 visit 
Relative cost to wage rate 2% month wage 1 % month wage 0.8% month wage 
Opportunity cost Waiting and treatment time 40-80 minutes 60-100 minutes 120-180 minutes 
Proportion of women with jobs 14% paid 21% paid 10% paid 
Time taken off work 2 hours Half day Half day 
Paid leave to attend ANC Yes If formal job No 
Average salarv 200 Peso/m 14 Baht I hour R566 I month 
Use of alternative Alternatives available Healer Healer, private Healer, private 
services Amount of use of alternatives Minimal Small % 50% of women 
Familiarity with % first pregnancies 18.5% 40.9% 35.8% 
modern health care Baseline average ANC visits 13-15 7-9 4-6 
% institutional delivery rates 100% 95% 60% 
Quality of care % of women happy with service 90% 96.5% nla 
% women happy with spacing 87% 76% nla 
Socio-economic Average age 26.2 24.5 25.5 
status % not in stable unionlmarriage - 9.9% 1.1% 84.6% 
Number of years of education 11.6 years 6.5 years nla 
Average rooms per house 2.3 rooms 2.6 rooms nla 
Average people per house 4.8 people 5.2 people nla 
Cultural attitudes Cultural acceptability of services Accepted Accepted Accepted 
To services Need permission from family No Some If'lebola' paid) 
Attitudes to risk Desire for minimum ANC visits Yes Yes Not available 
Actual risk levels Country-specific risk factors Abortion, CS Thalassemia Hypertension 
and previous 
surgery 
Other Weather patterns Heat and rain Heat and rain Not a barrier 
Provider factors 
Financial incentives Fee schedule None None None 
To providers Other payments to providers Sometime gift Sometimes gift None 
Compliance with General contents of ANC Western model Western model Western model 
standards of care Monitoring systems in place Health targets Supervision Suoervision 
Quality or Training level of main providers Obstetricians Midwives Midwives 
effectiveness Availability of diagnostic equip. In policlinics In hospitals Not laboratory 
of health care staff On-going refresher courses Yes Yes Yes 
Capacity use Average % of capacity used Variable Variable Alwavs very busy 
1 Lebola IS the payment made by the woman's famdy to her partner's farruly for the marrIage. After 




Average inpatient days per woman in the trial ranged from 0.08 in Thailand to 1.75 in 
Cuba. From the survey in South Africa the rate was 2.33 days per woman. As already 
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discussed above, the event rates in South Africa were higher than the other countries, 
possibly explaining why 32% of women were admitted to hospital during pregnancy. 
For example, hypertensive diseases of pregnancy were the primary reason for admission 
in a high proportion admissions in South Africa (10.8% of women had hypertensive 
diseases of pregnancy)52. However, the 22-fold difference in IPD per trial woman 
between Cuba and Thailand could not be explained using case-mix comparisons . 
. " . 
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Possible causes were the high rates of bleeding suffered by women in Cuba (40% 
compared to only 2.2% in Thailandi3, as well as higher rates for pregnancy-induced 
hypertension, pre-eclampsia, uterine height low for gestational age, premature rupture of 
mem~ranes, malpresentation, and renal disease. The significantly higher ALOS in Cuba 
suggests that the severity of conditions could have been worse there, although there was 
noticeable variation in hospital discharge policy as case-mix differences do not account 
for differences in ALOS. As was suggested by the high number of ANC visits, and the 
national focus on maternity care in Cuba, health care was provided more intensively in 
Cuba than the other countries, and this is likely to have accounted for a large proportion 
of the difference in mean inpatient stay per trial woman compared to Thailand. 
Cesarean section rates varied from 6.4% in Thailand to 22.3% in South Africa to 22.9% 
in Cuba. Differences in CS rates were due to practice style variations as well as case-
mix variations. Practice style variations were suggested by the very different intrapartum 
rates, suggesting that health care providers had different attitudes to risk. Cuba is typical 
of most Latin American countries, where CS rates are high, whereas South Africa (and 
possibly this study in South Africa) is unusual in that CS rates in Africa are generally 
low. CS rates should be interpreted with the level of health facilities of the samples in 
mind: in Cuba and South Africa health facilities were secondary level, and in in 
Thailand they were primary level. This is a potentially important determinant of CS rate, 
because the availability of a well equipped specialist maternity operating theatre is likely 
52 However, these data from South Africa should be interpreted based on the fact that the sample was 
hospital-based, meaning that the rates did not represent the population rates in Umlazi. 
53 This difference may be due to difference in definitions of bleeding, despite attempts made in the ANC 
trial tried to standardise definitions. 
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to affect the doctors use of CS. Also, four of the sample hospitals in Thailand did not 
perform CS, thus reducing rates there. 
Case-mix is also an important determinant of CS rates, although again there is limited 
data to conclude how important. For example, higher parity in Cuba meant that that 
women were more likely to require CS (such as previous CS). In South Africa there was 
a high incidence of fetal distress, although it is uncle'ar why. It may have been due to 
better diagnostic instruments, or due to risk aversity of doctors and nurses. 
. . . .' . 
Postpartum ALOS ranged from 1.8 in Thailand to 3.3 in South Africa to 3.8 in Cuba 
(significant difference between Cuba and South Africa compared to Thailand). Higher 
CS ra~es in Cuba and South Africa probably caused part of the higher postpartum ALOS 
in those countries. Post-CS ALOS was lowest in Thailand (2.6 days), followed by Cuba 
(5.9 days) and South Africa (7.3 days). Thailand has an average post-vaginal delivery 
stay of 1.6 days, half that of Cuba's. This is likely to reflect differences in practice style 
than differences in case-mix. 
Neonatal ALOS for the whole study population ranged from 0.27 in Thailand to 0.66 in 
Cuba to 1.58 in South Africa (p<0.05). Neonatal admission rates were 5.8% in Cuba, 
3.8% in Thailand, and 71% in South Africa. The rate was so high in South Africa, 
because the 'nursery' in Prince Mshiyeni hospital where most newborns are taken is both 
a high risk and low risk area. Also, there is a lower average Apgar score at five minutes 
after birth in South Africa. A score of 10 was achieved by 76% of neonates, compared 
to 92% in Thailand and 96% in Cuba. In Thailand, district hospitals did not have a 
separate neonatal ward, but the incubators and cots were usually kept in the female 
inpatient ward. The difference in facilities perhaps suggests why in Cuba 78% of LBW 
babies were admitted, compared with 21 % in Thailand. Also, neonates were more likely 
to be admitted following CS, with 8.6% of neonates in Cuba being admitted after CS 
compared to 4.6% after vaginal delivery; 12.4% versus 3.08% in Thailand, and 90.4% 
versus 49.2% in South Africa. 
Cuba had the highest neonatal ALOS for admitted babies at 11.3 days, 4.3 days more 
than Thailand, and 9 days more than South Africa. The ALOS is lowest in South Africa 
'-.. 
138 
due to the better average case-mix there. Again, these differences reflected differences 
in practice style more than differences in health status of the neonates. However, except 
for the Apgar score discussed above, there are limited data on the condition of the 
neonate to explain these differences further. ' 
6.1.4 Conclusions 
The above analyses have found that several factors were responsible for variations in 
health service use during pregnancy and delivery, both within and between countries. 
The analyses have benefited from detailed case-mix and health service use data from the 
ANC trial for large samples of women, and these were supplemented by data on the 
costs to women of attending ANC. Several conclusions are made. 
First,- the trial arm of women was the most important determinant of numbers of 
antenatal visits. However, for other types of care, health service use was more dependent 
on which provider she attended, rather than which trial arm she was in. Second, 
proximity to health services was a potentially important determinant of health service 
use, as suggested by the higher rates in Cuba; however, there are other factors 
confounding this comparison. Third, case-mix in the form of risk factors and event rates 
probably determined health service use, and explained some variation between health 
facilities within country, as well as differences between countries. Fourth, patient 
expense and opportunity cost were a likely determinant of health service use, although a 
detailed study was not done of the disincentive effect of time costs and official or 
unofficial user fees. Fifth, practice style such as risk aversity and medical training was 
probably an important determinant of health service use, as many variations could not 
be explained by other factors. Practice style variations were likely to occur both within 
and between countries. The implication of these findings for generalis ability is that, 
even when implementing a standardised programme in more than one country, health 
service use cannot be predicted without knowledge of local practices and populations, 
such as compliance with national guidelines, risk aversity of health care staff and 
women, availability of both primary and referral services, and case-mix. 
6.2 Causes of variation in resource use 
The aim of this section is to examine what factors are responsible for the different rates 
of resource use between trial arm, health care providers, and country. Resources are 
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examined in terms of both their availability and their productivity. Categories of 
resource examined include staff, equipment, drugs, materials, utilities and buildings. 
/ 
Each resource is examined in tum, before the last section brings the result(together. 
6.2.1 Staff 
Description of staffing patterns 
Appendix 6 Tables 6.1 to 6.4 provide summaries of staffing patterns in participating 
health facilities, broken down by relevant department or cost centre, and by staff types, 
with input/output ratios. Appendix 6 Table' 6.1 shows that there are between 153 and 
340 staff in the sample policlinics in Cuba. About a third or a half of these staff work in 
the family doctor clinics (FDC), most of which are separate buildings from the 
policlinics within the community. In each FDC there are usually two doctors and two 
nurses, thus giving an average doctor/nurse ratio of 1.05, although this varies between 
policlinics from 0.52 to 2.03. The rest of the policlinic staff either work in specialist 
clinics (33%) or in support departments (7.2%) inside the policlinic building. All 
services are outpatient in nature, although many specialists also do shift work in 
hospitals. 
Appendix 6 Table 6.2 shows that district hospitals in Thailand employ between 72 and 
224 staff, divided between inpatient, surgical, outpatient and support services. There are 
no specialists in these hospitals, and the number of doctors varies between 1 and 6 per 
hospital (of whom one is always the hospital director), and an average of 10 nurses for 
every doctor. ANC is usually restricted to 1-2 days per week, and is provided in the 
health promotion section of the outpatient department. The majority of ANC is provided 
by nurses. Appendix 6 Table 6.3 shows that sample health centres in South Africa are 
mainly staffed by nurses, with a few non-technical support staff, totalling between 27 
and 40 staff. There are no doctors in the health centres. Most administrative work is 
done by the nurses, although finances and services are controlled by the Community 
Care department in the hospital. ANC is usually restricted to 2 days per week, when 
several nurses are involved in ANC activities. 
Finally, data are provided in Appendix 6 Table 6.4 on staffing patterns in referral 
hospitals in' Cuba and South Africa. In Cuba, all health care in America Arias is 
provided by obstetricians or gynaecologists (as it is a maternity hospital) and nurses, and 
over 50% of the hospital staff are working in supportive activities (administration, 
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laboratory, pharmacy, laundry, etc). In South Africa, inpatient wards are staffed mainly 
by nurses, hence the lower proportion of medical doctors than in Cuba where there are 
about 8 nurses per doctor. 
Staff output ratios 
In this section the reader is referred again to the tables in Appendix 6, but graphical 
summaries are presented in the text below. Figure 6.i shows that the number of ANC 
visits per full-time equivalent worker (in direct health care activities) varies between 
. . . . 
policlinics in Cuba, between 66 visits per staff per month in 13 de Marzo to 157 in 
Vantroi, with an overall policlinic average of 89. 13 de Marzo and Vantroi have similar 
numbers of staff in family doctor clinics, but the throughput of patients is more than 
double in Vantroi. The cause of this difference does not appear to be due to much higher 
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Figure 6.2 shows that the number of ANC visits per full-time equivalent worker (in 
direct health care activities) also varies significantly between hospitals in Thailand, 
between 34 visits per staff per month in Kbaosankuang to 151 in Nongsonghong. 
Kbaosankuang is the smallest hospital in the sample, but has a relatively large number 
of non-medical staff working in the health promotion unit, which may partly explain the 
low rate. Most hospitals have rates in the 60-120 range, with an average of 87 visits per 
staff member per month, which is similar to Cuba (89). Also, staff productivity is an 
average 15% lower in intervention hospitals, possibly due to less ANC visits. 
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Finally, in South Africa the ANC visits per staff member are much higher than those in 
Cuba and Thailand, with an average of 314, ranging from 227 in U21 clinic to 392 in H 
clinic. Appendix 6 Figure 6.1 shows that low occupancy rates are not responsible for the 
low rate in U21 clinic, as U21 clinic has the highest capacity use. Prince Mshiyeni 
hospital has a significantly lower rate at 143 visits per FIE. 
The differences in visits per FIE within countries may be caused by a number of 
factors, First, lower ratios would be expected in secondary or tertiary health facilities, 
where higher risk patients need more staff time. This is observed in South Africa, but 
not in Cuba, where the outpatient clinic has a significantly higher number of visits per 
FIE at 283, compared to the policlinic average of 89. Second, morbidity differences 
could be causing the variation in rates of visit per FIE. However, examination of the 
data shown in Appendix 5 Tables 5.2 and 5.3 demonstrated that there are limited 
differences in morbidity levels between health facilities in both Cuba and Thailand. 
Between country there are greater differences in morbidity rates, although South Africa, 
the higher morbidity population, also has the highest staff productivity. 
Staffing patterns are also examined below for inpatient care. While there are unlikely to 
be systematic differences between trial arms (as the new programme only changes the 
way outpatient care is provided), it is useful to examine relative rates of staff 
productivity in order to understand unit costs later, and also it allows cross-country 
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comparisons. Appendix 5 Figure 5.2 shows summary data from the inpatient wards in 
study countries (the twelve hospitals in Thailand are summarised under control and 
intervention arms). The results indicate that high risk inpatient wards in both Cuba and 
South Africa have lower days per staff compared to low risk wards, ~s expected. In 
South Africa, post vaginal delivery wards have about the same staff productivity as post 
caesarean section wards, which is surprising considering one would expect higher staff 
levels per patient in post CS wards. Thailand has the highest days per PTE, despite low 
occupancy rates. Cuba, on the other hand, ,has long lengths of stay and low turnover 
rates, with similar rates of bed occupancy to Thailand. 
Data envelopment analysis 
The final analysis with regard to staff is the use of data envelopment analysis (DEA) to 
calculate technical efficiency scores, using staff numbers and building space as inputs. 
In Cuba, Vantroi and Guiteras policlinics are the most efficient from the model, both 
obtaining a TE score of 1.0. Four policlinics score around 0.6 (see Appendix 7 Figure 
7.1). The Pearson correlation coefficient of 0.37 between visits per PTE and the TE 
score suggest that they are not highly correlated in Cuba. Differences between the two 
ratios in Guiteras, Tamayo and Galvan suggest that these policlinics make better use of 
their building space compared to other policlinics. 
In Thailand, there was greater variation in the TE score than in Cuba, between 0.4 for 
Nampong and 1.0 for Manjakiri and Waengnoi. Figure 6.3 shows the technical 
efficiency ratios compared with the visits per PTE ratios for all hospitals. However, the 
Pearson correlation coefficient of 0.687 (p<0.05) suggests that the visits per PTE and 
TE score appear to be linked, although Phon, Sichompoo and Nampong showed some 
variation from that expected. 
Finally for outpatient ANC, in South Africa the TE score is 1.0 for all health centres 
except U21 clinic, where it is 0.78 and where the visits per PTE are the lowest (see 
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For the DEA in inpatient wards in Thailand, two models were run using inpatient days 
(IPD) and inpatient admissions (IP A) as the output measures. The results are presented 
in Appendix 7 Figure 7.3 show TE scores vary between 0.6 in Kranuan and 1.0 in four 
hospitals. The Pearson correlation coefficients of 0.358 and 0.347 for IPD and IPA 
respectively suggest that there is not a strong positive correlation between visits per FTE 
and both TE scores. One result that cannot be explained at this stage is that 
Khaosankuang is the least productive hospital in terms of visits per FTE, but attains a 
TE score of 1.0. Examining the data shows that the number of IPD per month is very 
low (522), but with a relatively large number of staff (522). 
The DEA results discussed above are all under the assumption of variable returns to 
scale, which is justified on the premise that the marginal cost is less than average cost in 
all hospitals54. The data were also tested under the alternative assumption of constant 
returns to scale. This had a surprisingly large effect on the TE score, reducing it by 
several tenths for some hospitals, but only with a marginal effect on others. The larger 
effects appeared to be on hospitals with lower throughput. Appendix 7 Table 7.1 shows 
all the DEA data from this chapter. A weakness of the DEA performed in this chapter is 
that only two inputs were included (staff numbers and building space), thus not covering 
the range of resources used in providing care. However, constraints on quantifying other 
54 This is the definition of variable returns to scale in IDEAS, the DEA software. 
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inputs in manageable and representative resource use indices prevented other inputs 
from being included. 
6.2.2 Equipment 
A first and general comment on the size and contents of these lists is that in all countries 
the lists are extensive, and some very expensive items appear on the lists which would 
not usually be found in typical health facilities in low income countries. In the 
policlinics in Cuba, for example, autoclaves worth over US$2,OOO were in common use, 
as well as expensive microscopes, cehtrifuges, air conditioning systems and 
refridgerators. Computers were also in commonly available, although not all records 
were entered on computer as they were not available in all departments. Also, cars have 
been purchased in a few policlinics. America Arias hospital was also well stocked with 
equipment, including ultrasound (US$37,OOO), neonatal incubators (US$7,OOO) and 
ventilator (US$9,OOO), as well as a special analysis machine in the laboratory 
(US$72,000) and computers. Therefore, the support departments (laboratories and 
sterilisation departments) in Cuba are well equipped to perform their tasks. 
While for these reasons the equipment appears adequate for high quality health care, 
there were also some differences between policlinics in terms of the length of list of 
items worth over US$200, with noticeably shorter lists in family doctor clinics in 
Manduley, Vantroi and Zuluetta policlinics. Also, there were few items of equipment 
worth over US$200 in the family doctor clinics. Most of these had a multipurpose table 
and special lamp (in the clinic) and a refridgerator and television (in the doctor' s house), 
although some family doctor clinics had no or few valuable items (Galvan, Guiteras, 
Manduley). Some family doctors also had an autoclave, gynaecological bed and 
expensive electronic scales55• Finally, an important point to note in terms of future 
investment requirements in the health sector is that it is also noticeable that all these 
equipment are many years old (10-30 years old), suggesting that the 'special economic 
situation' in Cuba is having its' effect in the health sector. 
In Thailand, in general there was more and newer equipment in the district hospitals 
than the policlinics. The economic boom in Thailand in the early-mid 1990s meant that 
a huge investment programme was initiated in the health sector, giving district hospitals 
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the means to purchase many types of equipment. The most expensive equipment were 
hospital cars and ambulances worth over US$20,000, followed by X-ray, ultrasound and 
/ 
- ~ 
dentistry equipment (US$1O-20,000) and laboratory or laundry equipment (US$5-
10,000). Many of these were imported from Japan, China, Germany, and the USA. 
Expensive surgical beds and lamps, laboratory equipment, refridgerators and televisions 
were also commonplace. However, in making comparisons, note that the policlinics in 
Cuba did not provide inpatient care but did provide specialist care, whereas the district 
hospitals in Thailand provided inpatient and ,outpatient non-specialist care. 
In South Africa, the health centres had minimal equipment worth over US$200. Items 
recorded in all clinics were fridges, filing cabinets, delivery beds, and weighing scales. 
Some _clinics had sterilising equipment and suction machines. A widely quoted reason 
for the low resourcing was that thefts occur with regularity from clinics, despite the 
. 
presence of security guards 24 hours a day. However, the lack of equipment compared 
to Thailand and Cuba does not necessarily mean that nurses could not perform their 
functions properly. First, they received additional resource support from the hospital 
(such as laboratory tests and ambulances), and second the resources were more or less 
comparable to the family doctor clinics in Cuba which also have minimum equipment. 
Prince Mshiyeni hospital, on the other hand, was very well equipped with the items 
necessary for a secondary level general hospital. The most expensive equipment were 
neonatal incubators (US$26-28,000) of which nine were found, and laboratory 
equipment (US$25,000) of which five items were found. In addition to these, the 
neonatal room and laboratory had several other items in the top cost end of the 
equipment list. In the obstetric operating theatre there was a ventilator (US$18,000), 
anaesthesia machine (US$12,000) and defibrillator (US$8,000). Also, in the labour 
room there were special items such as an 'Ivacs' (US$9,000) and an ECG machine 
(US$6,000). 
In conclusion, both lower level (primary) and secondary level health facilities in study 
countries were well equipped to provide quality health care. However, some disparity 
was observed between some health facilities in Cuba and Thailand, but this was 
sometimes due to the health facility size, or special functions performed (for example, 
55 This is one of the problems of only sampling 4 family doctor clinics, as they may not be representative. 
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more emergency room or surgical patients). Due to the relative economic prosperity of 
Thailand and South Africa, there is more importation of high quality equipment from 
/ 
Europe, Japan and USA, rather than choosing cheaper domestically produced options. 
For Cuba, importing many items is the only option as many items are not domestially 
produced, but the country faces very high prices due to the restrictions on suppliers 
imposed by the US trade embarg056• 
6.2.3 Drugs 
From the surveys of antenatal cards in Cuba'and Thailand, exact drug use of a sample of 
women was recorded57• Data from these two samples and other studies are discussed 
briefly. Table 6.5 below shows the number of prescriptions given to the sample of 
women in Cuba. The total prescriptions (shown in the end column) vary significantly by 
policlinic, with between 4 (13 de Marzo) and 34 (Manduley) prescriptions given to the 
sample (all samples are between 14-16 women, except Escalona where it was 10). The 
total drug prescriptions in the intervention arm (102) exceeded those in the control arm 
(61) in the sample. 
While drugs like diazepam and metronidazol were prescribed by providers in all 
policlinics in Cuba, there was particular variability in the prescribing patterns of other 
drugs, such as clotrimazol, fumerato ferroso, vitamins, and the 'others' category. It was 
unknown whether doctors did not prescrilJe these drugs because the women had no 
need, or because they were not available in the pharmacies. Inconsistent recording may 
also have been responsible for some of the variations, such as whether or not vitamins 
were recorded. Also, a large component of 'drug' use is routinely provided drugs, such 
as 'prenatales', which contains multi-vitamins and iron folate, as well as the routine 
tetanus toxoid given to all women as needed. Therefore, the drugs listed in Table 7.5 
only contribute a small proportion of total drug cost. 
56 The USA would be the cheapest source of import for many medical goods, but Cuba has to buy from 
more expensive suppliers due to the USA trade embargo. 
57 'Scaling up' these data to the rest of the trial population was thought to give better estimates of drug 
cost than other methods identified. ' 
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Table 6.5: Prescriptions given to sample of pregnant women in Cuba, by policlinic. 
Policlinic Sample Diaz Fum Clot Met Ben Sulf Folic Inf Vit Other Total 
size ~/ drugs 
Intervention 
13 de Marzo 15 2 0 1 1 .0 0 0 0 0 0 4 
Albarran 16 1 0 4 3 1 1 0 0 0 3 13 
Galvan 14 2 0 3' 4 0 1 0 0 0 0 10 
Manduley 15 6 0 9 4 0 1 1 0 6 7 34 
Romay 14 2 0 9 4 4 5 0 1 0 5 30 
Zuluetta 15 0 1 9 1 0 0' 0 0 0 0 11 
Control 
Abailli 15 4 0 1 .' 4 0 1 0 1 0 0 11 
Escalona 10 1 0 3 1 0 1 .0 0 0 1 7 
Guiteras 14 4 3 5 2 0 0 1 0 4 1 20 
Reina 15 2 2 0 5 0 1 2 0 0 0 12 
Tamayo 15 1 0 2 1 0 0 0 0 1 0 5 
Vantroi 15 2 1 0 1 0 2 0 0 0 0 6 
ALL 183 27 7 46 31 5 13 4 2 11 17 163 
DRUG KEY and USES: Diaz - diazepam (hypertension); Fum - fumerato ferroso (anemia), Clot -
clotrimazol (trichomoniasis); Met - metronidazol (vaginal parasites); Ben - penicillin benzatinica 
(infection); Sulf - sulfaprim (urinary sepsis) and sulfamida (vaginal parasites); Inf - inferon (anemia); Vit 
- vitamins (C, B 12, B6); Other - duragina (analgesic), tiroide (hypothyroidism), indometacina (anti-
inflammatory), nistatina (manilia), fenoterol (abortion threat), gravinol (anti-hystemine). 
The use of prescriptions was also variable between hospitals in Thailand, although 
consistently lower rates per woman were observed compared to Cuba. Obumin, 
'nataval' (vitamins and folic acid), and ferrous sulphate were provided to all women, 
although in differing quantities. For many hospitals, no additional prescriptions were 
given to the sample women. For others, a few drugs were given such as amoxytocin, 
ammumilk (an anti-acid), methergin (prevent and treat postpartum hemorrhage), 
bricanyl (treat pre-term labour), and others. The hospital with the most prescriptions 
were Nampong and Nongsonghong (4 prescriptions) and Kranuan (5 prescriptions). 
In South Africa the method of recording drug use of a sample of 15 women per clinic 
was not used, and instead monthly quantities of drugs typically given to pregnant 
women were recorded. Two categories were distinguished: those drugs provided to 
pregnant women by the health care providers such as ferrous sulphate and paracetemol, 
and those drugs that pregnant women picked up from the pharmacy such as penicillin, 
methyl dip a, and stronger painkillers such as ibuprofen. Comparison of the quantity of 
drugs used every month with the numbers of pregnant women suggests quite an 
intensive use of prescribed drugs. 
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6.2.4 Materials 
Typical medical supplies recorded in all countries included gauze, bandage, alcohol for 
medical use, detergent, thermometers, distilled water, soap, peroxide. CMaterials also 
included those for general use (such as cleaning materials and floor polish) and those for 
use in the laboratory. In Cuba, the laboratory was consistently the most intensive user of 
materials in all policlinics. However, in some policlinics it was evident that some basic 
materials such as soap and detergent were often not supplied for family doctors. In 
South Africa, all the essential materials were supplied on a monthly basis, and no 
.' . 
serious shortages were noted. A large proportion of materials in Prince Mshiyeni 
hospital were consumed by the laboratory, delivery room, nursery and obstetric 
operating theatre, with the inpatient wards and outpatient clinics using significantly less 
materials (non-maternity health care departments were not included in the study). 
In Thailand also, the outpatient clinics and inpatient wards consumed a relatively small 
share of materials compared to the laboratory, emergency room, operating theatre 
(general) and dentistry. Disinfectant and cleaning materials were by far the most costly 
item regularly supplied to all the departments. In neither Cuba nor Thailand did it appear 
that material quantities delivered differed systematically between trial arms. 
6.2.5 Utilities 
The representation and comparison of 'utilities' in physical quantities is the most 
difficult of all the resources, but is broadly similar across all countries in that adequate 
utilities were available to run a minimum quality health service. For example, electricity 
use is difficult to discern at the department or clinic level, and particularly at the 
individual patient level. The use of some utilities appeared to be fairly uniform within 
the health facilities, such as water and electricity, although some departments such as 
laboratory made heavier use of these as suggested by the numbers of taps and electrical 
machinery. Gas tended to be used more by the kitchen and laboratory, and was often 
supplied by canisters rather than on mains. External telephone lines tended to be used 
more by administration departments. Internal telephone lines were not counted, as they 
were costless to use once installed. While data were available on approximate use by the 
cost centres for all the utilities, it was not thought to be a fruitful use of time to analyse 
these data before they were converted to costs (see Chapter 8 for unit costs). 
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6.2.6 Buildings 
Details of buildings were collected, with details of room numbers and size within each 
/" 
department grouping, and the proportion of the total health facility. In Cuba, policlinic 
buildings were surprisingly uniform in size, with most around 600-800 m2 (average 693 
m2). Albarran is the smallest (398 m2) and Guiteras the largest (1334 m2). However, the 
size of policlinic did not necessarily correspond to output (outpatient visits). The 
variable more closely related to output was the total sIze of family doctor clinics, most 
of which are located outside the policlinic ~uilding. Figure 6.4 shows the relationship 
between floor space in the family doctor clinics and output. The Pearson correlation 
coefficient of 0.225 suggests that building space is not an important determinant of 
monthly output, and thi is confirmed by visual inspection. For example, Vantroi has a 
very high output for its' small size. Also, Guiteras has by far the lowest space in its' 
family doctor clinics, because most of them (11 out of 15) are located inside the 
policlinic building, and these rooms are very small, giving Guiteras a space productivity 
ratio almost as high as Vantroi. 
Figure 6.4: Building space 'productivity' in policlinics in Cuba 
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In Thailand, there is a significant variation in visits per square metre between hospitals, 
and again, there is limited association between building space and monthly output. For 
example, Banphai, Khaosankuang, Puvieng and Nongrua all have significantly more 
building space than the other hospitals, but do not necessarily produce more output. 
'-, 
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The results of this section help explain the technical efficiency scores, as building space 
is the second input to the DEA reported earlier. Using the data presented, it is possible 
/' 
to conclude that part of the reason that Khaosankuang and Nongrua had~{ow technical 
efficiency scores was that they had low staff and building productivity. Judging by visits 
per FfE alone, Banphai should have a TE score close to 1.0, but it also has very low 
visits per square metre, thus explaining why the TE score is 0.8 instead. 
Finally, for inpatient care the number of d~ys per square metre per month was similar 
between country, with most wards falling in the range 1.5~2.5 days per square metre per 
month. As with the measure 'visits per FfE' the high risk wards are expected to have 
lower rates of days per square metre, which was true in Cuba. However the high risk 
wards In South Africa (both pre- and postpartum) had higher output rates than the low 
risk wards, and this was not due to higher occupancy. Hospitals in Thailand showed the 
greatest variability, varying from 0.72 to 4.28 days per square metre, with an average of 
1.76 for all hospitals. 
6.2.7 Study limitations and conclusion 
This section has provided a useful insight into the way resources are used and allocated 
within health facilities, which will be useful in interpreting unit cost variation in the 
next chapter. From the results presented in this chapter, it can be concluded that 
variability was the norm rather than the exception in resource use per patient, at both 
health facility and country level. The analyses have suggested that neither the health 
status of the population nor the level of hospital studied were not good predictors of the 
quantity of resources used. 
The analysis of resource use variation also suffered several limitations, due to lack of 
detailed data and the constraints on summarising some resources in single indices. It 
was found that staff were the most amenable to conduct data analyses, although it too 
had limitations. For example, the analysis of average staffing levels did not take into 
account difficulties in staff recruitment, day-to-day reallocations of staff between 
departments, and the fact that staff numbers in support departments were not included in 
the ratios (thus suggesting that a potential further source of variability was missed). 
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A weakness of the DEA approach in calculating a technical efficiency score was that 
only two inputs (staff numbers and building space) were used. This reflec~s more the 
difficulties of appropriate quantification of inputs than underlying probl~ms with the 
DEA method itself. Other resources could have been included, such as numbers of drug 
prescriptions, but this would not have allowed for differences in case-mix between 
health facility. Therefore, technical efficiency scores should be interpreted with the fact 
in mind that only two resource ingredients were included. 
In addition, there may be case-mix, quality or and demand uncertainty differences not 
analysed that may explain differences observed in resource use. Other functional duties 
of staff may not be captured by the output measures used. Differences in the daily 
activities of staff causing different ratios should be taken into account in interpreting the 
data, such as the fact that family doctors in Cuba spend half the day 'in the field' where 
they see less patients per hour than in the clinic. 
Comparisons of resource use are also hampered by cross-country differences in resource 
type, such as the age, specifications and quality of equipment or training levels of staff. 
Also, the availability of equipment does not necessarily mean they are used 
productively. For example, computers may be used more effectively in some health 
facilities than others, due to the availability of staff trained in programming or computer 
use. The cross-country comparisons also need also to be interpreted with the economic 
situations of the countries in mind. In Cuba recently, both recurrent and capital 
expenditure has been reduced to a minimum, with focus on essential drugs (thus 
pregnant women in Cuba are quite looked after with respect to drugs). In Thailand, on 
the other hand, there were large expenditures on buildings and equipment recently, with 
imported products rapidly increasing. In South Africa, a country relatively rich in terms 
of health sector spending per capita, equipment was minimal in the health centres due to 
the security situation, and also because they are supported by the secondary hospital. 
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7 CAUSES OF VARIATION IN UNIT COST 
~/ 
The aims of this chapter are to identify and analyse variations in unit costs of selected 
health services. Unit cost differences are examined using a series of cost analysis tools 
described in the methods chapter, and implications of the results for the generalis ability 
of costs are drawn. In the first section, unit cost variation is analysed within country, 
both between trial arm and between individual health facilities or wards. In the second 
section, unit cost variation is analysed bet~een countries, and ranges on average costs 
are calculated using sensitivity analysis to reflect greater uncertainty in cross-country 
comparisons of unit cost. Each section begins by identifying whether unit cost variations 
are statistically and economically significant. In particular, those factors influencing unit 
cost are compared between the high and low cost providers, to see whether unit cost 
differences identified can be explained. While the focus of the analysis is on average 
costs, conclusions are also made about variability in marginal costs. 
7.1 Unit cost variations within countries 
7.1.1 Outpatient care 
7.1.1.1 Size of differences 
Table 7.1 below shows that the pooled average cost per outpatient antenatal care visit in 
Cuba58 of US$12.18 in the intervention policlinics (95% confidence interval US$9.05-
15.31) was almost identical to the control policlinics ofUS$12.12 (US$8.99-15.60). The 
marginal cost, however, was US$1.14 more in the intervention arm policlinics. 
Although this difference was not statistically different, the 95% confidence interval on 
the difference was close to zero (-US$2.5 to US$O.20, p=-O.027). The economic 
difference was 9.4% of the average cost of an antenatal visit. Therefore, there is no 
definitive proof that the new antenatal care programme alters unit costs of outpatient 
care, nor is the difference observed economically significant59• 
58 The nominal exchange rate was US$I=1 Peso on 8 January 1998. 
59 While there was an observed reduction in outpatient visits made by pregnant women to intervention 
policlinics, this reduction did not affect average costs because the overall reduction in outpatient visits 
was marginal compared to the total throughput of outpatients in policlinics. 
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While there was no observed change in average cost between trial arms, variation 
between individual policlinicswas considerable. Appendix 9 Table 9.1 and Appendix 9 
Figure 9.1 show that average cost in policlinics varies between US$8.28 ail'd US$18.36, 
with many statistically significant differences arising6o. The average cost per outpatient 
antenatal visit was the lowest in America Arias hospital at US$3.22 (95% CI US$2.82-
3.62). The coefficient of variation (standard deviation + mean) ranged from 0.06 
(Escalona) to 0.28 (Guiteras) in policlinics, thus suggesting greater inter-month 
variability in average costs in some polidini~s61. 
Table 7.1: Average and marginal costs per ANC visit in Cuba and Thailand. 
Country and Average cost per visit (US$) Marginal cost per visit (US$) 
trial arm Lower Mean Upper COY Mean %AC 
Cuba 
Interven_tion group 9.05 12.18 15.31 0.27 4.72 0.39 
Control group , 8.64 12.12 15.60 0.30 3.58 0.31 
Difference (9S% CI) -4.48 0.06 4.36 P=0.73 1.14 (-2.S-0.2) P=0.027 
Thailand 
Intervention group 5.73 6.56 7.39 0.23 1.45 0.22 
Control group 4.92 5.83 6.73 0.28 1.47 0.24 
Difference (9S% CI) -2.74 0.73 1.28 P=0.673 0.02 (-1.0S-1.07) P=0.746 
In Thailand62, the pooled average cost per visit in the intervention hospitals of US$6.56 
(US$5.73-7.39) is greater than in the control hospitals of US$5.83 (US$4.92-6.73), but 
this difference of US$0.73 is not statistically significant (p=0.673). This extra cost 
amounts to 12.5% the average cost of an antenatal visit. However, there is no difference 
in marginal cost. Therefore, there is no definitive proof that the new antenatal care 
programme altered unit costs of outpatient care in Thailand, nor is the difference 
observed economically significant. 
Appendix 9 Table 9.1 and Appendix 9 Figure 9.2 show that average cost also varies 
significantly between individual district hospitals in Thailand, from US$3.62 to 
US$9.13 per visit. The coefficient of variation ranges between 0.08 (Banphai and 
60 As discussed in Chapter 5, the confidence intervals for individual health facilities were based on 
variability between unit costs for months over the sample time period; however, it is recognised that this 
did not necessarily capture the actual variability in unit costs, as unit costs also vary at the patient level. 
However, the confidence intervals from month-to-month variability may have been greater than 
confidence intervals from patient-to-patient variability. This was because the most important resource 
varying between 'patients was drug cost, which is a much lower cost contributor than staff cost. Therefore, 
findings of significant difference between unit costs using these data are interpreted with this is mind. 
61 Month-to-month variability in unit costs was tested for serial correlation in all countries, but none was 
found. 
62 The nominal exchange rate was US$I=52.3 Baht on 8 January 1998. 
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Nongrua) and 0.26 (Nampong). The average cost of an antenatal visit is lower in both 
referral hospitals, with an average cost per visit of US$2.75 in Khon Kaen hospital and 
US$2.10 in Sririgarind hospital63• Appendix 9 Table 9.1 and Appendix 9 Fiiure 9.3 also 
shows average and marginal costs per antenatal visit in clinics and Prince Mshiyeni 
hospital in South Africa64• Average costs vary from US$6.37 in L clinic to US$8.63 in 
Q clinic, and to US$9.05 in the hospital (all differences are statistically non-significant). 
Marginal costs in the clinics vary between US$0.36 and US$0.56 (average US$0.42), 
. and is US$0.95 in Prince Mshiyeni hospital . .'. 
7.1.1.2 Causes of ANC outpatient unit cost variation in Cuba 
In the following analysis, the specific aims are to explain why average costs are lower in 
Manduley, Escalona and Vantroi policlinics, and why average costs are higher in Galvan 
and Guiteras. In terms of efficiency measured by visits per FTE, Figure 7.1 below shows 
a clear, though not perfect, negative correlation between unit costs and visits per FTE. 
The Pearson correlation coefficient of -0.554 confirms that correlation may exist, but it 
is not significant (p>0.05). The number of visits per FTE ranged from 66 to 157 per 
month (average 89) in the policlinics, and to 284 in America Arias hospital. In most 
cases a high average cost is associated with low visits per FTE, and vice-versa. 
However, Escalona has low staff productivity, thus suggesting other causes for its' low 
average cost. Other policlinics appearing not to have the expected negative correlation 
between visits per FTE and average cost are Zuluetta, 13 de Marzo, and Abailli 
policlinics. 
Figure 7.1 also shows average costs recalculated (termed 'potential AC') with the visits 
per FTE of the most efficient policlinic (Vantroi), to see whether average costs 
converge. Although some convergence is noticeable (particularly in the higher cost 
policlinics), divergence is also observed, especially for Escalona. An encouraging result 
for explaining cost variation is that average costs in Galvan and Guiteras are reduced by 
around US$7, taking them closer in terms of average cost to other policlinics. 
63 However, these data were gathered from other studies, and therefore some of the difference may be 
caused by differences in costing methods. Also, as the study in Sririgarind hospital was done in 1989, the 
inflation adjustment factor (of 6% per year) may underestimate the true hospital cost inflation over that 
period. 
64 The nominal exchange rate was US$1=4.93 Rand on 8 January 1998. 
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Policlinic efficiency is also measured using data envelopment analysis. Figure 7.2 shows 
that more of the policlinics in the lower end of average cost have higher TE scores; 
however, the inverse relationship suggested by the Pearson correlation coefficient of -
0.169 does not suggest that a clear relationship existed. Notable exceptions are Guiteras 
and Tamayo which had a high average cost and high TE score, and Escalona which had 
a low average cost and a low efficiency score. 
Figure 7.2: Average costs and TE score for outpatient care in Cuba 
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A further consideration in interpreting the results of the 'efficiency' analysis is that they 
are influenced by the fact that most if not all units are operating at below capacity level, 
thus influencing average costs. High average costs due to low occupancy rates is not 
'technical inefficiency' in its' truest sense. However, low occupancy rates could be 
influencing the TE scores. Therefore the effect of throughput on average cost is 
examined further. Figure 7.3 "below shows an example of the strength of correlation 
between average costs and monthly throughput (in Zuluetta policlinic, Cuba), with a 
Pearson correlation coefficient of -0.685 (p~.o.061). The explanation for the correlation 
is simply that fixed costs constituted the largest part of cost, thus making average costs 
very sensitive to throughput. 
Figure 7.3: Correlation between average cost and throughput in 
Zuluetta policlinic over 8 months (Cuba) 
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Therefore, due to different levels of capacity use between policlinics, returns to the 
variable factor may be an important source of unit cost variation. Figure 7.4 shows the 
change in average costs when recalculated under 80% and 100% capacity use 
assumptions. In general there is no discernible pattern, in that the values for low cost 
policlinics are not consistently higher than high cost policlinics. However, average costs 
are reduced substantially in Galvan (a high cost policlinic) under the capacity 
assumptions, and Escalona is seen to be operating at above optimal capacity, thus 
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Figure 7.4: Average cost and returns to the variable factor for 
outpatient care in Cuba 
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Another potential influence on average cost, economies of scale, is examined. Figure 7.5 
below shows a simple scatter plot of antenatal care average cost with policlinic size 
(both at 80% assumption). The Pearson correlation coefficient of -0.851 (p<O.OI) 
suggests a significant inverse relationship between size and average cost65 . Using visual 
inspection, a line is drawn to try and fit the points. The line also suggests a negative 
relationship between average cost and size. 
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65 The outlier, America Arias hospital, is excluded from this calculation. 
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The presence of economies of scale is also examined through the percentage 
contribution of overhead cost to average cost. If economies of scale ex~st, smaller 
~ 
policlinics are expected to have a higher proportion of overhead costs in average costs. 
Overhead costs are defined as service, administration and support departments. 
However, visual inspection of Appendix 8 Figure 8.1 does not suggest a relationship 
between optimal throughput and the proportion of overhead costs in average cost. 
Input mix also differs considerably betwee~policlinics in terms of the contribution of 
each resource to average cost. For example, equipment cost per visit varies between 
policlinics from US$0.04 to US$0.26, materials from US$0.08 to US$0.33, and drugs 
from US$3.02 to US$6.77 (see Appendix 9 Table 9.4). The two main contributors to 
cost are staff and drugs. High staff costs in Guiteras and Galvan explain their high 
average costs; low staff costs in Vantroi and Escalona explain their low average cost; 
high drug costs also exaplin the high average cost in Guiteras. 
The impact of case-mix on health service use was examined in detail in the last chapter. 
In this section, the impact of case-mix on average costs is examined briefly, although 
the conclusions that can be drawn from these data are limited. Appendix 10 Table 10.1 
shows the extent of inter-policlinic case-mix for Cuba in the intervention arm. These 
data are gathered from the W.H.O. trial classification form for women attending 
intervention providers. In terms of rates of overall eligibility, there is some consistency 
between policlinics, with an average of 26% of women excluded. There are differences 
between rates of women with different condition, but these are not statistically 
significant. Romay has both lower risk women and a marginally lower average cost than 
the average for all policlinics. 
In conclusion, low average costs in Vantroi and Manduley policlinics are partly 
explained by high staff productivity and economies of scale, and low average costs in 
Escalona are partly explained because it is operating at above optimal capacity. 
However, it is not fully clear from the analysis why Escalona is almost US$4 lower cost 
than the average cost for all policlinics. High average costs in both Galvan and Guiteras 
are explained by low staff productivity, and also due to small overall policlinic size. 
However, Guiteras is also operating at above optimal capacity. 
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7.1.1.3 Causes of outpatient ANC unit cost variation in Thailand 
In this analysis, the specific aim is to explain why average costs are very low in 
Nongsonghong, and low in Puvieng, Nongrua and Sichompoo, and whi~~erage costs 
are high in Khaosankuang and Kranuan (Appendix 9 Table 9.1 and Appendix 9 Figure 
9.1). In terms of efficiency measured by visits per FTE, Appendix 8 Figure 8.2 shows 
the inverse relationship between visits per FTE and unit costs does exist in Thailand, 
which according to the Pearson correlation coefficient of -0.568 is close to statistical 
significant at the 5% level (p=0.054). Visits per FTE in the health promotion units of 
. . . . 
district hospitals vary from 34.3 (Khaosank~ang) to 15i~066 (Nongsonghong), with an 
average of 97. The relationship therefore suggests that the low average cost in 
Nongsonghong is partly due to very high visits per FTE, whereas the high cost in 
Khaosangkuang is partly due to low visits per FTE. However, the low visits per FTE 
observed in Sichompoo and Nampong do not predict high average costs. Also, average 
costs in Kranuan are high, despite a medium level of visits per FTE. Further evidence 
that differences in visits per FTE cause average cost variations is shown by the fact that 
the average cost line converges when recalculated using the visits per FTE of the most 
'productive' hospital (Nongsonghong). 
Using the technical efficiency score, Appendix 8 Figure 8.3 shows that there is no clear 
inverse relationship apparent with average cost. For example, Nongsonghong and 
Puvieng have generally low TE scores, while Kranuan and Khaosankuang have TE 
scores of 1.0. For the hospitals with medium average cost, there is little consistency 
apparent in the TE score. 
Differences in capacity use also appear to have little bearing on average cost. Appendix 
8 Figure 8.4 shows that there are significant reductions in average costs under both 80% 
and 100% capacity use assumptions. However, under these assumptions, average costs 
between the district hospitals do not converge. For example, hospitals with medium 
average costs have the biggest cost reductions under capacity use assumptions 
(Sichompoo and Waengnoi). 
66 Note that Sichompoo, Waengnoi and Nongsonghong operated the ANC clinic for one day a week, 
instead of two like the other hospitals. 
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Economies of scale do not appear to be present to the same degree as in Cuba, although 
two interpretations are possible from the data, a horizontal line (constant returns to 
scale) and a downward sloping line (see Appendix 8 Table 8.5). However:~ high degree 
of variability prevents a strong conclusion concerning the existence of economies of 
scale. The Pearson correlation coefficient of -0.251 confirms that it is unlikely 
economies of scale existed in Thailand. 
A similar examination of case-mix, as···mea,sured by trial eligibility in the intervention 
arm, is conducted for Thailand (Appendix 10 Table 10.2). The data show that women in 
. Chumpae (9% ineligible), KSK (7%) and Waeng Noi (7%) are relatively more healthy 
(compared to an average of 11 % of women excluded from the new package). However, 
these hospitals are middle or high average cost hospitals. In none of the cases are 
hospitals with lower rates of risk status also lower average cost hospitals. An alternative 
measure of case-mix, women's health outcomes, show significant variability between 
hospitals, such as for STD treatment rates, UTI, HDP, and bleeding, but there is no or 
limited correlation with average costs recorded. 
In conclusion, hospitals in Thailand with high or low average costs cannot be explained 
in terms of the available indicators as well as in Cuba. Actual versus predicted average 
cost in Puvieng, Kranuan and Sichompoo have the greatest divergence. For example, 
Kranuan is not predicted to have a high average cost (except for high materials cost). 
Also, many hospitals with low or medium average costs are predicted to have high 
average costs, such as Puvieng and Sichompoo. However, some hospitals are more in 
line with expectations. For example, Khaosangkuang is correctly predicted to have 
higher average costs, due to the very low visits per FTE. Also, Manjakiri and Phon are 
correctly predicted to be medium cost hospitals. 
7.1.1.4 Causes of outpatient ANC unit cost variation in South Africa 
Although there were no statistically significant differences in average cost between 
clinics or the hospital in South Africa, it is worth examining the same indicators as 
above, in order to see whether average costs are at expected levels. Appendix 8 Figure 6 
shows that visits per FTE are lower in the clinics with higher average costs, but there 
was limited convergence in average costs when calculated using the visits per FTE of H 
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clinic. Note, however, that H clinic with the highest visits per FfE did not have the 
lowest average cost in the sample. 
The TE score shows three clinics to have a score of 1.0. U21 achieves roughly 80% the 
efficiency as the other clinics, and Q clinic 86%. These results are consistent with 
expectations, that the higher cost clinics are not as efficient as lower cost clinics. The 
effect of capacity use assumptions on average cost, except for Q clinic, are inconsistent 
with expectations. Appendix 8 Figure 8. 7 s~ows that the lower cost clinics have lower 
. ~, 
capacity use than the others (not as expected), while Q clinic has the greatest reduction 
in average cost under the capacity use assumptions (as expected). Therefore, except for 
Q clinic, there is no convergence in AC under alternative assumptions. 
Economies of scale are not evaluated for South Africa, as no correlation could be 
examined with a sample size of only five clinics (four of them have a similar size). 
However, note that the largest clinic is not the cheapest, and the smallest clinic is not the 
most expensive, suggesting that economies of scale are unlikely to exist. Input mix, on 
the other hand, did not vary significantly between clinic, except drug cost is higher in H 
clinic, but not enough to impact the rankings of average cost between clinics. Case-mix 
is also not evaluated in the same way as the other countries, as the trial risk 
classification form was not applied to the sample of women in the outcome survey. 
Also, the data from the survey is not disaggregated by which clinic they attended. 
However, it can be said in general terms that the clinics are no different in that none 
have special functions for treating women at risk, and they serve the same populations. 
In conclusion, although less cost analysis were used for South Africa compared to the 
other countries, some important cost determinants were identified, including 
staffingproductivity and occupancy rates (see Appendix 10 Table 10.3 for comparisons). 
7.1.2 Inpatient care 
7.1.2.1 Size of variations 
Table 7.2 shows average and marginal costs for inpatient care in all countries. The types 
. . 
of comparison made in this section are similar to those made in the last section, with 
more attention to the impact of variations in case-mix explaining unit cost differences. 
'-. 
This is especially important when comparing low- and high-risk wards, or adult and 
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neonatal wards. In Cuba, average costs per inpatient day are higher in the high risk 
wards (wards AB and F) than the low risk wards (p<0.05). Also, the neona~al intensive 
care unit is by far the most expensive form of care. Cost per admission also varies 
between wards, and again the high risk wards are more costly per admission. However, 
ALOS in the low risk antenatal ward is over 3 days longer than the high risk antenatal 
ward, a surprising result given illness severity is supposed to be less there. Marginal cost 
as a proportion of average cost is stable across wards (20-27%). 
In Thailand, the average cost per day in the control and intervention hospitals are 
similar, at US$6.50 (95% confidence interval US$5.74-7.26) and US$6.62 (95% CI 
US$5.30-7.94) respectively. Marginal cost per day is also similar, averaging 14-15% of 
average cost. Cost per admission is similar between trial arms, although the ALOS is on 
average longer in the control hospitals (not significant). Appendix 9 Table 9.2 shows 
that average costs for hospitals individually varied significantly, between US$3.34 (95% 
CI US$2.95-3.73) in Chumpae to US$1O.60 (95% CI US$9.69-11.51) in 
Khaosangkuang (p<0.05). 
Table 7.2: Average and marginal costs of inpatient care in study countries. 
COUNTRY and Average cost (US$) Marginal cost (US$) Cost per IPA (US$) 
TYPE of CARE Lower Mean Upper COY Mean %AC ALOS 
CUBA 
ANC high risk (AB) 39.37 51.72 64.07 0.25 10.39 0.20 9.65 
ANC low risk (E) 23.95 30.84 37.72 0.23 6.80 0.22 13.31 
Post VO ward (C) 13.89 16.76 19.63 0.18 4.04 0.24 3.15 
Post CS ward (F) 29.14 36.75 44.35 0.21 8.78 0.24 5.92 
Neonatology 88.37 118.09 147.82 0.26 31.32 0.27 11.27 
THAILAND 
Intervention average 5.30 6.62 7.94 0.36 1.00 0.15 2.90 
Control average 5.74 6.50 7.26 0.21 0.94 0.14 3.42 
SOUTH AFRICA 
ANC high risk (ANW) 27.24 33.13 39.02 0.11 1.51 0.05 4.25 
ANC low risk (El) 29.34 30.56 31.78 0.03 1.26 0.04 3.04 
Post VO ward (E2) 22.57 27.67 32.77 0.12 3.34 0.12 1.90 
Post VO ward (E5) 27.30 32.34 37.37 0.10 2.18 0.07 6.19 
Post CS ward (E3) 24.63 26.25 27.86 0.04 3.64 0.14 7.48 
Post CS ward (E4) 21.84 26.21 30.58 0.10 2.24 0.09 1.88 
Nursery 23.47 27.85 32.24 0.10 3.12 0.11 2.23 
.. TABLE KEY: COY - coeffiCient of variatIOn (standard deviatIOn/mean); AC - average cost; IPA -
















In South Africa, the average cost per inpatient day in Prince. Mshiyeni hospital is 
cheaper for low risk antenatal care (US$30.56) than high risk antenatal care (US$33.13) 
(p>0.05). However, both post-CS wards are lower cost than post-VD wards (statistically 
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non-significant difference). Neonatal care has a similar cost per day (US $27 .85 per day) 
as adult inpatient care. Marginal costs vary between 4-14% of average cost between 
----
wards. The average cost per admission ranges between US$49 and US$200, although 
the large variation reflects more the fact that women are frequently transferred between 
wards than actual variation in cost per inpatient admission between wards. 
7.1.2.2 Causes of inpatient care unit cost variatio~ in Cuba 
While case-mix differences no doubt explain a large part of variation between wards, 
the extent to which this affects efficiency measures is explored briefly. Figure 7.6 below 
shows a strong negative correlation between days per FTE and average cost for inpatient 
care. 
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Except for neonatal care in America Arias hospital, average occupancy levels are similar 
in all wards, and thus similar reductions are seen in average cost under 80% capacity 
assumption. The existence of spare capacity in the neonatal unit partley explains the 
higher unit costs there. Wards are similar in number of beds, and therefore economies of 
scale are unlikely to be responsible for average cost differences. Generic case-mix data 
are not available to examine the extent to which differences causes the variation in 
average cost between wards, although the high risk antenatal ward, post-CS ward and 
neonatal intensive care unit obviously have a heavier case-mix than the other wards. 
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7.1.2.3 Causes of inpatient care unit cost variation in Thailand 
Causes of low average cost in Chumpae and Phon are sought, as well as ~auses of high 
average costs in Khaosangkuang, Kranuan and Banphai. Figure 7.7 below shows the 
relationship between days per FrE and average cost for inpatient care. The Pearson 
correlation coefficient of -0.603 (p<0.05) indicates a significant relationship. Using 
visual examination, it can be seen that the high cost hospitals have low days per FrE, 
while the low cost hospitals have the highest days per FrE, although several hospitals 
(Manjakiri, Si Chompoo, Nongrua and Waengnoi) are inconsistent. 
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Appendix 8 Figure 8.8 shows mixed evidence for the inverse relationship between the 
TE score and average costs. On the one hand, Chumpae is low cost and high efficiency, 
and Kranuan has a low TE score. On the other hand, Khaosangkunag has a high TE 
score, and many of the middle cost hospitals have either a score of 1.0 or a very low 
score, thus making it very difficult to discern a pattern. The Pearson correlation 
coefficient of -0.409 confirms this finding. 
Appendix 8 Figure 8.9 shows that the largest percentage reductions in average cost 
under the capacity use assumptions are for the two lowest cost hospitals, which is 
inconsistent with expectations. This suggests that low occupancy rates do not explain 
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high average costs. However, Khaosankuang has low occupancy rates, thus explaining 
higher average costs. Appendix 8 Figure 8.10 shows a scatter plot of inpatient average 
cost with hospital size, based on days per month optimal capacity. It is not possible to 
conclude from this evidence whether or not economies of scale exist from this data, with 
two lines drawn in an attempt to 'fit' the points. However, the Pearson correlation 
coefficent of -0.631 (p<0.05) suggests that there is, in fact, a negative correlation. 
7.1.2.4 Causes of inpatient care unit cost variation in South Africa 
Appendix 8 Figure 8.11 shows that days per,FIE are marginally lower in the wards with 
higher average cost. This suggests that the post-CS wards are either less intensively 
staffed, or they have higher occupancy, accounting for the lower average costs. 
Occupancy is lowest in wards E4 (postpartum-CS) and E5 (postpartum-VD), thus giving 
these wards a greater reduction in average cost under the 100% capacity assumption. 
However, as all wards are operating at over 80% average capacity, the recalculated 
average costs at 80% capacity are in fact higher than the original average costs. In 
general, wards with high average costs do not consistently have lower average 
occupancy. Also, the wards are a similar size, and therefore economies of scale are 
unlikely to be responsible for average cost differences. Case-mix data are not in a form 
that allows examination of the extent to which variations caused variations in average 
cost. 
7 .1.3 Delivery care 
Table 7.4 shows that the average costs for vaginal delivery (VD) and caesarean section 
(CS) are significantly different in all countries. In Cuba, average costs are US$21.32 and 
US$113.98 respectively, in Thailand US$27.225 and US$83.00, in South Africa 
US$81.40 and US$140.60. Marginal costs in Cuba are US$5.79 for VD and US$43.54 
for CS, averaging 27% (VD) and 38% (CS) of average cost. In Thailand, marginal costs 
vary between 20% of average cost for VD and 56% for CS, and in South Africa 7% and 
18%. 
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Table 7.3: Average and marginal costs of delivery care in study countries. 
COUNTRY and Average cost Marginal cost 
TYPE of CARE Lower Mean Upper COV Mean %AC 
CUBA 
Vaginal delivery 16.45 21.32, 26.20 0.24 5.92 0.28 
Caesarean section 70.12 113.98 157.83 0.40 43.73 0.38 
THAILAND 
Vaginal delivery 
Intervention average 24.44 31.75 39.07 0.42 7.35 0.23 
Control average 19.57 22.75 25.93' 0.25 3.73 0.16 
Caesarean section 
Intervention average - 67.05 - - 40.32 0.60 
Control average - 98.95' '.- - - 51.95 0.52 
SOUTH AFRICA 
Vaginal delivery 74.49 81.40 88.30 0.05 5.38 0.07 
Caesarean section 105.71 140.60 175.48 0.16 24.91 0.l8 
Appendix 9 Table 9.3 shows that average costs for both VD and CS vary significantly 
between district hospitals, from US$9.86 to US$65.07 for VD (a difference of 660%) 
and from US$39.04 to US$185.10 for CS (a difference of 480%). Vaginal delivery has, 
not surprisingly, a lower unit cost in all countries compared with caesarean section, 
although the magnitude of difference differs between country. For example, vaginal 
delivery is under 20% the cost of CS in Cuba, but it is 57% the cost of CS in South 
Africa. 
7.1.4 Discussion and conclusions 
The analysis of costs has partly explained why such large differences were observed in 
unit costs between some health facilities. While significant differences was observed 
between individual health facilities, significant differences were not observed in unit 
costs between trial arms, thus suggesting that the W.H.O. antenatal care programme did 
not affect unit costs. 
The efficient use of the most important resources, most notably staff for all countries, 
drugs for outpatient care in Cuba, and drugs and materials for caesarean section, was 
shown to have significant implications for average costs. For example, the ratio of visits 
or days per FTE, the technical efficiency score, and the presence of spare capacity, have 
been shown to influence average cost in some or most comparisons made. Economies of 
scale possibly exist in Cuban policlinics for outpatient care, and for Thai hospitals for 
inpatient care. The impact of case-mix differences on unit costs could not be evaluated 
at an average level, although an additional drug cost could be calculated for an illness 
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treated on an individual patient level. There was mixed evidence whether clinics or 
wards treating high risk patients were higher cost than those treating low rjsk patients. 
Input mix variations were shown to be substantial between health facility, which 
remained largely unexplained by case-mix differences. 
Three points should be noted here in interpreting the TE score results. First, TE scores 
were influenced heavily by staffing numbers, and therefore the results from this analysis 
and the previous analysis are not 'additive' (in that the results are largely based on the 
.'. . 
same data). Second, note that 'efficiency' is interpreted in relation to what the model 
inputs (staff and capital) and output (outpatient visits) are. Thus other potentially 
important inputs are missing, such as drugs and materials. Third, the TE scores obtained 
using monetary cost as inputs were different to those obtained in the last chapter. This is 
not surprising considering the inputs used are different: the inputs in this section include 
equipment costs, and the inputs were measured in money cost. 
Results from the analysis of economies of scale should also be interpreted with caution. 
The most important point to note is that the size of clinic or ward was chosen at the 
maximum observed output during the study period, with no microeconomic study of the 
actual capacity levels. This affects comparability across health facilities, as they may 
operate at different levels of average capacity use. Also, economies of scale were 
assessed using visual inspection and the Pearson correlation coefficient, and regression 
techniques were not used; thus there could have been other factors responsible for the 
observed negative relationship between size and average cost in Cuban policlinics. The 
comparison of % contribution of overhead cost to average cost with health facility size 
did not reveal as significant results as the visual inspection and the Pearson correlation 
coefficient, and it is not clear how this difference can be interpreted. 
The conclusions concerning causes 'of variation in marginal costs are less certain, 
because there is less variability between health providers, and because drug costs were 
obtained from a limited sample in Cuba and Thailand as opposed to the whole 
population of ANC attenders. In general, the greatest drug costs ~ere from routine drugs 
and supplements, which were given to all women, and therefore there would exist 
minimum variability to examine. 
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7.2 Unit cost variations between countries 
7.2.1 Sizes of cost variation 
Table 7.4 summarises average costs (with 95% confidence interval) and marginal costs 
for all types of care in study countries, presented in US$ using both nominal exchange 
rates and purchasing power parities. Comparisons of average costs using the 'F' test 
shows some significant and some non-significant results. These are discussed below. 
Table 7.4: Summary of average and marginal costs in all countries. 
TYPE of CARE and Nominal exchange rate (US$) Purchasing power parit v (US$) 
COUNTRY A verage cost Marginal cost Average cost MC 
Lower Mean HiJ!:her Mean %AC Lower Mean HiJ!:her Mean 
OUTPATIENT ANC 
Primary health care 
Cuba 8.99 12.15 15.31 4.25 0.35 22.12 29.89 37.66 10.46 
Thailano 4.70 6.19 7.69 1.41 0.23 9.14 12.03 14.95 2.74 
South Africa 5.78 7.24 8.70 0.42 0.06 8.99 11.26 13.53 0.65 
Secondary health care 
Cuba 2.82 3.22 3.62 0.64 0.20 6.94 7.92 8.91 1.57 
Thailand 1.67 2.75 3.83 0.55 0.20 3.25 5.35 7.45 1.07 
South Africa 7.47 9.05 10.62 0.95 0.11 11.62 14.07 16.51 1.48 
INPATIENT CARE 
LowriskANC 
Cuba 23.95 30.84 37.72 6.80 0.22 58.92 75.87 92.79 16.73 
Thailand 5.54 6.56 7.58 0.97 0.15 10.77 12.75 14.74 1.89 
South Africa 29.34 30.56 31.78 1.26 0.04 45.62 47.52 49.42 1.96 
High risk ANC 
Cuba 39.37 51.72 64.07 10.39 0.20 96.85 127.23 157.61 25.56 
Thailand 39.43 49.29 59.15 9.86 0.20 76.65 95.82 114.99 19.17 
South Africa 27.24 33.13 39.02 1.51 0.05 42.36 51.52 60.68 2.35 
Neonatal care 
Cuba 88.37 118.09 147.82 31.32 0.27 217.39 290.50 363.64 77.05 
Thailand 13.12 16.41 19.69 3.28 0.20 25.51 31.90 38.28 6.38 
South Africa 23.47 27.85 32.24 3.12 0.11 36.50 43.31 50.13 4.85 
DELIVERY CARE 
Vaginal delivery 
Cuba 16.45 21.32 26.20 5.92 0.28 40.47 52.45 64.45 14.56 
Thailand 19.17 27.25 35.34 5.39 0.20 37.27 52.97 68.70 10.48 
South Africa 74.49 81.40 88.30 5.38 0.07 115.83 126.58 137.31 8.37 
Caesarean section 
Cuba 70.12 113.98 157.83 43.73 0.38 172.50 280.39 388.26 107.58 
Thailand67 58.1 83.00 107.9 46.74 0.56 113.4 161.35 209.3 90.86 
South Africa 105.71 140.60 175.48 24.91 0.18 164.38 218.63 272.87 38.74 
Average cost per outpatient visit was significantly less in Thailand (US$6.19) and South 
Africa (US$7.24) than Cuba (US$12.15), at primary health care facilities. Marginal cost 
in Cuba was on average three times that in Thailand, and on average ten times that in 
67 The range on the average cost for CS in Thailand was predicted as +/- 30% of the mean (the variability 
from other countries was used). 
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South Africa. In referral facilities Cuba (US$3.22) and Thailand (US$2.75 and 
US$2.1O) were similar, and both were significantly less than South Afric/a (US$9.04) 
~/ 
(p<0.05). Marginal costs were a substantially lower proportion of average cost in South 
Africa. At PPP, outpatient ANC in Cuba68 (US$29.89) was even more. expensive per 
visit than Thailand69 (US$12.04) and South Africa70 (US$I1.26) than at nominal 
exchange rates. 
Low risk inpatient antenatal care cost per day was similar in Cuba (US$30.84) and 
, . . . 
South Africa (US$30.56), and these were significantly more than in Thailand 
(US$6.56). High risk inpatient antenatal care per day was more expensive in Cuba 
(US$51.72) than in South Africa (US$33.13). In Thailand, as the high risk care average 
costs ~ere taken from a referral centre, average costs were much higher than low risk 
care, at US$49.29. Marginal cost was a higher proportion of average cost in Cuba (20-
24%) than Thailand (15%) and South Africa (4-14%). At PPP, Cuba was significantly 
more expensive than South Africa for low risk patients. 
Finally, for delivery care, South Africa has the highest average costs at nominal 
exchange rates. For vaginal delivery, average cost per case in South Africa (US$81.40) 
is significantly higher than Cuba (US$21.32) and Thailand (US$27.25). At PPP, these 
differences are smaller, but still significantly different from South Africa. For caesarean 
section, South Africa (US$140.60) is significantly more than in Thailand (US$83.00), 
but not significantly more than Cuba (US$113.98). At PPP, Cuba and South Africa unit 
costs are higher than Thailand. In general, for all forms of care, where statistical 
significance exists, there is also economic significance. Even for the lowest cost form of 
care, outpatient visits, Thailand and South Africa are US$5-6 less expensive than Cuba, 
which represents 68% (South Africa) and 96% (Thailand) of the cost of an outpatient 
ANC visit. For other forms of care statistically significant differences between country 
are at least 100% the average cost of an outpatient visit. 
In summary, Cuba has the most expensive health services for most forms of maternity 
care at official exchange rates, and is even more expensive at PPP. South Africa has 
68 The PPP rate was US$I=0.4065 Peso measured in 1998 (Appendix 4 Table 4.1). 
69 The PPP rate was US$I=26.9 Baht measured in 1998 (Appendix 4 Table 4.1). 
70 The PPP rate was US$I=3.17 Rand measured in 1998 (Appendix 4 Table 4.1). 
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comparable costs to Cuba for some forms of inpatient care, and delivery care. Thailand 
has the lowest cost care, except for inpatient care provided by referral facilities. The 
purpose of the following sub-sections is to explore the causes of difference in unit costs. 
7.2.2 The impact of different prices on unit costs 
The extent to which prices caused variations in average and marginal costs between 
countries is examined by comparing prices and unit costs across countries. Specifically, 
the inter-country average cost ratios are compared with the inter-country price ratios, at 
nominal exchange rates, to see whether they are similar. For example, if only prices are 
driving the cross-country differences, then the ratios would be the same. Table 7.5 
below shows that salaries in Cuba were on average 74% of salaries in Thailand, and 
salaries in Cuba and Thailand were 19% and 25% of those in South Africa, respectively. 
Equipment and materials were, on average, more expensive in Cuba than Thailand, and 
more expensive in South Africa than Thailand. For example, electrical equipment was 
on average 75% higher in Cuba than Thailand, but furniture prices were comparable. 
Materials in Cuba were 80% more expensive than Thailand, and 69% more expensive 
than South Africa. However, these average differences mask large variability for 
individual items (see details in Appendix 11 Table 11.1). 
Table 7.5: Price levels of resources and inter-country price ratios. 
COUNTRY TYPE OF RESOURCE 
Staff Electrical eq. Furniture Materials Drugs 
Relative prices (highest = 100) 
Cuba 19 54 72 100 100 
Thailand 25 31 72 56 59 
South Africa 100 100 100 87 22 
Price ratios 
Cubaffhailand 0.74 1.75 1.00 1.80 1.69 
Cuba/South Africa 0.19 0.54 0.72 1.15 4.55 
South Africaffhailand 3.98 3.27 1.39 1.56 0.37 
Figure 7.8 shows variations in salaries between health professionals within as well as 
between country, at nominal exchange rate and PPP. For all categories of staff, South 
Africa is the most costly country, although at PPP inter-country differences are reduced. 
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Figure 7.8: Com parison of selected staff salaries at nominal exchange rates and PPP. 
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Table 7.6 shows percentage differences in average cost between Cuba, Thailand and 
South Africa. Almost all average costs in Cuba exceeded those in Thailand: by 96% for 
outpatient ANC, 470% for inpatient antenatal care, 37% for CS, and by 720% for 
'. 
neonatal care. Normal vaginal delivery, on the other hand, is 28% more expensive in 
Thailand than Cuba. However, these variations do not appear to have been caused 
directly by consistently higher prices in Cuba, as salaries, which take the largest share of 
unit cost, are lower in Cuba. While average costs of outpatient ANC were comparable 
between Thailand and South Africa, inpatient care in South Africa was more similar to 
Cuban unit costs. Other major differences between countries were vaginal delivery, 
which was more than 300% greater in South Africa than in Cuba and Thailand, and 
neonatal care was 424% higher in Cuba than South Africa. 
Table 7.6: Unit costs of health services and inter-country unit cost ratios. 
COUNTRY TYPE OF HEALTH CARE 
COMPARISON Outpatient Inpatient Vaginal Caesarean Neonatal care 




















Figure 7.9 illustrates the findings discussed above. It is clear from a comparison of 
ratios that price differences alone were not responsible for differences in average cost, 
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based on the finding that there was limited correlation in cross-country resource price 
ratios and average cost ratios. The mixed findings presented above are an indication that 
price differences could not have been the only cause of average cost differences, 
although price differences obviously did influence average costs. From these data, 
however, it is possible to conclude that in some cases price differences helped reduce 
instead of increase average cost differences, suggesting that an even greater cause of 
unit cost variation must be found elsewhere. 
However, one weakness inherent in these analyses is that price differentials for the 
different resources were not uniform. There was a considerable amount of uncertainty 
surrounding the price differentials for tradeable goods, as some items were cheaper and 
some more expensive in different countries. A second weakness in these comparisons is 
that the prices used are assumed to be the 'correct' prices. That is, that they reflect 
opportunity cost. A related point is that · the two exchange rates used are assumed to 
reflect the full range of variation possible in exchange rates, which might not be the 
case. These issues are explored later in this chapter, in the sensitivity analysis. 
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7.2.3 The impact of different resource quantities on unit costs 
7.2.3.1 Causes of cross-country unit cost variation in outpatient ANC 
The following analysis seeks to explain why average costs per outpatient visit in primary 
providers in Cuba were almost twice those fn Thailand and South Africa, and why South 
Africa was three times the cost of Cuba and Thailand in referral centres. Also, the 
causes of large cross-country differences in marginal costs are also sought. 
Average numbers of visits per FfE are in fact very similar between Cuba (89) and 
Thailand (97), while in South Africa the average is 314. However, the average member 
of staff in Cuba is more highly trained than the other countries, indicated by the fact that 
the doctor:nurse and obstetrician:nurse ratios are higher. Therefore, despite higher wage 
levels in South Africa, the fact that nurses are the main care providers has a cost-
decreasing effect. Also, staff in South Africa are relatively productive in terms of the 
number of visits per FfE. The different average costs at referral centres are partly 
explained by the fact that visits per FfE of 284 are higher in referral than in primary 
health facilities in Cuba (leading to a lower average cost) and lower (143 visits per FfE) 
in South Africa (leading to a higher average cost). 
In terms of technical efficiency score (from DEA), no cross-country analyses were 
conducted due to the heterogeneous samples and currencies. However, the average TE 
scores are compared between countries. South Africa has the highest average TE score 
of 0.93, with 3 of the 5 clinics achieving 1.0. Cuba has an average score of 0.82, 
followed by Thailand with 0.78. Although no conclusions can be made about relative 
efficiency levels between country, the results do suggest that the clinics in South Africa 
are operating closer to the production possibility frontier, as suggested by the high 
average TE score, and the high visits per FfE. However, this finding could just reflect 
that health facilities are more homogeneous in South Africa, and the comparison above 
does not necessarily explain average cost differences between countries. 
The large inter-month variation in outpatient visits in Cuba and Thailand suggest that, 
on average, few health facilities are operating on their frontier much of the time, 
although they may reach it for several months per year. An important cause of this is 
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that demand for ANC is variable, as shown by variation in month to month throughput 
(although no seasonal trends were observed). 
Differences in average occupancy rates between country did not provide evidence for 
why Cuba is more costly than other countries. Average costs in policlinics in Cuba were 
on average only 13% above -their potential average cost of US$10.52, whereas in 
Thailand the average was 34% (potential average cost of US$4.07), and in South Africa 
the average was 27% (potential unit cost of US$5.78). Therefore the smallest average 
, . . . 
reduction in average cost was observed in Cuba under the assumption of full capacity. 
Appendix 9 Tables 9.4-9.6 show the contribution of each resource to average cost for all 
types of care. The data show evidence of significant variation both between and within 
countries for outpatient care. The proportion of staff cost in Cuba averaged 58% 
(between 50-73% for all policlinics), while in Thailand it averaged 66% (range 54-
76%), and South Africa it averaged 88% (range 86-91 %). The proportion of equipment 
cost averaged under 0.5-2% in Cuba and South Africa, and 7% in Thailand. The 
proportion of material cost in Cuba averaged 1 %, South Africa 2%, and Thailand 9%. 
The proportion of drug cost in Cuba averaged 34%, in Thailand 13%, and in South 
Africa under 3.2%. Finally, utilities and buildings contributed 2-4% to average cost in 
primary facilities in all countries, but tended to be higher in referral facilities (e.g. 
utilities 8% and buildings 12% in Prince Mshiyeni hospital). The causes of these 
variations between country can only be speculated. For example, the relatively low staff 
contribution in Cuba was due to the high drug cost, caused not by high prices faced on 
the international market but also more intensive usage than the other countries (which 
was concluded in Chapter 6). In Thailand more was spent on equipment and materials, 
but less on drugs, utilities and buildings, relative to Cuba. This was because Thai 
hospitals are relatively well resourced in terms of equipment lists and material supplies. 
South Africa had lower US$ cost and lower % contribution from non-staff items 
because there are very few resources in the clinics (equipment) and because these other 
resources were very cheap compared to staff. 
The very different staffing ratios (doctor:nurse ratios) in the three countries in shown 
Table 7.7 indicate that the production functions were highly flexible in terms of staff 
175 
input. For example, in Cuba outpatient care is provided by obstetricians and doctors on a 
one-to-one basis, whereas in Thailand and South Africa outpatient ANC was mainly 
nurse-based, and uses a production line system. One possible reason for the differences 
in ratios (staff:staff and staff:patient) was that higher trained staff in Cuba were not 
significantly more expensive than less trained staff. For example, doctors earned on 
average 40% more than nurses in Cuba, whereas the difference was more in Thailand 
(67%) and South Africa (250%). 
Table 7.7 also shows the ratio between a month's salary and various tradeable goods. In 
Cuba equipment, materials and drugs are relatively expensive. The relatively high cost 
of imported goods leads to two possible reactions - either there is no substitution and no 
change in demand for these items with a subsequently high contribution to average cost, 
or there is a reduction in demand for imported items. From the resource data collected, it 
appears that in Cuba there was no reduction in demand for drugs, but there was for 
materials and equipment. In contrast to the situation in Cuba, equipment, materials and 
drugs in South Africa were relatively cheap compared to salaries, leading to a low 
contribution of equipment cost «1 %), as well as low material and drug costs for most 
forms of care. Hence this suggests a relatively inflexible production function, as there 
was little substitution away from staff. The relatively high costs of equipment and drugs 
in Thailand, however, does not result in low contributions (>6% for equipment and 
>14% for drugs for ANC). 
Table 7.7: Relative prices and staff ratios for selected resources in study countries. 
Doctor: resource Price ratio Number of staff ratio (primary) 
Cuba Thailand South Africa Cuba Thailand South Africa 
Doctor:professional nurse 1.40 1.67 2.50 1.05 0.11 0 
Doctor:specialist 0.78 0.63 0.64 0.29 0 0 
Doctor:admin worker 2.06 1.93 2.00 3.37 0.64 0 
Health care staff:admin worker 
- - -
7.9 6.26 3.9 
Doctor:computer 0.18 0.62 1.28 - - -
Doctor:microscope 0.09 0.25 0.40 - - -
Doctor: 1000 litre detergent 0.19 0.92 1.56 - - -
Doctor: 1000 soap 0.66 3.68 20.00 - - -
Doctor: 10,000 paracetemol 1.75 4.78 41.67 - - -
Doctor: 10,000 folic acid 1.17 9.96 25.00 - - -
Doctor: 10,000 metronidazol 0.47 4.78 30.30 - - -
In conclusion, from these data presented, few similarities existed between countries 
concerning resource use ratios and % resource costs: low or high relative prices did not 
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consistently lead to higher or lower % contribution to average costs, but behaviour 
varies between countries. 
The impact of case-mix differences between countries on health service use has already 
been examined earlier, and data were provided in Appendix 5 Tables 5.2 and 5.3 for the 
three study countries. Data presented earlier in this chapter on risk factors showed Cuba 
to be a higher risk country. This was largely due to higher parity, making it more likely 
that women have risk factors. It is likely!. though cannot be proved precisely, that 
differences in case-mix influenced the resource use intensity, and thus the unit costs, in 
each country. For example, the higher risks and the higher rates of adverse event during 
pregnancy in Cuba were likely to be part of the cause of higher per visit drug costs there. 
For example, bleeding, sexually transmitted diseases, hypertensive diseases of 
pregnancy and urinary tract infection are higher in Cuba than Thailand. Therefore, the 
resource intensity of the health system in Cuba probably partly reflects' the ability to 
diagnose and treat the relatively higher number of risk cases. For example, every 
policlinic had between 2 and 4 full time obstetricians, and over 50 medical doctors, 
compared to zero obstetricians and under 6 doctors in Thailand in the district hospitals, 
which have a similar throughput of outpatients (both general and ANC). The high rates 
of adverse outcome during pregnancy in South Africa is not reflected in resource use in 
health centres, but more in high referral rates, visits at secondary hospital, and inpatient 
admission. 
7.2.3.2 Causes of cross-country unit cost variation in inpatient care 
This section seeks to explain why inpatient costs in Cuba and South Africa are similar, 
when prices have been shown to be so different between these countries. Also, the 
section seeks to explain why inpatient care is considerably more expensive in Cuba and 
South Africa than Thailand. 
In Cuba, the number of days per FTE in the adult wards average 34 in Cuba, 37 in South 
Africa, and 71 in Thailand. Therefore Cuba and South Africa are similar in staffing 
efficiency, and Thailand is on average about twice as 'efficient'. These data therefore 
explain part of the difference in average costs between Cuba/South Africa and Thailand. 
Operating at below capacity caused average costs in Cuban adult wards to be on average 
17% above their potential average cost. In Thailand, the average was 30% above the 
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potential average cost of US$4.7, and South Africa the average was between 4-10% 
above the potential average costs. Therefore, if anything, the lack of exploitation of full 
/' 
capacity levels caused unit costs to be closer, on average, than they would have been if 
all providers were operating at 100% capacity. 
Ward sizes (bed numbers) are'similar in Cuba and South Africa, and relatively smaller 
in Thailand. Therefore, it is unlikely that economies of scale could have explained 
average costs differences between these cO~Iltries. Input mix differences have already 
been discussed above, under the 'outpatient ANC' section. Differences are not quite so 
marked for inpatient care, with staff taking around 70% in Cuba and Thailand, and 75-
80% in South Africa. The staff contribution in Cuba is higher for inpatient than 
outpatjent care, due to lower drug contribution. Equipment proportions are 5-7% in 
Cuba and Thailand, but under 1 % in South Africa. The remaining resources contribute 
similar shares in all countries. 
Case-mix differences in inpatient care are difficult to link with average cost, as there are 
limited data on severity of diseases or events. Information on the average length of stay 
and bed turnover rates is not used, as they are poor predictors of severity difference 
between countries as medical practice was shown to differ significantly. Appendix 6 
Figure 6.3 showed occupancy plotted against turnover rate. A low ALOS and average 
cost in Thailand was thought to be due to a relatively light case-mix, as these are 
primary care hospitals with no specialist support. This is supported by the fact that 
secondary level inpatient care in Thailand is significantly more costly, on a par with 
average cost per day of Cuba and South Africa (see Appendix 9 Table 9.2). Case-mix is 
similar between Cuba and South Africa, giving further cause for similar average costs. 
7.2.4 Costing methods and uncertainty 
Uncertainty is present to some degree in these costing studies. Due to differences in the 
way clinics are organised to provide antenatal care, and differences in the quality of data 
systems and data availability, the standardised top-down costing approach was tailored 
to each country (for example, see the step-down allocation method used in Cuba in 
Appendix 4 Table 4.2). Also, the divergence between financial cost and opportunity cost 
may have been different in the three study countries. Therefore, the purpose of this 
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section is to examine whether systematic differences in unit cost may have been caused 
by the choice of one set of costing methods over another. 
Sources of uncertainty were listed in the methods chapter, and a prelimin~ assessment 
made of which were the most likely to affect unit cost. For those sources that could be 
tested and that were expected to have a potentially large impact on average costs, likely 
ranges or alternative values were identified, and average costs recalculated based on 
these ranges. In the absence of stochastic ,data at the patient level, some sources of 
uncertainty were not amenable to statistical or probabilistic testing, and it was concluded 
that simple sensitivity analysis (one-way and multi-way) would be used to test the 
impact of uncertainty on average costs. 
7.2.4.1 One-way sensitivity analysis 
International costs of equipment 
Appendix 9 Table 9.10 shows average costs when equipment costs are adjusted to 
reflect the scenario in which world market prices increase by 50%. The results show that 
the greatest impact is on the average costs of VD (increased 10%) and CS (5%) in 
Thailand, and for neonatal care (4%) in South Africa. In Cuba, the impact is under 2% 
for all types of care. However, the ranges were within the 95% confidence interval for 
all forms of care, thus suggesting average costs are sufficiently robust to this form of 
uncertainty. 
Change in cost of tradeable goods 
Appendix 9 Table 9.10 shows the average cost results when the cost of all tradeable 
goods (all equipment, materials and drugs) are increased by 50%, to reflect possible 
fluctuations in world prices. The greatest overall impact was in Cuba, where the impact 
is greater than 13% for all types of care. The biggest single impact was in Thailand, 
where the cost of CS increases by 37%, which is outside the 95% confidence interval of 
the base case average cost. The smallest impacts were in South Africa, where salaries 
made up the largest share of average cost. The results show that average costs were 
relatively robust to changes in the costs of tradeable goods. However, the impact on 
marginal cost was greater, as tradeable goods constitute 100% of marginal cost. Thus an 
increase in the prices of all tradeable goods by 50% would also lead to an increase in 
marginal costs of 50%. However, as some tradeable goods are not imported, the actual 
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impact of such as increase in the price of tradeables would be less than that reported 
here. 
Length of life of capital items 
Appendix 9 Table 9.10 shows the average cost results when the length of life of capital 
goods is halved and doubled. Average costs are shown to be relatively unaffected by this 
assumption, varying up to 14% when equipment length of life is doubled, and up to 28% 
when halved. However, the average impact .was much less. Again, the greatest impact 
.' . 
was in Thailand, where equipment were a larger share of average costs for ANC (7%, 
compared to 1 % in Cuba and South Africa). Thus inpatient care and vaginal delivery 
average costs were not robust, as the sensitivity analysis range is outside the 95% 
confidence interval. 
Alternative value for wages 
Appendix 9 Table 9.10 shows the average cost results when wage costs Cl!e increased by 
the average differential between public and private sector wages in Thailand and South 
Africa (to reflect a likely upper value for the opportunity cost of staff, because the public 
sector has to 'compete' with the private sector). In Cuba, the 50% increase reflects to 
some degree the nature of the communist economy, where wages do not take into 
account additional benefits, such as rations and housing. As expected, the large share of 
salaries in average costs resulted in significant impact on average costs, varying between 
28% and 44% (although CS was only 9% in Thailand, as the staff contribution was 
low). The highest increases were recorded in South Africa, with an average of 41 %. In 
conclusion, average costs are not robust to changes in staff costs. 
Use of average drug cost 
Appendix 9 Table 9.11 shows average costs for outpatient ANC in Cuba and Thailand 
based on pooled drug cost for each arm. The biggest impacts were in Romay (16% 
increase), Manduley (11 % increase) and Galvan (11 % decrease) in Cuba, and Puvieng 
(14% increase) and Khaosangkuang (8% decrease) in Thailand. However, the inter-
health facility differences are likely to represent real as opposed to artificial differences, 
due to differences in the rates of illness experienced in different health facilities. 
'-. 
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Simultaneous step-down cost allocation 
Appendix 9 Table 9.12 shows the average cost results when simultaneous step-down 
cost allocation was used instead of one-way step-down cost allocation. The potential 
inaccuracy of not using simultaneous step-down cost allocation was. taken from a 
previous study, with an estimated inaccuracy of +/- 20% for allocated costs. Allocated 
costs are defined as all costs excluding direct costs and laboratory costs, the proportion 
of which is shown in the first column. The impact on average cost was consistently 
close to 5% change from the base average c<?st. The greatest impact on average cost was 
+/- 8% of unit cost, for CS in Cuba, while the smallest impact was for CS in South 
Africa, which had an impact of +/- 1 %. Considering that the 20% inaccuracy used is 
likely to be a high overestimate of the inaccuracy likely in practice, this area of 
uncertainty is unlikely to have much impact on average costs. 
Alternative exchange rates 
Appendix 9 Table 9.12 shows data on average costs when alternative exchange rates 
were used. For all countries and all types of care, the impact on average costs was large, 
and very few costs were robust to the ranges used. The biggest impact was in Cuba, . 
where average cost was reduced by around 70%. This is because the value of non-traded 
goods on the international market are worth only 1I20th the original value (using the 
approximate black market exchange rate of US$1 = 20 Cuban Pesos). In Thailand, 
average costs were 42% higher (due to the appreciation of the exchange rate) and in 
South Africa the average costs were 21 % lower (due to the depreciation of the exchange 
rate). 
Uncertainty due to small number of months 
Appendix 9 Table 9.13 shows the impact of using differences in average cost from using 
a moving average of four and eight months in Thailand, to reflect the uncertainty of 
having only eight months data in Cuba and only four months data in South Africa. In 
Cuba, this had an impact of between 7-12%; while in South Africa, the impact was 
between 8-26%. These data indicate that using 8 months of average cost data instead of 
15 months in Cuba did not have a great impact on the accuracy of average costs, 
whereas in South Africa it did have. 
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Conclusions 
Some sources of potential uncertainty clearly had a large impact on average costs, while 
~ 
others had a less significant effect. Figure 7.10 summarises the sensitivity analysis 
results, showing clearly that the biggest impacts on average costs of antenatal care in 
Cuba were the exchange rate for non-tradeable goods (reducing unit cost), and the 
alternative wage rate (increasing unit costs). Similarly in Thailand, the biggest impacts 
were alternative values for exchanges rates and wages. In South Africa, the biggest 
impact was the alternative wage rate, where~s all the other sources of uncertainty did not 
have a major effect. The impact of small number of months on unit cost in Cuba and 
South Africa are not shown in the figure, but the impact on average costs in South 
Africa were the most significant. 
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Figure 7.10: Impact of uncertainty on unit costs of outpatient ANC 
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7.2.4.2 Multi-way sensitivity analysis 
Table 7.15 below shows the impact on unit costs of the multi-way sensiti~ity analysis at 
1998 OER, taking into account several areas of uncertainty simultaneously71. The areas 
of uncertainty combined are: 
• Adjustment of the value of tradeable goods (T in Table 7.8) by 50%, 
• Adjustment of the value of staff costs (W in Table ?8) by 50%, 
• Halving and doubling of the length of life of capital items (C in Table 7.8), and 
• The impact of data collection over a small number of months (M in Table 7.8). 
The overall adjustment factor for average costs is presented in the 'ALL' column, for 
both the high and low estimates. For the high estimate, the factor is remarkably 
consistent between country and type of health care, at around 60% (between 56% and 
78%), while for the low estimate, the factor was less consistent, ranging between a 
reduction of 5% and 28% (most values 10-20%). Therefore, in the later section when 
cost per pregnancy is recalculated based on these ranges, for simplicity all unit costs are 
increased by 60% for the high estimate, and reduced by 20% for the low estimate72• 
Implications for inter~country differences are significant, as some of the differences that 
were found to be highly significant before are reduced to almost non-significant levels. 
For example, the lower confidence limit from the sensitivity analysis for outpatient 
ANC in Cuba (US$IO.9) almost overlaps with the high estimate for Thailand (US$IO.3) 
and South Africa (US$10.2). Also, postpartum care cost per day is no longer 
significantly different between Cuba (upper limit US$27.6) and South Africa (lower 
limit US$23.3), and CS in Thailand (upper limit US$120.5) now overlaps with Cuba 
(US$99.2) and South Africa (US%101.2). 
71 It assumes that the four sources of uncertainty included are 'additive' in terms of their impact on cost. 
72 The crudity of this method was justified in that these factors were only approximations anyway. 
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Table 7.8: Impact on average costs of multi-way sensitivity analysis, with average cost 
range and % change. 
Health care Country Average cost High estimate Low estimate 
Low Base High T W C M ALL NEW C M ALL NEW 
US$ US$ US$ % % % % % US$ % % % US$ 
Antenatal Cuba 11.1 11.9 12.6 0.17 0.31 0.03 0.07 0.58 18.8 0.01 0.07 0.08 10.9 
care Thai 6.1 6.6 7.2 0.100.37 0.090.00 0.56 10.3 0.050.00 0.05 6.3 
S.Africa 4.2 6.4 8.5 0.03 0.44 0.04 0.08 0.59 10.2 0.020.08 0.10 5.8 
Inpatient Cuba 23.9 30.8 37.7 0.130.35 0.04 0.08 0.60 49.3 0.020.08 0.10 27.7 
care Thai 5.7 6.2 6.7 0.11 0.35 0.120.00 0.58 9.8 0.060.00 0.06 5.8 
S.Africa 29.3 30.6 31.8 0.02 0.41 0.07 0.16 0.66 50.8 0.030.16 0.19 24.8 
Vaginal Cuba 16.4 21.3 26.2 0.160.300.050.12 0.63 34.7 0.030.12 0.15 18.1 
delivery Thai 20.6 23.1 25.5 0.17 0~28 0.28 0.00 0.73 40.0 0.140.00 0.14 19.9 
S.Africa 74.5 81.4 88.3 0.03 0.41 0.07 0.17 0.68 136.8 0.03 0.17 0.20 65.1 
Caesarean Cuba 70.1 114.0 157.9 0.200.290.020.12 0.63 185.8 0.01 0.12 0.13 99.2 
section Thai nla 74.4 nla 0.37 0.09 0.160.00 0.62 120.5 0.080.00 0.08 68.4 
S.Africa 105.7 140.6 175.5 0.100.37 0.05 0.26 0.78 250.3 0.020.26 0.28 101.2 
Postpartum Cuba 13.9 16.8 19.6 0.140.33 0.05 0.12 0.64 27.6 0.030.12 0.15 14.3 
care S.Africa 22.6 27.7 32.8 0.070.38 0.07 0.12 0.64 45.4 0.040.12 0.16 23.3 
Neonatal Cuba 96.7 118.1 139.5 0.160.32 0.05 0.12 0.65 194.9 0.03 0.12 0.15 100.4 
care S.Africa 23.5 27.9 32.2 0.090.35 0.140.16 0.74 48.5 0.070.16 0.23 21.5 
Figures in bold means that the AC range is larger than the lower or higher confidence limits 
However, the presence of uncertainty does not impact other inter-country differences in 
average costs. For example, inpatient ANC cost per day is still significantly lower in 
Thailand, vaginal delivery is still significantly higher in South Africa, and cost per 
neonatal day is still significantly higher in Cuba. Also, in interpreting the confidence 
limits of the sensitivity analysis results, it should be taken into account that the upper 
limits of one country and unlikely to occur simultaneously as the lower limits in another 
country, as only the extreme scenarios are tested. These extremes are unlikely to occur 
in reality, but at least they give an estimate of the outer limits of average costs. In 
conclusion, the presence of uncertainty between country is unlikely to reduce the inter-
country differences in average costs greatly. 
7.2.5 Discussion and conclusion 
This section discusses some of the results and issues raised in the second half of this 
chapter, on cross-country unit cost comparisons and causes of variation. The data 
analysis in the cross-country comparison was different to the within-country comparison 
for several reasons. First, relative efficiency using DEA could not be calculated for the 
cross-country comparison, due to the problems of comparing costs in US$ after 
conversion from different local currencies. Second, case-mix and quality of care 
differences were possibly an important source of cross-country unit cost difference; 
however, neither of these were properly evaluated, although some conclusions were 
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made about their likely influence on unit costs. For example, the high visits per nurse 
FfE, as well as anecdotal evidence, suggest that outpatient ANC at the clinics in South 
-~-
Africa may not have been as high quality as in Cuba and Thailand, where on average 
more time was devoted to caring for each· woman. Third, price and costing method 
differences were more important to examine in the cross-country comparisons. 
The cross-country comparisons suffered other constraints. For example, resource use 
comparisons between the three cOUIitrie~. were constrained by the fact that the 
specifications of these resources varied between countries. For example, while FfE had 
the appearance of a generic measure, it hides differences in which staff comprise the 
full-time equivalent staff (nurse, doctors, obstetricians, or even non-health care 
personnel such as patient helpers in Thailand). Also, when making cross-country 
resource price comparisons, average prices for groups of resources were compared, and 
the matching process (e.g. drugs or equipment) was deemed to be far from perfect. 
Finally, the cross-country comparisons of cost using the 95% confidence intervals 
calculated from month to month variability suffers the same problems in interpretation 
of 'significant' differences discussed earlier. If these confidence intervals do not 
represent true variability, then the conclusions of significant differences are weakened. 
On the other hand, differences between US$ values between country are considerable 
for many of the cross-country comparisons, and therefore suggests analysis of variation 
is justified to explore what caused these differences. 
While bearing these facts in mind, some significant findings arose from the cross-
country cost comparisons and cost analyses. It was found that, on the whole, price 
differentials between country (either relative or absolute prices) were not responsible for 
unit cost variations, and in some cases they even reduced the differences that would 
have been observed if prices had been uniform across countries. Using purchasing 
power parities for currency conversion to US$ did not reduce the cross-country 
differences in unit costs; in fact, their use increased the differences, as the greatest 
change in US$ value occurred in Cuba, which was already the highest cost country. 
Differences in visits and days per FfE between countries were found to be consistent 
with unit cost differences, in that those countries with the lower ratios had the higher 
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unit costs, for all types of care. Cuba was the most intensive user of labour, followed by 
Thailand for outpatient care, and by South Africa for inpatient care. Cub~, was also the 
most intensive user of drugs, and combined with the fact that Cuba faced high drug 
prices on the international market meant that the drug cost contribution to average cost 
was higher than the other countries: Therefore, unit cost differences were more due to 
staff productivity and drug prescription differences than price differences. Equipment 
costs were found to be highest in referral centres; equipment lists were minimal in 
family doctor clinics in Cuba and healt~ centres in South Africa, and therefore 
contributed very little to average costs. 
The use of sensitivity analysis to explore the impact of uncertainty in key variables was 
found _to increase the ranges on average costs, significantly in some cases, such as 
alternative assumptions about wage rates, and alternative exchange rates. In some cases, 
allowance for uncertainty reduced the differences in average costs between countries to 
the point where some unit cost ranges overlapped. Also, uncertainty may have been 
greater in some countries for certain variables. For example, price uncertainty was 
considerable in Cuba, such as the wage rate that represented the opportunity cost; and 
the ranges chosen in sensitivity analysis may not have covered the entire range possible. 
Also, there was considerable uncertainty surrounding the true Cuban Peso: US$ 
exchange rate, as it was thought that the official exchange rate of 1: 1 overvalued the 
Cuban Peso, as suggested by black market nites. When using the black market exchange 
rate of US$1 :20 Cuban Pesos for non-tradeable goods, there were large reductions in 
Cuban unit costs when converted to US$. 
.~ 
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8 CAUSES OF VARIATION IN COST PER PREGNANCY 
The aim of this chapter is to identify and explain variations in cost per pregnancy, and is 
the final stage of cost analysis before cost prediction methods are tested. The first 
section identifies statistically significant variations in cost per pregnancy between trial 
arms, health facilities, and countries. Cost analyses are divided into three further 
sections. In second 8.2, cost per pregnancy variations are examined in terms of the 
extent to which they are caused by (a) variations in health service use and (b) variations 
.. 
in unit cost. In section 8.3, the cost per pregnancy of women with different risk factors 
and events are compared, using 2-way tabulations, to identify which appear to explain 
differences in cost per pregnancy. In section 8.4, multiple regression analyses are 
performed to identify predictors of cost per pregnancy, also using the results of previous 
sections and chapters to build the model. Section 8.5 concludes. 
8.1 Size and significance of cost per pregnancy variations 
8.1.1 Cost per pregnancy results 
8.1.1.1 Cost per pregnancy in Cuba 
Table 8.1 below shows the base case results of cost per pregnancy (CPP): the average 
and marginal CPP for women attending each health facility with 95% confidence 
intervals, and median CPP. In Cuba, the mean average cost per pregnancy (ACPP) at the 
policlinic level ranged from US$298 to US$504 in the intervention arm (average 
US$372) and from US$369 to US$447 in the control arm (average US$401). The 
difference of US$29 between trial arms was not statistically significant at the 95% level 
(95% confidence interval for the difference -US$2.46 to US$62.52). This finding is 
confirmed when using log cost to calculate the 95% confidence interval of the 
difference. However, to become statistically less expensive in the intervention arm, only 
0.2 visits less per woman would be required in the intervention arm (to 7.30 visits per 
woman), which is a possibility as this value is only just outside the lower 95% 
confidence interval of 7.36 visits per woman. A statistically significant difference would 
have also been concluded if the CS rate in the intervention arm had been 21.7% instead 
of 22.7%. The incremental cost of US$29 using average cost equalled 2.5 antenatal care 
visits, and therefore was economically meaningful. For no difference to exist in cost per 
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pregnancy between trial arms, numbers of ANC visits per woman would have had to 
increase to 10.0 from 7.50, or one more inpatient day per woman, or a CS rate of 42.7%, 
none of which are likely (in the trial population). Similarly, there was no difference in 
marginal cost between trial arms (95% confidence interval of -US$l.44 to US$4.34). 
The difference in cost per pregnancy using marginal cost amounted to roughly 0.58 
antenatal care visits, and therefore was not economically significant. 
Table S.l: Average and marginal cost per pregnancy in study countries. 
Country and health Cases Average cost per pregnancy. Marginal cost per pregnancy 
care provider (US$) (US$) 
No. % Mean Med Mean Med 
Low Mean High SE Low Mean High SE 
CUBA 
13 de Marzo 449 8.0 317.1 382.4 447.7 33.3 178.8 92.65 109.92 127.19 8.81 58.4 
Albarran 567 10.1 298.7 357.3 415.9 29.9 189.7 85.84 99.96 114.08 7.21 57.7 
Galvan _ 459 8.2 421.2 504.4 587.5 42.4 255.2 128.90 151.27 173.65 11.42 88.0 
Manduley 575 10.3 277.8 325.8 373.8 24.5 161.4 81.85 93.54 105.23 5.96 53.3 
Romay 418 7.5 304.9 369.3 433.6 32.8 156.8 86.22 103.23 120.24 8.68 45.5 
Zuluetta 402 7.2 261.6 298.1 334.6 18.6 162.4 88.60 98.74 108.88 5.17 59.2 
A verage Intervention 2870 51.2 346.9 37/.9 396.9 12.8 181.8 102.27 108.74 115.22 3.30 59.2 
Aballi . 514 9.2 376.5 419.6 462.7 22.0 243.9 104.92 116.72 128.51 6.02 67.5 
Escalona 628 11.2 354.5 401.4 448.2 23.9 187.8 106.61 119.28 131.94 6.46 60.9 
Guiteras 177 3.2 366.4 447.2 527.9 41.2 302.5 83.43 104.86 126.28 10.93 63.4 
Reina 648 11.6 347.0 382.0 417.0 17.9 241.7 99.38 108.35 117.31 4.57 70.4 
Tamayo 294 5.2 368.8 442.0 515.3 37.4 267.0 102.42 121.58 140.74 9.77 72.9 
Vantroi 473 8.4 317.6 368.8 419.9 26.1 187.4 107.18 120.98 134.79 7.05 72.3 
Average control 2734 48.8 381.5 401.9 422.4 lOA 240.8 110.36 1I5.81 121.27 2.78 68.6 
Difference 
-
- -2.46 30.03 62.52 16.6 59.0 -1.44 7.07 15.58 4.34 9.4 
Log difference 
- -
-0.67 1.477 3.626 1.10 -
- - - -
. 
THAILAND 
Chumpae 1001 15.7 63.0 68.4 73.8 2.8 39.4 19.63 20.80 21.98 0.60 14.4 
Banphai 729 11.4 109.6 115.9 122.2 3.2 87.1 29.39 30.93 32.46 0.78 25.2 
Phuwiang 558 8.8 62.2 65.1 67.9 1.5 54.1 9.18 9.87 10.55 0.35 6.4 
Manjakiri 476 7.5 74.5 77.8 81.1 1.7 70.1 11.37 12.34 13.31 0.50 9.3 
Khaosuankwang 306 4.8 92.1 100.8 109.5 4.4 78.2 21.53 23.27 25.01 0.89 18.7 
WaengNoi 208 3.3 107.4 113.9 120.4 3.3 104.0 16.78 18.62 20.47 0.94 13.2 
Intervention average 3278 51.5 83.1 85.7 88.2 1.3 67.9 19.44 20.1 20.67 0.3 15.6 
Kranuan 821 12.9 102.4 106.3 110.2 2.0 96.6 23.55 24.50 25.44 0.48 21.5 
Nongsonghong 323 5.1 75.6 87.3 98.9 5.9 46.8 16.77 19.32 21.86 1.30 10.3 
Phol 630 9.9 128.1 136.1 144.1 4.1 95.7 22.02 23.84 25.65 0.93 13.5 
Nongrua 400 6.3 105.2 114.5 123.8 4.7 70.1 22.81 24.93 27.06 1.08 14.6 
Srichompoo 595 9.3 66.4 69.4 72.3 1.5 67.3 16.85 17.64 18.44 0.41 16.3 
Nampong 322 5.1 105.1 117.5 129.9 6.3 91.2 22.11 25.11 28.12 1.53 17.8 
Control average 3091 48.5 102.5 105.5 108.6 1.6 8004 21.93 22.6 23.31 004 16.3 
Difference 
- -
15.9 19.86 23.8 2.01 12.5 1.64 2.57 3.45 0.47 0.7 
Log difference 
- -
1.07 1.301 1.53 0.117 . 
- - - - -
SOUTH AFRICA 
Prince Mshiyeni 785 100 323.7 347.0 370 11.9 214 37.4 41.1 44.8 1.87 20.8 
Figure 8.1 below shows clearly the inter-policlinic differences in ACPP and MCPP. The 
size of standard error indicates significant variability in cost per pregnancy in most 
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health facilities 73, as well as indicating statistically significant ACPP differences 
between policlinics (e.g. Zuluetta versus Galvan), although the studentised 't' test was 
done to show statistically significant differences74• The median CPP values were lower 
than the mean CPP values, because of the positive skewness of the cost data. Table 8.1 
shows that the median ACPP in the intervention arm (US$182) was US$59 less than 























Figure 8.1: Average cost per pregnancy and 95% confidence interval for 
pOliclinics in Cuba 
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Appendix 12 Table 12.1 shows that the greatest contributor to cost per pregnancy was 
antenatal care - an average of 24% in the intervention arm and 36% in the control arm. 
Other contributors were postpartum care (22-24%), neonatal care (18-22%) antenatal 
inpatient care (10-13%), and delivery care (11 %). On the whole, there was consistency 
between policlinics within each arm, although some differences between providers 
emerged (e.g. Guiteras policlinic has very high outpatient ANC costs, at 49% of ACPP). 
Staff was the highest resource contributor to CPP in Cuba (61 %), followed by drugs 
(20%), materials (10%), and equipment, utilities and buildings combined taking 9%. 
73 This variation was partly caused by the fact that women who had CS and neonates who were admitted to 
the intensive care unit were substanitally more costly, thus causing a bimodal distribution. 
74 This test allows for the skewed nature of the dependent variable cost per pregnancy. The measure of 
skewness for the 12 policlinics varied between 4.2 and 8.4; however, when log cost per pregnancy was 
used, the measure of skewness reduced to 1.3 to 2.1. A value of greater han 1 indicates a non-normal 
distribution. 
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8.1.1.2 Cost per pregnancy in Thailand 
Table 8.1 shows the cost per pregnancy results for Thailand, and Figure 8.2 shows 
clearly the inter-hospital differences in ACPP and MCPP. The mean ACPP in the 12 
participating district hospitals ranged from US$65 to US$116 in the intervention arm 
(average US$86) and from US$69 to US$136 in the control arm (average US$105). This 
difference of US$20 between "arms was statistically significant at the 95% level (95% 
confidence interval of difference US$15.9 to US$23.8). Therefore, although the US$ 
difference between arms was smaller in Thailand than in Cuba, the fact that there were 
less outlying high cost values in Thailand lead to a lower standard error, and thus a 
statistically significant difference. This finding is confirmed when using log cost to 
calculate the 95% confidence interval of the difference. The difference was also 
economically meaningful, at a cost of 3 ANC visits. For the cost difference to become 
non-significant, 2.4 more ANC visits or 2.44 more inpatient days per woman, or a CS 
rate of 42% would be required in the intervention arm. For zero incremental cost to 
exist, similarly large and unrealistic changes would be required in the intervention arm. 
Also, the difference in the mean MCPP between trial arms was statistically significant 
(95% confidence interval for the difference US$1.64 to US$3.45), although not 
economically significant. The median ACPP in the intervention arm (US$67.9) was 
US$12.5 less than that of the control arm (US$80.4)(economically significant). The 














Figure 8.2: Average cost per pregnancy and 95% confidence interval for 
hospitals in Thailand 
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The measure of skewness varied for cost per pregnancy between 2.1 and 9.4 in the 
//' 
district hospitals, reducing to between -1.3 and 2.1 for log cost per pregnancy. 
Appendix 12 Table 12.1 shows that the. greatest overall contributor to cost per 
pregnancy was antenatal care - an average of 32% in the intervention arm and 42% in 
the control arm. Other contributors were delivery care (36% and 29%), postpartum care 
(29% and 26%), neonatal care (3% and 2%), and inp'atient antenatal care (I % in both 
arms). On the whole, there was consistency between hospitals within arm in terms of % 
, .. 
contribution, although some differences between hospitals also emerged (e.g. Kranuan 
had a high ANC cost of 52%, and Sichompoo had a low postpartum care cost of 11 %). 
Again, staff was the highest resource ingredient, contributing 67% to ACPP, followed 
by materials (11 %), drugs (9%), and equipment (8%), buildings (4%) and utilities (2%). 
There was also some variation between hospital in these rates. 
8.1.1.3 Cost per pregnancy in South Africa 
Table 8.1 shows that the ACPP in South Africa was US$347, with a 95% confidence 
interval of US$324 to US$370. The median CPP was US$214. The range in ACPP for 
individual women was very large, from US$140 to US$3,800. The MCPP was 
US$41.10 with a 95% confidence interval of US$37.4 to US$44.8. The median MCPP 
was US$20.8. Inter-hospital differences are not measured in South Africa, as the entire 
sample was drawn from one hospital, and women are not distinguishable by which 
clinic they attended ANC. The measure of skewness for cost per pregnancy was 3.3, 
reducing to 1.2 for log cost per pregnancy. 
Appendix 12 Table 12.1 shows that the greatest contributor to cost per pregnancy was 
delivery care (38%), followed by postpartum care (25%). Outpatient antenatal care 
contributed 17% to ACPP, followed by inpatient antenatal care (II %) and neonatal care 
(10%). Again, staff was the highest resource contributor to ACPP in South Africa 
(76%), followed by materials (8%), buildings (6%), utilities (5%), and equipment (I %). 
8.1.1.4 Cross-country comparisons of cost per pregnancy 
From these results presented above, Cuba had the highest CPP in US$ (using nominal 
exchange rates) in both the traditional and new models of ANC (US$402 and US$372 
respectively), compared to South Africa (US$347 for the current model) and Thailand 
(US$106 and US$86 respectively). The difference in the costs of the traditional models 
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between Cuba and South Africa of US$55 was statistically significant. However, both 
countries were significantly more expensive than Thailand. In terms ,of economic 
differences, ACPP in Cuba was about 50 ANC visits more expensive than in Thailand 
(at Thai average cost per ANC visit), and marginal cost about 15 ANC visits more 
expensive. Similarly, ACPP in Cuba was about 9 ANC visits more expensive than in 
South Africa (at South African average cost per ANC visit), and marginal cost about 12 
ANC visits more expensive. Thus Cuba was significantly more expensive than Thailand 
and South Africa, at nominal exchange rates: . 
Table 8.2 below shows the same comparisons using PPP values, which resulted in even 
greater costs in Cuba compared to Thailand and South Africa. ACPP in Cuba averaged 
US$951, in South Africa US$540, and Thailand US$285. MCPP was by far the greatest 
in Cuba (US$146 to US$169) while in Thailand and South Africa they were similar at 
around US$30-US$33. 
Table 8.2: Cost per pregnancy (average and marginal) using purchasing power parity. 
Health care Average cost per pregnancy (US$) Marginal cost per pregnancy (US$Y 
provider unit Mean Median Mean Median 
Low Mean High SE Low Mean High SE 
CUBA 
Average Intervention 853.3 914.8 976.4 31.4 447.2 251.6 267.5 283.4 8.1 145.7 
Average control 938.4 988.7 1039.0 25.7 592.3 271.5 284.9 298.3 6.8 168.9 
THAILAND 
Average Intervention 161.6 166.5 171.5 2.5 132.0 37.8 39.0 40.2 0.6 30.3 
Average control 199.2 205.1 211.0 3.0 156.3 42.6 44.0 45.3 0.7 31.7 
SOUTH AFRICA 
Average control 503.4 539.6 575.8 18.5 332.5 58.2 63.9 69.7 2.9 32.3 
SE - standard error 
In terms of contributors to cost per pregnancy, there were many differences between 
countries. In both Cuba and Thailand, the contribution of ANC costs not surprisingly 
reduced under the new ANC programme (36% to 24% in Cuba and 42% to 32% in 
Thailand). Delivery care received a larger proportion in Thailand (29-36%) and South 
Africa (about 38%) compared with Cuba (11 %), but inpatient ANC and neonatal care 
received significantly less in Thailand (1 % each) compared with 16% and 20% in Cuba, 
and 11 % and 10% in South Africa. Staff consistently took the largest share of ACPP in 
all countries, ranging from 61 % to 76%. There were also some differences in resource 
contribution shares to ACPP, with drugs most significant in Cuba. 
'-. 
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8.1.2 Impact of uncertainty on cost per pregnancy comparisons 
Chapter 7 examined the impact of uncertainty on average costs, and found that this 
uncertainty reduced the extent to which cost differences between countries were 
statistically different. This section uses the. ranges on average costs obtained in the 
sensitivity analysis to calculate new ranges on cost per pregnancy, to examine whether 
further or fewer differences between countries emerge. Table 8.3 presents new upper 
and lower confidence limits, taking into account the average cost range from the multi-
way sensitivity analysis. 
Table 8.3: Cost per pregnancy ranges using results from sensitivity analysis and 
alternative currency conversion methods. 
CURRENCY Average cost per pregnancy (US$) Mar2inal cost per pregnancy (US$) 
CONVERSION Mean Mean 
METHOD and Low Mean High Low Mean High 
COUNTRY/ARM 
NOMINAL EXCHANGE RATE (January 1998) 
Cuba 
Average Intervention 277.5 371.9 635.0 81.8 108.7 184.4 
Average control 305.2 401.9 675.8 88.3 115.8 194.0 
Thailand 
Intervention average 66.5 85.7 141.1 15.6 20.1 33.1 
Average control 82.0 105.5 173.7 17.5 22.6 37.3 
South Africa 
Average control 259.0 347.0 592.4 29.9 41.1 71.7 
PURCHASING POWER PARITY 
Cuba 
Average Intervention 682.6 914.8 1562.2 201.3 267.5 453.5 
Average control 750.7 988.7 1662.4 217.2 284.9 477.3 
Thailand 
Intervention average 129.3 166.5 .. 274.4 30.2 39.0 64.3 
Average control 159.4 205.1 337.6 34.1 44.0 72.5 
South Africa 
Average control 402.7 539.6 921.2 46.5 63.9 111.5 
NOMINAL EXCHANGE RATE (May 1999)1 
Cuba 
Average Intervention 108.7 135.9 217.4 86.2 107.81 172 
Average control 115.8 144.7 231.5 93.1 116.43 186 
Thailand 
Intervention average 94.5 121.7 200.6 22.1 28.5 47.0 
Average control 116.5 150.0 246.8 24.9 32.2 53.0 
South Africa 
Average control 205.6 275.5 470.3 23.8 32.6 56.9 
I For Cuba, the black market rate ofUS$l = 20 Pesos is applied to non-traded goods. 
Results are presented at nominal exchange rates in January 1998, purchasing power 
parity in January 1998, and nominal exchange rates in May 1999. The lower confidence 
limit reflects both stochastic variability (minus 2 standard errors of the mean) and 
deterministic variability (20% reduction in cost). The upper confidence limit likewise 
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reflects stochastic variability (plus 2 standard errors of the mean) and deterministic 
variability (60% increase in cost). 
At both 1998 nominal exchange rates and PPP, the ACPP results still sh?w Thailand to 
have significantly lower costs than in Cuba and South Africa. However, at 1999 nominal 
exchange rates, costs in Thailand increased dramatically compared to Cuba and South 
Africa, which both experienced a decrease. Intervention arm costs in Thailand were only 
US$14 less than in Cuba (worth the value of two ANC visits in Thailand). At OER and 
" , 
PPP, marginal costs were significantly greater in Cuba co'mpared to the other countries, 
but Thailand and South Africa were no longer significantly different. Using 1999 
nominal exchange rates, the difference between control arm in Thailand and South 
Africa was reduced to non-significance. However, costs did not change in Cuba using 
marginal costs as the exchange rate with the US$ remained at 1: 1. In conclusion, the 
tabulation of ranges on cost per pregnancy using unit cost values from sensitivity 
analysis caused a decrease in some CPP variations to non-significance. Also, the use of 
1999 nominal exchange rates (and black market rates for Cuba) had a significant impact 
on the results, making Cuba relatively less costly, and Thailand relatively more costly. 
8.2 Main causes of cost per pregnancy variation 
This section examines the relationship between health service use, unit costs, and cost 
per pregnancy, to explain why cost per pregnancy varied between trial arms, individual 
health facilities, and countries. 
8.2.1 Cost per pregnancy variation between trial arms 
The conclusions of the previous two chapters showed that some types of health service 
use varied between trial arms in Cuba and Thailand, but unit costs did not vary 
systematically between trial arms. In Cuba, the reduction in ACPP was US$29. 
However, with a reduction in the average ANC visits of 5.6, ceteris paribus the expected 
saving would be US$68, using the overall policlinic average cost of US$12.15. This 
reduction was not achieved due to greater use of other health services, including an 
average of 0.42 inpatient days longer during pregnancy and 0.1 neonatal days longer per 
baby born, in the intervention arm. 
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In Thailand, with a reduction of 2.7 visits per woman in the intervention arm, the 
expected reduction of US$17.5 was close to the actual reduction of US$19.9. However, 
~/ 
this similarity masked other small differences between trial arms in terms of use and 
unit costs of other health services, including CS unit costs, CS rates, and postpartum 
average length of stay (see Table 6.3). 
8.2.2 Cost per pregnancy variation between health facilities 
8.2.2.1 Cost per pregnancy variation between health facilities in Cuba 
The cost per pregnancy variation between policlinics within arm must be explained by 
identifying variations in health service use or unit cost. Figure 8.3 below shows the . 
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Figure 8.3: Cost per pregnancy and average inpatient stay in Cuba 
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The high ACPP and MCPP in Galvan were partly explained by high average inpatient 
days, as well as neonatal days (1.17 per neonate). On the other hand, there was no 
discernible pattern amongst the other policlinics: the ones with high ACPP did not tend 
to have more IPD per trial woman. Zuluetta may have had a low ACPP because of low 
antenatal IPD. Therefore, it appears that health service use only partially explained cost 
per pregnancy differences in Cuba. 
Figure 8.4 shows that intervention arm policlinics, with less visits per woman, did not 
have consistently lower ACPP than control policlinics. For example, Galvan was in the 
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control group, and had the highest ACPP. The reason for this is that ANC is relatively 
low cost compared to other types of maternity care, and therefore rates of other HSU 
-,./" 
were also important determinants of CPP. High average costs for ANC may have 
contributed to Galvana nd Guiteras having high CPP, although the effect of average cost 
did not appear to be strong for other policlinics. 
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8.2.2.2 Cost per pregnancy variation between health facilities in Thailand 
Figure 8.5 below shows the variation in. antenatal and postpartum days between 
hospitals, compared with ACPP and MCPP. There appeared to be no strong relationship 
between average days per woman and ACPP or MCPP. The low CPP in Sichompoo was 
partly due to the low rates of health service use for all types of care by women there, 
especially postpartumm stay. In Chumpae, there was a higher postpartum IPD than the 
average, but ACPP was low. 
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Figure 8.5: Cost per pregnancy and average inpatient stay in Thailand 
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Figure 8.6 shows limited correlation between outpatient visits and average cost with the 
ACPP and MCPP. Using visual inspection the high ACPP in Phon was partly explained 
by the high ANC visits and high average cost for CS (not in Figure), but average costs 
of ANC and other health service use measures were in the middle range. Nampong also 
had high ANC visits and ACPP, but other indicators were in the middle range, Also, 
two hospitals with high average costs (Khaosankuang and Kranuan) only had middle-
range ACPP, The causes of the low CPP in Phuvieng and Chumpae were not apparent 
from these Figures, 
Figure 8.6: Cost per pregnancy and ANC visits/cost in Thailand 
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A final determinant of CPP in Thailand not shown in the Figures was the rate of referral 
to secondary hospitals for delivery or inpatient care, where average costs were 
significantly higher. The average referral rate for all hospitals was 14.5%, but individual 
hospitals varied between 1 % (Puvieng) or 1.3% (Sichompoo) and 25.2% (Banphai) or 
Phon and Nongrua (27%). Therefore, it seems that the referral rate is an important 
determinant of CPP. 
8.2.3 Cost per pregnancy variation between countries 
Figure 8.7 shows the relation between cost per pregnancy, and selected health service 
use and unit costs, for control arms in all countries. A clear finding was that Thailand 
had a lower CPP than Cuba and South Africa due to both lower average costs, and 
consistently lower health service use. It was less clear, however, what factors 
deterrriined differences between Cuba and South Africa, as South Africa had lower 
health service use and unit costs for some.activities, but higher for others. For example, 
CS rates and adult inpatient days were similar across Cuba and South Africa, neonatal 
days were higher and had lower cost per day in South Africa, delivery care was more 







Figure 8.7: Cost per pregnancy, health service use and unit costs in 
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A few conclusions are made from the results of this section, and implications drawn. 
/' 
First, differences in cost per pregnancy between arm in both Cuba and Thailand were 
due to differences in health service use, mainly in the numbers of ANC visits, and 
average days of inpatient stay (both ANC and postpartum). Average costs did not 
increase significantly through introduction of the new ANC programme. Therefore, this 
finding would not be generalis able to countries where the average costs of maternity 
care would increase with the introduction of the new ANC programme. For example, in 
" , 
poorly resourced settings implementation of the recommended model would require 
considerable investment in health services. Second, there were large differences between 
health facilities in both health service use and unit costs, which were jointly driving the 
differences in cost per pregnancy. However, in neither country were all intervention 
providers lower cost per pregnancy than control providers. This finding has important 
implications for prediction of costs of 'the new antenatal care programme in these 
countries. Third, the differences in cost per pregnancy between country were due to 
significant differences in both average costs (at both nominal exchange rates and PPP) 
and health service use. The causes of differences in HSU and unit costs are not . 
discussed here, as they received attention in Chapters 6 and 7. In particular, it appeared 
that intensive resource use, high ANC visits and inpatient days per woman and high CS 
rates caused cost per pregnancy to be the highest in Cuba. 
8.3 Comparisons between groups of women using 2-way analysis 
The 2-way analysis involved comparing the ACPP of women with selected risk factors 
or events with women without these risk factors or events. Appendix Tables 13.1 to 13.3 
show the differences in costs for different types of care, thus allowing conclusions to be 
made about which types of health services the presence or absence of certain variables 
impact. The weaknesses of 2-way comparisons were comparisons were discussed in 
Chapter 5, but the analysis contributes to interpretation of the multiple regression 
analysis results in the next section. 
8.3.1.1 2-way comparison results in Cuba 
Appendix 13 Table 13.1 shows the results of the 2-way analysis for Cuba, on selected 
dummy variables. The complete data set, broken down by arm and with 95% confidence 
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intervals, is provided in Appendix 13 Table 13.4. Those differences that were 
statistically significant are shown in bold in Appendix 13 Table 13.1. 
Thus the interpretation on the first variable is that those in their first pregnancy cost 
US$4 more for outpatient care, and US$45 more for overall CPP, compared to women 
not in their first pregnnacy. Statistically significant variables are shown in bold in Table 
9.4, and many of these are highly economically meaningful (>US$12). Of particular 
note are previous stillbirth or neonatal loss (US$170), previous reproductive tract 
. '," ;", 
surgery (US$256), referral to a higher 'level (US$441), hospital admission during 
pregnancy (US$660), and pre-term infant (US$973), and LBW baby (US$1052). Why 
these risk factors or conditions were so costly cost can be examined by observing where 
the c~st occurs. For example, most of the costs of pre-term or LBW infants were 
associated with neonatal care, and women referred to a higher level of care were more 
expensive in all categories, especially inpatient care during pregnancy. Note that for 
some variables, such as congenital malformation and adverse pregnancy event, some 
cost categories are significant, but overall cost is not significant. There were no events 
or risk factors that had a non-significant impact on costs (whether a single cost category 
or overall CPP). 
8.3.1.2 2-way comparison results in Thailand 
Appendix 13 Table 13.2 shows the 2-way results for Thailand. Again, most of the 
" 
variables were statistically significant, especially elective CS (US$119), adverse 
diagnosis at labour (US$65) and previous surgery on reproductive tract (US$96). The 
cost category with largest costs is postpartum care for the woman, which was largely 
related to the long length of stay following CS. The Table also shows that women with 
adverse outcomes of the labour or delivery period also have significantly higher ANC 
costs, such as post-term and induced labour. Risk factors or events that have a non-
significant impact on costs included previous stillbirth, last baby LBW, and postpartum 
anaemia. The complete data set, broken down by arm and with 95% confidence 
intervals, is provided in Appendix 13 Table 13.5. 
8.3.1.3 2-way comparison results in South Africa 
Appendix 13 Table 13.3 shows that many of the variables are significantly different in 
South Africa, both statistically and economically. Women admitted for HDP in last 
pregnancy cost on average US$157 more than women who were not; also referral 
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(US$163), hospital admission in this pregnancy (US$200), and adverse pregnancy event 
(US$97) were highly significant. Also, adverse events during labour and delivery were 
responsible for higher costs, including adverse diagnosis at delivery (US$107), preterm 
infant (US$136), induced labour (US$III), and elective CS (US$413) .. Inpatient care 
both during pregnancy and after deliver were consistently the highest contributors to 
cost for most risk factors and events. Some events were significant for categories of 
cost, but not overall CPP, such as prelabour rupture of membranes and congenital 
malformation. The complete data set, brok~Il down by arm and with 95% confidence 
intervals, is provided in Appendix 13 Table 13.6. 
8.3.1.4 Cross-country comparisons and conclusions 
The above analysis of comparing womenlbabies with risk factors or events against 
womefllbabies without these same risk factors or events has shown some significant 
findings, and some agreement as well as disagreement between countries. For example, 
there was agreement between countries that previous reproductive tract surgery, referred 
women, and women who had preterm infants increased costs. The significance of some 
factors has, however, merely confirm expectations, such as the cost impact of caesarean 
section or hospital admission. Cuba was the only country where previous stillbirth was 
significant, and Thailand was the only country where adverse pregnancy event was not 
significant. In Cuba, postpartum syhplis was not significant whereas it was in the other 
countries. Also, sizes of cost impact were different. For example, the cost increasing 
impact of a LBW baby and preterm infant were much greater in Cuba than in Thailand. 
This analysis has also identified risk factors and events unlikely to influence cost, such 
as first or repeat pregnancy, previous baby LBW, congenital malformation (at overall 
CPP level), and postpartum anaemia. However, these variables are still included as 
independent variables in the regression analysis, in case their impacts are significant 
taking into account the multivariate effect. The next section tackles cost determinants in 
more depth using the technique of regression analysis. 
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8.4 Multiple regression analysis 
8.4.1.1 MRA results in Cuba 
The hand-built model gave an adjusted R2 (R2'') of 0.85 in Cuba. This means that 
approximately 85% of the total variability in log ACPP was explained by the parameters 
listed in Table 8.7 below. Columns 2-5 show coefficients on variables found to be 
significant, with the mean value and lower and upper 95% confidence limits. Columns 
6-9 show the percentage impact on' base cost (the constant term) through back-
transforming the log (base 10) value. The constant term is US$1004, with a 95% 
confidence interval ofUS$763 to US$132475• 
Table 8.4: Results of final regression model in Cuba 
Variable Coefficient Change in cost (factor) Pvalue 
Lower Mean Upper Lower Mean Upper 
Constant term 2.882 3.0021 3.122 763 1004 1324 9.82E-24 
Pre-term labour 0.013 0.0267 0.040 1.031 1.06347 1.097 9.27E-05 
Premature rupture of membranes 0.008 0.0178 0.027 1.019 1.04189 1.065 0.000289 
Adverse diagnosis at labour -0.018 -0.0099 -0.002 0.960 0.97754 0.995 0.013508 
Birth weight (1 gramme change) 0.000 -0.0004 0.000 0.999 0.99912 0.999 9.82E-24 
Birth weight squared 0.000 0.0000 0.000 1.000 1.00000 1.000 9.82E-24 
Congenital malformation -0.515 -0.3732 -0.231 0.305 0.42346 0.587 2.63E-07 
Trial arm 0.016 0.028 0.040 1.0382 1.0674 1.0966 7.25E-14 
Outpatient visits per full-time -0.001 -0.0007 -0.001 0.998 0.99829 0.999 2.27E-18 
equivalent staff member 
Occupancy rate -0.004 -0.0033 -0.002 0.990 0.99250 0.995 1.43E-12 . 
Monthly throughput of patients 0.000 0.0000 .. 0.000 1.000 0.99998 1.000 4.65E-14 
Hospital admission in pregnancy 0.336 0.3469 0.358 2.168 2.22265 2.279 9.82E-24 
Mode of delivery (vaginal) 0.328 0.3364 0.345 2.128 2.16985 2.212 9.82E-24 
Neonatal admission 0.628 0.6448 0.661 4.249 4.41323 4.584 9.82E-24 
IPD - inpatient day 
Examining the signs of the coefficients shows that the congenital malformation variable 
has a value of less than one, whereas the expected value is more than one. This result (of 
negative correlation) is supported by the findings of the univariate regression analysis, 
but contradicts the findings of the 2-way analysis where a net effect on CPP of 
congenital malformation is to increase it by US$10. While the conflicting results may be 
due to interaction with other variables in the regression analysis, action was not 
considered essential due to the low incidence of congenital malformation. Before the 
7S However, this value corresponds to all independent variables taking a value of zero. For the average 
woman, values for birth weight, occupancy, and PTE per IPD take values of more than one, and therefore 
the constant term alone does not have any economic meaning on its' own. 
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coefficients are interpreted further, the strengths of the model are examined using 
various routine statistical tests. Table 8.8 shows how the regression model rated with 
,/' 
respect to important model aspects (multicollinearity, cluster effect, normal distribution, 
heteroskedasticity, impact of outlying patients, comparison of model with step-wise). 
Table 8.5: Diagnostic tools for regression models for Cuba, Thailand and South Africa. 
Aspect of model Details (& data Cuba Thailand South Africa 
source) 
Correct signs Compare signs Congenital All correct signs Previous LBW: 
with expectations malformation -ive -ive impact 
of economic impaCt when +ive when +ive 
theory expected expected 
Multicollinearity (Appendix 14 Some, but none Some, but minor Some, but minor 
(Pearson corr. coeff.) Tables 14.1-14.3) >0.4 
Cluster effect Comparison of Insignificant Insignificant Not relevant 
variance between difference difference 
clusters between clusters between clusters 
Normal distribution (Appendix 14 Log Log Log 
Figures 14.1- transformation transformation transformation 
14.10) adequate adequate adequate 
Heteroskedasticity (Appendix 14 Not a problem Minor heteroske- Minor heteroske-
Figures 14.1-14.9) dasticity present dasticity present 
Impact of outlying Cook's distance Four cases Two cases Zero cases 
patients excluded excluded excluded 
Comparison of (hand- Differences in Step-wise had Step-wise had Step-wise did 
built) model with step- significant birth weight gestational age not have 
wise model variables between cubed at first visit previous LBW 
two models 
Multicollinearity does not appear to be problem in Cuba. Appendix 14 Table 14.1 shows 
the Pearson correlation coefficients (between variables in Table 8.7 only). There appears 
to be some, though not serious, correlation between pre-term delivery and birth weight 
and between pre-term delivery and admission to the intensive care unit «0.4). However, 
these rates are acceptable, and taking them out would lead to mis-specification, and 
therefore no adjustments were made to the model. The effect of the cluster design on the 
results was examined, by comparing the variability in cost per pregnancy between 
clusters, which was not found to be significantly different, using the F distribution. 
Appendix 14 Figures 14.1 to 14.4 show that the skewness of the cost data was reduced 
considerably by applying a log transformation, so that OLS would be expected to give 
BLUE estimators. Appendix 15 Figure 15.1 shows that the regression residuals followed 
a normal distribution, and this is confirmed in Appendix 15 Figure 15.2 by a quartile-
quartile plot. Appendix 15 Figure 15.3 indicates using a scatter plot of the regression 
standardised residual against the regresslon standardised predicted value that 
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heteroskedasticity is not a serious problem. This is because the variance in error term for 
larger cost values is not significantly (or consistently) greater than at lower cost values. 
/' 
In conclusion, no further transformations were considered necessary. 
The impact of the leverage of outliers was examined using Cook's distance on all cases. 
The number of cases excluded due to the Cook's distance being >0.5 were four, thus not 
having significant impact on the results when these were excluded. The step-wise 
approach for Cuba, where inclusiorilex~l~sion was .. controlled by the computer 
(inclusion criterion: p<0.05) did not fit the regression better, with an R211 of 0.85. The 
step-:wise approach gave one more significant variable - birth weight cubed. The effects 
are relatively minor, and the F test for the difference between the two models was not 
signi~cant at the 5% level. In conclusion, the step-wise and hand-built models give 
almost identical results. The results of the hand-built models are interpreted below. 
As expected, the results in Table 8.7 show that the 'E' variables, actual health service 
use, were the most important predictors of cost, with a combined R211 of 0.82, thus 
accounting for virtually all of explainable variation in cost per pregnancy. The . 
coefficients on all these variables were large, ranging from an impact on cost of a factor 
of 2.17 for a CS instead of vaginal delivery to 4.4 for admission to intensive care unit. 
This corresponds to the expected cost impact76• The cost impact if a woman is admitted 
to hospital during pregnancy is a factor of 2.2. If a woman had more than one of these, 
the impact on cost per pregnancy is multiplicative. 
The other significant variables had less explanatory power than the health service use 
variables. In Cuba, there were no pre-pregnancy or pregnancy events that are 
significantly correlated with cost per pregnancy, from the regression, despite the 
significant results of the 2-way analysis in the previous section (e.g. previous 
reproductive tract surgery, previous spontaneous abortions, first pregnancies and 
postterm delivery). This is largely due to the effect of analysing variables together rather 
than separately. On the other hand, some indicators from the labour and delivery period 
were found t? be predictive of cost per pregnancy. For example, pre-term labour 
76 For example, a neonatal admission would increase costs by an average (11 days ALOS x US$114 per 
day) = US$1254. Compared to an ACPP of perhaps US$300 without a neonatal admission, the factor 
impact of 4.4 is more or less correct. 
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increases costs by 6.3% and prelabour rupture of membranes by 4.2%, while adverse 
diagnosis at labour had a cost impact of -2.24%.' Also, birth weight had an overall 
/ 
negative effect, as expected: as birth weight rises, ACPP reduces, although this would 
not apply outside the normal range of birth weight. Unfortunately, in the literature 
review there were no previous studies on maternal health events and outcomes against 
which to compare these results. 
The characteristics of the policlinic where ,\Vomen received outpatient care were also 
significant predictors of cost. For example~ an increase in the number of outpatient visits 
per FTE by one unit decreased cost per pregnancy by 0.174%. Also, larger facilities had 
lower cost per pregnancy: roughly a 2% decrease for every 1,000 patient more per 
month. Facilities with higher occupancy rates had lower cost per pregnancy: a 1 % 
increase in occupancy reduced cost by 0.75%. Although these effects were small - even 
for large differences between policlinics ~ they were still significant, and confirms some 
results from the unit cost analysis in Chapter 8. Also, if the woman was in the 
intervention arm instead of the control arm, the cost impact was 6.6% (which is close to 
the observed average impact of 8% from the trial data set). 
8.4.1.2 MRA results in Thailand 
The hand-built model gave an R2" of 0.505 in Thailand. This means that approximately 
50% of the total variability in log ACPP was explained by the parameters listed in Table 
8.9 below. The predicted cost when all parameters took a value of zero was US$34.5, 
with a 95% confidence interval of US$31.7 to US$37.5. On examination for correct 
signs of the coefficients, all coefficients have the sign that would be expected. However, 
one variable - years at school - was ambigious in its' impact on cost; the regression 
analysis found that more years at school had a significant increasing cost impact (1.6% 
for every additional year spent at school). 
Appendix 14 Table 14.2 shows the bivariate correlations between variables in the final 
model, as measured by the Pearson correlation coefficient. There appears to be some, 
though not serious, correlation between which clinic the woman attended and the 
number of visits she had (as would be expected, due to intervention clinic consistently 
with less visits). As in Cuba, none of these variables were omitted in order to avoid mis-, 
specification. 
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Table 8.6: Results of final regression model in Thailand 
Variable Coefficient Change in cost (factor) Pvalue 
Lower Mean Upper Lower Mean Upper 
Constant 1.502 1.538 1.574 31.735 34.506 37.519 8E-24 
Years at school 0.005 0.007 0.009 1.012 1.0163 1.021 7.9E-13 
Previous abortion 0.013 0.025 ·0.037 1.029 1.0589 1.089 7.2E-05 
Previous surgery 0.066 0.112 0.157 1.165 1.2934 1.436 1.5E-06 
Adverse diagnosis at labour 0.048 0.066 0.083 1.117 1.1634 1.211 2.3E-14 
Induced labour '0.018 0.041 0.064 1.059 1.0990 1.480 0.0006 
Postpartum syphilis 0.025 0.098 0.170 1.042 1.2519 1.160 0.0085 
Trial arm 0.062 0.081 0.1001 1.153 1.2056 1.259 5.4E-12 
Hospital identification 0.020 0.022 .0.023 0.998 1.0514 0.999 8E-24 
Inpatient days per full-time -0.001 -0.001 . ~O.OOl 1.048 0.9983 1.055 8E-24 
equivalent staff member 
Hospital admission in pregnancy 0.008 0.035 0.062 1.019 1.0840 1.154 0.0110 
Mode of delivery (vaginal) 0.248 0.268 0.288 1.771 1.8533 1.939 8E-24 
Neonatal admission 0.215 0.239 0.262 1.641 1.7328 1.830 8E-24 
-
Appendix 15 Figure 15.4 shows using a histogram that the regression standardised 
residual does not follow a normal distribution, and has a long right hand tail. This shows 
up in the expected cumulative probability plot in Appendix 15 Figure 15.5, where the 
expected against observed cumulative probability plot is not close. The impact of this 
was not expected to change the results considerably, and the results are interpreted with 
this in mind. Appendix 15 Figure 15.6 indicates using a scatter plot of the regression 
standardised residual against the rgeression standardised predicted value that 
heteroskedasticity is not a serious problem. The impact of the leverage of outliers is 
examined using Cook's distance on all cases. The number of cases excluded due to the 
Cook's distance being >0.5 are two, thus not having significant impact on the results 
when these were excluded. The step-wise approach for Thailand fitted the regression 
slightly better, with adjusted R2 of 0.52, and one two significant variables - gestational 
age at first visit (linear and cubed terms). 
Table 9.9 shows that the 'E' variables, actual health service use, are the most important 
predictors of cost, with a combined adjusted R2 of 0.382, thus accounting for a 
significant proportion of the explainable variation. The impact on cost of all these 
variables ranged from a factor of 1.084 for a hospital admission to 1.853 for a caesarean 
section. 
Other parameters included in the model had less explanatory power. In Thailand, several 
risk factors, events at labour and delivery,and health provider characteristics were 
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significant. The risk factors influencing cost were the number of years at school, 
previous abortion and previous surgery on the reproductive tract, all of which had 
/ 
positive coefficients. The 2-way comparisons presented earlier showed that postpartum 
stay represented the major increase in cost due to these risk factors. Non-significant 
variables that were significant in the 2-way analysis included previous reproductive tract 
surgery, first pregnancies, premature rupture of membranes, and pre- and postterm 
delivery). 
Three labour/delivery/postpartum events· determined costs. Induced labour increased 
costs by 10%, adverse diagnosis at labour by 16% and postpartum syphilis by 25%. 
Most of the cost increases were in postpartum stay for the woman, but delivery costs 
were_also increased. Some events that were expected to affect costs, such as birth 
weight, Apgar scores and fetal presentation at delivery, were found not to have a 
significant impact. 
Only three hospital characteristics were significant determinants of cost. The results 
show that for an increase in one inpatient day per FrE, there was a decrease in cost of 
0.17%. Inter-hospital differences were significant, with a move from the average 
hospital to the next costly hospital there was an increase in cost of 5%77. Also, if the 
woman was in the intervention arm instead of the control arm, the cost impact was 
20.5% (which is close to the observed average impact of 23.2% from the trial data set). 
Other measures of efficiency or cost determinants such as occupancy and size did not 
have significant impact on cost per pregnancy, although they were found to have some 
relationship in the unit cost analysis earlier. However, the unit cost analysis reported in 
Chapter 7 showed that efficiency indicators and size did not predict with confidence the 
unit cost of a hospital in Thailand, and it is assumed that was why they were not 
significant in the regression analysis. 
8.4.1.3 MRA results in South Africa 
The hand-built model gave an R2/\ of 0.57 in South Africa. This means that 
approximately 57% of the total variability in log ACPP was explained by the parameters 
listed in Table 8.10 below. However, some variables were excluded due to the low 
77 This is used to calculate, for example, that the most expensive hospital is on average 6 x 5% = 30% 
more expensive than the average hospital. 
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response rate, such as for gestational age at first visit, birth weight, and apgar score. 
Also, provider characteristics were not included, as women were not differentiated by 
"/ 
which clinics or wards they attended. The predicted cost when all parameters take a 
value of zero was US$158, with a 95% confidence interval of US$140 to US$177. On 
examination for correct signs of the coefficients, it appears that all coefficients were as 
expected, except 'previous low birth weight' which had a negative sign, when a positive 
sign was more likely. 
Appendix 14 Table 14.3 shows the bivariate correlations between variables in the final 
model, as measured by the Pearson correlation coefficient. There appears to be some, 
though not serious, correlation between 'adverse diagnosis at labour' and neonatal 
admission, as well as malpresentation and CS, although no coefficients were over 0.3. 
Finally, CS and neonatal admission were correlated (0.34). However, none of these 
correlations were serious enough to exclude parameters from the model. 
Table 8.7: Results of final regression model in South Africa 
Variable Coefficient Change in cost (factor) P value 
Lower Mean Upper Lower Mean Upper 
Constant 2.148 2.198 2.248 140.6 157.76 177.03 4.32E-22 
Previous low birth weight -0.072 -0.035 0.002 0.847 0.92267 1.006 0.067366 
Previous admission 0.029 0.121 0.213 1.068 1.32137 1.635 0.010461 
First ANC visit < 20 weeks -0.074 -0.041 -0.009 0.844 0.90906 0.979 0.012267 
Referral to higher level care 0.005 0.040 0.076 1.011 1.09741 1.191 0.026401 
Pre-term delivery 0.008 0.049 0.090 1.019 1.12003 1.231 0.019182 
Prelabour rupture membranes 0.007 0.068 0.129 1.015 1.16823 1.344 0.030372 
Malpresentation at delivery 0.006 0.036 0.066 1.014 1.08726 1.165 0.018471 
Postpartum syphilis 0.024 0.088 0.152 1.058 1.22511 1.419 0.006913 
Congenital malformation 0.027 0.173 0.318 1.065 1.48828 2.079 0.020083 
Hospital admissi~n in pregnancy 0.075 0.093 0.112 1.188 1.23981 1.294 2E-21 
Mode of delivery (vaginal) 0.242 0.280 0.317 1.745 1.90373 2.077 4.32E-22 
Neonatal admission 0.100 0.129 0.159 1.258 1.34620 1.440 5.19E-17 
Appendix 15 Figure 15.7 shows using a histogram that the regression standardised 
residual followed roughly a normal distribution, which is confirmed in Appendix 15 
Figure 15.8 where the expected against observed cumulative probability plot is 
acceptably close to the diagonal line. Appendix 15 Figure 15.9 indicates using a scatter 
plot of the regression standardised residual against the regression standardised predicted 
value that heteroskedasticity was not a serious problem, although there was a small 
funnel effect for the dense area of points shown by a darker shade. In conclusion, 
although some heteroskedasticity is likely to exist, it was not a serious enough problem 
208 
to require further transformation. The impact of the leverage of outliers was examined 
using Cook's distance on all cases. The number of cases excluded due to the Cook's 
/'" 
distance being >0.5 was zero. 
The results show that the 'E' variables, actual health service use, were the most 
important predictors of cost, with a combined adjusted R2 of 0.536, thus accounting for 
most of the explainable variation. The impact on costs of all these variables was large, 
ranging from a factor of 1.24 for anad~ssion to hospital to 1.904 for a caesarean 
section. 
Other parameters had less explanatory power. In South Africa, risk factors, events at 
labour and delivery, and health provider characteristics affected cost per pregnancy. The 
risk factors that determined cost are previous admission (positive effect), previous low 
birth weight (negative effect), referral this pregnancy (positive effect) and gestational 
age at first visit (negative effect). This latter variable suggests that women that report 
later have a lower cost, probably because they receive less ANC visits. Four 
labour/delivery/postPartum events were found to determine costs. Pre-term delivery . 
increases costs by 12%, PROM by 17%, malpresentation by 8.7%, postpartum syphilis 
by 22.5%, and congenital malformation by 49%. Non-significant variables that were 
significant in the 2-way analysis included admission for hypertension during a previous 
pregnancy, an adverse outcome during pregnancy, and induced labour. 
8.4.1.4 Cross-country comparison of MRA results 
The purpose of this section is to briefly identify similarities and differences between the 
results for Cuba, Thailand and South Africa, and make conclusions about the 
implications for cross-country prediction. Not only is there the issue of whether 
variables that are significant and non-significant are consistent between country, but also 
whether those parameters that have significant influence on cost per pregnancy have 
similar coefficient sizes. 
First, R2" was considerably higher in Cuba than in Thailand and South Africa. Almost 
half of the variability in Thailand and South Africa could not be explained using 
parameters included in the model. The reason for this residual variation is likely to be 
because data were not collected on parameters that should have been included. There 
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may have been other patient or provider parameters influencing health service use or 
average cost, such as those identified and tested in Chapter 7. Some of these differences 
were identified using anecdotal data, such as the low postpartum stay in Si Chompoo 
hospital in Thailand due to a strict discharge policy. Also, variability in inpatient and 
delivery parameters was greater between health facilities in Thailand, because all 
women were assumed to receive inpatient and delivery care in the same hospital in Cuba 
and in South Africa. This may have accounted for a part of the difference in explained 
variation between Cuba and the other countries. 
In terms of significant parameters, there were both important similarities and differences 
between countries. In all countries, for example, all health service use parameters were 
highl~ significant, and accounted for a large proportion of the explained variation. The 
coefficients were larger in Cuba for delivery and neonatal care, and this was probably 
due to the much higher cost and longer average length of stay for CS cases. Also, 
neonatal intensive care unit costs were high in Cuba. 
The other significant parameters varied considerably between country. In Thailand and 
South Africa there were three risk factors having a statistically significant influence on 
cost, whereas in Cuba there were none, despite the significant results of the 2-way 
analysis. This suggests that low-risk women in Cuba did not receive considerably 
different amounts of care than women with risk, but also risk rates were much higher in 
Cuba due mainly to higher parity and a higher abortion rate. 
On the other hand, women in Cuba and South Africa that had pre-term delivery or 
premature rupture of membranes had higher cost, whereas in Thailand the model 
predicts that these events do not affect cost significantly. Adverse diagnosis at labour 
was significant in Thailand and South Africa, but was negative and has limited impact 
on costs in Cuba. In Cuba, increasing birth weight had a small but negative effect on 
cost, probably because LBW babies were more likely to be admitted to the neonatal 
ICU. In Thailand, the low ICU admission and the relatively low cost of neonatal ICU 
means that it was not statistically significant. 
.~ 
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Provider characteristics had a much greater effect on cost in Cuba. As already suggested, 
this was for the principal reason that unit cost was explained by efficiency indicators in 
Cuba better than in Thailand. However, due to the significant inter-provider variation in 
cost per pregnancy, the clinic identification variable was a highly significant parameter 
in both countries. Also, the clinic identification variable was a more important variable 
than whether it was in the control or intervention arm of the trial. This finding has 
serious implications for prediction of the costs of the new ANC programme, as 
additional information is needed on whether the provider tends to be a high, medium or 
, . . . 
low cost provider (due to the combined interaction of unit cost and health service use). 
This supports earlier conclusions of this chapter. 
In conclusion, the MRA results have added an important additional perspective to the 
analysis of cost per pregnancy, and can potentially be used for cost prediction in the next 
chapter. Although the regression models for each country did not perform perfectly 
using the diagnostic instruments (some heteroskedasticity and multicollinearity), as well 
as some signs not as expected, OLS has explained cost per pregnancy relatively well. 
8.5 Discussion and conclusion 
This chapter has used several tools to explore determinants of cost per pregnancy, 
essentially to understand why cost per pregnancy varies between women who have 
different characteristics and who receive their care in different health facilities and 
countries. Also, the findings of previous analyses on the variability in health service use 
and unit costs was discussed further in the context of their impact on cost per pregnancy. 
Cost analysis found that cost per pregnancy varied significantly at the four levels at 
which it was examined: subgroup of women, the health provider, the trial arm, and the 
country. Variations at all levels have important implications for the generalis ability of 
the costs of the W.H.O. ANC programme, both within and between countries. Findings 
are summarised and implications discussed below. 
First, cost differences between arm in Cuba were not those expected from the reduction 
of 5.6 visits per woman, as more inpatient care was provided to intervention arm 
women. On the other hand, cost differences between arm in Thailand were roughly 
those expected from an average 3 reduction of three visits in the new ANC programme. 
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Also, the percentage reduction in cost in Thailand (19%) was much greater than in Cuba 
(7.5%). Therefore, careful thought needs to go into the prediction of costs for the new 
/" 
ANC programme in South Africa, depending on the impact on inpatient as well as 
outpatient care, rather than assuming a cost reduction. 
Second, cost differences between health facilities were considerable, in fact making the 
cost differences between arm look less important. Table 8.1 clearly showed that the 
average reduction in CPP in each coun~ hid some larger differences between 
, " 
individual health facilities within and between arm. This finding was confirmed in the 
regression analysis by the fact that both the trial arm variable and the health facility 
identification variable were both significant. Also, provider characteristics in the 
regression equation such as occupancy level, 'visits per FfE' , and size were found to be 
especially significant in Cuba. In Thailand, 'days per FfE' was the only significant 
provider variable. The implications for cost prediction within country is that health 
facilities should be identified according to whether they tend to be high, medium or low 
cost, based on available data on health service use rates and unit cost levels. 
Third, analysis of cost differences between women based on their defining 
characteristics gave some significant results, in both 2-way and multiple regression 
analysis. There were some similarities and differences between country in terms of 
which variables were significant, and the" cost impact. Previous abortion, stillbirth, 
neonatal loss and surgery on reproductive tract in general were significant predictors of 
cost per pregnancy, while number of previous pregnancies, last baby LBW, previous 
pregnancy admission to hospital for HDP and the use of addictive substances did not 
have significant influence. Several events during pregnancy and delivery had a 
significant effect in all countries, including adverse diagnosis at labour, elective CS, and 
hospital admission during pregnancy, although the size of effect differed across country, 
being greater in Cuba and South Africa. Pre-term delivery and PROM were not 
significant in Thailand, but were significant in the other countries. Therefore, despite the 
cross-country similarities, it is unlikely that coefficients are generalisable between 
countries, due to different there being ACPP determinants, and different sizes of effect. 
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Fourth, cross-country differences in cost per pregnancy had several sources, including 
uncertainty, unit costs, and health service use. The greatest differences occurred where 
//"-
the high cost events (such as hospital admission, CS, or neonatal ICU admission) also 
had different rates between countries. This occurred particularly between Thailand and 
Cuba/South Africa. There was uncertainty in the most appropriate values for opportunity 
cost and exchange rates, thus reducing the confidence of conclusions reagrding cost 
comparisons between countries. Also, the exclusion of private health care costs in 
Thailand and South Africa meant that CPP was underestimated. 
In conclusion, this chapter has drawn together results from previous chapters, and 
placed them in the overall context of cost per pregnancy. This chapter also conducted 
furthe~ analyses to explore the causes of cost variation at the- overall patient level. With 
the understanding and insights gained, the next chapter examines alternative cost 
prediction methods, to make final conclusions about the ability to predict the cost of 
pregnancy in developing countries. 
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9 COST PREDICTION 
Following on from the last three chapters, where cross-setting cost variations were 
tested for significance and causes of variation examined, this chapter tests alternative 
cost prediction methods. The literature review identified a variety of techniques for 
predicting costs, based on different types of information and from different data sources. 
The five categories of cost prediction method tested are: direct cross-country transfer of 
costs; adjusted cross-country transfer of cos~s; cost predictions using assumptions about 
proportion of staff cost in average cost; incremental cost impact, based on detailed 
assessment of expected changes in health care provision, unit costs, morbidity rates and 
health service use; and cost prediction using coefficients from a regression model. In the 
first two sections, the incremental cost impact and the regression model methods are 
applied, and predictions presented. In the third section, the results of all the cost 
prediction results are presented, and comparisons made with observed costs to make 
conclusions about predictive accuracy. In the fourth section, the five cost prediction 
methods are critically evaluated. In particular, the performances of the cost prediction 
methods are compared with the expectations from earlier empirical results and from the 
literature review, and divergences explained. Also, their potential application and 
accuracy in lower income countries is explored. In the fifth section, the cost predictions 
in South Africa are interpreted, and conclusions made about which methodes) are likely 
to give the most accurate predictions there. The final section summarises and concludes. 
9.1 Application of the incremental cost impact method 
This section compares antenatal care practices as recommended in the W.H.O. antenatal 
care programme with current antenatal care practices in Cuba, Thailand and South 
Africa, and examines the likely impact on average costs and health service use of 
implementing the W.H.O. programme. Current and new ANC programmes were 
compared in terms of the number and timing of visits, content of visits, average impact 
on health outcomes, health service use, and costs. 
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9.1.1 Predicted changes to implement W.H.O. ANC programme 
Number of antenatal visits 
The expected number of antenatal visits in the intervention arm in Cuba is 6.06 visits 
per woman (range 4.72 to 7.1 visitsf8. In Thailand, the expected number is 4.23 visits 
per woman (range 4.11 to 4.55 visits)79. In South Africa, the expected number is 4.3 
visits per woman (range 3.6 to 5.0 visits)8o. 
Content of antenatal visits 
As well as the average number of antenatal visits, the contents of visits also affects the 
cost per pregnancy via the cost per visit. Therefore the hypothetical changes to medical 
practice required for each country to adopt the W.H.O. programme are examined, thus 
allowing assessment of likely changes in rates of morbidity, health service use, unit cost 
and finally cost per pregnancy. Appendix 16 Table 16.1 compares all aspects of the 
W.H.O. programme with current antenatal care in all three countries. Table 9.1 
summarises the main differences between the W.H.O. programme and current practice, 
to allow assessment of potential impacts on costs and health status. The main difference 
78 The hypothetical effect of the new programme for low risk women in Cuba was a reduction in visits 
from an average of 13 per woman to 4, a reduction of 9 visits per woman. However, given the 
determinants of numbers of ANC visits discussed in Chapter 6, it is unlikely that a 4 visit average would 
be experienced in Cuba as 72% of women suffered some form of morbidity in Cuba (this includes any 
adverse pregnancy event, including mild sexually transmitted diseases) thus requiring further visits or 
inpatient stay. As the additional numbers of visits for these women cannot be predicted with the 
information available, assumptions were made that the average number of additional visits these women 
required was 3 (range 1 to 5). This figure is justified on the grounds that some women with adverse events 
would have up to 10 or 12 visits, while most would only have one or two extra, thus averaging around 3 
extra each. This gives the average additional number of visits of 2.06 (= 3 visits per woman x 72% of 
women with a morbid condition requiring 3 extra visits) over the minimum of 4 visits extra visits per 
woman in all the trial population, with a range of 0.72 to 3.10 additional visits. 
79 The same calculation was done in Thailand as in Cuba, but with 7.5% of women having an adverse 
event during pregnancy leads to an average 0.23 additional visits per woman over the minimum of 4 visits 
(3 visits x 7.5% of women with a morbid condition requiring 3 extra visits) with a range of 0.11 to 0.55 
additional visits. 
80 It is clear from the late reporting in South Africa that a large proportion of women under the W.H.O. 
programme would receive the health care interventions of visits 1 and 2 (and maybe visit 3) when they 
first attend ANC. Assuming these women are low risk and they comply with scheduled visits, these 
women would receive a maximum of 3 visits under the W.H.O. programme. This does not include women 
needing more visits, due to risk status or pregnancy events. Out of the 785 women in the sample, there 
were 550 medical events suffered by 377 women (urinary tract infection, trichomoniasis and syphilis 
accounted for 60% of these events). Assuming each event required an average of 2 visits additional visits 
each (range 1-3) this would lead to an extra 1.4 (550n85 x 2) visits per woman (range 0.7 - 2.1 visits) 
from reporting after medical events [2 additional visits are assumed compared to 3 in Thailand and Cuba, 
because of later reporting in South Africa]. Added to the average number of visits of 2.9 visits per woman 
(from normal reporting), this would give 4.3 visits per woman (range 3.6 to 5.0). The figure of 2.9 visits 
per woman is arrived at by multiplying 4 visits by % women reporting under 20 weeks, 3 visits by % 
women reporting 20-32 weeks, and 2 visits by % women reporting >32 weeks. 
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in Cuba between the ANC programmes was expected to be the number of diagnostic 
tests required: multiple dipstick and rapid plasma reagent (syphilis test) to be added, and 
~' 
several tests to be reduced for low risk women, or taken out altogether. In Thailand, 
there were several interventions to add, including more history taking a~d risk scoring, 
as well as more records kept and a change to the appointment schedule. In South Africa, 
more background and history tiling is required, as well as more formal risk scoring and 
laboratory tests, and time spent with the patient giving' one-to-one advice and answering 
questions. ',' . 
Table 9.1: Health care changes required from 'old' to 'new' antenatal care programmes. 
ITEM CUBA THAILAND SOUTH AFRICA 
1. More • More data on habits • More data on • More data on 
interventions • Use handheld doppler background, habits, and background, medical 
required • Multiple dipstick for UTI other health care received history, HIV status, 
- • On-the-spot RPR by woman habits, and other health 
• More pap smear • Multiple dipstick for UTI care recei ved 
• Formal risk score • On-the-spot RPR • Pregnancy test in clinic 
• Emergency phone number • Pap smear • Take height on 151 visit 
• Keep home-based record • Formal risk score • Multiple dipstick protein 
• Partner referral (syphilis) • On-the-spot RPR 
• Advise individually • Pap smear 
• Question and answer • ABO and rhesus test 
• Emergency phone number • Symphus-fundus on card 
• Appointment system • Formal risk score 
• Keep home-based record • Partner referral (syphilis) 
• Advise individually 
• Question and answer 
• Emergency phone number 
• Appointment system 
• Keep clinic-based record 
2. Less • Less vaginal exams • Less protein in urine tests • Less tetanus toxoid doses 
interventions (not • Less protein in urine tests • Less haemoglobin tests 
at all visits • Less haemoglobin tests 
and/or only Cor • Less Hep B and HIV test high risk women) 
• Less trichomoniasis test 
• Less ultrasound (HR) 
3. Stop • Do not monitor weight • Do not monitor weight • Do not monitor weight 
interventions • Do not do fasting glucose • Do not do haematocrit (because not • Do not do haematocrit 
beneficial) 
Table key: UTI - unnary tract mfectiOn; RPR - rapid plasma reagent test for syphilis; HR - high risk 
Unit cost per ANC visit 
It was assumed that, as the main change in medical practice of the ANC programme was 
in outpatient ANC visits, these were the only unit costs that were likely to be affected. 
Any change predicted in the inpatient rate was assumed not to be sufficient to change 
occupancy levels, and therefore average costs of inpatient stay remained unchanged. 
Potential impact on outpatient ANC average cost was examined with respect to the use 
of staff, equipment, consumables, and change in monthly throughput of patients. Table 
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9.2 summarises the expected changes in resource use. The predicted impact on average 
cost in the c01:lntries were (see Table 9.2 for details): . 
• Cuba: a 10% increase in the base case (range no change to 20% increase) to 
US$13.33 (range US$12.12 to US$14.54) 
• Thailand: no impact was predicted in the base case (range 32% reduction to 32% 
increase) at US$6.56 (range US$4.46 to US$8.66) 
" 
• South Africa: a 30.5% increase of US$2.21 was predicted (range US$1.13 increase 
to US$3.53 increase) to US$9.45 (nmge YS$8.37 to US$1O.78) . 
..... 
Inpatient admission 
Following identification of the expected changes in the content and frequency of 
antenatal care, predictions were made about the likely impact of the W.H.O. programme 
on inpatient admission. In all countries, the main hypothesised effects of the W.H.O. 
recommended programme on women's health are through earlier diagnosis and 
treatment of syphilis81, and treatment of urinary tract infection (UTI). In fact, it was also 
likely that not only would women be treated earlier, but also rates might increase 
through improved diagnosis. For example, UTI 'no treatment' rates were expected to 
fall, and UTI 'with antibiotic treatment' expected to rise. Appendix 16 Table 16.2 shows 
the numbers and percentages of different adberse outcomes for women attending control 
arm clinics in study countries. In order to predict the increase in inpatient admissions 
due to higher detection rates, the rates of untreated UTI and hyperensive disorders of 
pregnancy (HOP) were taken from the control arm data set. However, there was 
considerable uncertainty associated with the actual change in diagnosis and admission 
rates, and therefore wide ranges are given on the base case prediction. In the base case 
scenario, the improved diagnosis and referral of women with UTI was assumed to lead 
to an increase in admission rate of 25% for women with untreated severe UTI (range 0% 
to 50%), with a length of stay of 7 days (the average for UTI cases). Also, the improved 
diagnosis and referral of women with HOP was assumed to lead to an increase in 
admission rate of 50% for women with untreated HOP (range 25% to 75%), with a 
length of stay of seven days (based on inpatient admission data for HOP). Few other 
81 The numbers of diagnosed and treated sexually transmitted diseases were expected to rise due to 
immediate diagnosis and treatment, but these were assumed to have no impact on inpatient admission 
rates. 
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interventions in the W.H.O. programme were thought likely to impact major health 
outcomes listed in Appendix 16 Table 16.2. 
Table 9.2: Average cost impact for outpatient ANC in study countries. 
ITEM 
Staff 
More staff time 









Change in materials 
required 
Expected overall 






impact on unit cost 
CUBA 
Formal risk score, rapid 
syphilis test, vaginal 
examinations and home-based 
record in the clinics. 
Less diagnostic tests from the' 
laboratory. 
10% increase in average cost 
per visit was assumed (range 
0-20%)1. 
Rapid plasma reagent (for 
syphilis test) and a handheld 
doppler. 
Noimpace. 
Less materials required due to 
less laboratory tests 
performed. 
The reduction in antenatal 
visits predicted were assumed 




Additional personal data, 
formal risk score, rapid 
syphilis test, pap ~mear, and 
home-based record. 
Less diagnostic tests from the 
laboratory. . .c· 
Noimpace. 
Rapid plasma reagent (for 
syphilis test). 
No impace. 
Less materials required due to 
less laboratory tests 
performed. 
Three assumptions: 
I.Upper range: ANC receives 
2 days a week'. 
2. Base case: no effect on 
throughput. 
3. Lower range: ANC 
receives 1 day a week. 
The upper and lower ranges 
lead to a 32% increase and 
32% decrease in average cost, 
respectively. 
SOUTH AFRICA 
Additional personal data, 
formal risk score, rapid 
syphilis test, pap smear, one-
to-one advice, and clinic-
based record. 
No third dose of tetanus 
toxoid administered. 
No impace. 
Rapid plasma reagent (for 
syphilis test). 
No impace. 
More materials required due 
to more laboratory tests 
performed. 
Unit cost is increased by 
US$0.40 (US$7.25 x 1.055)\ 
range US$O to US$0.80. 
ANC continues to be 
provided 2 days a weeks. 
The increase in average cost 
was predicted at US$1.81 
(US$7.25xO.25) 10. The range 
on this is US$1.13 to 
US$2.73 11• 
I An IOcrease 10 UDlt cost was assumed because routme ANC reqUIred more tIme from obstetricians. 
2 Assuming the extra staff time required could be provided with the extra time available to staff due to less visits per 
day in the health promotion unit (Thailand) and health centre (South Africa), the impact on unit cost is assumed to 
occur due to changes in throughput, and not changes in total staff costs per se. 
3 The investment in these equipment was assumed to have minimal impact on the cost per visit, given both the long 
life of equipment (depreciation) and the annual volume of patients using these equipment. 
4 The expected saving in materials from less laboratory tests was difficult to identify, and was assumed to be minimal 
compared to unit costs. 
5 Laboratory costs were assumed to increase by an average of 50% per visit (with a range of 'no impact' to 
'doubling'). As laboratory contributes 11 % of average cost, average cost was increased by 5.5%. 
6 It was assumed that less ANC patients are replaced by other patients in the longer term, so that the net effect on 
throughput is zero. 
, Resulting in an average reduction of 42% of visits per day (visits reduced from 7.2 to 4.2). 
S Resulting in an average reduction of 27% of visits per day (visits reduced from 6 to 4.3). 
9 Using data from the control group, where 77% of cost was fixed cost, this leads to a change in average cost of 32%. 
10 Given that 94% of cost is fixed cost there would be an increase in average cost of 25%, 
II US$1.13 (with an average 5 visits per woman, leading to a reduction of 16.7% of visits) to US$2.73 (with an 
average 3.6 visits per woman, leading to a a reduction of 40% of visits). 
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9.1.2 Overall implications for cost per pregnancy 
Table 9.3 shows the summary cost impacts for outpatient and inpatient care services 
(per woman and per visit, as sepcified), and predicted cost per pregnancy impacts. This 
table is built using the results of section 9.1.1; Table 9.3 shows that a sav~ng of US$81.2 
was expected under the W.H.O. ANC programme in Cuba, with upper and lower values 
of US$57.8 and US$107 respectively. US$81.2 was calculated by subtracting the 
predicted rise in inpatient cost of US$1,8 from the pr~dicted saving in outpatient care 
cost of US$83). 
',' . 
• ' ! 
Table 9.3: Summary of cost impact from W.H.O. ANC programme using incremental 
cost impact method 
Variable CII Cuba Thailand South Africa 
Outpatient antenatal care 
1. ANC visits in control arm Low cost 13.0 & 7.1 visits 7.0 & 4.55 visits 5.8 & 3.6 visits 
and predicted ANC visits in Base case 13.1 & 6.06 visits 7.1 & 4.23 visits 6.0 & 4.3 visits 
intervention arm High cost 13.2 & 4.72 visits 7.3 & 4.11 visits 6.2 & 5.0 visits 
2. Outpatient ANC cost per Low cost No change 32% decrease 15.4% increase 
visit change in intervention Base case 10% increase No change 30.5% increase 
arm High cost 20% increase 32% increase 48.7% increase 
3. Outpatient ANC cost Low cost US$61 saving US$6.3 saving US$13.4 saving 
impact per woman in Base case US$83 saving US$16.7 saving US$2.9 saving 
intervention arm High cost US$107 saving US$25.1 saving US$10.4 increase 
Inpatient antenatal care 
4. Inpatient admissions (IPA) Low cost 17.5 IPA 15.5 IPA 13 IPA 
- total increase in intervention Base case 154IPA 63IPA 31IPA 
arm compared to control arm High cost 273IPA 110 IPA 49IPA 
5. Inpatient cost increase per Low cost US$3.2 increase US$0.2 increase US$3.54 increase 
woman in intervention arm Base case US$I.8 increase US$O.1 increase US$8.45 increase 
High cost US$0.2 increase US$O increase US$13.35 increase 
Cost per pregnancy 
6. Cost impact per woman Low cost US$57.8 saving US$6.1 saving US$9.86 saving 
with W.H.O. ANC Base case US$81.2 saving US$16.6 saving US$5.6 cost 
programme (3. minus 5.) High cost US$107 saving US$25.1 saving US$23.8 cost 
1 Confidence interval: The low and high cost scenarios reflect the ranges predicted in the text above. 
In Thailand, a saving of US$16.6 was expected under the W.H.O. ANC programme, 
with upper and lower values of US$6.1 and US$25.1 respectively. In South Africa, a 
cost increase of US$5.6 per woman was predicted under the W.H.O. ANC programme, 
with range US$9.86 saving to US$23.8 cost. This gives a predicted increase in cost per 
pregnancy from US$347 to US$352.6 (new programme cost range US$337 to US$371). 
Therefore, the inclusion of ranges in the analysis has shown that the new programme in 
South Africa may result in a cost saving as well as a cost increase. 
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9.2 Application of cost predictors from regression analysis 
Cost predictions are made from regression analysis both within and between countries. 
// 
In the first of three subsections, costs are predicted in each country by applying values 
for the average patients in each trial arm tothe transformed coefficients (which give the 
cost impact of a unit change in the variable) Jrom the same country. In the second 
subsection, costs are predicted in each country for 'typical' women by applying values 
" 
for different profiles of women (such as high risk and low risk). In the third subsection, 
costs are predicted in each country by "applying values f<?r the average patients in each 
trial arm to the transformed coefficientsJrom the other countries. 
9.2.1 Cost prediction within country using 'average' trial patients 
Table 9.4 shows which variables were included in the final regression models for each 
country ('NS' in the table indicates that the variable was either not significant and that 
there were no economic reasons apparent for retaining the variable in th~ final model). 
The values represent the cost impact associated with a unit change in the variables, with 
lower confidence limit, mean impact, and upper confidence limit. The interpretation of 
the coefficients, discussed in Chapter 8, is important for cost prediction. For example, if 
a woman has a pre-term delivery in Cuba, the cost per pregnancy increases by a factor of 
1.063 from US$1004.8 (the constant term) to US$1068. If the same woman also has a 
CS, the percentages are multiplied (1.063 x 2.17 = 2.31) giving US$2321. If the average 
values for all parameters are applied to these cost impact factors, the cost for each trial 
arm is predicted. However, without all the values entered for those variables included in 
the final regression model, the constant term has limited meaning on its' own. When 
average values for patients in the control arm in Cuba were applied to the coefficients, 
the mean predicted cost was US$289 per pregnancy (lower and upper 95% confidence 
limits US$78 and US$1071). For the intervention arm, the predicted cost was US$216 
per pregnancy (US65 to US$720). This gave a predicted incremental saving of US$73 
per pregnancy in Cuba (from the control to the intervention arms). 
In Thailand, the predicted cost for the 'average' woman in the control arm was US$98.9 
per pregnancy (95% confidence limits US$47 and US$21O). The predicted cost in the 
intervention aim was US$69 per pregnancy (95% confidence limits US$45 and 
US$106). The predicted incremental cost was US$30 per pregnancy. 
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Table 9.4: Independent variables explaining cost per pregnancy in study countries. 
Parameterl Unit changel 
Cuba Thailand South Africa 
Low Mean High Low Mean High Low Mean 
Constant term 763 l00~ 1324 31.73 34.51 37.52 140.6 157.8 
Previous history 
Years at school* NS NS NS 1.012 1.016 1.021 NS NS 
Abortion** NS NS NS 1.029 1.059 1.089 NS NS 
Surgery** NS NS NS 1.165 1.293 1.436 NS NS 
Pregnancy admission** NS NS NS NS NS NS NS NS 
Low birth weight** NS NS NS NS NS NS 0.847 0.923 
This pregnancy 
First visit < 20 weeks** NS NS NS NS NS NS 0.844 0.909 
Referral to higher level** NS NS NS NS NS NS 1.011 1.097 
Pre-term labour** 1.031 1.063 1.097 NS NS NS 1.019 1.120 
Premature rupture** 1.019 1.042 1.065 NS NS NS 1.015 1.168 
Malpresentation at delivery** NS NS NS NS NS NS 1.014 1.087 
Adverse diagnosis at labour** 0.960 0.978 0.995 1.117 1.163 1.211 NS NS 
Induced labour** NS NS NS 1.059 1.099 1.480 NS NS 
Birth weight (lg change)*"' 0.999 0.999 0.999 NS NS NS NS NS 
Birth weight (lg) squared*J 1.000 1.000 1.000 NS NS NS NS NS 
Congenital malformation** 0.305 0.423 0.587 NS NS NS 1.065 1.488 
Postpartum syphilis** NS NS NS 1.042 1.252 1.160 1.058 1.225 
Trial arm** 1.038 1.067 1.097 1.153 1.205 1.259 NS NS 
Hospital identification* 0.96 0.969 0.978 0.998 1.051 0.999 NS NS 
Inpatient days per FfE* 0.998 0.998 0.999 1.048 0.998 1.055 NS NS 
Occupancy rate (OPD)* 0.990 0.993 0.995 NS NS NS NS NS 
Monthly outpatients* 1.000 1.00C 1.00C NS NS NS NS NS 
Hospital admission** 2.168 2.22 2.279 1.019 1.084 1.154 1.188 1.240 
Delivery (vaginal)** 2.128 2.17C 2.212 1.771 1.853 1.939 1.745 1.904 
Neonatal admission** 4.249 4.4L 4.584 1.641 1.733 1.830 1.258 1.346 
NS - non-significant variable that was also not included in the final regression model for economic 
reasons; FTE - full-time equivalent staff member; OPD - outpatient department. 
1 * indicates a continuous variable; ** indicates a dummy variable. For continuous variables, the unit 
change value indicates the change that is predicted due to a one unit rise in the value of the variable. 
2 'Low' = lower 95% confidence limit; 'High' = upper 95% confidence limit 



























In South Africa, the predicted cost for the 'average' woman in the control arm was 
US$271 per pregnancy (95% confidence limits US$181 and US$407). Values were then 
entered for a hypothetical intervention arm (values taken from the incremental cost 
impact method), with the same values for all parameters, except a rise in referrals from 
23.2% to 28%, and inpatient admissions from 33.8% to 35.7%. This gave a predicted 
increase in cost per pregnancy of US$4 to give an ACPP of US$275. 
9.2.2 Cost prediction within country using profiles of women 
Another exercise that tests the accuracy of cost predictions was to give different values 
to the parameters in Table 9.4, thus building a profile for types of women, and then 
predicting costs for women with these characteristics. Column 2 in Table 9.5 gives 
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information on four different profiles of women/neonates/provider, stating where the 
profile deviates from the base (in the base, dummy variables take a value of zero to 
reflect the low risk case, and continuous variables take the average ./value, unless 
otherwise stated). Table 9.5 shows that woman 2 is predicted to have the highest cost 
per pregnancy in all countries (see columns marked 'A'), at US$1626 in Cuba, US$406 
in Thailand and US$669 in South Africa. Ranges for each woman were also calculated, 
using the lower and upper values simultaneously for 'all significant coefficients, which 
reflected the lower and upper boundaries. for women with those characteristics. 
However, these ranges are not provided '~~ they we~~' very wide (e.g. US$485 to 
US$5450 per pregnancy in Cuba for woman 2), and thus did not give a high degree of 
confidence to the predictions of average cost per pregnancy for women with these 
profiles. 
Table 9.5: Cost predictions for women, neonates and providers with different profiles. 
Woman Characteristicsl Cuba Thailand South Africa 
(US$ 1 (US$)l (US$)l 
A B AlB A B AlB A B AlB 
1 Provider is inefficient, woman 1127 1787 63~ 201 218 92~ 378 460 82~ 
receives risk care and has hospital 
admission, neonate is admitted3 
2 High number of ANC visits, woman 1626 965 165~ 406 227 179~ 669 613 109~ 
receives referral ANC, has hospital 
admission and CS, neonate is low 
birth weight but not admiued4 
3 Low ANC visits, neonate has high 158 178 89~ 79 99 80~ 215 177 121~ 
birth weight, woman has syphilisS 
4 Woman has admission and provider 978 564 172~ 102 103 99~ 344 410 84~ 
is efficient' 
1 ' . The charactenstlcs of women, prOViders and neonates are provided In thiS column that varied from the 
base profile (i.e. where dummary variables take a value of zero, and continuous variables take the average 
value) 
1 A: Predicted cost using regression model; B: Predicted cost using expected health service use of women 
and average costs; therefore AlB gives the percentage pfpredicted cost (using MRA) to 'expected' cost. 
3 Woman 1 is predicted to have 13 ANC visits in Cuba, 7 ANC visits in Thailand, 6 ANC visits in South 
Africa; 7 ANC inpatient days, vaginal delivery, and neonatal admission. 
4 Woman 2 is predicted to have 19 ANC visits in Cuba, 10 ANC visits in Thailand, 9 ANC visits in South 
Africa; 7 ANC inpatient days, caesarean delivery. 
5 Woman 3 is predicted to have 9 ANC visits in Cuba, 4 ANC visits in Thailand, 3 ANC visits in South 
Africa; and vaginal delivery. 
'Woman 4 is predicted to have 13 ANC visits in Cuba, 7 ANC visits in Thailand, 6 ANC visits in South 
Africa; 7 ANC inpatient days and vaginal delivery. 
These predictions were also compared with the cost per pregnancy expected from the 
health service use for women with each profile (health service use detailed in footnotes 
3-6 in Table 9.5). The columns marked 'B' show the cost per pregnancy built up in this 
way. For example, the health service use of woman 2 in 'Cuba was predicted at 
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approximately 19 ANC visits, 7 inpatient days during pregnancy, CS, and 7 postpartum 
days, giving a cost per pregnancy of US$965. The columns marked 'NE' show the 
predicted cost per pregnancy from the regression model as a proportion of cost per 
pregnancy from building using expected health service use. The accuracy is discussed 
further in section 9.3. 
9.2.3 Cost prediction between countries 
Cost per pregnancy was predicted in e~ch country by substituting parameter values into 
the regression equations of other countries -(see Appendix 16 Table 16.3). For example, 
all the average parameter values for Thailand (each trial arm separately) and South 
Africa were applied in the Cuban cost prediction equation. This gave predicted cost per 
pregnancy in Thailand of US$182 (intervention arm) and US$192 (control arm), thus 
giving an incremental cost of US$lO. The predicted cost in South African (using the 
Cuban regression results) was US$400 in the control arm. 
Using the Thai regression results, cost per pregnancy in Cuba was predicted at US$150 
(intervention arm) and US$156 (control arm), giving an incremental cost of US$6, and 
in South Africa US$148 in the control arm. Using the South African regression results, 
cost per pregnancy in Cuba was predicted at US$268 in the control arm, and in Thailand 
US$190 in the control arm. Section 9.3.5 also presents these results adjusted for 
differences in purchasing power between countries (see Appendix 16 Table 16.4). 
9.3 Cost prediction results for all methods 
Table 9.6 shows the summary results for the accuracy of all cost prediction methods at 
nominal exchange rates. Judgements about accuracy are made for· both cost per 
pregnancy and incremental cost predictions in intervention and control arms, and are 
made according to: (1) predicted cost as a % of observed cost; (2) whether 95% 
confidence intervals of predicted and observed cost overlap (yes/no); (3) US$ difference 
between predicted and observed cost; and (4) the difference in predicted and observed 
cost represented by the number of ANC visits. Appendix 16 Table 16.1 shows the full 
results at nominal exchange rates, and Appendix 16 Table 16.2 shows the same results, 
but at PPP values. The text also presents summary results on the accuracy of predicted 
marginal cost per pregnancy and median cost per pregnancy. The purpose of this section 
is to summarise how well each cost prediction method performs with respect to the 
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indicators of accuracy and eCOnOIll1C significance. The discussion of why different 
methods were accurate or inaccurate, and whether they were in line with expectations 
given the conclusions of earlier chapters, follows in section 9.4. 
Table 9.6: Summary results for all cost prediction methods, at nominal exchange rates. 
Method Sourc Arm2 Cuba Thailand S Africa 
e1 %;1 Over US$~ ANCti %a Over US$~ ANCti %a Over US$5 ANCti 
_la.,4 
-laD4 _laD4 
Direct Cu C - - - - 381% n· 296.4 45.2 116% n 54.~ 
transfer I 
- - - -
434% n 286.2 43.6 
- - -
C-I 
- - - -
151% v 10.2 1.6 
- - -
Th C 26°;' n -296.4 -24.1 
- - - -
30% n -24U 
I 230/. n -286.2 -23.1 
- - " - - - - -
C-I 660/. Y -10.2 -0.1 - - - - - - -
Sa C 86°;' n -54.9 -4.1 335% n 247.5 37.7 - - -
Adjusted Cu C 
- - - -
166% n 69.5 10.6 137% v 130.C 
transfer: I 
- - - -
177% n 66.3 10.1 
- - -
Unit cost C-I 
- - - -
116% v 3.1 0.5 
- - -
transfer Th C 41°;' n -235.9 -19.E - - - - 41% n -205] 
I 370/. n -235.9 -19.E - - - - - - -
C-I 1000/. Y 0.0 O.C 
- - - - - - -
- Sa C 95°;' y -18.8 -1.€ 196% n 101.7 15.5 - - -
Adjusted Cu C 
- - - -
157% n 60.5 9.2 105% y 19.( 
transfer: I 
- - - -
159% n 50.3 7.7 
- - -
Health C -I 
- - - -
151% n 10.1 1.5 
- - -
service use Th C 44°;' n -226.9 -18. 
- - - -
57% n -148] 
transfer I 410/. n -219.9 -18.1 
- - - - - - -
C-I 770/. y -7.0 -O.€ 
- - - - - - -
Sa C 113°;' y 51.6 4. 124% Y 25.5 3.9 - - -
Staff method C 76°;' Y -97.9 -8.1 136% Y 38.5 5.9 102% Y 6.C 
I 770/. n -84.9 -7.( 147% Y 40.3 6.1 - - -
C -I 57°;' y -13.0 -1.1 91% v -1.9 -0.3 - - -
Incremental cost C' 
- - - - - - - - - - -
impact method 1 86°;' n -50.9 -4.~ 104% v 3.7 0.6 - - -
C-I 2690/. y 50.9 4. 81% y -3.8 -0.3 
- - -
Regression Own C 720/. Y -112.6 -9.~ 94% Y -6.5 -1.0 78% Y -76.0 
model II 
i 580/. y -155.9 -12.~ 81% y -16.7 -2.5 
- - -
C -I 220°;' y 36.0 3.( 151% n 10.1 1.5 
- - -
Cu C - - - - 182% Y 86.2 13.1 115% Y 52.~ 
I 
- - - -
212% v 96.3 14.7 
- - -
C -I 
- - - -
49% Y -10.2 -1.5 - - -
Th C 39°;' n -246.0 -20.~ 
- - - -
43% n -199.( 
I 400/. n -221.9 -18. 
- - - - - - -
C-i 200/. y -24.1 -2.( 
- - - - - - -
Sa C 67°;' n -133.7 -11.( 183% n 87.1 13.3 
- - -
The data source for the prediction. Cu - Cuba, Th - Thailand, Sa - South Africa. 
2 The trial arm for which cost is predicted (I-intervention arm; C - control arm; or 'c -I' equals the difference) 
3 % indicates (predicted cost + observed cost) x 100 • 
4 Overlap: 'y' indicates that the confidence intervals for predicted cost and observed cost overlap. 'n' means no overlap. 
S US$ indicates the money amount by which predicted cost exceeds observed cost, at the nominal exchange rate. If 
the number is negative, it means that observed cost> predicted cost. 
6 ANC indicates the value by which predicted cost exceeds observed cost represented by number of ANC visits. If the 
number is negative, it means that observed cost> predicted cost. 
7 For South Africa, there are no intervention arm observed costs, and therefore judgements about accuracy in the 
intervention arm cannot be made. 
a There is no predicted cost in the control arm for the incremental cost impact method. 








































9.3.1 Direct transfer method 
Table 9.6 shows that the direct transfer method was 'inaccurate,82 when transferring 
average cost per pregnancy (ACPP) between Thailand and the other two countries at 
nominal exchange rates. For example, when transferring ACPP from Thailand to Cuba, 
predictions were 23% to 26% of observed ACPP in Cuba, and were inaccurate by over 
US$250. On the other hand, transfer of incremental cost from Thailand to Cuba was 
accurate; also, the inaccuracy of US~ 10 in incremental cost was not 'economically' 
significant83. Direct transfer of ACPP bet~een Cuba and South Africa proved to be 
closer to observed ACPP, due to the similarity in costs between countries at nominal 
exchange rates. For example, South African ACPP transferred to Cuba was 86% of 
observed ACPP in Cuba, but the US$55 difference with observed ACPP was 
economically significant, and confidence intervals did not overlap. In summary, at 
nominal exchange rates direct transfer of ACPP was not consistently accurate between 
country, whereas direct transfer of incremental costs was accurate in all transfers. 
Cost predictions were also made and compared using alternative assumptions. First, the 
cost predictions were compared using the confidence intervals for observed cost that 
were obtained from the sensitivity analysis (see Chapters 7 and 8). While the confidence 
intervals for Thailand and the other countries became closer using the ranges from 
sensitivity analysis (see Table 8.3), the changes were not large enough to make cost 
predictions under uncertainty accurate between Thailand and other countries. Second, 
costs were predicted using purchasing power parities (PPP) instead of nominal exchange 
rates. Appendix 16 Table 16.2 shows the full cost prediction results using PPP, and the 
levels of accuracy obtained. The results show that cost predictions using PPP were less 
accurate for predictions involving Cuba than under nominal exchange rates. This was 
because the adjustment factor for converting nominal exchange rates to purchasing 
power parities was larger in Cuba (2.38) compared to Thailand (1.94) and South Africa 
(1.55). The implications of Cuban costs having the greatest upward adjustment means .' 
that money transfers between Cuba and the other two countries were less accurate than 
previously at nominal exchange rates. Therefore, some of the direct transfers between 
82 As described in Chapter 5, an 'accurate' prediction occurs when the 95% confidence intervals (or range 
if confidence intervals not available) of predicted and observed costs overlap. 
83 As described in Chapter 5, if the difference between predicted and observed cost is more than the cost 
of one antenatal care visit (in each country), then it is judged to be economically meaningful. 
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Cuba and South Africa that were previously accurate became inaccurate using PPP. On 
the other hand, there was a small convergence between costs in South Africa and 
Thailand, because the lower cost country (Thailand) had a larger adjustment factor. 
However, as cost transfers between these two countries were highly inaccurate 
previously, the change was not large enough for cost predictions between Thailand and 
South Africa to become accurate. 
Third, costs were predicted using black market exchange rates for non-traded goods in 
,'. .,' 
Cuba, and May 1999 instead of JanuarY 1998 nomin~ exchange rates for the other 
countries. Under these assumptions considerable convergence was found, with ACPP in 
Cuba reducing to US$144 (range US$137-US$151) in the control arm compared to 
US$275 (US$257-US$294) in South Africa and US$150 (US$146-US$154) in 
Thailand. Therefore ACPP prediction under alternative exchange rates lead to similar 
costs in Cuba and Thailand, and therefore the direct transfer method as accurate, and 
economically insignificant. However, the convergence seen between Thailand and South 
Africa at alternative exchange rates was not sufficient to be considered accurate. On the 
other hand, when the ACPP ranges from the sensitivity analysis were used, predictions 
were accurate (95% confidence interval in Thailand US$116-US$247 and in South 
Africa US$206-US$470). Therefore, the exchange rate chosen and the degree of 
uncertainty present both heavily influence whether or not cost predictions using direct 
transfer are accurate or not. 
Fourth, marginal cost per pregnancy (MCPP) was predicted. Under nori'linal exchange 
rates, MCPP in Cuba was substantially higher than the other countries, and direct 
transfer did not give accurate ACPP predictions (Table 8.1 provides the data). For 
example, in the control arms MCPP was US$116 in Cuba (95% confidence interval 
US$110-US$121), compared with US$41 in South Africa (US$37-US$45) and US$22.6 
in Thailand (US$22-US$23). When purchasing power parities were used, costs in Cuba 
became even higher, and also costs did not converge sufficiently between Thailand and 
South Africa for cost predictions to become accurate (Table 8.2 provides the data). 
However, when May 1999 nominal exchange rates were used (instead of January 1998), 
cost per pregnancy converged sufficiently for cost trabsfers to be accurate (Table 8.3 
provides the data). Finally, when cross-country differences in uncertainty were taken 
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into account, marginal cost per pregnancy ranges overlapped between Thailand and 
South Africa (Table 8.3 provides the data). 
Fifth, median costs were also predicted across country using the direct ~ansfer method. 
Confidence intervals were not presented for median costs and therefore conclusions 
were not made about accuracy of direct transfer of median costs. In predicting point 
estimates from one country to another, the differences between predicted and observed 
median costs were economically significant"For example, in the control arms, observed 
.': ... ;. 
median costs were highest in Cuba (US$240), followed by South Africa (US$214) and 
Thailand (US$80). 
Sixth, using the same approach as in the regression analysis, ACPP predictions were 
built by identifying the likely health service use of different profiles of women. The 
accuracy of cost per pregnancy predictions were compared between the highest cost 
woman (number 2 in Table 9.5) and the lowest cost woman (number 2 in Table 9.5), to 
see whether there are differences in accuracy of different profiles of women. The low 
cost woman was predicted to cost US$178 in Cuba, US$177 in South Africa, and 
US$99 in Thailand. Therefore, cost transfer between Cuba and South Africa would be 
accurate (with only US$l difference) and between these countries and Thailand would 
be inaccurate (Thailand ACPP is under 56% of ACPP in the other countries). The high 
cost woman was predicted to cost US$980 in Cuba, US$613 in South Africa, and 
US$227 in Thailand. Therefore, cost transfer between Cuba and South Africa would be 
less accurate (South Africa ACPP 62% of Cuba) and between these countries and 
Thailand would be inaccurate (Thailand ACPP is under 40% of ACPP in South Africa 
and under 25% in Cuba). In conclusion, direct transfers are more accurate using low cost 
women in terms of % difference between predicted and observed costs. 
9.3.2 Adjusted transfer method 
The results of two types of adjustment to predict ACPP are presented in Table 9.6. First, 
unit costs were transferred between countries, using local health service use data. 
Compared to the direct transfer method, cost predictions in Cuba and Thailand became 
considerably more accurate, with differences reducing from US$296 under direct 
transfer to US$69 under adjusted transfer. However, changes were not large enough for 
ACPP predictions to become accurate or economically insignificant, although 
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incremental cost was accurate (US$23 predicted versus US$20 observed), with the 
difference not economically different. On the other hand, transfer of unit costs from 
./" 
Cuba to South Africa lead to less accurate ACPP predictions than the direct transfer 
method, with inaccuracy increasing from US$55 to US$130 in the contr~l arms. At PPP, 
as under the direct transfer method, ACPP transfers involving Cuba became less 
accurate, whereas between Thailand and South Africa accuracy improved (but not 
enough for confidence intervals to overlap). 
,t, : 
Second, health service use was transferred between countries, with local unit costs data. 
When using local prices in Thailand and transferred health service use from Cuba and 
South Africa, the predictions of cost per pregnancy increased in accuracy. Accurate 
predictions occurred using the control arm data from South Africa in Thailand, giving 
US$131 (range US$103 to US$159) and overlapping confidence intervals. Using 
transferred health service use data from the control arm in Cuba to predict cost per 
pregnancy in South Africa gave an accurate cost prediction: at US$366 it was only 
US$19 from observed cost (economically meaningful). Finally, using South African 
health service use data to predict ACPP in the control arm in Cuba gave an accurate 
ACPP prediction. 
9.3.3 Simplified staff cost prediction method 
Predicting unit costs using the simplified staff method, and using local health service 
use data to predict cost per pregnancy, gave overlapping confidence intervals84 for all 
ACPP predictions in Thailand and South Africa. In South Africa predicted ACPP was 
US$24 less than observed costs in the control arm. In Thailand, predicted costs were 
US$38-US$40 more than observed costs (confidence intervals overlapping, but 
economically significant difference); however, predicted incremental costs were within 
US$2 of observed incremental costs. In Cuba the simplified staff cost prediction method 
under-predicted costs by as much as US$100 (and thus there was no overlap with 
observed costs), although incremental costs were accurate at US$13 different (on the 
border of economic significance). 
84 Using this method, ranges were calculated using ranges on input values for% staff and % direct cost in 
average costs (Appendix 16 Tables 5 and 6 give these ranges). 
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9.3.4 Incremental cost impact method 
The incremental cost impact method gave a predicted cost per pregnancy in the 
~' 
intervention arm in Cuba at US$321 (range US$295 to US$344) and in Thailand at 
US$89 (range US$81 to US$100). Therefore, predictions were accurate for both 
countries (when compared with observed costs, see Appendix 16 Table 16.3). Predicted 
ACPP was 87% and 103% of observed cost in Cuba and Thailand, respectively, giving 
accurate predicted incremental costs of US$81 in Cuba (range US$58 to US$107) and 
US$16.6 in Thailand (range US$6' to,US$25). Although accurate, all recorded 
.,' . 
, ' 
differences in predicted and observed costs using ICIM were economically significant. 
Predicted incremental cost was over four ANC visits inaccurate in Cuba (US$51). In 
South Africa, as already presented in section 9.1 the ICIM predicted cost pre pregnancy 
to increase by US$5.65 to US$353. However, the predicted incremental cost range 
covered zero, from a saving of US$10 per pregnancy to an additional cost of US$24 per 
pregnancy under the W.H.O. ANC programme. 
9.3.5 Regression analysis cost predictors 
Using coefficients from the final regression model to predict costs within the orignal 
country, and applying values for the average patients in each trial arm, gave predicted 
costs less than observed costs in all trial arms and for all countries. In Cuba, the 
predicted cost was US$156 and US$113 less than observed cost in the intervention and 
control arms respectively (58% and 72% of observed cost). The predicted incremental 
cost of US$73 was outside the base case incremental cost confidence interval of -US$2 
to US$63, and the difference with observed incremental cost of US$43 (US$73 minus 
US$30) was economically significant. In Thailand, predicted cost was 80-83% of 
observed cost, with a difference of between US$7 and US$17. The predicted 
incremental cost ofUS$16.6 was very close to the base case incremental cost confidence 
interval of US$20 (range US$16 to US$24), and therefore the difference of US$3.40 
was not economically meaningful. In South Africa, predicted cost was US$271 (a 
difference of US$82 with observed ACPP), which was 76% of observed cost, and an 
economically meaningful difference. Predicted cost was closer to observed cost in the 
control arm compared to the intervention arm in both Cuba and Thailand. 
Applying values for profiles of patient gave mixed results, as shown in Table 9.5. In all 
countries there were both over- and under-predictions. Two women were consistently 
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under- and over-predicted: woman 1 was under-predicted in all countries (63-92% of the 
cost expected from the likely health service use of the woman), while ~oman 2 was 
// 
over-predicted in all countries (109-165% of the cost expected from the likely health 
service use of the woman). The smallest range of inaccuracy occurred .in South Africa 
(predicted cost 84% to 121 % of observed cost) and the largest Cuba (predicted cost 63% 
to 172% of observed cost). Only for woman 4 in Thailand was the prediction very close 
to observed cost (US$1 different); the next closest prediction was US$17 different for 
woman 1 in Thailand and then US$56 different for woman 2 in South Africa . 
. , .... 
Using the Cuban regression results to predict costs in the other countries lead to an over-
prediction, from 115% of observed cost in South Africa to 181% observed costs in 
Thailand in the control arms, to 212% observed costs in Thailand in the intervention 
-
arm. The Thai regression results under-predicted costs in the other countries, where 
predicted cost was around 40-50% of observed cost in both Cuba and South Africa. 
Finally, the South African regression results under-predicted costs in Cuba by US$113-
133 (67-76% of observed cost) and over-predicted costs in Thailand by US$87-96 (183-
222% observed cost). While most predictions were accurate (on account of the very 
wide confidence intervals from the regression equation), all differences were 
economically meanigful. The predicted incremental cost in all cross-country predictions 
were not more than US$1O-21 different from the observed incremental cost, and these 
differences were worth between 1.6 and 3.0 antenatal visits in all countries, and 
therefore economically significant. 
Finally, cross-country predictions were adjusted by differences between country in 
purchasing power, to take into account different prices in the three countries. Two 
measures of purchasing power were used: (1) the PPP values used earlier, and (2) 
average staff salary levels. Out of these two measures, the use of PPP resulted in greater 
accuracy between Cuba and the other countries. For example, cost predicted in Cuba 
from the Thai regression equation improved from US$156 to· US$190 in the 
intervention arm; and from the South African regression equation from US$268 to 
US$410, compared with US$402 observed cost in the control arm in Cuba. In the latter 
case, the cost prediction was almost exact. Using the average staff salary levels as 
adjustment factor in cross-country predictions, costs prediction~. in all countries became 
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less accurate than they were in the original predictions. For example, costs predicted in 
Cuba from South Africa were adjusted down to US$51, on account of the very high 
/" 
salary levels in South Africa. 
9.4 Critical evaluation of cost prediction methods and results 
This section evaluates each of the cost prediction methods in tum, in terms of: which 
cost(s) can be predicted, whether expectations of performance were in line with actual 
performance, and what factors affecte~ : performance. If methods did not meet 
'", 
expectations, reasons are examined why not. Cost prediction methods are also critiqued 
in terms of what the method can and cannot do (for example, how they deal with 
distributions of cost). Finally, the methods are assessed in terms of how they might 
perfo~ in other settings, in particular in lower income settings. 
9.4.1 Direct transfer method 
Any cost component (see Box 1.1) can be predicted using the direct transfer method, 
although only cost per pregnancy was predicted in this thesis. Chapters 6 and 7 provided 
a detailed examination of how much countries varied in components of cost per " 
pregnancy (with confidence intervals provided), and by implication that direct transfers 
would be inaccurate. How the method was expected to perform was based on how 
similar cost magnitudes are across countries, such as might be suggested by health care 
expenditure of gross national product (GNP) per capita, or price levels of key resources. 
At nominal exchange rates, 1997 GNP per capita was marginally higher in South Africa 
(US$3160) than Thailand (US$2740), and both were higher than Cuba (US$1021) 
(W orId Bank 1997). Therefore, under the naIve assumption that health care costs and 
GNP per capita are linearly related, Cuba was expected to have the lowest cost per 
pregnancy at nominal exchange rates. At PPP, the ranking between countries changed, 
with GNP per capita US$7540 in Thailand greater than South Africa (US$5030) and 
Cuba (US$2430)85. However, given that Cuba is well known for having a high level of 
health care expenditure per capita, the expectation was that GNP per capita would not 
be a good indicator of cost per pregnancy. 
The results did indeed show that GDP per capita is not a good predictor of cost per 
pregnancy. In fact, the predictive accuracy of cost per pregnancy (both mean and 
231 
median) between Cuba and South Africa was much higher than with Thailand. Using 
MCPP resulted in less accurate predictions, as the proportion of variable cost to fixed 
cost was higher in Cuba. 
In terms of expected incremental costs, the expected change in all countries was a zero 
change or cost saving under- the W.H.O. programme, due to the reduction in average 
ANC visits per woman and negligible expected impact on inpatient services. The direct 
transfer in incremental costs between countries resulted in accurate predictions for most 
.'.. ",' 
transfers. This was not greatly surprising, given that similar changes were expected in 
all countries (Le. in no country was there required increases in the levels of services). 
However, it is clear that these predictions were only accurate because in all countries the 
cost changes were minimal (countries faced similar levels of change) and that the same 
accuracy would not be experienced occur where larger changes are needed. Therefore, 
when applying this method in lower income countries, it is likely to be inaccurate. 
Also, the results showed clearly that accuracy depended to a large degree on which 
currency conversion method was used. While costs were transferred accurately between 
Cuba and South Africa at nominal exchange rates, they were not transferred accurately 
using PPP for all countries or black market rates for Cuba. The result that the use of 
PPPs did not make costs between countries converge has implications for the use of 
PPPs in generalising cost data across countries - that cost magnitude is not necessarily a 
direct function of local prices, due to the influence of the quantity elements and in unit 
costs (resource use) and cost per pregnancy (health service use). 
The main disadvantage of the direct transfer method is that it does not take into account 
different absolute and relative prices or unit costs, and therefore input and service 
intensity and mix. In transferring unit costs between country, inefficiency that may not 
exist in the target country is also transferred. However, cross-country differences in 
efficiency were not calculated, although proxied by visits or days per full-time 
equivalent staff member, where South Africa was shown to be the most efficient country 
for outpatient services. Also, in transferring health service use between countries, the 
way local practice style and rationing measures interact with unit costs are not allowed 
8S Using PPP values used in this thesis. 
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for. For example, if caesarean sections were to cost more, they may be rationed more 
severely. 
Another disadvantage of the direct transfer method is that it does not t.ake into account 
differences in cost per pregnancy distributions between countries, or the causes of these 
distributions. For example, iii both Cuba and Thailand there were bimodal distributions 
(refer to Appendix 14 Tables 14.3, 14.4, 14.7, 14.8) whereas in South Africa there was a 
single mode and a long right-hand taif (Appendix 14 Table 14.10). In Cuba, the smaller 
. . ~ . , 
second mode was caused by women having a CS or babies who are admitted. In 
Thailand, the second mode was caused by women admitted to a secondary hospital 
(where the average costs were substantially higher than at the district hospitals). In Cuba 
the second mode occurred at US$450-600, while in Thailand it was at US$170-230. 
-
Therefore, direct transfer does not predict mean costs, median costs or special 
characteristics of cost distributions, unless similarities exist between countries. 
Finally, in support of the direct transfer method it is a quick method and it has minimal 
data requirements, and therefore can be used for back-of-the-envelope calculations· 
before adjustments are made. However, if data are disaggregated and cost determinants 
are known, then the adjusted transfer method is recommended. 
9.4.2 Adjusted transfer method 
By definition, the adjusted transfer method requires some data to be transferred and 
mixed with some local data, to predict cost per pregnancy. In this thesis, unit costs and 
health service use were transferred. It therefore gives an opportunity to improve on the 
accuracy of the direct transfer method, but only where data are sufficiently 
disaggregated and cost determinants are understood. In general the adjusted transfer 
method improved on the direct transfer method. For example, predicting ACPP in the 
control arm in Thailand using Cuban unit costs lead to a US$175 ACPP prediction in 
the intervention arm compared to US$402 using the direct transfer method, which is 
closer to the observed US$106 ACPP. However, using Cuban unit costs to predict 
ACPP in South Africa lead to less accuracy than the direct transfer method. This was 
because very high neonatal care average costs in Cuba were applied to a very high days 
per neonate rate in South Africa, thus leading to a higher ACPP in South Africa than 
that observed. 
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A disadvantage of this method is that, while it does separate the two main components 
of cost per pregnancy, it does not allow for interactions between average/ ~ost and health 
service use that occur. This point can be illustrated by the Cuba/South Africa case just 
mentioned, where the transfer of a higher neonatal day average cost as experienced in 
Cuba (US$114) is likely to cause lower health service use rate from the average 1.69 
days per neonate. " 
The adjusted transfer method potentially reflects the local distribution in cost per 
pregnancy. However, this only occurs if the local data used (e.g. health service use) is 
the main determinant of the shape of the distribution, and that the transferred data does 
not change the distribution. For example, if the presence of a CS in Cuba causes a 
bimodal distribution due to the associated length of postpartum stay (and not the high 
cost of a CS itself), then it could be concluded that the second mode is caused mainly by 
high health service use and not by high unit costs. Thus the bimodal distribution is 
successfully predicted in Cuba when unit costs are transferred from Thailand or South 
Africa. Conversely, the bimodal distribution is not successfully predicted when health 
service use is transferred from a country with a short postpartum length of stay and/or 
low CS rate. Therefore, the successful prediction of distribution depends on which cost 
component is transferred, and whether the transferred data varies substantially from the 
observed values in the country of the cost prediction. 
Finally, an aspect of the adjusted transfer method to note is that if adjustments are made 
without any analysis of cost determinants, one does not know much accuracy is 
increased. Cost differences between country may be driven by one or two components, 
such as the price or use of a particular service. For example, both the unit cost of 
neonatal care in Cuba and the number of days per neonate in South Africa are major 
forces driving cost differences with Thailand. Therefore these cost drivers must be 
identified before adjustments are attempted. This is a particularly important point to 
bear in mind if the adjusted transfer method is used to predict costs in lower resourced 
settings. 
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9.4.3 Simplified staff cost method 
The simplified staff cost method essentially predic~s average costs (per health service) 
based on assumptions about the values of key variables. These values' can either be 
based on locally collected data, as was done in this study, or using transferred data86• 
. " 
Average costs can then be combined with either local or transferred health service use 
data to predict cost per pregnancy. In this study, predicted average costs were combined 
with local health service use data, to pinpoint the' inaccuracy in cost per pregnancy 
caused by inaccuracy in average costs. As . .this method was not found in the literature 
review, there are no expectations from pr~~ious findings. Accuracy depends on which 
data are used to reflect % of staff cost and % direct cost in average costs, whether the 
average salaries reflect the average staff, and whether full-time equivalent staff and 
throughput are measured accurately. Using data from the costing study, these data were 
considered to be good quality and therefore the expectation was that average costs 
would be predicted reasonably well. In .both Thailand and South Africa, ACPP and 
incremental costs were predicted accurately; in Cuba, incremental cost only was 
predicted accurately. 
While these results could lead one to conclude that this method was a success, inter-
health facility variability was examined to identify whether aggregate predictions 
masked greater variability elsewhere. Appendix 17 Tables 17.3 and 17.4 show variation 
between health facilities within Cuba and Thailand. In Cuba, predicted cost as a % of 
observed cost ranged from 43% to 98% (outpatient clinics) and 68% to 95% (inpatient 
wards), giving an overall under-prediction of about 24%. In Thailand, these figures 
ranged from 55% to 162% (outpatient clinics) and from 97% to 500% (inpatient care). 
Delivery care in Thailand had even greater variability (57% to 667%) with an average of 
143%. However, due to over-prediction in some clinics and under-prediction in others, 
the net result appeared much more accurate in Thailand. The implication of this result is 
that if average costs were predicted in any single clinic, there is considerable uncertainty 
over whether it under- or over-predicts, and therefore there is a much wider confidence 
interval than would occur under a large sample of health facilities. Therefore, this 
method is not recommended for single centre cost studies where predictions cannot be 
validated. 
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The next issue concerns what factors actually cause variability and inaccuracy. First, 
~' 
some variability was observed within and between countries in the % contribution of 
staff and direct costs to average cost. (see Appendix 9 Tables 9.4 to 9.9).However, there 
were few patterns found between countries and different types of care in % contribution 
of staff and direct costs to· average cost. For example, % staff contribution to an 
outpatient visit ranged from 56% in Cuba to 88% iri South Africa. Also, staff may not 
always be the main resource ingredierit, su.ch as in Thailand where the % contribution 
... , ,":., 
for vaginal deliveries was as low as 29%. Therefore, there is considerable uncertainty in 
using this method in a country where this data is not available, as it would require 
making assumptions about cost contributors. Also, average (mid-scale) salary levels for 
a country may not apply to all the facilities within that country, as lower or higher 
grades of staff may be employed in some facilities. Therefore, there is considerable 
potential for inaccuracy, as was found when individual health facilities were compared. 
9.4.4 Incremental cost impact method 
All components of cost can be predicted using the incremental cost impact method - Le. 
unit costs, health service use, and cost per pregnancy. However, this method relies on 
baseline data on unit costs, health service, health service use, and patient characteristics. 
The expectations were that the predictive accuracy would be high, and at least improve 
on the adjusted transfer method, due to the setting-specific nature of the method, and the 
detail of the data available for this study. 
Section 9.3 presented the results, showing that the ACPP predictions were accurate, 
although the US$ differences compared to observed ACPP and incremental cost were 
more than expected for Cuba. In Cuba, the observed effect of the intervention arm was 
to increase costs for inpatient care more than expected, and the predicted reduction of 
seven visits was not quite achieved (6 instead). Table 6.2 shows the differences between 
trial arms for inpatient services. Chapter 6 concluded that these differences could not be 
explained by the change in the ANC intervention alone, and that some of the effect was 
likely to be due to random variation. Therefore, this raises questions about whether the 
86 Local data was used in order to maximise the chance of getting accurate predictions, to see whether this 
method works, and if not, why not. 
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same costs would be observed if the trial were run again, therefore with implications for 
the accuracy of the incremental cost impact method .. 
Another feature of ICIM was that ACPP predictions are made for the .. aggregate level, 
but variability is not expressed in terms of probability distributions, but only ranges 
where the upper and lower likelihood for the whole population ACPP is predicted. Also, 
the results are open to manipulation, due to the subjective and even arbitrary nature of 
defining ranges on some cost and morbidity.impacts. In this thesis the ICIM had to be 
." ". 
" . '. 
run after the data was known, and therefore it may have influenced the analysis. 
In a different setting with less detailed data, and perhaps where ANC programmes are 
more different to the W.H.O. programme, more difficulties will be faced in predicting 
-
incremental changes, thus probably leading to greater inaccuracy. Comparing the 
activities of the W.H.O. programme and current practice requires highly detailed data, 
including surveys and observations (as opposed to reading national guidelines) as well 
as expert opinion. 
9.4.5 Regression analysis predictors method 
Only cost per pregnancy and incremental cost were predicted using regression analysis. 
There was some uncertainty about how this method would perform, given the different 
levels of predictive accuracy of previous studies. Also, no previous regression analyses 
were found that modelled cost per pregnancy to allow comparison of significant 
variables and coefficient sizes between studies. For within country cost predictions, this 
method was expected to perform well, in that it takes into account complex cost 
relationships, it is based on expectations of economic relationships, and there was a 
large and high quality data sets available. However, the expectation of the accuracy of 
the between country predictions was dependent on whether cost determinants were 
similar between countries, including patient and provider characteristics and price 
levels. Following the results of chapters 6 to 8 it was thought unlikely that cost 
predictions between country would be accurate, even when adjusting for differences in 
price levels. 
This chapter has shown that within country ACPP predictions were not as close to 
observed cost as was expected (or hoped for). Incremental costs were found to be 
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accurate, due to the minor differences in variable values for each trial arm. All cost 
predictions were accurate, using the definition of 'overlapping confidence interval', but· 
this was due to the wide confidence intervals, thus exposing a weakness of thi~ 
definition. For example, the range for woman 1 in Cuba was US$2~5 to US$5634. 
Therefore, it did not seem meaningful to make conclusions about accuracy using these 
ranges. In fact, the lower ranges were found to be unfeasible. For example, woman 1 
(with normal number of ANC visits and normal "delivery, hospital admission and 
neonatal admission) is unlikely to incur a cost as low as US$225. 
...... :" 
In terms of % of observed cost, ACPP predictions were closest to observed cost in 
Thailand (94% in control arm) and lowest in Cuba (60% in intervention arm). This 
chapter has also shown that between country predictions were less accurate than within 
country predictions, as expected. Accuracy did not improve substantially when 
adjustments were made for differences in price levels between countries, using staff 
salaries as the price comparison. This was largely because price ratios and cost per 
pregnancy ratios between country were very different. However, the approximations of 
price levels may have been unsatisfactory representatives of health sector price levels, 
first as PPPs were not health care-specific, and second as staff price ratios between 
country were different from other resources (see Table 7.8). 
Whilst the tests for best-linear unbiased estimators (BLUE) were applied and found to 
be generally acceptable, several criticisms can be levelled at the model and data. First, 
some independent variables could not be included that may have influenced either unit 
costs or health service use, due to lack of data or difficulty in quantifying them. For 
example, while 'practice style' was concluded to be an important cause of within and 
between country variation in health service use, it could not be quantified for inclusion 
as an independent variable. Second, there was overlap in the influence of some 
variables, such as between 'adverse diagnosis at labour' and 'malpresentation at 
delivery'. All variables in the final model were examined for multicollinearity, and 
Pearson correlation coefficient were considered low enough to warrrent retaining all 
variables in the final model. Third, some significant variables had rather doubtful 
connections to cost, such as postpartum syphilis, which would not have been picked up 
in average costs, and does not typically cause a longer length of stay. Therefore, this 
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result may have been a spurious finding or indicates that women with postpartum 
syphilis are more likely to use health services for other reasons. Fourth, the way some 
variables were defined may not have allowed their true effect to b; captured. For 
example, the variable 'adverse outcome' contained some morbidity which may not have 
had a significant cost-increasing effect, such as mild sexually transmitted diseases. The 
effect of this is to underestimate the true effect of the cost-driving adverse outcomes 
contained within that variable. Fifth, the 2-way anaIysis of determinants of cost per 
pregnancy gave some significant variables, that the regression did not find significant. 
. ",' '. 
For example, in Cuba some risk factors were shown to be related to cost per pregnancy, 
including previous stillbirth and previous surgery on reproductive tract. Subsequently, 
these variables were run in the final regression model to check whether they were 
significant, and if not they were excluded. The most favoured explanation for this 
occurring is that variables become insignificant due to their interaction (or duplicate 
effect) with other variables, which the multivariate analysis can capture. 
Sixth, it could be mentioned that alternative functional forms such as logit/probit or the 
Cox model were not compared with the OLS regression. However, as the OLS model 
was concluded to perform relatively well, it was thought unnecessary to use different 
functional forms. Seventh, alternative analysis options could have been used, such as 
separating high and low cost cases, and evaluating separately. However, as the purpose 
is to predict cost per pregnancy mainly from a priori factors, it is most useful to now 
cost determinants (for example the predictors of high cost) at the population level as 
opposed to the sub-group level. 
Dudley et al (1993) found that the accuracy of predictions of mean, median and % high 
cost patients varied between models: the OLS predicted mean cost most accurately, the 
Cox model predicted the median cost most accurately, and the logistic model predicted 
the % high cost patients most accuraately. They also showed how much case costs were 
affected by small differences in values for clinical and age parameters. Therefore, cost 
predictions from regression analysis can be highly accurate and unbiased if the right 
model is used. 
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9.5 Interpreting cost prediction results in South Africa 
Given the preceeding results on the accuracy of different cost predictio~ methods, this 
section evaluates which methods and data sources are most likely to be accurate in 
South Africa. Several methods were found to be accurate in predicting cost per 
pregnancy. Given the findings in Chapters 6 to 8 concerning the magnitude of unit costs, 
and health service use, and the findings of the cost p~edictions methods for the control 
arm in South Africa, it is likely that cost transfers of the intervention arm from Cuba 
will be accurate at nominal exchange rates., Using direcqransfer, an ACPP of US$372 is 
predicted in South Africa in the intervention arm, giving an incremental cost of US$25 
(US$372 minus US$347). This may seem quite a reasonable prediction, given that both 
health service use and unit costs may increase for some aspects of care in South Africa 
under introduction of the W.H.O. ANC programme (from the ICIM method). However, 
it could also be argued that such a result, if accurate, is a fluke, especially as direct 
transfer of cost per pregnancy using MCPP or at PPPs would give a much less accurate 
prediction. Therefore, while potentially accurate, the direct transfer method is unreliable 
for predicting costs in South Africa from the study countries. This conclusion is 
supported by the findings of the adjusted transfer method, where the transfer of unit 
costs from Cuba results in a higher ACPP prediction in the intervention arm (of 
US$465) which represents over US$l 00 increase, which is unlikely in the South Africa 
setting. On the other hand, transferring health service use from Cuba gives an ACPP 
prediction in the intervention arm of US$453, which is a small incremental cost from 
US$347 and more likely than US$453. From Thailand, adjusted transfers lead to a 
significant reduction in ACPP in South Africa, which is unlikely. 
While the staff method is accurate for predicting ACPP of the control arm in South 
Africa (within 2% of observed ACPP), there are no local intervention arm health service 
use data to apply to predicted average costs. Theerfore, health service use data would 
have to ve transferred from Cuba or Thailand to predict ACPP in the intervention arm in 
South Africa. This would lead to the uncertainties inherent in the adjusted transfer 
method, and predictions should be interpreted in the light of thes uncertainties. 
Likewise, predicting ACPP in the intervention arm in South Africa using the regression 
model requires values to be entered in the model for the variables, if different from the 
control arm. Each variable in the model could therefore be evaluated in terms of whether 
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a change is likely under the W.H.O. ANC programme. Variables in Table 9.4 that may 
feasibly be different include the proportion of women reporting before 20 weeks 
/'-
gestation, rates of referal, rates of postpartum syphilis, hospital admission rates, and 
possibly CS rates and neonatal admissionr ates. Therefore, alternatiye values would 
have to be predicted for these variables, and entered in the regression equation to predict 
ACPP in the intervention aim. However, the general problems with the regression 
model have already been discussed, in particular the' fact that for all countries it under-
predicts observed cost (predicted cost wa,s ,only 78% ?~ observed cost for the control 
arm in South Africa). Therefore, while the cost prediction may not be very close to the 
true cost of the intervention arm in South Africa, the coefficients do provide some 
indication of the size of change expected from small changes in variable values. 
Finally, the incremental cost impact method was found to be accurate in Cuba and 
Thailand, although differences were economically significant in Cuba. While random 
variations between trial arms could not be accounted for in the ICIM (which were partly 
responsible for the differences between predicted and observed costs in Cuba), it was 
concluded that ICIM is the most reliable method when there are detailed data present to -
make assessments of likely impacts on health service use and unit costs. Reliability is 
enhanced when local health care providers and/or policy makers are involved in its' 
application. In South Africa, the ICIM predicted that costs would rise by US$6 to 
US$353 under the W.H.O. ANC programme, with a range US$337 to US$371. Whether 
the US$6 extra cost would be experienced depends critically on whether (a) ANC visits 
were reduced by 1.7 visits, (b) ANC visit average costs increased by an average of 30%, 
(c) inpatient admissions for severe UTI and HDP increased slightly, and (d) CS rates, 
postpartum length of stay and neonatal admission rates do not increase in the 
intervention arm. Ranges for the first three of these were provided, and was responsible 
for the range in incremental cost of -US $ 10 to +US$24. However, taking into account 
breakdown in the assumption (d) may make this range even wider, and change the base 
case ACPP prediction. However, there was no reason why (d) would not hold for the 
sample population. Therefore, in conclusion, while other cost prediction methods gave 
ACPP values within these ranges predicted using the ICIM, the ICIM results are likely 
to be the most reliable. However, there are other issues to take into account, which are 
discussed briefly below. 
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First, the issue of generalis ability to the whole pregnant population of Umlazi Township 
has already been rasied, and is an important issue for policy makers:/The sample is 
unlikely to be fully representative of the whole pregnant population .. Therefore, these 
predictions are based on the caveat that they refer to a smilar sample as the control arm 
in South Africa. However, data are not available on the proportion of women who did 
not attend ANC at all in Umlazi Township, although an estimated 40% of women do not 
deliver in health facilities87• Therefore~ the.:~~ssing' population from the data sets may 
have more adverse events and use less services, and therefore change the average costs 
per pregnancy actually measured as well as predicted in the study setting. The problem 
for policy makers is that less is known about this missing population, and therefore their 
ACPP may have a substantially wider range. 
Second, there are issues of initial investments in health systems to make the W.H.O 
ANC programme work as it was intended. For example, clinics must be equipped to do 
a rapid syphilis test and also a hand-held doppler, as shown in Table 9.2. Also, staff 
must be trained in the philosophy and contents of the WHO programme; and incentives 
must be created for compliance by both health care providers and patients. Also, 
services may need to be restructured to allow for likely changes in referral patterns, such 
as more risk cases and deliveries dealt with at health centre level, due to recent 
overcrowing of referral facilities with low risk cases in Umlazi Township (CHESS 
1996). This would require standardisation of management and referal protocols, which 
are currently not standardised (CHESS 1996), and which is responsible for delay in 
referral for hypertension and valvular heart disease (Moodley et al 1998). If more 
deliveries take place at health centres, unit costs would reduce significantly, and thus 
cost per pregnancl8• 
Third, low quality of care was raised as a serious concern among health care providers 
in the participating health facilities in Umlazi Township. For example, nurses 
87 This figure is based on the pilot study for the W.H.O. antenatal care trial, where only 160 out of 250 
women recruited before delivery had their delivery in a health care institution (personal communication 
Professor Ross, CHESS, Durban, 1996). 
88 A survey recorded that 36-50% of deliveries at Prince Mshiyeni hospital could have taken place in 
health centres, but that 90% of women said they would be willing to use the 24 hour clinic service if it was 
provided (Ramdas et aI1996). 
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complained that there are too many patients to devote adequate time to, including 
pregnant women. Although nursing guidelines and maternity care manuals exist, nurses 
/' 
do not have the time to provide the quality of care that they are trained to. Therefore, in 
order for the W.H.O. programme to have its' full effect, norms of st~ff:patient ratios 
should be set and adhered to (Chess 1996), thus requiring large initial investments in 
staff, and possinly leading to'larger increases in unit costs than those predicted in the 
incremental cost impact approach. 
, " '" ~ 
In conclusion, the cost predictions made for the W.H.O. ANC programme in South 
Africa in this study are clearly a starting point as opposed to a finishing point. The 
issues raised in the cost prediction process, combined with the further issues raised 
above concerning the unsampled pregnant population, initial investment and quality of 
care, leads to the conclusion that the dynamics of different impacts needs to be assessed 
in more detail by local health service research teams who are responsible for budget 
allocation and planning services, and that they can use this analysis as a point of 
departure. 
9.6 Conclusion 
This section first discusses general findings, and then makes conclusions about each 
cost prediction method. First, the results showed that there was substantial variability in 
accuracy both within and between cost prediction methods. This variability was caused 
by differences between countries in prices and resource use (and thus unit costs) and 
health service use, as well as the extent to which different cost prediction methods took 
into account these differences. For example, ACPP predictions using transfer methods 
tended to be closer to observed cost between Cuba and South Africa than between 
Thailand and Cuba or Thailand and South Africa. These patterns emerged due to 
similarities in both unit costs and health service use between Cuba and South Africa, but 
differences between Cuba and South Africa compared with Thailand. In the latter, 
inaccuracies were particularly related to differences in the rates and unit costs of 
caesarean section and the associated longer postpartum average length of stay, as well as 
differences in neonatal admission rates (Thailand compared to South Africa) and 
average costs per neonatal day (Thailand compared to Cuba). 
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In examining the components of unit cost - prices and resource use quantities per visit -
it became apparent that the main inter-country differences were in resource use, in 
particular staff and drug use. These could be compared between countrY to examine 
their influence on unit costs. However, price comparisons were less. simple: due to 
variations in inter-country price ratios for different resources, it was not possible to 
construct a single price index' that reflected price differences (shown in Table 7.8). Two 
indicators of price levels were chosen to adjust cost predictions - PPP and staff salaries 
- but neither of these increased accurac~ sufficien~ly to make more predictions 
'accurate', and some were even made less·- accurate. Therefore, there were no 
straigntforward conclusions about the extent to which price differences caused 
differences in unit costs and cost per pregnancy between country. However, the 
conclusion was made that to make adjustments to cost per pregnancy based on price or 
GNP per capita levels does not necessarily increase cross-country cost per pregnancy 
predictions, and may even decrease accuracy. 
Another key finding was that, using the definitions of accuracy and economic 
significance, and given the settings of the study, it was commonplace for a cost 
prediction to be considered 'accurate'. However, in some instances predicted and 
observed costs differed by up to 40%, and were still considered 'accurate' due to 
overlapping confidence intervals. This raises questions about whether the definition of 
accuracy used in this study is sufficient for policy makers to be confident that the 
appropriate decision will be made based on cost predictions. For the predictions using 
predictors from regression analysis, this was especially true, due to the very wide 
confidence intervals. On the other hand, for a difference to be economically insignificant 
was rare, as cost predictions had to be within US$12 of observed cost (in Cuba) and 
within US$7 of observed cost (in Thailand and South Africa). Therefore, it often 
happended that predictions were 'accurate' but still differences were economically 
significant. The cost of an antenatal visit was clearly one of many measures to judge 
economic significance, and in that sense is an arbitrary measure. These results are 
important findings of this study, and are discussed further in the next chapter. 
The main conclusion regarding the data transfer methods to predict costs are that they 
are generally unreliable, unless either (a) components of cost are known not to vary 
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substantially (thus 'allowing' a direct transfer without cause for concern) such as was 
the case between Cuba and South Africa, or (b) cost determinants are known, and 
adjustments are made based on these determinants to improve acuracy. _Therefore, cost 
predictions are generally safer if they are based on informed judgement about expected 
changes in both health service use rates and average costs. However, even when 
differences were known, because they occurred in both unit costs and health service use, 
adjustment of only one of these lead to predictions not being accurate. This suggests that 
an approach using local data is important.to achieve accurate cost predictions when 
,'. ',' 
several cost components vary between countries. For this reason,the incremental cost 
impact method was found to be the most consistently accurate method for both Cuba 
and Thailand. The degree of confidence in the results was high because local unit costs 
and health service use levels were used in the calculations, and adjustments were made 
for expected changes based on detailed analysis. 
However, the incremental cost impact method relies on a string of assumptions and/or 
highly detailed data in order to predict changes in health service use, morbidity rates and 
unit costs. Even with the detailed data available to this study, some of the assumptions 
made for Cuba and Thailand proved to be incorrect when predicted impacts were 
compared with observed impacts. For example, there was no average cost change 
observed in Cuba due to the W.H.O. ANC programme, although the costing instruments 
may not have been sensitive enough to pick up marginal changes. Also there were 
changes in inpatient admission rates and lengths of stay that were not predicted, 
especially in Cuba (although these changes were not necessarily ralted to the impact of 
the new programme). In conclusion, the incremental cost impact method assesses 
changes on a hypothetical level, and uses health systems data that may riot reflect actual 
practices or allow real changes to be pinpointed. 
The main finding regarding the use of staff costs to predict average cost for health 
services is that it is a potentially accurate method, but also substantial variability was 
found in many of the predictions at the health facility level, thus making it a particularly 
unreliable prediction method for small sample sizes. This is likely to be due to 
inaccuracies in both prices and resource use, as average salary levels may not reflect 
actual salary levels in any given health facility, the proportion of staff and direct cost in 
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unit cost varies between health facility, and identification of full-time equivalents may 
not reflect the true staff costs. Therefore, until further work is conducted on this method 
it is not recommended as a reliable means of predicting average costs, and estimation is 
advised using a more complete picture of resource use. 
The main finding regarding the use of cost predictors from mUltiple regression analysis 
is that it identifies multiple influences on cost per pregnancy simultaneously. Also, it 
was found to be more accurate for 'identifying cost changes associated with small 
changes in independent variables (Le.' '~~cremental "tosts) compared with overall 
prediction of cost per pregnancy. However, inaccurate or incomplete data may mean that 
predictors are less efficient, and interaction terms cannot be included, and therefore cost 
per pregnancy predictions were les than observed cost for all within-country predictions. 
Also, -the differences in signifiant variables between countries suggest that results are 
not generalisable between countries, unless (a) through chance, as possibly happended 
in the case of Cuba and South Africa or (b) cost determinants are identical. 
In conclusion, different cost prediction methods can be used depending on the context of 
the research, including the aims of the cost prediction, the research funding, data sources' 
and availability, data quality and skills available for the cost prediction, and key 
differences between health care settings. Cost transfer is particularly useful when 
research resources are very limited and/or ~hen settings do not vary substantially (such 
as practice patterns, staff productivity ratios, prices). However, when using this method, 
the cost boundaries, cost valuation techniques, and the degree of uncertainty in the 
original study should be clear. If cost data are disaggregated, and with some local data, 
adjustments are possible to increase accuracy. When settings vary with respect to several 
cost determinants, and data are available on the base conditions (under current care), the 
incremental cost impact can be used to provide a more reliable, but not necessarily 
highly accurate, cost prediction. However, the analyst must be especially aware in this 
method that they are not influenced by expectations, and that realistic ranges are given 
to reflect uncertainty. Finally, when several inter-related cost determinants exist, and 
where resources are sufficient to collect (if not already available) and analyse the data, 
regression analysis can be used to identify cost relationships and predict costs. However, 
this method is only truly worthwhile when the analyst is confident that there will be 
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important benefits (such as added understanding of costs or accuracy) over and above 
the other cost prediction methods. Therefore, the analyst is advised to spend time 
considering the advantages and limitations of the alternative cost prediction methods, to 
----' 
make an informed decision about which is/are optimal. 
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10 DISCUSSION 
The last four chapters have addressed the empirical objectives, and presented the costs 
of aspects of maternity care in Cuba, Thailand and South Africa; tested these costs for 
robustness and presented measures of variability; analysed costs to understand causes of 
variation; predicted costs in each country using a range of methods, validated predicted 
costs against observed costs, and drawn conclusions about the strengths and weaknesses 
of each method. This chapter examines important methodological issues and choices 
! . . . .' 
with respect to cost prediction that have been raised in this thesis, drawing on both the 
literature review and data analysis chapters, and considers the wider policy implications 
of the results. The first section discusses choices that must be made in predicting costs, 
choices that determine not only the accuracy of cost predictions, but also their 
usefulness to policy makers in different settings. These choices include the cost 
boundary, the measure of central tendency, valuing resources at opportunity cost, the 
currency conversion method, and sampling and data issues. The second section critically 
examines the approach used in this thesis to judge the performance of the cost 
prediction methods, and the cost prediction methods are examined with respect to 
whether they are likely to perform better or worse under alternative performance 
measures. The third section appraises the approaches to examining cost variation, 
including how much economic theory contributed to the cost analysis, and how much 
methodological and data constraints in analysing data reduced the strength of the 
conclusions. Also, the interpretation of cost variability and cost uncertainty, and the 
ability to quantify these appropriately, are discussed. The fourth section discusses the 
policy implications of the cost prediction methods and results in planning maternity 
services in the study settings and lower-income countries. 
10.1 Choices in predicting costs 
Before predicting costs, analysts should be aware of the choices or issues to consider in 
cost prediction. While these choices must be guided by the ultimate purpose of the cost 
prediction as well as research constraints, it is useful to clarify the options, and the 
advantages and disadvantages of each. 
~. 
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10.1.1 Costing boundary 
The choice of which costs to include is essential in both measuring and generalising cost 
evidence between settings, and can critically influence study conclusions (Torrance et al 
1996)89. This study focussed on prediction of cost per pregnancy,. as well as its' 
components unit costs and health service use. It is therefore recognised that if the study 
boundary had been different, different conclusions may have been reached. For 
example, if the costs of neonatal care had been excluded in Cuba, the cost saving in the 
intervention arm of US$42 would have peen US$12.greater than in the base case 
analysis, leading to a conclusion of statisti~aIly signific~t difference between trial arms 
as well as a less skewed cost distribution. It is also recognised that in other settings there 
may be other health services that vary between trial arms, such as the number of home 
visits or private health care visits, or in the costs of care following hospital discharge 
-
after delivery. For example, if women are not happy with receiving fewer antenatal 
visits under the W.H.O. programme, they may choose to attend private clinics as well. 
The implication is that case cost should be defined to include all important and relevant 
costs, and where they can be attributed to the intervention (Johnston et al 1999), 
particularly those costs that vary between two or more health care alternatives. 
10.1.2 Average or marginal cost 
In measuring and predicting cost per pregnancy, a choice is also faced concerning 
whether the unit cost should be measured using all resource ingredients or only variable 
ingredients. The distinction between marginal and average cost is important from both 
the analytical and policy standpoints, because a unit of production should sometimes be 
assessed at its' marginal cost, and at other times at its' average cost (Luce and 
Elixhauser 1990). At the patient level, when small changes in the health system are 
considered, it can be argued that marginal costs are of more interest than average costs. 
The rationale behind this is that, when an additional patient is treated, the 'true' cost 
(opportunity cost) is the change in resource use, involving only variable inputs, and not 
the average cost which usually contains an element of fixed cost. Therefore, in the short-
term, the average cost is not saved when throughput decreases by one unit. 
89 The types of health care included in cost per pregnancy were defined by the clinical study design, and 
included outpatient and inpatient ANC, delivery care, postpartm and neonatal care until hospital 
discharge. 
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However, the BMJ economic evaluation guidelines argue that the choice over which 
cost to use in economic evaluation is related to the context and time frame of the 
decision (Drummond and Jefferson 1996). In the short run few costs may be variable if 
a change in treatment is introduced, whereas over longer periods all resources, including 
buildings, can be switched to other uses (Drummond and Jefferson 1996)90. However, as 
well as opportunity cost varying according to time, period, the 'next best' use of 
resources also varies by setting, as the ability to redeploy resources may vary between 
settings (Drummond et al1997, Coast et al.,2~00). The implication of this debate is that 
. '. '.' . 
cost increments or cost savings of the new ANC programme in the short-, medium- and 
long-term depend on the policy context. For example, in the short-term in Cuba, other 
types of patient may not 'replace' the reduced ANC visits saved by pregnant women 
attending the W.H.O. ANC programme. Therefore, the savings in this case are purely 
the variable costs, such as drugs and materials. In the medium-term, if still no 
replacement occurs, staff and buildings can be put to different uses or made redundant, 
and in the long-term there is reduced investment in equipment. For these reasons, this 
study presented, compared and predicted health service unit costs and cost per 
pregnancy at both average and marginal costs, to represent two extreme viewpoints. 
However, it should be noted that the choice of cost was shown to make a difference to 
cost generalis ability using the cost transfer methods, as marginal costs were a higher 
proportion of average costs in Cuba, and a lower proportion in South Africa. 
10.1.3 Measure of central tendency 
In the presence of skewed data sets or non-normal distributions, measures of central 
tendency other than the mean, such as the mode or median, may be important to present, 
and also predict. The main variable of interest in this thesis, cost per pregnancy, was 
found to be skewed (see tables in Appendix 14), although this was reduced to normality 
or near normality through a log transformation. The advantages and disadvantages of 
different measures of central tendency are discussed briefly below. 
The median cost reflects the 'mid-patient' - that is, the cost per pregnancy of the (nJ2yh 
patient, where on' is the sample size. The benefit of the median value is that the impact 
of a few very high or very low cost (depending on the skewness) do not have a large 
90 This viewpoint is also supported by the US cost-effectiveness guidelines (Luce et al 1996) and the 
World Health Organization (Murray et aI2000). 
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effect on the measure, and thus allows health services to be directed towards patients 
with the average cost or characteristics. The median is likely to be useful for primary 
care providers, as high cost patients are referred to secondary providers; thus the cost 
influence of high cost women is excluded when transferring cost per pregnancy between 
primary providers. The problem with the median is that health planning does not take 
account of high cost patients, and therefore the median will underestimate the resources 
required for maternity care. In the recognition that the median value may be useful for 
researchers and policy makers alike in predicting costs, this study evaluated the accuracy 
, . . '. ' 
of predicted median costs, and they were' found to i;e inaccurate in cross-country 
transfers by the same order of magnitUde as mean costs (in terms of % 
predicted/observed cost). 
The mode reflects the cost value with the highest number of observations. While it is 
beneficial for the same reason as the median in that it allows health services to be 
planned for average or low risk patients, again it does not reflect groupings of patients in 
other parts of the distribution that have an impact on the overall expenditure 
requirements. An additional disadvantage of using the mode is that it may not even 
reflect the majority of patients, as the highest number of observations may only be a 
small percentage of patients. Also, when there exists more than one mode such as it did 
in study countries, this should be reported in predicting costs as it is of policy interest. 
The mode is shown in this thesis in the cost distribution diagrams (Appendix 14), but it 
is not used for predicting costs. 
Finally, the mean value is argued to be the most relevant for policy making, for the 
simple reason that (n x mean ACPP) equals the total expenditure for the population on' 
(Johnston et alI999). In cost and cost-effectiveness studies, it is by far the most widely 
reported measure of central tendency, and most discussion of statistical issues centres on 
the mean (Bouckaert and Crott 1997, Coyle 1999). In addition, the advantage of the 
mean is that confidence intervals can be calculated to reflect the range containing a 
given percentage of observations, with important implications for the comparability of 
costs and cost generalisability. The disadvantage of the mean, as already mentioned, is 
that it can be heavily influenced by skewed cost data or outlying cost values. In Cuba, 
for example, there were 312 patients with a cost greater than US$I,OOO (just over 5% of 
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the overall sample). While these women were included in the base case analysis, mean 
cost per pregnancy for women with ACPP of less than US$1 ,000 _~as recalculated, 
giving US$300 in the control arm (from US$406 in the base case) and US$247 in the 
intervention arm (from US$376), a reduction of over US$100. Therefore, the small 
proportion of very high cost patients had a large impact on mean ACPP. In addition, 
policy makers should also be aware of the main cost i~creasing events. In Cuba, the high 
cost of a CS and neonatal day meant that women/neonates having one or other of these 
caused a second mode at around US$500-US$600. Therefore, alongside mean values, 
.. ,... . 
.' . 
other data are important in understanding the cost distribution, with implications for 
predicting and interpreting costs, and therefore in planning health services. 
10.1.4 Valuation 
Valuation is a critical stage in costing, as conversion to monetary units allows resource 
use to be summarised in a single easily recognisable and comparable index. However, 
the approach chosen has potentially important implications for how costs can be 
interpreted and used, including how generalisable costs are. In this study, the initial aim 
was to measure costs according to the economic definition, that is, the 'opportunity 
cose: "the opportunity lost due to not using the resources in their next best use" 
(Drummond et al 1997, page 54). A step-by-step approach for valuation was outlined in 
Box 5.1, which drew on the development project appraisal literature (Little and Mirrlees 
1982, Curry and Weiss 1993, MacArthur 1997). However, while prices were available 
for all ingredients, a key problem arose in deciding whether current prices reflected the 
opportunity cost. This was particularly true for non-traded goods, where resource 
markets were possibly far from perfect. The approach recommended in the development 
project appraisal literature, that of identifying the 'next best use of the resource', was 
not used, due to the difficulties inherent in assessing the market for health care resources 
outside their current uses. Therefore, the extent of the distortion introduced by using 
financial prices for staff wages, utility and building costs was not known, and possible 
ranges were tested for the most important resource, staff, in the sensitivity analysis91 • 
91 In Thailand and South Africa private sector wages were substituted as an alternative measure of 
opportunity cost. However, private sector wages were not considered appropriate for use in the base case 
as they may include an element of 'rent', as health care workers in the private sector may be willing to 
accept a reduction in their wages there. In Cuba, take home wages were also unlikely to represent the 
opportunity cost of labour, because in a communist state welfare services are not charged for (e.g. health 
care) or are provided at a subsidised rate (e.g. food and clothes rations). However, because the appropriate 
percentage 'mark-up' from the take-home pay could not be assessed, and no previous research indicates 
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10.1.5 Currency conversion 
This thesis has shown that the currency conversion method chosen has important 
/,' 
implications for cost generalis ability and the predictive accuracy of different cost 
prediction methods. The choice of exchange rate to convert local costs into international 
currencies such as the US$ depends on what the data are used for. Three possible 
purposes are identified. 
1. To estimate the cost of health care programmes funded by external bodies in their 
own currency. For example, the UK. government wishing to invest in safe 
. "', " 
motherhood programmes in developing' countries. For this, the nominal exchange 
rate gives the out-of-pocket cost to the funder, at a specified point in time. 
2. To compare or pool health care costs between countries. For example, international 
researchers are interested in relative costs of different interventions in different 
countries, or they may wish to pool health care costs in a multinational trial. While 
nominal exchange rates gives the out-of-pocket cost, PPPs provide a better means of 
comparing costs internationally as they allow judgements about the magnitude of 
cost as perceived by a local decision maker, as the measure is relative to local 
purchasing power. In addition, PPPs remain relatively constant through time, and are 
not affected by transient fluctuations in exchange rates (Drummond et alI992). 
3. To value the contribution of a project to national income, as in development project 
appraisal, whose aim is to maximise export earnings or national income (Curry and 
Weiss 1993). For this, the shadow exchange rate is argued to be the most relevant, as 
it removes distortions present in the nominal exchange rate. However, where 
nominal exchange rates are determined by the market, as in Thailand and South 
Africa, no shadow exchange rate needs to be calculated. In Cuba the shadow 
exchange rate was approximated by the black market rate. 
When presenting costs in US$ in this study, the interpretation of costs depends on the 
currency conversion method used. Several points are raised with regard to exchange 
rates used in this study. First, the nominal exchange rate in Cuba is a government-fixed 
rate (US$1 equals 1 Peso), and is different to the black market rate of US$1 = 20 Peso. 
This suggests that the government rate does not reflect the opportunity cost; however, 
the rates, actual wages were used in the base case, and a nominal (though in itself highly uncertain) 
upward adjustment of 50% was applied. 
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the black market rate may not reflect the opportunity cost either92• Average costs were 
found to be highly sensitive to this area of uncertainty. 
Second, there was a problem of exchange rate fluctuation between the ~ate used for the 
cost data in the W.H.O. trial (lst January 1998 was the mid-point of the ANC trial) and 
the date at which the data were analysed (May 1999). This point is particularly relevant 
to this study, because since the mid-point of the economic study there were significant 
exchange rate variations in both Thaila'nd and South Africa93• Therefore, exchange rates 
..... .';' 
on 1st May 1999 were used in the sensiti~ity analysis to~eflect this variation, which had 
substantial impacts on average costs. 
Third, the generation, use and interpretation of the PPP measure are also important to 
consider. In this thesis, a 'home made' measure of PPP was estimated for all countries to 
allow consistency in comparisons between countries,- as PPP rates from international 
sources were not available for Cuba. A problem with the use of PPP in this study as well 
as more generally is that its' measurement can rarely make price comparisons using 
identical items in each country (same quality, size, etc) (World Bank 1997). Also, the 
'bundle of goods' contained some imported items, as few food products were grown in 
all three countries94• Health care-specific PPPs have been used by some authors, as they 
have been found to be different to general PPP measures (Van Ineveld et al 1993). 
However, these were not available for all study countries. Therefore, the 'home-made' 
measure was considered to be most appropriate for this study (details provided in 
Appendix 4 Table 4.1), and allowed conclusions to be drawn about the relative cost of 
alternative types of care in different countries, as well as the overall costs of pregnancy. 
Interestingly, rather than reduce the differences between countries at nominal exchange 
rate, using PPPs actually increased some differences, with implications for direct 
transfer of costs between countries with similar GNP per capita. For example, cost 
92 The shadow exchange rate used may be unrealisticly high as luxury items and also many necessities can 
only be bought in US$ and therefore creates high demand for US$. 
93 In Thailand, this was due initially to unrealistic expectations of future growth (where US$1 = 30 Baht in . 
1997), followed by a stock market crash, which caused a massive devaluation of the Thai Baht to over 
US$1 = 60 Baht (in 1998), followed by slow recovery throughout 1998 and 1999 (US$1 = 37 Baht). In 
South Africa, the Rand was affected by the Asian economic crisis, but the impact was delayed, and 
between 1997 and 1999 the Rand depreciated from US$1 = 4.9 Rand to over 6 Rand. 
94 However, whether goods are imported or not, the PPP measure reflects t.lte cost of commonly bought 
food items, and therefore reflects the local cost of living. 
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prediction from Thailand to Cuba using the direct or adjusted transfer methods were 
more accurate using nominal exchange rate than PPP. 
The implication of this discussion is that neither of the rates used are entirely 
appropriate for converting from one currency to another, when costs from different 
countries need to be pooled or compared. This finding exposes the fundamental problem 
of any type of currency conversion, that unless there is a methodologically sound 
method for comparing costs in different currencies, cross-country cost comparisons are 
",.", .,' 
likely to give misleading conclusions. Ho~e~er, the reference case does not provide any 
guidance on the choice of exchange rate (Weinstein et al1996). Nominal exchange rates 
are not entirely appropriate or useful because they do not reflect the cost to local 
economies, as well as the fact that exchange rate volatility changes the 'international' 
value of local currencies over time. The general PPP, on the other hand, was based on 
subjective comparisons between the cost of a bundle of goods, and these comparisons 
may not apply to the health care market. Therefore, these issues throw doubt on the 
cross-country comparisons and analysis of costs, and cross-country cost generalisability. 
Therefore, whilst the cross-country cost comparisons allowed some conclusions about 
cost determinants at an international level, analysts should exercise caution in 
interpreting costs when currencies are converted into a common currency such as US$. 
10.1.6 Sampling and data issues 
Alternative cost prediction methods were shown in Chapter 9 to require different levels 
of detail and draw on different data sources. Economic evaluation and costing 
guidelines advise that costs should be dis aggregated by unit cost and health service use. 
This study explored in detail the determinants of cost per pregnancy by analysing cost 
components (unit costs and health service use) separately. Also, unit cost behaviour was 
analysed by separating unit costs into prices and resource use. In fact, four of the five 
cost prediction methods required disaggregation of components of cost per pregnancy: 
the adjusted transfer method, incremental cost impact method, simplified staff cost 
method, and the regression method. Out of these methods, only the adjusted transfer 
method could be applied without breaking unit costs into prices and resource use95• 
Therefore, the more reliable cost prediction methods depend critically on data being 
95 However, the regression method could have excluded unit cost determinants (such as staff productivity), 
but less of the variation in the dependent variable would have been explained in the regression equation. 
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approximating unit cost using staff costs alone, staff costs were scaled up by two 
multiplication factors (% staff costs and % direct costs in unit cost), thus leading to 
~/' 
more accurate predictions of unit cost. 
In conclusion, not only should the cost prediction methods tested here be evaluated in 
other countries and health care contexts, but also there exists scope for testing other 
methods of cost prediction, to increase the comprehensivenes of conclusions regarding 
the strengths and limitations of alternative cost prediction, methods. 
,",.. ," 
10.2 Judging performance of cost prediction methods 
This thesis judged the cost per pregnancy predictions using two main measures. The 
first related to whether the predictions were accurate - that is, the extent to which 
predictions reflected observed costs. This was reflected or judged in three ways: the 
US$ difference, predicted cost as a perc'entage of observed cost, and whether confidence 
intervals for predicted and observed cost overlapped. The third of these was used to 
make the final judgement about accuracy. The other measure for judging the cost 
prediction methods is whether the inaccuracies observed were economically significant. 
Therefore, this study recognised that statistical significance cannot be equated with 
economic significance (McCloskey and Ziliak 1996). While it was recognised earlier 
that economic significance is a highly context-specific concept, depending on a variety 
of factors, this thesis also had to choose a measure that could be applied consistently in 
a variety of settings and that allowed preliminary conclusions about economic 
significance. This section critically appraises the measures of accuracy and economic 
significance chosen, and whether different conclusions could have been drawn if 
different definitions had been chosen. 
10.2.1 Accuracy 
In using 95% confidence intervals, conclusions about accuracy were based on widely 
accepted norms of statistical practice. By judging accuracy on the basis of whether 
confidence intervals of predicted and observed cost per pregnancy overlapped, 
conclusions were made (with at least 5% confidence) whether the mean values of 
predicted and observed costs were either the same or there was a reversal in outcome. 
However, three initial problems with the use of confidence intervals to judge accuracy 
are noted. The first problem was that some methods did not generate confidence 
257 
intervals, but instead ranges, because the predictions were not based on many 
observations of patients. Both the simplified staff method and the incremental cost 
// 
impact method generated ranges based on alternative values for variables in the cost 
equation. This leaves the methods open to manipulation, and therefore t~e possibility of 
, 
generating very wide confidence intervals to ensure an 'accurate' result. 
The second problem was that some methods generated such wide confidence intervals 
that an accurate result was found even wh~n the predicted cost was a small fraction of 
.. ':. . 
observed cost. This was found in the regression analysis results, where the use of lower 
and upper confidence intervals on all significant coefficients simultaneously calculated 
very wide confidence intervals on predicted cost per pregnancy. Conversely, the fact that 
cost per pregnancy was calculated from large samples gave narrower the confidence 
intervals than would have occurred under smaller samples, thus reducing the chances of 
overlapping confidence intervals, and thus creating incentives for small sample sizes. 
The third problem was that often a cost prediction method was found to be inaccurate 
for cost per pregnancy but accurate for incremental cost, thus not allowing a final 
conclusion about whether the prediction method was accurate or not. In this case, it 
depends on which type of cost the researcher or policy maker is interested in. If only 
incremental costs are required, then some methods could be judged to be accurate and 
therefore usable for cost predictions. However, this thesis did not calculate costs under a 
do-nothing alternative, the approach advocated by Murray et al (2000) for estimating the 
average cost-effectiveness ratio, as there was no do-nothing alternative in the W.H.O. 
ANC trial. A fourth problem is that of test-retest reliability. If a different researcher had 
conducted the same analyses for some cost prediction methods (those that give the 
analyst more discretion, such as the incremental cost impact method and regression 
analysis), different results and conclusions may have been obtained. This is due to the 
sometimes subjective nature of the cost prediction techniques, where boundaries and 
types of cost predicted must be chosen, and ranges of cost impact decided in the absence 
of cost distributions. 
In these cases, where there is some doubt about whether the ranges on cost reflect 
quantifiable confidence, it may be wise to use a series of measures in combination, so 
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that conclusions of accuracy cannot be made when predictions are clearly not 
sufficiently close to observed cost, and likely to give misleading conclusions. Two 
~ 
initial options are proposed. The fIrst is the use of another measure of accuracy, such as 
predicted cost as a proportion of observed cost, with the use of a arbitrary cut-off point 
to judge accuracy, such as 80-120% or a stricter 90-110%. This approach implicitly 
ignores confIdence intervals,:and is useful when confIdence intervals or ranges do not 
contain the information to make conclusions about accuracy. Referring to Appendix 16 
Table 16.3, some conclusions about accuracy would have changed using this measure. 
", ' .. ' 
For example, the simplifIed staff method predicted coststo within 76-77% of observed 
cost in Cuba and over-predicted observed costs by 136-147% in Thailand. In both these 
cases the use of the '80-120% criterion' for accuracy lead to a reversing of the 
conclusions. Also, the conclusions of accuracy in the within country cost predictions 
using regression analysis would have also been reversed in Cuba (60-72%) and South 
Africa (78%), although in Thailand the predictions using the regression model were 
more accurate (81-94%). All the inter-country cost predictions would have become or 
remained inaccurate. 
The second solution to overcome the limitations of relying on confIdence intervals to 
judge accuracy is to avoid any judgement of accuracy using statistical methods, but to 
judge cost prediction inaccuracies using an economic measure of signifIcance. This 
approach is supported by the argument that policy makers are not always necessarily 
concerned with 95% or even 90% probabilities in cost savings or increments occurring, 
as they may be less risk averse than statisticians. For example, they may be willing to 
accept 80% probability of a cost saving and a 20% probability of a cost increment. 
Therefore the use of statistical analyses, and judgements based on statistical theory, have 
less practical use when it comes to making changes in policy. In this case, the 
signifIcance of a cost difference could either be based on different signifIcance levels 
(based on the risk aversity of policy makers), or based on an economic measure to 
inform them the mean cost saving or cost increment. This is discussed further in section 
10.2.2. 
10.2.2 Economic significance 
Ultmately, economic signifIcance should be based on whether an inaccurate cost 
<-.. 
prediction would be likely to lead to a different decision that that which would have 
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been made if costs were predicted accurately (or alternatively if costs were observed). In 
the context of this thesis, it means: "would a decision about which ANC programme to 
/" 
adopt be different if an inaccurate prediction was made instead of an accurate one?" For 
example, directly transferring Thai cost per pregnancy in the interventi.on arm to Cuba 
using nominal exchange rates leads to an inaccuracy of US$286 per pregnancy. Also, 
directly transferring Cuba cost per pregnancy to South Africa leads to an inaccuracy of 
US$19 per pregnancy. The key question concerns whether policy makers in Cuba or 
South Africa would make a different decision concerning the frequency or content of 
.. :. " 
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health care using these data compared to using data on observed costs. However, there 
were several problems with this 'decision change' approach that prevented it from being 
applied in this thesis. First, there are measurement problems: even if managers were 
surveyed about what cost changes might affect their decisions, it is not sure whether 
their answers would reflect what they actually do. Also, what they actually do is 
difficult to measure until policy changes have been observed over time, which was 
beyond the scope of this thesis. Second, policy makers will vary between institutions 
and country and over time, thus making it very difficult to make a consistent judegment 
about economic significance even across a small sample of providers. Third, decisions 
of policy makers depend on many complex and inter-related factors that cannot easily be 
determined or generalised. Decisions may, for example, depend on a mix of political 
will, time of year with regard to budgeting, budget over- or underspend forecast, staff 
availability to implement changes, etc. Therefore, the accuracy of the cost prediction is 
only one of many issues policy makers need to consider in health planning. 
For these reasons, this thesis chose a simple and easily applicable definition of 
economic significance - more than the cost of one ANC visit (averaged for each 
country) - instead of attempting to model complex decision making proceses. This 
definition was chosen because ANC is the focus of this study, and also local cost levels 
are taken into account in each country.? However, there were also several problems with 
this definition. First, economic and statistical significance rarely agreed, in that most of 
the time differences were economically significant, but a lot of predictions were 
accurate. This introduces the problem that predictions that are not statistically different 
from observed costs at the 95% level cannot be economically significant, as it could be 
argued that the difference may not actually exist. This again raises the point that policy 
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makers may be willing to accept different significance levels than statisticians. Second, 
as in the case of judging accuracy, the inaccuracy of some prediction methods were 
-,-' 
economically significant for cost per pregnancy but economically insignificant for 
incremental costs. For example, adjusted transfer from Thailand to Cuba was highly 
significant economically for cost per pregnancy (over the cost of 18 ANC visits) but 
economically insignificant for incremental cost «1 ~C visit). 
Third, the measure chosen had different relative values in all countries. The relative cost 
,',,': ' 
of an ANC visit compared to cost per pregnancy varied from 2% in South Africa, to 
2.8% in Cuba, to 5.6% in Thailand. Compared to the cost of a normal delivery, an 
antenatal visit was 23% in South Africa, 26% in Thailand, and 57% in Cuba. Also, the 
US$20 per woman cost saving in Thailand was 19% of the cost per pregnancy in the 
control arm, compared to the cost saving in Cuba of US$30 only having a 7.5% impact. 
Therefore, relative costs and cost savings differed between country, and therefore 
economic significance as measured in this thesis had different interpretations. 
Fourth, the measure chosen to conclude whether inaccuracy was economically 
significant varied within as well as between countries. For example, the cost of an ANC 
visit varied from US$8.3 to US$18.4 between policlinics in Cuba (average US$12), and 
from US$3.6 to US$9.1 (average US$6.5) between hospitals in Thailand, and from 
US$6.83 to US$8.63 (average US$7.24) in South Africa. Therefore, applying health 
facility-specific ANC visit costs may have lead to different conclusions about economic 
significance. In conclusion, the weaknesses of the definition of economic significance 
used in this study suggest that it is better to judge cost prediction methods based on their 
general performance using a range of definitions and understanding of performance. 
10.3 Contribution of cost analysis to cost prediction methods 
Cost analysis was discussed earlier as an essential intermediate stage between locating 
sources of cost data or measuring costs and using these costs in making cost predictions. 
In understanding components of cost that varied between settings, cost analysis helped 
explain why direct cost transfers were inaccurate, it increased confidence in making 
adjusted transfers and assessment of incremental impact, and it guided variable choice 
in the multiple regression analysis. Chapter 2 outlined the relevance of economic theory 
~. 
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for the health sector, particularly in relation to conducting and interpreting cost analyses 
of unit costs, and highlighted some difficulties in analysing costs in the health sector. 
. ~/ ~ 
Chapters 3 described and evaluated cost analysis methods, distinguishing between the 
three components of case cost: health service use, resource use quant~ties, and prices. 
Chapter 4 reviewed evidence for the link between cost-determining factors and costs, 
using the methods described in Chapter 3. Chapters ~-8 all found that the cost analyses, 
used in this study were partially successful in explaining costs (see conclusions in each 
chapter). However, there were several limitations of approaches adopted in this thesis. 
" . 
These are critically evaluated in four subsections: the contribution of economic theory to 
the analysis of health care costs; methods for measuring variation and comparing costs; 
variation left unexplained; and other issues in cross-country cost analysis. 
10.3.1 Contribution of economic theory to understanding costs 
This section discusses the extent to which the factors identified to cause cost variation 
could be applied. In general, in presenting different attributes of the cost function 
Chapter 2 helped provide an understanding of cost behaviour in the health sector, and 
provided a platform by which to compare and analyse costs. However, there remained 
some uncertainties concerning how to conduct costs analyses (due to unavailability of 
key data) and also interpret cost analysis results. First, in the absence of profit 
maximisation, public health systems were discussed in Chapter 2 and found to be more 
liable to suffer from X-inefficiency, unless another maximisation condition holds. 
Although incentive systems, staff motivation, and accountability were not measured 
quantitatively in this study, nor resource wastage measured in detail to calculate 
minimum feasible cost (Zuckerman et al 1994), differences were recorded in the 
regularity of stock taking, recording of resource distribution in the health facilities, and 
staff productivity. These findings suggest that staff management and efficiency levels 
differed between health facilities both within and between countries, thus accounting for 
some cost variation. This finding was highlighted in the results of the data envelopment 
analysis which showed that technical efficiency was likely to vary between health 
facilities, due to different output levels from given inputs. However, DEA results should 
be interpreted with the points in mind that technical efficiency scores did not include all 
inputs, case-mix differences were not taken into account, and cross-country comparisons 
could not be made. 
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Second, returns to the variable factor as a cause of cost variation was identified 
successfully, as average monthly throughput levels could be compared with optimal 
/" 
(80%) and full capacity (100%) throughput levels. Two particular problems were faced. 
For inpatient wards, the full capacity for bed days was not equal to [n~mber of beds x 
number of days] due to the variable number of beds, as some beds were collapsable or 
makeshift in nature. Therefore, a large variation was recorded in bed days used per 
month. It was decided for both inpatient and outpatient departments to approximate 
capacity as the maximum monthly" throughput recorded in the study period. This 
,'.'. ":,:' 
implicitly assumes that in the months with higher output staffing patterns are not 
changed to deal with the extra patients. Therefore, the full capacity measure may have 
overestimated the sustainable capacity, and for this reason 80% was also used. 
Economies of scale were recognised in the literature review as a potential determinant of 
unit cost, as distinct from returns to the variable factor. Without time series data and 
without controlling for confounding factors (Le. so that as size increases case-mix does 
not change, for example), economies of scale are difficult to prove. As time series data 
were not available, this thesis adopted a cross-section approach, under the assumption 
that any differences in unit cost at optimal capacity were due to size only, and not due to 
other factors96• The other approach adopted in this thesis, that of comparing % of costs 
that were incurred by overhead departments, was expected to identify whether larger 
health facilities had lower % overhead costs. This approach was based on the 
assumption that most of the efficiency savings as health facilites become larger is in the 
administrative and support departments. However, the results of this method were 
unsupportive of the earlier findings in Cuba of economies of scale. 
Input mix, or input intensity, was also used to examine causes of cost variation between 
health facilities, using both monetary and non-monetary comparisons. At the within 
country level, it was hypothesised to identify whether input intensity or use varied 
between levels of the sysem (e.g. primary versus secondary) or within levels of the 
system. However, it is recognised that any differences identified could have been the 
96 As all health facilites compared within country were of the same level (policlinics in Cuba and district 
hospitals in Thailand) such an assumption was not unrealistic. Note that the measure of provider size was 
different in Cuba and Thailand - in Cuba the provider was the whole policlinic, while in Thailand the 
provider was the health promotion unit. 
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result of quality of care, case-mix or efficiency differences, and therefore input mix 
comparisons served to identify where the cost differences were originating. Due to the 
~-
multiple input-multiple output nature of health facilities, and due to measurement 
difficulties, input relationships could not· be easily represented or understood. For 
example, isoquants could not be mapped in two- or three-dimensional space, as six main 
resource inputs were identified, and for each of these six resources there are many 
heterogeneous items, thus precluding quantificatio~ in a single index. Also, input 
substitution could not be examined empirically, due to the short-run nature of the 
"',: ", 
research (thus changes in relative prices could not be observed), although it has been 
claimed that there are limited options for input substitution (Barnum and Kutzin 1993). 
The differences in relative prices of resources in the study countries meant that the 
relation between relative prices and input mix could be examined. Two possible 
relationships were identified as relative prices changed: one that in the face of limited 
input substitution, the increase in the price of a resource meant that the cost share of that 
resource increases; the other that relative price changes lead to substitution. The former 
was concluded to be the most likely, although empirical evidence was not strong. This is 
because substitution options between resources are limited: staff roles are very different 
between countries, but largely defined by historical factors as opposed to marginal 
relations (MC = MB); in antenatal care there are limited options for substitution 
between staff and equipment, staff and drugs, or equipment and drugs. However, given 
the higher training level of the primary ANC provider in Cuba (obstetricians) than the 
other countries (nurses), it could be argued that some ANC in Cuba could be delegated 
to staff with less training. 
The three remaining factors affecting resource use identified in Chapter 2 - economies 
of scope, quality of care and case-mix - were not examined within country, and these 
were assumed not to differ sufficiently to cause unit cost differences within country. The 
assumption of 'no economies of scope' was likely to be realistic, as comparisons were 
between health facilities within the same level of the health system which did not vary 
with respect to the number of services offered. As the contents of health care were 
standardised in each country for the control and intervention arms, the assumption of 
similar quality of care was not unrealistic either. This assumption as supported by the 
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W.H.O. baseline surveys that found no major differences between contents of care 
between health facilities, and resource inventories that found that resources were 
/ 
sufficient to provide a minimum quality of care. Finally, whether differences in case-
mix were causing cost per pregnancy· variations was examined.. using 2-way 
comparisons and regression analysis. However, the absence of a single case-mix 
indicator made assessment of impact on unit cost difficult. 
10.3.2 Measuring variation 
'., 
The use of confidence intervals in this. thesis has been an important aspect of cost 
presentation, comparison and generalis ability. However, as few economic evaluations 
collect data at the patient level, it is not common to report ranges or confidence intervals 
in case costs (Briggs and Gray 1999)97. In this study, variability was expressed for unit 
costs, health service use and cost per pregnancy, to make comparisons between health 
facilities, and ultimately conclusions about the probability that costs varied between 
health facilities. This was an important first stage before the causes of these differences 
were sought. 
For health service use and cost per pregnancy, the confidence intervals were calculated 
using data on the patient sample from the W.H.O. ANC trial. These confidence intervals 
were interpreted as "the population mean is 95% likely to fall within this confidence 
interval". However, confidence interval do not reflect the skewed nature of the data, nor 
is the true size of the sample variability captured by the standard error (whereas it is by 
the standard deviation). Two options were faced in dealing with this problem (Briggs 
and Gray 1999): either to transform the data to take into account the skewness, or to 
calculate confidence intervals using a nonparametric method such as 'bootstrapping'. 
The computationally easier approach of log transformation was chosen in this study, and 
the values for skewness obtained from the statistical package (SPSS for Windows) were 
reduced to normality in Thailand and near normality in Cuba and South Africa, thus 
allowing (a) testing of the equality of two means, and (b) use of cost per pregnancy as 
the dependent variable in multiple regression analysis98. 
97 In their review of economic evaluations reporting QAL Y s before December 1996, Briggs and Gray 
(1999) found only 53 out of 492 studies had patient-level cost data, and only 4 reported a 95% confidence 
interval on cost per QAL Y. 
98 Also, the cost distributions were found to be similar between trial arms within country, but not 
necessarily between country (number of ANC visits in Apendix 5 Table 5.I-and Table 5.2, and cost per 
pregnancy in Appendix 14 Tables 14.1 to 14.10). 
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For unit costs, variability was calculated using a different method, as unit costs were not 
measured for specific individuals, but for groups of patients (including patients not in 
the trial) receiving specified health services in different health facilities .. Therefore other 
options for representing variability were assessed. The measure chosen was the 
variability between unit costs for the months of the study period (as unit costs were 
measured on a monthly basis). This gave confid~nce intervals for unit cost that 
represented the 95% probability that the true unit cost would fall within this confidence 
,"" ,".;" , 
interval. Therefore, this measure was recognised not to reflect inter-patient variability, 
and that a large proportion of patients could potentially have unit costs well above and 
well below that range. However, the measure of unit cost variability did allow 
comparison of unit costs between health facilities, and whether there are likely to be 
differences at an average level that includes all patients99• Finally, the sensitivity 
analysis showed the how unit costs altered under alternative assumptions, and the new 
ranges were used to calculate a new range for cost per pregnancy thus adding to 
variability and reducing cross-country variation. 
10.3.3 Explained and unexplained variation 
Using the cost analyses, a proportion of the cost variation within and between countries 
could be explained, and tables showed that for many health facilities expected levels of 
unit cost based on the cost analysis results were close to observed unit costs. Staff 
productivity was found to be the most important determinant of unit cost, as well as 
occupancy rates and economies of scale in some settings. However, there still remained 
unexplained variation, for which four causes are discussed. 
First, although economic theory was consulted in identifying potential influences on unit 
costs, it is recognised that the literature review may not have identified all factors that 
cause variation in costs. Despite this, the approach of this study attempted to move 
towards establishing a framework for identifying cost-determining factors and analysing 
costs using accounting methods. 
99 Also, note that as most of the costs of ANe are from routine procedures, the presence of morbid 
conditions does not lead to a substantially higher cost per ANe visit: it may lead to (1) a higher drug cost 
if a presciption is made, and (2) a slightly longer consultation with staff. However, many high risk or 
unwell patients would be referred or admitted to hospital, therefore not burdening the ANe clinic further. 
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Second, data were lacking to test all the hypothesised factors. For example, time series 
data were not available to identify whether economies of scale actually existed; detailed 
data were not collected to measure resource wastage; a quality of care~easure and case-
mix indices were not constructed due to lack of data, or complexity and uncertainty of 
constructing such measures 100. Also, with respect to health service use the sample sizes 
were not sufficient to make confident conclusions about variations between health 
facilities. This was true for aspects of women's cost collected from the survey (30 
women per health facility) and also case-mix collected from the trial data set. 
,'-. ;. 
Comparisons were therefore stronger at the 'between arm' and 'between country' levels 
of comparison. Finally, not all the variability in cost per pregnancy could be explained 
using the independent variables in the regression analysis, thus suggesting omitted 
variables. 
Third, measurement error may have caused some cost variation. Measurement error is 
divided into (a) unknown error introduced by health service workers recording the 
routine data systems or the researchers in extracting the data from the records, and (b) 
filling gaps when data did not exist for some cost variables. The size and impact of (a). 
cannot be known or tested for, but in interpreting the data assumptions are implicitly 
made that no errors were made. The size and impact of (b) can be tested for by 
substituting alternative values where gaps were filled, and testing the sensitivity of the 
results. With respect to the health service use data extracted from the WHO trial, there 
were data collection and data entry mechanisms in place that ensured high quality data, 
including pre-trial training for local data managers, monitoring visits by W.H.O. staff, 
monthly report sheets sent to W.H.O., double entry, and follow-up of missing data and 
cases (Pinol et al 1998). Also, any cases that were lost at or after the delivery period 
were excluded from the analysis as lost-to-follow-up. Therefore, measurement error in 
the trial data set was concluded to be minimal. 
With respect to unit cost data, there was more room for measurement error, although 
there were also procedures in place to minimise researcher error. While on the one hand 
the researchers were highly dependent on the quality of the rou~ine data records, on the 
100 However, even with detailed studies of quality of care, the relationship between unit costs and quality 
of care may not be determinable (Gilson 1992, Broomberg 1997). Also,.-diagnostic related groups to 
reflect case-mix have ben found not to reflect cost closely (TatchellI983). 
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other hand the systems and staff were in place in most health faciliites to record this 
data, for purposes of fulfilling monthly reporting requirements. However, there were 
staff shortages in one or two policlinics in Cuba leading to in~~mplete data on 
throughput and accounting information; in these cases data were generalised from other 
policlinics in the same municipality, with adjustments taking into account differences in 
sizes of policlinics. Also, in Thailand the incomplete recording of material distribution 
in some departments of some district hospitals "meant that material costs were 
generalised with adjustments for differences in patient throughput between hospitals. 
,"; ..... 
Fourth, uncertainties in costing methodologies may have caused unit cost variations 
between health facilities. Therefore, uncertain parameters were identified, likely ranges 
assumed, and ranges calculated to reflect the unit cost values under alternative 
-
assumptions or methods (Briggs et al 1994). However, this thesis suffered similar 
problems to other costing studies in choosing parameters and identifying an appropriate 
range (Briggs et al 1995)101. On the whole, this thesis used ranges based on informed 
judgement; therefore a degree of confidence (e.g. 95%) could not be attached to the 
resulting intervals. In additional to the problems discussed above in identifying types 
and magnitude of uncertainty in individual parameters, uncertainty was also faced in the 
conduct of multi-way sensitivity analysis: in identifying which uncertain parameters to 
include, quantifying correlation between uncertain variable, and deciding what size of 
change in the base case causes results to not be robust. Therefore, careful consideration 
was given to which variables should be included. Also, due to poor data to estimate 
correlations (such as the change in medication use with increase in cost) and probability 
distributions, or flat probability distributions (such as for alternative values for 
opportunity cost), probabilistic sensitvity analysis was not attempted. 'Unacceptable' 
changes in cost were defined to take place if the new value fell outside the confidence 
interval provided by the variability estimate. 
10.3.4 Issues in cross-country cost analysis 
Several issues in cross-country cost analysis have been discussed earlier in this chapter, 
including choice of currency conversion method, and choice of value to represent 
101 According to Manning et al (1996), one of the least-addressed areas of CEA concerned "how to 
incorporate the inherent uncertainty regarding parameters, relationships and model structure into 
estimated cost-effectiveness ratios ... and then to represent the impact of this uncertainty on the elements of 
the analysis critical to decision making." 
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opportunity cost. Several other difficulties were faced in the cross-country cost analysis. 
First, when comparing resource use or productivity between countries, the outputs or 
/--' ' 
quality of care were not identical. For example, an antenatal care visit may be 
considered to be qualitatively different between countries, despite the standardising 
effect of the W.H.O. programme, as staff with similar qualifications receive different 
training. Hence when comparing visits per FrE, this difference in output quality should 
be taken into account. 
--.' 
Second, case-mix varied significantly between countries, but was not examined in 
depth. The analytic methods used were not detailed enough to identify the size of impact 
of case-mix differences on cost. Therefore, it was unclear how much the differences in 
risk factors and morbidity between Cuba and Thailand caused the differences in 
numbers of antenatal visits, and subsequently cost per pregnancy. Third, the main 
hypothesised cause of inter-country health service use variation, practice style, could not 
be measured quantitatively, except in isolated situations. For example, the different rates 
of intrapartum caesarean section suggested that risk aversity was different between 
country, as these rates should be relatively stable across setting (Villar et al 2000). 
Fourth, price comparisons between countries that tested whether they explained unit 
cost differences should be interpreted in the light of differences between resources. For 
example, nurses had different tasks and amounts of training in the study countries, and 
equipment quality varied. Fifth, the static framework of data substitution had 
limitations. While causes of unit cost variation were sought by substituting resource 
quantities and prices across countries, this method of analysis did not take into account 
production function dynamics, such as input substitution under different prices. The 
degree of input substitution, and thus the elasticity of substitution, was difficult to 
quantify in the study settings, and therefore allowances could not be made for dynamic 
effects in data substitution. In conclusion, although cross-country cost analyses were 
important for assessment of cost generalis ability of the W.H.O. ANC programme, the 
results of the cost analyses should be interpreted with these issues in mind. 
269 
10.4 Cost prediction and policy making 
In the following section, policy implications are discussed at three levels of decision 
making, although it is recognised that these may not reflect the full range of levels at 
which decisions are made. The highest level of decision making is at the international 
level such as the W.H.O., the World Bank, or multilateral donors such as the UK 
Department for International Development. While on~ function of these organisations is 
to provide direct support to research and decision making at country level, they also 
devote resources to drawing lessons for cro.ss-countrry.or cross-regional comparisons. 
This is an important role of international organisations, who have the data sets and 
technical expertise to make generalised policy recommendations. The next level of 
decision making is national governments, who tend not only to pursue policies 
ad~ocated by international organisations, but also have an interest in providing the 
health services that are most relevant to their population and can be provided within 
budget. This requires skilful translation of generalised guidelines or policy advice from 
international organisations to a range of settings that may exist in anyone country. A 
lower level of decision making is the provincial or district level. These levels are the 
implementation levels for government policies, and therefore determine hospital or 
health centre budgets and influence expenditure patterns (if this is not done at national 
level). The following discussion refers to all these levels. 
10.4.1 Interpretation of cost results 
Economic results from a clinical trial should first be interpreted in the light of the 
clinical component and health outcomes in their original setting, before cost prediction 
can be further interpreted and implications discussed. The W.H.O. antenatal care trial 
offered many opportunities for the economic evaluation, as well as some limitations102• 
The trial methods are described more fully in Lumbiganon et al (1998). In brief, the 
opportunities offered by the trial included a large sample (four country sites; at least 
twelve participating health facilities within each country; and at least 4,000 women 
enrolled in each country), health service use data for all enrolees, and a structure of 
collaborators who helped with the smooth running of the economic evaluation. Also, as 
the costing study was linked to effectiveness outcomes, issues of allocative as well as 
technical efficiency could be addressed. However, allocative efficiency could only be 
102 The trial was described briefly in Section 5.1, with more details provided in Appendix 2. 
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evaluated at the level of mothers and for the health outcomes selected for measurement 
in the trial, and not for society as a whole (for which all health interventions need to be 
compared and health interventions are chosen on the basis of comparative cost-
effectiveness (Bobadilla et al1994)). 
There were, however, some limitations of conducting a cost study alongside a clinical 
trial, due to reliance on the trial structure and data: sets. First, some types of health 
service use relevant to pregnant women ,was not collected in the trial data forms, 
. '. : ~, . 
including home visits and use of private health care. Therefore, it is possible that some 
small differences between intervention and control groups existed but could not be 
detected. On the other hand, these differences were known to be minimal in all 
countries103• In addition to these health services, follow up costs beyond six weeks 
postpartum were not included. The absence of these data, however, was not expected to 
affect the economic conclusions, due to the finding of equivalence in health outcomes 
(Villar et al 2000). 
Another limitation imposed by the trial was that sample sizes, although admittedly large, 
were not calculated on the basis of economic outcomes; therefore, it was not known in 
advance whether there was sufficient sample size to make conclusions about the 
statistical significance of economic differences. Two factors made it difficult to make 
conclusions about economic differences. First, the skewed nature of the cost distribution 
cast some doubt on using mean values for comparing costs between trial arms. In this 
case, log transformed costs were used to validate the t tests performed by the data 
software package. Second, what constitutes an economic difference could not be 
objectively defined. Therefore, cost differences were judged using an arbitrary measure 
of the cost of one antenatal visit to make conclusions about economic significance. The 
implication is that there was no sound basis for concluding whether or not economic 
differences existed, and therefore cost differences should be interpreted by those 
actually making decisions, as opposed to researchers not familiar with the decision 
making process. 
103 Except home visits in Cuba, of which there were at least five per woman. However, the trial managed 
to record all those home visits where an intervention was performed, such as blood pressure measurement, 
or formal advice outlined in the ANC model, and these were included as antenatal visits. 
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A third limitation imposed by the trial was that there were constraints to using the 
bottom-up costing method to calculate unit costs. The implication was that with no 
--../'/ 
patient-specific unit costs there was a missed opportunity for presenting cross-patient 
cost differences, and enhancing the analysis of cost variation. Several justifications were 
given for not using the bottom-up costing method in Mugford, Hutton and Fox-Rushby 
(1998). One significant factor preventing collection of unit cost data on individual 
patients was that to collect information on resource use measurement at the patient level 
would have required using either an outside. observer or detailed recording by the health 
." .... ;. 
providers. While such methods of costing are not unknown, the problem in this context 
was that data collection may have changed the behaviour of health providers in terms of 
quality or quantity of care, and it would have imposed data collection costs to the health 
system. Therefore, there was a risk that resource use measurement at the patient level 
could have altered trial health and economic outcomes. 
As well as the ANC trial structure, cost prediction results should also be interpreted in 
the light of the economic framework chosen, as results are often highly dependent on the 
types of cost included. The overall economic outcome, cost per pregnancy, consisted of 
antenatal, delivery, postpartum, and neonatal intensive care. In Chapter 1, the reference 
case was discussed as a means by which the comparability and generalis ability of cost-
effectiveness ratios are increased across health care settings (Luce et al 1996). In this 
thesis, the reference case was used as guidance for cost inclusions, but was not 
presented as defined by Luce et al. While all resource ingredients and health service use 
affected by the intervention were included to calculate cost per pregnancy, there were 
two main differences with the reference case. First, as mentioned above, home visits, 
use of private care, and long-term care costs were not included, and these were assumed 
to be similar between trial arms. Second, patient or wider societal costs were not 
included in the costs of pregnancy. While patient costs were included in the economic 
study alongside the trial, they were not analysed in this thesis as provider costs were the 
focus of the thesis. The policy implications are that, when costs of pregnancy are 
compared with the costs of other health care interventions using the reference case, the 
time horizon and range of services should be adjusted to be consistent with other 
studies, and patient costs and any wider societal costs should be added. 
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Using these costing boundaries, and based on assumptions previously described, 
average cost per pregnancy (ACPP) in Cuba was reduced from US$402 to US$372 per 
woman (7.5% reduction), in Thailand ACPP was reduced from US$106 to US$86 per 
woman (18.9% reduction). However, as previously stated, these cost savings may not be 
enjoyed in full until fixed resources are redeployed, such as being used by other patients 
who would benefit from them. Also, 95% confidence intervals showed costs not to be 
statistically different between trial arms in Cuba,and statistically different in Thailand. 
Given that the trial concluded that health outcomes were similar between trial arm 
.. ".-
.. 
(Villar et al 2000), policy makers are advised to adopt the programme in Thailand where 
there is a high chance of a cost saving, whereas in Cuba policy makers should be aware 
that a cost reduction is not guaranteed (at the 95% level). 
The debate so far has focussed on observed values. The question also needs to be 
addressed concerning the implications of cost predictions for policy making. Chapter 10 
presented the difference between observed costs and cost predictions, and it was 
concluded that decisions are likely to be affected by whether observed or predicted cost 
values are used. Even where cost predictions were concluded to be 'accurate', decisions 
may still change when predicted values are used instead of observed values. For 
example, the incremental cost impact method in Cuba was found to be 'accurate', but at 
least a US$57 saving was predicted, almost double the observed saving of US$30. In a 
hypothetical scenario, a decision maker may react to a US$57 saving per pregnancy but 
not to a US$30 saving per pregnancy. However, the true threshold at which the change 
in decision occurs is not known, and depends not only on the person making the 
decision but also how close to year end one is and what budget is left. Other cost 
prediction methods, such as the data transfer and multiple regression methods, were 
even more inaccurate than the incremental cost impact method. Therefore, while no 
overall conclusion is possible due to uncertainties about 'thresholds' at which decisions 
change when using different data sets, the findings of this thesis suggest that caution is 
required in using predicted costs in policy decisions where there are limited means of 
validating these costs. 
10.4.2 Wider implications for trial countries 
Three particular issues are discussed with respect to using the ANC trial cost results in 
nontrial settings within country, those of (a) the wider policy context of antenatal care, 
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(b) cost variability, and (c) cost generalis ability. The first is important, because the 
antenatal care trial may not incorporate all the issues faced by policy makers and how 
/ 
they might wish to use the results, or take into account the complexity of the decision 
making process. As mentioned earlier, the. trial countries and their he~th systems are 
classified as those belonging to middle- as opposed to low-income countries. Therefore, 
while they do not enjoy the same spending levels as richer countries, at least a minimum 
level of antenatal, essential obstetric, delivery and 'neonatal care is provided, and in 
some cases health care provision is above this. minimum (Piaggio et al1998). In fact, the 
, .. ". .: 
antenatal care trial has collected data that·· suggests over- or inappropriate use of 
resources - such as laboratory tests that are high cost and with limited benefit 
(especially Cuba), the use of obstetricians for some tasks that general practitioners or 
nurses/nurse midwives could perform equally well (Cuba and Argentina), high levels of 
inpatient admission in Cuba and Argentina compared to Thailand and Saudi Arabia, 
higher levels of caesarean section in Cuba compared to the other coutnries, and high 
levels of neonatal intensive care admission in Argentina compared to the other 
coutnries. While this variability in rates of health service use may reflect practice style 
differences (due to differences in perceptions of risk at health care provider and/or at 
national levels), it does suggst that some procedures are used more out of habit than 
medical need, thus pointing to the potential to reduce health service use in some 
settings. 
Recent events have meant that in three of the four trial countries, Ministries of Health 
are looking to cut costs or at least to rationalise services104• In this respect, the W.H.O. 
antenatal care trial results are of some interest to these countries. However, as the 
W.H.O. trial has shown, providing information on effectiveness is not sufficient to 
change policy practice. For example, external cephalic version to reduce the rates of 
breech presentation and CS were not practised widely in some trial countries, despite 
being an effective intervention (Villar et al 2000). Another issue relevant to all trial 
countries is that women in experimental clinics showed some concern about the number 
of visits being too small and the spacing between them too long (Villar et al 2000). 
Therefore, policy makers should take account of women's views in deciding whether to 
104 This is due to: economic crisis in Thailand; withdrawal of support by the Soviet Union in Cuba; and 
the under funding of public health services in Argentina 
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follow the recommended four visits for low risk women. Policy issues specific to 
antenatal care are discussed briefly for Cuba and Thailand below. 
In Cuba, despite the remarkable achievements in the health sector in terms of reduction 
in rates of all major disease categories and the equity in distribution of the benefits (Pan-
American Health Organization 2000), there is still potential for improving health service 
delivery in some if not all policlinics in the W.H.O. antenatal care trial. This is 
suggested in differences in staff productivity levels, and the fact that many of the 
.': '. . 
policlinics were not operating up to their 'quota of staff,' in terms of health staff and key 
administrative personnel such as accountants and statisticians. Also, the data showed 
that some equipment such as laboratory equipment and fridges have not been replaced 
for a long time (some are as old as fifty years), and given the current economic situation 
in Cuba it is unclear whether these are high priority to replace. 
In Cuba, the extent of changes in health service organisation through implementation of 
the W.H.O. antenatal care programme is not major. One finding of the trial was that the 
ANC programme could be implemented with no major changes to health care delivery, 
except for reduced antenatal visits and increased involvement of the obstetrician in 
visiting the family doctor clinics when a pregnant woman is booked for an appointment. 
Therefore, the ANC programme accords well with the current Cuban approach to 
antenatal care (Piaggio et alI998), in particular the focus on developing the relationship 
between the health care provider and the pregnant woman; information, education and 
counselling; risk assessment and referral; and the emphasis on accessible primary health 
care. In Cuba, maternity homes are still popular, and are used mainly for women from 
poorer households to reduce stress during the closing stages of pregnancy, those with 
nutritional deficiencies, and those needing bed rest. This does not go against the W.H.O. 
ANC programme, although the programme does not actively promote this concept. 
Finally, HN rates are very low in Cuba, with 1,468 HN -positive individuals detected 
between 1984 and 1996 (in a population of 11 million people), with a larger share male 
(Ministry of Health 1996). With the operation of the Cuban sero-epidemiological 
surveillance programme, it is unlikely that antenatal HN testing is likely to be a major 
policy issue. 
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In Thailand, the health system has gone through a massive upgrading during the early 
and mid-1990s due to economic progress, although since 1996 there has been a slowing 
--
of government spending on health sector infrastructure (Bureau of the Budget 1990-9). 
Maternal and child health has been one area to benefit from this llpgrading, with 
outpatient departments in all district hospitals for 'health promotion' (separated 
physically from general outpatient departments), consisting of ANC, family planning, 
school health outreach, and a well-baby clinic. Health centres, the lowest level of care, 
are managed by the planning departments of the district hospitals (up to ten health 
"'.", '":.' 
centres per district hospital). Health centres also provide ANC, but high risk women are 
referred to district or higher level hospitals using a detailed risk assessment form in the 
antenatal card. Like in Cuba, the author observed that the evidence-based medicine 
approach of the W.H.O. antenatal care programme accords well with the Thai interest in 
modem medicine at the individual and government levels (although traditional medicine 
is still practised), and the programme also fits in with the national focus on primary 
health care in Thailand. One issue Thailand faces, like most countries, is how to slow 
the spread of HNIAIDS. Given that roughly SO% of the 16,200 AIDS patients in 
Thailand in 1996 were male (Ministry of Pubic Health 1997), and that Khon Kaen 
province had 404 AIDS patients in 1996, it is likely that under 100 women in Khon 
Kaen province had AIDS, of which only a small percentage were pregnant. Given these 
small numbers, it is unlikely that antenatal testing would significantly impact the spread 
of the disease, and therefore is not a priority public health issue. However, for those 
women with identified HNIAIDS, reducing mother-to-child transmission using a short 
course of zidovudine and using alternatives to breast feeding is a feasible option in 
terms of cost (Dabis et al 2000). The impact of this policy on the average cost per 
antenatal visit and delivery would need to be examined. 
The second issue, that of cost variability, is important, because the conclusions 
concerning the strengths and weaknesses of cost prediction methods are based on the 
average values for each trial arm, and they do not reflect differences between 
randomised units within arm (see Tables 6.3, 7.4, and S.l). Therefore, at the individual 
health facility level, the conclusions about the accuracy of the cost prediction methods 
would change, with important implications for health service planning for health 
facilities that fall into the 'high cost' or 'low cost' categories. At the district level, policy 
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makers should identify whether more hospitals tend to fall into 'high' or 'low' cost 
categories, for budget-setting purposes. Therefore, policy makers need to collect data on 
~/ 
the characteristics of providers found in Chapters 6 to 8 that predict them as high or low 
cost (size, occupancy, staff productivity, . inpatient admission rate, CS rate, neonatal 
admission rate). 
The third issue, that of cost generalisability, concerns what differences may exist 
between trial and nontrial settings· within Cuba. and Thailand to reduce the 
.': .... 
generalisability of the trial results. For the incremental cost per pregnancy results to be 
the same in other settings within study countries, three assumptions must hold: 
• The rest of the country provides ANC in a similar way to the control group in the 
trial (and therefore has similar unit costs and health service use). For example, if 
quality of care is lower in other settings, average costs may rise in implementing the 
W.H.O. programme. 
• The WHO programme is implemented successfully, in a similar way to the trial. For 
example, costs would not be the same if hospital managers adapt the programme to 
suit their own resource availability. 
• Costs associated with the new programme, such as training costs, initial monitoring 
costs, and friction costs of changing staffing patterns, are short-term and not 
substantial. This assumption is important, because these costs were excluded from 
the costs reported in Chapters 6, 7 and 8. 
Therefore, in order to examine whether these assumptions are likely to hold, the 
representativeness of the health facilities in the study countries should be considered. 
Clinics were chosen that met a set of criteria. Table 10.1 lists these criteria which 
include both scientific criteria, such as adequate sample size and follow-up, as well as 
pragmatic criteria, such as the ability of the clinics to implement the new ANC 
programme. It was also important to have high institutional delivery rate, so that data 
could be collected for a high proportion of women without incurring expenses 
associated with follow-up at home. Criteria 1-4 relate to the ability to perform a 
scientific study; criteria 5-8 relate to the generalis ability of the results, and therefore 
other health facilities within country should be compared using these final four criteria. 
277 
Table 10.1: Criteria for clinic selection for WHO antenatal randomised controlled trial 
Criteria 
1. Each clinic should be able to provide at least 300 new patients in a period not longer than 24 months. 
2. Intervention and control clinics will be in the same geographical area, but serving distinct 
neighbourhoods. 
3. All women from these ANC clinics will be traceable at delivery. 
4. The follow up mechanism will have access to the hospitals which are the referral place for all high-
risk patients. . 
S. The clinics should be part of a public (or semi-public) ANC system. Military hospitals or social 
security institutions are also eligible. The study will not inchide clinics where direct fee-for-service 
payments are required. 
6. All clinics should have an ANC system already in place with norms and predefined activities which 
are followed. . : .... 
7. The clinics should be able to implement new simple tests or activities as required by the protocol. 
Funds for these new activities should be provided by the institution(s), as they will be for direct 
patient care only. These few new activities will replace several currently implemented. 
8. The clinics should have an already working and economically supported minimum staff required for 
patient care as per the protocol. 
(taken from Villar et a11998, page 34) 
In Cuba, policlinics are part of a public health system, where budgets are allocated 
according to standard criteria, although some inter-regional variation has been found in 
rates of resource use from government documents. In Havana city, a rate of one doctor 
per 111 inhabitants was the highest in Cuba, dropping to one doctor per 251 inhabitants 
in Granma province (Ministry of Health 2000). There was less variability for nurses, 
with one nurse per 117 inhabitants in Havanna, varying between 100 and 167 in the rest 
of Cuba. In terms of numbers of policlinics, Havanna contains 20% of the population 
and 19.3% of the policlinics, and therefore the inhabitants in Havanna are not better 
served than the rest of the country (although average distance to a policlinic will be less, 
due to the density of the population of Havanna). In Havanna, the inpatient admission 
rate for obstetrics of 3.5 per 100 female inhabitants between 15-49 years was close to 
the national average of 3.3 (variation between provinces of 2.2 to 4.5), while for 
neonatal admission rates the rate of 22.1 admissions per 100 live births was just above 
the national average of 20.7 (variation between provinces of 10 to 30). Therefore, these 
comparisons suggest that average cost per pregnancy may be slightly higher than in the 
rest of Cuba, due to higher resource and health service use rates, although at the 
provincial level there is some variation. 
Like in Cuba, the participating health facilities in Thailand were part of a public system, 
where budgets are also allocated according to standard criteria. In fact, a visit was made 
by the author to Southern Thailand, where three district hospitals (one small, one 
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medium and one large) were visited. These hospitals were found to be remarkably 
similar in terms of staffing patterns and activities when compared with hospitals from 
Khon Kaen province. In terms of inter-regional resource comparisons, the Northeast 
Region rates the worst in Thailand. In 1994·there were 941 inhabitants per physician in 
Bangkok compared with 10,900 inhabitants per physician in the Northeast, compared to 
a country average of 4,192' inhabitants per physician, thus showing considerable 
inequality in distribution (Ministry of Public Health 1997). On the other hand, Khon 
Kaen province was closer to the country ~verage, due to the location of the regional 
.' . ~. .'. . . 
hospital in Khon Kaen city 1 05 • A second iss~e is that di~trict hospitals only account for 
about 50% of antenatal care provision in Thailand, with health centres and referral 
hospitals providing the rest. While referral centres were included in this study, unit costs 
and average health service use were not measured at health centres. This has 
implications for whether the cost per pregnancy figures reflect costs at other levels 
where patients receive care. Thus without further cost studies or collection of published 
evidence, the generalisability of the results to health centres is limited. Given that the 
variability reported reflects women reporting to district hospitals, the implications are 
that cost per pregnancy may be different at other levels of care. For example, at health 
centres in Thailand, the inpatient admission rate and institutional delivery rate may be 
lower due to less geographical access to hospitals. 
10.4.3 Implications for South Africa 
In addition to the detailed cost prediction exercise and validations between Cuba and 
Thailand, this study benefited from cost analysis and prediction in a third setting in 
South Africa. Not only did the setting in South Africa allow further cost comparisons 
and cost analyses, but also in the absence of data from a trial, issues in cost prediction 
were made more 'real world'. The last chapter suggested that the best estimate of the 
impact on cost per pregnancy of the W.H.O. programme in South Africa should be taken 
from the results of the incremental cost impact method, as the Cubaffhailand analysis 
found the ICIM to be the most reliable. Therefore, in the base case ACPP was predicted 
to increase by US$5.65 (-US$lO to US$24), leading to an ACPP of US$352.65 
(increase of 1.6%). This increase in cost per pregnancy suggests that the point estimate 
of the cost-effectiveness ratio enters a different cost-effectiveness 'quadrant' to that of 
lOS 1996 data show that Khon Kaen province has 3.6% of physicians in Thailand compared to only 2.8% 
of the population (Ministry of Public Health 1997). 
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Cuba and Thailand (Wakker and Klaasan 1995, Laska et al 1997). However, given that 
the new programme may also involve a US$1O saving per pregnancy (the lower 
/ 
confidence limit), the cost-effectiveness ratio is not entirely in a different quadrant. 
Added to uncertainty in incremental cost, the health impact of the W.H.O. programme is 
uncertain. Although it was not the purpose of this thesis to predict cost-effectiveness in 
South Africa, it could be speculated that with successful implementation of the W.H.O. 
programme the primary health outcomes are reduced to nearer the levels in Cuba and 
Thailand (see Appendix 16 Table 16;"2). For example, urinary tract infection may be 
,"; .', 
treated earlier thus reducing severe UTI rates to below 10% from 16%; postpartum 
anaemia prevalence may also be reduced to below 10% with improved compliance with 
iron folate supplementation and dietary advice. However, this assumes that the antenatal 
care programme changes the behaviour of both patients and health care providers. 
This discussion about effectiveness is particularly important for decision makers in 
South Africa due to the uncertainty surrounding whether costs will increase or not, 
because if health outcomes can also be improved, it could be argued that the additional 
cost is worth it. Also, there may be some interactions between effects and costs: 
improved health may lead to lower costs (Willke et al 1998). In addition to these issues, 
the base case cost results must be interpreted with caution, given that (a) the base case 
difference is not economically significant, being less than the cost of an ANC visit; (b) 
there is uncertainty about the true impact on health service use, unit cost and morbidity, 
due to the assumptions inherent in the ICIM; (c) the ACPP of US$347 in the control 
group does not reflect the full pregnant population, due to the hospital-based sample, not 
taking into account the estimated 20% of births that take place at home, as well as a 
proportion in clinics; and (d) other issues such as initial investments and quality of care 
improvements are not considered (this issue is covered in section 9.6). In addition to 
these issues, there are several current policy issues in South Africa that concern 
antenatal care, but are not raised in the W.H.O. antenatal care programme, or are raised 
in a limited way. These are: abortion care, fertility regulation, HN/AIDS, access to care 
and other factors affecting health service use, and the main obstacles facing health 
services in improving the quality of maternity care in South Africa. 
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Abortion was illegal in South Africa until 1996. In 1994 there were estimated to be 
200,000 unsafe abortion in South Africa, with Rands 9.74 million (US$1.4 million) 
~-
spent on treating women with unsafe incomplete abortions (Kay et al 1997). With the 
1996 law Choice on Termination of Pregnancy, this cost should be significantly reduced 
assuming abortion services are accessible, acceptable and that there exists public 
awareness about their availability and safety (Kay et al 1997)106. Antenatal care could 
provide an opportunity for informing women of their rights with respect to abortion. 
However, as few women who are planning to have an abortion are likely to attend 
,' .. ' .. " 
- . . 
antenatal care, the information may be used for future pregnancies. ---
Second, fertility regulation is being promoted as an important right of people living in a 
new democracy such as South Africa, whose main aim to reduce unwanted and teenage 
pregnancies (Health Systems Trust 1996). Antenatal care is also an important time to 
promote fertility regulation measures, and therefore specific advice would need to be 
incorporated into the antenatal care programme outlining' the available and 
recommended options for contraception that are relevant in South Africa. 
Third, from recent research studies that measured HIV prevalence in antenatal attenders, 
the true scale of HIV I AIDS is being measured in South Africa. Research studies have 
shown that in some areas, roughly one in three pregnant women are affected by the 
virus. Antenatal care presents several opportunities to reduce transmission and improve 
health outcomes, assuming those found to be infected change their behaviour and do not 
knowingly put others at risk. These include testing and counselling, information and 
education about the disease, advice about safe sex, and finally reducing mother-to-child 
transmission during and after childbirth (as discussed for Thailand above). The 
feasibility and affordability of these strategies are not known exactly, but certainly there 
is potential to reduce infection rates. However, it is recognised that many of these 
strategies might not work without men also being informed and educated, and changing 
their attitudes and behaviour. 
106 This figure of 200,000 unsafe abortions in 1994 is significatly higher than the official number of 
abortions in South Africa in 1997 (29,326 abortions) and 1998 (40,568) reported by the Health Systems 
Trust, suggesting the data from these two data sources are not comparable. 
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Fourth, there is a need to improve the timing and rates of use of health services in South 
Africa, to move towards those recommended by the W.H.O. ANC programme. First, 
despite free antenatal care services, gestational age at first visit is, on average, very late 
in South Africa, with 70% of people of African origin reporting after 6 months of 
. . 
pregnancy (from a recent Household Survey of Health Inequalities in South Africa). 
Numbers of visits for many is well below four and home deliveries are still common. 
However, health service use is affected by several factors simultaneously, and the exact 
contribution of individual factors is not kno;.vn (e.g. distance from the clinic, availability 
of transport, availability of 24 hour serVi6e~, etc), making it difficult to identify and 
implement effective policy measures. 
Fifth, there are numerous problems with the health services, including lack of basic 
resources in health centres (up to half health centres in North and Northwest Provinces 
had inadequate water, electricity, washing facility, and building structure (Fonn et al 
1998)), poor management, low salaries and demotivated staff, and staff shortages. In 
many areas, 24 hour health services have been suspended due to security problems; also 
patients do not use them sufficiently due to transport problems getting to clinics during 
the night, and operational problems in the clinics (Ramdas et al 1996). Clearly the 
potential of the W.H.O. ANC programme to improve health outcomes is reduced unless 
these problems are addressed. 
In conclusion, the discussion above has highlighted several important issues to consider 
when predicting the costs of the W.H.O. ANC programme in South Africa. Therefore, in 
using the results of the cost study and cost prediction exrercise, it should be recognised 
not only that several issues with cost implications need to be considered, but also that 
the sampled health facilities do not reflect all health care settings, nor the health service 
use rates reflect the entire population of South Africa. 
10.4.4 Implications for other countries 
The cost implications of the new ANC programme for other developing countries is a 
key question that this thesis raises, and several issues relating to this question are 
discussed below. One questions concerns whether costs are likely to be similar to the 
countries of this study. This depends on which other countries are being considered. 
Caution was recommended in Chapter lOin using average trial data on health service 
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use and unit costs to predict the costs of the W.H.O. programme in lower-income 
countries, due to differences in key cost variables. Trial countries wer~ chosen for the 
~' 
principal reasons that (a) there was a minimum level of antenatal care in place to act as 
the comparison group, (b) appropriate care could be provided w~en women are 
identified as needing inpatient care or caesarean section, and (c) there existed an 
infrastructure (researchers, facilities and data systems) for high quality research. 
Therefore, not only did these criteria exclude most low-income countries from 
participating, but they also reduce theappli~ability of the trial results to these countries, 
" . 
. '. . . . 
as they are likely to have different resource use, resource price, and morbidity levels. 
While a detailed assessment of the generalis ability of the cost or cost-effectiveness 
results to low-income countries was not within the scope of this thesis, the case study in 
South Africa gave some indication of issues that must be addressed in predicting cost 
impact in non-trial countries. It is likely that unit costs will vary between study countries 
and lower income countries, although unit costs are not necessarily lower in low-income 
countries107• The impact on average costs of the W.H.O programme is unclear without 
knowledge about the resource availability and efficiency levels of specific health 
facilities. Also, it is not known whether the adoption of the W.H.O programme would 
change efficiency levels through affecting staff motivation or returns to the variable 
factor through higher uptake of health services. Average costs would be expected to be 
lower in low-income countries, due to lower wage rates as well as lower drug and 
equipment costs for goods manufactured in the local economy (valued in US$ using 
nominal exchange rates). However, without a detailed break down of the resource use, 
prices and content of ANC, the impact of the W.H.O. programme on average costs 
cannot be predicted. Also, access to services may be much lower in low-income 
countries, thus reducing health service use, especially caesarean section and neonatal 
admission. This should be balanced with possibly more ANC visits received at the home 
of the patient, provided by traditional birth attendants or midwives. However, other 
African countries may be faced with a different set of policy issues or different levels of 
107 For example, an outpatient antenatal care visit in 1998 prices was found to cost between US$1.56 and 
US$4.30 in Uganda (Levin et al 1999), US$6.01 in Ecuador (US$3.35 in 1996 adjusted by two years of 
the average annual inflation rate of 34%), and US$14.9 in Mexico (US$7.19 in 1994 adjusted by the 
average annual inflation rate of 19.9%). In The Gambia average costs varied between US$I1.37 and 
US$27.5 (US$8.3 and US$20.1 in 1991 adjusted by an average annual inflation rate of 4.6%). It should 
..... 
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priority to those issues discussed for study countries, and therefore careful local 
interpretation of the W.H.O. antenatal care programme impact is required. 
~ 
A second key question relates to whether the same results concernin~cost prediction 
methods would be found in other developing countries. As discussed above, unit costs 
and health service use rates "are likely to differ, therefore direct and adjusted transfer 
methods are unlikely to be accurate. Regression analysis is also very unlikely to yield 
accurate predictions, especially for C"ountries with different health service use and 
. '. ~ . "; . 
morbidity rates. Therefore, some form of the incremental cost impact method would 
need to be applied to give the most reliable, although not necessarily accurate, cost 
predictions. As previously mentioned, highly detailed data are needed to make an 
ass..essment of the expected impact on average costs, morbidity, referral rates and health 
service use. Therefore, in the absence of these data, rates will need to be assumed, from 
consultation with experts where possible, although efforts should be made to collect 
reliable data and not rely on assumptions or unreliable data. One important finding 
presented earlier that international agencies should note is that GNP per capita (at either 
nominal exchange rates or PPP) does not reflect the mean ACPP well 108 • This 
contradicts some views expressed in the literature, that cost magnitude is largely related 
to GNP per capita (Tinker and Koblinsky 1992, Barnum and Kutzin 1993). In this 
respect, Murray et al (2000) appear to support the view that broad generalisations should 
not be made based on one indicator such as GNP per capita, stating that countries 
should be grouped for estimating costs based also on region, public/private splits in 
health care financing and provision, and burden of disease. The conclusions of this 
thesis would support the Murray et al view, and in the context of public health facilities 
the cost prediction results in this thesis can potentially contribute to future work on 
grouping health facilities and countries. 
A third key question concerns whether the W.H.O. guidelines are affordable in lower-
income countries, and raises the point that alternative models of service provision may 
be recognised, in interpreting 1998 cost figures, that the average annual inflation rate used to adjust prices 
before 1998 may not reflect the inflation rate of health services. 
lOS Not only was Cuba found to have a high cost per pregnancy compared to its' relatively low GNP per 
capita, but also Thailand had a relatively low cost per pregnancy compared to South Africa despite similar 
GNP per capita levels. However, note that these cross-country comparisons are based on the exchange 
rates underlying them. 
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need to be considered, as suggested for Safe Motherhood programmes (Koblinsky et al 
1998)109. Therefore, alternative ways of providing care must be sought, not only to make 
/-
the minimum package more affordable, but to be relevant for local systems in term~. of 
practice patterns and staff availability. For example, the infrastructure may not currently 
exist for all women to deliver their babies in secondary hospitals, and attendance by 
midwives or traditional birth· attendants at home deliveries may be more appropriate. 
Therefore, cost predictions should be made based on s'eparate consideration of unit costs 
and health service use, and thus provide justification for the decision on whether costs 
,": ,';', 
can or cannot be transferred. 
A fourth key question concerns what other implementation issues affect the 
generalisability of the results from Cuba and Thailand to low-income countries. First, 
high gestational age at first visit and inaccessible services means that the four-visit 
minimum will not be achieved for many women. In the light of this, a rethinking of the 
recommended location, timing and contents of each antenatal visit is needed. For 
example, mobile clinics may be a viable although possibly expensive alternative (Fox-
Rushby and Foord 1996). Second, rates of CS and inpatient admission are currently very 
low in most African countries, although rates vary by region and rural/urban location. 
Recently the international community has focussed on essential obstetric care (BOC), 
with the implication that the rates observed in W.H.O. trial countries are not expected to 
occur, or even desirable, in lower-income settings (Koblinksky et al 1999). The EOC 
approach reflects more the difficulties faced by most developing countries, as opposed 
to reflecting best practice. The implication of the EOC approach where routine care is 
minimal is that most pregnant women will have minimal or zero health service cost (if 
they have a home delivery), but a minority will have high health service cost (inpatient 
stay and hospital delivery), thus leading to different cost distributions to those found in 
this study. Third, the realizable impact on health outcome will not be achieved without 
compliance with quality standards, but this will impact unit costs110. Fourth, in addition 
109 The expectation of the unaffordability of the W.H.O. programme is supported by evidence from 
Uganda, where cost per capita of the W.H.O. Mother-Baby package was compared with the costs of 
current care, and it was found that spending would have to increase by about 3 times US$1.80 per capita 
per year to provide care according to the W.H.O. Mother-Baby package recommendations (Weissman et 
aI1999). . 
110 One previous study, Ogunbekun et al (1996) assessed the feasibility and cost of improvements in the 
quality of reproductive health services through the Bamako initiative in Nigeria. Current practice and 
guidelines were compared to assess cost implications, and investment required, and prioritisation was 
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to estimating the likely incremental cost of the W.H.O programme, estimates would be 
needed of the required investments and time periods for implementing the new 
programme, due to the constraints imposed by annual budgets for maternity care 
spending. Also, the feasibility of changing the clinic operations al~o needs to be 
considered, such as the opening hours, appointment system, and patient card system, 
before policy is made, and whether changes fit in with other health policy aims. 
In conclusion, to allow calculation of cost-effectiveness ratios for ANC and delivery 
," :' 
care, more research on alternative means of providing care (with economic components) 
will be necessary in low-income countries. Due to the cost variation shown in this 
thesis, these trials should be both multicentre and multinational, with provisions to 
examine heterogeneity between centres. This viewpoint supports the Willke et al (1998) 
finding of large differences between country in case cost, and goes some way to 
answering the question raised by Johnston et al (1999) over whether cost data need to be 
collected in all centres in a multinational trial. In addition to clinical trial research, more 
research is needed to understand determinants of cost (as a first step) and to predict 
costs in specific settings, as well as at the generalised country or regional level 
suggested by Murray et al (2000) (as a next step). While some variables were concluded 
to explain cost variation, there was also unexplained variation which needs further 
examination. This will allow further conclusions about the causes of cost behaviour in 
different settings and for different health interventions, and therefore suggest to policy 
makers the likely cost variability in clinical protocols (such as those published by the 
W.H.O.) implemented in different settings. In order to improve the accuracy of cost 
predictions, key components (prices, resource use, and health service use), cost profiles, 
and cost determinants (economies of scale, efficiency, occupancy, case-mix, referral 
rate, hospital level) should be collected and reported routinely. 
made of the most critical items to make the initiative work. Quality improvements involved increased unit 
costs, for example, of up to 40% for delivery care. 
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11 CONCLUSION 
11.1 Summary of thesis 
The aims of this thesis were to identify and test alternative methods for analysing and 
predicting health care costs, to construct a framework for guiding analysts in predicting 
costs, and to identify future areas of research in this area. A related aim of this thesis 
. was to understand why cost generalisations between health care settings might be 
inaccurate. With the thesis aims and context in mind, objectives for the literature review 
. . '. ~ . 
and data analysis were chosen in Chapter 1. The objectives of the literature review were 
to critically review the current literature on: the contribution of economic theory to 
understanding health care costs; the methods of cost analysis for understanding cost 
determinants and explaining cost variations; the empirical evidence for factors 
explaining cost variations; and to identify alternative cost prediction approaches. The 
literature review chapters therefore served to build frameworks for analysing and 
predicting health care costs for use in the thesis, and to provide a context within which 
to interpret the results. 
The objectives of the data analysis were to: estimate health care costs associated with 
pregnancy and childbirth in study settings; understand cost determinants and behaviour; 
evaluate the robustness and generalisability of costs; and test alternative methods of 
predicting costs. Using the results of these data analyses, a series of issues to consider 
when making cost predictions were discussed, and recommendations for researchers and 
policy makers drawn up. How this thesis achieved these literature review and data 
analysis objectives is described below. 
Chapters 2 to 4 reviewed the literature. Chapter 2 summarised the production and cost 
functions underlying health care processes, defined different aspects of efficiency and 
outlined the economic relationships driving health care production and costs. The 
implications for cost behaviour and interpretation under breakdown of neoclassical 
assumptions were examined. Several factors were found that may cause unit costs to be 
different to. what they would be under perfect competition: the presence of X-
inefficiency in public sector organisations, economies of scale, the lack of perfect 
information, and barriers to closure of public hospitals or demand uncertainty leading to 
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over-capacity. Also, variations in resource prices, case-mix, input mix and quality of 
care were concluded to be likely causes of unit cost variations between health care 
providers. 
Chapter 3 reviewed cost analysis methods used in the health care literature. Several 
studies were found that reviewed alternative cost analysis approaches. Theoretical 
foundations and methodological developments were generally more developed for 
statistical methods (regression analysis .~d data e~~elopment analysis) than for 
accounting methods. In order to provide a framework of cost analysis using accounting 
methods, several approaches were distinguished from the literature: cross-setting data 
substitution; cost profiles; efficiency scores; 2-way relationships; and output profiles. 
The advantage of statistical methods over accounting methods was that statistical 
methods take into account the impact on unit cost of several variables simultaneously. 
However, statistical methods required more data points (many time periods or many 
health facilities) compared to accounting methods. In general, all methods required cost 
data to be dis aggregated to allow an understanding of costs. The chapter concluded that 
the cost analysis methods identified are generally complementary, as they can be used in 
combination to understand cost behaviour more fully. 
Chapter 4 critically evaluated empirical. evidence on several factors hypothesised to 
determine cost identified in Chapter 2. The review found few studies that 
comprehensively evaluated all factors hypothesised to cause cost variations, or that used 
the full range of cost analysis methods, although many examined various factors in 
isolation. Two main components of cost of particular relevance for the thesis were 
distinguished (together contributing to total cost): health service use and unit costs. 
Determinants of health service use were divided into patient factors and provider 
factors, and the empirical evidence from the developing country maternity care literature 
was reviewed. Although few studies made conclusions about the exact impact of each 
factor on health service use, some impact was identified using quantitative methods. 
Determinants of unit cost were also examined. Again, few studies drew exact links 
between each factor and unit cost, and the evidence was mixed for many of the factors 
(such as economies of scale) or insufficient to make conclusions (such as quality of 
care). Measurement problems of some factors was discussed (such as for X-inefficiency, 
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economies of scale, case-mix and quality of care). Therefore, this chapter provided a 
valuable basis from which to plan which factors to focus on, and how !o interpret the 
results. The review on causes of cost variation and analysis methods helped identify 
alternative ways to make cost predictions, and these were described wit~ examples from 
the literature. 
, 
Chapter 5 presented the empirical context of the 'thesis, empirical objectives, data 
requirements, data sources and data inaly~is methods. The main data source for the 
., .. , . ,.:., 
thesis were the clinical and economic components of the W.H.O. antenatal care trial, 
which was conducted in settings in four middle-income countries. Two of these, Cuba 
and Thailand, as well as a non-trial country South Africa, were the focus of this thesis. 
First the methods of data collection alongside the trial were described (with reference to 
publications from the trial), followed by a description of the sensitivity analysis, and 
finally the methods of data analysis. The cost analysis framework was described as 
consisting of cost comparisons at four 'levels' relevant to the study settings: between 
groups of woman based on case-mix; between health facilities; between trial arms; and 
between countries. Costs comparisons were described and justified in non-monetary 
(resource use and health service use) and monetary (unit costs and cost per pregnancy) 
units. Data analysis methods include identifying statistically significant cost variations, 
examining causes of cost variation, and finally predicting costs using alternative cost 
prediction methods. 
In the recognition that cost analysis in non-monetary units can provide useful 
understanding of costs before valued in monetary units, Chapter 6· presented and 
analysed health service use and resource use data. Significant variation was found 
between individual health facilities in both health service use and resource use, thus 
suggesting that the trial arm a woman receives care in is not the major predictor of cost. 
The analysis found that there were multiple determinants of health service use, including 
patient costs, case-mix and practice style. The analysis of resource use was found to be 
valuable in providing information about the main cost drivers and the requirements for 
health care, and some inter-health facility differences were found in staff productivity, 
drug use, equipment lists, and building space. 
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Chapter 7 presented and analysed unit cost variation to understand causes of unit cost 
variations. Health facilities were found to vary significantly in tenns of resource use 
quantity as indicated by staffing ratios, technical efficiency scores (from DEA), input 
mix, and scatter plots (for economies of scale). The results showed that ~taffing patterns 
were the main determinant of average cost, due to the high proportion of cost accounted 
for by salaries. Variations in staffing patterns were concluded to be more related to non-
patient factors within country (which includes variation in management practice), than 
patient (case-mix) differences. Drug costs.a~ a proportion of unit cost were found to 
,", .... 
vary within and between countries (due partly to case-mix differences). Prices were also 
different between countries, but were found not to explain much or any of the unit cost 
differences. Differences in uncertainty between country also changed the cross-country 
unit cost variations under certain assumptions, especially alternative values for the 
opportunity cost of staff, and the conversion factor to present costs in US$. Finally, 
some aspects were not examined in sufficient detail to allow conclusions, including the 
impact of quality of care differences on unit costs, and the presence of economies of 
scope. In conclusion, the large differences within and between countries in unit costs are 
a warning that unit costs cannot easily be generalised, at least not without making 
adjustments for known differences between settings. 
Chapter 8 combined the results of previous chapters to understand variations in cost per 
pregnancy and also presented the results of new cost analyses. The large inter-setting 
variations in unit costs and health service use both contributed to large variations in cost 
per pregnancy, both within and between countries. Also, the results of the 2-way 
comparisons and regression analysis contributed to an understanding of the factors or 
variables most likely to influence average cost per pregnancy. Health service use 
differences were largely responsible for the cost per pregnancy variations in all 
countries, especially caesarean section and neonatal admission. Also, some risk factors 
and events during pregnancy, delivery and postpartum were significant predictors of 
cost. While some of these were significant in all three countries, the percentage impact 
on cost was different (due to different unit costs) thus suggesting non-generalis ability of 
coefficients across countries. The large variability in cost per pregnancy between health 
facilities suggests that in predicting cost it is important to identify whether a health 
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facility is a high, mid or low cost provider, and which ANC programme is being 
providing. 
Chapter 9 tested a range of cost prediction methods, and compared the .cost predictions 
with observed costs. While all the cost prediction methods gave some accurate results 
(especially cost transfer between Cuba and South Africa), the incremental cost impact 
method was found to be the most reliable in that cost per pregnancy and incremental 
costs were accurate in both countries .. The adjusted transfer method was found to work 
between countries with similar unit cost' and health'~ervice use levels, and where 
adjustments could be made for identified differences. Cost prediction using regression 
models gave predicted cost less than observed cost in all countries, and cross-country 
predictions gave similar results to the direct transfer method. As the incremental cost 
impact method was concluded to be the most reliable cost prediction method, it was 
used as the base case in South Africa, where a small cost increase was predicted under 
the W.H.O. programme (although the range of predicted cost covered zero). Due to 
larger cost impacts, the incremental cost impact method was thought to be less reliable 
in lower-income countries, as there would be wider ranges on the mean values due to 
greater uncertainty about the cost and health status impact of the W.H.O. programme. 
Finally, Chapter 10 discussed issues relevant to cost prediction. First, several choices 
that must be made by the analyst in predicting costs were clarified. For example, the 
analyst must define the type of cost required, the data sources, and the relevant measure 
of central tendency. Also, how resources are valued nationally and internationally is 
critical to the accuracy of the cost prediction, and the interpretation of the results. 
Second, as the definitions of accuracy and economic significance were central to 
judging the success of cost prediction methods, these definitions were critically 
evaluated and alternative ones proposed. For this reason, it was recommended not to 
judge a cost prediction method based on a single criterion, but instead using a range of 
measures, and determinants of performance. Third, the role and limitations of cost 
analysis was discussed, in terms of both the shortcomings of the analytic options to 
analyse costs, and why some cost variation remained unexplained. The limitations of 
cross-country cost analyses were discussed. In particular, currency conversion, the use 
of a static framework and cross-country heterogeneity of inputs and outputs were cited 
~. 
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as reasons why cost differences should be interpreted with caution. Finally, issues for 
policy makers to consider when generating and using cost prediction results in planning 
maternity services were discussed, and included the direction of impact on health 
outcomes, and changes required to the health system to implement the programme. The 
cost results were discussed in the context of current antenatal care policy issues in the 
study countries. Not only was cost variability mentioned as a cause for caution when 
predicting costs, but also the possibly increased inaccuracy when predicting costs in 
lower-resourced settings, where unit costs, ~ealth service use, and cost determinants are 
,', "' . 
. . 
likely to be different to study countries, and also there exist some constraints to 
implementing the W.H.O. ANC programme in its' original form. 
11.2 Thesis conclusions 
To date, few studies have taken a comprehensive approach to analysing and predicting 
costs, which is part of the reason why cost generalis ability has not been explored in the 
depth that it deserves. The conclusions of this thesis cover empirical, methodological 
and policy issues, and are aimed at both researchers in terms of the methodology and 
focus of future research, and policy makers in terms of implications for resource 
allocation. 
Empirical conclusions 
[J Magnitude of unit costs. The most expensive type of maternity care (per health 
service use) in all countries was caesarean section, followed by neonatal intensive 
care (per day) in Cuba, and vaginal delivery in South Africa and Thailand. However, 
the hospital stay following caesarean section in Cuba and South Africa (ALOS = 7 
days) was more costly than CS itself. 
[J Profiles of unit costs. Staff costs were consistently the highest resource contributor 
to unit cost in all countries and for all types of care (>58%), except CS in Thailand 
(29% average). Drug costs were also a significant resource contributor for outpatient 
ANC in Cuba (38% average). Technical support (all support departments providing 
direct services to health care departments except laboratory) contributed towards 13-
30% of unit costs in Cuba and Thailand and <10% in South Africa, followed by 
administration costs (4-8% in all countries). Laboratory costs contributed towards 4-
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13% of unit costs in all outpatient departments, except 47% in America Arias 
hospital in Cuba. 
Q Profiles of cost per pregnancy. Antenatal care consistently took less than 42% of 
cost per pregnancy in all settings (as low as 17% in South Africa), leaving the rest to 
inpatient care during pregnancy (up to 19% in Cuba), delivery care (up to 38% in 
South Africa), postpartum care (up to 19% in Thailand), and neonatal care (up to 
22% in Cuba). 
Q Variability in cost per pregnancy~' Co~ts varied significantly between randomised 
. . ~ 
health facilities both within and between countries. For example, cost per pregnancy 
within the intervention arm policlinics in Cuba ranged from US$298 to US$504. 
Between countries, cost per pregnancy in the intervention arm ranged from US$86 
in-Thailand to US$402 in Cuba, at nominal exchange rates (at purchasing power 
parity the costs were US$167 and US$989, respectively). Cost per pregnancy was 
positively skewed in all health facilities and countries. 
Q Impact of uncertainty. Unit costs were found to be relatively robust to most sources 
of uncertainty, except valuation of staff cost, and the currency conversion method. 
Threshold analysis showed that only minor reductions in health service use in the 
intervention arm in Cuba would have been necessary to generate a result of 
significant difference between trial arms (a 1 % lower CS rate or 0.2 antenatal visits 
less per woman in the intervention arm). 
Q Causes of unit cost variation. A multitude of factors was found to be responsible for 
unit cost variations between settings. Unit cost variations reduced when staff 
productivity and occupancy rates were standardised in all health facilities within 
country. Also, economies of scale were suspected in Cuba, but evidence was weaker 
for Thailand. Between countries, price differences were not found to be the main 
cause of cost variation. 
Q Causes of cost per pregnancy variation. Both unit cost and health service use 
variations were responsible for cost per pregnancy variations. Regression analysis 
found several characteristics of patients that determined cost per pregnancy, 
although there was limited consistency in significant predictors between countries. 
Q Cost per pregnancy prediction. Most of the cost prediction methods gave accurate 
predictions between Cuba and South Africa, due to the similarities in unit costs and 
health service use between these two countries. However, cost predictions using 
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transferred data were generally inaccurate in Thailand. The only method that was 
consistently accurate for all countries was the incremental cost impact method. 
,,/ 
Methodological conclusions 
o Cost inclusion. When comparing, predicting, or generalising costs between settings, 
it should be made clear which costs are included and why, and how this compares 
with current economic evaluation standards (such'as the reference case). 
o Cost presentation. Cost presentation and tabulation are important in understanding 
., . .': -, .:~ , 
cost determinants before more complex analyses are undertaken. Therefore, for both 
those conducting economic evaluations alongside clinical trials and those predicting 
costs using trial data, it is important to distinguish between unit costs and health 
sety'ice use. Also, confidence intervals and measures of central tendency provide 
useful additional information. 
o Cost measurement. Cost measurement alongside a randomised clinical trial was 
found to have some disadvantages (such as constraints to collecting unit costs on 
individual patients due to interfering with health care), but these were thought to be 
outweighed by the advantages, the main one of which was the availability of data 
from the trial data forms on health service use per patient. 
o Cost robustness. Uncertainty in some key areas was shown to influence costs 
significantly, and therefore a detailed sensitivity analysis should be done and the 
results consulted before costs data are generalised or conclusions made about 
predictive accuracy. 
o Cost analysis. A range of cost analysis methods should be used when trying to 
understand cost behaviour. If statistical methods are used, the results should be 
interpreted in the light of the findings of cost analysis using cost profiles and 
sensitivity analysis. However, the range of options for cost analysis is highly 
dependent on the data sets available. Also, there exist constraints in measuring some 
relationships in the health sector predicted by economic theory. This is due to data 
deficiencies, measurement error, and constraints in cross-country cost analysis. 
o Cost prediction. The more reliable forms of cost prediction can only be undertaken 
when data are available to examine or model differences between settings (adjusted 
transfer method), to assess the likely cost impact (when using the incremental cost 
impact approach), or to conduct a regression analysis. Conclusions about the 
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perfonnance of the cost prediction methods depended critically on how 'accuracy' 
and 'economic significance' are defined. 
/' 
[J Currency conversion. Both national and international policy makers should be 
careful not to generalise resource price or unit cost data across borders without 
taking into account differences in price levels between countries, which is partially if 
not totally taken into account in the purchasing power parity measure. 
[J A set of prescriptive guidelines for making cost predictions cannot be drawn up until 
further work has been conducted to test other cost prediction methods and compare 
..... . 
findings with this study. However, the choice of c~st prediction method is highly 
dependent on which type of cost is being predicted, the relative importance of the 
cost prediction, the data and skills available, and the funding available. 
Policy conclusions 
[J Cost contributors. In view of the main contributors to cost, measures for improving 
efficiency should be aimed at improving the use of contributors to unit cost (staff, 
drugs) and case cost (reducing unnecessary CS, inpatient admissions, or antenatal 
visits). 
[J Implications of cost variation. Unit costs are higher in many health facilities than 
they would have been if resources were used efficiently (e.g. from the results of the 
data envelopment analysis). Unit costs variations are likely to be reduced if health 
services are planned so that staff productivity and occupancy rates are standardised 
between health facilities. Also, case cost variation could be reduced by standardising 
medical practice ('practice style'). 
[J Implications for Cuba. The findings suggest that the antenatal care programme could 
be implemented nation-wide with no major changes, although the reduction in 
antenatal visits towards the recommended may not be immediate. Other fonns of 
care, such as home visits, ultrasound, and maternity homes, can operate alongside 
the ANC programme. Due to the almost unique character of Cuban health services, 
and its' isolation from the world currency markets, it is not advisable to generalise 
cost data from other countries. However, within country health care costs are not 
likely to vary substantially outside those observed in those health facilities studied, 
due to the standardised structure of health services throughout Cuba. 
'~ 
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[J Implications for Thailand. Similarly, the findings suggest that the antenatal care 
programme could be implemented nation-wide with no major changes, although in 
settings where there are less staff there may be time constraints to provide the 
programme. Again, it is not advisable to generalise cost data from . other countries, 
unless it can be proved that prices and health service use rates are similar. Within 
country, due to the variation in unit costs and cost per pregnancy found between 
hospitals, and the variation in resource availability between regions, it is advisable to 
identify hospitals according to whether t~ey are low, mean or high cost providers . 
• ': '""I' 
[J Implications for South Africa. It is unclear how easily the ANC programme would 
be adopted in South Africa, due to the extra staff that may be required to give 
women additional time during outpatient visits. However, the staff skills and referral 
systems exist in the setting of the study for implementation of the ANC programme. 
[J Implications for other countries. In lower-resourced settings, where variations 
between current care and the W.H.O. ANC programme are even greater than study 
countries, cost per pregnancy predictions should be based on local data, such as 
levels of efficiency, staff productivity, impact on morbidity, accessibility, patient 
and provider compliance, carrying capacity of the health system, prices, and the 
availability of operative delivery and neonatal intensive care facilities. 
[J Requirements for further research. Policy makers at the international level should 
support the further development and validation of cost prediction methods. 
Investment into research in these issues in the short-run to improve methods will 
save resources in the longer run from the use of inaccurate cost data in decision 
making. 
11.3 Recommendations and agenda for research 
Although this thesis has highlighted a range of issues in the field of health economics 
that require further discussion and agreement, the most important recommendations for 
researchers and policy makers listed below include those of: measuring and reporting 
cost data routinely, in clinical trials, and in multi-country trials; applying cost analysis 
methods; making international comparisons; using and judging cost prediction methods; 
and defining economic importance. 
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Measuring and reporting cost data in clinical trials 
Researchers should consider generalisability issues in the design of costing studies. The 
following recommendations are already part of current economic evaluation guidelines 
(Weinstein et al 1996, Drummond et al 1996): clearly define and j~stify the study 
boundary; collect patient level data on health service use and unit costs, if possible; 
measure opportunity cost; present confidence intervals; and quantify uncertainty using 
sensitivity analysis. These recommendations are concerned with the measurement, 
presentation and robustness of the data; In addition, several further recommendations are 
made for researchers for better underst~d~~g of the ·:data (some of which are also 
recommended in current economic evaluation guidelines): report cost components 
separately, by price, resource use and health service use; report skewed cost data using 
mean, _median, mode, and confidence intervals; report important determinants of cost, 
such as staff productivity and case-mix; and identify opportunity cost when it diverges 
from market prices. When reporting cost results in a different currency, researchers 
should state and justify the currency conversion method based on the aims of the study 
(whether for international comarison or health care planning purposes), and interpret the 
cost results for the reader who may not be familiar with the context of the study. 
Finally, when a trial runs over a time period of several months or years, it must be 
decided which period the cost data refer to, and how many months of unit costs are 
collected. The year or month for which cost data are reported depends on which is the 
most useful for policy making, and when the data collection period is (it may be at the 
start or the end of the trial, and therefore not reflect the whole trial period). The choice 
of number of months 111 that unit cost data refer to depends on whether throughput and 
expenditure are seasonal variables. If they are, then some idea of the variation of unit 
cost over the year is needed, to approximate the average. Experience has shown that 
research costs of collecting additional months of data decline after the first month is 
collected, due to familiarity with staff providing the information, and the fact that staff 
and equipment lists are already drawn up and only monitoring of month to month 
changes is needed. It is therefore recommended that more than a single month is 
collected, to see whether variability exists. If variability does exist, the number of 
months required depends on the extent of variability. If just a few months of data are 
...... 
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collected, these can be supplemented with aggregate monthly expenditure and 
throughput patterns for a whole year to check whether they are related to season. 
/ 
Measuring and reporting cost data in multi-country trials 
While the above recommendations apply to cost studies alongside clinical trials 
generally, special recommendations are necessary for data collected and reported 
alongside multi-country trials, where additional decisions are needed concerning 
sampling methodologies. First, how many ,countries should be included? Current cost 
.': ". 
and economic evaluation guidelines are not clear about how to choose sample size. Few 
previous multi-country trials have measured costs in all countries, but they have shown 
cross-country variation, thus suggesting evidence is required to justify not collecting 
cost data in some countries. The findings of this study suggest that cross-country 
variability is sufficient to justify reporting of primary cost data for all countries in the 
study. Second, how many health facilities should cost data be collected in, in each 
country (assuming there is more than one per country)? There may exist cross-facility 
unit and/or case cost variation, and again, evidence is required to justify not collecting 
cost data in some facilities. For both these questions, two viewpoints should be 
considered - the scientific and the practical. The first, the scientific viewpoint, asks 
what sample size is necessary to prove whether or not a difference exists between the 
treatment options. This must naturally take account of what variation exists between 
health facilities. If prices, efficiency, health service use, etc, are similar between health 
facilities, then it may not be necessary to collect data in all of them. Also, when it is not 
known what facility-by-facility variation exists, either a pilot study should be conducted 
if time allows to make a more informed decision, or the sample size chosen should err 
on the cautious side. The findings of this study were that inter-health facility variation 
was significant, and omission of one health facility from each trial arm may have 
changed the results (if a high cost facility from one arm, and a low cost facility from the 
other arm). However, objective criteria are needed for judging what level of variation is 
large enough to warrant collecting data from all health facilities in a multicentre study. 
The second, the pragmatic viewpoint, asks what resources have been made available to 
the economic study, and tries to make the best use of those resources - first identifying 
111 Months were chosen in the antenatal care trial as it reflected the accounting period for costs and 
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the availability and quality of data from routine sources, and second identifying low cost 
but reliable means of filling data gaps. The clinical trial may be able to provide 
~--' 
important data on health service use, as was the case in the antenatal care trial. Where 
significant additional cost data collection .or data compilation efforts .. are required, a 
trade-off must necessarily be made between the number of countries, health facilities 
and months of data collection that can be included, and the final decision about sample 
sizes of each will depend on where the greatest variability exists, if known (greater 
variability requires greater sample size). The analyst must bear in mind that the sample 
,t'<" 
size should be sufficient to answer the study question. Where countries are known to be 
heterogeneous, it would seem safest to first ensure that a minimum cost data set is 
available for each country (one month and one health facility). If research funds are 
availa~le to collect more than this minimum cost data set, then health facility sample 
size should be judged based on known causes of variation, which include size 
(economies of scale), occupancy (returns to the variable factor), case-mix, 'level' of 
health facility, and staff mix. Other characteristics not examined in this study that 
distinguish hospitals should also be taken into account (from the findings of the review 
in Chapter 4), such as rural/urban location, with/without emergency department, 
whether or not a teaching hospital, and any other factors that may alter unit costs. 
Measuring and reporting cost data in routine data systems 
While research as outlined above is important, it tends to be one-off, and therefore does 
not provide decision makers with continuous and up-to-date monitoring of how key 
economic data change as health systems change. Also, the greater the investment in 
routine data systems, the easier and cheaper it is to do research. Such routine data 
systems will be useful in assessing the appropriateness of cost transfers from other 
settings, and in making appropriate adjustments. 
Recommendations for routine data collection at the national level include: price lists for 
each type of resource (personnel, equipment, drugs, materials); equipment plan for 
different types of health facility; staffing plan for different types of health facility; 
numbers of sta.ff at national, regional and district level; population size and population 
reporting rates by region and district; and health facility and staff coverage rates (per 
throughput data. 
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100,000 population). It is better if actual data are available on equipment and staff lists, 
as opposed to just the plans. Some of these data will be aggregations of data collected 
./ 
and reported routinely by health facilities, and would most likely be done once a year. 
Countries can be compared using these data and, with other macro-econ?mic data, allow 
conclusions about whether data transfer will be highly inaccurate from another country. 
Recommendations for routine data collection at the health facility level (minimum list) 
include: equipment lists and differences with 'plan', staff lists and differences with 
..... :. .":.:, 
'plan' , throughput (by category) per department, staff productivity, health care provision 
schedules; occupancy rates; average length of inpatient stay. These data should be 
updated on a monthly basis, when available. These data allow a comparison across 
health_ facilities for a crude assessment of whether unit costs can be transferred within 
country and crude cost analyses (when transferring data from outside the country, some 
of the national level data will also be needed). 
An advanced list of recommendations for routine data collection at the health facility 
level include, in addition to the minimum list: unit costs for important procedures, 
measures of case-mix, average length of inpatient stay by patient/disease type, measures 
of quality of care and patient satisfaction. However, how case-mix, quality of care and 
patient satisfaction are measured will need to be defined in order for collection to be 
standardised, and therefore comparable across settings. These data allow a comparison 
across health facilities for a more refined assessment of whether cost findings from 
other settings can be transferred within country. These data will also help for: budgeting 
purposes, deciding which services to provide, refined cost analyses, where and how to 
improve efficiency, and what investments are required. While routine collection and 
reporting is recommended for these data, this may not be necessary or feasible for some 
variables, and well-conducted periodic research studies may be conducted instead to 
provide such data. 
Cost analysis to understand cost determinants and cost variations 
Researchers should examine cost distributions and confidence intervals instead of point 
estimates in comparing costs and making conclusions about cost variations. Also, to 
improve the understanding of unit costs, studies are needed examining the micro-level 
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causes of inefficiency, and assessing the impact of quality of care and case-mix on unit 
costs. Policy makers should pay attention to results of cost analyses that have 
/ 
implications for how to improve efficiency by reducing resource wastage and 
considering input substitution options to reduce unit costs. Also, policy makers should 
help implement (evidence-based) health care guidelines to reduce unit and case cost 
variability (especially with regard to staff policy and length of hospital stay), bearing in 
mind the cost-effectiveness of alternative health care delivery approaches . 
..... 
.~ .. 
International cost comparisons 
International researchers need to clarify the purposes of international valuation, whether 
for comparison or pooling of cost data, or assessing US$ cost to funding agencies, as 
this will determine the appropriate currency conversion method. In order to avoid some 
of the problems associated with cross-country cost comparisons, researchers should 
consider comparing costs internationally' using non-monetary cost units. However, all 
types of cost comparison should bear in mind qualitative differences in health care 
inputs and outputs between country. Finally, policy makers should understand that 
cross-country cost transfers should not be made without taking account of different 
purchasing power, prices, resource use efficiency, and health service use differences. 
Cost prediction methods 
Researchers should develop a language and framework for different aspects of cost 
generalisability or cost prediction that allows a common understanding and increases 
clarity. Such a framework would force researchers to be more explicit about what they 
are doing and why, and also help policy makers interpret research. Also, researchers are 
recommended to test and compare alternative cost prediction methods in a range of 
settings. While the findings from this thesis have moved the debate on in terms of 
defining a cost prediction framework, linking it to cost analysis, and testing cost 
prediction methods, it is recommended that researchers seek alternative (both simple 
and complex) cost prediction methods, and further test and compare cost prediction 
methods between studies. Also, costs should be predicted using different measures of 
central tendency and confidence intervals or ranges, as well as marginal and average 
costs. In order to help judgement about cost prediction methods, measures of 'accuracy' 
and definitions of what constitutes 'acceptable' inaccuracy sh~uld be agreed. Finally, 
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policy makers should examine the cost implications of implementing a reduced-form 
W.H.O. ANC programme in lower-resourced settings, and the resulting implications for 
accuracy of cost transfer methods. Policy makers should also be open to collaboration 
with researchers to predict costs using the incremental cost impact. method, using 
costing spreadsheets such as the one developed by the W.H.O. for the Mother-Baby 
package (Weissman et al1999). 
Economic importance \ ' . 
Researchers are recommended to develo;' 'further a w~rking definition of economic 
significance, taking into account the viewpoints of both statisticians and policy makers, 
and conduct research into whether a widely applicable working definition is possible. 
Also, - further research is needed into whether different definitions of economic 
significance are appropriate when predicting different types of cost (e.g. unit cost, cost 
per pregnancy, incremental cost) and in different settings. Policy makers will playa key 
role in determining what costs changes are economically significant. 
In conclusion, this thesis has demonstrated that considerable thought needs to go into . 
cost prediction when inadequate primary data are available for estimating costs. Cost 
data transfers (generalisation) have been shown to be unreliable in terms of accuracy for 
both within and between country cost predictions. An incremental cost impact approach 
to cost prediction, although it requires more detailed health service and patient data, was 
shown to be more reliable, as it takes into account local impacts on prices, resource use 
and health service use. Therefore, researchers and policy makers are encouraged to work 
together in improving routine reporting of cost and epidemiological data to improve the 
accuracy of costs when prediction is necessary, and separate reporting of resource use, 
prices, and health service use. A working party is therefore recommended to discuss in 
greater depth the issues raised in this study surrounding cost prediction and cost 
generalisation, and to build consensus amongst both researchers and policy makers. 
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Appendix 1: Summary of cost analysis literature 
Table 1.1: Regression analyses with total costs as the dependent variable ~ .. 
Author(s). VNlr Data set nnd I.~ountrv Causes of I.~ost variation 
Cohen (1970) 25 hospitals in USA 1. Teaching hospitals have a larger optimum size 
2. Qualit~ influences the oEtimum size 
Francisco (1970) 4.710 hospitals in USA 1. EOS existed in small hospitals, while there was 
CRS in large hosEitals 
Baron (1978) 803 hospitals in UK 1. EOS existed in large units of hospitals 
2. Qualit~ increased with the size of the hosEital 
Pauly (1978) 50 hospitals in USA 1. Input prices explained 6% of unit cost variation 
2. Case-mix had a significant impact on unit cost 
3> . Admitting Eh~sicians increases cost marginall~ 
Jenkins (1980) 10 1 hospitals in Canada .1. DOS existed, optimum size 100-300 beds 
Conrad and Strauss 114 hospitals in USA 1. CRS existed 
(1983) 
Cowling and 138 hospitals in USA 1. Economies of scope were significant 
Holtman (1983) 
Sloan et al (1983) 367 hospitals in USA 1. Non-physician costs were higher in teaching 
hosEitals 
Chernichovsky 19 hospitals in Israel 1. Case-mix had a significant impact on unit costs 
~1986) 2. Inflation rates were higher in health sector 
Granneman et al 1.690 hospitals in USA 1. EOS existed 
(1986) 2. Case-mix had a significant imEact on unit costs 
Frank and Taube 755 free standing mental 1. DOS existed 
(1987) health clinics in USA 2. Decentralisation increased efficiency 
3. There was excess doctor time available 
Kass (1987) 1.704 health agencies in 1. EOS inconclusive 
USA 
Vitaliano (1987) 166 hosEials in USA 1. EOS existed 
Vita ~1990) 296 hosEitals in USA 1. EOS inconclusive 
Custer and Willke 564 hospitals in USA 1. EOS existed 
~1991) 2. Economies of scoEe were significant 
Wouters (1993) 42 health centres in 1. Staff mix had a significant impact on unit costs 
Nigeria 2. The efficiency index did not affect unit costs 
3. Qualit~ reduces unit costs 
Bitran-Dicowsky 15 hospitals in Ethiopia 1. CRS and small DOS exist 
and DunloE (1993) 
Zuckerman et al 4,149 hospitals in USA 1. Occupancy, size, input use intensity, and the 
(1994) presence of skilled workers had a significant 
imEact on unit costs 
Scott and Parkin 76 hospitals in UK 1. EOS and economies of scope were inconclusive 
~1995) 
Csaba (1997) >200 hospitals in UK 1. Trust status increases costs 
2. Market capacity influences costs 
3. ComEetition increases efficienc~ 
Table key: EOS - Economies of scale; DOS - Diseconomies of scale; CRS - Constant returns to scale 
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Table 1.2: Regression analyses with average costs as the dependent variable 
Author(s}, rear Data set find countrv Causes of cost variHI:ioll 
Carr and Feldstein 3,147 hospitals in USA 1. EOS existed until 190 beds, then DOS 
(1967~ 
Mann and Yett Comparing 3 cost 1. . One study showed significant EOS, two studies did not 
(1968) studies from USA 
Be!:!): (1970) HosEitals in USA 1. Case-mix had a significant imEact on unit cost 
Lave and Lave 74 hospitals ~n USA 1. Weak evidence of EOS 
(1970) 
Evans (1971) 185 hospitals in 1. CRS and DOS existed 
Canada 2. Case-mix had a significant impact on unit costs 
3. OccuEancx had a significant imEact on unit costs 
Salkever (1972) 86 hospitals in USA V There was a delayed impact between general inflation 
and health sector inflation rates 
Lee and Wallace 52 hospitals in USA 1. EOS existed 
(1973) 2. Case-mix had a significant imEact on unit costs 
Lave & Leinhardt 2,449 patients in USA 1. Case-mix had a significant impact on unit costs 
(1976) 
Feldstein and 55 hospitals in USA 1. Case-mix explained more than 50% of unit cost 
Shuttinga ~1977) variation 
Bays (1980) 41 hospitals in USA 1. CRS existed 
2. Admitting physician, case-mix, and case flow had a 
significant imEact on unit costs 
Birnbaum et al 11 previous cost 1. Size and occupancy rate had a minimal impact on unit 
(1981) analyses by the authors costs 
in USA 2. Type of facility and ownership had a significant impact 
on unit costs 
Friedman and 800 hospitals in USA 1. Low capacity use increased unit costs 
Pauly (1981) 2. Large size leads to higher occupancy rates 
3. Case-mix had a significant imEact on unit costs 
Barer (1982) 87 hospitals in Canada 1. Case-mix had a significant impact on unit costs 
2. Teaching had a significant imEact on unit costs 
Hosek and palmer 360 hospitals in USA 1. Case-mix had a significant impact on unit costs 
(1983) 2. QualitX of care had a significant imEact on unit costs 
Lee and Birnbaum 671 nursing facilities in 1. Scale and occupancy had a minimal impact on unit costs 
(1983) USA 2. Case-mix and service-mix had a significant impact on 
unit costs 
3. Reimbursement grouping had the most significant 
imEact on unit costs 
Schlenker et al 78 nursing homes in 1. Case-mix had the most significant impact on unit costs 
~1983) USA 2. QualitX of care had a significant imEact on unit costs 
Hornbrook and 380 hospitals in USA 1. EOS existed 
Monheit (1985) 2. Case-mix had a significant imEact on unit costs 
Wan et al (1987) 23 hospitals 1. EOS existed 
2. Ownership had a significant impact on unit costs 
3. The oEtimal staff mix was 1.8 residents Eer dentist 
Keeler (1990) 7,156 patients in USA 1. Case-mix had a significant impact on unit costs 
2. Prices had a significant imEact on unit costs 
Dor et al (1992) 767 haemodialysis 1. DOS exist 
units in USA 2. Case-mix had a significant imEact on unit costs 
Shiell et al (1993) 123 residential 1. There was an n-shaped cost curve 
facilities in USA 2. Case-mix had the most significant impact on unit costs 
3. Ownershi£ had a si~nificant im£act on unit costs 
Table key: EOS - Economies of scale; DOS - Diseconomies of scale; CRS ..:. Constant returns to scale 
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Table 1.3: Regression analyses with case costs as the dependent variable 
Aulhor(s), rear Data set and conntrr Causes of cost variation 
Cromwell (1987) 150,000 patients, USA 1. Urban location resulted in 13% to 61 % higher unit costs 
2. Case severity and level of technology was higher in 
. urban locations 
Coverdale et al 1,150 hospitals, UK L Larger hospitals has higher unit costs 
(1990) 2. The impact of hospital age and specialisation did not 
influence unit costs 
Frank et al (1990) 2,802 patients, USA 1. Ownership had a significant impact on unit costs 
2. Health and mental status did not have a significant 
imEact on unit costs 
KnaEE et al (1990) 136 Eatients, UK 1. Case-mix had a Significant imEact on unit costs 
Ashford (1991) 395 hospitals, UK 1.' Length of stay had a significant impact on unit costs 
2. Specialty size had a non significant impact on unit costs 
3. Diagnostic mix had a non significant impact on unit 
costs 
Samson (1991) 70 nursing institutions, 1. Low birth-weight had a significant impact on unit costs 
USA 2. Teaching status resulted in lower marginal costs 
Beecham et al 216 patients, UK 1. Case-mix had a significant impact on unit costs 
(1993) 2. Owners hiE had a significant imEact on unit costs 
Dudle~ et al (1993) 155 Eatients, USA 1. Case-mix had a highl~ significant imEact on unit costs 
Knapp et al (1993) 140 patients, UK 1. Pre-admission variables had a significant impact on unit 
costs 
2. Low educational status resulted in higher unit costs 
Voss et al (1994) 464 patients, Holland 1. Case-mix had a significant impact on unit costs 
2. Length of sta~ had a significant imEact on unit costs 
Butler et al (1995) 301 patients, Australia 1. Case-mix had a significant impact on unit costs 
2. Length of sta~ had a significant imEact on unit costs 
French et al (1995) 60 patients, UK 1. Case-mix had a significant impact on unit costs 
2. Length of sta~ had a significant imEact on unit costs 
Soderlund et al 12 hospitals, UK 1. Case-mix had a significant impact on unit costs 
(1995) 2. Hospital size had a non significant impact on unit costs 
3. Occupancy had a non significant impact on unit costs 
4. . Teaching status had a non significant impact on unit 
costs 
Clarke et al (1996) 363 patients, UK 1. Staff-patient contact time had a significant impact on 
unit costs 
2. Length of sta~ had a significant imEact on unit costs 
Conrad (1996) 44,397 patients, USA 1. Capitation payments resulted in low.er unit costs 
2. Clinicians given cost data resulted in lower unit costs 
3. Care co-ordination mechanism being used resulted in 
lower unit costs 
Khoshnood et al 588 patients, USA 1. Case-mix had a significant impact on unit costs 
(1996) 2. Mechanical ventilation resulted in higher unit costs 
3. Discharge status had a significant impact on unit costs 
4. Insurance type had a non significant impact on unit 
costs 
Cowper et al 92,449 patients, USA 1. Case-mix had a highly significant impact on unit costs 
(1997) 2. Teaching hospital had higher costs and a longer LOS 
3. Medicare/aid patients had lower unit costs 
4. High throughput resulted in lower unit costs 
5. Higher wages (wa~e index) resulted in hi~her unit costs 
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Table 1.4: Data envelopment analysis studies. 
Authors, ;vear Data set Inent Hlriables Ontent vnriabJes Eflidcnev results 
Nunamaker 17 hospitals, Inpatient routine costs. Geriatric IPD, Cost per case is highly 
(1983) USA Paediatric IPD, correlated to efficiency 
Maternit~ IPD. rankings (0.73 & 0.94) 
Sherman 7 hospitals, Non-physician FrE, IPD « and> age 65), Inefficiency from over-
(1984) USA Available bed days, Number of nurses stated supply costs, 
SUEEI~ costs. and residents trained. excess beds & FrEs 
Banker et al 114 hospitals Beds, nursing services, Adult IPD, paediatric RTS depends on age, 
(1986) USA 0Eeratin~ costs. IPD,' ~eriatric IPD 45 efficient hosEitals 
Grosskopf & 82 hospitals, No. physicians, FrE IPD (acute, ICU), Public hospitals more 
Valdamis USA non-physicians, Adm., Number of surgeries, efficient than private 
(1987~ Net Elant assets.· ." Number ofOPV. not-for-Erofit hosEitals 
Huang and 193 rural PHC StaffFrE, Total number of Larger programmes 
McLaughlin programmes, Age of programme, "encounters" with 3 tended to be less 
(1989) USA User characteristics. t~Ees of staff. efficient 
Valdmanis 41 hospitals, Staff numbers, IPD (acute, ICU and Public hospitals more 
~1990) USA CaEital assets sur~er~), OPV. efficient than NFP. 
Ozcan et al 3,000 Capital, No. services, Hospital discharges, 43% of hospitals 
(1992t hospitals, Size, Staff/supply cost. Training FrEs, OPV. efficient (more public) 
USA 
Grosskopf & 88 hospitals, Staff numbers, IPDs, No. surgeries, Most hospitals are 
Valdmanis USA Net plant assets, OPVs, ICU days, operating at -85% 
~1993) Case-mix index emergenc~ visits efficienc~ 
Ozcan and 3,000 Capital assets, Number Treated cases, OPYs, % of efficient hospitals 
Luke (1993) hospitals, of non-physicians, Teaching FrEs in an area depends on 
USA SUEEI~ costs. local EOEulation size 
Ehreth (1994) All USA Capital and salary Discharges (by type). Efficiency differences 
Medicare costs. explained part of cost 
hosEitals differences. 
Kooreman 292 Dutch Staff numbers. Full care patients, 20% of nursing homes 
~1994) nursing homes Da~ care Eatients. are efficient. 
Bannick 284 hospitals, Beds, No. services, IPD (case-mix 20% of hospitals are 
(1995) USA FrE, 0Eeratin~ costs. adjusted),OPV. efficient (more small) 
Luoma et al 202 health Operating costs .. ' IPD (by type), 12% of hospitals are on 
(1996) centre,Finland OPY (b~ t~Ee). the efficienc~ frontier 
Magnussen All Norwegian No. physicians, nurses IPD, OPY, Medical Efficiency depends on 
(1996) hosEitals & other labour, Beds. /sur~ical cases. outEut sEecification. 
Broomberg 9 hospitals, Recurrent costs, IPAs, IPDs, OPYs, Results sensitive to 
(1997) South Africa Capital costs, (by Number of operations inputs and outputs, and 
resource + (annual). which model used. 
deEartment). 
Gordon et al All Scottish Beds, Nursing/medical Inpatient cases. Results sensitive to 
~1997) hosEitals staff costs, Other costs. inEuts and outEuts. 
Giuffrida and 90 health Gross expenditure, GP practices and 50% of agencies are on 
Gravelle agencies in Quality indicators, output targets met the efficiency frontier, 
(1997) UK SMR Erofit & NFP avo 67%. 
Rosenmanet 28 HMOs in Capital assets, Number of members Large HMOs are the 
al (1997) USA 0Eeratin~ eXEenses in health Elan most efficient 
Bates et al 107 general Staff, medicine, capital Size of GP practice Efficiency depended on 
(1998) practices in and rental costs. list, by type of patient output measure chosen, 
UK 7 were efficient. 
Puig-Junoy 16 ICUs in 6 types of labour input. Patients treated, 15.4% of patients were 
(1998) . Spain (993 Mortality risk, managed efficiently. 
Eatients~ Status at discharse. 
Table key: IPD - Inpatient day; IPA - Inpatient admission; OPY - Outpatient visit; FrE - Full-time 
equivalent staff; ICU - Intensive care unit; HMO - Health maintenance organization; PHC - Primary 
health care; NFP - Not-for-profit; GP - General practitioner; SMR - Standardised mortality rate 
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Table 1.5: Characteristics of regression analysis and data envelopment analysis 
Characteristic Regression analysis DEA / 
Assumptions about production/cost frontier Strong None 
Test assumptions about frontier Yes No 
Assumptions about error distributions Strong None 
Test distributional assumptions Yes No . 
Test for inclusion of variables Yes No 
Distinguish random factors from efficiency variations Yes No 
Allow for environmental factors Yes Yes 
Allow for multiple outputs! multiple inputs Only if canonical Yes 
Problems if multicollinearity 
Provide information on "peer" organisations 
Vulnerable to small number of observations 
Vulnerable to endogeneity bias 
Test for endogeneity bias 














Table 1.6: Findings of the literature on patient factors affecting health service use 
Factor Study Country Care type* 
Geographical accessibility V oorhoeve et al 1984) Kenya DEL 
Materia et al (1993) Kenya MAT 
Dujardin et al (1995) Zaire DEL 
Swain et al (1992) India ANC 
Rasmussen (1990) Guatemala, Indonesia ANC 
Abbas et al (1986) Jordan MAT 
Ossis et al (1993) Brazil ANC 
Hamilton et al (1987) South Africa ANC 
Fantahun et al (1995) Ethiopia ANC 
Out-of-pocket expenses or factors Nylander et al (1990) Africa MAT 
related to poverty Monteith et al (1987) Panama, Guatemala MAT 
Swain et al (1992) India ANC 
Jaswal et al (1992) India ANC 
Abbas et al (1986) Jordan MAT 
Hamilton et al (1987) South Africa ANC 
McCoy (1997) South Africa ANC 
Fantahun et al (1995) Ethiopia ANC 
- Owa et al (1992) Nigeria ANC 
Opportunity cost (lost income) Monteith et al (1987) Panama, Guatemala MAT 
Quality of care or perceived Voorhoeve et al 1984) Kenya DEL 
health impact of health service Marshall (1985) Papua New Guinea ANC 
Islam et al (1993) Bangladesh MAT 
Atkinson et al (1995) Brazil ANC 
Previous use of health services Monteith et al (1987) Panama, Guatemala MAT 
Dujardin et al (1995) Zaire DEL 
Marshall (1985) Papua New Guinea ANC 
Cultural or family factors Sargent (1985) Benin MAT 
Rahman et al (1982) Bangladesh ANC 
Marshall (1985) Papua New Guinea ANC 
Galloway et al (1994) General ANC 
Bamisaiye et al (1986) Nigeria ANC 
Islam et al (1993) Bangladesh MAT 
Poor education, literacy, general Nylander et al (1990) Africa 
awareness of health services Monteith et al (1987) Panama, Guatemala MAT 
Nwakoby (1994) Nigeria DEL 
Jaswal et al (1992) India ANC 
Abbas et al (1986) Jordan MAT 
Ossis et al (1993) Brazil ANC 
Fawcus et al (1992) Zimbabwe ANC 
Age, marital status and previous Nwakoby (1994) Nigeria DEL 
pregnancies McCaw-Bins (1995) Jamaica ANC 
Abbas et al (1986) Jordan MAT 
Fawcus et al (1992) Zimbabwe ANC 
Lumbiganon (1991) Thailand ANC 
Use of alternative health service Nylander et al (1990) Africa MAT 
Jaswal et al (1992) India ANC 
Weather patterns (e.g. rains) Voorhoeve et al (1984) Kenya DEL 
*Care type the study analyses: ANC - antenatal care; MAT - matermty care (any); DEL - delIvery care. 
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Appendix 2: W.H.O antenatal care trial clinical component information 
Trial background and rationale 
According to experts, the 'industrialised model' 1 of antenatal care has never been 
properly evaluated with scientific objectivity (Fathalla 1998). Van Look (1998) claims 
that this fact is surprising especially in the context of 'resource-strapped' developing 
countries, given the cost of adopting the 'industrialised model' of antenatal care. 
Although many of the tests and screening procedures conducted during antenatal care 
have been studied in isolation, mainly in' d~veloped country settings, there has been 
limited evaluation of whole programmes of antenatal care, and thus of how these health 
care interventions work in combination. Until the middle of the 1990s there was limited 
evidence of the effectiveness of alternative programmes of antenatal care, such as the 
optimal content, timing and frequency of visits. More recently there have been a number 
of studies that showed no significant he,alth effect of a reduction in the number of visits 
from 10 or more to four visits, but with more focussed health care interventions 
(Binstock and Wolde-Tsadik 1995, McDuffie et al 1995, Munjanja et al 1996, Sikorski 
et al 1996, Walker and Koniak-Griffin 1997). These findings at least provide some ex 
post rationale for the design of the WHO antenatal care trial2• 
Trial aims and objectives 
The overall objectives of the W.H.O. antenatal care trial were (WHO 1996, page 8): 
To conduct a multicentre, multi-country controlled trial comparing two models of ANC 
(the W.H.O. rationalised model versus the current standard of care). 
• To establish the relative merits of each model. 
• To test whether the proposed new model is more effective than the traditional multi-
visit model with regard to maternal morbidity and mortality, satisfaction, and cost 
(italics added). 
1 The 'industrialised model' refers to the practice of antenatal care developed this century in European 
countries. 
2 Refer to Belizan et al (1998), Lindmark et al (1998), Khan-Neelofur et al (1998), and Villar et al (1998) 
for a more detailed rationale for conducting the antenatal care trial, with a focus on developing countries. 
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Therefore, the hypothesis of the trial was: 
"A new model of antenatal care which includes only those components shown to be 
effective in improving maternal, perinatal and neonatal outcomes, is more efficient than 
the traditional model with regard to specific maternal and perinatal endpoints, among 
singleton pregnancies, and is not more expensive". (WHO 1996, page 9) 
Trial design 
This trial was designed to be a multlcentre multi-country randomised controlled trial. 
Trial centres were in Argentina, Cuba, Saudi Arabia ~d Thailand3 (see Table 1 for a 
description of these sites). As Pocock (1999) notes, the principal advantages of such a 
multicentre trial is that the intended sample size can be achieved more quickly than in a 
single centre trial, and also that the involvement of diverse settings allows conclusions 
to have a broader more representative base. Various aspects of the trial design relevant 
to the economic evaluation are described in this section, including the sample size, 
randomisation procedure, trial entry criteria, contents of the new ANC programme, 
health outcomes, data collection and data analysis methods. 










300 km from Buenos Aires 
Capital city, North central coast 
Central part of country 
Arabia. 
Thailand Khon Kaen 450 km North East of Bankok 
South Africa Umlazi 20 km from Durban (East coast) 







Number of units 
2 large, 15 small 
12 small 
4 medium, 8 small 
2 large, 6 medium, 4 small 
5 large 
Sample size: Various extracts are taken from Donner et al (1998) in describing sample 
size issues: "The determination of sample size required for the trial corresponds to the 
stratified cluster randomisation design, taking into account that there are four study sites 
with clinics within each site randomly assigned to intervention or control. .. Further 
stratification was made by clinic size, to ensure balanced allocation of subjects across 
intervention groups. The approach for estimating the sample size requirements took 
account of the intracluster correlation coefficient, the stratum-specific event rates in the 
control group, and the value of the intervention odds ratio of interest to detect... With 12 
3 These countries were chosen for two principal reasons: 
• There was a minimum level of antenatal care in place to act as the comparison group. 
• There was the basic infrastructure (researchers, facilities and data systems) for high quality work. 
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clinics per site, each clinic recruiting 450 patients, and 90% power for detecting an 
intervention odds ratio of 1.2 on a two-sided test with a level of significance of 5%, 
19,087 subjects are needed in the four study sites ... The value 1.2 was chosen as the 
maximum value of the odds ratio that would be regarded as consistent with the 
conclusion that the new programme is as 'equally effective' as the new programme. 
Assuming an average outcome rate across control group sites of 0.10, this implies that 
an elevation in this rate to approximately 0.12 is regarded as substantively important to 
detect" (Donner et al1998, pages 62-64). 
A relevant point to note here is that the sample size under a cluster design is bigger than 
would be required if patients were individually randomised, to take account of the fact 
that subjects' responses within a cluster cannot be regarded as statistically independent, 
thus reducing the effective sample size. Also, note that economic factors were not 
considered explicitly in calculating the .sample size. 
Randomisation procedure: The trial randomisation design was based on health facilities 
rather than patients ('cluster' design). This was necessary for three principal reasons 
(Donner et a11998, page 61): 
1. To reduce the risk of treatment contamination, which would be more likely to 
happen if two forms of ANC were being provided in the same clinic. 
2. To encourage the participation of the women. 
3. To facilitate logistic and administrative convenience in the implementation of the 
intervention. 
Therefore, any woman reporting to one particular health care facility would receive the 
form of care that has been allocated to it, assuming she agreed to participate. Clinics 
were matched by size groups. However, clinics were not matched individually due to 
the difficulty of creating matched pairs on the basis of risk (Donner et al 1998). The 
allocation schedule for randomly assigning clinics was computer generated, stratified by 
study site and clinic size at W.H.O., Geneva. 
Trial entry criteria: For women reporting for their first antenatal visit to intervention 




listed4 she was not eligible for the new programme, and was treated as a high risk 
patient in the usual way. If the woman was eligible for the new progr~mme, she was 
informed about the aims and purpose of the new programme, and ~;as asked if she 
would like to participate. If she refused to give her consent, she received the traditional 
form of antenatal care. The rate of non-participation, however, was very low. Informed 
consent was not necessary for women reporting to control clinics, as they would receive 
'best standard treatment' as presently offered in the clinics. 
The intervention: In each country at least six health facilities5 provided the new 
antenatal programme, and at least six the current model of care, The new programme 
consisted of tests, clinical procedures and follow-up actions scientifically demonstrated 
to be effective in improving maternal and newborn outcomes, avoiding the use of 
technology not affordable in developing country settings. These interventions were 
distributed among four visits over the ~ntire course of pregnancy, with additional visits 
for women with signs of risk or symptoms/actual presence of disease, or if the woman 
insisted on more visits. Table 1 below provides a summary of the contents of the new 
ANC programme. Each country was responsible for monitoring compliance with the 
new protocol by making unannounced clinic visits, as well as investigating whether 
control clinics changed their ANC practice (contamination). 
4 High risk women were excluded. High risk women were those that had a anyone of the following 
conditions: 
Obstetric history: previous stillbirth or neonatal loss, history of 3 or more spontaneous abortions, last 
baby <2500g or >4500g, hospital admission for hypertension or pre-eclampsia/eclampsia in the last 
pregnancy, previous surgey on reproductive tract, 
• Current pregnancy: diagnosed or suspected multiple pregnancy, age less than 16 or more than 40 
years, iso-immunisation Rh (-) in current or in previous pregnancy, vaginal bleeding, pelvic mass, 
diastolic blood pressure 90mm Hg or more at booking. 
• General medical: insulin dependent diabestes mellitus, renal disease, cardiac disease, known 
'substance' abuse, any other severe disease or medical condition. 




Table 2.2: W.H.O. antenatal care programme basic checklist 
••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• 
CHECK THE ACTIVITIES CARRIED OUT WHERE APPROPRIATE (UNSHADED BOXES) 
Use the closest gestational age at the time of visit 
Patient's Name ______ .Clinic record No. _ Study Subject No. _, __ , __ ,_ 
FIRST VISIT for all women at first contact with clinics, regardless of Visits 
gestational age. If first visit later than recommended, carry out all 1 st 2nd 3rd 
activities up to that time DATE: I I <12 wks 
4th 
CLassifying form indicates eligibiLity for the basic programme l ~t1t~:, I r::i:~\~':. ',\"" ._. 
Clinical examination 1 ;::':','lJ::~ 1 ::il'1f:~:';'~~: ":~:<;.':,,~.~ 
Clinically severe anaemia: Hb test ,:.-:: ... ,'~: I :>,;':_,,,~~ .,.: 
Ob exam: gestational age examination, uterine height :'.~':.,l;. I\' .... '<;!~· "'; 
Gyn exam (can be postponed until second visit) "?>:::' .~ .,:;':' ,;;.' ,', 
Blood pressure ')_l..~\;t.:~' ;~.":: ;Yf ',' ,'}: 
Maternal weight' height ;L. , " 
Rapid syphilis test, detection of symptomatic STDs - treatment 
Urine test (multiple dipstick) 
Blood test and Rh .. ," 
Tetanus toxoid .. -
Fe , folic acid supplementation ., ;.::;':",> !\, '(~ .;.", , 
Recommendation for emergencies l o ,.'~",,;:: I'" . ,,:..:., 
Compete antenatal card -'. I· 'r" ,-
SECOND VISIT AND SUBSEQUENT VISITS Gestational age - approx. # of weeks: 
DATE: I I 26 32 38 
Clinical examination for anaemia ';!,i\~iY ., ""' ~: 
Ob exam: gestational age estimation, uterine height, fetal heart rate '~'(''::'i :' 
Blood pressure :-S';,~~. 
Maternal weight (only women with low weight at first visit) ,;":::!~",,,y,;, 
Urine test for protein (onl)'nulliparous/women with previous eclampsia) .; > 
Fe , Folic acid supplementation {"','C
y
' 
Recommendation for emergencies ~',',;,_i~:":; 
Complete antenatal card .. ,:';'Y;~' 
THIRD VISIT: add DATE: / / 
Hemoglobin :.::~.;;',;~ ,\;~; 
Tetanus toxoid ~;;C-:r:M;";: ,~~~¥{ ~,''''''$.''< 
Instructions for delivery 
Recommendations for lactation' contraception '~',,"," 
FOURTH VISIT: add DATE: / / 
Detection of breech presentation and referral for external version I,;c,,:~i~~ I ·."":t.~~~~,. :~, :.;·L~,A ,,' "" 
Complete ANC card, recommend it to be brought to hospital Ii; , "ii.;.:':f'if\.,;~;~~. ~,;; I ,:~,,,.,. ~1t 1 
Staff responsibLe for antenataL care: Name _____________ _ 




Health outcomes: The effectiveness of the programmes was compared in terms of two 
primary outcomes: low birth weight and an index of maternal morbidity. In addition, 
~/ 
several secondary outcomes and process outcomes (including perceived quality of care, 
satisfaction, and cost) were compared. However, during the implementation of the trial, 
the Steering committee gradually moved to regarding the trial as an equivalence study 
(health outcomes are not expected to differ significantly between arm) (Donner et al 
1998). 
Table 2.3: Outcomes of the W.H.O. antenatal care randomised controlled trial 
OUTCOMES 
A. Primary outcomes 
Rate of maternal morbidity indicator index6 
Rate of low birth weight « 2500 g) 
B. Secondary outcomes 
Maternal 
Rate of treated syphilis and any other STD during pregnancy 
Rate of postpartum positive syphilis test (among women without treatment during pregnancy) 
Rate of incomplete tetanus immunisation 
Rate of postpartum hospital stay ~ 7 days for maternal complications 
Rate of pre-eclampsia or eclampsia 
Rate of postpartum anaemia 
Rate of severe urinary tract infection 
Newborn 
Rate of intrauterine growth retardation 7 
Rate of pre term delivery « 37 weeks) 
Rate of spontaneous and predelivery rupture of membranes « 35 weeks, and 36-36 weeks) 
Rate of medically indicated preterm delivery « 35 weeks, and 36-36 weeks) 
Rate of breech presentation at birth 
Rate of very low birth weight « 1500 g) 
Rate of Apgar score < 5 at 5 minutes 
Rate of intensive care unit stay> 2 days 
Rate of fetal death (macerated stillbirth; fresh stillbirth) 
Rate of neonatal death before discharge from hospital 
C. Process outcomes . 
Rate of antenatal hospital admission - total and by cause 
Rate of elective and emergency Caesarean section associated with pregnancy complicationsS 
Days of hospital admission during pregnancy (median) 
D. Economic outcomes 
Cost-effectiveness 
E. Satisfaction outcomes 
Rate of women satisfied with the two antenatal care models 
Qualitative analyses of reasons underlying satisfaction I dissatisfaction 
6 Maternal morbidity indicator index: the presence of at least one of the following conditions (1) pre-
eclampsia or eclampsia during pregnancy or within 24 hr of delivery; proteinuria defined as 2.0g or more 
in 24 hr or 2+ or more on quantitative examination (dipstick); (2) postpartum anaemia « 90 gIL); (3) 
severe urinary tract infection I pyelonephritis (requiring antibiotic treatment or hospitalisation but 
excluding the antibiotics given to treat asymptomatic bacteriuria). 
7 If last normal menstrual period not available, use the best 'obstetric' estimate; below 10th percentile of 
international standard. 
S Excluding intrapartum Caesarean section for fetal distress or cephalopelvic disproportion. 
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Data collection and entry: Research centres within each country conducted the research 
and entered the data, with co-ordination and technical support from WHO. There were 
/~ 
three main sets of data collection forms of relevance to the economic study: 
1. The baseline survey forms. These surveys were conducted before the trial began, 
and collected data on health service structure, resources available, antenatal care 
content, and the incidence of pregnancy-related conditions and events. Two sets of 
forms were applied to collect these data (patient and clinic level forms). 
2. The summary form. This was completed for all women, and recorded data on health 
care, health events and health outcomes~ health serVice use covering the pregnancy 
and delivery period, and medical history and personal details. 
3. The antenatal inpatient form. This was completed for all women admitted to hospital 
during pregnancy, and contained data on the principal reason for admission, and the 
length of stay of the woman. 
Data analysis: Several aspects of data analysis in the clinical trial are of relevance to the 
economic evaluation, and therefore listed briefly. First, data were analysed only for 
those women who completed their pregnancies, and for whom at least one primary 
health outcome was available. Therefore women who (a) were found not to be pregnant 
after entering the trial (b) women who had abortions and (c) women lost-to-follow-up, 
were excluded from all analyses. Second, single and multiple births were reported 
separately, and only single births are analysed in keeping with the trial aims. Third, 
women were analysed on an intention-to-treat basis. Therefore, even if a woman did not 
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study from the WHO Antenatal Care Randomised 
Controlled Trial 
Miranda Mugforda, Guy Huttonb and Julia Fox-Rushbyb 
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The other members of the WHO Antenatal Care Research Group 
and participating institutions are listed at the end of the paper 
aSchool of Health Policy and Practice, University of East Anglia, 
Norwich, and bHealth Policy Unit, London School of Hygiene and 
Tropical Medicine, London, UK 
Summary. The WHO is testing a new rationalised programme of 
antenatal care in a multicentre randomised trial. The motivation for this 
trial arose from the current uncertainty about the effectiveness of 
different approaches to provision of routine antenatal care. Decision 
makers also lack information about the costs of providing routine 
antenatal care and the cost-effectiveness of one programme over another. 
Such information will be needed before the final choice of programme 
can be made. The WHO trial provides an ideal opportunity to estimate 
and compare the incremental costs and cost-effectiveness of the new 
programme in four countries (Argentina, Cuba, Saudi Arabia, Thailand). 
A separate economic component has been organised to measure the costs 
of antenatal care. Methods for cost identification and measurement, and 
methods for economic analysis in the context of an international study 
are based on current recommendations for the conduct of economic 
evaluations alongside trials. However, several aspects require further 
development. In particular, this includes defining standard methods for 
costing in different countries; measuring women's costs of access to care; 
and making comparisons across international settings. The economic 
evaluation will also inform similar multicentre international trials and 
investigate issues of generalisability beyond trial settings. 
Address for correspondence: Miranda Mugford, Sch001 of Health Policy and Practice, 
University of East Anglia, Norwich NR4 7TJ, UK. 
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Introduction 
Reproductive health is high on the agenda of many non-governmental and 
governmental international agencies, such as the WHO, the World Bank, Mother 
Care in the United States and the Department for International Development 
(DfID) in the United Kingdom. These agencies recognise that, although huge sums 
of money are being spent on reproductive health care, little of the expenditure is 
supported by good-quality evidence that'can prove its value for money.1 One 
purpose of health services research, and in particular randomised controlled trial 
methodologies, is to provide evidence to inform the more effective provision of 
services. The WHO Antenatal Care Trial2,3 has been designed for this purpose. It has 
also been designed to address the question of the economic efficiency or 'value for 
money' of the alternative patterns of care. 
Economics is gaining increasing importance in health-care practice and 
research. Economic evaluation methods provide a framework to inform 
programme planners what the viable options are for intervention, and the levels 
at which they would best be implemented, taking into account the objectives of 
the intervention. Although costs are usually measured after health-care interven-
tions have been implemented, many studies are now being reported in which 
costs have been estimated at the technology assessment stage of interventions.4 
This allows early recognition of the relative efficiencies of health-care technologies, 
and allows those that are expensive and have limited health effects to be 
discouraged from being adopted more widely. 
Reproductive health covers a broad range of health concerns, including 
sexually transmitted diseases, family planning, mother and child nutrition, health 
care for pregnant women and the newborn, and postnatal care. While there is 
some evidence about the effectiveness of screening and treatment procedures in 
antenatal care, among others, questions still remain about when and how often 
screening should take place and what treatment schedules are affordable.2,5 Only 
a handful of studies have evaluated the effectiveness of programmes of antenatal 
care, in which the interventions are assessed as a package rather than as several 
separate components of a package.6-11 We have found only two such studies from 
the developing world, in Zimbabwe10 and The GambiaY In The Gambia, a study 
of mobile antenatal clinics did not test alternative routine visiting patterns for 
outpatient antenatal clinics but evaluated whether reproductive outcomes were 
improved by taking care to women in remote areas. The studies that did evaluate 
routine visits suggest that antenatal care can be provided as effectively in fewer, 
more focused visits, but they have not reported clear evidence of the change in 
cost of care that would result. Therefore, the need to assess the cost-effectiveness 
of these antenatal care programmes remains. 
Although the antenatal period is often quoted as being an important period for 
medical intervention, the evidence available about the cost-effectiveness of 
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antenatal care is very limited,uz,13 particularly in developing countries. However, 
evidence from developed countries is by no means adequate either.14,1S As a 
result, antenatal interventions in both developed and developing countries are 
based more on established clinical opinion than on scientific evidence.s This is 
particularly true of recommended content and patterns of routine antenatal visits. 
Although there is increasing scientific evidence on the costs and effects of single 
interventions during pregnancy and childbirth, much of this research has been 
carried out in developed countries and is therefore biased towards the 
technologies available in high-income countries.12 
The WHO antenatal care trial is comparing a rational programme of care with 
current routine antenatal care practice in cities or regions in four middle-income 
countries: Argentina, Cuba, Saudi Arabia and Thailand. The protocol for the trial 
has been based on reviews of evidence about effective clinical practice in antenatal 
care.2,S,12,16 Although the agreed protocol is being followed in every centre, the 
trial has a pragmatic design, allowing the new rational programme of care to fit in 
with local circumstances, such as who the main care givers are, or requirements to 
screen or treat particular conditions peculiar to that setting. 
The clinical and statistical aspects of the trial are discussed elsewhere in this 
Supplement. Economic considerations were included in the design from the first 
stages of planning for the trial. Funds were granted by the United Kingdom DfiD 
(formerly the ODA) for a pilot study that took place during 1996 to establish the 
feasibility of the additional data collection necessary for economic evaluation. In 
the pilot study, conducted during 1996, we found that the data were available, or 
could be collected, to estimate unit costs, and that local collaborators in each 
country were willing to supervise the work. Funds have now been granted for 
economic data collection in the centres in Thailand and Cuba for a two and a half 
year project, which will estimate the costs of the alternative antenatal care 
interventions and assess the cost-effectiveness of the new programme. Funds have 
also been granted as part of the same project by the DfiD for a study in KwaZulu-
Natal in South Africa to investigate international generalisability of the cost data 
beyond trial centres. We are still seeking funds to conduct the economic evaluation 
in Argentina and Saudi Arabia. 
Aims of the economic evaluation 
The aim of an economic evaluation, ultimately, is to provide evidence to estimate 
the net benefit or loss to society of adopting a particular policy. The aim is to help 
decision makers to establish whether the gain in health from a new programme of 
care is worth the cost of the additional resources used. 
The objectives of the economic evaluation of the antenatal care trial are: 
• to compare the costs of the new model of antenatal care with the traditional 
package of antenatal care 
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• (if the WHO trial shows a difference in any of the primary outcomes) to assess the 
cost-effectiveness of the new model of care compared with the traditional package 
• to explore whether the economic results of the trial are generalisable to other, 
lower-resourced settings. 
The aims will allow us to address the primary hypothesis of the WHO trial: 
'a new model of antenatal care which includes only those components shown 
to be effective in improving maternal,'perinatal and neonatal outcomes, is 
more efficient than the traditional package with regard to specified maternal and 
perinatal end points, among singleton pregnancies, and is not more expensive.,2 
It is important to note that, although the new package of antenatal care is 
expected to be cheaper, should it prove more expensive, it may still be considered as 
a more cost-effective option if the additional cost is accompanied by greater benefits. 
The third aim of the economic evaluation reflects the priorities of the DfID, the 
agency funding the economic evaluation. The question of the applicability of the 
results of the WHO trial in poorer countries is of key importance to such agencies 
with responsibility for international aid for development of effective health services. 
Other objectives of the economic evaluation include: 
• local capacity building for health economics research, which is also a priority 
of the DfID and WHO 
• collaborating with local policy makers, to assess their needs for information, 
and ensure the results of the economic evaluation are useful to them. 
Methods for the economic evaluation 
This study has been designed as a cost-effectiveness analysis (CEA) alongside a 
randomised controlled trialP-19 In the CEA, changes in health are expressed in 
terms of the primary health outcome measured in the study, such as life-years 
gained, or in the case of the WHO trial, changes in the maternal morbidity index 
and rate of low birthweight. The costs of resources used in alternative treatment 
options will be compared in terms of these primary health outcomes. If there is no 
difference in the primary health outcomes of the alternatives, then the analysis is 
sometimes referred to as cost minimisation analysis (CMA). 
Economic evaluation requires specification of: 
• the question of the study 
• the treatment alternatives 
• the health outcomes 
• the 'economic' outcomes 
• the resources to be included in unit cost estimation 
• the unit cost estimation method 
• da ta collection 
© 1998 Blackwell Science Ltd. Paediatric and Perinatal Epidemiology 12, Supp!. 2, 75-97 
343 
APPENDICES 
The WHO antenatal care ReT: evaluating costs . 79 
• data presentation and analysis 
• how issues of generalisability are to be dealt with. 
Finally, before conclusions can be drawn about the cost-effectiveness of the 
new form of care, any uncertainty, weaknesses and limitations in the data 
definitions and measurement should be considered, and their impact explored in 
sensitivity analysis. . .. 
What is the question? 
The central concern of this economic evaluation is that the new programme of 
antenatal care does not result in higher costs overall, to both the health services 
and to the women receiving care, than the currently practised antenatal programme. 
Several other questions are relevant for interpretation of the meaning of the 
results from different viewpoints and for extrapolation to different settings: 
• Is an antenatal visit more or less costly under the new programme of care? 
• Which costs are borne by different agencies or participants? How much do 
estimates vary when different costs are included/excluded, such as women's 
time costs? The relative cost-effectiveness of the two programmes of antenatal 
care may change considerably when women's costs are included, as has been 
shown elsewhere.2o,21 This leads us to ask whose viewpoint the analysis 
should represent. While it is important for an economic evaluation to adopt a 
societal perspective in order to illustrate where the most benefit could be 
gained, the costs of different agencies should also be presented separately, as 
they may highlight conflicts in incentive to change practice. 
• How much do the costs of antenatal care vary by setting? If routine antenatal 
care is as effective but cheaper in primary health centres than in hospital 
clinics, this has important implications for where resources for low-risk care 
should be concentrated. Although it is not an objective of the trial to assess 
differences between types of clinic, information about cost variation may 
stimulate questions about relative effectiveness. 
What are the treatment alternatives? 
A second step in an economic evaluation is to identify and define the alternative 
intervention possibilities and choose which to evaluate. The interventions under 
comparison have been decided, and the rationale for this is provided elsewhere.3 
The alternatives being compared are a new model of antenatal care, developed by 
experts, and the baseline model of antenatal care as currently implemented in the 
selected sites. The baseline models differ to some degree between the study sites,22 
which may affect estimated differences between costs of the two programmes of 
care in the four trial centres. For example, the average number of visits in the 
© 1998 Blackwell Science Ltd. Paediatric and Perinatal Epidemiology 12, Suppl. 2, 75-97 
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baseline model of antenatal care varies from roughly four routine visits per 
women in Argentina to over eight in Cuba. ' 
In each of the centres, outpatient antenatal clinics which provide routine antenatal 
care at community level based in health centres or attached to a hospital are the 
unit of randomisation. In some countries, such as Thailand, there are also primary-
care health posts which may also be used to a greater or lesser extent by pregnant 
women, but these are not included as part of the programme being evaluated. 
The WHO trial is based on cluster randomisation with clinics as the unit of 
randomisation. The population participating 'in the trial'is women attending 
antenatal clinics in publicly funded health-care facilities, with the exClusion of 
those women classified as high risk. Socio-economic and epidemiological 
indicators collected alongside the trial show that women participating in the trial 
are likely to represent the majority of women eligible for routine pregnancy care in 
the participating countries?2 The advantage of the cluster design for the economic 
evaluation is that the unit of randomisation is also a key unit of health 
management and cost generation. 
What are the health outcomes of the treatments? 
The primary outcomes are an index of maternal morbidity and the rate of low 
birthweight. There are several secondary 'clinical' outcome measures, and these 
are listed in full elsewhere? The trial is also evaluating both women's and 
providers' views of care and their satisfaction with the health-care process. These 
views may relate either to the different frequency or to the different contents of the 
new programme of care, or both, compared with the traditional programme of 
care. Details of these outcomes are provided elsewhere?3 
What are the 'economic' measures? 
The third group of outcomes being measured in the antenatal care trial indicate 
the quantity of resources used to provide health care. These, together with unit 
cost estimates for these items of resource use, allow estimation of differences in 
cost of providing care between the two programmes of antenatal care. These 
'economic' outcomes relate to the changes in inputs required for the routine 
intervention and those required as a consequence of that care. This includes costs 
associated with routine care, provided at antenatal visits and during delivery, but 
also the other health-care costs associated with the progress of pregnancy and 
delivery, diseases and complications, and any inpatient stay that results. The 
elements of care we chose as outcome measures for the WHO trial were chosen 
• to represent the range of care likely to be provided 
• to be mutually exclusive 
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Table 1. Items of resource use chosen to estimate'cost differences 
• Antenatal care visits (routine and other) 
• Days of inpatient care during pregnancy 
• Days of inpatient care during labour, delivery and post partum 
• Surgical procedures associated with pregnancy and labour complications 
• Days of neonatal specialist care 
• Any other outpatient or inpatient postnatal care until six weeks after delivery 
• to be reasonably homogeneous in cost between cases 
• to minimise the extra data collection burden for trial participants. 
As a result, the WHO trial includes data collection about the use of the 
different services listed in Table 1. We refer to these as resource quantity data. The 
work of the economics researchers is to estimate unit costs both for the health 
providers and for women for each of these types of care, to combine the costs and 
quantity data in cost analyses for the two arms of the trial and to compare the 
resulting cost differences with any differences in health outcome. 
What resources should be included in unit cost estimation? 
To estimate the unit costs of the health-care services listed above, we have applied 
the following criteria for an input type to be included in unit costs: 
• the resource must either be an input to the health-care process, or be affected 
by it 
• the resource must be relatively significant, that is, it must contribute 
significantly to the cost of the item of care 
• the resource must be measurable in physical units 
• the value of the resource must be convertible to monetary units via a unit price 
or cost. 
In Table 2, we list the resource inputs that were found to have met these 
criteria during our pilot study. Some of these resources are involved directly in the 
health-care process, while some are inputs to overheads or support services, such 
as laboratory and management inputs. 
Table 2. Items of resource input to health care included in cost estimation 
• Staff 




• Utilities (gas, electricity, water, telephone) 
• Buildings and land 
© 1998 Blackwell Science Ltd. Paediatric and Perinatal Epidemiology 12, Suppl. 2, 75-97 
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With respect to women's costs, the aim of the study is to estimate the net effect 
of attending antenatal care on women's own economic circumstances. Indicators 
of possible variations in costs that women bear in order to attend the antenatal 
clinic are listed in Table 3. We will also estimate the cost incurred by women in the 
trial who are delivered in private hospitals. 
There are other social costs that may not be captured by measuring these costs 
alone, such as knock-on costs in the family and wider community. For example, a 
child may have to take the morning off school to look after a junior sibling, to 
enable the mother to attend the clinic. We will have data to estimate the degree to 
which such costs may be different between types of care, although not to quantify 
the overall economic impact. 
How should unit costs be estimated? 
Two main options are possible for unit cost estimation. The first option is to 
measure all the resources consumed by individual patients and then calculate the 
unit cost for each type of resource consumed. For example, for estimating the cost 
of an antenatal visit, this would involve recording all drugs, tests, staff time, 
equipment and so on, used by each of a selected sample of women attending a 
clinic. The cost per visit is then calculated using these data, together with the unit 
cost of each input. This is often termed the bottom-up approach. A second option is 
to estimate total resource cost for a given volume of patients, and the unit costs per 
patient are calculated, by dividing the total cost by the volume of service use. This 
is often termed the top-down approach. Each of these approaches has advantages 
and disadvantages, listed in Table 4. The distinction between methods is often one 
of degree. Usually some element of simplification and averaging is used in 
bottom-up exercises, and it is also frequently the case that bottom-up methods are 
needed to apportion top-down costs correctly between cases of different types. An 
advantage of top-down costing is that it ensures that the whole cost of the service 
is equal to the sum of the parts and that any errors of costing in one part will be 
offset by errors in other parts. 
Table 3. Aspects of cost to women to be estimated in the study 
• Travel costs (e.g. bus or taxi fare, or private car) 
• Out-of-pocket expenses for the antenatal visit (e.g. consultation fees, laboratory tests, 
prescription charges) 
• Other out-of-pocket expenses to attend the clinic (e.g. child-minding expenses) 
• Insurance premiums for government or private insurance schemes 
• Lost income as a result of attending the clinic 
• Opportunity costs of time spent travelling and in the clinic 
• Costs for a companion to accompany the women to the clinic 
• Other costs (e.g. dietary supplements, antenatal care received at rrivate clinics) 
© 1998 Blackwell Science Ltd. Paediatric and Perinatal Epidemiology 12, Supp!. 2, 75-97 
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Table 4. Some advantages and disadvantages of bottom-up and top-down costing 
Bottom up Top down 
Advantages 
• Measures details of inputs to costs more • Easy to perform 
reliably • Fewer data requirements 
• Gives data on effects of case-mix (inter- • Uses data routinely collected for 
patient variation) on costs ·accounts and management 
• Number of observations more likely to • Less research time and less cost 
facilitate statistical analysis of cost • Fewer research skills needed 
variation • Likely to cover all relevant inputs to 
• Can be specific to women taking part in care 
WHO trial 
Disadvantages 
• Greater presence of cost researchers • No data about inter-patient variation 
may disrupt clinical trial within cost centres (e.g. clinics) 
• Can inadvertently omit or underestimate • Use of secondary data may require 
key inputs to care validation 
• More complex primary research work • May be biased by inclusion of 
• More costly to perform research women not in the WHO trial 
• Overheads and joint costs are difficult 
to allocate between patients and activities 
The bottom-up approach relies on more intensive primary research, based on 
interviews, case notes, observation and/or time and motion methods. Such an 
approach provides reassurance that details of inputs to costs are more reliably 
included, gives data on inter-patient variation, and also allows statistical analysis 
of cost variation within a health centre or clinic. The method can also be specific to 
women taking part in the WHO trial, whereas the top-down method at its 
simplest would estimate an average cost for all women attending a particular 
facility, regardless of their trial status. On the other hand, there are disadvantages 
to the detailed bottom-up approach to costing. The greater presence of economics 
researchers may disrupt the smooth running of the service and therefore the 
pragmatic nature of the clinical trial. This method can also inadvertently omit or 
underestimate key inputs to care. Where costing is based on observation of inputs 
used during patient contacts, it is possible to miss costs incurred for the care of the 
patient which do not occur at the time of patient contact. Examples of this might 
include a case conference, or time spent arranging referral between carers. A 
related difficulty in bottom-up costing, also found to some extent in tOp-'down 
costing, is that overheads and joint costs are difficult to allocate between patients 
and activities. Finally, because the method requires more complex primary 
research work, it is more costly to do. Top-down methods are made easier by 
presence of available data. This is possible in centres such as those taking part in 
the WHO trial. Even where such data exist, however, we must reassure ourselves 
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as to what is included in the costs, and whether accounting conventions are the 
same between the participating centres. 
Choice of approach for estimation of unit costs 
The advantages and disadvantages of the different methods can have different 
weights or priorities in different circumstances. In the context of the WHO 
antenatal care trial, the greatest constraint is the availability of research time, and 
this is needed in much greater quantity for the bottom-up method. Therefore, a 
top-down approach has been chosen, although this will be supplemented and 
validated by some bottom-up estimates. However, we also feel that a detailed 
bottom-up approach is unlikely to give more accurate data in these circumstances, 
because of the greater complexity involved in allocating overhead and joint costs 
between patients and activities. We are further justified in this decision by 
analyses comparing different methods of costing in cost-effectiveness analysis that 
suggest that more complex costing approaches do not result in significantly 
different estimates of cost difference.24 
The approach used for estimating unit costs in the WHO antenatal care trial is 
therefore a combination of the two approaches. Some unit costs, such as surgical 
procedures and laboratory tests, will be estimated using the bottom-up approach, 
because the procedures are heterogeneous and there are limited routine data 
available about these costs. Most other unit costs will 'be estimated using the top-
down approach, where we have evidence that patients are more homogeneous in 
their resource use. For example, in the antenatal clinics, high-risk cases are often 
referred to higher level care, leaving only low-risk cases in the primary health 
clinics. Also, the care provided in different inpatient wards is usually determined 
according to intensity or type of care, thus separate unit costs can be estimated for 
different types of ward. 
Data collection 
Health-service costs 
Data for costing are being collected at all of the participating clinics and associated 
hospitals where women receive care in Cuba and Thailand. Data forms have been 
designed to record the physical quantity and money value of resources at the 
participating health facilities. These facilities not only include those that have been 
randomised to either arm of the trial, but also those health facilities that provide 
secondary and higher levels of health care to women taking part in the trial. These 
will include central referral hospitals for high-risk cases, delivery and intensive care. 
The data forms will be completed for each month for 1 year during the trial 
period by the economics researcher in Cuba and Thailand. The methods for 
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measuring the physical and monetary values were tested during the pilot study, 
and the results are summarised in Table 5. Although there will be some differences 
in measurement and valuation me~hods between study sites because of differences 
in both political context and data availability, the results will be presented in 
, standard format to increase their international comparability. The sources of data 
depend largely on the degree of autonomy of the hospitals and clinics from the 
local health administration, which determines. the amount of accounting and 
administrative information kept in the health facilities themselves. For example, 




Physical resource measurement 
Amount of health-care staff time 
spent in different activities, 
recorded by heads of departments 
Amount of staff time spent 
working for each health-care 
department, depending on service 
use by the health-care departments 
Drugs, medications Supplies consumed by pregnant 
and supplements women in health-care departments 





Materials consumed by . health-care 
and support departments 
Numbers of items in inventory, 
verified by the researcher 
Number of journeys and miles 
undertaken per month for pregnant 
women 
Quantity or value consumed by 
each department, measured using 
an appropriate allocation unit-
e.g. number of taps for water costs 
Land and buildings Number of buildings and land area, 
area occupied by clinic/ward 
Monetary unit valuation 
Add together salary, 'perks' 
allowances and overtime 
payments. Shadow prices 
in Cuba 
Add together salary, 'perks', 
allowances and overtime 
payments. Shadow prices 
in Cuba 
Market or govemment-
supplied prices. Shadow 
price estimates for 
imported items 
Market or govemment-
supplied prices. Shadow 
price estimates for 
imported items 
Monthly depreciation value 
(using replacement cost) . 
plus maintenance. Shadow 
price estimates for 
imported items 
Monthly depreciation value 
(using replacement cost) 
plus maintenance, staff and 
fuel costs. Shadow price 
estimates for imported items 
Monthly payments made to 
utility companies 
Monthly depreciation value 
(using replacement cost) 
plus maintenance cost 
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where there is centralised organisation of personnel and supplies, as is often the 
case, there may not be detailed record keeping at clinic level about the costs of 
these inputs. 
The data sources chosen to measure the economic variables will be verified 
, periodically to ensure that the data are accurate. For example, in Thailand, data 
collected on staff salaries and overtime will be compared with expenditure 
summary sheets sent to the Ministry of Health every month, and the budgets that 
are allocated to the hospitals. Information on equipment lists and unit prices will 
be compared between different sources of information, and any differences will be 
investigated. 
Women's costs 
A questionnaire to measure the costs borne by women was developed in each 
country during 1996. This provided the information to design a final questionnaire 
for women in the main economic study. The questionnaire will be administered by 
interviewers fluent in the local language and includes closed questions (with 
options for 'no response' and 'don't know') asking how the woman travelled to 
the clinic, the cost of the travel, how long she spent travelling and at the clinic, and 
whether she incurred other health-related costs in respect of this visit and more 
generally in this pregnancy. To estimate opportunity costs, we also ask about 
occupation, lost earnings and health insurance status. Over 300 questionnaires will 
be completed in each country for a sample of women in a representative sample of 
clinics in the WHO trial. To ensure that they represent the population of clinic 
attenders, the sample of women will include women having first or subsequent 
visits and will be analysed by whether they are attending intervention arm or 
control arm clinics. This part of the costing research will be coordinated as far as 
possible with the women's satisfaction survey, in order to minimise both the costs 
of research and disruption in the clinics?3 The costs survey is being carried out 
separately from the women's satisfaction survey in Thailand and Cuba, but in 
Thailand the same researchers are conducting both costs and satisfaction surveys. 
A reduced form of the questionnaire has been designed for use in the two 
countries, Argentina and Saudi Arabia, where the economic evaluation is not 
yet funded. 
The opportunity cost of women's time will be valued in monetary units, using 
a range of different approaches. These data will not be combined with out-9f-
pocket expenses. There is no consensus among economists on a single appropriate 
valuation method. For example, we will use an estimate based on valuation at average 
wage rates for women, and a more exact method based on what would have to be 
paid for the work which would have been done if the women were not at the 
clinic. Data on women's time costs will also be presented in natural units, to allow 
for cross-country comparisons of quantity of women's inputs to their own care. 
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The data from this survey will be verified using information about local 
transport fares, local incomes for various professions and clinic charge schedules. 
Waiting times will be difficult to verify exactly without time-and-motion studies, 
which will not be an option. 
Data presentation and analysis 
Data from the health costing and survey of women will be collated to produce 
tables of costs 
• at health facility level 
• at country level 
• at international level. 
The first will be completed, as far as is relevant for each health facility, such as 
clinic or hospital ward. This summarises the costs of each of the key 'cost generating 
events' such as antenatal visits, a day of inpatient antenatal care, a normal delivery 
and so on, at each individual clinic or ward. From these data, the country-level tables 
can be constructed, which summarise the costs in the control and intervention anns at 
the country level. Finally, all country-level costs will be summarised with conversion to 
a common currency. This final stage allows an overall comparison of the costs in the 
control and intervention anns, which are combined with effectiveness data. Each table 
will indicate not only the average values at each stage but the variability of estimates. 
In pooling and comparing data from each of the participating centres, local 
currencies will be converted into a common currency (US$) using an official 
exchange rate and a shadow exchange rate, which reflects the full value of changes in 
foreign exchange. Current estimates of shadow exchange rates for each centre are 
available from international agencies such as the World Bank.25 Cost estimates 
based on exchange rates can overestimate real purchasing power. Therefore, 
currencies will also be adjusted using purchasing power parities. These are 
calculated by comparing the costs of similar bundles of goods in a common 
currency and, again, can be collected from international agencies. 
Interpretation of the cost differences between countries is complicated by the 
methodological difficulties of such conversions. It is therefore also important to 
express differences in natural units, such as units of types of health-care staff time. 
If the skills and input values are similar across countries, these data can be compared 
across currency borders. This is particularly important in the WHO antenatal care 
trial, which includes centres within countries of types of economies as diverse as 
Argentina, Cuba, Thailand and Saudi Arabia. There can be no assumption that 
relative and absolute prices within these countries reflect similar values. 
Cost data will also be presented in a variety of 'cost profiles' for each type of 
health care costed, showing the proportion of each resource used, comparing and 
contrasting the health facilities within and between the four study centres. 
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Differences in costs and effects of the two programmes of care will be 
combined to estimate the incremental cost-effectiveness of one programme over 
another. This identifies the cost associated with a given change in health effect. If 
one programme is both more effective and less costly thiln the other, and if there 
are no other unmeasured factors that would alter choices, then it is dominant and 
should be adopted widely. If one programme is more effective and more costly 
than the other, then the results will inform society of the extra, cost of an increase in 
a specified health gain. . 
Before any conclusions are made, any assumptions and uncertainties should be 
tested. This is done using sensitivity analysis. This will include testing whether the 
inclusion of women's costs has any impact on the result. The possible influence of 
future costs will be tested, such as a reversal of the relative effectiveness of the 
pr~grammes after 6 weeks post partum. Finally, the sensitivity of the results to 
changes in the cost of resources, such as staff time input and unit prices, will be 
tested in a multiway sensitivity analysis. 
Issues of generalisability of the costs and cost-effectiveness within and beyond the 
WHO trial centres 
Health-service costs and women's costs will not be combined into a single cost 
estimate, for reasons already given. For each of, these two broad areas of cost, 
however, costs can be compared assuming the shadow pricing and purchasing 
power parity weighting method can be justified to express the relative values of 
resources between different countries. Because the baseline programme of 
antenatal care, which forms the control group for the WHO trial, may differ 
substantially between countries,22 comparison of average costs across trial centres 
for 'baseline' care and differences between the new and baseline programmes may 
be fairly meaningless. Therefore, the costs and outcomes in control clinics ~ill be 
compared considering, in sensitivity analysis, whether the differences affect 
overall conclusions about the cost-effectiveness of the new programme of care. 
However, in a developed country, comparison of drug treatment for gastric ulcer, 
Drummond and his colleagues26 conclude that, despite.practice variations in the 
countries they studied, the similarity of results in four countries greatly increases 
their confidence that cross-national assessments of health technologies are both 
feasible and useful. 
The generalisability of cost and cost-effectiveness evidence will be an 
important consideration in collecting and analysing the trial data. For this 
purpose, data on health services will also be collected in other lower-resourced 
settings, to investigate the feasibility of generalising cost and cost-effectiveness 
data. The countries to be included in this part of the analysis include South Africa, 
The Gambia, Zimbabwe, Indonesia and Bangladesh. The choice represents 
countries where the authors have contacts in Maternal and Child Health activities. 
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South Africa is a special case, as funds have been granted by the DFID to 
investigate the issue of generalisability in depth. This research will take place in 
KwaZulu-Natal province. . 
From the data collected from 'non-trial' countries, investigations will be made 
of whether enough resources are available to adopt either programme of care, and 
whether the skills are available to deliver it as effectively as in the antenatal care 
trial. Data will be collected on local characteristics ~nd features of the health service, 
including prices, morbidity and utilisation patterns. Also, women's costs will be 
modelled in these countries, based on local prices, practices and utilisation patterns. 
There are several factors that must be recognised in pooling the data and 
interpreting the results from the economic evaluation of the trial. First, because of 
the diversity of the settings taking part in the trial, the trial protocol has minor 
differences in each country. This relates to both local government laws on minimal 
health care for pregnant women and local morbidity patterns. For example, in 
Cuba there are several compulsory home visits by nurses, which could be 
interpreted as additional antenatal visits (as .they might lead to better outcomes). 
Also, in Argentina, diagnosing and treating Chagas' disease will still take place.in 
the intervention arm of the trial, with its associated costs and benefits, despite not 
being in the WHO protocol. In both cases, as these externally imposed aspects of 
care occur in both arms of the trial, they will not be included in the economic 
evaluation. They will only affect the evaluation in the degree to which they alter 
women's health status and use of antenatal services within that trial centre. 
Secondly, women may make visits to private clinics during their pregnancy, 
and these may not be recorded in the summary forms. The problem is that such 
visits both increase the costs of antenatal care and may alter the outcome of 
pregnancy; however, they will not necessarily be captured in the economic 
evaluation. Efforts will be made to identify these visits in the women's cost 
questionnaire. If the number of visits to private clinics is high, and varies between 
arms of the trial, then some steps will have to be taken to include associated costs. 
On the other hand, outcomes for women recruited to the trial who deliver in 
private hospitals or at home will be recorded in the trial summary form. 
Thirdly, there are several costs that the health facilities incur that are associated 
witli. the trial only and would not continue after the trial has ended. These costs 
are related to the additional form filling required for the trial. The economic 
evaluation will exclude these costs, however. 
Fourthly, the countries in the WHO trial have such different economic 
structures that it will be very difficult to ensure equivalent methods for estimation 
of opportunity costs. If distortions are found to exist in the market, then the 
market price does not represent the true opportunity cost of the resource and 
alternative values must be sought. For example, in the case of government salaries 
for health-sector workers, the price paid to labour may be artificially depressed 
because of government control of prices. In this case, the private-sector rate should 
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be examined, if it exists, although this again may be artificially high because of 
government-imposed restrictions or punitive tax rates. The approach being 
adopted is to conduct the analysis with both public- and private-sector values, 
giving an upper and a lower limit for the costs of health-care staff, between which 
the true opportunity cost is likely to fall. In Cuba, where almost all health-care 
workers work in the public sector, the opportunity cost will be constructed using 
all forms of payment, both monetary and in k~d, made by the State to employees. 
Study organisation and collaboration 
The economic evaluation is being administered by the UK project team (MM, GH 
and JF-R) and is based jointly at the University of East Anglia and the London 
School of Hygiene and Tropical Medicine. In addition to the UK project team, 
there will be research teams in Cuba, Thailand and South Africa. While we have so 
far been unsuccessful in seeking funds for data collection in Argentina and Saudi 
Arabia, we still hope that costs will be ,estimated at all those health facilities 
participating in the clinical trial in these countries. The research teams in Cuba, 
Thailand and South Africa will run their economic evaluation with support from 
the UK team members. Each centre is responsible for producing a report of results 
within the centre, and a comparative report will be written by the UK team in 
collaboration with the research teams in each centre. 
Discussion 
The WHO antenatal care trial, and associated economic evaluation, provides a 
unique opportunity to measure the costs of antenatal care prospectively, alongside 
the actual health-care processes for which effectiveness is being measured. There is 
much excitement about the data that will be forthcoming from such a large 
multicentre trial as this one, which is the first of its kind in reproductive health. In 
this paper, the methods have been described for evaluating whether a new, 
'evidence-based' programme of antenatal care will be more or less costly for the 
health service and for women, and whether it would be more cost-effective. The 
methods reflect the state-of-the-art in multicentre economic evaluations. 
Two broad issues will affect the interpretation of the results of this study. The 
first is the confidence we can have that the results represent local cost differences, 
which in tum depends on the completeness and validity of research methods and 
assumptions. The second is whether the results can be combined to predict a general 
relationship between costs and outcomes of antenatal care, both within the range 
of the study centres and also extrapolated from them to other countries and settings. 
The reliability of results is enhanced by the association of the economic study 
with a carefully designed randomised trial, in which bias is minimised regar<iing 
the differences in quantities of service used. However, there is less certainty about 
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the methods for estimating unit money costs. Practical measurement of the 
derived cost variables has not been an area of research that has received much 
attention from health economics methodologists, and the methods used in this 
study are little tested. 
There may be broader, long-term economic effects on the population or health 
service that have not been accounted for in the instruments of the clinical, 
economic or satisfaction components of the trial. For example, if the new 
programme of care eventually leads to lower fertility rates, there would be long-
term social and health service implications. However, it was not within the scope 
of this study to address these issues. Furthermore, the economic evaluation will 
only measure the short-term costs and consequences of care. This is largely due to 
the fixed end point of the trial at 6 weeks post partum, but is also because it would 
require a larger research effort than can be managed within· the available 
resources. If there are large changes in short-term severe maternal morbidity as a 
result of the new programme, then there are likely to be associated longer-term 
economic changes. 
Finally, policy implications of the results have been considered in shaping both 
the methods and the presentation of the data. The costs of adopting the new 
programme of care as routine practice will be calculated for the participating 
centres, and cost simulations will be made for non-trial settings. This will give 
an indication of the ch~ui.ges in budget requirements, investment in certain 
resources and other essential changes for a newly adopted programme of care to 
be successful. 
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Appendix 4: W.H.O. antenatal care trial economic evaluation information 
Table 4.1: Calculation of purchasing power parities / " /' 
Food item Quantity Thai Cuba South Africa UK USA' 
Baht Centavo Rand Pence Cents 
Rice 1 kg 19.5 50 4.1 69 111 
Sugar 0.5 kg 13 50 2.15 45 72 
Bread 3 loaves 55 80 6.4 34 55 
Dried beans 1 kg 75 70 5.1 95 153 
Eggs 6 12 60 2.95 75 121 
Chicken 1 kg 44 100 8.5 245 394 
Cooking oil 0.5 litre ',14 30 3.15 39 63 
Salt 0.5 kg 3.5 30 0.74 25 40 
Milk 1 litre 29 16 2.84 52 84 
Potato 1 kg 45 40 2.5 76 122 
Coffee 0.1 kg 42 40 4.1 53 85 
Tea 25 bags 20.6 15 1.5 52 84 
Total cost (all items) 372.6 581 . 44.03 860 1385 
Official exchange rate Actual 52.3 1 4.93 0.62 1 
Cost in US$ at OER Actual 7.12 5.81 8.93 13.85 13.85 
PPP exchange rate Estimated 26.91 0.42 3.18 0.62 1 
Adjustment Estimated 1.94 2.38 1.55 1.00 1 
Table key: 1 This is estimated from the UK price data, as the bundle of goods was not estimated in USA. 
It was necessary to estimate the prices in US$ so that comparisons could be made between official 
exchange rates and PPP with the US$ .. The UK: US$ exchange rate was US$l = UKO.621 
As there were no international estimates available for purchasing power parities (PPP) 
values in Cuba, it was decided to estimate our own 'bundle of goods' in all the study 
countries in order to maintain consistency between countries. The items were chosen 
based on what was considered to be essential foodstuffs that were available in all 
countries, and the quantities were chosen based on expected consumption in roughly a 2 
week period. 
Therefore, to get US$ values using PPP, the US$ values for each country (obtained 
using OER) are multiplied by the adjustment factor in the last row. 
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Table 4.2: Step-down allocation for calculation of unit costs in Cuban poIiclinics 
CENTRE 
Resources COSTS ALLOCATED TO / USING 
SERVICES ADMINISTRATION 
Staff LABORATORY % FULL TIME 
Equipment DIRECT COSTS TECHNICAL SUPPORT . EQUIVALENTS Materials FAMILY DOCTOR CLINIC (TOTAL - SERVICES) 
Buildings OBSTETRICS 
Overheads OTHER SPECIALISTS 
ADMINISTRATION LABORATORY 
Staff DIRECT COSTS TECHNICAL SUPPORT % FULL TIME 
Equipment + FAMILY DOCTOR CLINIC EQUIVALENTS 
Materials Allocated from OBSTETRICS (TOTAL-SERVICES-
Buildings SERVICES OTHER SPECIALISTS ADMIN) 
Overheads 
TECHNICAL SUPPORT DIRECT COSTS 
Staff + FAMILY DOCTOR CLINIC %VISITS 
Equipment Allocated from 
Materials SERVICES OTHER SPECIALIST CLINICS %VISITS 
Buildings & 
Overheads ADMINISTRATION OBSTETRICS INCLUDED IN F.D.C. 
EXTERNAL PHARMACY 
Staff CLINICS (1) %VISITS 
Equipment 
DIRECT COSTS Materials OTHER SPECIALIST CLINICS %VISITS 
Buildings INCLUDED IN Overheads OBSTETRICS CLINICS 
LABORATORY DIRECT COSTS 
Staff + CLINICS(ANC)(i) %PREGNANT TESTS 
Equipment Allocated from 
Materials SERVICES 
Buildings & REMAlNDER %NOT PREGNANT 
Overheads ADMINISTRATION TESTS 
F.D.C. (I) Allocated from 
Equipment SERVICES CLINICS(2) %CLINICS VISITS 
Materials ADMINISTRATION 
Buildings TECH. SUPPORT FIELD(l) %HOME VISITS Overheads EXT. PHARMACY 
F.D.C. (II) CLINICS(3) %CLINICS TIME 
Staff DIRECT COSTS FIELD(2) %HOMETIME 
OTHER %OTHERTIME 
F.D.C. (III) 
Equipment, Materials, DIRECT COSTS CLINICS(4) 100% 
Buildings. Overheads 
OBSTETRICS DIRECT COSTS CLINICS(ANC)(ii) Staff %CLINICS TIME 
Equipment + Allocated from 
Materials SERVICES FIELD(ANC)(j) %HOMETIME 
Buildings & Overheads ADMINISTRATION OTHER %OTHERTIME 
CLINICS Allocated from 
(1)+(2)+(3)+(4) EXT. PHARMACY CLINICS(ANC)(iii) %CLINICS & PREGNANT VISITS 
FDC (I. II. III) 
FIELD (1)+(2) Allocated from FDC FIELD(ANC)(jj) %FIELDPREGNANT (I,ll) VISITS 
The calculation of Antenatal Care Costs in Clinics (ANC CL COST) and Fields (ANC FIELD COST) 
used the following formulae: 
-ANC CL COST=CLIN(ANC)(i)+CLIN(ANC)(ii)+CLIN(ANC)(iii)+DRUGS 
-ANC FIELD COST= FIELD(ANC)(j)+ FIELD(ANC)(jj) 
(Clinic unit cost = ANC cl cost I clinic throughput) 
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Table 4.3: Background and tasks of research team members in study countries. 
Country and collaborator 
Cuba 
Ana Maria Galvez (PI) 
Manuel Alvarez 
Dr Giselda Sanabria 
Dr Martha Morales 
MPH students 
Thaiklnd 
Background and training 
Health economist 
Geographer and health planner 




Tasks in economic study 
Supervision and data collection 
Data entry and processing 




Dr J adsada Thinkhamrop (PI) 
Dr Bandit Thinkhamrop 
Chusri Chaisiri and Chintana 








Supervision and data collection 




Prof Noddy Jinabhai (PI) 
Joseph Wamukuo 
Dr Chauntelle Bagwandeen 
Four research nurses 
Others 
Doctor of Community Health 
Health economist 
Obstetrician 
Nurse and social science 
researcher 
Various research staff 
Supervision 
Data collection 
Supervision and data collection 
Data form administration 
Questionnaire translation and 
statistical support 
Table key: PI - Principal Investigator; MD - Medical Doctor 
Table 4.4: Site visit details by UK research team 















GH (1 month) 
GH (1 month) 
JFR (2 weeks) 
GH (10 days) 
MM (lOdays) 
GH (2 weeks) 
JFR (1 week) 
GH (1 month) 
MM (2 weeks) 
GH (1 month) 
MM (10 days) 
GH (2 weeks) 
GH (1 month) 
GH (1 month) 
GH (3 weeks) 
Purpose of trip 
Identify economics collaborators 
Assess data availability 
Set up data collection 
Train local collaborators 
Assess progress 
Finalise data collection 
Agree further plans 
Identify economics collaborators 
Assess data availability 
Set up data collection 
Train local collaborators 
Finalise data collection 
Agree further plans 
Identify economics collaborators 
Assess data availability 
Set up data collection 
Train local collaborators 
Finalise data collection 
Agree further plans 
Table key: MM - Miranda Mugford; JFR - Julia Fox-Rushby; GH -Guy Hutton. 
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Table 4.5: Sources of uncertainty and alternative values - Insufficient observations on a parameter I 
Area of uncertainty (criticism) Base case Alternative value(s) or design 
Number of months of data collection was 15 months of data in Thailand 1. Examine Thai data set to see the extent to which reductions in 
insufficient in Cuba and South Africa, and 8 months of data in Cuba number of months impact on unit costs. Apply the % unit cost impact 
therefore do not reflect the seasonal variation 4 months of data in South Africa to Cuban and South African data to get new ranges. 
over a year period 
Number of women from whom drug costs were Antenatal cards of 12-15 women per 1. Combine all health facilities in same arm to increase sample size, and 
collected for outpatient visits may not be health facility in Cuba and Thailand (not apply the averages within each arm (outpatient visits only). 
sufficient done in South Africa) 2. Examine wh)"drugcost per visit varied between health facility. 
Material and drug costs were averaged over the Thailand: materials and inpatient drugs Other data were not collected, and therefore it is unclear how alternative 
period of the study, and the average was applied in district hospitals value(s) can be supported 
to each month (data systems did not record actual Cuba: materials in policlinics 
usage) 
The actual use of utilities by each department was The number of utility 'outlets' was used Other data were not collected, and therefore it is unclear how alternative 
not measured to proxy utility usage value(s) can be supported 
Numbers of uses of support and overhead Number of full-time equivalents were Other data were not collected, and therefore it is unclear how alternative 
departments by each other and by health care used to proxy the use between cost value(s) can be supported 
departments is unknown centres 
The connection between cost centres was not Cost centres were categorised according 1. Inaccuracies of +1- 20% were assumed, based on a previous study 
measured for step-down allocation of costs, and to likely uses by other cost centres, and that measured inaccuracy of not using simultaneous methods (Graves 
step-down allocation was not simultaneous. one-way step-down allocation. 1998), and unit costs recalculated based on these alternative values 
'Average' costs do not take account of different Thailand: Inpatient care in district Other data were not collected, and therefore it is unclear how alternative 
case-mix between pregnant women and other hospitals reflected general inpatients. value(s) can be supported 
patients Cuba: Outpatient care in policlinics 
reflected general population (except drug 
cost). 
In all countries: laboratory test unit cost 
\ reflected the 'average' test 
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Table 4.6: Sources of uncertainty and alternative values· Inaccuracies in recording systems 
- --
Area of uncertainty (criticism) Base case Alternative value(s) or desi2n , 
Material recording systems were poor quality in A vail able data were collected, and some Other data were not collected, and therefore it is unclear how 
Thailand and Cuba generalised across hospital in Thailand alternative value(s) can be supported I 




wer~ inflated by estimates of the age. equipment could cost in the international market 
Table 4.7: Sources of uncertainty and alternative values· Uncertainty over the best method to value a parameter 
Area of uncertainty (criticism) Base case Alternative value(s) or design I 
Salary costs may not represent opportunity cost In all countries, gross salary costs plus 1. In Thailand and South Africa, the public sector wage was I 
accommodation costs were used. increased 50% to reflect roughly the private sector wage. I 
2. In Cuba, wages were arbitrarily increased to reflect the cost. I 
The method used for annualising capital items Number of months for categories of 1. The number of months of life of equipment of buildings was I 
was only approximate. equipment was estimated using adjusted arbitrarily halved and doubled, thus doubling and halving the I 
historic prices, and straight-line depreciation monthly cost. 
Utility costs may not represent opportunity cost The costs incurred by the health facilities The subsidy/profit margins of the utility companies is unknown. I 
(charged by the companies) were used. Therefore no adjustments were made. 
Exchange rates do not reflect the shadow Official exchange rates and purchasing power 1. The black market exchange rate was used for NTG in Cuba ! 
(socially optimal) exchange rates.~arit~ were used (January 1997). 2. May 1999 OERs were used for Thailand and South Africa. 
Table 4.8: Sources of uncertainty and alternative values - Uncertainty over generalisabiIity of values across settings: ~ 
Area of uncertainty (criticism) Base case Alternative value(s) or design 
No data to support whether unit costs can be Thailand: Unit costs generalised to referral hospital. Other data were not collected, and therefore it is unclear how 
generalised across (referral) hospitals Cuba: America Arias unit costs were used in Naval alternative value(s) can be supported. 
and other maternity hospitals Uncertainty already reflected within ranges in sensitivity analysis. 
Material and drug costs were generalised over Cuba: In America Arias, 1996 material and drug Other data were not collected, and therefore it is unclear how 
time or space costs were adjusted by differences in throughput. alternative value(s) can be supported. Minimum impact expected. 
I Thailand: material costs 2eneralised for 2 hospitals. 
Statistics data generalised between health Cuba: In Romay, statistics data were not available, Other data were not collected, and therefore it is unclear how I 
facilities and were generalised from surrounding policlinics alternative value(s) can be sUPl'orted 
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Table 4.9: Measurement and data sources of patient factors determining health service use 
Patient factors determining Data being used Data source 
health service use 
Geographical accessibility Average distance from the clinic Women's cost survey 
Average time from the clinic Women's cost survey 
Availability of transport Women's cost survey 
Average cost of transport Women's cost survey 
Cost of health care services Cost of consultation Women's cost survey 
Cost of medicines Women's cost survey 
Abilit)' to Jlay expenses Average income versus costs Women's cost survey 
Other expenses of visit Cost of food and drink Women's cost survey 
Opportunity cost Proportion of women with jobs Women's cost survey 
Time taken off work Women's cost survey 
Paid leave to attend ANC Women's cost survey 
Average salary Women's cost survey 
Availability or use of alternative Alternatives services available Women's cost survey 
services Amount of use of alternatives Women's cost survey 
Familiarity with and use of health % first pregnancies ANC trial summary forms 
services National average ANC visits Ministry of Health documents 
- % institutional delivery rates ANC trial summary forms 
Perception of quality of care % of women happy with service ANC trial satisfaction survey 
Education and socio-economic Average age ANC trial summary forms 
status Marital status ANC trial summary forms 
Number of years of education ANC trial summary forms 
A verage rooms per house ANC trial summary forms 
Cultural attitudes to modern health Cultural acceptability of services ANC trial satisfaction survey 
services Need for permission from family ANC trial satisfaction survey 
Attitudes to risk Desire for minimum ANC visits ANC trial satisfaction survey 
Risk levels Outcomes of previous pregnancy ANC trial summary forms 
Presence of other risk factors ANC trial summary forms 
Morbidity levels Presence of morbidity ANC trial summary forms 
External factors Weather patterns Excessive rain, heat or cold 
Table 4.10: Measurement and data sources of provider factors determining health service use 
Provider factors affecting health Data being used Data source 
service use 
Financial incentives to providers Fee schedule General knowledge of 
Other payments to health providers systems 
Women's cost survey 
Compliance with standards of care General contents of ANC WHO baseline survey 
Compliance with WHO checklist Unannounced observations 
Monitoring systems in place Morbidity targets 
Quality or effectiveness of health Training level of main providers Costing study 
care staff Availability of diagnostic equipment Costing study 
On-going refresher courses Costing study 
Health care provider risk aversity National norms for dealing with risk National guidelines 
Risk referral practices ANC trial summary forms 
Capacity use of health facilities Average % of capacity used Costing study 
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Table 4.11: Risk factors in multiple regression analysis 
-- .. --.~ 
VARIABLE HYPOTHESISED RELATIONSHIP TO COST EXPECTED SIZE MULTICOLLINEARITY VALUE DEFINITION 
Women's a priori risks 
Age Young and old women expected to receive more medical Unknown, probably With age category (below) Continuous variable 
attention minimal 
Schooling Women with more schooling are likely to attend medical Unknown, probably Continuous variable 
care minimal 
Smoking Women who smoke are more likely to have adverse Unknown, probably Possibly with substance o = no smoking; 1 = smoking 
outcomes minimal abuse 
Substance abuse Women who abuse alcohol or take drugs are more likely Unknown, probably Possibly with smoking o = no substance abuse; 1 = 
to have adverse outcomes minimal substance abuse 
Previous pregnancies Women in first pregnancy are at higher risk and are Unknown, probably Age o = first pregnancy; 1 = repeat 
expected to receive more medical attention minimal 
_preEnancy 
Previous stillbirth I NN Women with previous stillbirth more likely to receive Unknown, probably Possibly with pro pregnancy o = no previous stillbirth I NN loss; 
loss more medical attention and have adverse outcomes minimal and pro adverse outcome· 1 = previous stillbirth I NN loss 
Previous abortion Women with previous abortion more likely to receive Unknown, probably Possibly with pro pregnancy o = no previous abortion; 1 = 
more medical attention and have adverse outcomes minimal and pro adverse outcome previous abortion 
Last baby LBW Women with last baby LBW more likely to receive more Unknown, probably Possibly with pro pregnancy 0= last baby not LBW; 1 = last 
medical attention and have adverse outcomes minimal and pro adverse outcome babyLBW 
Hospital admission in last Women with hospital admission in last pregnancy more Unknown, probably Possibly with pro pregnancy o = no admission in last pregnancy; 
pregnancy for HDP likely to receive more medical attention and have minimal and pro adverse outcome 1 = admission in last pregnancy 
adverse outcomes 
Previous surgery on Women with previous surgery on reproductive tract Unknown, probably Possibly with previous o = no previous surgery on 
reproductive tract more likely to receive more medical attention and have minimal pregnancy adverse outcome reproductive tract; 1 = previous 
adverse outcomes surgery on reproductive tract 
Previous iso-immunisation Women with previous iso-immunisation more likely to Unknown, probably Possibly with previous 0= no previous iso-immunisation; 
receive more medical attention and have adverse minimal pregnancy adverse outcome 1 = previous iso-immunisation 
I outcomes 
\ 
I Last pregnancy adverse Women with last pregnancy adverse outcome more Unknown, may be Likely to be positively o = last pregnancy not adverse 
I 
. outcome likely to receive more medical attention and have significant related to all other previous outcome; 1 = last pregnancy 
! adverse outcomes outcome variables adverse outcome i -_ .. ----
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Table 4.12: Pregnancy and delivery events in multiple regression analysis 
VARIABLE HYPOTHESISED RELATIONSHIP TO COST EXPECTED SIZE MULTICOLLINEARITY VALUE DEFINITION J 
Pregnancy events 
Week at which first Women reporting later are likely to have less ANC visits, Unknown direction or Possibly with ANC visits 0= first visit <20 weeks; 1 = first I 
reported but possibly more adverse outcomes size of cost impact visit >20 weeks 
Referral to higher level Women referred are more likely to receive more medical Expected significant May be related to pregnancy o = no referral; 1 = referral 
attention impact on costs event 
Pregnancy event (HDPI Women with pregnancy event are more likely to receive Expected significant May be related to referral to o = no event; 1 = pregnancy event 
UTI/haem/anaemialSTD). more medical attention impact on costs higher level I 
Events around delivery 
Preterm Women pre-term likely to receive less ANC visits Probably minimal - o = normal term; 1 = preterm I 
Postterm Women postterm likely to receive more ANC visits Probably minimal - o = normal term; 1 = J)ostterm i 
Prelabour rupture of Women with PROM more likely to receive medical Unknown, probably - 0= no PROM; 1 = PROM 
membranes attention, and babies more neonatal care minimal , 
Condition at labour Women with adverse condition at labour more likely to Expected significant Possibly related to pre-term o = condition normal at labour; 1 = 
receive medical attention during pregnancy and delivery impact on costs and PROM adverse condition at labour 
Fetal presentation at Women with adverse fetal presentation at delivery more Expected significant Possibly related to condition o = cephalic presentation at 
delivery likely to receive medical attention impact on costs at labour delivery; 1 = breech presentation 
Labour induced Unclear Unknown Possibly related to condition 0= normal; 1 = labour induced 
at labour and post-term 
Elective caesarean section Women with elective CS more likely to receive medical Expected significant Possibly related to condition o = vaginal delivery or emergency 
attention impact on costs at labour and fetal present. CS; 1 = elective CS 
Postpartum information 
LBW (very LBW and LBW babies more likely to receive neonatal care Expected significant May be related to previous 0= >2500 grammes; 1 = <2500 
LBW categories, cont.) impact on costs LBW and neonatal ICU grammes; also continuous 
Apgar score (1 minute, 5 Babies with low apgar scores (especially at 5 minutes) Expected impact on May be related to LBW, Continuous variables 
minutes) more likely to receive neonatal care costs congo mal. and neonatal ICU \ 
Postpartum anaemia Women with postpartum anaemia more likely to stay Unknown, probably May be related to pregnancy o = no postpartum anaemia; 1 -
longer following delivery, and have had adverse event minimal event postpartum anaemia 
Postpartum syphilis Women with postpartum syphilis more likely to stay Unknown, probably May be related to pregnancy o - no postpartum syphilis; 1 -
longer following delivery, and have had adverse event minimal event postpartum syphilis 
Congenital malformation Malformed babies more likely to receive neonatal care Expected significant May be related to LBW and o - baby not malformed; 1 - baby 
impact on cosL_~ neonatal ICU congenitally malformed 
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Table 4.13: Provider characteristics and women's health service use in multiple regression analysis 
VARIABLE HYPOTHESISED RELATIONSHIP TO COST EXPECTED SIZE MULTICOLLINEARITY VALUE DEFINITION 
Provider characteristics 
Throughput per staff FTE Health facilities with lower outpatient visits / IPD per Expected significant 
- Continuous variable 
staff FTE more likely to have higher costs impact on costs 
Occupancy Health facilities with higher occupancy more likely to Expected significant 
- Continuous variable 
have lower costs impact on costs 
Health facility throughput Larger health facilities may have different costs on Unknown size and - Continuous variable 
account of their size direction of impact 
Health facility Some health facilities, due to high or low unit costs and Expected significant May be related to trial arm Continuous variable 
health service use, have different cost per pregnancy impact on costs 0= Median facility (6/12) 
Practising new or old Women receiving care under WHO programme likely to Expected significant - o = practising control ANC; 1 = 
model receive less ANC visits impact on costs practising intervention ANC 
Health service use 
Inpatient admission during An inpatient admission during pregnancy is likely to Expected significant May be correlated with some o = no admission; 1 = admission 
pregnancy increase costs impact on costs risk factors/pregnancy event 
Type of delivery A caesarean section will increase costs Expected significant May be correlated with some 0= vaginal delivery; 1 = caesarean 
impact on costs risk factors/pregnancy event section 
Neonatal admission to Neonatal admission will increase costs Expected significant May be correlated with CS, o = no admission; 1 = admission 
intensive care unit impact on costs and health of neonate 
This is because all trial women cost the same in America Arias, as the policlinics do not provide inpatient care 
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Appendix 5: Trial data 
" 
Table 5.1: Assessment of factors explaining health service use variation/between trial arm. 
Determinants of Data available on factors Expectation Actual difference 
health service use being compared of difference Cuba Thailand 
Patient factors 
Accessibility Average distance from the clinic NDE NDO NDO 
A veragetime from the clinic NDE NDO NDO 
Availability or use of transport NDE NDO SDO 
Average cost of transQort NDE NDO NDO 
Cost of health services Cost of consultation VISIT NDO NDO 
Cost of medicines ;' VISIT SDO SDO 
Cost of food and drink VISIT NDO SDO 
Relative cost to wage rate VISIT SDO SDO 
Opportunity cost Waiting and treatment time EXU NDO SDO 
Proportion of women with jobs NDE NDO SDO 
Time taken off work VISIT NDO SDO 
Paid leave to attend ANC NDE NDO NDO 
A verage salar~ NDE' NDO NDO 
Use of alternative Alternatives available NDE NDO NDO 
services Amount of use of alternatives EXU NDO NDO 
Familiarity with % first pregnancies NDE NDO NDO 
modern health care Baseline average ANC visits NDE NDO NDO 
% institutional deliver~ rates NDE NDO NDO 
Quality of care % of women happy with service EXU SDO SDO 
% women haQQ~ with sQacing EXU SDO SDO 
Socio-economic status Average age, marital status, NDE NDO NDO 
number of years of education, 
average rooms Qer house 
Cultural attitudes Cultural acceptability of services EXU NDO NDO 
To services Need for permission from NDE NDO NDO 
famil~ 
Attitudes to risk Desire for minimum ANC visits NDE NDO NDO 
Actual risk levels Outcomes of previous NDE SDO SDO 
pregnancy NDE SDO SDO 
Presence of other risk factors 
Morbidit~ levels Presence of morbidit~ EXU SDO SDO 
Other Weather Qatterns NDE NDO NDO 
Provider factors 
Financial incentives Fee schedule NDE NDO NDO 
to Qroviders Other Qa~ments to Eroviders NDE NDO NDO 
Compliance with General contents of ANC DE SDO SDO 
standards of care Monitoring s~stems in Elace DE SDO SDO 
Quality or Training level of main providers NDE NDO NDO 
effectiveness Availability of diagnostic eq. DE SDO SDO 
of health care staff On-going refresher courses NDE NDO NDO 
Health care provider Norms for handling risk DE SDO SDO 
risk aversit~ Risk referral Eractices DE SDO SDO 
CaEacit;i use facilities A vera~e % of caEacit;i used EXU NDO NDO 
TABLE KEY: NDE - No Difference Expected; VISIT - Difference expected due to different numbers 
of visits, but not due to different cost per visit; EXU - Expected Difference Unknown; DE - Difference 
Expected; NDO - No Difference Observed; SDO - Some Difference Observed. 
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Table 5.2: Case-mix comparison between policIinics and trial ann in Cuba. 
PERIOD VARIABLE DATA 12 1 9 4 5 10 INT 7 11 6 3 8 2 CONT ALL 
Previous First pregnancy % 0.20 0.17 0.21 0.16 0.21 0.18 0.19 0.16 0.19 0.16 0.18 0.19 0.19 0.18 0.18 
history Previous stillbirth or neonatal loss % 0.04 0.02 0.04 0.02 0.02 0.02 0.03 0.03 0.02 0.03 0.02 0.06 0.03 0.03 0.03 
>3 spontaneous abortions % 0.84 0.89 0.83 0.84 0.86 0.79 0.84 0.86 0.85 0.83 0.87 0.86 0.87 0.86 0.85 
Previous low birth weight % 0.01 0.01 0.07 0.02 0.02 0.05 0.03 0.05 0.05 0.05 0.06 0.07 0.03 0.05 0.04 
Previous birth outcome negative % 0.75 0.78 0.77 0.74 0.72 0.70 0.75 0.76 0.75 0.69 0.75 0.80 0.74 0.75 0.75 
Hosp admission in last pregnancy % 0.03 0.03 0.03 0.04 0.02 0.04 0.03 0.01 0.02 0.01 0.01 0.01 0.00 0.01 0.02 
Previous surgery on RT % 0.03 0.03 0.06 0.05 0.03 0.05 0.04 0.01 0.01 0.03 0.01 0.03 0.01 0.01 0.03 
Antenatal Gest age at 1 st visit <12 weeks % 0.78 0.82 0.81 0.84 0.84 0.83 0.82 0.83 0.88 0.83 0.86 0.86 0.86 0.86 0.84 
care Gest age at 1 st visit 12-15 weeks % 0.18 0.14 0.14 0.12 0.11 0.13 0.14 0.14 0.10 0.13 0.10 0,10 0.11 0.11 0.12 
Gest age at 1 st visit 16-19 weeks % 0.02 0.02 0.03 0.03 0.02 0.03 0.03 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 
Gest age at 1 st visit >20 weeks % 0.02 0.02 0.02 0.01 0.02 0.01 0.02 0.01 0.01 0.02 0.02 0.01 0.01 0.01 0.01 
Iron supplementation given % 0.09 0.07 0.06 0.06 0.05 0.07 0.07 0.05 0.07 0.07 0.08 0.05 0.06 0.06 0.07 
Referred to higher level % 0.16 0.15 0.16 0.14 0.14 0.13 0.15 0.13 0.15 0.07·0.11 0.12 0.12 0.12 0.14 
Hospital admission during AN % 0.02 0.03 0.03 0.02 0.02 0.03 0.03 0.01 0.03 0.02 0.04 0.04 0.02 0.03 0.03 
Events Treated for syphilis No. 20 51 131 46 39 36 323 47 28 18 84 45 50 272 595 
Treated for trichomoniasis No. 9 21 11 17 11 16 85 11 6 '3 14 5 5 44 129 
Treated for any STO % 0.06 0.13 0.31 0.11 0.12 0.13 0.14 0.11 0.05 0.12 0.15 0.17 0.12 0.12 . 0.13 
Bleeding during pregnancy % 0.34 0.35 0.31 0.40 0.36 0.37 0.36 0.39 0.36 0.34 0.42 0.48 0.39 0.40 0.38 
UTI - no treatment No. 13 17 10 15 5 25 85 13 13 4 23 4 9 66 151 
UTI - with treatment No. 6 6 6 12 13 6 49 9 9 3 18 6 6 51 100 
UTI cases (a") % 0.04 0.04 0.03 0.05 0.04 0.08 0.05 0.04 0.04 0.04 0.06 0.03 0.03 0.04 0.04 
HOP cases (a") % 0.08 0.08 0.08 0.08 0.07 0.08 0.08 0.06 0.09 0.06 0.08 0.08 0.07 0.08 0.08 
Labourand . Breech presentation % 0.03 0.03 0.04 0.03 0.02 0.02 0.03 0.03 0.02 0.03 0.05 0.04 0.04 0.04 0.03 
Delivery Adverse diagnosis at delivery % 0.18 0.16 0.20 0.14 0.15 0.16 0.16 0.12 0.15 0.09 0.15 0.13 0.12 0.13 0.15 
Induced labour % 0.18 0.20 0.18 0.17 0.19 0.17 0.18 0.17 0.18 0.13 0.20 0.19 0.16 0.18 0.18 
CSdueto CPO % 0.22 0.09 0.14 0.13 0.14 0.17 0.15 0.14 0.16 0.14 0.07 0.10 0.09 0.11 0.13 
CS due to previous CS 0/0 0.23 0.35 0.25 0.35 0.36 0.30 0.31 0.31 0.31 0.46 0.29 0.37 0.24 0.31' 0.31 
CS due to breech position 0/0 0.10 0.12 0.13 0.10 0.10 0.10 0.11 0.13 0.08 0.11 0.15 0.12 0.17 0.13 0.12 
CS due to failure to progress % 0.13 0.19 0.10 0.13 0.14 0.06 0.13 0.15 0.14 0.08 0.20 0.15 0.15 0.15 0.14 
CS due to fetal distress % 0.22 0.17 0.28 0.15 0.18 0.20 0.20 0.18 0.22 0.14 0.25 0.24 0.27 0.23 0.21 
Postpartum Neonate admitted to intensive care 0/0 0.06 0.05 0.08 0.05 0.06 0.05 0.06 0.05 0.07 0.07 0.04 0.05 0.06 0.06 0.06 
Outcomes Postpartum syphilis test positive No. 8 19 13 14 14 17 85 14 6 3 15 7 8 53 138 
Low birth weight % 0.07 0.06 0.09 0.07 0.08 0.08 0.07 0.08 0.07 0.06 0.07 0.06 0.06 0.07 0.07 
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Table 5.3: Case-mix comparison between hospitals and trial arm in Thailand, and South Africa. 
PERIOD VARIABLE DATA 1 3 4 6 11 12 INT 2 5 7 8 9 10 CO NT ALL SA 
Previous First pregnancy % 0.41 0.38 0.44 0.49 0.36 0.37 0.41 0.38 0.40 0.43 0.39 0.42 0.42 0.40 0.41 0.36 
history Previous stillbirth or neonatal loss % 0.03 0.03 0.05 0.02 0.02 0.02 0.02 0.05 0.06 0.04 0.00 0.02 0.04 0.02 0.03 0.09 
>3 spontaneous abortions % 0.22 0.24 0.33 0.30 0.27 0.21 0.15 0.29 0.29 0.23 0.21 0.21 0.30 0.15 0.26 0.11 
Previous low birth weight % 0.09 0.09 0.08 0.10 0.09 0.06 0.05 0.05 0.07 0.09 0.17 0.07 0.13 0.05 0.09 0.24 
Previous birth outcome negative % 0.26 0.24 0.26 0.29 0.24 0.15 0.15 0.29 0.28 0.27 0.38 0.18 0.29 0.16 0.26 0.19 
Previous surgery on RT % 0.02 0.01 0.02 0.01 0.02 0.02 0.01 0.02 0.02 0.01 0.02 0.00 0.03 0.01 0.02 0.15 
Antenatal care Gest age at 1 st visit <12 weeks % 0.29 0.26 0.29 0.37 0.47 0.36 0.32 0.46 0.27 0.30 0.41 0.38 0.38 0.38 0.35 0.01 
Gest age at 1 st visit 12-15 weeks % 0.24 0.21 0.16 0.17 0.22 0.18 0.20 0.26 0.24 0.20 0.24 0.27 0.27 0.25 0.22 0.05 
Gest age at 1 st visit 16-19 weeks % 0.17 0.17 0.11 0.13 0.09 0.13 0.14 0.15 0.18 0.14 0.17 0.15 0.13 0.15 0.15 0.14 
Gest age at 1 st visit >20 weeks % 0.30 0.35 0.44 0.34 0.22 0.33 0.34 0.12 0.32 0.36 0.19 0.19 0.22 0.23 0.28 0.80 
Iron supplementation given % 0.87 0.99 0.92 0.98 0.97 0.97 0.94 0.99 0.97 0.97 0.98 0.97 0.99 0.98 0.96 0.91 
Hospital admission during AN % 0.03 0.02 0.03 0.03 0.05 0.02 0.03 0.03 0.02 0.03 0.01 0.01 0.10 0.03 0.03 0.32 
Events Treated for syphilis No. 5 3 2 0 0 0 10 0 2 1 0 0 1 4 14 80 
Treated for trichomoniasis No. 140 7 21 24 13 3 208 2 1 3' 1 0 2 9 217 130 
Treated for any STD % 0.15 0.02 0.05 0.06 0.05 0.02 0.08 0.01 0.01 0.01 0.00 0.00 0.01 0.01 0.04 0.27 
Bleeding during pregnancy % 0.01 0.03 0.04 0.05 0.04 0.03 0.03 0.01 0.02 0.01 - 0.01 0.00 0.03 0.01 0.02 0.02 
UTI - no treatment No. 1 18 10 3 5 1 38 2 30 3' 0 1 2 38 76 18 
UTI - with treatment No. 9 6 12 17 9 3 56 12 3 4 2 0 7 28 84 119 
UTI cases (all) % 0.01 0.03 0.04 0.04 0.05 0.02 0.03 0.02 0.10 0.01 0.01 0.00 0.03 0.02 0.03 0.17 
HOP cases (all) % 0.01 0.01 0.01 0.01 0.02 0.01 0.00 0.01 0.02 0.06 0.01 0.01 0.01 0.01 0.01 0.11 
Labour and Breech presentation % 0.03 0.02 0.03 0.02 0.03 0.03 0.03 0.02 0.02 0.01 .. 0.02 0.01 0.02 0.02 0.02 0.03 
Delivery Adverse diagnosis at delivery % 0.04 0.05 0.07 0.07 0.07 0.05 0.06 0.09 0.04 0.06 0.01 0.02 0.06 0.05 0.05 0.28 
Induced labour % 0.04 0.02 0.07 0.03 0.02 0.05 0.04 0.06 0.03 0.08 0.02 0.00 0.03 0.04 0.034 0.06 
CS due to CPO % 0.36 0.22 0.26 0.45 0.22 0.13 0.02 0.33 0.43 0.36 0.19 0.36 0.18 0.02 0.30 0.16 
CS due to previous CS % 0.22 0.30 0.31 0.05 0.33 0.38 0.02 0.30 0.21 0.18 0.29 0.09 0.27 0.01 0.25 0.31 
CS due to breech position % 0.22 0.13 0.24 0.18 0.11 0.00 0.01 0.17 0.07 0.14 0.19 0.09 0.18 0.01 0.17 0.12 
CS due to failure to progress % 0.16 0.17 0.14 0.09 0.11 0.25 0.01 0.26 0.29 0.11 0.10 0.18 0.23 0.01 0.17 0.33 
CS due to fetal distress % 0.11 0.09 0.03 0.18 0.11 0.00 0.01 0.15 0.14 0.36 0.10 0.09 0.14' 0.01 0.13 0.41 
Postpartum Neonate admitted to intensive care % 0.06 0.05 0.02 0.03 0.03 0.03 0.04 0.02 0.07 0.04 0.04 0.01 0.06 0.03 0.04 0.71 
Outcomes Postpartum syphilis test positive No. 4 3 3 1 0 0 11 3 3 4 0 1 1 12 23 33 
Low birth weight % 0.09 0.09 0.09 0.11 0.09 0.11 0.09 0.09 0.09 0.08 0.05 0.09 0.07 0.08 0.09 n/a 
KEY; !NT - Intervention arm; CONT - Control arm; ALL - Intervention plus control arms; SA - South Africa; Gest - Gestational age; CPD - Cephalo-pelvic disproportion; CS 
- Caesarean section; UTI - Urinary tract infection; HDP - Hypertensive disorders of pregnancy; STD - Sexually transmitted disease. 
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Table 5.4: Health service use data by health facility, trial arm, and country. 
Country and Number Outpatient ANC Inpatient ANC Deliveries Postpartum stay NeonatallCU 
health care of cases AveraQe visits Cases Mean LOS Med LOS PercentaQe Mean LOS Median LOS Cases Neonate LOS 
provider Mean Med LR HR LR HR ALL LR HR VD CS VD CS VD CS No. Mean Med ALL 
CUBA 
13de Marzo 450 7.5 6 42 30 16.3 10.5 2.22 7 6 n 23 3.0 6.8 2 5 24 11.5 8 0.61 
Albarran 567 7.8 6 69 21 10.6 14.0 1.81 7 6 82 18 3.3 5.5 2 5 27 14.4 9 0.69 
Galvan 459 7.3 5 60 14 17.3 9.5 2.56 9 7 74 26 3.8 6.3 2 5 39 13.8 10 1.17 
Manduley 576 7.6 5 53 31 12.2 11.7 1.76 9 8 75 25 2.9 5.7 2 5 27 10.4 6 0.49 
Romay 418 7.4 5 47 15 15.6 11.3 2.15 9 7 76 24 3.1 6.2 2 5 25 12.6 8 0.75 
Zuluetta 402 7.3 5 43 11 10.1 5.9 1.24 7 4 79 21 3.3 5.6 3 5 22 7.7 6.5 0.42 
Average intervention 2872 7.50 6 314 122 13.61 10.92 1.95 8 6 77.4 22.6 3.22 6.03 2 5 164 12.0 8 0.7 
Aba/Ii 514 13.3 13 53 17 14.9 7.1 1.n 9 6 n 23 3.1 6.0 2 5 29 9.8 9 0.55 
Escalona 628 13.0 12 69 28 15.0 6.7 1.93 9 5 76 24 3.2 5.7 2 5 46 11.0 6 0.81 
Guiteras 178 12.4 12 10 3 14.1 8.7 0.94 10 6 79 21 3.3 5.2 2 5 12 9.6 6 0.65 
Reina 648 13.0 13 56 19 11.3 11.7 1.32 9 10 76 24 2.9 5.5 2 5 27 10.1 7 0.42 
Tamayo 296 13.6 13 32 5 8.5 8.4 1.06 8 7 n 23 2.9 6.0 2 5 16 14.1 6.5 0.76 
Vantroi 473 13.1 13 46 12 13.3 8.0 1.50 9 8 n 23 3.1 6.4 2 5 . 30 10.2 10 0.65 
Average control 2737 13.14 13 266 84 13.07 8.25 1.53 9 6 76.6 23.4 3.04 5.82 2 5 160 10.68 7 0.6 
THAILAND 
Chumpae 1001 4.05 4 30 2.5 0.075 2 94 6 2.11 3.96 2 4.0 62 4.79 3 0.30 
Banphai 729 4.58 4 7 2.0 0.019 1 91 9 1.79 3.83 2 4.0 36 11.89 3 0.59 
Phuwiang 558 4.74 4 14 3.4 0.086 3 87 3 1.40 2.26 1 3.0 8 7.88 6 0.11 
Manjakiri 476 4.43 4 16 2.9 0.099 2 95 5 1.53 2.48 1 3.0 16 3.94 3 0.13 
Khaosuankwang 306 4.24 4 12 4.0 0.157 2 97 3 1.69 2.05 2 0.0 9 2.78 2 0.08 
Waeng Noi 208 4.47 4 8 2.3 0.087 2 95 5 1.95 1.53 2 1.0 6 6.17 5 0.18 
Intervention average 3278 4.38 4 87 2.87 .073 2 93.0 7.0 1.78 3.00 2 4 137 7.44 3 0.28 
Kranuan 821 6.56 7 34 3.4 0.141 2 93 7 1.50 4.95 1 6.0 19 5.16 3 0.12 1 
Nongsonghong 323 6.19 6 4 1.8 0.022 1 96 4 1.73 3.32 2 3.5 21 5.14 3 0.33 
Phol 630 8.11 8 16 4.2 0.106 3 93 7 1.92 3.70 2 4.0 25 12.68 4 0.50 
\ 
\ 
Nongrua 400 6.37 6 2 2.0 0.010 2 95 5 1.43 4.65 1 6.0 15 3.40 2 0.13 
Srichompoo 595 7.10 7 1 3.0 0.005 3 98 2 1.03 0.23 1 0.0 8 6.75 5 0.09 
Nampong 322 8.42 9 24 2.6 0.193 2 93 7 1.49 2.85 1 3.0 18 8.94 3 0.50 
Control average 3091 7.11 7 91 3.19 0.085 2 95.0 5.0 1.64 2.26 1 3 106 6.60 3 0.25 
SOUTH AFRICA 
Prince Mshiyeni 785 5.97 6 249 6.9 2.330 3 0.78 0.22 2.21 7.33 1 7.0 423 3.13 1 1.69 
-- - --
TABLE KEY: LOS -length of stay; HR -high risk woman; LR -low risk woman; VD- vaginal delivery; CS -ceasareran section; med. - median; ALL-all cases. 
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Appendix 6: Staff productivity 
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Figure 6.2: Inpatient days per FTE and occupancy in all countries 
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Key: FIE - full-time equivalent staff. 
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Figure 6.3: Occupancy, average discharges per bed, and average length of stay ('Lasso' graph). 
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Table 6. t: Staff, building" space, and hesIth servfcs output In Cuban poIiclinics. 
DEPARTMENT STAFF I I I I I POLICLINIC I r I I I 
GROUPING TYPE 13 de Marzo Albarran Galvan Manduley Romay Zuluetta AbailJi Escalona Guiteras Reina Tamayo Vantroi Averase 
Raw Data Staff Metres Staff Metres Staff Metres Staff Metres Staff Metres Staff Metres Staff Metres Staff Metres Staff Metres Staff Metres Staff Metres Staff Metres Staff Metres 
Service Non-health 32 294 10 132 20 288 9 344 16 492 18 242 17 310 18 288 25 389 15 140 12 166 16 259 17 279 
Admin Non-health 25 184 18 154 22 170 18 129 22 160 23 220 16 140 21 188 21 254 23 202 18 151 20 188 21 178 
Lab Non-health 15 48 8 35 5 52 6 35 6 68 6 59 8 30 8 52 15 52 7 92 15 35 7 52 9 51 
Support Non-health 10 215 7 67 5 130 8 58 5 68 5 170 10 125 7 166 9 624 10 166 6 105 6 166 7 172 
eMF Obstet 3 4 2 2 3 3 4 2 3 4 2 4 3 0 
Doctor 48 48 34 52 42 34 48 64 15 48 26 42 42 0 
Nurse 48 48 34 37 42 34 48 64 15 48 26 42 41 0 
Non-health 12 6 6 11 11 85 9 16 9 22 9 15 18 0 
TOTAL 111 2850 106 1782 76 435 102 1502 98 2256 156 1622 109 3521 146 3472 42 206 122 1552 63 809 103 924 103 1744 
Other Soecial. 28 22 4 10 20 21 15 10 25 25 20 3 17 0 
Doctor 28 24 45 0 45 40 10 28 44 28 35 4 28 0 
Nurse 57 24 5 0 12 71 18 56 52 8 52 46 33 0 
TOTAL 113 70 54 10 77 132 43 94 121 61 107 53 78 0 
Total 306 3591 219 2170 182 1075 153 2068 224 3044 340 2313 203 4126 294 4166 233 1525 238 2152 221 1266 205 1589 235 2424 
Average throughput 0 0 
Averaae OPV/month 7305 8916 5151 11322 10707 11662 7487 11074 3297 12202 4940 16149 9184 0 
Averaolab tests/month 5487 3680 3758 2369 6174 2282 5488 7712 5487 5488 5218 7127 5023 0 
Input/output ratios 0 0 
OP oar FTElmetre 65.8 2.6 84.1 5.0 67.8 11.8 111.0 7.5 109.3 4.7 74.8 7.2 68.7 2.1 75.8 3.2 78.5 16.0 100.0 7.9 78.4 6.1 156.8 17.5 89 8 
LAB per FTElmetre 365.8 114.3 460.0 105.1 751.6 72.3 394.8 67.7 1029.0 90.8 380.3 38.7 686.0 182.9 964.0 148.3 365.8 105.5 784.0 59.7 347.9 '149.1 1018.1 137.1 629 106 
Staff ratios 
Admin worker 25 18 22 18 22 23 16 21 21 23 18 20 20.58 
Specialist 31 26 6 12 23 24 19 12 28 29 22 7 19.92 
Nurse 105 72 39 37 54 105 66 120 67 56 78 88 73.92 
Doctor 76 72 79 52 87 74 58 92 59 76 61 46 69.33 
Nurse/doctor 0.72 1.00 2.03 1.41 1.61 0.70 0.88 0.77 0.88 1.36 0.78 0.52 1.05 
Doctor/SPeCialist 0.41 0.36 0.08 0.23 0.26 0.32 0.33 0.13 0.47 0.38 0.36 0.15 0.29 
Doctor/admin worker 3.04 4.00 3.59 2.89 3.95 3.22 3.63 4.38 2.81 3.30 " " 3.39 2.30 3.38 
Overhead staff 82 43 52 41 49 52 51 54 70 55 . 51 49 54.08 
Health care staff 224 176 130 112 175 288 152 240 163 183 170 156 180.75 
Ratio overheadlhealth care 0.37 0.24 0.40 0.37 0.28 0.18 0.34 0.23 0.43 0.30 0.30 0.31 0.31 
I 
Table keY: OPV - outoatient visits; LAB - laboratorv tests; FTE - Full-time eauivalent staff; 
\ 
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Table 6.2: Staff. building space, and health service DUIpUt In Thai hospitals. 
DEPARTMENT STAFF I I I I I HEALTH CARE PROVIDER UNIT T I GROUPING TYPE Chum ae Banphai Puwleng Manjakiri Khaosankuang Waengnoi Kranuan N~ngsonghonQ Phon Nooarua Sichompoo Nampong Average 
Raw Data Staff Metres Staff Metres Staff Metres Staff Metres Staff Metres Staff Metres Staff Metres Staff Metres Staff Metres Staff Metres Staff Metres Staff Metres Staff Metres 
Service Non-health 27 1807 17 810 11 507 11 222 8 805 13 477 21 164 37 206 28 615 14 525 4 108 28 573 18 568 
Admin Non-health 9 240 15 182 6 30 7 390 4 72 4 227 7 308 10 208 7 168 5 136 4 516 11 138 7 218 
Lab Non-hea~h 10 49 5 40 5 24 5 32 2 24 2 16 6 24 2 24 6 80 4 20 3 30 6 40 5 34 
SuPPOrt Non-hea~h 46 780 19 545 12 360 22 378 7 398 12 386 21 670 14 644 20 394 12 687 17 168 14 850 18 522 
Other Non-hea~h 7 116 4 20 8 28 4 72 3 0 2 35 5 64 4 68 8 50 7 75 4 20 10 155 6 59 
Outpatient Nurse 4 3 3 2 3 4 3 4 4 5 4 5 4 0 
Non-hea~h 4 2 2 3 4 0 3 1 0 2 9 5 3 0 
TOTAL 8 80 5 434 5 213 5 110 7 117 4 38 6 56 5 104 4 52 7 297 13 73 10 120 7 141 
I"calient Doctor 1 1 2 1 1 1 2 1 1 1 1 1 1 0 
Nurse 20 27 21 16 13 11 31 10 20 18 14 19 18 0 
Non-health 16 12 3 12 1 6 16 6 18 6 7 10 9 0 
TOTAL 37 2200 40 1546 26 665 29 379 15 726 18 525 49 3200 17 362 39 1084 25 713 22 532 30 980 29 1076 
Labour Nurse 2 10 1 5 2 1 9 5 4 10 4 6 5 0 
Non-hea~h 0 7 2 1 1 1 4 1 2 3 0 5 2 0 
TOTAL 2 21 17 40 3 27 6 50 3 25 2 68 13 140 6 73 6 77 13 36 4 64 11 60 7 57 
Suraerv Nurse 16 4 3 3 1 1 5 1 6 0 2 6 4 0 
Non-hea~h 14 1 1 1 1 1 2 1 2 0 1 0 2 0 
TOTAL 30 184 5 100 4 27 4 108 2 25 2 56 7 162 2 48 8 127 0 49 3 100 6 90 6 90 
Other Doctor 6 4 2 2 3 1 2 3 5 3 2 5 3 0 
Nurse 16 13 9 14 5 10 14 10 16 12 2 14 11 0 
Non-hea~h 26 32 13 15 13 13 21 14 18 15 15 23 18 0 
TOTAL 48 900 49 605 24 386 31 484 21 392 24 268 37 572 27 540 39 684 30 396 19 488 42 255 33 498 
Total 224 6377 176 4322 104 2267 124 2225 72 2584 83 2096 172 5360 124 2277 165 3331 117 2934 93 2097 168 3261 135 3261 
AveragtJ throughput 
Averaoe OPV/month 303 208 200 171 96 51 270 151 115 313 162 219 188 0 
Averaae IPD/month 5378 1846 1674 1622 522 864 2382 1180 2249 421 1194 1938 1773 0 
Aver8Qe IPAlmonth 3147 574 728 494 191 210 760 322 755 138 361 598 690 0 
Averaoe NVD/month 157 116 137 67 24 14 240 82 62 72 59 96 94 0 
Averaoe suroerv/month 110 60 176 22 60 4 3026 19 12 23.5 27.5 622 347 0 
Averaa lab tests/month 3540 3032 4083 1494 610 1060 1580 1380 98 1725 1234 298 1678 0 
Aver8Qe NN days/month 236 242 0 138 0 26 305 170 3959 0 107 170 446 0 
Input/output ratios 
OPV oor FTElmetre" 94.7 9.5 104.0 1.2 100.0 2.3 85.5 3.9 34.3 2.1 63.8 6.7 112.5 12.1 151.0 7.3 71.9 5.5 111.8 2.6 62.3 11.1 54.8 4.6 872 5.7 
IPDper FTElmetre 151.7 2.4 522 1.2 64.4 2.5 60.7 4.3 34.8 0.7 49.4 1.6 54.8 0.7 79.4 3.3 159.2 2.1 16.8 0.6 59.1 2.2 70.3 2.0 71.1 2.0 
IPA per FTE/metre 85.1 1.4 14.4 0.4 28.0 1.1 17.0 1.3 12.7 0.3 11.7 0.4 15.5 02 18.9 0.9 19.4 0.7 5.5 0.2 16.4 0.7 19.9 0.6 22.0 0.7 
DEL Der FTElmetre 78.5 7.5 6.8 2.9 45.7 5.1 112 1.3 8.0 1.0 7.0 0.2 18.5 1.7 13.7 1.1 10.3 0.8 5.5 2.0 14.8 - 0.9 8.7 1.6 19.1 2.2 
SURG per FTElmetre 3.7 0.6 12.0 0.6 44.0 6.5 5.5 0.2 30.0 2.4 2.0 0.1 432.3 18.7 9.5 0.4 1.5 0.1 0.0 ,0.5 9.2 0.3 103.7 6.9 59.4 3.1 
LAB lier FTElmetre 354.0 722 606.4 75.8 816.6 170.1 298.8 46.7 305.0 25.4 530.0 66.3 263.3 65.8 690.0 57.5 16.3 1.2 431.3 '86.3 411.3 41.1 49.7 7.5 397.7 59.7 
Staff ratios 
Admin worker 9 15 6 7 4 4 7 10 7 5 4 11 7.42 
Specialist 0 0 0 0 0 0 0 0 0 0 0 0 0.00 
Nurse 58 57 37 40 24 27 62 30 50 45 26 50 42.17 
Doctor 7 5 4 3 4 2 4 4 6 4 3 6 4.33 
Nurse/doctor 0.12 0.09 0.11 0.08 0.17 0.07 0.06 0.13 0.12 0.09 0.12 0.12 0.11 
Doctor/specialist 0 0 0 0 0 0 0 0 0 0 0 0 0.00 
Doctor/admin worker 0.78 0.33 0.67 0.43 1.00 0.50 0.57 0.40 0.86 0.80 0.75 0.55 0.64 
Overhead staff 99 60 42 49 24 33 60 67 69 42 32 69 
Hea~h care staff 125 116 62 75 48 50 112 57 96 75 61 99 
Ratio overheadlhea~h care 0.79 0.52 0.68 0.65 0.50 0.66 0.54 1.18 0.72 0.56 0.52 0.70 
I 6.27 
"Note: Waengnoi, Sichompoo and Nongsonghong operate the Health Promotion Unit onl~ 1 days a week for ANC instead of the usual 2 days a week 
Table keY: OPV - outpatient vis~s; IPD/A - Inpatient days/admissions; LAB - laboratory tests; FTE - Full-time equivalent staff; DEL - Number of deliveries; SURG - Number of ooorations 
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Table 6.3: Staff, space and output in clinics in South Africa 
VARIABLE o clinic H clinic L clinic Q clinic U21 clinic 
No. ANC rate* All rate** No. ANC rate* All rate** No. ANC rate* All rate** No. ANC rate* All rate** No. ANC rate* All rate** 
Staff 
Nurse 19 293.16 16 390.88 16 365.31 18 295.39 26 238.35 
NurseANC 3.7 298.92 2.19 392.24 1.68 363.10 1.69 291.72 3.5 227.43 
Non-health 9 12 10 9 14 
TOTAL 28 39.50 198.93 28 30.68 223.36 26 23.46 224.81 27 18.26 196.93 40 19.90 154.93 
RATIO 0.47 0.75 0.63 0.5 0.54 
Space . 
General rooms 311 17.91 208 30.07 185 31.59 194 27.41 348 17.81 
AN consult. 34 81.32 31 69.27 12 127.08 7 176.07 26 76.54 
Maternity ward 62 64 18 24 78 
Other space 65 52 21 23 28 
TOTAL 472 11.80 355 17.62 236 24.77 248 21.44 480 12.91 
Output 
ANCOPV 1106 859 610 493 796 
TotalOPV 5570 6254 5845 5317 6197 
* ANC rate = ANC OPV / ANC staff; ** All rate = OPV / staff 
Table key: ANC - Antenatal care; OPV - outpatient visits. .' 
\ 
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Table 6.4: Staff, building space, and health service output from referral hospitals in Cuba and South Africa. 
Country & Staff Square Output Output Output Output Output 
cost centre Specialist Doctor Nurse Non-health Total metres OPV IPD CASES per staff Ipersq.m 
Cuba (America Arias hospital 
Services 0 0 0 43 43 350 0 0 0 n1a n/a 
Administration 0 0 0 55 55 446 0 0 0 n1a n/a 
Laboratory 0 0 0 69 69 760 0 0 0 n1a n1a 
S~ort 0 0 0 98 98 603 0 0 0 n/a n/a 
OP department 3 0 7 2 12 535 3404 0 0 283.7 6.4 
ABward 6 0 10 3 19 211 0 290 0 15.3 1.4 
Cward 5 0 9 5 19 327 0 848 0 44.6 2.6 
Eward 10.5 0 8 2 20.5 223 0 520 0 25.4 2.3 
Fward 3.7 0 7 4 14.7 272 ,0 334 0 22.7 1.2 
Labour room 1 0 14 6 21 313 0 0 725 34.5 2.3 
Neonatal room 11.1 0 38 4 53.1 325 0 313 0 5.9 1.0 
Operating theatre 7.5 0 24 2 33.5 290 0 0 220 6.6 0.8 
Other 0 0 0 0 0 4917 O. 0 0 n/a n/a 
TOTAL 47.8 0 117 293 457.8 9572 3404 2305 945 n/a n1a 
South Africa (Prince Mshiyeni hospital) 
Services 0 0 0 119 119 1405 0 0 0 n/a n/a 
Administration 0 0 0 24 24 8250 0 0 0 n/a n1a 
Laboratory 0 0 0 36 36 1610 0 0 0 n/a n/a 
Support 0 0 0 74 74 7688 0 0 0 n1a n/a 
OP department 0 0 12 4 16 980 2295 0 0 143.4 2.3 
ANW ward 1 3 19 4 27 300 0 797 0 29.5 2.7 
E1 ward 1 2 15 4 22 468 0 815 0 37.0 1.7 
E2ward 1 2 5 4 12 468 0 881 0 73.4 1.9 
E3ward 1 2 17 4 24 468 0 1028 0 42.8 2.2 
E4ward 1 2 18 4 25 468 0 970 0 38.8 2.1 
E5 ward 1 2 15 4 22 468 0 798 0 36.3 1.7 
Labour room 1 4 36 17 58 1200 0 0 870 15.0 0.7 
Neonatal room 37 4 41 0 82 1000 0 1643 0 20.0 1.6 
O..Qerating theatre 0 8 12 0 20 440 0 0 300 15 1 
Other n/a n/a n/a n/a 1042 35528 n1a n1a n/a n/a n/a 
TOTAL 44 29 190 298 1603 60741 2295 6932 1170 n/a n/a 
Table key: OPV - outpatient visits; IPD - Inpatient days; CASES - Number of operations or deliveries 
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Figure 7.1: Technical efficiency scores for ANC visits in Cuba 
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Figure 7.2: Technical efficienc;y scores for ANC visits in S Africa 
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Figure 7.3: Technical efficiency scores for wards in Thailand 
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Key:TE - technical efficiency; IPD - inpatient days; IP A - inpatient admissions. 
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Table 7.1: Input data, output data, and technical efficiency results from the resource use OEA model. 
Country Provider Provider Staff Square Through- FTE TE score TE score 
number name FTE metres put ratio (VRS) (CRS) 
CubaANC 1 Albarran 106 1782 6721 63 -0.7 0.59 
2 Vantroi 103 924 10983 107 1 1 
3 Reina 122 1552 8092 66 0.69 0.62 
4 Manduley 102 1502 7902 77 0.81 0.73 
5 Romay 98 2256 7796 80 0.83 0.75 
6 Guiteras 42 206 1826 43 1 0.75 
7 Abailli .109 3521 5199 48 0.59 0.45 
8 Tamayo 63 809 2857 45 0.78 0.43 
9 Galvan 76 435 3591 47 0.79 0.69 
10 Zuluetta 156 ·1622 10085 65 0.62 0.61 
11 Escalona 146 3472· 8664 59 0.6 0.56 
12 13 de Marzo 111 2850 5998 54 0.63 0.51 
ThaiANC 21 Chumpae 8 80 270 34 0.57 0.56 
22 Kranuan 6 56 303 51 0.9 0.9 
23 Banphai 5 434 200 40 0.8 0.51 
24 Puwieng 5 213 201 40 0.8 0.51 
25 Nong's'h 5 104 171 34 0.8 0.44 
- 26 Manjakiri 5 110 151 30 0.8 0.39 
27 Phon 4 52 115 29 1 1 
28 Nongrua 7 297 313 45 0.57 0.57 
29 Sichompoo 13 73 96 7 0.52 0.22 
30 Nampong 10 120 51 5 0.4 0.07 
31 Khao's'k 7 117 162 23 0.57 0.3 
32 Waengnoi 4 38 219 55 1 0.96 
SAfrica ANC 82 0 3.7 34 1106 299 1 0.8 
83 H 2.19 31 859 392 1 1 
84 L 1.68 12 610 363 1 1 
85 Q 1.69 7 493 292 1 1 
86 U21 3.5 26 796 227 0.78 0.62 
Thai IPO 33 Chumpae 37 2200 5379 145 1 1 
34 Kranuan 49 3200 2383 49 0.46 0.33 
35 Banphai 40 1546 1846 46 0.5 0.44 
36 Puwieng 26 665 1674 64 0.82 0.8 
37 Nong's'h 17 362 1180 69 1 0.97 
38 Manjakiri 29 379 1622 56 1 1 
39 Phon 39 1084 2249 58 0.69 0.68 
40 Nongrua 25 713 1119 45 0.67 0.52 
41 Sichompoo 22 532 1194 54 0.78 0.7 
42 Nampong 30 980 1939 65 0.7 0.69 
43 Khao's'k 15 726 522 35 1 0.28 
44 Waengnoi 18 525 864 48 0.91 0.55 
Thai IPA 33 Chumpae 37 2200 3147 85 1 1 
34 Kranuan 49 3200 760 16 0.39 0.18 
35 Banphai 40 1546 574 14 0.46 0.26 
36 Puwieng 26 665 728 28 0.94 0.77 
37 Nong's'h 17 362 322 19 1 0.62 
38 Manjakiri 29 379 494 17 0.96 0.12 
39 Phon 39 1084 755 19 0.59 0.49 
40 Nongrua 25 713 266 11 0.66 0.26 
41 Sichompoo 22 532 361 16 0.76 0.08 
42 Nampong 30 980 598 20 0.63 0.43 
43 Khao's'k 15 726 191 13 1 0.18 
44 Waengnoi 18 525 210 12 0.91 0.28 
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Figure 8.1: Correlation between optimal throughput and % overhead cost 
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Figure 8.3: Average costs and TE scores for outpatient care in 
Thailand 
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Figure 8.4: Average cost and returns to the variable factor 
for outpatient care in Thailand 
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Figure 8.5: Hospital clinic size and average cost in Thailand 
(at 80% capacity) 
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Figure 8.7: Average cost and returns to the variable factor 
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Figure 8.8: Average costs and TE score for inpatient care in 
Thailand 
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Figure 8.9: Average cost and returns to the variable factor 
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Figure 8.10: Hospital ward sizes and average cost in Thailand 
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Figure 8.12: Average cost and returns to the variable factor 
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Appendix 9: Unit cost results from Cuba, Thailand and South Africa 
Table 9.1: Average and marginal costs for outpatient antenatal care. ~/ 
Country, trial arm Average cost Marginal cost 
and health facility Lower CL Mean UpperCL COY Mean %AC 
CUBA 
Intervention group 
13 de Marzo 11.46 12.27 13.08 0.07 4.68 0.38 
Albarran 11.06 11.86 12.65 0.07 4.01 0.34 
Galvan 16.12 18.36 20.60 '0.13 7.11 0.39 
Manduley 8.39 9.13 9.86 0.08 3.61 0.40 
Romay 9.22 10.01 10.81 0.08 3.27 0.33 
.. 
Zuluetta 10.58 11.46 . 12.34 0.08 5.66 0.49 
Intervention average 9.05 12.18 15.31 0.27 4.72 0.39 
Control group 
Aballi 11.16 12.31 13.45 0.10 3.57 0.29 
Escalona 7.77 8.28 8.79 0.06 3.09 0.37 
Guiteras 12.95 17.85 22.74 0.28 3.77 0.21 
Reina 11.02 12.15 13.27 0.10 3.79 0.31 
Tamayo 12.27 13.85 15.44 0.12 3.98 0.29 
Vantroi 7.71 8.28 8.86 0.07 3.30 0.40 
Control average 8.64 12.12 15.60 0.30 3.78 0.31 
Policlinic average 8.99 12.15 15.31 0.27 4.25 0.35 
America Arias 2.82 3.22 3.62 0.13 0.64 0.20 
THAILAND 
Intervention group 
Chumpae 5.36 5.73 6.10 0.12 1.23 0.22 
Banphai 6.14 6.44 6.73 0.08 1.85 0.29 
Phuwiang 4.09 4.60 5.11 0.20 0.60 0.13 
Manjakiri 6.39 6.81 7.24 0.11 1.82 0.27 
Khaosuankwang 8.51 9.13 9.75 0.12 2.30 0.25 
WaengNoi 6.07 6.64 7.21 0.16 0.92 0.14 
Intervention average 5.73 6.56 7.39 0.23 1.41 0.22 
Control group 
Kranuan 7.68 8.40 9.11 0.15 3.37 0.40 
Nongsonghong 3.41 3.62 3.83 0.10 0.69 0.19 
Phol 6.19 6.56 6.92 0.10 1.20 0.18 
Nongrua 4.78 5.00 5.22 0.08 1.36 0.27 
Srichompoo 4.74 5.21 5.67 0.16 1.31 0.25 
Nampong 5.30 6.18 7.06 0.26 0.86 0.14 
Control average 4.92 5.83 6.73 0.28 1.40 0.24 
District average 4.70 6.19 7.69 0.44 1.41 0.23 
Khon Kaen Hospital 1.67 2.75 3.83 0.20 0.55 0.20 
Sririgarind Hospital 1.28 2.10 2.93 0.20 0.42 0.20 
SOUTH AFRICA 
D clinic 4.30 6.51 8.72 0.21 0.36 0.06 
H clinic 6.64 7.10 7.55 0.04 0.55 0.08 
L clinic 4.21 6.38 8.54 0.21 0.37 0.06 
Q clinic 5.59 8.63 11.66 0.22 0.37 0.04 
U21 clinic 5.47 7.61 9.74 0.18 0.43 0.06 
Sample average 5.78 7.24 8.70 0.13 0.42 0.06 
Prince Mshyeni 7.47 9.05 10.62 0.11 0.95 0.11 
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Table 9.2: Average and marginal costs for inpatient antenatal/postpartum care. 
Country, trial arm and Average cost Marginal cost 
health facility Lower CL Mean UpperCL COY Mean'" %AC 
CUBA 
America Arias 
ANC high risk (AB) 39.37 51.72 64.07 0.25 10.39 0.20 
ANC low risk (E) 23.95 30.84 37.72 0.23 6.80 0.22 
Postpartum VO (C) 13.89 16.76 19.63 0.18 4.04 0.24 
Postpartum CS (F) 29.14 36.75 44.35 0.21 8.78 0.24 
Neonatology 88.37 118.09 147.82 ,0.26 31.32 0.27 
THAILAND 
Intervention group 
Chumpae 2.95 3.34 3.73 0.21 0.20 0.06 
Banphai 6.92 7.44 7.95 0.13 0.86 0.12 
Phuwiang 6.10 6.48 6.87 0.11 1.47 0.23 
Manjakiri 5.16 5.67 6.18 0.16 0.54 0.09 
Khaosuankwang 9.69 10.60 11.51 0.16 2.80 0.26 
\yaengNoi 5.66 6.20 6.73 0.16 0.91 0.15 
Intervention average 5.30 6.62 7.94 0.36 1.00 0.15 
Control group 
Kranuan 8.61 9.19 . 9.77 0.11 1.89 0.21 
Nongsonghong 5.99 6.29 6.60 0.09 0.61 0.10 
Phol 4.93 5.32 5.71 0.13 0.50 0.09 
Nongrua 5.51 6.07 6.62 0.17 0.37 0.06 
Srichompoo 5.35 5.81 6.27 0.14 1.53 0.26 
Nampong 5.86 6.33 6.80 0.13 0.92 0.15 
Control average 5.74 6.50 7.26 0.21 0.94 0.14 
District average 5.54 6.56 7.58 0.28 0.97 0.15 
Khon Kaen Hospital 
Postpartum CS 50.51 63.14 75.76 0.20 12.63 0.20 
Obstetric cases 39.43 49.29 59.15 0.20 9.86 0.20 
Neonatology 13.12 16.41 19.69 0.20 3.28 0.20 
Sririgarind Hospital 
Postpartum CS 52.45 65.56 78.68 0.20 13.11 0.20 
Obstetric cases 2.13 2.66 3.19 0.20 0.53 0.20 
Neonatology 8.72 10.90 13.08 0.20 2.18 0.20 
SOUTH AFRICA 
Prince Mshiyeni 
ANC high risk (ANW) 27.24 33.13 39.02 0.11 1.51 0.05 
ANC low risk (El) 29.34 30.56 31.78 0.03 1.26 0.04 
Postpartum VO (E2) 22.57 27.67 32.77 0.12 3.34 0.12 
Postpartum VO (E5) 27.30 32.34 37.37 0.10 2.18 0.07 
Postpartum CS (E3) 24.63 26.25 27.86 0.04 3.64 0.14 
Postpartum CS (E4) 21.84 26.21 30.58 0.10 2.24 0.09 
Nursery 23.47 27.85 32.24 0.10 3.12 0.11 
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Table 9.3: Average and marginal costs for delivery care. 
Country, trial arm Average cost Marginal cost 
and health facility LowerCL Mean UpperCL COV Mean %AC 
CUBA 
America Arias 
Vaginal delivery 16.45 21.32 26.20 0.24 5.92 0.28 
Caesarean section 70.12 113.98 157.83 0.40 43.73 0.38 
THAILAND 
Vaginal delivery· Intervention group 
Chumpae 9.16 9.86. 10.55 0.13 3.19 0.32 
Banphai 37.47 40.05 .'42.63 . :.0.12 2.82 0.07 
Phuwiang 21.95 22.76 . 23.56 0.06 11.53 0.51 
Manjakiri 29.96 31.53 33.10 0.09 4.27 0.14 
Khaosuankwang 19.84 21.25 22.67 0.12 4.63 0.22 
WaengNoi 58.07 65.07 72.07 0.19 8.80 0.14 
Intervention average 24.44 31.75 39.07 0.42 7.35 0.23 
Vaginal delivery. Control group 
Kranuan 20.43 20.83 21.24 0.04 2.56 0.12 
Nongsonghong 11.57 12.46 13.36 0.13 0.96 0.08 
Phol 24.68 26.09 27.49 0.10 4.92 0.19 
Nongrua 24.23 29.03 33.82 0.30 2.26 0.08 
Srichompoo 23.35 25.05 26.75 0.12 8.88 0.35 
Nampong 20.63 23.07 25.51 0.19 3.74 0.16 
Control average 19.57 22.75 25.93 0.25 3.73 0.16 
District average 19.17 27.25 35.34 0.54 5.39 0.20 
Khon Kaen Hospital 35.14 39.10 43.06 0.20 7.82 0.20 
Sririgarind Hospital 50.54 56.23 61.93 0.20 11.25 0.20 
Caesarean section - Intervention group 
Chumpae 67.00 46.14 0.69 
Banphai 47.27 27.53 0.58 
Phuwiang 39.04 22.89 0.59 
Manjakiri 83.00 59.00 0.71 
Khaosuankwang 83.00 43.14 0.52 
WaengNoi 83.00 43.14 0.52 
Intervention average 67.05 40.32 0.60 
Caesarean section - Control group 
Kranuan 56.21 13.80 0.25 
Nongsonghong 185.10 69.88 0.38 
Phol 141.57 83.00 0.59 
Nongrua 53.42 29.54 0.55 
Srichompoo 83.00 53.29 0.64 
Nampong 74.40 55.47 0.75 
Control average 98.95 51.95 0.52 
District average 83.00 46.74 0.56 
Khon Kaen Hospital 63.14 12.63 0.20 
Sririgarind Hospital 65.56 13.11 0.20 
SOUTH AFRICA 
Prince Mshiyeni 
Labour and VD 74.49 81.40 88.30 0.05 5.38 0.07 
Caesarean section 105.71 140.60 175.48 0.16 24.91 0.18 
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Table 9.4: Ingredients of outpatient antenatal care cost. 
Country, trial arm Money contribution to cost (US$) Percent contribution to cost (%) 
and health facility Staff Eq Mat Drug Util Build Staff Eq Mat Drug Util Build 
CUBA 
Intervention group 
13 de Marzo 6.20 0.10 0.09 4.59 0.36 0.93 0.51 0.01 0.01 0.37 0.03 0.08 
Albarran 7.48 0.07 0.06 3.95 0.04 0.25 0.63 0.01 0.01 0.33 0.00 0.02 
Galvan 10.02 0.11 0.33 6.77 0.53 0.59 0.55 0.01 0.02 0.37 0.03 0.03 
Manduley 4.97 0.11 0.11 3.50 0.09 0.34 0.54 0.01 0.01 0.38 0.01 0.04 
Romay 6.09 0.08 0.13 3.14 0.31 0.27 .0.61 0.01 0.01 0.31 0.03 0.03 
Zuluetta 5.13 0.04 0.08 5.58 0.20 0.42 0.45 0.00 0.01 0.49 0.02 0.04 





































8.09 0.12 0.10 3.48 '0.21 0.31 0.66 0.01 0.01 0.28 0.02 0.02 
4.13 0.15 0.07 3.02 0.17 0.74 0.50 0.02 0.01 0.36 0.02 0.09 
13.00 0.26 0.23 3.54 0.58 0.22 0.73 0.01 0.01 0.20 0.03 0.01 
7.32 0.22 0.11 3.68 0.34 0.48 0.60 0.02 0.01 0.30 0.03 0.04 
9.13 0.11 0.11 3.87 0.26 0.37 0.66 0.01 0.01 0.28 0.02 0.03 
4.31 0.06 0.15 3.15 0.27 0.35 0.52 0.01 0.02 0.38 0.03 0.04 
7.41 0.15 0.13 3.65 0.30 0.48 0.61 0.01 0.01 0.30 0.02 0.04 
7.04 0.12 0.13 4.12 0.27 0.47 0.58 0.01 0.01 0.34 0.02 0.04 
2.13 0.17 0.50 0.'15 0.24 0.04 0.66 0.05 0.15 0.05 0.07 0.01 
4.12 0.27 0.32 0.91 0.03 0.07 0.72 0.05 0.06 0.16 0.01 0.01 
4.16 0.27 0.58 1.27 0.00 0.16 0.65 0.04 0.09 0.20 0.00 0.03 
3.39 0.23 0.31 0.29 0.05 0.34 0.74 0.05 0.07 0.06 0.01 0.07 
4.23 0.40 0.45 1.37 0.11 0.25 0.62 0.06 0.07 0.20 0.02 0.04 
5.68 0.83 0.68 1.63 0.04 0.27 0.62 0.09 0.07 0.18 0.00 0.03 
4.91 0.47 0.60 0.32 0.21 0.13 0.74 0.07 0.09 0.05 0.03 0.02 
4.47 0.39 0.49 0.92 0.07 0.22 0.68 0.06 0.07 0.14 0.01 0.03 
4.28 0.46 2.59 0.78 0.29 0.10 0.51 0.06 0.31 0.09 0.03 0.01 
2.40 0.23 0.15 0.55 0.03 0.27 0.66 0.06 0.04 0.15 0.01 0.07 
5.00 0.20 0.27 0.93 0.06 0.10 0.76 0.03 0.04 0.14 0.01 0.02 
2.72 0.58 0.50 0.86 0.04 0.29 0.54 0.12 0.10 0.17 0.01 0.06 
3.24 0.48 0.39 0.93 0.02 0.16 0.62 0.09 0.07 0.18 0.00 0.03 
4.57 0.43 0.56 0.30 0.20 0.12 0.74 0.07 0.09 0.05 0.03 0.02 
3.73 0.41 0.64 0.76 0.09 0.20 0.64 0.07 0.11 0.13 0.02 0.03 
4.09 0.41 0.57 0.84 0.08 0.21 0.66 0.07 0.09 0.14 0.01 0.03 
5.68 0.06 0.19 0.17 0.15 0.26 0.87 0.01 0.03 0.03 0.02 0.04 
6.12 0.05 0.17 0.39 0.16 0.21 0.86 0.01 0.02 0.05 0.02 0.03 
5.60 0.05 0.21 0.16 0.17 0.18 0.88 0.01 0.03 0.03 0.03 0.03 
7.89 0.04 0.16 0.21 0.13 0.19 0.91 0.01 0.02 0.02 0.02 0.02 
6.68 0.05 0.18 0.24 0.18 0.27 0.88 0.01 0.02 0.03 0.02 0.04 
6.38 0.05 0.19 0.23 0.16 0.22 0.88 0.01 0.03 0.03 0.02 0.03 




Table 9.5: Ingredients of outpatient antenatal/postpartum inpatient cost. 
Country, trial arm and Money contribution to cost (US$) Percent contribution to cost (% ) 
health facility Staff Eq Mat Drug Util Build Staff Eq Mat Drug Util Build 
CUBA 
America Arias 
ANC high risk (AB) 34.93 2.77 8.54 1.85 3.36 0.27 0.68 0.05 0.17 0.04 0.06 0.01 
ANC low risk (E) 21.35 1.06 4.87 1.93 1.48 0.16 0.69 0.03 0.16 0.06 0.05 0.01 
Postpartum VD (C) 10.90 0.72 2.86 1.18 0.98 0.11 0.65 0.04 0.17 0.07 0.06 0.01 
Postpartum CS (F) 24.34 1.31 5.93 2.85 2.08 0.24 0.66 0.04 0.16 0.08 0.06 0.01 
Neonatology 75.90 5.87 23.10 8.21 4.57 0.44 0.64 0.05 0.20 0.07 0.04 0.00 
THAILAND : 
Intervention group 
Chumpae 2.66 0.18 0.18 0.02 0.12 0.18 0.80 0:05 0.06 0.01 0.04 0.05 
Banphai 5.87 0.48 0.67 0.19 0.00 0.23 0.79 0.06 0.09 0.03 0.00 0.03 
Phuwiang 4.34 0.31 1.22 0.25 0.06 0.31 0.67 0.05 0.19 0.04 0.01 0.05 
Manjakiri 4.36 0.37 0.29 0.24 0.12 0.29 0.77 0.06 0.05 0.04 0.02 0.05 
Khaosuankwang 6.16 0.63 1.95 0.86 0.05 0.95 0.58 0.06 0.18 0.08 0.00 0.09 
WaengNoi 4.35 0.47 0.74 0.17 0.20 0.27 0.70 0.08 0.12 0.03 0.03 0.04 
Intervention average 4.75 0.40 0.76 0.24 0.11 0.35 0.72 0.06 0.11 0.04 0.02 0.05 
Control group 
Kranuan 6.23 0.66 0.77 1.12 0.41 0.49 0.68 0.07 0.08 0.12 0.04 0.05 
Nongsonghong 4.35 0.75 0.10 0.52 0.13 0.45 0.69 0.12 0.02 0.08 0.02 0.07 
Phol 4.37 0.21 0.43 0.07 0.04 0.20 0.82 0.04 0.08 0.01 0.01 0.04 
Nongrua 4.78 0.44 0.33 0.04 0.08 0.39 0.79 0.07 0.05 0.01 0.01 0.06 
Srichompoo 3.55 0.36 0.83 0.69 0.03 0.34 0.61 0.06 0.14 0.12 0.01 0.06 
Nampong 4.44 0.48 0.75 0.17 0.21 0.28 0.70 0.08 0.12 0.03 0.03 0.04 
Control average 4.65 0.48 0.54 0.40 0.13 0.36 0.72 0.07 0.08 0.06 0.02 0.05 
District average 4.70 0.44 0.65 0.32 0.12 0.35 0.72 0.07 0.10 0.05 0.02 0.05 
SOUTH AFRICA 
Prince Mshiyeni 
ANC high risk (ANW) 28.35 0.10 0.85 0.66 1.57 1.59 0.86 0.00 0.03 0.02 0.05 0.05 
ANC low risk (El) 24.84 0.10 0.80 0.45 2.46 1.90 0.81 0.00 0.03 0.01 0.08 0.06 
Postpartum VD (E2) 21.12 0.38 2.28 1.06 1.27 1.56 0.76 0.01 0.08 0.04 0.05 0.06 
Postpartum VD (E5) 26.39 0.14 1.71 0.47 1.56 2.06 0.82 0.00 0.05 0.01 0.05 0.06 
Postpartum CS (E3) 19.81 0.07 2.45 1.19 1.16 1.55 0.75 0.00 0.09 0.05 0.04 0.06 
Postpartum CS (E4) 20.97 0.10 1.24 1.00 1.23 1.67 0.80 0.00 0.05 0.04 0.05 0.06 
Nursery 19.34 2.12 2.35 0.76 1.39 1.89 0.69 0.08 0.08 0.03 0.05 0.07 
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Table 9.6: Ingredients of delivery care cost. 
Country, trial arm Money contribution to cost (US$) Percent contribution to cost (% ) 
and health facility Staff Eq Mat Drug Util Build Staff Eq Mat Drug Util Build 
CUBA 
America Arias 
Vaginal delivery 12.92 1.04 4.40 1.52 1.34 0.11 0.61 0.05 0.21 0.07 0.06 0.01 
Caesarean section 65.03 2.03 21.51 22.22 2.76 0.44 0.57 0.02 0.19 0.19 0.02 0.00 
THAILAND 
Vaginal delivery. Intervention group 
Chumpae 6.34 0.13 2.54 0.65 0.07 0.13 0.64 0.01 0.26 0.07 0.01 0.01 
Banphai 33.45 2.89 2.81 0.01 0.00 0.89 0.84 0.07 0.07 0.00 0.00 0.02 
Phuwiang 9.10 1.38 11.30 0.23 0.19 0.55 0.40 0.06 0.50 0.01 0.01 0.02 
Manjakiri 23.29 2.36 2.72 1.54 0.61 1.00 0.74 0.07 0.09 0.05 0.02 0.03 
Khaosuankwang 10.50 4.98 1.89 2.74 0.10 1.05 0.49 0.23 0.09 0.13 0.00 0.05 
WaengNoi 36.81 13.18 6.98 1.82 1.05 5.24 0.57 0.20 0.11 0.03 0.02 0.08 
Intervention average 19.46 3.48 5.86 1.49 0.30 1.17 0.61 0.11 0.18 0.05 0.01 0.04 
Vaginal delivery. Control group 
Kranuan 15.82 1.52 0.00 2.56 0.94 0.27 0.76 0.07 0.00 0.12 0.04 0.01 
Nongsonghong 7.17 2.21 0.09 0.87 0.91 1.22 0.58 0.18 0.01 0.07 0.07 0.10 
Phol 19.53 0.86 3.05 f.87 0.27 0.50 0.75 0.03 0.12 0.07 0.01 0.02 
Nongrua 22.36 2.04 1.76 0.50 0.29 2.08 0.77 0.07 0.06 0.02 0.01 0.07 
Srichompoo 14.08 1.02 4.33 4.55 0.13 0.93 0.56 0.04 0.17 0.18 0.01 0.04 
Nampong 16.40 1.60 2.99 0.75 0.85 0.48 0.71 0.07 0.13 0.03 0.04 0.02 
Control average 15.65 1.76 1.85 1.88 0.68 0.98 0.69 0.08 0.08 0.08 0.03 0.04 
District average 17.72 2.55 3.62 1.77 0.54 1.09 0.65 0.09 0.13 0.06 0.02 0.04 
Caesarean section - Intervention group 
Chumpae - 12.56 5.11 16.70 29.44 0.91 2.28 0.19 0.08 0.25 0.44 0.01 0.03 
Banphai 10.90 7.74 19.91 7.62 0.01 1.10 0.23 0.16 0.42 0.16 0.00 0.02 
Phuwiang 4.45 4.43 14.08 8.81 1.34 5.93 0.11 0.11 0.36 0.23 0.03 0.15 
Manjakiri 18.63 3.76 30.29 28.71 0.50 1.12 0.22 0.05 0.36 0.35 0.01 0.01 
Khaosuankwang 34.09 3.69 18.50 24.65 0.38 1.70 0.41 0.04 0.22 0.30 0.00 0.02 
WaengNoi 34.09 3.69 18.50 24.65 0.38 1.70 0.41 0.04 0.22 0.30 0.00 0.02 
Intervention average 17.63 5.45 20.58 19.74 0.70 2.95 0.26 0.08 0.31 0.29 0.01 0.04 
Caesarean section - Control group 
Kranuan 34.08 8.26 13.40 0.40 0.02 0.06 0.61 0.15 0.24 0.01 0.00 0.00 
Nongsonghong 109.72 3.70 41.78 28.09 0.37 1.44 0.59 0.02 0.23 0.15 0.00 0.01 
Phol 16.15 16.06 51.07 31.93 4.86 21.50 0.11 0.11 0.36 0.23 0.03 0.15 
Nongrua 10.38 9.04 11.66 17.88 0.72 3.75 0.19 0.17 0.22 0.33 0.01 0.07 
Srichompoo 15.70 8.27 28.97 24.32 1.12 4.62 0.19 0.10 0.35 0.29 0.01 0.06 
Nampong 18.12 0.60 21.83 33.64 0.14 0.08 0.24 0.01 0.29 0.45 0.00 0.00 
Control average 31.99 9.19 27.80 24.15 1.08 4.74 0.32 0.09 0.28 0.24 0.01 0.05 
District average 24.33 7.23 24.40 22.34 0.89 3.81 0.29 0.09 0.29 0.27 0.01 0.05 
SOUTH AFRICA 
Prince Mshiyeni 
Labour and VD 66.82 0.17 3.88 1.50 3.77 5.25 0.82 0.00 0.05 0.02 0.05 0.06 
Caesarean section 103.91 2.35 17.74 7.17 4.79 4.65 0.74 0.02 0.13 0.05 0.03 0.03 
Key: Direct - direct helth care costs; Admin - administrative costs; Lab -laboratory costs; Tech -
departments providing direct support to health care departments; Gen - general services. 
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Table 9.7: Components of antenatal outpatient cost. 
Country, trial arm Components of cost (US$) Components of cost (%) 
and health facility Direct Admin Lab Tech Gen Direct Admin Lab ~ Tech Gen 
CUBA 
Intervention group 
13 de Marzo 10.27 0.62 0.58 0.25 ·0.55 0.84 0.05 0.05 0.02 0.04 
Albarran 9.92 1.35 0.26 0.15 0.18 0.84 0.11 0.02 0.01 0.01 
Galvan 13.55 1.93 1.62 0.10 1.16 0.74 0.11 0.09 0.01 0.06 
Manduley 7.46 1.13 0.23 0.10 0.21 0.82 0.12 0.02 0.01 0.02 
Romay 8.29 0.93 0.33 0.06 0.40 0.83 0.09 0.03 0.01 0.04 
Zuluetta 8.76 1.08 1.04 0.08 0.49 0.77 0.09 0.09 0.01 0.04 
Intervention average 9.79 1.18 0.62 0.13 0.46 0.80 0.10 0.05 0.01 0.04 
Control group 
Aballi 10.79 0.59 0.47 0.11 0.35 0.88 0.05 0.04 0.01 0.03 
Escalona 7.40 0.38 0.19 0.12 0.20 0.89 0.05 0.02 0.01 0.02 
Guiteras 14.94 0.86 0.57 0.48 1.00 0.84 0.05 0.03 0.03 0.06 
Reina 10.68 0.64 0.43 0.14 0.26 0.88 0.05 0.04 0.01 0.02 
Tamayo 10.65 1.57 1.01 0.12 0.51 0.77 0.11 0.07 0.01 0.04 
Vantroi 6.52 1.04 0.15 0.08 0.50 0.79 0.13 0.02 0.01 0.06 
Control average 10.18 0.88 0.44 0.16 0.46 0.84 0.07 0.04 0.01 0.04 
Policlinic average 9.99 1.03 0.53 0.14 0.46 0.82 0.08 0.04 0.01 0.04 
America Arias 0.91 0.12 1.50' 0.62 0.07 0.28 0.04 0.47 0.19 0.02 
THAILAND 
Intervention group 
Chumpae 2.92 0.32 1.76 0.53 0.19 0.51 0.06 0.31 0.09 0.03 
Banphai 4.38 0.37 0.32 1.02 0.34 0.68 0.06 0.05 0.16 0.05 
Phuwiang 3.09 0.33 0.46 0.52 0.20 0.67 0.07 0.10 0.11 0.04 
Manjakiri 4.40 0.46 0.57 0.72 0.67 0.65 0.07 0.08 0.11 0.10 
Khaosuankwang 5.20 0.75 0.52 2.45 0.21 0.57 0.08 0.06 0.27 0.02 
WaengNoi 3.95 0.55 0.64 0.93 0.57 0.59 0.08 0.10 0.14 0.09 
Intervention average 4.01 0.45 0.76 0.96 0.37 0.61 0.07 0.12 0.15 0.06 
Control group 
Kranuan 4.84 0.33 1.07 1.80 0.35 0.58 0.04 0.13 0.21 0.04 
Nongsonghong 2.23 0.19 0.51 0.54 0.15 0.62 0.05 0.14 0.15 0.04 
Pho} 4.40 0.32 0.90 0.61 0.34 0.67 0.05 0.14 0.09 0.05 
Nongrua 3.67 0.17 0.27 0.57 0.31 0.73 0.03 0.05 0.11 0.06 
Srichompoo 3.24 0.42 0.36 0.77 0.40 0.62 0.08 0.07 0.15 0.08 
Nampong 3.75 0.41 0.37 1.07 0.57 0.61 0.07 0.06 0.17 0.09 
Control average 3.72 0.31 0.57 0.87 0.36 0.64 0.05 0.10 0.15 0.06 
District average 3.87 0.38 0.66 0.91 0.36 0.62 0.06 0.11 0.15 0.06 
SOUTH AFRICA 
D clinic 4.77 0.45 0.82 0.00 0.47 0.73 0.07 0.13 0.00 0.07 
H clinic 4.96 0.39 0.91 0.00 0.83 0.70 0.06 0.13 0.00 0.12 
L clinic 4.34 0.44 0.81 0.00 0.79 0.68 0.07 0.13 0.00 0.12 
Q clinic 6.73 0.48 0.71 0.00 0.71 0.78 0.06 0.08 0.00 0.08 
U21 clinic 5.33 0.41 0.84 0.00 1.02 0.70 0.05 0.11 0.00 0.13 
Control average' 5.20 0.44 0.83 0.00 0.77 0.72 0.06 0.11 0.00 0.11 
Prince Mshyeni 7.89 0.21 0.36 0.35 0.24 0.87 0.02 0.04 0.04 0.03 
Key: Direct - direct helth care costs; Admin - administrative costs; Lab -laboratory costs; Tech -
departments providing direct support to health care departments; Gen - general services. 
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Table 9.8: Components of antenataVpostpartum inpatient cost. 
Country, trial arm Components of cost (US$) Components of cost (% ) 
and health facility Direct Admin Lab Tech Gen Direct Admin Lab Tech Gen 
CUBA 
America Arias 
ANC high risk (AB) 21.07 2.64 12.47 13.97 1.58 0.41 0.05 0.24. 0.27 0.03 
ANC low risk (E) 13.25 1.53 7.02 8.11 0.92 0.43 0.05 0.23 0.26 0.03 
Postpartum VD (C) 6.88 0.92 3.54 4.87 0.55 0.41 0.05 0.21 0.29 0.03 
Postpartum CS (F) 15.84 1;89 7.86 10.02 1.13 0.43 0.05 0.21 0.27 0.03 
Neonatology 60.45 6.36 13.90 33.58 3.80 0.51 0.05 0.12 0.28 0.03 
THAILAND 
Intervention group 
Chumpae 2.26 0.24 0.28 0.41 0.15 0.68 0.07 0.08 0.12 0.04 
Banphai 4.97 0.52 0.77 0.84 0.33 0.67 0.07 0.10 0.11 0.04 
Phuwiang 4.61 0.55 0.11 0.88 0.34 0.71 0.08 0.02 0.14 0.05 
Manjakiri 3.96 0.39 0.16 0.61 0.56 0.70 0.07 0.03 0.11 0.10 
Khaosuankwang 7.59 0.61 0.21 2.01 0.17 0.72 0.06 0.02 0.19 0.02 
WaengNoi 4.05 0.41 0.61 0.70 0.43 0.65 0.07 0.10 0.11 0.07 
Intervention average 4.55 0.46 0.39 0.86 0.36 0.69 0.07 0.06 0.13 0.05 
Control group 
Kranuan 6.22 0.33 0.50 1.80 0.35 0.68 0.04 0.05 0.20 0.04 
Nongsonghong 4.23 0.38 0.28 1.07 0.30 0.67 0.06 0.05 0.17 0.05 
Phol 3.25 0.43 0.33 0.84 0.46 0.61 0.08 0.06 0.16 0.09 
Nongrua 4.26 0.27 0.17 0.89 0.48 0.70 0.04 0.03 0.15 0.08 
Srichompoo 4.39 0.34 0.14 0.62 0.46 0.76 0.06 0.02 0.11 0.08 
Nampong 3.98 0.39 0.38 1.02 0.55 0.63 0.06 0.06 0.16 0.09 
Control average 4.38 0.37 0.30 1.02 0.46 0.67 0.06 0.05 0.16 0.07 
District average 4.47 0.42 0.34 0.94 0.41 0.68 0.06 0.05 0.14 0.06 
SOUTH AFRICA 
Prince Mshiyeni 
ANC high risk (ANW) 27.46 1.31 0.57 .. 2.23 1.56 0.83 0.04 0.02 0.07 0.05 
ANC low risk (El) 25.92 1.21 0.16 1.92 1.35 0.85 0.04 0.01 0.06 0.04 
Postpartum VD (E2) 23.20 1.13 0.27 1.80 1.27 0.84 0.04 0.01 0.07 0.05 
Postpartum VD (E5) 26.14 1.25 1.56 1.99 1.40 0.81 0.04 0.05 0.06 0.04 
Postpartum CS (E3) 22.16 1.02 0.31 1.61 1.14 0.84 0.04 0.01 0.06 0.04 
Postpartum CS (E4) 21.82 1.10 0.31 1.75 1.24 0.83 0.04 0.01 0.07 0.05 
Nursery 23.92 1.01 0.15 1.62 1.15 0.86 0.04 0.01 0.06 0.04 
Key: Direct - direct helth care costs; Admin - administrative costs; Lab -laboratory costs; Tech -
departments providing direct support to health care departments; Gen - general services. 
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Table 9.9: Components of delivery care cost. 
Country, trial arm Components of cost (US$) Components of cost (%) 
and health facility Direct Admin Lab Tech Gen Direct Admin Lab Tech Gen 
CUBA 
America Arias 
Vaginal delivery 8.36 1.03 5.81 5.51 0.62 0.39 0.05 0.27 0.26 0.03 
Caesarean section 69.93 6.40 0.00 33.82 3.82 0.61 0.06 0.00 0.30 0.03 
THAILAND 
Vaginal delivery. Intervention group 
Chumpae 7.49 0.72 0.00.' 1.21 0.44 0.76 0.07 0.00 0.12 0.04 
Banphai 32.55 1.61 0.00 4.42" ','1.47 0.81' :,: 0.04 0.00 0.11 0.04 
Phuwiang 14.81 2.46 0.00 3.96 1.53 0.65 ' 0.11 0.00 0.17 0.07 
Manjakiri 25.40 1.53 0.00 2.39 2.21 0.81 0.05 0.00 0.08 0.07 
Khaosuankwang 16.40 1.06 0.00 3.50 0.30 0.77 0.05 0.00 0.16 0.01 
WaengNoi 41.72 6.24 0.00 10.60 6.51 0.64 0.10 0.00 0.16 0.10 
Intervention average 23.50 2.20 0.00 4.29 1.76 0.74 0.07 0.00 0.14 0.06 
Vaginal delivery. Control group 
Kranuan 17.99 0.38 0.00 2.06 0.41 0.86 0.02 0.00 0.10 0.02 
Nongsonghong 9.06 0.74 0.00 2.07 0.59 0.73 0.06 0.00 0.17 0.05 
Phol 18.06 2.00 0.00 3.87 2.15 0.69 0.08 0.00 0.15 0.08 
Nongrua 21.88 1.16 0.00 3.89 2.10 0.75 0.04 0.00 0.13 0.07 
Srichompoo 19.46 1.48 0.00 2.70 1.41 0.78 0.06 0.00 0.11 0.06 
Nampong 17.34 1.15 0.00 2.98 1.60 0.75 0.05 0.00 0.13 0.07 
Control average 17.31 1.15 0.00 2.98 1.32 0.76 0.05 0.00 0.13 0.06 
District average 20.45 1.63 0.00 3.62 1.54 0.75 0.06 0.00 0.13 0.06 
SOUTH AFRICA 
Prince Mshiyeni 
Labour and VD 71.50 2.78 0.18 3.81 3.13 0.88 0.03 0.00 0.05 0.04 
Caesarean section 130.85 2.51 0.34 4.06 2.85 0.93 0.02 0.00 0.03 0.02 
Key: Direct - direct helth care costs; Admin - administrative costs; Lab - laboratory costs; Tech _ 
departments providing direct support to health care departments; Gen - general services. 
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Table 9.10: Sensitivity analysis results for changes in prices and length of life of capital 
items. ----
Health Country A veraJ!e cost Equipment Traded 200ds Capital items Wa2es 
care Low Base High Cost t 50% Cost t 50% LoL t 100% LoL J. 50% Cost t 50% 
AC %A AC %A AC %A AC %A AC 
ANC Cuba 11.1 11.9 12.6 11.9 0.00 13.9 0.17 11.7 -0.01 12.2 0.03 15.6 
Thai 6.1 6.6 7.2 6.9 0.03 7.3 0.10 6.3 -0.05 7.2 0.09 9.1 
S.Africa 4.2 6.4 8.5 6.4 0.00 6.6 0.03 6.3 -0.02 6.6 0.04 9.2 
IPC Cuba 23.9 30.8 37.7 31.4 0.02 34.8 0.13 30.2 -0.02 32.1 0.04 41.5 
Thai 5.7 6.2 6.7 6.4 0.04 6.9 '0.11 5.8 -0.06 6.9 0.12 8.4 
S.Africa 29.3 30.6 31.8 30.6 0.00 31.2 0.02 29.6 -0.03 32.6 0.07 43.0 
VD Cuba 16.4 21.3 26.2 21.9 0.02 24.8 0.16 20.8 -0.03 22.5 0.05 27.8 
Thai 20.6 23.1 25.5 25.4 0.10 - 27.0 0.17 19.8 -0.14 29.6 0.28 29.6 
S.Africa 74.5 81.4 88.3 81.5 0.00 84.2 0.03 78.7 -0.03 86.8 0.07 114.8 
CS Cuba 70.1 114.0 157.9 115.0 0.01 136.9 0.20 112.7 -0.01 116.4 0.02 146.5 
Thai 52.08 74.4 96.7 78.1 0.05 102.0 0.37 68.6 -0.08 86.0 0.16 81.4 
S.Africa 105.7 140.6 175.5 141.8 o.ot 154.2 0.10 137.1 -0.02 147.6 0.05 192.6 
PP Cuba 13.9 16.8 19.6 17.1 0.02 19.1 0.14 16.3 -0.03 17.6 0.05 22.2 
S.Africa 22.6 27.7 32.8 27.9 O.ot 29.5 0.07 26.7 -0.04 29.6 0.07 38.2 
NN- Cuba 96.7 118.1 139.5 121.0 0.02 136.7 0.16 114.9 -0.03 124.4 0.05 156.0 
S.Africa 23.5 27.9 32.2 28.9 0.04 30.5 0.09 25.9 -0.07 31.9 0.14 37.5 
..,A - percentage change; Figures in bold means that the AC range is larger than the lower or higher 
confidence limits 
Table 9.11: Sensitivity analysis results for use of pooled drug cost. 
Cuban policlinics Average cost under: % Thai hospitals Average cost under: 
Base Pooled change Base Base Pooled 
13 de Marzo 12.27 12.36 o.ot Chumpae 5.73 5.74 
Albarran 11.86 12.52 0.06 Banphai 6.44 6.10 
Galvan 18.36 15.94 -0.13 Phuwiang 4.60 5.24 
Manduley 9.12 10.13 0.11 Manjakiri 6.82 6.38 
Romay 10.01 11.60 -- 0.16 Khaosuankwang 9.13 8.43 
Zuluetta 11.46 10.52 -0.08 WaengNoi 6.64 7.24 
Aballi 12.31 11.98 -0.03 Kranuan 8.40 8.34 
Escalona 8.28 8.80 0.06 Nongsonghong 3.62 3.79 
Guiteras 17.85 18.13 0.02 Phol 6.56 6.35 
Reina 12.15 11.90 -0.02 Nongrua 5.00 4.86 
Tamayo 13.86 13.82 0.00 Srichompoo 5.21 5.00 
Vantroi 8.28 8.08 -0.02 Nampong 6.18 6.61 



































Table 9.12: Sensitivity analysis results for changes in methodology. 
Health care Country Average cost (US$) Simultan. step-down allocation Exchange 
Low Base High % cost 20% less 20% more alternative 
direct AC % diff AC % diff AC % diff 
(US$) (US$) (US$) 
ANC Cuba 11.1 11.9 12.6 0.86 11.5 -0.03 12.2 0.03 4.4 -0.63 
Outpatient Thai 6.1 6.6 7.2 0.69 6.2 -0.06 7.1 0.06 9.4 0.42 
Visit S.Africa 4.2 6.4 8.5 0.81 6.1 -0.04 6.6 0.04 5.1 -0.21 
ANC Cuba 23.9 30.8 37.7 0.66 28.7 -0.07 32.9 0.07 8.9 -0.71 
Inpatient Thai 5.7 6.2 6.7 0.75 5.9 -0.05 6.5 0.05 8.8 0.42 
Day S.Africa 29.3 30.6 31.8 0.86 29.7 -0.03 31.4 0.03 24.3 -0.21 
Vaginal Cuba 16.4 21.3 26.2 0.66 19.9 -0.07 22.8 0.07 7.6 -0.64 
Delivery Thai 20.6 23.1 25.5 0:75 21.9 .~O.05 24.2 0.05 32.7 0.42 
S.Africa 74.5 81.4 88.3 ·0.88 79.5 -0.02 83.3 0.02 64.6 -0.21 
Caesarean Cuba 70.1 114.0 157.9 0.61 105.2 -0.08 122.8 0.08 48.9 -0.57 
Section Thai 52.08 74.4 96.7 nla nla nla nla nla 105.5 0.42 
S.Africa 105.7 140.6 175.5 0.93 138.7 -0.01 142.5 0.Q1 111.6 -0.21 
Postpartum Cuba 13.9 16.8 19.6 0.65 15.6 -0.07 17.9 0.07 5.3 -0.68 
Day S.Africa 22.6 27.7 32.8 0.85 26.9 -0.03 28.5 0.03 22.0 -0.21 
Neonatal Cuba 96.7 118.1 139.5 0.63 109.4 -0.07 126.8 0.07 40.9 -0.65 
Day S.Africa 23.5 27.9 32.2 0.87 27.1 -0.03 28.6 0.03 22.1 -0.21 
Figures ID bold means that the AC range IS larger than the lower or hIgher confidence hmIts 
Table 9.13: Unit cost range taking into account small number of months. 
Health care Average cost (US$) Possible impact on average cost 
Low Base High AC range (US$) % difference with 
base average cost 
Cuba 
Antenatal care 11.1 11.9 12.6 11.03· 12.75 0.07 
Inpatient care 23.9 30.8 37.7 28.32 - 33.58 0.08 
Vaginal delivery 16.4 21.3 26.2 18.87 - 24.10 0.12 
South Africa 
Antenatal care 4.2 6.4 .. 8.5 5.86 - 6.92 0.08 
Inpatient care 29.3 30.6 31.8 25.64 - 35.05 0.16* 
Vaginal delivery 74.5 81.4 88.3 67.82· 97.67 0.17* 
Caesarean section 105.7 140.6 175.5 104.15· 169.02 0.26* 
Postpartum care 22.6 27.7 32.8 24.29 - 31.52 0.12 
Neonatal care 23.5 27.9 32.2 23.44 - 33.09 0.16* 
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Appendix 10: Risk factors for patients in interventions arms in Cuba and Thailand 
Table 10.1: Eligibility for the WHO ANC programme in Cuba· risk factors. 
Policlinic Number Obstetric history Current pregnancy 
of Previous >2 Last Last Admission Previous Multiple <16 >40 Rh-
women Stillbirth abortion <2500g >4500g last preg. surgery Pregnancy I years years 
Albarran 631 13 2 12 9 26 11 2 2 1 6 
Manduley 654 14 8 8 11 22 23 4 0 1 4 
Romay 473 5 4 9 6 6, 9 4 13 5 2 
Galvan 521 14 2 24 10 11 19 4 2 2 4 
Zuluetta 446 9 7 18 10 17 15 5 2 1 1 
13 de Marzo 527 15 10 7 :: ,6 8 9 1 4 1 3 
ALL 3252 70 33 78 '52 90 86 20 23 11 20 
Policlinic Average Current pregnancy General medical Eligibility 
cost Vaginal Pelvic DBP>90 IDDM Renal Cardiac Substance Other No. % 
Bleeding mass mmHg disease disease Abuse severe 
Albarran 11.86 32 25 16 1 9 5 10 90 171 0.27 
Manduley 9.12 19 14 9 1 7 3 14 74 168 0.26 
Romay 10.01 10 5 10 1 6 5 0 33 101 0.21 
Galvan 18.36 12 11 7 1 12 4 0 65 148 0.28 
Zuluetta 11.46 32 2 6 2 2 1 1 9 114 0.26 
13 de Marzo 12.27 16 8 9 0 4 7 2 70 137 0.26 
ALL 12.18 121 65 57 6 40 25 27 341 839 0.26 
Table 10.2: Eligibility for the WHO ANC programme in Thailand· risk factors. 
District Number Obstetric history Current pregnancy 
hospital of women Previous <2 Last Last Adm. Previous Multiple <16 >40 Rh-
stillbirth Abortion <2500g >4500g last preg. surgery pregnancy years years 
Chumpae 1064 3 2 35 0 0 13 0 11 7 0 
Banphai 759 15 6 31 0 31 2 16 4 1 
Puvieng 594 15 4 27 2 3 24 1 3 4 0 
Manjakiri 493 6 0 23 0 1 5 0 2 3 0 
KSK 320 1 0 8 0 0 2 0 5 1 1 
WaengNoi 219 3 0 4' 1 0 3 0 2 3 0 
ALL 3449 43 12 128 3 4 78 3 39 22 2 
District Average Current pregnancy General medical Eligibility 
hospital cost Vaginal Pelvic DBP>90 IDDM Renal Cardiac Substance Other No. % 
bleeding Mass mmHg disease disease abuse severe 
Chumpae 5.39 1 1 0 1 0 0 0 20 91 0.09 
Banphai 6.17 1 0 4 1 3 0 3 6 106 0.14 
Puvieng 4.12 2 0 0 4 1 4 1 10 86 0.14 
Manjakiri 6.42 31 0 1 0 2 2 0 3 75 0.15 
KSK 8.56 0 0 0 0 0 0 0 4 22 0.07 
WaengNoi 6.12 0 0 0 1 0 0 0 2 16 0.07 
ALL 5.80 35 1 5 7 6 6 4 45 396 0.11 
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Table 11.1: Comparison of resource prices in Cuba, Thailand and South Africa (US$). APPENDICES 
Name of material Cost in 1998 (US$) Comparisons 
Cuba Thailand South Africa TH>CU SA>CU SA>TH 
Alcohol (litre) 1.3 0.8 0.62 ./ 
Catheter (Foley's) 0.67 0.8 1.19 
Detergent (litre) 1.89 0.52 1.28 0.28 0.68 2.46 
Elastic Bandage 4" (dozen) 7.07 14.21 2.01 
Garbage bags (roll) 0.96 1.1 1.15 
Gauze swabs (box) 1.6 1.43 1.58 0.89 0.99 1.10 
Gloves (box of disposable) 2.29 3.73 1.63 
Gloves (surgical) 4.21 6.97 1.66 
Needle (box of disposable) 1.4 2.49 1.78 
Plaster 2" (box) 4.65 5 1.08 
Soap (bar) 0.53 0.13 .. 0.1 0.25 0.19 0.77 
Toilet paper (roll) 0.08 . 0.22 2.75 
Washing liquid (litre) 2.16 3.25 3.55 1.50 1.64 1.09 
Average ratio 0.71 0.87 1.56 
I I 
Name of drug Cost in 1998 (US$) Comparisons 
Cuba Thailand South Africa TH>CU SA>CU SA>TH 
Adrenaline 0.2 0.16 0.80 
IT (dosel 0.4 0.6 1.50 
Vit C (pill) 0.13 0.02 0.15 
MUlti-vitamins (pill) 0.056 0.091 0.017 1.63 0.30 0.19 
Paracetamol (500mg pill) 0.02 0.01 0.0048 0.50 0.24 0.48 
Folic acid (5mg pill) 0.03 0.0048 0.008 0.16 0.27 1.67 
Amoxyl (250 mg pill) 0.0573 0.0327 0.57 
Diazepam (500mg 100 pill) 6 1.91 0.32 
Vitamina B1 (10mg, 100 pill) 0.10 0.02 0.20 
Vitamin B complete (pill) 0.0096 0.00242 0.25 
Erythromycin (125mg, 100ml) 0.87 0.92 1.06 
Ferrous sulphate (pills) 0.00956 0.0039 0.41 
Magnesium sulphate (75g powder) 0.19 0.03 0.16 
Pennicilin (250mg pill) 0.019 0.016 0.84 
Vitamin K (10mg, infection) 0.48 1.25 2.60 
Clotrimazol (pill) 0.2 0.01 0.05 
Metronidazol (pill) 0.075 0.01 0.0066 0.13 0.09 0.66 
Benzatinica (inj) 1.5 1.91 1.27 
Theophyllin (200mg pill) 0.057 0.019 0.33 
Average ratio 0.59 0.22 0.77 
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Table 11.1: Comparison of resource prices in Cuba, Thailand and South Africa (US$). APPENDICES 
Member of staff Gross salary per month (US$) Comparisons 
(job description) Cuba Thailand South Africa TH>CU SA>CU SA>TH 
Head of HCPU (hospital) 500 642 4'566 1.28 9.13 7.12 
Head of HCPU (clinic) 450 642 1'175 1.43 2.61 1.83 
Specialist 450 765 3'145 1.70 6.99 4.11 
Doctor 350 478 2'000 1.37 5.71 4.18 
Senior nurse 298 397 1'100 1.33 3.69 2.77 
Professional nurse 250 286 800 1.14 3.20 2.80 
Enrolled/empirical nurse 200 230 600 1.15 3.00 2.61 
Science technician 211 256 1'173 1.21 5.56 4.58 
Radiologist 211 268 1'300 1.27 6.16 4.86 
Pharmacist 198 325 1'000 1.64 5.05 3.08 
Accountant 170 248 .' - 1'000 1.46 5.88 4.03 
Typist 170 172 700 1.01 4.12 4.07 
Clerk 128 191 900 1.49 7.03 4.71 
Security guard 126 150 600 1.19 4.76 4.00 
Driver 110 134 600 1.22 5.45 4.48 
Cleaner 100 120 450 1.20 4.50 3.75 
AVERAGE 261.47 353.54 1'407.27 . 1.41 5.52 4.20 
1 1 1 1 
Item of equipment Cost in 1998 (US$) Comparisons 
Cuba Thailand South Africa TH>CU SA>CU SA>TH 
Machinary/electrical 
Autoclave 2117 3400 10'000 1.61 4.72 2.94 
Centrifuge 846 726 1670 0.86 1.97 2.30 
Computer 2000 765 1560 0.38 0.78 2.04 
ECG machine (8 channel) 6960 2868 3'600 0.41 0.52 1.26 
Fridge (food, large) 700 250 400 0.36 0.57 1.60 
Incubator (ICU, premature) 7200 3060 26'000 0.43 3.61 8.50 
Microscope 3866 1920 5'000 0.50 1.29 2.60 
Photocopier 2700 1720 1'100 0.64 0.41 0.64 
Type writer (electric) 336 573 600 1.71 1.79 1.05 
AVERAGE 267251 152821 49'930 0.76 1.74 2.55 
Non-machinary .. 
Bed (fowler) 83 192 165 2.31 1.99 0.86 
Cabinet (4 drawer filing, steel) 124 66 42 0.53 0.34 0.64 
Case (book) 124 115 143 0.93 1.15 1.24 
Chair (arm) 80 29 75 0.36 0.94 2.59 
Chair (normal) 8 7 13 0.88 1.63 1.86 
Clock (wall) 30 15 32 0.50 1.07 2.13 
Desk (office) 39 25 68 0.64 1.74 2.72 
Scales & height measure 100 191 203 1.91 2.03 1.06 
Scales (baby) 30 17 165 0.57 5.50 9.71 
Table Joffice) 62 29 53 0.47 0.85 1.83 
Trolley (medicine) 100 97 130 0.97 1.30 1.34 
AVERAGE 780 783 1089 0.92 1.69 2.36 
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Appendix 12: Cost per pregnancy results in study countries 
./ 
Table 12.1: Percent contributors to cost per pregnancy, by type of care and resource 
ingredient. 
Country, trial arm Cases Health care type (% ) Resource ingredientJ. %1 
and health facility No. % OP IP DEL PP NN ST EQ MA DR UT BU 
CUBA 
13 de Marzo 449 8.0 0.24 0.22 0.11 0.25 0.19 0.58 0.03 0.11 0.20 0.05 0.04 
Albarran 567 10.1 0.25 0.19 0.11 0.22 '0.23 0.64 0.03 0.10 0.19 0.03 0.01 
Galvan 459 8.2 0.26 0.17 0.09 0.21 0.27 0.60 0.03 0.10 0.21 0.04 0.02 
Manduley 575 10.3 0.21 0.21 0,14 0.27 0.18 0.61 0.03 0.12 0.19 0.04 0.02 
Romay 418 7.5 0.20 0.20 0.12 0.24 0.24 0.63 0.03 0.12 0.16 0.05 0.01 
Zuluetta 402 7.2 0.27 0.14 0.14 0.28 0.17 0.56 0.03 0.11 0.24 0.04 0.02 
A verage Intervention 2870 51.2 0.24 0.19 0.11 0.24 0.22 0.60 0.03 0.11 0.20 0.04 0.02 
Aballi 514 9.2 0.39 0.14 0.10 0.21 0.15 0.65 0.02 0.08 0.19 0.03 0.02 
Escalona 628 11.2 0.27 0.17 0.11 0.22 0.24 0.58 0.03 0.10 0.21 0.04 0.04 
Guiteras 177 3.2 0.49 0.07 0.09 0.18 0.17 0.70 0.03 0.07 0.15 0.04 0.01 
Reina 648 11.6 0.41 0.13 0.11 0.22 0.13 0.62 0.03 0.08 0.20 0.04 0.03 
Tamayo 294 5.2 0.42 0.08 0.10 0.20 0.20 0.65 0.02 0.08 0.20 0.03 0.02 
Vantroi 473 8.4 0.29 0.14 0.12 0.25 0.21 0.58 0.03 0.10 0.22 0.05 0.02 
Average control 2734 48.8 0.36 0.13 0.11 0.22 0.18 0.63 0.03 0.09 0.19 0.04 0.02 
AVERAGE ALL 5604 100 0.30 0.16 0.11 0.23 0.20 0.61 0.03 0.10 0.20 0.04 0.02 
THAILAND 
Chumpae 1001 15.7 0.34 0.01 0.28 0.34 0.03 0.72 0.04 0.11 0.09 0.01 0.02 
Banphai 729 11.4 0.25 0.00 0.38 0.31 0.05 0.76 0.06 0.08 0.06 0.00 0.03 
Phuwiang 558 8.8 0.34 0.01 0.41 0.24 0.01 0.58 0.05 0.28 0.03 0.01 0.05 
Manjakiri 476 7.5 0.39 0.01 0.42 0.18 0.01 0.70 0.07 0.07 0.11 0.02 0.04 
Khaosuankwang 306 4.8 0.38 0.03 0.27 0.31 0.01 0.57 0.12 0.11 0.14 0.00 0.05 
WaengNoi 208 3.3 0.26 0.00 0.47 0.25 0.02 0.64 0.14 0.11 0.03 0.02 0.06 
Intervention average 3278 51.5 0.32 0.01 0.36 0.29 0.03 0.66 0.08 0.13 0.08 0.01 0.04 
Kranuan 821 12.9 0.52 0.01 0.24 0.22 0.01 0.61 0.06 0.18 0.11 0.04 0.02 
Nongsonghong 323 5.1 0.28 0.01 0.29 0.38 0.04 0.65 0.11 0.02 0.11 0.03 0.08 
Phol 630 9.9 0.39 0.01 0.28 0.29 0.03 0.77 0.03 0.07 0.09 0.01 0.02 
Nongrua 400 6.3 0.28 0.00 0.36 0.35 0.01 0.70 0.09 0.07 0.07 0.01 0.07 
Srichompoo 595 9.3 0.53 0.00 0.35 0.11 0.01 0.60 0.07 0.12 0.17 0.00 0.04 
Nampong 322 5.1 0.44 0.02 0.26 0.23 0.05 0.72 0.07 0.11 0.04 0.03 0.02 
Control average 3091 48.5 0.42 0.01 0.29 0.26 0.02 0.67 0.07 0.09 0./0 0.02 0.04 
AVERAGE ALL 6369 100 0.37 0.01 0.32 0.27 0.02 0.67 0.08 0.11 0.09 0.02 0.04 
SOUTH AFRICA 
Prince Mshiyeni 785 100 0.17 0.11 0.38 0.25 0.10 0.76 0.01 0.08 0.04 0.05 0.06 
Key: OP - outpatient care; IP - inpatient care during pregnancy; DEL - delivery care; PP - postpartum 
care; NN - neonatal care; St - staff cost; EQ - equipment cost; MA - material cost; DR - drug cost; UT -
utility cost; BU - building cost. 
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Table 12.2: US$ contributors to cost per pregnancy, by type of care and resource 
ingredient. /' 
Country, trial arm Cases Health care type (% ) Resource ingredient (% ) 
and health facility No. % OP IP DEL PP NN ST EQ MA DR UT BU 
CUBA 
13 de Marzo 449 8.0 90.5 83.13 42.56 93.79 72.48 223.5 10.96 40.63 76.38 17.27 13.66 
Albarran 567 10.1 91.0 66.58 38.32 80.37 81.02 227.9 9.73 36.74 66.41 11.94 4.56 
Galvan 459 8.2 131.0 84.86 45.14 104.6 138.7 301.1 13.08 51.97 107.3 21.75 9.24 
Manduley 575 10.3 68.2 67.44 44.57 88.15 '57.46 197.3 10.48 38.57 60.61 13.07 5.75 
Romay 418 7.5 73.4 74.84 43.49 88.55 88.99 232.3 11.17 43.20 59.99 17.45 5.10 
Zuluetta 402 7.2 81.8 41.73 40.68 84.25 49.65 167.2 8.20 32.44 72.56 12.16 5.53 
Average Intervention 2870 51.2 88.9 69.99 42.41 89.65 80.94 223.6 10.49 39.85 75.25 15.29 7.40 
Aballi 514 9.2 162.7 59.47 42.41 90.04 65.02 273.5 10.29 34.57 79.93 14.37 7.00 
Escalona 628 11.2 106.8 66.31 43.90 89.02 95.34 231.3 12.81 40.29 83.07 15.89 17.98 
Guiteras 177 3.2 218.3 32.01 40.61 79.95 76.35 311.9 11.33 32.30 68.69 18.37 4.57 
Reina 648 11.6 156.4 48.02 43.20 84.76 49.57 236.7 11.22 31.74 77.24 15.45 9.62 
Tamayo 294 5.2 186.8 35.74 42.57 87.30 89.68 288.5 9.90 33.91 86.72 14.82 8.16 
Vantroi 473 8.4 107.3 50.53 42.48 91.85 76.65 214.5 9.58 37.07 82.26 16.64 8.69 
A verage control 2734 48.8 145.0 52.42 42.85 87.91 73.72 251.6 10.99 36.19 77.64 15.98 9.50 
AVERAGE ALL 5604 100 116.3 61.41 42.62 88.80 77.42 236.7 10.74 38.42 76.70 15.65 8.35 
THAILAND 
Chumpae 1001 15.7 23.14 0.89 19.06 23.07 2.21 49.1 2.73 7.57 6.46 0.94 1.56 
Banphai 729 11.4 29.51 0.40 44.26 36.37 5.35 88.5 7.10 9.36 7.02 0.02 2.93 
Phuwiang 558 8.8 21.80 0.56 26.50 15.46 0.76 37.5 3.51 18.23 2.24 0.59 3.03 
Manjakiri 476 7.5 30.19 0.64 32.39 13.76 0.80 54.2 5.20 5.66 8.41 1.43 2.86 
Khaosuankwang 306 4.8 38.57 2.54 27.22 31.56 0.92 57.8 12.47 11.01 13.77 0.44 5.30 
Waeng Noi 208 3.3 29.66 0.54 54.08 27.91 1.71 73.4 15.64 12.04 3.77 2.75 6.34 
Intervention average 3278 51.5 27.21 0.82 30.85 24.48 2.31 56.8 6.75 10.74 6.84 1.02 3.35 
Kranuan 821 12.9 55.07 1.25 25.95 22.97 1.07 64.6 6.71 19.55 11.33 4.14 2.22 
Nongsonghong 323 5.1 24.26 0.67 25.69 32.73 3.92 56.4 9.93 1.99 9.25 2.70 6.99 
Phol 630 9.9 52.99 1.61 37.57 40.11 3.86 105.4 4.53 9.97 11.90 1.27 3.03 
Nongrua 400 6.3 31.82 0.21 41.08 39.83 1.59 79.9 9.96 8.27 7.74 1.19 7.47 
Srichompoo 595 9.3 36.97 0.00 24.34 7.33 0.73 41.6 4.86 8.09 12.07 0.32 2.45 
Nampong 322 5.1 51.91 2.15 30.40 27.28 5.76 85.1 8.36 12.60 4.65 3.91 2.91 
Control average 3091 48.5 44.60 0.98 30.40 27.10 2.43 70.8 7.75 10.01 10.68 2.25 4.41 
AVERAGE ALL 6369 100 35.65 0.90 30.63 25.75 2.36 63.8 7.19 10.22 8.73 1.61 3.87 
SOUTH AFRICA 
Prince Mshiyeni 785 100 60.03 38.17 130.8 86.75 34.70 264.9 4.78 28.62 13.31 15.87 19.53 
Key: OP - outpatient care; IP - inpatient care during pregnancy; DEL - delivery care; PP - postpartum 
care; NN - neonatal care; St - staff cost; EQ - equipment cost; MA - material cost; DR - drug cost; UT -
utility cost; BU - building cost. 
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Appendix 13: Cost per pregnancy and sub-group analysis 
Table 13.1: Summary of mean differences between categories of women in Cuba 
RISK FACTORS or EVENTS Cost cate20ry (presented in US$) 
INFLUENCING COST PER Antenatal care Delivery Postpartum care Total 
PREGNANCY OP IP care Woman Baby 
Previous pregnancy (-ies) 
First pregnancy 4 0 3 0 38 45 
Previous stillbirth or neonatal loss . 43 15 12 20 80 170 
3 or more previous spontaneous abortions 0 -4 0 -9 -7 -20 
Last baby LBW 40 -20 1 5 30 56 
Admission for HDP in last pregnancy 30 53 2 5 30 120 
Previous reproductive tract surgery 32 .. 82 45 72 25 256 
Events this pregnancy and delivery 
Referred to a higher level 18 263 19 60 78 441 
Hospital admission during pregnancy 2 450 15 50 143 660 
Adverse pregnancy event (*) 8 35 5 0 0 48 
Prelabour rupture of membranes 
-5 10 -16 -7 34 16 
Induced labour 11 111 19 37 14 192 
Elective caesarean section 7 75 93 157 48 380 
Postpartum information 
LBWbaby -11 175 5 100 782 1052 
Pre-term infant -20 128 2 73 800 983 
Post-term infant 6 69 9 132 -11 87 
Congenital malformation 
-39 -10 -15 -20 74 10 
TABLE KEY: In bold: means the figure is statistically significnt (p<0.05); (*) includes sexually 
transmitted diseases, urinary tract infection, hypertensive diseases of pregnancy, anemia and bleeding. 
Table 13.2: Summary of mean differences between categories of women in Thailand 
RISK FACTORS or EVENTS Cost cate20ry 
INFLUENCING COST PER Antenatal care Delivery Postpartum care Total 
PREGNANCY OP IP care Woman Babv 
Previous pre2nancy (-ies) 
First pregnancy 2 0 0 2 0 4 
3 or more previous spontaneous abortions 2 0 1 9 1 13 
Previous reproductive tract surgery 2 5 17 70 2 96 
Events this pregnancy and delivery 
Referred to a higher level 12 14 -6 9 0 29 
Hospital admission during pregnancy 4 13 0 9 13 39 
Adverse pregnancy event (*) 4 3 3 -6 7 -11 
Pre labour rupture of membranes 3 2 3 10 7 25 
Adverse diagnosis at admission to labour 4 5 7 38 13 65 
Induced labour 10 3 5 24 3 45 
Elective caesarean section 6 5 24 68 15 119 
Postpartum information 
LBWbaby -7 0 1 6 18 18 
Pre-term infant -7 2 -4 -5 22 8 
Post-term infant 8 0 4 -2 -1 9 
Postpartum syphilis -1 -2 11 30 -2 36 
TABLE KEY: In bold: means the figure IS statistically slgmficnt (p<0.05); (*) Includes sexually 
transmitted diseases, urinary tract infection, hypertensive disorders of pregnancy, anemia and bleeding. 
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Table 13.3: Summary of mean differences between categories of women in South Africa 
RISK FACTORS or EVENTS Costcat~~ 
INFLUENCING COST PER Antenatal care Delivery Pos~rtum care Total 
PREGNANCY OP IP care Woman Baby 
Previous pregnancy (-ies) 
First pregnancy 7 16 1 3 -11 16 
3 or more previous spontaneous abortions -4 19 1 -16 -2 -2 
Admission for HDP in last pregnancy 3 37 33 83 1 157 
Previous reproductive tract surgery 0 -16 -5 0 -6 -27 
Events this pregnancy and delivery 
Referred to a higher level 14 81 14 42 12 163 
Hospital admission during pregnancy 10 .. 138 12 35 5 200 
Adverse pregnancy event (*) 8 65 3 22 0 97 
Prelabour rupture of membranes 0 
-48 4 3 13 -27 
Adverse diagnosis at admission to labour 2 85 6 19 -5 107 
Induced labour -3 102 2 7 3 111 
Elective caesarean section 10 184 49 108 61 413 
Postpartum information 
Pre-term infant 14 68 -4 -3 61 136 
Post-term infant 33 15 16 2 6 62 
Congenital malformation 4 2 6 120 20 152 
Postpartum syphilis 7 4 10 78 31 130 
TABLE KEY: In bold: means the figure 1S statistically s1gmficnt (p<0.05); (*) mcludes sexually 
transmitted diseases, urinary tract infection, hypertensive disorders of pregnancy, anemia and bleeding. 
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Table 13.1: Differences between cost for women with different risks or event status in Cuba. 
VARIABLES Arm Detail N Outpatient ANC Inpatient ANC Delivery care Postpartum care Neonatal care All care 
Low Mean High Low Mean High Low Mean High Low Mean High Low Mean High Low Mean High I 
Overall 
CONTROL 2559 139 140 141 50 54 58 42 43 44 87 88 90 65 74 82 388 399 410 
INTERVENTION 3050 95 96 97 63 68 73 42 42 43 87 89 91 72 81 89 364 376 389 
ALL WOMEN 5609 116 116 117 58 61 65 42 43 43 87 89 90 71 77 83 378 387 395 
Risk 
Age C <16 12 109 118 126 0 21 41 21 29 37 109 147 186 448 1043 1638 765 1358 1951 
16-40 2538 139 140 141 49 53 57 42 43 44 86 88 90 61 68 76 383 393 403 
>40 9 110 125 141 101 302 502 28 42 56 34 59 84 0 236 472 472 764 1055: 
I <16 24 112 122 133 26 221 416 27 33 39 60 74 87 25 69 113 314 519 723 
16-40 3012 95 96 97 62 66 71 42 42 43 87 89 91 72 81 89 362 375 387 
>40 14 128 141 155 39 106 173 42 54 67 60 79 98 0 84 169 333 465 597 
Number of pregnancy C First 469 136 138 140 46 55 64 38 40 42 88 92 97 91 117 142 413 443 472 
> First 2090 139 140 141 49 54 58 43 44 45 85 88 90 55 64 72 378 389 400 
I First 568 90 92 94 70 84 98 38 40 41 86 91 96 76 101 126 374 408 442 
> First 2482 96 97 99 59 64 69 42 43 44 87 89 91 67 76 85 356 369 382 
Previous stillbirth C No 2497 139 139 140 49 53 57 42 43 44 86 88 90 63 71 79 384 395 405 
Yes 61 152 158 164 63 88 114 43 49 54 90 103 116 89 174 259 479 573 667 
I No 2986 94 95 96 62 67 73 41 42 43 87 89 90 69 77 85 358 370 382 
Yes 64 152 158 165 52 83 113 42 47 53 96 112 129 125 255 384 500 655 809 
Previous abortion C No 759 137 139 140 51 58 66 41 43 44 90 93 97 '. 76 94 112 405 427 449 
Yes 1799 139 140 141 47 52 57 42 43 44 84 86 89 56 65 74 375 387 399 
I No 957 95 96 98 61 70 80 42 43 44 92 96 101· . 63 79 95 363 385 408 
Yes 2093 95 96 98 61 67 72 41 42 43 84 86 88 71 81 92 358 372 387 
Last baby <2500g C No 2040 139 140 141 50 55 59 43 44 45 85 87 89 56 65 73 378 390 402 
Yes 51 156 163 170 0 4 8 39 45 51 83 96 109 6 35 63 308 343 378 
I No 2439 95 96 98 59 65 70 42 43 44 86 89 91 68 76 85 356 369 382 
Yes 43 139 148 156 15 33 52 39 45 51 74 92 110 11 . 49 87 297 367 438 
Previous admission C No 1983 139 140 141 49 53 58 43 43 44 84 86 .8B 54 63 72 374 386 397 
Yes 21 159 171 183 37 70 104 31 39 47 72 96 119 0 34 67 337 410 483 
I No 2280 95 96 97 58 58 58 43 43 43 88 88 88 67 77 86 347 361 374 
Yes 76 134 139 145 76 121 165 42 45 47 82 98 113 52 109 166 438 511 584 
Previous RT surgery C No 2062 139 140 141 48 53 58 42 43 44 84 86 88 55 64 72 375 386 398 
Yes 25 149 158 166 42 97 153 101 107 112 163 184 206 28 71 114 533 617 701 
I No 2388 94 96 97 56 61 66 40 41 42 84 86 88 66 75 84 346 359 371 
Yes 95 140 145 151 104 150 195 77 82 86 139 152 165 49 102 155 540 631 721 
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Table 13.1: Differences between cost for women with different risks or event status in Cuba. 
VARIABLES-~~ Arm Detail N Outpatient ANC Inpatient ANC Delivery care Postpartum care Neonatal care All care 
. 
Low Mean High Low Mean High Low Mean High 
ANC and pregnancy events 
Low Mean High Low Mean High Low Mean High 
First visit (weeks) C <12 1870 143 144 145 46 50 55 42 43 44 83 85 87 53 63 72 372 384 397 
12 to 15 595 132 133 135 54 63 72 43 44 46 91 97 102 81 100 118 412 437 462 
16 to 20 66 108 112 116 57 84 111 35 40 44' 83 95 106 57 115 172 374 445 515 
>20 28 75 81 87 3 25 47 40 48 56 91 116 142 68 156 244 314 427 540 
I <12 2108 97 98 99 61 67 73 42 43 43 86 88 91 62 70 79 353 366 379 
12 to 15 771 94 96 97 59 70 81 41 43 44 88 92 96 74 91 108 365 391 418 
16 to 20 122 84 88 93 60 82 103 38 41 45 78 86 93 67 157 246 356 453 551 
>20 49 63 69 75 4 17 30 27 31 35 59 79 99 39 178 318 217 375 532 
Refer to higher level C No 2396 138 139 140 35 38 42 41 42 42 83 85 87 58 66 74 360 370 3811 
Yes 162 146 150 153 247 279 311 59 63 66 130 140 150 113 163 214 726 794 863 
I No 2842 94 95 96 44 49 53 40 41 42 83 85 86 68 76 85 333 345 357 
Yes 208 117 121 125 291 329 367 56 60 63 137 149 161 102 140 179 727 799 871 
Hospital admission C No 2230 139 140 141 0 1 2 40 41 42 81 83 85 53 61 69 317 326 335 
Yes 329 135 137 139 389 412 435 55 58 60 119 127 135 124 159 195 843 894 945 
I No 2618 94 95 96 0 0 0 40 40 41 80 81 83 49 56 63 264 272 280 
Yes 432 103 106 109 450 478 506 52 55 57 128 136 144 190 232 274 943 1006 1070 
Event in pregnancy C No 1163 136 138 139 26 30 33 41 42 43 83 85 88 53 64 75 345 358 371 
Yes 1396 141 142 143 67 74 81 43 44 45 88 91 94 70 82 94 417 433 450 
I No 1406 90 91 92 46 53 60 42 43 44 87 90 93 '. 73 86 98 345 362 380 
Yes 1644 100 101 102 73 80 88 41 42 43 86 88 91 65 76 88 371 388 405 
Prelabour rupture C No 1914 140 141 142 54 59 64 42 43 44 86 89 91 . 56 65 74 385 397 410 
Yes 645 136 138 139 32 37 43 40 42 44 84 88 92 80 98 117 380 403 426 
I No 2282 97 98 99 63 68 74 42 42 43 87 89 91 63 72 81 356 370 383 
Yes 768 89 91 93 56 66 76 41 42 43 86 90 94 87 106 126 367 395 423 
Delivery and postpartum 
Adverse diagnosis at C No 2065 137 138 139 25 28 31 37 37 38 74 76 77 52 . 61 69 330 340 349 
admission to labour Yes 494 147 149 151 146 161 177 64 66 68 137 143 .149 104 128 152 611 647 682 
I No 2417 91 92 93 21 24 26 37 37 38 75 77 79 49 56 64 277 287 296 
Yes 633 110 112 114 215 236 257 59 61 63 130 136 141 144 173 203 674 718 762 
Labourr C Spont 1839 139 140 141 25 29 32 30 31 31 65 67 68 55 65 75 320 331 342 
Induced 456 140 142 144 116 128 141 50 52 54 99 105 110 71 89 108 489 517 545 
ElectiveCS 264 133 136 138 82 101 120 112 113 114 205 213 222 77 105 133 624 667 710 
I Spont 2158 93 95 96 30 34 38 29 30 31 65 67 68 59 70 80 282 295 308 
Induced 547 95 97 99 138 154 170 45 47 48 98 102 107 73 93 113 461 493 525 
ElectiveCS _~44 104 107 110 118 144 170 112 112 113 201 208 216 104 131 158 657 703 748 
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Table 13.1: Differences between cost for women with different risks or event status in Cuba. 
VARIABLES Arm Detail N Outpatient ANC Inpatient ANC Delivery care Postpartum care Neonatal care All care 
Low Mean High Low Mean High Low Mean High Low Mean High Low Mean High Low Mean High 
Postpartum anaemia C No 2298 139 140 141 49 53 58 43 43 44 86 88 90 64 74 83 387 398 410 
Yes 259 136 138 140 47 59 70 38 40 42 85 91 96 56 74 92 376 401 427 
I No 2762 95 96 97 62 67 72 42 43 43 87 89 91 75 84 93 366 379 392 
Yes 285 93 97 100 59 74 89 37 39 41 , 82 89 95 34 49 63 315 347 379 
Postpartum syphilis C No 2507 139 140 141 50 55 59 42 43 44 87 89 91 66 74 83 390 401 412 
Yes 50 135 141 147 11 20 30 35 40 45 66 76 85 9 31 53 269 308 346 
I No 2960 95 96 97 62 67 72 42 42 43 86 88 90 69 77 86 360 372 384 
Yes 88 93 99 105 45 80 116 37 41 45 100 119 138 70 191 311 392 530 669 
Mode of delivery C Spont 1877 138 139 140 32 36 40 21 21 21 48 49 50 59 70 80 303 315 327 
ElectiveCS 269 134 137 139 80 98 117 114 114 114 205 213 221 66 94 121 613 655 697 
Intra CS 330 143 145 148 97 112 126 114 114 114 207 213 219 65 82 98 639 665 692 
Forceps 79 145 149 154 57 92 127 21 21 21 71 78 86 42 69 96 361 410 458 
Ass breech 4 170 188 206 0 0 0 21 21 21 50 50 50 0 0 0 241 260 278 
I Spont 2268 93 94 95 40 44 49 21 21 21 51 52 53 51 60 68 260 271 283 
ElectiveCS 346 104 107 110 107 129 151 114 114 114 202 209 216 100 127 153 643 686 729 
Intra CS 344 94 97 100 129 154 179 114 114 114 212 219 226 89 11.7 146 656 702 748 
Forceps 89 101 108 114 74 94 114 21 21 21 64 69 75 169 300 431 458 592 726 
Ass breech 2 95 181 268 0 0 0 21 21 21 50 50 50 0 0 0 166 253 339 
Birth weight C LBW 180 120 123 127 117 148 178 41 44 47 164 180 196 663 761 859 1140 1256 1372 
NBW 2366 140 141 142 43 47 50 42 43 44 80 82 83 . 19 22 25 328 334 340 
I LBW 223 88 92 96 238 284 330 47 50 53 169 184 199 738 838 937 1321 1452 1583 
NBW 2811 96 97 98 47 50 54 41 42 42 80 81 83 18 21 23 285 291 297 
Gest age at birth C Preterm 128 104 108 112 102 139 175 35 39 42 139 157 174 . 671 797 923 . 1097 1239 1381 
Normal 2259 140 141 142 40 44 48 42 42 43 81 83 85 31 36 41 339 347 355 
Post-term 172 145 148 151 100 116 132 52 55 59 100 107 114 17 25 34 428 451 474 
I Preterm 178 83 88 92 164 207 250 41 44 47 140 157 174 738 858 979 1209 1361 1513 
Normal 2669 95 97 98 50 54 59 41 42 43 83 84 86 30 _ 33 37 302 310 318 
Post-term 203 99 103 107 98 121 144 45 48 51 86 92 98 9 19 29 355 383 411 
Congen malform C No 2543 139 140 141 50 54 58 42 43 44 87 89 91 65 73 81 388 399 410 
Yes 15 74 84 94 0 43 86 25 34 42 46 70 95 8 181 354 209 412 615 
I No 3034 96 97 98 63 68 73 42 42 43 87 89 91 72 81 89 364 377 389 
Yes 10 58 69 80 16 55 93 21 21 21 49 65 82 43 165 288 234 376 517 
\ 
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Table 13.2: Differences between cost for women with different risks or event status in Thailand. 
VARIABLE Arm Detail N Outpatient ANC Inpatient ANC Delivery care Postpartum care Neonatal care All care 
Low Mean High Low Mean High Low Mean High Low Mean High Low Mean High Low Mean High 
Overall 
CONTROL 3112 39 39 39 1 1 1 32 32 32 39 41 43 1 1 2 111 114 116 
INTERVENTION 3197 38 39 39 1 1 1 37 38 38 66 69 71 3 3 4 146 150 153 
ALL WOMEN 6369 39 39 39 1 1 1 34 35 35 53 55 56 2 2 3 130 132 134 
Risk 
Number of pregnancy C First 1328 38 39 39 1 1 1 31 32 32 35 38 41 1 3 4 108 112 115 
> First 1844 38 39 39 1 1 1 32 32 33 40 42 45 1 1 1 112 115 118 
I First 1277 39 40 41 1 1 1 37 38 39 67 71 75 3 4 5 150 155 160 
> First 1920 37 38 38 1 1 1 36 37 38 64 67 70 2 3 3 142 146 150 
Previous stillbirth C No 1786 38 39 39 1 1 1 37 38 38 66 69 72 3 3 3 146 150 153 
Yes 59 40 43 46 1 1 2 29 32 35 24 37 50 0 1 2 97 114 130 
I No 1859 37 38 38 1 1 1 36 37 38 63 66 69 2 3 3 140 144 148 
Yes 62 37 40 43 0 3 7 35 39 43 83 104 126 5 10 15 168 197 226 
Previous abortion C No 1341 38 39 39 1 1 1 31 31 32 33 36 39 0 1 1 103 107 110 
Yes 504 39 40 41 1 1 1 34 35 36 53 59 66 1 1 1 129 136 144 
I No 1458 37 37 38 1 1 1 36 36 37 60 63 66 2 3 4 136 140 145 
Yes 463 38 39 40 1 2 3 38 40 41 74 81 88 2 3 4 156 164 173 
Last baby <2500g C No 1695 39 39 40 1 1 1 32 32 . 33 41 43 46 1 1 1 113 116 120 
Yes 150 33 34 36 0 1 1 29 30 32 22 31 40 0 1 1 86 97 107 
I No 1811 37 38 38 1 1 1 36 37 38 64 67 70 2 2 3 141 145 149 
Yes 111 33 35 37 0 1 2 34 37 39 60 78 96 ; 4 8 12 138 159 180 
Previous RT surgery C No 3140 38 39 39 1 1 1 31 32 32 38 40 42 1 1 2 110 113 115 
Yes 32 41 45 49 1 8 14 49 53 58 82 106 131 1 2 4 185 214 244 
I No 3168 38 39 39 1 1 1 37 38 38 65 68 70 3 3 4 145 148 151 
Yes 29 31 35 39 0 4 7 46 52 57 155 187 220 2 4 6 245 282 320 
ANC and pregnancy events 
First visit (weeks) C <12 1006 43 44 45 1 1 1 32 33 33 43 47 51 1 1 1 120 125 130 
12 to 15 786 40 41 42 1 1 2 31 32 33 38 42 46 1 2 4 114 119 124 
16 to 20 613 36 36 37 0 1 1 31 32 33 38 42 46 1 2 3 107 113 118 
>20 767 31 32 32 0 0 0 30 31 31 26 29 33 0 1 1 89 93 97 
I <12 786 41 42 43 1 2 2 38 39 41 71 76 81 2 3 5 156 163 169 
12 to 15 748 37 38 39 1 1 2 37 38 39 68 73 78 2 3 5 147 154 161 
16 to 20 635 35 36 36 0 0 1 36 38 39 63 68 73 1 2 4 137 144 150 
>20 1028 37 38 39 0 1 1 35 36 37 57 61 65 3 4 5 135 140 145 
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Table 13.2: Differences between cost for women with different risks or event status in Thailand. 
VARIABLE Arm Detail N Outpatient ANC Inpatient ANC Delivery care Postpartum care Neonatal care All care 
Low Mean High Low Mean High Low Mean High Low Mean High Low Mean High Low Mean High 
Refer to higher level C No 3106 38 38 39 0 0 1 32 32 32 39 41 43 1 1 2 111 114 116 
Yes 66 54 56 59 11 14 17 25 27 29 11 12 14 0 1 1 105 110 115 
I No 3117 38 39 39 0 1 1 37 38 38 66 68 71 3 3 4 145 149 152 
Yes 78 35 42 50 8 16 23 29 32 35 73 90 107 3 7 11 161 187 214 
Hospital admission C No 3079 38 39 39 0 0 1 32 32 32 38 40 42 1 1 2 110 113 115 
Yes 91 42 45 47 11 12 14 30 33 35 40 51 63 1 3 4 129 144 159 
I No 3095 38 39 39 0 1 1 37 38 38 66 69 71 2 3 3 145 148 151 
Yes 90 36 38 41 9 15 21 34 38 41 72 86 101 14 27 40 177 204 232 
Event in pregnancy C No 2951 39 39 39 0 1 1 31 32 32 38 40 42 1 1 1 110 112 115 
Yes 221 35 36 37 3 4 4 33 34 36 39 46 53 4 10 16 118 130 142 
I No 2804 39 39 40 0 1 1 38 39 40 69 71 74 2 3 3 150 153 156 
Yes 393 33 34 35 2 4 5 27 28 29 47 53 59 4 7 10 116 126 135 
Prelabour rupture C No 2965 38 39 39 1 1 1 32 32 32 38 40 42 1 1 2 110 113 115 
Yes 205 39 41 42 2 2 3 31 32 34 37 45 53 2 3 5 113 123 133 
I No 3069 38 39 39 1 1 1 37 38 38 66 68 71 2 3 3 145 148 151 
Yes 122 42 44 46 2 5 7 39 42 44 74 85 97 9 19 29 175 194 214 
Delivery and postpartum 
Adverse diagnosis at C No 2919 38 39 39 0 1 1 31 32 . 32 37 39 41 1 1 1 108 111 113 
admission to labour Yes 253 38 40 41 2 3 4 35 36 38 49 56 64 5 11 16 135 146 157 
I No 2931 38 39 39 0 1 1 36 37 37 60 62 65 1 2 2 137 140 143 
Yes 266 39 40 42 4 7 10 47 48 50 128 139 150 ; 13 18 24 238 253 268 
Labour C Spont 2943 38 38 39 0 1 1 31 31 32 37 39 41 1 1 2 108 111 113 
Induced 118 42 45 47 2 2 3 30 32 34 38 47 57 0 1 2 116 127 138 
Elective CS 106 43 46 48 2 4 6 49 51 53 65 76 88 4 8 12 171 185 199 
I Spont 3003 38 38 39 0 1 1 36 37 37 63 65 67 2 2 3 140 143 146 
Induced 128 48 50 52 2 5 8 44 47 50 98 113 128 4 9 13 205 224 2421 
Elective CS 59 41 44 47 2 9 16 57 59 61 155 176 197 15 33 51 289 321 3521 
Postpartum anaemia C No 3020 38 39 39 1 1 1 31 32 32 38 40 42 1 1 2 111 113 115i 
Yes 146 39 41 43 1 1 1 32 34 36 36 50 63 1 3 5 113 128 143 
I No 3015 39 39 39 1 1 1 37 38 38 66 69 71 2 3 4 146 149 152 
Yes 176 34 35 37 0 0 1 37 39 42 66 77 88 3 5 8 143 157 1711 
-
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Table 13.2: Differences between cost for women with different risks or event status in Thailand. 
VARIABLE Arm Detail N Outpatient ANC Inpatient ANC Delivery care 
Low Mean High Low Mean High Low Mean High 
Mode of delivery C Spont 2862 38 38 39 1 1 1 30 30 30 
Elective CS 121 42 44 46 2 4 6 51 52 54 
Intra CS 79 33 35 37 0 1 2 48 50 51 
Forceps 40 49 53 57 0 0 1 53 60 66 
Ass breech 25 32 36 40 0 0 1 25 28 31 
I Spont 2860 37 38 38 1 1 1 35 35 36 
Elective CS 76 46 49 52 0 6 11 58 60 62 
Intra CS 127 43 45 47 2 5 9 62 64 66 
Forceps 52 47 50 53 0 0 0 60 66 72 
Ass breech 22 25 30 34 0 2 4 25 32 39 
Birth weight C LBW 265 30 31 32 1 1 2 29 30 31 
NBW 2887 39 40 40 1 1 1 32 32 33 
I LBW 281 32 35 37 1 2 3 38 39 41 
NBW 2888 39 39 40 1 1 1 37 38 38 
Gest age at birth C Preterm 243 25 26 27 1 2 2 27 28 29 
Normal 2694 39 39 40 1 1 1 32 32 33 
Post-term 232 45 46 48 1 1 2 30 32 33 
I Preterm 288 29 31 33 1 2 4 33 35 . 37 
Normal 2702 38 39 39 1 1 1 37 37 38 
Post-term 199 47 49 50 0 1 1 43 46 48 
Congen malform C No 3127 39 39 39 1 1 1 32 32 32 
Yes 28 29 32 35 0 0 0 31 36 41 
I No 3155 38 39 39 1 1 1 37 38 38 
Yes 20 33 37 40 0 1 2 36 43 50 
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Postpartum care 
Low Mean High 
32 34 35 
71 82 93 
95 115 134 
137 182 226 
9 24 39 
54 56 58 
156 174 191 
194 210 226 
186 219 251 
31 50 69 
30 38 46 
39 41 43 
73 82 91 
66 68 70 
24 32 39 
40 42 44 
29 35 40 
55 64 72 
66 68 71 
78 88 97. 
38 40 42 ; 
32 71 110 
67 69 72 
41 63 84 
Neonatal care 
Low Mean High 
1 1 2 
4 7 11 
2 4 6 
0 0 1 
0 2 4 
2 2 3 
6 10 14 
14 22 31 
1 5 8 
2 3 5 
7 12 18 
0 0 1 
20 26 33 
1 1 1 
6 12 17 
1 1 1 
0 0 1 
.. 15 22 28 
1 1 2 
1 1 1 
1 1 2 
0 2 4 
3 3 4 
















































































Table 13.3: Differences between cost for women with different risks or event status in South Africa. 
VARIABLE Detail N Outpatient ANC Inpatient ANC Delivery care Postpartum care Neonatal care All care 
Low Mean High Low Mean High Low Mean High Low Mean High Low Mean High Low Mean High 
Overall 
CONTROL 785 43 44 45 64 70 77 94 95 95 89 94 99 40 44 48 335 347 358.7 
Risk 
Age <16 8 28 34 41 21 56 90 93 104 114 60 85 110 20 28 35 261 306 351.5 
16-40 764 43 44 45 64 71 77 94 94 95 90 95 100 41 45 49 336 348 360.5 
>40 11 41 48 54 37 72 108 85 92 99 52 67 82 9 15 21 241 294 346.9 
Substance abuse No 281 43 44 45 65 75 86 93 94 96 87 94 101 49 59 68 346 366 387.3 
Yes 501 42 44 45 59 68 76 94 95 96 87 94 100 32 36 40 322 336 350.4 
Number of pregnancy First 735 42 43 44 65 72 79 94 95 95 89 94 99 40 45 49 336 348 360.9 
> First 46 46 50 53 37 54 71 92 96 99 78 91 104 27 36 46 293 327 359.9 
Previous stillbirth No 727 42 43 44 63 69 75 93 94 95 87 91 96 41 45 50 331 343 354.7 
Yes 54 49 53 58 49 91 134 95 99 103 97 134 171 23 30 37 349 408 466 
Previous abortion No 530 44 45 46 60 67 74 94 95 96 88 94 99 41 46 52 333 347 360.3 
Yes 123 39 41 43 60 86 112 92 94 96 71 78 85 31 44 57 305 343 380.4 
Last baby <2500g No 697 43 43 44 60 67 74 93 94 95 88 93 99 41 45 50 330 343 355.8 
Yes 21 48 59 71 177 235 293 112 118 124 155 185 215 32 49 66 559 647 734.8 
Previous admission No 664 42 43 44 60 68 75 91 91 92 81 87 92 39 44 49 320 333 346.2 
Yes 80 45 48 51 82 105 128 121 124 127 ,155 170 186 36 ,45 54 456 492 527.8 
Previous RT surgery No 672 44 44 45 67. 75 82 94 95 96 90 95 101 41 46 51 342 355 368.4 
Yes 20 39 44 48 32 59 86 85 90 95 70 95 119 29 52 74 271 339 406.6 
ANC and pregnancy events 
First visit (weeks) <12 5 56 66 77 57 153 249 102 117 131 74 148 223 0 0 0 339 484 629.7 
12 to 15 19 63 69 75 45 92 140 88 94 100 63 88 114 13 23 34 303 367 430.9 
16 to 20 131 53 56 58 78 101 125 92 94 96 100 119 138 40 52 64 384 422 460.6 
>20 587 39 40 41 55 62 68 94 95 96 83 87 92 37 42 - 47 314 326 337.8 
Refer to higher level No 547 40 41 42 42 49 56 90 91 92 77 83 89 34 • 39 44 291 304 316.5 
Yes 182 52 54 57 113 130 147 103 105 107 114 125 135 43 51 59 438 465 491.7 
Event in pregnancy No 408 39 40 41 33 39 45 92 93 94 79 84 89 38 44 51 287 300 313.1 
Yes 377 46 48 49 92 104 116 95 96 98 97 106 114 39 44 50 378 398 417.8 
Prelabour rupture No 489 43 44 45 59 67 75 93 95 96 87 93 99 40 45 50 329 343 357.9 
Yes 30 40 44 48 9 19 29 94 99 104 80 96 113 43 58 73 286 316 346 
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Table 13.3: Differences between cost for women with different risks or event status in South Africa. 
VARIABLE Detail N Outpatient ANC Inpatient ANC Delivery care Postpartum care Neonatal care All care 
Low Mean High Low Mean High Low Mean High Low Mean High Low Mean High Low Mean High 
Delivery and postpartum 
Adverse diagnosis at No 470 42 43 44 31 36 41 91 92 93 81 87 93 40 46 52 292 304 316.8 
admission to labour Yes 315 44 45 46 107 121 136 97 98 100 98 106 114 35 41 47 389 411 433.2 
Labour Spont 610 42 43 44 41 46 51 89 90 91 78 83 89 34 39 43 290 301 312.8 
Induced 44 37 40 43 93 148 202 89 92 96 72 90 108 26 42 59 341 412 482.7 
Elective CS 77 50 53 56 196 230 265 138 139 140 179 191 204 78 100 122 668 714 759.8 
Postpartum anaemia No 547 44 45 46 66 74 82 95 96 97 91 96 101 39 44 48 341 355 368.2 
Yes 83 39 42 44 32 49 66 92 95 98 69 89 108 26 37 48 282 311 340.4 
Postpartum syphilis No 291 45 46 47 56 65 73 95 96 98 88 95 102 43 51 58 335 353 370.8 
Yes 33 46 51 56 44 74 104 91 96 100 116 176 235 59 89 119 400 485 570.1 
Mode of delivery Spont 583 41 41 42 31 37 42 81 81 81 60 65 70 26 30 34 245 255 264.7 
Elective CS 91 50 54 57 160 191 222 141 141 141 175 186 197 65 84 103 614 655 695.9 
Intra CS 84 48 51 54 133 163 193 141 141 141 184 199 213 76 92 108 599 644 690, 
Gest age at birth Preterm 123 31 32 34 104 128 153 92 94 97 99 113 127 75 98 120 418 466 513.8 





Appendix 14: Cost per pregnancy distributions (log and linear) 
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Table 14.1: Correlation coefficients between independent variables for regression analysis in Cuban model 
CPRETERM CPROM CADVLAB CBWEIGHT CBWEIGT2 CCONGMAl DFTEOPD DOCCOPD DSIZEOPD EHOSPADN ECS ENNICU 
CPRETERM Pearson Correlation 1.000 0.051 0.086 -0.381 -0.336 0.076 -0.001 0.007 -0.Q15 0.079 -0.006 0.307 
Sig. (2-tailed) 0.000 0.000 0.000 0.000 0.000 0.919 0.617 0.290 0.000 0.652 0.000 
CPROM Pearson Correlation 0.051 1.000 0.008 -0.121 -0.106 0.008 -0.013 0.031 -0.004 0.341 0.273 0.082 
Sig. (2-tailed) 0.000. 0.545 0.000 0.000 0.552 0.365 0.025 0.802 0.000 0.000 0.000 
CADVLAB Pearson Correlation 0.086 0.008 1.000 -0.050 -0.046 0.005 0.035 0.000 -0.002 0.007 -0.017 0.036 
Sig. (2-tailed) 0.000 0.545. 0.000 0.001 0.748 0.014 0.986 0.896 0.594 0.218 0.010 
CBWEIGHT Pearson Correlation -0.381 -0.121 -0.050 1.000 0.989 -0.084 0.009 0.006 0.020 -0.007 0.046 -0.269 
Sig. (2-tailed) 0.000 0.000 0.000. 0.000 0.000 0.530 0.686 0.146 0.630 0.001 0.000 
CBWEIGT2 Pearson Correlation -0.336 -0.106 -0.046 0.989 1.000 -0.058 0.006 0.004 0.018 0.007 0.056 -0.222 
Sig. (2-tailed) 0.000 0.000 0.001 0.000. 0.000 0.647 0.785 0.191 0.598 0.000 0.000 
CCONGMAL Pearson Correlation 0.076 0.008 0.005 -0.084 -0.058 1.000 -0.015 -0.024 0.003 0.014 -0.013 0.030 
Sig. (2-tailed) 0.000 0.552 0.748 0.000 0.000. 0.272 0.091 0.845 0.306 0.346 0.035 
DFTEOPD Pearson Correlation -0.001 -0.013 0.035 0.009 0.006 -0.015 1.000 -0.251 0.432 -0.016 0.013 0.001 
Sig. (2-tailed) 0.919 0.365 0.014 0.530 0.647 0.272. 0.000 0.000 '0.260 0.351 0.930 
DOCCOPD Pearson Correlation 0.007 0.031 0.000 0.006 0.004 -0.024 -0.251 1.000 0.366 0.034 0.009 -0.008 
Sig. (2-tailed) 0.617 0.025 0.986 0.686 0.785 0.091 0.000. 0.000 0.015 0.524 0.567 
DSIZEOPD Pearson Correlation -0.015 -0.004 -0.002 0.020 0.018 0.003 0.432 0.366 1.000 0.007 0.005 0.000 
Sig. (2-tailed) 0.290 0.802 0.896 0.146 0.191 0.845 0.000 0.000. .. 0.643 0.734 0.983 
EHOSPADM Pearson Correlation 0.079 0.341 0.007 -0.007 0.007 0.Q14 -0.Q16 0.034 0.007 1.000 0.129 0.109 
Sig. (2-tailed) 0.000 0.000 0.594 0.630 0.598 0.306 0.260 0.015 ·0.643. 0.000 0.000 
ECS Pearson Correlation -0.006 0.273 -0.017 0.046 0.056 -0.013 0.013 0.009 .. :0.005 0.129 1.000 0.074 
Sig. (2-tailed) 0.652 0.000 0.218 0.001 0.000 0.346 0.351 0.524 0.734 0.000. 0.000 
ENNICU Pearson Correlation 0.307 0.082 0.036 -0.269 -0.222 0.030 0.001 -0.008 0.000 0.109 0.074 1.000 
Sig. (2-tailed) 0.000 0.000 0.010 0.000 0.000 0.035 0.930 0.567 0.983 0.000 0.000. 
F 
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Table 14.2: Correlation coefficients between independent variables for regression analysis in Thai model 
BSCHOOL BPRABORT BPRSURG CADVLAB CINDUCE CPPS DCLINIC DFTEIPD EHOSPADM ECS ENNICU 
BSCHOOL Pearson Correlation 1.0000 -0.0061 -0.0197 -0.0155 0.0338 -0.0115 r -0.0061 0.0251 0.0169 0.0366 0.0262 
Sig. (2-tailed) 0.6398 0.1284 0.2325 0.0090 0.3738 0.6378 0.0529 0.1924 0.0047 0.0431 
BPRABORT Pearson Correlation -0.0061 1.0000 0.0096 0.0183 0.0081 0.0127 0.0021 -0.0275 0.0311 0.0144 0.0051 
Sig. (2-tailed) 0.6398. 0.4598 0.1586 0.5310 0.3250 0.8742 0.0337 0.0164 0.2676 0.6909 
BPRSURG Pearson Correlation -0.Q197 0.0096 1.0000 0.0211 -0.Q111 0.0219 -0.0011 -0.0005 0.0038 0.1984 0.0428 
Sig. (2-tailed) 0.1284 0.4598. 0.1037 0.3918 0.0913 0.9317 0.9691 0.7691 0.0000 0.0009 
CADVLAB Pearson Correlation -0.0155 0.0183 0.0211 1.0000 0.1040 0.0233 0.0183 0.0183 0.0759 0.3106 0.1687 
Sig. (2-tailed) 0.2325 0.1586 0.1037 . 0.0000 0.0724 0.1566 0.1574 0.0000 0.0000 0.0000 
CINDUCE Pearson Correlation 0.0338 0.0081 -0.0111 0.1040 1.0000 0.0023 0.0163 0.0559 0.0090 0.1041 0.0437 
Sig. (2-tailed) 0.0090 0.5310 0.3918 0.0000. 0.8594 0.2071 0.0000 0.4858 0.0000 0.0007 
CPPS Pearson Correlation -0.0115 0.0127 0.0219 0.0233 0.0023 1.0000 0.0036 0.0163 -0.0103 0.0186 0.0026 
Sig_. (2-tailed) 0.3738 0.3250 0.0913 0.0724 0.8594. 0.7803 0.2091 0.4281 0.1505 0.8416 
DCLINIC Pearson Correlation -0.0061 0.0021 -0.0011 0.0183 0.0163 0.0036 1.0000 -0.1038 0.0267 0.0002 0.0058 
Sig. (2-tailed) 0.6378 0.8742 0.9317 0.1566 0.2071 0.7803. 0.0000 0.0390 0.9857 0.6532 
DFTEIPD Pearson Correlation 0.0251 -0.0275 -0.0005 0.0183 0.0559 0.0163 -0.1038 1.0000 0.0138 0.0120 0.0549 
Sig. (2-tailed) 0.0529 0.0337 0.9691 0.1574 0.0000 0.2091 0.0000. 0.2880 0.3537 0.0000 
EHOSPADM Pearson Correlation 0.0169 0.0311 0.0038 0.0759 0.0090 -0.0103 0.0267 0.0138 1.0000 0.0495 0.0745. 
Sig. (Nailed) 0.1924 0.0164 0.7691 0.0000 0.4858 0.4281 0.0390 0.2880. 0.0001 O.OOOOi 
ECS Pearson Correlation 0.0366 0.0144 0.1984 0.3106 0.1041 0.0186 0.0002 0.0120 0.0495 1.0000 0.1173 
Sig. (2-tailed) 0.0047 0.2676 0.0000 0.0000 0.0000 0.1505 0.9857 0.3537 0.0001 . 0.0000 
ENNICU Pearson Correlation 0.0262 0.0051 0.0428 0.1687 0.0437 0.0026 0.0058 0.0549 0.0745 0.1173 1.0000 




Table 14.2: Co"elation coefficients between independent variables for regression analysis in South African model 
BPRLBW BPRADM BGESTVIS BREFER CPRETERM CPROM CADVLAB CPRESENT CPPS CCONGMAL EHOSPADM ECS ENNICU 
BPRLBW Pearson Correlation 1.0000 0.0154 0.0244 -0.0126 -0.0412 -0.0243 0.0546 -0.0142 -0.0554 -0.0414 0.0190 -0.0120 0.0799 
Sig. (Nailed) 0.6664 0.4948 0.7245 0.2490 0.4965 0.1261 0.6916 0.1211 0.2605 0.5954 0.7380 0.0319 
BPRADM Pearson Correlation 0.0154 1.0000 0.0054 0.1895 0.0154 -0.0428 0.1059 0.0403 0.0046 0.0724 0.0644 0.1578 0.0355 
Sig __ (Nailed) 0.6664. 0.8800 0.0000 0.6664 0.2312 0.0030 0.2594 0.8974 0.0486 0.0711 0.0000 0.3409 
BGESTVIS Pearson Correlation 0.0244 0.0054 1.0000 0.0410 0.0163 -0.0320 -0.0152 0.0308 -0.0391 -0.0095 -0.0006 0.0010 0.00151 
Sig. (2-tailed) 0.4948 0.8800 . 0.2507 0.6477 0.3703 0.6697 0.3887 0.2736 0.7963 0.9862 0.9780 0.9687 
BREFER Pearson Correlation -0.0126 0.1895 0.0410 1.0000 -0.0126 0.0704 0.0860 0.0513 -0.0700 0.0451 0.1683 0.2279 0.0504 
Sig. (2-tailed) 0.7245 0.0000 0.2507. 0.7245 0.0487 0.0159 0.1514 0.0501 0.2198 0.0000 0.0000 0.1768 
CPRETERM Pearson Correlation -0.0412 0.0154 0.0163 -0.0126 1.0000 0.2220 0.0332 0.0074 0.0843 0.0383 0.0288 -0.0035 0.0634 
Sig. (2-tailed) 0.2490 0.6664 0.6477 0.7245. 0.0000 0.3529 0.8350 0.0181 0.2979 0.4197 0.9211 0.0889 
CPROM Pearson Correlation -0.0243 -0.0428 -0.0320 0.0704 0.2220 1.0000 0.0466 -0.0131 0.0247 0.0319 0.0830 0.0136 0.0648 
Sig. (2-tailed) 0.4965 0.2312 0.3703 0.0487 0.0000 . 0.1922 0.7137 0.4901 0.3862 0.0200 0.7032 0.0819 
CADVLAB Pearson Correlation 0.0546 0.1059 -0.0152 0.0860 0.0332 0.0466 1.0000 0.1108 -0.1067 0.0616 0.1793 0.1172 0.3108 
Sig. (Nailed) 0.1261 0.0030 0.6697 0.0159 0.3529 0.1922. 0.0019 0.0027 0.0934 0.0000 0.0010 0.0000 
CPRESENT Pearson Correlation -0.0142 0.0403 0.0308 0.0513 0.0074 -0.0131 0.1108 1.0000 0.0019 -0.0041 0.0573 0.3033 0.1251 
Sig. (2-tailed) 0.6916 0.2594 0.3887 0.1514 0.8350 0.7137 0.0019. 0.9566 0.9112 0.1090 0.0000 0.0008 
CPPS Pearson Correlation -0.0554 0.0046 -0.0391 -0.0700 0.0843 0.0247 -0.1067 0.0019 1.0000 -0.0211 0.0062 0.0098 -0.0350 
Sig. (Nailed) 0.1211 0.8974 0.2736 0.0501 0.0181 0.4901 0.0027 0.9566. 0.5669 0.8628 0.7837 0.3482 
CCONGMAL Pearson Correlation -0.0414 0.0724 -0.0095 0.0451 0.0383 0.0319 0.0616 -0.0041 -0.0211 1.0000 -0.0078 0.0451 0.0125 
Sig. (Nailed) 0.2605 0.0486 0.7963 0.2198 0.2979 0.3862 0.0934 0.9112 0.5669. 0.8314 0.2198 0.7414 
EHOSPADM Pearson Correlation 0.0190 0.0644 -0.0006 0.1683 0.0288 0.0830 0.1793 0.0573 0.0062 -, -0.0078 1.0000 0.1465 0.0433 
Sig. (Nailed) 0.5954 0.0711 0.9862 0.0000 0.4197 0.0200 0.0000 0.1090 0.8628 ,'0.8314. 0.0000 0.2460 
ECS Pearson Correlation -0.0120 0.1578 0.0010 0.2279 -0.0035 0.0136 0.1172 0.3033 0.0098 0.0451 0.1465 1.0000 0.3452: 
Sig. (Nailed), 0.7380 0.0000 0.9780 0.0000 0.9211 0.7032 0.0010 0.0000 0.7837 0.2198 0.0000. 0.0000 
ENNICU Pearson Correlation 0.0799 0.0355 0.0015 0.0504 0.0634 0.0648 0.3108 0.1251 -0.0350 0.0125 0.0433 0.3452 1.0000 
Sig. (Nailed) 0.0319 0.3409 0.9687 0.1768 0.0889 0.0819 0.0000 0.0008 0.3482 0.7414 0.2460 0.0000. 
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Appendix 15: Diagnostic tests for multiple regression analysis 
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Figure 15.2: Normal P-P plot of regression standardized residuals in Cuba 
Dependent Variable: ATOTLOO 
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Figure 15.3: Scatter plot of regression standardized residuals and regression 
standardized predicted values in Cuba 
Scatterp lot 
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Table 15.4: Distribution of log cost in Thailand 
Histogram 
Dependent Variable: ATOTLOG 
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Std . Dev = 1.00 
Mean = 0.00 
N = 5965.00 
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Figure 15.6: Scatter plot of regression standardized residuals and regression 
standardized predicted values in Thailand 
Scatterp lot 
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Table 15.7: Distribution of log cost in South Africa 
Histogram 
Dependent Variable: ATOTLOG 
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Figure 15.8: Normal P-P plot of regression standardized residuals in South Africa 
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Figure 15.9: Scatter plot of regression standardized residuals and regression 
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Appendix 16: Cost prediction methods and results 
Table 16.1: Comparison of antenatal care interventions in Cuba, Thailand, and South Africa, compared with the new model 
INTERVENTION WHO RECOMMENDATION CUBA THAILAND SOUTH AFRICA 
1. Personal informationl (these interventions were done at all visits, unless indicated otherwise) 
Personal Name, age, address, marital status (l st visit) ALL ALL ALL 
Social Housingand sanitary conditions (l st visit) ALL NOT SYSTEMATIC NOT SYSTEMATIC 
Educational Literacy, level of schooling (l st visit) ALL 53% NO 
Current work Employment (patient & husband) (1 st visit) ALL ?? NO 
2. Medical history 
Specific diseases & conditions All known conditions' (1 st visit) ALL ALL ALL (not HIV status) 
Medication Details of current medicines used (l st visit) ALL ALL ALL 
Periods of infertility When, duration, causes (1 st visit) ALL NOT SYSTEMATIC NO (older women asked) 
3. Obstetric history 
Previous pregnancies and outcomes Dates and outcomes of previous pregnancies and births' (1 st visit) ALL ALL ALL 
Maternal complications & events All risk conditions' (1 st visit) ALL ALL ALL 
4. History of present pregnancy 
Last Menstrual Period Use the best available method for date (l st visit) ALL ALL ALL 
Habits Smoking/chewing tobacco, alcohol, drugs (1 st visit) NO(?) NO NOT SYSTEMATIC 
Untoward events Pain, bleeding, discharge, malaria attacks, edema ALL ALL ALL 
Other health care received. Note other consultations since last visit ALL 11 NO 
Fetal movements Time of first recognition (3rd and 4th visits) ALL ALL ALL 
5. Physical examination 
Weight & height 1st visit only Monitoring 76% Monitoring 72% Monitoring 71 % 
Symphysis-to-fundus distance Record on graph 79% 99% 1.2% 
Heart and chest auscultation 1 st visit only ALL .ALL ALL 
Blood pressure Measure and record 99% 97% 98% 
Palpation (handheld doppler) Palpate for multiple pregnancy/fetal heart (3"'& 4" visits) No HHD in policlinics YES ? 
Breast exatnination All women at 3ru visit. 98% 99% 49% 
Vaginal examination Consider if untoward events are positive ALL 1% 2% 
Check signs of severe anaemia Complexion, fingernails, oral mucosa, tip of tongue ALL ALL ALL 
Other alarming signs Shortness of breath, coughing, bleedin& edema ALL ALL ALL 
Dental examination Not recommended as part of programme 85% 95% NO 
6. Special tests \ 
Pregnancy test If unsure about whether pregnant (1 st visit) When required When required When required (ho~ta\) 
Rhesus antibodies I ABO At 1 st visit, all. (l st visit) 93% 27% 29% 
Bacteriuria (multiple dipstick urine) All at 1 st visit. Repeat at 20d visit if positive from 1 st. 6% NO 98% 
Protein (multiple dipstick urine) All at 1 st visit. HR retest at 2oa• NP/ HR MP at 3rd & 4th. ALL ALL NO 
Haemoglobin 1 st visit if signs of severe anaetnia. 2oa,if first test <70gll. 3ra Hb to all. ALL ALL 56% 
Pap smear ALL 44% NO NO 
Alpha-fetoptotein HR 69% NO NO 
--
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INTERVENTION WHO RECOMMENDATION CUBA 
Syphilis test At 1 st visit, RPR on spot 98% (delayed result) 
Hepatitis B HR 48% 
HIV antibody HR 93% 
Malaria screening HR HR 
Toxoplasmosis HR 1% 
Trichomoniasis lyeast HR 88% 
Gonococcal investigation HR NO 
Ultrasound scanning HR 57% 
Oral glucose test Do not perfonn 12% 
Fasting blood glucose test Do not perfonn 96% 
Haematocrit Do not perfonn 96% 
7. Risk assessment and referral 
Risk assessment Fonnal risk score assessment of high risk conditions· at 1 st visit; update on later visits 88% 
Referral for untoward symptoms If protein, bacteriuria after treating, bleeding, pre-eclampsia, IUGR, no fetal movement. ALL 
Hospital delivery mandatory At 4th visit, if twins or breech suspected; Hb continuously <70g!l, > 130g!l. ALL 
8. Intervention 
Iron 60mg elemental iron & 250 micrograms folate - once a day for all women (twice if 
severe); check compliance. At 2nd and 3n1 visits, increase dose if <70gll. 
83% 
S)'JJhilis Treat those who are RPR positive, with partner referral YES 
Tetanus toxoid First injection at 1 st visit. Second at 3"'visit 34% 
Malaria Malaria endemic area - chl~roquin, if not resistant No malaria 
9. Advice and education 
Advice on reproductive health One-to-one advice on safe sex, contraception, breastfeeding and lactation (all visits), and ALL 
postpartum visit (4n1 visit) 
Advice on habits One-to-one advice on smoking, alcohol, drugs ALL 
Advice on danger signs Give the woman emergency numbers. Advise woman what to do when bleeding, and at 
3n1 and 411> visits, action in case of labour. Advise on trans~rt for delivery. 
ALL 
Questions and answers Session on one-to-one basis ALL 
Next appointment Arrange date of next visit. ALL 
10. Record keepinll! 
Office record URdate record ALL 
Home based record Update record NO 
KEY: HR - High risk women only; ALL - All women; NP - Nulliparous women; MP - MUltiparous women; YES - Means a service is available for those who need it. 
I For repeat visits, check that there are no changes since the previous visit. 
2 TB, heart disease, chronic renal disease, epilepsy, diabetes mellitus, VD, HIV, hepatitis, malaria, sickle cell trait, Rh status, allergies, blood transfusions. 
3 Twins, LBW, HBW, IUGR, death, malfonnation, Rh-antibody affection, resuscitation. 
THAILAND 
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4 Recurrent early abortion, induced abortion complications, thrombosis, embolus, hypertension/pre-eclampsia/eclampsia, placental abruptio, placenta previa, breech, obstructed labour, CS/forceps/vacuum, manual removal 
of placenta, tears, excessive bleeding, puerperal sepsis, gestational diabetes. 
5 Diabetes (R), heart disease (R), renal disease(R), epilepsy (T), drug abuse (T), signs of severe anaemia (R, T), HIV positive (R), risk of genetic disease (R), primigravida (H), previous stillbirth (R), previous growth-
retarded fetus (R), hospital admission for pre-eclampsia/eclampsia (R), previous CS (H), high BP (R), body mass index (R-nutritional evaluation). Key: R=Refer. H=Hospital delivery. T=Treat. 
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Table 16.2: Rates of adverse events or conditions in control arms in study countries. 
Adverse event or condition Cuba Thailand South Africa 
No. % No. % /No. % 
Number of women 2559 100% 3172 100% 785 100% 
Pregnancy events 
HDP, with treatment 92 3.60% 0 0.00% 42 5.35% 
HDP, no treatment 71 2.77% 9 0.28% 53 6.75% 
Eclampsia 0 0.00% 4 0.13% 3 0.38% 
Pre-eclampsia 44 1.72% 19 0.60% 27 3.44% 
Severe UTI 252 9.85% 41 1.29% 125 15.92% 
UTI, with antibiotic treatment 219 8.56% 50 1.58% 119 15.16% 
UTI, no treatment 48 1.88% 18 0.57% 18 2.29% 
Vaginal bleeding during pregnancy . 83- 3.24% 34 1.07% 15 1.91% 
Severe pregnancy anemia 153 ·5.98% 56 1.77% N/a N/a 
Syphilis, treated 41 1.60% 3 0.09% 80 10.19% 
Sypilis, untreated 20 0.78% 9 0.28% N/a N/a 
Trichomoniasis, treated 1010 39.47% 50 1.58% 130 16.56% 
Other STD, treated 254 9.93% 18 0.57% 63 8.03% 
WOMEN WITH ANY EVENT 1847 72.18% 238 7.50% 377 48.03% 
Labour and delivery events 
Prelabour rupture of membranes 645 25.21% 205 6.46% 30 3.82% 
Adverse diagnosis at admission for labour 494 19.30% 253 7.98% 315 40.13% 
Pre-term 128 5.00% 243 7.66% 123 15.67% 
Post-term 172 6.72% 232 7.31% 5 0.64% 
Post-delivery outcomes 
Low-birth weight 180 7.03% 263 8.29% N/a N/a 
Neonatal death 7 0.27% 23 0.73% 15 1.91% 
Postpartum syphilis test positive 50 1.95% 9 0.28% 33 4.20% 
Postpartum anemia 279 10.90% 125 3.94% 83 10.57% 
Stillbirth 36 1.41% 42 1.32% 33 4.20% 
Maternal morbidi2 index (no.l* 575 22.47% 189 5.96% 238 30.32% 
* The maternal morbidity index includes severe UTI, eclampsia, pre-eclampsia and postpartum anaemia, 
which are all shown in italicised bold in the table. N/a - not available. 
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Table 16.3: Cost predictions at nominal exchange rates. 
Method Transfer from Trial arm Cuba Thailand South Africa 
Lower Mean Upper %ofCPP OveriaQ US$diff ANCvis Lower Mean Upper %ofCPP Overlap US$diff ANCvis Lower Mean Upper %ofCPP Overlap US$diff ANCvis 
Observed COST Control 382 402 422 103 106 109 324 347 370 
Intervention 347 372 397 83 86 88 
Difference -2 30 63 -30.0 -2.5 16 20 24 -19.8 -3.0 
Direct transfer From Cuba Control 382 402 422 381% n 296.4 45.2 382 402 422 116% n 54.9 7.6 
Intervention 347 372 397 434% n 2862 43.6 
Difference -2 30 63 151% Y 102 1.6 
From Thai Control 103 106 109 26% n -296.4 -24.5 103 106 109 30% n -241.5 -33.4 
Intervention 83 86 88 23% n -286.2 -23.6 
Difference 16 20 24 66% Y -10.2 -0.8 
FromSAF Control 324 347 370 86% n -54.9 -4.5 337 353 371 335% n 247.5 37.7 
Unit cost transfer From Cuba Control 132 175 217 166% n 69.5 10.6 361 477 594 137% 'i 130.0 18.0 
Intervention 115 152 188 177% n 66.3 10.1 
Difference 23 116% Y 3.1 0.5 
From Thai Control 129 166 203 41% n -235.9 -19.5 112 142 173 41% n -205.0 -28.3 
Intervention 106 136 165 37% n -235.9 -19.5 
Difference 30 l00"k Y 0.0 0.0 
FromSAF Control 337 383 433 95% Y -18.8 -1.6 182 207 234 196% n 101.7 15.5 
HSU transfer From Cuba Control 129 166 203 157% n 60.5 9.2 315 366 418 105% 'L 19.0 2.6 
Intervention 106 136 165 159% n 50.3 7.7 
Difference 30 151% n 10.1 1.5 
From Thai Control 132 175 217 44% n -226.9 -18.7 171 199 227 57% n -148.0 -20.4 
Intervention 115 152 188 41% n -219.9 -18.1 
Difference 23 n% y -7.0 -0.6 
FromSAF Control 343 454 564 113% Y 51.6 4.3 103 131 159 124% 'i 25.5 3.9 
Staff method Control 264 304 347 76% Y -97.9 -8.1 89 144 198 136% Y 38.5 5.9 337 353 371 102% 'i 6.0 0.8 
Intervention 255 287 323 77% n -84.9 -7.0 74 126 178 147% Y 40.3 6.1 
Difference 17 57% Y -13.0 -1.1 18 91% Y -1.9 -0.3 
ICIM Control 382 402 422 100"/. y- 0.0 0.0 103 106 109 100% Y 0.0 0.0 324 347 370 100% Y 0.0 0.0 
Intervention 295 321 344 86% n -50.9 -4.2 81 89 100 104% Y 3.7 0.6 337 353 371 
Difference 81 269% Y 50.9 4.2 16 81% Y -3.8 -0.3 9 -6 -24 
Regression Own country Control 78 289 1071 72% y -112.6 -9.3 47 99 210 94% Y -6.5 -1.0 181 .' 271 407 78% 'i -76.0 -10.5 
Intervention 65 216 720 58% Y -155.9 -12.9 45 69 106 81% y -16.7 -2.5 189 . 275 410 
Difference 73 244% Y 43.3 3.6 30 151% n 10.1 1.5 -4 
From Cuba Control 65 192 568 182% _'1 86.2 13.1 116 400 1376 115% Y 52.9 7.3 
Intervention 60 182 540 212% Y 96.3 14.7 
Difference 10 49% Y -10.2 -1.5 
From Thai Control 41 156 595 39% n -246.0 -20.3 77 148 285 43% n -199.0 -27.5 
Intervention 37 150 580 40% n -221.9 -18.3 
Difference 6 20% Y -24.1 -2.0 
FromSAF Control 191 268 378 67% n -133.7 -11.0 _151 
-




Table 16.4: Cost predictions using purchasing power parities. 
Method 
-
friinsfer from Trial arm Cuba Thailand South Africa 
Lower Mean Upper %ofCPP Overlap US$diff ANCvis Lower Mean Upper %ofCPP Overlap_ US$diff ANCvis Lower Mean Upper %ofCPP Overlap US$diff ANCvis 
Observed COST Control 908 957 1005 199 205 211 502 538 574 
Intervention 826 885 945 162 167 171 
Difference 
-6 71 149 -71.4 -5.9 31 39 46 -38.5 -5.9 
Direct transfer From Cuba Control 908 957 1005 4.66 n 751.4 62.0 908 957 1005 1.78 n 418.7 34.5 
Intervention 826 885 945 5.31 n 718.5 59.3 
Difference 
-6 71 149 1.85 Y 32.9 2.7 
From Thai Control 199 205 211 0.21 n -751.4 -62.0 199 205 211 0.38 n -332.8 -27.5 
Intervention 162 167 171 0.19 n -718.5 -59.3 
Difference 31 38 46 0.54 Y -33.0 -2.7 
FromSAF Control 502 538 574 0.56 n -418.7 -34.5 522 547 575 2.67 n 342.1 28.2 
Unit cost transfer From Cuba Control 314 417 516 2.03 n 211.4 17.4 859 1135 1414 2.11 n 597.4 49.3 
Intervention 274 362 447 2.17 n 195.2 16.1 
Difference 55 1.42 Y 16.1 1.3 
From ThaI Controt 251 323 395 0.34 n -633.8 -52.3 218 276 336 0.51 n -261.8 -21.6 
Intervention 206 264 321 0.30 n -620.7 -51.2 
Difference 58 0.82 Y -13.2 -1.1 
FromSAF Control 522 594 670 0.62 n -362.8 -29.9 282 321 363 1.57 n 116.0 9.6 
HSU transfer From Cuba Control 251 323 395 1.57 Y 117.6 9.7 309 353 397 0.66 n -164.9 -15.3 
Intervention 206 264 321 1.59 n 97.8 8.1 
Difference 58 1.51 'Y 19.7 1.6 
From Thai Control 314 417 516 0.44 n -540.0 -44.6 265 308 352 0.57 n -229.4 -18.9 
Intervention 274 362 447 0.41 n -523.4 -43.2 
Difference 55 0.77 Y -16.7 -1.4 
FromSAF Control 532 703 874 0.73 Y -253.5 -20.9 201 255 309 1.24 n 49.6 4.1 
Staff method Control 628 724 826 0.76 n -233.0 -19.2 173 280 385 1.36 
-'i 74.8 6.2 522 547 575 1.02 Y 9.3 0.8 
Intervention 607 683 769 0.77 Y -202.1 -16.7 144 245 346 1.47 Y 78.3 6.5 
Difference 40 0.57 Y -31.0 -2.6 35 0.91 Y -3.6 -0.3 
ICIM Control 908 957 1005 1.00 n 0.0 0.0 199 205 211 1.00 Y 0.0 0.0 502 538 574 1.00 Y 0.0 0.0 
Intervention 702 764 819 0.86 Y -121.1 -10.0 157 174 194 1.04 Y 7.2 0.6 522 54.7 575 
Difference 193 2.69 Y 121.1 10.0 31 0.81 n -7.3 -0.6 9 -9 -24 
Regression Own country Control 186 689 2550 0.72 Y -268.0 -22.1 91 192 408 0.94 'i. -12.6 -1.0 293 426 636 0.79 Y -111.6 -9.2 
Intervention 155 514 1714 0.58 Y -371.0 -30.6 87 134 206 0.81 Y -32.5 -2.7 280 420 630 
Difference 174 2.44 n 103.0 8.5 58 1.51 Y 19.7 1.6 .. 6 
From Cuba Control 154 456 1351 2.22 Y 251.2 20.7 277 '952 3275 1.77 Y 413.9 34.2 
Intervention 143 433 1285 2.60 Y 286.6 22.0 
Difference 23 0.60 Y -15.5 -1.3 
From Thai Control 80 303 1157 0.32 Y -653.5 -53.9 149 286 555 0.53 Y -250.1 -20.6 
Intervention 72 292 1128 0.33 y- -593.5 -49.0 
Difference 11 0.16 Y -60.0 -5.0 










Table 16.5: Cost prediction using simplified staff costing method in Cuba 
Workers Salary Total cost OPV Predicted cost Actual Ratio Overlap 
Obstet Doctor Nurse Other costs High Mean Low Low Mean High Low Mean Hiah 
13 de Marzo 3 48 48 12 31950 75855 68962 62968 7305 8.62 9.44 10.38 11.46 12.27 13.08 1.30 n 
Albarran 4 48 48 6 31500 74786 67991 62081 8916 6.96 7.63 8.39 11.06 11.86 12.65 1.55 n 
Galvan 2 34 34 6 22200 52707 47917 43752 5151 8.49 9.30 10.23 16.12 18.36 20.60 1.97 n 
Manduley 2 52 37 11 30000 71225 64753 59125 11322 5.22 5.72 6.29 8.39 9.13 9.86 1.60 n 
Romav 3 42 42 11 28200 66952 60868 55577 10707 5.19 5.68 6.25 9.22 10.01 10.81 1.76 n 
Zuluetta 3 34 34 85 34500 81909 74466 67994 11662 5.83 6.39 7.02 10.58 11.46 12.34 1.79 n 
Abailli 4 48 48 9 31950 75855 68962 62968 7487 8.41 9.21 10.13 11.16 12.31 13.45 1.34 n 
Escalona 2 64 64 16 41700 99003 90006 82184 11074 7.42 8.13 8.94 7.77 8.28 8.79 1.02 Y 
Guiteras 3 15 15 9 11700 27778 25254 23059 3297 6.99 7.66 8.43 12.95 17.85 22.74 2.33 n 
Reina 4 48 48 22 33900 80484 73171 66811 12202 5.48 6.00 6.60 11.02 12.15 13.27 2.03 n 
Tamayo 2 26 26 9 17850 42379 38528 35179 4940 7.12 7.80 8.58 12.27 13.85 15.44 1.78 n 
Vantroi 4 42 42 15 29250 69444 63134 57647 16149 3.57 3.91 4.30 7.71 8.28 8.86 2.12 n 






% staff 0.54 0.565 0.59 
% direct 0.78 0.82 0.86 • 
Workers Salary Total cost IPDor Predicted cost Actual Ratio Overlap 
Obstet Doctor Nurse Other costs High Mean Low cases Low Mean HTah Low Mean High 
AB 6 0 10 3 5650 13414 12195 11135 290 38.40 42.05 46.26 39.37 51.72 64.07 1.23 n 
C 5 0 9 5 5250 12464 11332 10347 848 12.20 13.36 14.70 13.89 16.76 19.63 1.25 y 
E 10.5 0 8 2 7025 16679 15163 13845 520 26.63 29.16 32.07 23.95 30.84 37.72 1.06 y 
F 3.7 0 7 4 4015 9532 8666 7913 334 23.69 25.95 28.54 29.14 36.75 44.35 1.42 Y 
LABOUR 1 0 14 6 4850 11515 10468 9559 725 13.18 14.44 15.88 16.45 21.32 26.20 1.48 Y 
NNICU 11.1 0 38 4 15095 35838 32581 29750 313 95.05 104.09 114.50 88.37 118.09 147.82 1.13 Y 
OT 7.5 0 24 2 9675 22970 20883 19068 220 86.67 94.92 104.41 70.12 113.98 157.83 1.20 Y 
Obstet 450 
Doctor 350 
Nurse 250 , 
Worker 150 , 
% staff 0.54 0.565 0.59 
% direct 0.78 0.82 0.86 
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Table 16.6: Cost prediction using simplified staff costing method in Thailand 
IWorkel I Salary ITotal col Its lopv 1 Predict fActual [RatiO 






















6. 4663 431 303'5. 6.€ 5.4 5.7 6.1 
3030 280E 208 . 5. 6.:! 6.1 6.4 ' 6.7 
3030 280E 200 " 5. s: 4.1 -4.6 5.1 
2798 25ge 171 . 6. 7.'SA ' 6.8 7.2 
3964 3670 96 -15.'1 17. !I.E -9.1 9.8 
l79 2796 2588 51 10. 1 6. 6.6 '7.2 
372' 3497 3238 270 4.1 5.2 5.! 7. 8.4 9.1 
3262 3020 151 4. -4. '3.4 3.6 3.8 
2796 2588 11 1 f.2 -6.6 6.9 
4428 4100 31 ;'-0 ' 5.2 
699' 6477 16 ::2 -5.7 
5828 5396 " 21 i.2 7:1 
3924.1 188. 5. 6 i.04 
3 
, 0.93 y 










, 0.5S n 
O:S y 
IOveriap IWorker iSalary rotal costs IIPO 
IOoctol INurse Other Icosts IHich IMean Low Low 
I Predict I Actua I Ratio 
IMean HTcih L()w [Mean Hiah 
20 16 254 16473 17369 1667' 15371.0 
27 ~92 20945 190! 1 & 10. 1 6. 7. 
~6 535 1504, 1 157<116: 
7346 146€ 123~ 116 1.0 
8. 6. 6. 
8.5 l.O 5.: 5. 
13 1387 87 190! 5 i.e 1 15.8 11>'8 9.7 10. '1 
1 1770 95l 851 10. 1 5. 
31 1 1: 1878 257' ~321 123 10. 11 8. 
10 1464 89! 8e 7. 6. 
20 l636 192: 1731 122. 8. 4. 
6772 135' 1221 4: 21 30. 3 5. 
1 5819 116' 109: 1048511191.0 9. 5.: 5.1 
1 10 7822 156' 1461 14094119311.0 7. 7.E 5. 6.: 




0.69 0.7, 0.74 
0.726 0.74 0.75 
Salary r otal COlitS 
,Nurse Other costs IHial IMean Lo~ 
o 72 168 40; 1737 
10 7 4' '04 2650 !429 
204 2650 !429 
5 1\ ,81 244: !242 
2 63 3799 3466 317: 











l.61 0.65 1.6S 
O. 0.72 '.74 
Cases I Predict 
Low Mean Hial 
11 23. 26. !8. 
116 20.9 22.8 25.0 
1:17 17.7 19.3 21.2 
,7 33.5 36.5 40.0 
24 132.4 144.4 158.3 




9: 3 89, 
IActual 
Low IMeanHig 
Q. 9. II 
37.5 40.1 4: :.6 
21.9 22.8 2: 1.6 




























IWorkel ! Sal illY ITotal cOI,Is I Predict IACtual I Ratio IOveriap 
Other Icc IHlgh IMean Low IMel lHIch loW IMean IHRm' 
1\ 14 9785 643 7 6111 67.(J 
6359 548 '4 84 1 2 39Ji 
733S '632 5 302 -26-:-9 n 
6646590 . 5 50 1 "0.6 n 
c 20, 5867 505' 4 14 ' 1 [141.6 0.3 n 
o 9292 8011 6991 24 297. '341.9 395. 53.4 0.2 n 
1716 12231 10544 9201 622 14. 17.ij 19. 74.4 4.4 n 





).26 0.29 0.32 
0.75 0.78 1.81 
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